data_2llp_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2llp _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo . . . . . 0 N--CA 1.457 -0.644 0 CA-C-O 121.136 0.39 . . . . 2.86 111.236 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.49 175.26 6.9 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 127.892 2.477 . . . . 3.28 113.084 -177.472 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.94 173.48 52.43 Favored Glycine 0 N--CA 1.479 1.542 0 N-CA-C 116.595 1.398 . . . . 1.66 116.595 -168.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.2 pt -71.51 145.09 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 O-C-N 120.905 -1.35 . . . . 4.12 110.256 -177.079 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.94 139.9 58.36 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-O 121.441 0.638 . . . . 1.78 112.207 -176.33 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.51 161.14 2.53 Favored Glycine 0 CA--C 1.526 0.744 0 C-N-CA 127.202 2.334 . . . . 1.31 115.682 178.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 22.1 mp0 -68.17 148.9 50.23 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-N 113.708 -1.246 . . . . 4.69 110.042 -174.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.86 130.41 45.57 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.774 -0.579 . . . . 7.92 110.277 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.04 150.38 50.26 Favored Glycine 0 CA--C 1.526 0.723 0 C-N-CA 124.073 0.844 . . . . 1.47 111.841 175.021 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 32.9 m -64.04 145.11 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 123.968 0.907 . . . . 2.87 111.514 -179.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 19.1 m -52.83 149.74 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 124.177 0.991 . . . . 2.54 113.359 -177.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.15 158.64 53.02 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-N 115.985 -0.552 . . . . 1.56 112.091 168.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 9.0 mp -89.2 158.04 47.08 Favored Pre-proline 0 CA--C 1.544 0.72 0 C-N-CA 123.221 0.608 . . . . 5.74 110.813 -176.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -78.19 -166.04 0.37 Allowed 'Trans proline' 0 CA--C 1.537 0.633 0 C-N-CA 123.596 2.864 . . . . 2.98 109.446 160.267 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.153 0 CA-C-O 117.35 -1.806 . . . . 3.58 111.952 150.297 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo . . . . . 0 N--CA 1.481 0.759 0 CA-C-O 118.484 -0.715 . . . . 2.65 111.482 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.02 159.62 51.09 Favored Glycine 0 CA--C 1.539 1.588 0 N-CA-C 110.886 -0.886 . . . . 1.29 110.886 150.245 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -72.09 177.45 7.14 Favored 'Trans proline' 0 CA--C 1.539 0.76 0 C-N-CA 123.244 2.63 . . . . 2.23 108.859 156.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 11.5 tt0 -60.19 172.63 0.78 Allowed 'General case' 0 CA--C 1.544 0.731 0 N-CA-C 114.935 1.457 . . . . 5.59 114.935 -175.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.17 159.48 51.77 Favored Glycine 0 CA--C 1.527 0.811 0 O-C-N 120.995 -1.066 . . . . 1.0 113.563 176.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 29.9 mm -60.25 141.48 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 123.669 0.788 . . . . 4.0 109.578 168.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.42 151.63 31.97 Favored 'General case' 0 CA--C 1.542 0.66 0 CA-C-O 122.756 1.265 . . . . 1.37 113.773 -179.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.19 137.67 38.25 Favored Glycine 0 CA--C 1.523 0.531 0 C-N-CA 125.25 1.405 . . . . 1.67 112.42 -179.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 94.9 mm-40 -81.92 124.84 30.08 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.577 -0.811 . . . . 4.54 109.167 -175.039 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 10.9 ptt180 -55.15 153.64 6.55 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 126.215 1.806 . . . . 7.33 114.064 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.92 173.65 54.69 Favored Glycine 0 CA--C 1.529 0.922 0 C-N-CA 124.133 0.873 . . . . 1.76 113.355 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 59.5 t -93.43 131.64 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 124.503 1.121 . . . . 3.58 112.83 -165.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 19.0 m -60.39 159.99 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 127.61 2.364 . . . . 3.0 114.414 -173.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.81 -136.7 5.25 Favored Glycine 0 CA--C 1.529 0.908 0 C-N-CA 124.191 0.9 . . . . 2.15 112.09 168.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -170.71 160.81 5.88 Favored Pre-proline 0 CA--C 1.543 0.705 0 C-N-CA 124.766 1.226 . . . . 3.98 111.534 -161.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo . . . . . 0 C--O 1.256 1.42 0 C-N-CA 124.586 3.524 . . . . 3.17 112.249 161.422 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo . . . . . 0 N--CA 1.486 1.076 0 CA-C-O 118.989 -0.505 . . . . 2.61 111.251 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -73.18 -130.07 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.939 0 C-N-CA 123.198 2.599 . . . . 2.45 107.778 162.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.29 168.23 48.14 Favored Glycine 0 CA--C 1.536 1.391 0 CA-C-N 119.509 1.049 . . . . 1.35 111.496 164.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.99 -44.83 0.31 Allowed 'Trans proline' 0 N--CA 1.458 -0.562 0 C-N-CA 122.578 2.185 . . . . 3.95 112.329 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 30.5 tp60 166.83 137.44 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 127.926 2.49 . . . . 1.73 105.526 -153.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.36 160.04 37.67 Favored Glycine 0 N--CA 1.468 0.823 0 C-N-CA 125.958 1.742 . . . . 1.16 112.927 169.228 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 46.7 mt -61.69 143.73 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 124.055 0.942 . . . . 3.15 111.022 -179.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.88 148.14 21.72 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.313 1.045 . . . . 1.44 113.559 174.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.87 149.42 34.61 Favored Glycine 0 C--N 1.339 0.712 0 C-N-CA 123.778 0.704 . . . . 1.14 111.375 -178.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 13.5 mp0 -90.85 -177.84 5.07 Favored 'General case' 0 CA--C 1.539 0.536 0 O-C-N 122.156 -0.614 . . . . 3.33 109.956 177.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 9.6 ptp180 -67.22 164.48 18.15 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-O 122.301 1.048 . . . . 6.27 113.592 -174.2 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.9 165.62 49.5 Favored Glycine 0 CA--C 1.531 1.031 0 C-N-CA 124.77 1.176 . . . . 1.17 111.862 166.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.7 t -64.08 144.99 14.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.282 1.033 . . . . 2.12 110.782 177.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 29.6 m -79.83 -171.67 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.833 0 C-N-CA 125.081 1.353 . . . . 3.59 111.622 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.13 179.42 7.05 Favored Glycine 0 CA--C 1.533 1.174 0 C-N-CA 124.842 1.211 . . . . 2.21 114.775 174.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 7.5 mt . . . . . 0 C--O 1.249 1.057 0 N-CA-C 114.527 1.306 . . . . 4.59 114.527 -169.77 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo . . . . . 0 N--CA 1.456 -0.697 0 CA-C-O 121.351 0.479 . . . . 2.58 111.225 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -76.32 -166.96 0.69 Allowed 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 127.017 2.127 . . . . 3.05 112.681 167.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.19 174.48 49.59 Favored Glycine 0 N--CA 1.472 1.088 0 O-C-N 121.308 -0.87 . . . . 1.5 114.737 -178.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 33.2 pt -73.15 150.38 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 O-C-N 122.329 -0.512 . . . . 4.27 109.693 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -49.1 131.98 19.26 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-O 121.775 0.798 . . . . 1.9 112.421 177.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.55 148.36 9.49 Favored Glycine 0 CA--C 1.519 0.344 0 C-N-CA 127.305 2.383 . . . . 1.25 112.856 166.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 78.7 mm-40 -80.64 132.61 35.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.081 -0.559 . . . . 4.26 109.534 -166.354 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 60.6 ttp180 -52.88 127.94 25.29 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.76 1.624 . . . . 9.0 113.292 -173.273 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.21 159.83 53.61 Favored Glycine 0 N--CA 1.468 0.78 0 N-CA-C 116.012 1.165 . . . . 1.72 116.012 -170.521 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 27.8 m -72.39 143.13 14.36 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 C-N-CA 124.357 1.063 . . . . 3.27 111.365 176.114 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 31.0 m -50.58 156.48 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 C-N-CA 126.803 2.041 . . . . 2.94 116.116 -168.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -81.27 -173.54 47.94 Favored Glycine 0 CA--C 1.533 1.187 0 C-N-CA 123.804 0.716 . . . . 1.81 113.028 162.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 7.2 mp -120.88 163.09 31.56 Favored Pre-proline 0 CA--C 1.542 0.656 0 C-N-CA 125.745 1.618 . . . . 4.98 111.427 178.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -83.17 -138.11 0.02 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.691 0 C-N-CA 123.738 2.959 . . . . 2.4 107.708 156.285 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.329 0 CA-C-O 116.907 -2.052 . . . . 3.41 113.292 142.836 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo . . . . . 0 N--CA 1.489 1.259 0 N-CA-C 109.306 -1.075 . . . . 2.85 109.306 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.13 147.46 37.87 Favored Glycine 0 CA--C 1.538 1.52 0 CA-C-O 118.546 -1.141 . . . . 1.46 110.718 162.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -72.29 179.89 4.61 Favored 'Trans proline' 0 CA--C 1.54 0.797 0 C-N-CA 123.871 3.047 . . . . 2.5 109.9 163.059 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 12.1 tt0 -53.71 162.82 0.79 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.087 1.355 . . . . 5.43 114.437 178.511 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.25 161.23 51.7 Favored Glycine 0 N--CA 1.47 0.965 0 O-C-N 121.289 -0.882 . . . . 1.11 112.989 -178.415 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.6 pp -65.58 150.13 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 O-C-N 121.944 -0.739 . . . . 5.46 111.117 171.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.47 147.15 49.75 Favored 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 114.431 1.271 . . . . 1.85 114.431 -175.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.58 158.45 53.19 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 124.821 1.2 . . . . 1.77 111.492 170.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 21.2 mp0 -69.1 150.52 47.49 Favored 'General case' 0 CA--C 1.536 0.418 0 O-C-N 121.979 -0.718 . . . . 4.15 111.408 -173.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 17.0 mtt180 -67.55 148.74 51.05 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 109.693 -0.484 . . . . 6.89 109.693 160.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.3 165.53 43.04 Favored Glycine 0 CA--C 1.533 1.165 0 N-CA-C 115.052 0.781 . . . . 2.19 115.052 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 23.3 m -78.97 130.18 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 114.432 1.271 . . . . 4.41 114.432 -168.383 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.7 m -85.23 154.96 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 126.119 1.767 . . . . 3.1 112.113 -170.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.57 -134.4 8.46 Favored Glycine 0 CA--C 1.53 0.994 0 C-N-CA 124.442 1.02 . . . . 1.72 113.273 179.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -166.31 161.04 12.43 Favored Pre-proline 0 CA--C 1.547 0.831 0 C-N-CA 125.498 1.519 . . . . 3.79 112.326 -165.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo . . . . . 0 C--O 1.254 1.323 0 C-N-CA 124.821 3.681 . . . . 2.66 112.249 152.161 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo . . . . . 0 N--CA 1.487 1.097 0 CA-C-O 119.017 -0.493 . . . . 2.42 111.099 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -71.78 -138.87 0.02 OUTLIER 'Trans proline' 0 CA--C 1.546 1.1 0 C-N-CA 123.465 2.776 . . . . 2.06 107.988 157.704 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.87 168.48 37.59 Favored Glycine 0 CA--C 1.54 1.598 0 CA-C-N 119.383 0.992 . . . . 1.12 112.23 166.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -79.28 -43.65 0.14 Allowed 'Trans proline' 0 CA--C 1.535 0.555 0 C-N-CA 123.021 2.481 . . . . 3.65 113.662 -176.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.42 HE21 ' N ' ' C' ' 16' ' ' GLY . 30.4 tp60 171.61 141.12 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 127.452 2.301 . . . . 1.81 105.865 -154.355 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . 0.42 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -91.17 173.37 37.56 Favored Glycine 0 N--CA 1.466 0.634 0 C-N-CA 126.263 1.887 . . . . 1.19 114.474 171.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 3.9 mp -63.03 132.0 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 C-N-CA 124.464 1.106 . . . . 4.36 111.303 -175.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.66 135.05 57.18 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.824 0.85 . . . . 1.4 112.337 175.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -68.06 139.18 33.93 Favored Glycine 0 C--N 1.334 0.446 0 C-N-CA 124.835 1.207 . . . . 1.43 111.014 -173.202 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 98.8 mm-40 -93.19 158.22 15.87 Favored 'General case' 0 C--N 1.324 -0.501 0 O-C-N 122.026 -0.691 . . . . 5.24 111.856 -168.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.51 133.56 46.06 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 115.866 -0.606 . . . . 4.71 110.146 178.208 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.62 163.95 49.12 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 123.328 0.489 . . . . 1.21 113.491 -172.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 1.7 t -64.82 154.9 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 C-N-CA 123.372 0.669 . . . . 2.27 110.517 175.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 30.5 m -75.54 -173.5 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.816 0 C-N-CA 124.704 1.202 . . . . 3.71 110.898 170.611 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.97 -132.66 0.14 Allowed Glycine 0 CA--C 1.536 1.396 0 C-N-CA 125.078 1.323 . . . . 3.43 112.583 167.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 7.7 tt . . . . . 0 C--O 1.251 1.143 0 C-N-CA 126.643 1.977 . . . . 6.26 112.771 178.722 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo . . . . . 0 N--CA 1.46 -0.491 0 N-CA-C 110.9 -0.461 . . . . 2.51 110.9 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.12 176.45 9.74 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 127.938 2.495 . . . . 2.68 114.357 -172.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.9 177.44 44.77 Favored Glycine 0 N--CA 1.48 1.633 0 N-CA-C 116.8 1.48 . . . . 1.3 116.8 -169.404 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 7.8 pt -70.04 147.84 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 O-C-N 121.192 -1.181 . . . . 4.05 110.608 -173.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.14 134.78 44.24 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.77 0.795 . . . . 1.85 112.154 -179.058 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.76 144.85 25.78 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 126.364 1.935 . . . . 1.21 112.814 173.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 84.7 mm-40 -67.91 125.22 25.61 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 108.651 -0.87 . . . . 3.8 108.651 -170.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 32.1 ttt-85 -69.53 145.43 52.63 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-O 121.832 0.825 . . . . 5.54 112.779 -156.016 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.28 144.31 37.34 Favored Glycine 0 CA--C 1.524 0.611 0 CA-C-O 122.296 0.942 . . . . 1.69 113.458 -175.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.3 t -62.79 150.17 9.31 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.521 0 C-N-CA 127.398 2.279 . . . . 3.71 111.444 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.4 m -48.44 158.83 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 C-N-CA 125.809 1.644 . . . . 2.51 113.993 173.154 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.85 174.09 40.52 Favored Glycine 0 CA--C 1.53 1.027 0 CA-C-N 115.999 -0.546 . . . . 1.41 111.931 160.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 79.8 mt -113.04 157.3 41.14 Favored Pre-proline 0 CA--C 1.539 0.526 0 C-N-CA 124.219 1.008 . . . . 4.31 110.181 -178.375 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -79.74 -158.26 0.09 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.793 0 C-N-CA 123.395 2.73 . . . . 2.66 108.96 160.13 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.225 0 CA-C-O 118.06 -1.411 . . . . 3.4 113.251 154.182 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo . . . . . 0 CA--C 1.544 1.01 0 CA-C-O 119.493 -0.295 . . . . 2.46 111.769 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.15 170.72 37.2 Favored Glycine 0 CA--C 1.54 1.614 0 CA-C-O 118.86 -0.967 . . . . 1.35 112.175 125.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -72.23 -179.78 4.29 Favored 'Trans proline' 0 CA--C 1.541 0.829 0 C-N-CA 123.439 2.759 . . . . 2.37 108.742 148.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 pm0 -70.39 -175.15 0.95 Allowed 'General case' 0 CA--C 1.546 0.8 0 N-CA-C 113.946 1.091 . . . . 5.2 113.946 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.89 168.12 50.65 Favored Glycine 0 CA--C 1.528 0.901 0 O-C-N 120.347 -1.471 . . . . 0.92 114.187 -178.507 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 79.0 mt -76.01 145.56 10.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 124.569 1.148 . . . . 3.46 108.988 167.465 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -73.65 152.78 40.38 Favored 'General case' 0 CA--C 1.543 0.686 0 N-CA-C 115.161 1.541 . . . . 1.32 115.161 -170.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.36 132.74 21.12 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 125.615 1.579 . . . . 1.5 110.863 173.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -95.16 143.68 26.39 Favored 'General case' 0 N--CA 1.465 0.29 0 O-C-N 121.501 -0.999 . . . . 3.76 111.195 -172.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 3.2 mtm180 -55.83 150.89 12.26 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 125.605 1.562 . . . . 6.46 113.802 175.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.79 179.22 44.26 Favored Glycine 0 CA--C 1.538 1.521 0 C-N-CA 124.929 1.252 . . . . 2.05 113.252 165.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 58.4 t -112.43 148.63 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 C-N-CA 125.138 1.375 . . . . 4.61 113.019 -154.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.9 p -53.19 152.56 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 128.92 2.888 . . . . 4.91 115.708 -172.382 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.38 -131.59 3.4 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 125.097 1.332 . . . . 2.16 111.193 165.299 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -172.68 161.57 3.94 Favored Pre-proline 0 CA--C 1.544 0.745 0 C-N-CA 126.153 1.781 . . . . 3.92 111.018 -165.082 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo . . . . . 0 C--O 1.255 1.371 0 C-N-CA 124.644 3.563 . . . . 3.13 112.045 154.05 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo . . . . . 0 CA--C 1.547 1.14 0 CA-C-O 119.265 -0.389 . . . . 2.21 112.302 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -71.37 -132.24 0.01 OUTLIER 'Trans proline' 0 CA--C 1.542 0.893 0 C-N-CA 123.413 2.742 . . . . 2.11 108.121 162.524 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.3 162.09 34.72 Favored Glycine 0 CA--C 1.534 1.242 0 CA-C-N 119.821 1.191 . . . . 1.37 112.532 166.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -73.59 -49.11 0.22 Allowed 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 122.795 2.33 . . . . 3.62 112.079 176.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.456 HE21 ' N ' ' C' ' 16' ' ' GLY . 18.2 tp60 175.26 138.35 0.05 OUTLIER 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.129 1.772 . . . . 1.87 107.392 -152.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . 0.456 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -87.42 166.43 36.36 Favored Glycine 0 CA--C 1.527 0.84 0 C-N-CA 125.807 1.67 . . . . 1.03 112.677 169.256 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 72.6 mt -69.18 138.57 22.0 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 O-C-N 121.84 -0.8 . . . . 2.95 109.335 -179.33 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -65.13 158.72 25.14 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.868 1.062 . . . . 1.18 113.868 177.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -82.51 -168.36 42.07 Favored Glycine 0 CA--C 1.528 0.859 0 CA-C-O 122.384 0.991 . . . . 1.52 111.14 170.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -158.44 179.72 8.87 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 124.265 1.026 . . . . 3.04 109.711 -172.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 5.1 tmm_? -64.95 141.97 58.59 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 125.781 1.632 . . . . 6.29 111.791 -174.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.73 -165.66 35.71 Favored Glycine 0 CA--C 1.532 1.148 0 C-N-CA 125.144 1.354 . . . . 1.4 115.542 -174.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 48.6 t -64.49 147.43 12.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.807 1.643 . . . . 2.35 110.029 176.043 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 33.3 m -102.17 -178.49 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 C-N-CA 125.351 1.46 . . . . 3.31 112.223 -175.126 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.51 171.4 6.84 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 125.061 1.315 . . . . 1.81 115.503 176.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 2.7 mm? . . . . . 0 C--O 1.249 1.072 0 C-N-CA 126.408 1.883 . . . . 4.0 113.116 -166.185 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo . . . . . 0 CA--C 1.537 0.647 0 CA-C-O 121.14 0.391 . . . . 3.54 111.29 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.95 -152.16 0.35 Allowed 'General case' 0 CA--C 1.548 0.889 0 C-N-CA 126.789 2.036 . . . . 3.17 110.449 175.791 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.37 162.63 44.03 Favored Glycine 0 N--CA 1.473 1.12 0 O-C-N 120.629 -1.295 . . . . 1.47 114.268 -173.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 25.4 pt -69.88 149.03 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 O-C-N 121.226 -1.161 . . . . 3.61 110.525 178.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.98 132.56 50.25 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 123.555 0.742 . . . . 1.81 111.767 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.2 136.69 25.46 Favored Glycine 0 CA--C 1.522 0.498 0 C-N-CA 126.021 1.772 . . . . 2.11 112.13 169.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 77.7 mm-40 -72.48 140.14 48.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.198 -0.501 . . . . 4.01 110.438 -166.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 46.8 ttt85 -66.63 134.24 51.91 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-O 121.372 0.606 . . . . 7.22 111.287 -172.625 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.53 146.77 46.33 Favored Glycine 0 CA--C 1.527 0.798 0 CA-C-O 122.08 0.822 . . . . 1.78 113.41 178.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.6 t -67.01 118.61 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 C-N-CA 125.819 1.648 . . . . 3.0 110.475 -171.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 24.3 m -44.84 143.71 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 C-N-CA 125.042 1.337 . . . . 2.94 114.383 -170.093 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -75.08 174.06 52.12 Favored Glycine 0 CA--C 1.533 1.174 0 N-CA-C 111.884 -0.486 . . . . 1.68 111.884 165.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 7.0 mp -122.24 160.32 48.3 Favored Pre-proline 0 CA--C 1.539 0.541 0 C-N-CA 125.273 1.429 . . . . 4.14 109.943 175.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.405 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 41.4 Cg_endo -75.98 -158.22 0.08 OUTLIER 'Trans proline' 0 CA--C 1.537 0.666 0 C-N-CA 122.882 2.388 . . . . 3.43 109.256 157.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.192 0 CA-C-O 116.76 -2.133 . . . . 5.32 112.532 142.762 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo . . . . . 0 N--CA 1.491 1.352 0 N-CA-C 109.089 -1.158 . . . . 3.38 109.089 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.27 144.88 36.74 Favored Glycine 0 CA--C 1.543 1.822 0 CA-C-O 118.697 -1.057 . . . . 1.81 111.415 164.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -77.04 -176.12 3.02 Favored 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 124.675 3.583 . . . . 2.52 110.134 163.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -61.19 173.47 0.84 Allowed 'General case' 0 CA--C 1.546 0.804 0 N-CA-C 116.336 1.976 . . . . 4.83 116.336 -175.247 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -90.01 154.37 23.7 Favored Glycine 0 CA--C 1.526 0.726 0 O-C-N 121.147 -0.971 . . . . 1.18 113.677 -174.062 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 79.7 mt -60.63 134.12 26.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 108.347 -0.983 . . . . 3.68 108.347 168.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.09 152.21 39.97 Favored 'General case' 0 CA--C 1.544 0.719 0 N-CA-C 112.752 0.649 . . . . 1.77 112.752 -177.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -83.81 -168.9 44.43 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 124.076 0.846 . . . . 2.5 111.003 169.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -148.6 176.21 10.53 Favored 'General case' 0 CA--C 1.536 0.431 0 O-C-N 120.961 -1.317 . . . . 4.44 112.231 171.048 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.2 ttm180 -59.65 159.47 8.53 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 125.661 1.585 . . . . 6.64 115.07 -164.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -63.66 157.91 40.94 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-N 116.276 -0.42 . . . . 2.42 114.136 170.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 35.9 t -85.61 121.27 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 C-N-CA 123.742 0.817 . . . . 3.94 111.86 -165.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 6.3 m -69.06 156.51 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 126.154 1.781 . . . . 3.48 113.715 -170.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.29 -142.66 10.99 Favored Glycine 0 N--CA 1.469 0.878 0 C-N-CA 124.17 0.89 . . . . 2.04 112.436 167.059 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.405 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.6 pt? -172.73 160.48 3.87 Favored Pre-proline 0 CA--C 1.545 0.786 0 C-N-CA 124.854 1.262 . . . . 4.8 111.714 -158.428 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo . . . . . 0 C--O 1.255 1.336 0 C-N-CA 124.828 3.686 . . . . 3.02 112.329 155.292 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo . . . . . 0 N--CA 1.487 1.092 0 CA-C-O 119.2 -0.417 . . . . 2.98 111.125 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.56 -131.27 0.01 OUTLIER 'Trans proline' 0 CA--C 1.542 0.895 0 C-N-CA 122.362 2.041 . . . . 2.26 106.859 152.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.99 -179.78 48.74 Favored Glycine 0 CA--C 1.535 1.326 0 CA-C-N 119.558 1.072 . . . . 1.38 113.075 169.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -78.45 -110.0 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.039 0 C-N-CA 124.867 3.712 . . . . 2.59 109.718 161.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.501 HE21 ' N ' ' C' ' 16' ' ' GLY . 8.5 tp60 -146.58 134.51 21.37 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 127.904 2.482 . . . . 2.35 107.676 -159.395 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . 0.501 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -74.34 169.52 54.01 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 124.614 1.102 . . . . 1.45 113.728 170.51 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 65.8 mt -73.16 131.44 34.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 121.745 -0.856 . . . . 3.78 111.221 -174.083 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.37 154.17 35.16 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 113.693 0.997 . . . . 1.74 113.693 178.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -82.99 162.4 40.71 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 124.806 1.193 . . . . 1.66 112.711 177.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 13.9 mp0 -101.69 -175.87 2.97 Favored 'General case' 0 CA--C 1.545 0.753 0 O-C-N 121.425 -1.044 . . . . 3.17 111.189 -178.115 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.46 140.66 54.07 Favored 'General case' 0 CA--C 1.541 0.601 0 O-C-N 121.514 -0.741 . . . . 6.49 111.561 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.57 154.63 36.49 Favored Glycine 0 N--CA 1.47 0.942 0 C-N-CA 125.517 1.532 . . . . 1.76 113.151 179.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 17.7 t -64.0 144.86 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 124.525 1.13 . . . . 3.29 111.02 -179.015 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 78.2 t -101.47 168.58 1.94 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.896 0 C-N-CA 126.603 1.961 . . . . 5.85 109.484 -175.143 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.25 177.43 3.35 Favored Glycine 0 CA--C 1.538 1.516 0 C-N-CA 124.196 0.903 . . . . 3.43 114.181 169.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 11.9 mt . . . . . 0 N--CA 1.484 1.241 0 N-CA-C 114.711 1.374 . . . . 4.79 114.711 -169.401 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo . . . . . 0 CA--C 1.535 0.563 0 N-CA-C 110.327 -0.682 . . . . 2.37 110.327 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 14.8 mm100 -56.51 -177.6 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 129.084 2.953 . . . . 6.07 116.256 -173.221 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -91.35 -173.05 43.26 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 124.309 0.957 . . . . 1.23 112.968 161.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 9.5 mt -72.05 128.09 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 N-CA-C 109.229 -0.656 . . . . 2.58 109.229 -177.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -52.92 135.15 36.99 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.487 0.715 . . . . 1.8 110.727 174.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.65 154.55 48.61 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 125.327 1.441 . . . . 1.27 113.387 -170.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 71.4 mm-40 -69.91 106.55 3.21 Favored 'General case' 0 CA--C 1.532 0.258 0 N-CA-C 109.877 -0.416 . . . . 3.77 109.877 -171.11 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.0 ttp180 -61.49 143.17 56.37 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 125.069 1.348 . . . . 4.93 114.186 -163.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.26 136.96 30.73 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 124.839 1.209 . . . . 1.57 113.517 -167.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 8.8 p -60.9 134.88 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 C-N-CA 125.493 1.517 . . . . 4.55 111.005 177.112 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 30.0 m -46.13 157.96 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.984 0 C-N-CA 127.148 2.179 . . . . 2.77 115.616 -171.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.42 171.6 43.36 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-N 115.424 -0.807 . . . . 1.35 113.476 168.315 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 87.6 mt -120.36 159.68 46.81 Favored Pre-proline 0 CA--C 1.54 0.566 0 C-N-CA 124.952 1.301 . . . . 3.31 110.776 -173.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -76.42 -169.56 0.72 Allowed 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 123.208 2.605 . . . . 2.16 109.797 161.006 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.182 0 CA-C-O 117.837 -1.535 . . . . 3.14 113.189 155.143 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo . . . . . 0 CA--C 1.545 1.073 0 CA-C-O 119.209 -0.413 . . . . 2.47 111.317 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.25 171.42 10.35 Favored Glycine 0 CA--C 1.54 1.613 0 C-N-CA 119.259 -1.448 . . . . 1.36 112.634 123.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -75.73 -57.89 0.05 OUTLIER 'Trans proline' 0 CA--C 1.535 0.554 0 C-N-CA 123.974 3.116 . . . . 2.7 111.042 170.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 175.55 152.38 0.14 Allowed 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 127.464 2.306 . . . . 5.67 107.702 -164.309 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.66 153.88 35.39 Favored Glycine 0 CA--C 1.527 0.785 0 C-N-CA 123.817 0.722 . . . . 0.92 112.695 174.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 4.7 mp -67.36 136.1 27.29 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 108.657 -0.868 . . . . 3.58 108.657 173.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.24 153.85 41.43 Favored 'General case' 0 CA--C 1.541 0.634 0 N-CA-C 113.277 0.843 . . . . 1.63 113.277 -179.154 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -66.98 141.73 40.29 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 111.312 -0.715 . . . . 1.63 111.312 172.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -81.04 164.96 22.1 Favored 'General case' 0 CA--C 1.54 0.576 0 O-C-N 120.899 -1.354 . . . . 3.39 112.218 173.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -63.6 146.15 54.3 Favored 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 125.926 1.69 . . . . 5.29 112.586 173.231 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.55 157.97 53.4 Favored Glycine 0 CA--C 1.533 1.216 0 N-CA-C 115.087 0.795 . . . . 2.25 115.087 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 17.9 m -91.65 133.08 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 N-CA-C 114.708 1.373 . . . . 4.69 114.708 -164.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -56.36 150.81 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 C-N-CA 127.791 2.436 . . . . 4.13 115.164 -165.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -84.72 -122.49 1.05 Allowed Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.217 0.913 . . . . 2.12 111.182 165.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.3 pt? -170.8 156.65 5.04 Favored Pre-proline 0 CA--C 1.543 0.696 0 C-N-CA 124.756 1.223 . . . . 3.76 112.014 -161.291 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo . . . . . 0 CA--C 1.552 1.379 0 C-N-CA 124.123 3.215 . . . . 2.58 111.767 159.1 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo . . . . . 0 N--CA 1.488 1.168 0 CA-C-O 118.779 -0.592 . . . . 3.12 111.591 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 80.0 Cg_exo -50.6 177.41 0.03 OUTLIER 'Trans proline' 0 CA--C 1.537 0.656 1 C-N-CA 125.565 4.177 . . . . 2.64 113.568 162.599 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.26 178.85 53.69 Favored Glycine 0 CA--C 1.541 1.711 0 C-N-CA 123.575 0.607 . . . . 1.22 112.6 167.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_endo -70.18 156.78 61.47 Favored 'Trans proline' 0 N--CA 1.457 -0.628 0 C-N-CA 123.319 2.679 . . . . 2.49 111.571 171.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.0 tp60 -39.25 126.21 1.69 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 127.609 2.363 . . . . 1.52 113.046 164.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.9 168.48 49.92 Favored Glycine 0 CA--C 1.529 0.922 0 C-N-CA 124.75 1.167 . . . . 0.99 112.67 170.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 29.7 mt -67.51 143.26 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 O-C-N 121.228 -1.16 . . . . 3.2 110.747 -172.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.77 151.82 28.62 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 112.891 0.7 . . . . 1.17 112.891 172.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.0 169.64 52.13 Favored Glycine 0 CA--C 1.527 0.816 0 CA-C-O 122.823 1.235 . . . . 1.12 113.519 178.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 40.0 mt-30 -95.84 154.29 17.3 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.355 -1.085 . . . . 4.66 111.767 -170.029 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -62.72 135.17 57.22 Favored 'General case' 0 C--O 1.234 0.253 0 N-CA-C 109.207 -0.664 . . . . 6.05 109.207 168.501 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -66.65 173.07 26.97 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 116.204 1.242 . . . . 1.11 116.204 -165.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 61.0 t -66.95 136.88 25.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 C-N-CA 124.443 1.097 . . . . 2.19 109.013 173.264 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 33.9 m -100.82 -169.68 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 C-N-CA 124.53 1.132 . . . . 2.97 110.845 -169.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.33 155.22 4.91 Favored Glycine 0 CA--C 1.532 1.154 0 C-N-CA 124.657 1.122 . . . . 1.58 114.27 172.39 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 8.8 mt . . . . . 0 C--O 1.249 1.079 0 CA-C-O 117.637 -1.173 . . . . 4.46 113.998 -162.871 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo . . . . . 0 N--CA 1.461 -0.436 0 N-CA-C 110.534 -0.602 . . . . 2.41 110.534 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.72 -179.14 0.35 Allowed 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.931 2.493 . . . . 3.34 113.978 176.559 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.98 -178.74 44.64 Favored Glycine 0 CA--C 1.527 0.797 0 C-N-CA 125.556 1.551 . . . . 1.29 114.686 174.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.8 mt -65.63 134.0 30.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 123.951 0.9 . . . . 2.96 109.922 -172.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.93 129.76 38.84 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 123.703 0.801 . . . . 2.34 111.471 173.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.78 166.77 54.18 Favored Glycine 0 CA--C 1.522 0.477 0 C-N-CA 127.44 2.447 . . . . 1.69 113.069 -177.396 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 14.0 mp0 -82.38 113.58 20.25 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 108.591 -0.892 . . . . 4.9 108.591 -162.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 73.8 ttt180 -49.56 130.66 20.71 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 124.2 1.0 . . . . 4.69 112.199 -173.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.26 145.58 39.5 Favored Glycine 0 N--CA 1.464 0.523 0 C-N-CA 124.75 1.167 . . . . 1.66 113.102 -173.544 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 28.2 m -63.89 161.28 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 124.566 1.147 . . . . 3.04 111.615 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.8 m -47.97 157.22 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 125.443 1.497 . . . . 2.6 113.667 177.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.29 173.33 39.87 Favored Glycine 0 CA--C 1.527 0.812 0 CA-C-N 115.391 -0.822 . . . . 1.42 112.171 162.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 87.6 mt -111.57 158.19 37.1 Favored Pre-proline 0 CA--C 1.537 0.451 0 C-N-CA 123.687 0.795 . . . . 4.58 110.523 -178.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -81.39 -160.56 0.13 Allowed 'Trans proline' 0 N--CA 1.454 -0.829 0 C-N-CA 123.302 2.668 . . . . 3.1 108.889 158.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.135 0 CA-C-O 117.75 -1.583 . . . . 3.91 113.021 152.076 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo . . . . . 0 CA--C 1.543 0.927 0 CA-C-O 119.157 -0.435 . . . . 2.44 111.664 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.57 162.99 43.93 Favored Glycine 0 CA--C 1.543 1.834 0 C-N-CA 119.516 -1.326 . . . . 1.38 111.766 130.018 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -76.49 -53.54 0.08 OUTLIER 'Trans proline' 0 CA--C 1.536 0.618 0 C-N-CA 124.876 3.717 . . . . 3.22 113.055 177.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -177.13 159.16 1.6 Allowed 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 128.45 2.7 . . . . 4.8 106.8 -162.471 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.11 155.26 22.88 Favored Glycine 0 N--CA 1.468 0.817 0 C-N-CA 124.189 0.899 . . . . 1.03 113.039 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 34.4 mm -67.94 130.37 33.1 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 N-CA-C 109.107 -0.701 . . . . 3.4 109.107 172.601 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -73.28 166.76 22.57 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 113.866 1.062 . . . . 2.12 113.866 -174.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -73.93 113.63 4.25 Favored Glycine 0 CA--C 1.53 1.027 0 C-N-CA 124.313 0.958 . . . . 2.21 112.516 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 -66.23 141.51 58.02 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 123.683 0.793 . . . . 4.88 112.769 178.44 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 9.2 mtt85 -62.05 159.44 14.43 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 115.096 1.517 . . . . 6.59 115.096 -176.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.99 -179.29 44.46 Favored Glycine 0 CA--C 1.538 1.474 0 C-N-CA 125.453 1.501 . . . . 2.0 113.151 163.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 15.6 m -112.03 146.97 16.2 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 N-CA-C 115.015 1.487 . . . . 3.83 115.015 -158.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 8.9 p -54.36 152.42 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 127.973 2.509 . . . . 4.8 115.351 -170.332 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -85.72 -129.23 2.24 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 124.599 1.095 . . . . 1.99 111.062 162.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -170.79 159.94 5.71 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 125.252 1.421 . . . . 3.76 111.777 -168.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo . . . . . 0 C--O 1.256 1.397 1 C-N-CA 125.306 4.004 . . . . 2.69 111.931 155.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo . . . . . 0 CA--C 1.547 1.149 0 CA-C-O 118.318 -0.784 . . . . 2.82 111.433 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -54.04 -169.49 0.02 OUTLIER 'Trans proline' 0 CA--C 1.541 0.864 1 C-N-CA 126.043 4.495 . . . . 2.16 113.595 164.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -83.83 175.03 51.76 Favored Glycine 0 CA--C 1.542 1.779 0 O-C-N 121.769 -0.582 . . . . 1.15 112.345 165.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -69.47 157.91 59.26 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 122.996 2.464 . . . . 2.53 111.166 170.076 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 tp60 -41.09 124.87 2.32 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.82 2.048 . . . . 1.61 113.439 165.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.65 154.65 53.01 Favored Glycine 0 CA--C 1.53 0.974 0 C-N-CA 124.391 0.996 . . . . 1.03 112.382 171.135 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 1.8 mp -67.87 146.1 13.21 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 C-N-CA 124.524 1.129 . . . . 3.73 110.99 -168.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.95 142.0 54.54 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 125.216 1.406 . . . . 1.48 113.197 178.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -76.07 134.04 15.21 Favored Glycine 0 C--N 1.333 0.366 0 N-CA-C 110.384 -1.086 . . . . 1.41 110.384 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -88.09 171.9 9.92 Favored 'General case' 0 CA--C 1.542 0.644 0 CA-C-N 115.088 -0.556 . . . . 3.1 109.524 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -61.12 155.27 20.95 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.711 0.767 . . . . 5.65 112.279 179.544 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.44 -176.62 25.09 Favored Glycine 0 CA--C 1.53 1.012 0 C-N-CA 124.995 1.283 . . . . 1.45 113.512 179.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 49.0 t -59.13 143.5 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.879 1.272 . . . . 2.74 110.279 176.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 30.9 m -97.76 -175.75 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.056 1.342 . . . . 4.11 112.024 -173.665 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.43 167.35 19.02 Favored Glycine 0 CA--C 1.532 1.127 0 C-N-CA 124.984 1.278 . . . . 2.23 114.867 175.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 9.6 mp . . . . . 0 C--O 1.249 1.046 0 C-N-CA 126.516 1.927 . . . . 4.7 113.463 -166.9 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo . . . . . 0 CA--C 1.538 0.704 0 N-CA-C 109.981 -0.815 . . . . 4.8 109.981 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.9 -137.18 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 124.583 1.153 . . . . 3.38 110.188 157.295 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.52 -148.78 17.59 Favored Glycine 0 N--CA 1.468 0.83 0 CA-C-O 122.827 1.237 . . . . 1.87 114.75 172.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.9 mt -84.1 158.38 3.6 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.506 0 C-N-CA 124.131 0.972 . . . . 4.03 108.435 177.371 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.65 46.69 0.09 Allowed 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 126.807 2.043 . . . . 4.24 112.599 170.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 61.56 -155.09 37.51 Favored Glycine 0 C--N 1.337 0.609 0 C-N-CA 125.289 1.424 . . . . 2.09 112.627 -171.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -105.56 160.92 14.8 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.935 0.874 . . . . 6.42 110.408 158.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.4 tpt180 -66.0 141.24 58.25 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.203 -0.908 . . . . 4.58 109.828 163.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -93.29 -167.18 38.39 Favored Glycine 0 C--O 1.227 -0.308 0 C-N-CA 125.324 1.44 . . . . 2.45 112.787 177.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 52.8 t -82.61 132.93 30.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 124.524 1.13 . . . . 3.75 109.035 -176.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.8 m -56.37 145.61 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 C-N-CA 124.47 1.108 . . . . 3.3 112.926 -178.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.402 ' H ' ' HB ' ' B' ' 23' ' ' VAL . . . -90.96 145.13 17.64 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 109.951 -1.26 . . . . 1.75 109.951 165.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 85.3 mt -91.18 156.43 43.86 Favored Pre-proline 0 N--CA 1.472 0.662 0 CA-C-O 117.161 -1.4 . . . . 4.86 110.444 171.202 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -80.24 -158.04 0.09 OUTLIER 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 123.645 2.897 . . . . 4.01 109.23 166.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.24 0 CA-C-O 117.549 -1.695 . . . . 5.43 113.458 154.643 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo . . . . . 0 N--CA 1.491 1.364 0 N-CA-C 109.165 -1.129 . . . . 4.5 109.165 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.04 140.92 30.72 Favored Glycine 0 CA--C 1.539 1.55 0 CA-C-O 118.044 -1.42 . . . . 2.46 110.003 158.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -68.62 -175.01 0.79 Allowed 'Trans proline' 0 CA--C 1.538 0.695 0 C-N-CA 123.787 2.991 . . . . 2.43 109.878 162.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 4.7 tp-100 -50.47 148.79 3.5 Favored 'General case' 0 CA--C 1.541 0.599 0 N-CA-C 114.734 1.383 . . . . 5.83 114.734 -174.476 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.15 165.83 48.62 Favored Glycine 0 C--N 1.339 0.736 0 CA-C-O 123.285 1.492 . . . . 1.97 112.854 169.145 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 8.2 mm -71.67 160.84 5.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 123.279 1.514 . . . . 4.81 110.722 178.336 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -46.35 147.67 1.09 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.854 1.261 . . . . 3.12 112.975 153.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -82.55 169.16 48.79 Favored Glycine 0 C--N 1.336 0.574 0 CA-C-O 122.626 1.125 . . . . 2.97 112.681 178.726 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -118.41 123.59 45.61 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 123.487 0.715 . . . . 4.73 111.014 -166.247 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 14.9 ptt180 -55.16 134.21 49.42 Favored 'General case' 0 N--CA 1.47 0.546 0 O-C-N 122.056 -0.403 . . . . 6.08 110.703 179.112 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.18 -45.4 93.76 Favored Glycine 0 N--CA 1.477 1.407 0 N-CA-C 114.825 0.69 . . . . 4.28 114.825 -150.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . 0.402 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 55.3 t -158.99 164.37 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.877 1 C-N-CA 132.117 4.167 . . . . 4.6 105.613 179.699 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 23.0 m -134.34 156.25 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 C-N-CA 125.989 1.716 . . . . 4.47 109.051 168.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -79.62 -175.28 47.54 Favored Glycine 0 C--N 1.335 0.515 0 CA-C-O 122.189 0.883 . . . . 2.9 114.263 179.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -159.08 158.11 28.5 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 126.982 2.113 . . . . 6.72 109.921 175.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.256 1.381 0 C-N-CA 125.293 3.996 . . . . 5.34 111.831 164.375 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo . . . . . 0 N--CA 1.486 1.04 0 CA-C-O 118.616 -0.66 . . . . 3.92 111.097 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -68.73 -163.78 0.1 OUTLIER 'Trans proline' 0 CA--C 1.544 0.987 0 C-N-CA 123.469 2.779 . . . . 3.34 109.466 157.182 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.91 154.09 52.72 Favored Glycine 0 CA--C 1.541 1.706 0 O-C-N 121.751 -0.593 . . . . 1.64 113.8 172.102 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -79.83 87.15 1.56 Allowed 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 124.504 3.469 . . . . 2.97 111.664 -173.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 30.4 tp60 67.8 -124.12 0.19 Allowed 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.615 1.166 . . . . 2.82 108.777 -176.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.63 -179.4 41.07 Favored Glycine 0 CA--C 1.534 1.256 1 C-N-CA 131.956 4.598 . . . . 2.81 107.523 -171.58 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -74.69 156.44 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 O-C-N 120.726 -1.455 . . . . 3.06 110.223 176.232 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.26 159.03 30.99 Favored 'General case' 0 CA--C 1.543 0.675 0 O-C-N 120.215 -1.553 . . . . 1.98 112.165 173.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -97.93 160.75 20.9 Favored Glycine 0 CA--C 1.53 0.988 0 C-N-CA 124.502 1.049 . . . . 1.9 112.124 177.576 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 22.9 mp0 -101.87 -179.79 4.11 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 124.376 1.071 . . . . 3.45 111.862 -170.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 6.2 tpt85 -66.8 138.62 57.49 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.908 0.883 . . . . 4.33 110.103 162.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.83 172.07 30.78 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 124.175 0.893 . . . . 1.9 112.009 172.214 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 1.9 t -57.15 144.64 9.07 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 124.914 1.285 . . . . 2.43 110.872 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 7.5 p -75.9 -169.32 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.189 0 C-N-CA 124.557 1.143 . . . . 4.97 109.129 164.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.5 168.29 0.83 Allowed Glycine 0 CA--C 1.541 1.656 0 CA-C-N 119.858 1.208 . . . . 1.99 113.913 161.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 10.2 mp . . . . . 0 C--O 1.249 1.03 0 C-N-CA 125.72 1.608 . . . . 5.4 112.723 -171.784 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo . . . . . 0 N--CA 1.458 -0.596 0 CA-C-O 121.035 0.348 . . . . 2.23 111.312 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -60.92 167.07 3.04 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 126.473 1.909 . . . . 3.12 113.627 173.654 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -78.48 166.52 52.43 Favored Glycine 0 CA--C 1.518 0.247 0 CA-C-N 114.986 -1.007 . . . . 1.39 113.587 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 21.2 mt -51.93 124.76 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 C-N-CA 125.698 1.599 . . . . 2.91 109.557 178.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -42.9 132.45 3.91 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.715 1.206 . . . . 1.97 112.597 178.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.43 149.78 51.67 Favored Glycine 0 CA--C 1.517 0.195 0 C-N-CA 125.129 1.347 . . . . 1.33 111.673 -178.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 7.3 mp0 -62.68 114.53 3.64 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 114.962 -0.619 . . . . 4.66 109.636 -173.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 48.6 ttt85 -54.56 139.75 37.08 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.686 1.195 . . . . 5.51 112.435 -173.673 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.41 142.62 32.91 Favored Glycine 0 CA--C 1.525 0.698 0 C-N-CA 124.242 0.925 . . . . 1.73 112.71 -175.525 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -60.37 153.42 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 C-N-CA 126.4 1.88 . . . . 2.81 113.231 178.035 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 m -66.99 150.61 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 124.85 1.26 . . . . 2.81 112.924 -175.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.58 153.34 51.51 Favored Glycine 0 CA--C 1.531 1.037 0 CA-C-N 115.899 -0.591 . . . . 1.48 112.436 170.44 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 10.1 mp -83.62 160.25 59.29 Favored Pre-proline 0 CA--C 1.544 0.723 0 C-N-CA 123.882 0.873 . . . . 4.25 111.166 176.608 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -81.9 -158.71 0.1 OUTLIER 'Trans proline' 0 CA--C 1.537 0.649 0 C-N-CA 123.997 3.131 . . . . 2.01 109.127 158.228 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.169 0 CA-C-O 117.336 -1.813 . . . . 3.09 112.843 155.802 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo . . . . . 0 CA--C 1.545 1.056 0 CA-C-O 119.289 -0.38 . . . . 2.29 111.143 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.08 -178.49 10.44 Favored Glycine 0 CA--C 1.544 1.882 0 CA-C-O 119.035 -0.869 . . . . 1.59 112.625 125.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -77.83 -134.99 0.02 OUTLIER 'Trans proline' 0 CA--C 1.546 1.1 1 C-N-CA 125.642 4.228 . . . . 2.18 109.071 160.535 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.37 176.44 9.68 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 124.986 1.314 . . . . 4.75 110.99 166.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.14 157.85 39.49 Favored Glycine 0 N--CA 1.472 1.047 0 O-C-N 121.357 -0.839 . . . . 0.93 112.698 154.318 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 28.3 mm -77.88 131.49 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 108.596 -0.89 . . . . 4.09 108.596 173.647 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -77.4 157.67 30.46 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 114.078 1.14 . . . . 1.88 114.078 -173.063 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.01 121.31 8.39 Favored Glycine 0 CA--C 1.529 0.957 0 C-N-CA 124.298 0.951 . . . . 1.68 111.687 -179.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.96 155.54 40.7 Favored 'General case' 0 CA--C 1.54 0.58 0 O-C-N 121.496 -1.003 . . . . 3.2 111.759 174.344 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.7 ptt-85 -66.14 161.47 21.83 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 122.297 1.046 . . . . 5.22 113.045 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.75 -179.18 49.12 Favored Glycine 0 CA--C 1.529 0.91 0 C-N-CA 125.59 1.567 . . . . 1.89 111.865 172.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 7.0 m -100.89 139.79 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 N-CA-C 114.253 1.205 . . . . 4.06 114.253 -160.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 26.5 m -64.49 160.27 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 C-N-CA 126.292 1.837 . . . . 2.98 113.502 -174.386 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -88.92 -135.82 5.53 Favored Glycine 0 CA--C 1.529 0.914 0 C-N-CA 124.147 0.879 . . . . 1.78 111.84 171.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -167.29 163.65 9.94 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 125.576 1.55 . . . . 3.76 110.745 -167.031 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo . . . . . 0 C--O 1.257 1.445 0 C-N-CA 124.264 3.309 . . . . 2.61 112.163 167.177 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo . . . . . 0 N--CA 1.487 1.102 0 CA-C-O 119.059 -0.476 . . . . 2.39 111.837 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.28 -137.78 0.02 OUTLIER 'Trans proline' 0 CA--C 1.54 0.825 0 C-N-CA 123.298 2.665 . . . . 1.83 108.226 163.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -79.0 151.7 35.65 Favored Glycine 0 CA--C 1.542 1.753 0 CA-C-N 119.557 1.071 . . . . 1.2 112.758 173.431 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -85.19 64.08 6.08 Favored 'Trans proline' 0 CA--C 1.541 0.849 0 C-N-CA 124.556 3.504 . . . . 3.17 111.34 -176.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 71.89 151.52 0.11 Allowed 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 125.343 1.457 . . . . 2.55 112.716 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.03 153.74 22.05 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 124.769 1.176 . . . . 1.25 111.416 166.152 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 66.0 mt -71.62 144.77 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.8 0 O-C-N 121.805 -0.821 . . . . 2.89 111.193 -177.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.17 149.02 48.68 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.97 1.308 . . . . 1.39 113.205 175.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -88.7 140.95 16.23 Favored Glycine 0 CA--C 1.532 1.138 0 C-N-CA 125.106 1.336 . . . . 1.27 114.686 -175.124 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -71.51 157.15 38.52 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 126.641 1.976 . . . . 4.39 112.059 168.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 46.3 ttp180 -62.07 158.12 17.35 Favored 'General case' 0 CA--C 1.54 0.581 0 N-CA-C 114.331 1.234 . . . . 4.91 114.331 176.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -66.14 168.96 32.66 Favored Glycine 0 CA--C 1.537 1.434 0 CA-C-O 122.112 0.84 . . . . 1.13 113.237 158.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.2 t -68.03 160.85 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 125.86 1.664 . . . . 2.42 111.097 179.111 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 28.6 m -83.17 -175.19 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 125.896 1.678 . . . . 2.86 111.774 175.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.37 173.5 5.38 Favored Glycine 0 CA--C 1.537 1.409 0 C-N-CA 125.164 1.364 . . . . 1.61 114.55 169.073 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 5.7 mt . . . . . 0 C--O 1.25 1.113 0 N-CA-C 114.136 1.162 . . . . 4.15 114.136 -159.072 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo . . . . . 0 CA--C 1.541 0.848 0 N-CA-C 109.571 -0.973 . . . . 2.23 109.571 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -87.07 -168.68 2.33 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 127.414 2.286 . . . . 3.02 111.909 168.142 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.91 177.98 45.0 Favored Glycine 0 N--CA 1.474 1.209 0 C-N-CA 125.978 1.752 . . . . 1.63 112.957 161.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.483 ' H ' HD13 ' A' ' 17' ' ' ILE . 2.8 mp -61.98 141.44 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 O-C-N 121.813 -0.816 . . . . 3.82 110.372 -174.544 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.88 133.88 56.52 Favored 'General case' 0 CA--C 1.537 0.469 0 CA-C-N 119.039 0.836 . . . . 1.74 110.946 170.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.57 146.53 41.08 Favored Glycine 0 CA--C 1.523 0.581 0 C-N-CA 126.569 2.033 . . . . 1.43 114.603 -178.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 73.1 mm-40 -77.56 134.89 38.16 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 114.604 -0.798 . . . . 4.32 110.816 -166.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 31.6 mtt180 -59.21 137.46 57.96 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 121.642 0.734 . . . . 5.09 112.529 -171.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -78.35 -179.41 50.77 Favored Glycine 0 CA--C 1.523 0.581 0 CA-C-O 123.271 1.484 . . . . 1.87 115.363 -168.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -71.6 156.56 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 CA-C-N 113.489 -1.356 . . . . 3.09 111.826 -169.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 p -56.4 143.06 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 125.263 1.425 . . . . 6.49 111.967 168.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.433 ' H ' ' HB ' ' B' ' 23' ' ' VAL . . . -93.62 -162.78 36.25 Favored Glycine 0 N--CA 1.472 1.059 0 C-N-CA 124.426 1.013 . . . . 2.42 113.873 170.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 93.0 mt -142.43 153.47 62.46 Favored Pre-proline 0 N--CA 1.471 0.59 0 C-N-CA 126.044 1.738 . . . . 4.24 109.823 172.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -79.21 -155.6 0.06 OUTLIER 'Trans proline' 0 CA--C 1.539 0.752 0 C-N-CA 123.138 2.559 . . . . 2.58 108.909 159.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.291 0 CA-C-O 118.002 -1.443 . . . . 3.84 113.51 158.225 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo . . . . . 0 CA--C 1.544 0.994 0 CA-C-O 118.791 -0.587 . . . . 2.72 111.773 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.0 159.66 49.28 Favored Glycine 0 CA--C 1.548 2.147 0 C-N-CA 118.977 -1.582 . . . . 1.23 110.886 127.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . 0.422 ' HG2' ' H ' ' B' ' 15' ' ' GLN . 59.3 Cg_endo -75.84 -66.84 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.617 1 C-N-CA 125.349 4.033 . . . . 3.04 111.809 177.061 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.422 ' H ' ' HG2' ' B' ' 14' ' ' PRO . 0.0 OUTLIER -155.16 161.64 41.18 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 128.892 2.877 . . . . 5.39 107.182 -176.812 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.42 160.44 31.72 Favored Glycine 0 N--CA 1.464 0.555 0 C-N-CA 123.629 0.633 . . . . 1.04 112.922 174.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.3 pp -78.23 149.37 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 O-C-N 122.313 -0.522 . . . . 5.1 111.215 176.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.8 153.12 38.89 Favored 'General case' 0 CA--C 1.543 0.698 0 N-CA-C 113.528 0.936 . . . . 1.35 113.528 -174.777 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.81 147.7 26.7 Favored Glycine 0 CA--C 1.528 0.866 0 C-N-CA 125.947 1.737 . . . . 1.59 114.572 -172.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 37.4 tt0 -77.95 148.08 34.65 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 126.386 1.874 . . . . 4.86 111.599 172.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 31.6 mtt180 -64.86 164.37 12.57 Favored 'General case' 0 N--CA 1.473 0.702 0 O-C-N 121.306 -0.871 . . . . 4.99 112.299 174.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.3 -144.1 3.47 Favored Glycine 0 CA--C 1.534 1.222 0 CA-C-N 114.959 -1.018 . . . . 2.6 110.96 161.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . 0.433 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 49.8 t -53.26 137.52 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 C-N-CA 124.3 1.04 . . . . 6.39 112.687 -176.44 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 26.4 m -103.12 162.41 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 125.651 1.58 . . . . 4.08 111.23 172.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.14 171.7 24.75 Favored Glycine 0 C--N 1.338 0.656 0 C-N-CA 125.412 1.482 . . . . 2.83 113.507 -176.18 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -169.38 157.59 6.92 Favored Pre-proline 0 CA--C 1.545 0.754 0 C-N-CA 126.105 1.762 . . . . 4.43 111.521 -168.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo . . . . . 0 C--O 1.256 1.39 0 C-N-CA 124.611 3.541 . . . . 3.62 111.803 159.363 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo . . . . . 0 CA--C 1.548 1.178 0 CA-C-O 118.951 -0.521 . . . . 2.71 111.667 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -56.18 -174.4 0.04 OUTLIER 'Trans proline' 0 CA--C 1.539 0.756 0 C-N-CA 124.994 3.796 . . . . 2.39 112.863 164.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.71 178.13 54.1 Favored Glycine 0 CA--C 1.541 1.682 0 C-N-CA 123.628 0.633 . . . . 1.02 112.145 165.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -67.91 155.96 67.75 Favored 'Trans proline' 0 N--CA 1.457 -0.62 0 C-N-CA 122.904 2.403 . . . . 2.59 111.001 171.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 22.0 tp60 -40.55 121.36 1.42 Allowed 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 127.384 2.274 . . . . 1.53 112.946 169.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.4 157.08 44.72 Favored Glycine 0 CA--C 1.527 0.814 0 C-N-CA 124.29 0.948 . . . . 1.05 112.091 170.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 2.2 mp -65.22 140.55 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 123.548 0.739 . . . . 3.23 110.486 -169.129 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.51 156.57 15.98 Favored 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 123.065 1.412 . . . . 1.12 114.748 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.83 145.85 39.04 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 108.994 -1.643 . . . . 1.19 108.994 174.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 7.2 mp0 -82.99 -179.46 7.45 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.884 0.85 . . . . 4.02 110.441 -170.077 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 1.9 tmt_? -57.63 138.39 55.39 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-O 121.618 0.723 . . . . 3.96 110.095 169.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.46 148.25 51.09 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 124.367 0.985 . . . . 2.25 112.04 178.299 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 91.2 t -64.86 148.43 11.96 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.603 0 C-N-CA 124.246 1.018 . . . . 2.67 110.447 -173.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 12.3 p -97.24 171.79 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.995 0 C-N-CA 127.982 2.513 . . . . 3.9 111.059 -178.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.5 -168.66 0.61 Allowed Glycine 0 CA--C 1.54 1.614 0 C-N-CA 125.203 1.382 . . . . 2.08 116.083 171.102 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 15.5 mt . . . . . 0 C--O 1.249 1.047 0 C-N-CA 125.736 1.614 . . . . 4.14 115.12 -170.544 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo . . . . . 0 N--CA 1.458 -0.575 0 N-CA-C 111.39 -0.273 . . . . 2.63 111.39 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 31.2 tp60 -46.07 163.73 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 129.228 3.011 . . . . 5.34 115.53 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.56 172.47 42.82 Favored Glycine 0 CA--C 1.524 0.638 0 C-N-CA 124.388 0.994 . . . . 1.21 114.616 168.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.481 ' H ' HD13 ' A' ' 17' ' ' ILE . 3.0 mp -60.41 140.53 18.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 C-N-CA 124.975 1.31 . . . . 4.08 109.858 -179.369 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.41 130.01 37.82 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 123.318 0.647 . . . . 2.58 111.291 170.512 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.59 161.49 54.22 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 126.122 1.82 . . . . 1.62 113.58 176.447 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 11.0 mm100 -74.33 115.35 13.74 Favored 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 109.675 -0.491 . . . . 4.43 109.675 -168.248 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -58.46 139.26 55.86 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.564 0.746 . . . . 4.54 112.219 -175.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.38 147.3 35.65 Favored Glycine 0 CA--C 1.522 0.527 0 C-N-CA 125.848 1.689 . . . . 1.59 113.542 -173.093 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.0 p -66.6 144.82 14.32 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 125.465 1.506 . . . . 4.88 110.573 176.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -50.69 157.61 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 126.09 1.756 . . . . 2.63 114.716 -175.257 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.5 175.4 53.49 Favored Glycine 0 N--CA 1.474 1.207 0 N-CA-C 110.787 -0.925 . . . . 1.69 110.787 158.311 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 17.6 mt -149.84 157.04 38.46 Favored Pre-proline 0 N--CA 1.471 0.621 0 N-CA-C 115.884 1.809 . . . . 4.01 115.884 -152.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -68.2 104.66 1.09 Allowed 'Trans proline' 0 N--CA 1.449 -1.09 0 N-CA-C 106.529 -2.143 . . . . 2.62 106.529 154.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.231 0 CA-C-O 118.923 -0.932 . . . . 6.39 114.218 -160.405 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo . . . . . 0 CA--C 1.544 0.987 0 N-CA-C 110.993 -0.426 . . . . 3.11 110.993 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.63 -170.4 0.41 Allowed Glycine 0 CA--C 1.538 1.488 0 C-N-CA 120.457 -0.878 . . . . 1.86 113.875 125.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -74.38 -123.39 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 0.998 0 C-N-CA 124.069 3.179 . . . . 2.17 107.545 157.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -100.29 178.7 4.68 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.309 1.443 . . . . 7.4 112.218 175.137 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.46 145.72 25.46 Favored Glycine 0 N--CA 1.472 1.047 0 O-C-N 121.202 -0.936 . . . . 1.22 112.684 164.215 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 96.7 mt -63.38 132.77 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 O-C-N 121.079 -1.248 . . . . 4.22 108.659 170.375 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -77.55 157.05 30.53 Favored 'General case' 0 CA--C 1.542 0.65 0 N-CA-C 114.151 1.167 . . . . 2.13 114.151 -169.382 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.54 140.27 40.64 Favored Glycine 0 CA--C 1.524 0.634 0 C-N-CA 126.229 1.871 . . . . 2.06 110.5 169.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 10.4 mp0 -95.95 147.86 23.24 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 123.308 0.643 . . . . 4.59 110.84 -165.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 3.8 ttt180 -64.12 154.76 33.61 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 124.525 1.13 . . . . 5.97 113.722 -176.229 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.68 155.86 52.35 Favored Glycine 0 CA--C 1.531 1.05 0 C-N-CA 124.042 0.83 . . . . 1.99 115.115 176.053 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 27.7 m -75.58 136.8 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 114.677 1.362 . . . . 4.08 114.677 -174.023 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.6 m -56.43 156.5 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.002 0 N-CA-C 116.729 2.122 . . . . 3.34 116.729 -162.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.56 -177.06 42.93 Favored Glycine 0 C--N 1.34 0.753 0 C-N-CA 125.864 1.697 . . . . 2.75 115.8 -167.087 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.6 mp -147.72 158.37 42.92 Favored Pre-proline 0 CA--C 1.546 0.813 0 C-N-CA 125.453 1.501 . . . . 5.93 113.031 -165.428 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo . . . . . 0 C--O 1.255 1.343 0 C-N-CA 123.843 3.029 . . . . 3.42 112.635 148.585 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo . . . . . 0 CA--C 1.547 1.151 0 CA-C-O 118.323 -0.782 . . . . 2.52 111.855 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_exo -49.58 -179.35 0.02 OUTLIER 'Trans proline' 0 C--N 1.35 0.655 1 C-N-CA 126.571 4.847 . . . . 2.67 114.402 166.549 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.26 148.55 51.41 Favored Glycine 0 CA--C 1.547 2.035 0 CA-C-O 119.368 -0.685 . . . . 1.46 112.059 162.327 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -81.55 61.95 8.17 Favored 'Trans proline' 0 CA--C 1.542 0.899 0 C-N-CA 125.036 3.824 . . . . 3.6 113.058 -169.056 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 74.7 147.32 0.09 Allowed 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.402 1.881 . . . . 2.48 112.774 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -85.85 146.08 21.17 Favored Glycine 0 CA--C 1.527 0.842 0 O-C-N 121.299 -0.875 . . . . 1.43 112.145 170.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 97.5 mt -63.46 148.77 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 124.607 1.163 . . . . 2.97 110.883 175.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.97 150.43 39.02 Favored 'General case' 0 CA--C 1.548 0.887 0 N-CA-C 114.383 1.253 . . . . 1.19 114.383 177.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -80.63 152.79 34.1 Favored Glycine 0 C--N 1.338 0.679 0 C-N-CA 125.44 1.495 . . . . 1.06 111.176 177.211 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 10.5 mp0 -101.18 161.0 13.92 Favored 'General case' 0 C--N 1.326 -0.419 0 O-C-N 121.726 -0.867 . . . . 3.42 110.095 -172.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -53.34 134.85 39.71 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 123.483 0.713 . . . . 4.74 109.804 172.62 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.25 177.19 29.4 Favored Glycine 0 CA--C 1.522 0.483 0 CA-C-N 115.713 -0.676 . . . . 1.06 112.105 -175.281 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 45.2 t -58.58 131.74 23.0 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 CA-C-O 121.464 0.65 . . . . 2.16 110.564 -177.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 8.7 p -70.23 158.68 5.99 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.394 0 C-N-CA 129.374 3.069 . . . . 4.51 112.774 177.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.72 167.1 1.09 Allowed Glycine 0 CA--C 1.538 1.53 0 N-CA-C 115.288 0.875 . . . . 1.81 115.288 159.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 2.8 mm? . . . . . 0 C--O 1.25 1.094 0 C-N-CA 125.595 1.558 . . . . 4.72 113.683 -164.968 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo . . . . . 0 CA--C 1.54 0.821 0 N-CA-C 109.927 -0.836 . . . . 2.21 109.927 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -87.74 -173.14 4.18 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.074 1.75 . . . . 3.21 112.187 169.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -93.37 -171.61 39.69 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 125.884 1.707 . . . . 1.32 113.881 163.603 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.2 mt -62.24 139.88 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.103 0 O-C-N 121.784 -0.833 . . . . 2.71 110.481 -173.477 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -57.32 133.35 55.04 Favored 'General case' 0 CA--C 1.536 0.426 0 CA-C-N 118.692 0.678 . . . . 1.82 110.509 168.712 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.46 147.14 18.88 Favored Glycine 0 CA--C 1.52 0.405 0 C-N-CA 127.546 2.498 . . . . 1.23 113.665 177.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 87.3 mm-40 -71.57 125.72 27.8 Favored 'General case' 0 CA--C 1.535 0.403 0 N-CA-C 108.159 -1.052 . . . . 3.8 108.159 -177.182 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.9 ttt180 -57.97 137.07 57.11 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 123.639 0.776 . . . . 5.85 111.54 -169.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -65.8 163.33 40.72 Favored Glycine 0 C--N 1.338 0.679 0 C-N-CA 124.985 1.279 . . . . 1.54 115.577 -169.623 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 45.3 t -66.88 132.17 32.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 C-N-CA 126.617 1.967 . . . . 3.79 109.5 -175.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 1.7 t -56.26 145.78 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 124.974 1.31 . . . . 3.58 112.224 -173.526 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.11 175.33 42.46 Favored Glycine 0 CA--C 1.535 1.286 0 N-CA-C 112.019 -0.432 . . . . 1.46 112.019 163.408 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 6.4 mp -129.68 156.71 78.36 Favored Pre-proline 0 CA--C 1.538 0.505 0 C-N-CA 124.636 1.174 . . . . 3.61 109.447 178.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -77.74 -165.03 0.3 Allowed 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.951 2.434 . . . . 2.0 109.44 161.264 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.259 0 CA-C-O 117.67 -1.628 . . . . 3.38 112.588 153.863 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo . . . . . 0 CA--C 1.54 0.81 0 CA-C-O 118.047 -0.897 . . . . 3.01 110.573 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.77 162.87 25.32 Favored Glycine 0 CA--C 1.551 2.299 0 C-N-CA 118.882 -1.628 . . . . 1.57 111.144 126.414 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -79.0 -51.8 0.06 OUTLIER 'Trans proline' 0 CA--C 1.536 0.599 0 C-N-CA 124.746 3.631 . . . . 3.21 112.302 178.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 177.93 160.58 0.53 Allowed 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 129.731 3.213 . . . . 5.05 105.443 -165.381 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.07 -173.78 46.48 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 116.873 1.509 . . . . 1.31 116.873 -168.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 4.0 mp -71.78 121.31 21.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 108.473 -0.936 . . . . 4.49 108.473 168.284 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -68.5 137.63 54.55 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-O 121.542 0.686 . . . . 1.62 111.419 176.611 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.09 147.2 40.81 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 124.698 1.142 . . . . 1.64 112.826 -170.717 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . 0.426 ' H ' ' NE2' ' B' ' 20' ' ' GLN . 0.0 OUTLIER -82.08 147.79 28.92 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 123.764 0.826 . . . . 4.4 111.327 169.541 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 6.0 ptt180 -52.27 157.17 1.47 Allowed 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 114.63 1.344 . . . . 6.1 114.63 168.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.03 179.1 53.16 Favored Glycine 0 CA--C 1.532 1.111 0 C-N-CA 124.331 0.967 . . . . 1.88 114.035 177.131 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 24.2 t -91.93 122.33 43.28 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 N-CA-C 113.648 0.981 . . . . 3.59 113.648 -152.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.1 m -58.89 154.28 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 127.06 2.144 . . . . 3.12 114.272 -173.096 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.63 -146.71 16.91 Favored Glycine 0 CA--C 1.53 0.996 0 C-N-CA 124.196 0.903 . . . . 1.71 112.026 163.069 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -171.12 161.06 5.42 Favored Pre-proline 0 CA--C 1.546 0.823 0 C-N-CA 126.097 1.759 . . . . 4.12 111.568 -164.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo . . . . . 0 CA--C 1.552 1.386 0 C-N-CA 125.292 3.995 . . . . 2.83 112.595 153.901 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 CA--C 1.547 1.125 0 CA-C-O 118.765 -0.598 . . . . 3.67 111.467 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -55.94 -179.4 0.08 OUTLIER 'Trans proline' 0 CA--C 1.537 0.652 0 C-N-CA 124.477 3.452 . . . . 2.96 112.583 164.071 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.84 179.54 47.27 Favored Glycine 0 CA--C 1.54 1.615 0 C-N-CA 124.662 1.125 . . . . 1.52 114.028 176.227 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_endo -70.61 156.69 60.62 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 123.383 2.722 . . . . 2.39 111.116 172.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 22.2 tp60 -32.22 120.34 0.29 Allowed 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 127.648 2.379 . . . . 1.63 113.546 167.055 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.62 158.35 53.63 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.345 -0.702 . . . . 1.05 111.345 166.376 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 68.1 mt -61.84 143.55 15.0 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 C-N-CA 123.203 0.601 . . . . 3.05 111.528 -169.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -67.7 158.44 32.28 Favored 'General case' 0 CA--C 1.545 0.754 0 CA-C-O 122.722 1.248 . . . . 1.12 114.234 177.177 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.28 163.18 54.44 Favored Glycine 0 CA--C 1.527 0.782 0 C-N-CA 124.625 1.107 . . . . 1.2 112.909 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 9.8 mp0 -96.38 -178.83 4.42 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 124.264 1.026 . . . . 4.06 111.491 -171.193 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.49 142.91 46.78 Favored 'General case' 0 N--CA 1.473 0.686 0 O-C-N 121.06 -1.025 . . . . 4.26 110.868 172.438 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.41 173.26 55.21 Favored Glycine 0 N--CA 1.47 0.919 0 C-N-CA 124.895 1.236 . . . . 1.04 112.817 177.121 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 38.1 t -71.3 138.45 21.71 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 C-N-CA 123.803 0.841 . . . . 2.34 110.164 179.206 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -91.81 173.45 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 C-N-CA 127.277 2.231 . . . . 3.61 109.763 -179.301 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -50.99 149.13 7.34 Favored Glycine 0 CA--C 1.533 1.182 0 CA-C-N 119.076 0.853 . . . . 1.79 113.13 170.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 8.6 tt . . . . . 0 C--O 1.25 1.097 0 C-N-CA 127.322 2.249 . . . . 5.27 113.766 -167.205 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo . . . . . 0 CA--C 1.534 0.515 0 N-CA-C 110.965 -0.436 . . . . 2.9 110.965 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.58 -155.44 0.15 Allowed 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.933 1.693 . . . . 2.81 111.034 165.586 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -85.67 173.0 47.09 Favored Glycine 0 N--CA 1.47 0.943 0 N-CA-C 115.701 1.041 . . . . 1.47 115.701 -173.29 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.449 ' H ' HD13 ' A' ' 17' ' ' ILE . 2.8 mp -66.16 137.49 24.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 108.468 -0.938 . . . . 3.79 108.468 177.517 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.73 131.26 50.35 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 121.569 0.699 . . . . 1.71 110.632 170.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.78 153.17 30.07 Favored Glycine 0 CA--C 1.519 0.301 0 C-N-CA 126.651 2.072 . . . . 1.62 113.004 174.135 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 5.4 mp0 -74.37 143.66 44.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 114.78 -0.71 . . . . 4.76 110.738 -164.173 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 16.8 tpp85 -52.22 135.55 31.97 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 123.553 0.741 . . . . 5.32 110.992 173.101 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.84 167.54 54.44 Favored Glycine 0 CA--C 1.522 0.485 0 CA-C-O 122.587 1.104 . . . . 1.51 113.819 -173.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 15.4 t -66.06 129.2 30.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 C-N-CA 125.78 1.632 . . . . 3.36 109.392 -178.497 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 31.4 m -58.69 146.98 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 N-CA-C 114.355 1.243 . . . . 2.51 114.355 -172.268 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.11 159.48 53.52 Favored Glycine 0 CA--C 1.536 1.358 0 CA-C-O 121.903 0.724 . . . . 1.37 112.051 161.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 11.0 mp -120.05 136.82 25.25 Favored Pre-proline 0 CA--C 1.532 0.262 0 C-N-CA 126.314 1.846 . . . . 3.74 109.815 -177.152 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -74.42 -172.05 1.08 Allowed 'Trans proline' 0 N--CA 1.456 -0.679 0 C-N-CA 122.729 2.286 . . . . 2.68 109.861 169.666 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.245 0 CA-C-O 117.659 -1.634 . . . . 4.58 113.095 151.359 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo . . . . . 0 N--CA 1.491 1.347 0 N-CA-C 109.248 -1.097 . . . . 2.88 109.248 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.64 147.38 49.65 Favored Glycine 0 CA--C 1.541 1.678 0 CA-C-O 118.898 -0.946 . . . . 1.35 111.308 162.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -77.42 176.94 9.46 Favored 'Trans proline' 0 CA--C 1.538 0.707 0 C-N-CA 124.116 3.211 . . . . 2.28 110.315 164.041 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.1 tp-100 -38.91 143.61 0.15 Allowed 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 127.743 2.417 . . . . 4.91 115.594 176.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.14 163.36 53.11 Favored Glycine 0 CA--C 1.529 0.949 0 C-N-CA 124.031 0.824 . . . . 1.02 113.028 175.298 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . 0.407 ' H ' HD13 ' B' ' 17' ' ' ILE . 2.9 mp -65.28 134.7 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 O-C-N 121.733 -0.863 . . . . 3.61 109.328 175.118 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.68 148.76 51.47 Favored 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 119.093 0.86 . . . . 1.56 112.196 176.427 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -68.41 153.2 52.85 Favored Glycine 0 CA--C 1.527 0.826 0 C-N-CA 124.57 1.081 . . . . 1.75 111.746 174.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.59 155.26 25.77 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.999 0.92 . . . . 3.45 111.332 -176.64 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 41.0 mtt-85 -53.53 148.1 9.92 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 125.204 1.402 . . . . 6.85 113.905 -169.076 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.78 166.43 54.3 Favored Glycine 0 CA--C 1.535 1.299 0 CA-C-N 116.133 -0.485 . . . . 1.92 113.813 175.445 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 27.6 t -72.59 121.77 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 N-CA-C 113.56 0.948 . . . . 3.49 113.56 -161.114 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -65.95 161.37 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 125.481 1.512 . . . . 3.16 114.758 -165.615 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -85.0 -155.91 24.91 Favored Glycine 0 CA--C 1.528 0.903 0 C-N-CA 125.776 1.655 . . . . 1.7 113.461 175.294 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.1 pp -161.9 145.86 9.55 Favored Pre-proline 0 CA--C 1.541 0.63 0 C-N-CA 124.628 1.171 . . . . 3.49 111.499 -177.113 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo . . . . . 0 C--O 1.255 1.367 1 C-N-CA 126.087 4.524 . . . . 3.28 112.765 158.012 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo . . . . . 0 CA--C 1.543 0.93 0 CA-C-O 118.607 -0.664 . . . . 2.42 111.959 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -70.98 -150.23 0.03 OUTLIER 'Trans proline' 0 CA--C 1.541 0.869 0 C-N-CA 123.95 3.1 . . . . 1.93 108.523 164.515 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.66 169.49 40.98 Favored Glycine 0 CA--C 1.531 1.072 0 O-C-N 121.575 -0.703 . . . . 1.05 113.29 172.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -72.49 160.88 45.68 Favored 'Trans proline' 0 N--CA 1.454 -0.794 0 C-N-CA 123.081 2.521 . . . . 2.46 110.674 171.137 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 34.0 tp60 -52.77 120.13 5.38 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 126.249 1.82 . . . . 1.75 112.798 170.642 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -60.06 150.28 40.29 Favored Glycine 0 CA--C 1.53 1.028 0 C-N-CA 123.876 0.751 . . . . 1.05 111.639 168.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 78.0 mt -67.14 145.86 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.409 1.084 . . . . 3.65 110.676 -176.037 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.13 154.89 29.65 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 114.824 1.416 . . . . 1.25 114.824 178.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -76.75 148.24 34.84 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 124.739 1.162 . . . . 1.04 112.596 176.151 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -83.33 171.11 13.87 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.475 1.11 . . . . 5.28 112.294 -177.159 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.29 138.49 58.24 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 121.398 -0.814 . . . . 4.2 111.97 178.672 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.84 159.0 51.26 Favored Glycine 0 CA--C 1.528 0.857 0 C-N-CA 125.657 1.598 . . . . 0.99 112.933 177.183 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 23.7 t -68.76 136.43 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 124.054 0.941 . . . . 2.04 109.095 171.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 31.0 m -87.9 -165.54 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.843 0 C-N-CA 125.053 1.341 . . . . 3.34 111.623 -179.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.51 -138.79 0.15 Allowed Glycine 0 CA--C 1.54 1.628 0 C-N-CA 125.109 1.338 . . . . 1.69 113.562 164.365 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.251 1.162 0 C-N-CA 126.413 1.885 . . . . 7.78 114.682 -177.017 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo . . . . . 0 N--CA 1.459 -0.534 0 N-CA-C 111.229 -0.335 . . . . 2.1 111.229 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.99 162.68 8.85 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 126.253 1.821 . . . . 3.58 113.695 172.744 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.71 -179.54 47.92 Favored Glycine 0 CA--C 1.525 0.693 0 C-N-CA 124.639 1.114 . . . . 1.29 112.547 171.42 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.3 mt -61.28 138.01 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 C-N-CA 123.488 0.715 . . . . 2.73 109.506 -172.402 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.93 135.62 56.67 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-O 120.961 0.41 . . . . 2.04 110.727 170.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.26 151.79 49.84 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 126.286 1.898 . . . . 1.52 112.876 179.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 57.7 mm-40 -69.86 155.71 40.15 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 114.744 -0.728 . . . . 4.57 111.336 -174.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -68.0 145.8 54.16 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 121.028 0.442 . . . . 6.32 111.961 -177.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.45 141.48 28.81 Favored Glycine 0 C--N 1.333 0.413 0 CA-C-N 115.52 -0.764 . . . . 1.59 112.1 -178.156 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 27.2 m -61.4 141.42 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 CA-C-O 121.173 0.511 . . . . 3.18 111.248 -179.615 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.1 m -48.89 150.9 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 125.585 1.554 . . . . 2.92 113.878 -172.14 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.83 -153.8 26.16 Favored Glycine 0 N--CA 1.471 1.0 0 C-N-CA 123.165 0.412 . . . . 1.94 112.556 165.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 85.7 mt -149.48 155.47 39.13 Favored Pre-proline 0 N--CA 1.472 0.631 0 C-N-CA 125.677 1.591 . . . . 4.09 109.532 178.186 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -80.04 -162.1 0.17 Allowed 'Trans proline' 0 CA--C 1.539 0.747 0 C-N-CA 122.641 2.227 . . . . 2.71 109.392 158.08 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.239 0 CA-C-O 117.071 -1.961 . . . . 4.47 112.069 142.241 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_exo . . . . . 0 CA--C 1.544 1.015 0 N-CA-C 111.154 -0.364 . . . . 3.44 111.154 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -63.66 -177.49 4.49 Favored Glycine 0 CA--C 1.542 1.728 0 C-N-CA 120.187 -1.006 . . . . 2.52 112.446 126.217 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -74.64 -135.7 0.01 OUTLIER 'Trans proline' 0 CA--C 1.546 1.113 0 C-N-CA 124.571 3.514 . . . . 2.76 108.19 155.623 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 -87.33 -176.88 5.8 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 124.903 1.281 . . . . 4.91 111.454 171.812 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -84.75 158.97 34.13 Favored Glycine 0 CA--C 1.528 0.899 0 O-C-N 121.86 -0.525 . . . . 1.05 111.955 161.183 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 53.5 mt -72.77 133.26 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 123.389 0.676 . . . . 4.6 109.291 179.116 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.52 145.41 52.68 Favored 'General case' 0 CA--C 1.547 0.834 0 CA-C-N 119.39 0.995 . . . . 1.53 113.387 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.72 140.5 29.18 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 125.328 1.442 . . . . 1.52 111.694 173.591 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -95.37 153.09 17.85 Favored 'General case' 0 CA--C 1.532 0.257 0 O-C-N 121.729 -0.865 . . . . 3.5 111.604 -175.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 5.7 ttt85 -62.94 149.57 44.33 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.086 1.355 . . . . 7.49 112.221 -172.195 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.73 -174.86 26.61 Favored Glycine 0 CA--C 1.532 1.14 0 N-CA-C 114.463 0.545 . . . . 1.95 114.463 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 75.8 t -44.66 142.17 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 C-N-CA 128.016 2.526 . . . . 5.24 114.057 -172.501 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -93.1 156.95 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 124.13 0.972 . . . . 3.73 113.613 178.059 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.18 -162.62 29.57 Favored Glycine 0 C--N 1.341 0.828 0 C-N-CA 125.535 1.541 . . . . 2.38 114.23 -178.251 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.8 pp -153.76 141.83 13.98 Favored Pre-proline 0 CA--C 1.542 0.656 0 C-N-CA 124.287 1.035 . . . . 4.41 110.904 174.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo . . . . . 0 C--O 1.254 1.292 1 C-N-CA 126.282 4.654 . . . . 4.75 113.147 160.135 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo . . . . . 0 CA--C 1.547 1.152 0 CA-C-O 119.178 -0.426 . . . . 3.69 111.917 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -72.5 -135.59 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.075 0 C-N-CA 123.502 2.802 . . . . 2.3 108.351 162.447 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -81.04 175.42 54.78 Favored Glycine 0 CA--C 1.543 1.786 0 CA-C-N 119.303 0.956 . . . . 1.54 111.552 163.355 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -80.14 170.64 16.13 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 123.676 2.917 . . . . 2.42 110.46 161.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 28.7 tp60 -43.31 117.58 1.14 Allowed 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 125.33 1.452 . . . . 1.63 112.133 161.005 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.5 145.98 49.96 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.331 -1.108 . . . . 1.07 110.331 166.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 36.2 mm -66.51 145.33 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 O-C-N 122.367 -0.49 . . . . 5.18 110.567 -174.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -68.52 166.56 16.72 Favored 'General case' 0 CA--C 1.543 0.687 0 N-CA-C 114.394 1.257 . . . . 1.91 114.394 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.58 155.17 43.0 Favored Glycine 0 CA--C 1.527 0.81 0 C-N-CA 125.007 1.289 . . . . 1.05 112.6 -179.384 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -95.92 167.73 11.06 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.1 0.96 . . . . 4.89 111.164 -176.671 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.69 134.5 51.37 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.243 0.617 . . . . 4.94 111.038 178.501 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -63.72 178.49 7.12 Favored Glycine 0 N--CA 1.469 0.868 0 C-N-CA 126.41 1.957 . . . . 1.24 114.667 -175.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 93.1 t -74.83 138.09 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 108.969 -0.752 . . . . 2.54 108.969 -179.023 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 13.9 m -99.93 174.35 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 C-N-CA 126.305 1.842 . . . . 3.19 110.335 -178.386 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.92 -178.16 9.6 Favored Glycine 0 CA--C 1.534 1.227 0 C-N-CA 123.615 0.626 . . . . 1.81 113.673 167.308 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.479 0.987 0 N-CA-C 114.649 1.351 . . . . 6.67 114.649 173.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo . . . . . 0 CA--C 1.538 0.716 0 N-CA-C 110.249 -0.712 . . . . 2.6 110.249 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . 0.253 0.0 OUTLIER -89.99 -156.65 0.43 Allowed 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 125.984 1.714 . . . . 3.18 111.699 173.435 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.03 178.47 45.03 Favored Glycine 0 N--CA 1.475 1.257 0 C-N-CA 124.95 1.262 . . . . 1.39 114.535 178.354 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.9 mt -76.06 130.41 36.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 O-C-N 121.261 -1.14 . . . . 3.17 108.579 -176.724 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.66 127.65 30.93 Favored 'General case' 0 CA--C 1.539 0.554 0 CA-C-N 119.318 0.963 . . . . 2.02 111.571 178.73 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.86 164.29 35.68 Favored Glycine 0 CA--C 1.528 0.869 0 C-N-CA 126.097 1.808 . . . . 1.33 112.803 -176.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -71.95 112.3 7.92 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 121.894 -0.768 . . . . 5.99 110.574 -169.431 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 67.4 ttt-85 -60.9 127.04 29.63 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 123.425 0.69 . . . . 4.58 109.402 177.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -78.57 171.99 55.19 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 125.002 1.287 . . . . 1.55 115.318 -166.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -64.38 147.52 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 CA-C-N 113.78 -1.21 . . . . 3.42 110.538 -173.875 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.0 m -54.14 150.58 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 123.146 0.578 . . . . 3.06 111.491 167.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.2 148.98 46.71 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 110.538 -1.025 . . . . 1.98 110.538 159.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 7.4 mp -101.35 167.04 11.27 Favored Pre-proline 0 C--N 1.328 -0.337 0 C-N-CA 124.027 0.931 . . . . 4.31 110.748 174.512 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.416 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 44.3 Cg_endo -69.94 -155.38 0.04 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 121.789 1.659 . . . . 2.07 108.55 155.113 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.259 0 CA-C-O 117.019 -1.989 . . . . 3.31 112.683 152.373 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_exo . . . . . 0 N--CA 1.481 0.765 0 CA-C-O 117.618 -1.076 . . . . 2.61 110.268 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -63.97 153.08 48.15 Favored Glycine 0 CA--C 1.548 2.131 0 C-N-CA 119.758 -1.211 . . . . 1.32 111.06 144.055 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -78.88 -47.96 0.09 OUTLIER 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 124.461 3.44 . . . . 2.88 114.628 -179.417 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.8 tp-100 -170.8 146.76 2.64 Favored 'General case' 0 N--CA 1.463 0.204 0 C-N-CA 124.285 1.034 . . . . 4.51 110.722 -161.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -86.51 149.8 22.94 Favored Glycine 0 CA--C 1.527 0.792 0 CA-C-O 121.822 0.679 . . . . 1.05 113.149 -178.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 65.7 mt -69.31 122.45 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 108.481 -0.933 . . . . 3.9 108.481 175.592 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.92 136.65 58.06 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 113.126 0.788 . . . . 1.28 113.126 -174.008 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -67.81 129.38 27.21 Favored Glycine 0 CA--C 1.523 0.533 0 C-N-CA 125.287 1.422 . . . . 1.65 110.183 169.429 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 8.8 tp-100 -96.89 150.34 20.86 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 123.685 0.794 . . . . 7.25 110.195 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.96 157.17 10.33 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 112.912 0.708 . . . . 5.38 112.912 171.461 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.46 -174.65 49.43 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 124.417 1.008 . . . . 2.05 112.455 170.701 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 13.4 m -93.31 141.9 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 115.133 1.531 . . . . 4.53 115.133 -156.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 12.9 m -69.5 154.17 8.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 125.796 1.638 . . . . 3.07 113.274 -166.816 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.72 -136.66 9.45 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 123.931 0.777 . . . . 1.77 113.117 170.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.416 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.6 pt? -172.18 158.57 4.18 Favored Pre-proline 0 CA--C 1.546 0.804 0 C-N-CA 126.085 1.754 . . . . 3.56 110.788 -157.41 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo . . . . . 0 C--O 1.256 1.424 0 C-N-CA 122.294 1.996 . . . . 2.79 111.013 160.851 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo . . . . . 0 CA--C 1.544 1.015 0 CA-C-O 118.783 -0.59 . . . . 3.05 111.939 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -55.39 -176.1 0.04 OUTLIER 'Trans proline' 0 CA--C 1.536 0.625 0 C-N-CA 124.707 3.605 . . . . 2.46 112.582 162.14 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -89.64 -172.85 45.55 Favored Glycine 0 CA--C 1.537 1.425 0 C-N-CA 124.882 1.23 . . . . 1.31 113.202 171.047 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -72.96 159.13 48.68 Favored 'Trans proline' 0 N--CA 1.456 -0.703 0 C-N-CA 123.211 2.607 . . . . 2.57 111.858 178.443 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -45.7 130.02 9.1 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.461 1.904 . . . . 1.75 112.947 161.916 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -79.15 174.77 55.26 Favored Glycine 0 CA--C 1.53 0.981 0 C-N-CA 125.471 1.51 . . . . 1.17 114.06 174.521 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 97.0 mt -63.98 145.87 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 124.958 1.303 . . . . 3.63 111.76 -174.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -85.44 157.24 20.52 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 125.609 1.563 . . . . 1.55 114.115 177.189 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -98.02 138.06 13.66 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 124.945 1.26 . . . . 1.43 112.605 178.269 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -70.73 -179.07 2.04 Favored 'General case' 0 CA--C 1.543 0.709 0 CA-C-O 122.479 1.133 . . . . 5.2 111.797 170.199 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 17.8 ttt85 -55.41 149.34 13.43 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 124.588 1.155 . . . . 4.85 110.917 161.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.45 171.54 46.58 Favored Glycine 0 CA--C 1.533 1.17 0 N-CA-C 111.423 -0.671 . . . . 1.11 111.423 161.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 6.3 t -66.53 144.02 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 C-N-CA 124.13 0.972 . . . . 2.17 110.972 -179.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 12.4 m -85.77 175.0 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 C-N-CA 127.342 2.257 . . . . 3.39 112.497 179.384 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.26 173.71 10.53 Favored Glycine 0 CA--C 1.537 1.419 0 C-N-CA 124.619 1.104 . . . . 2.15 114.809 162.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 21.7 mt . . . . . 0 N--CA 1.484 1.242 0 N-CA-C 115.474 1.657 . . . . 3.98 115.474 -155.556 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo . . . . . 0 N--CA 1.459 -0.553 0 CA-C-O 120.897 0.29 . . . . 2.77 111.477 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.1 161.96 23.36 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 127.269 2.228 . . . . 3.04 113.257 175.29 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.26 -152.02 21.94 Favored Glycine 0 N--CA 1.472 1.053 0 C-N-CA 125.454 1.502 . . . . 1.55 115.457 -170.515 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -66.92 132.18 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 O-C-N 121.09 -1.241 . . . . 3.03 109.796 -176.384 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -72.39 64.49 0.59 Allowed 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 125.797 1.639 . . . . 3.43 112.435 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.35 -175.35 32.99 Favored Glycine 0 CA--C 1.527 0.784 0 C-N-CA 125.722 1.629 . . . . 2.06 112.402 -174.064 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 80.4 mm-40 -106.92 154.94 20.33 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.222 -0.658 . . . . 4.2 109.222 145.371 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 24.0 ttt180 -70.89 107.54 4.08 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 108.673 -0.862 . . . . 5.85 108.673 169.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -76.81 -81.81 0.57 Allowed Glycine 0 N--CA 1.472 1.083 0 C-N-CA 124.696 1.141 . . . . 4.36 112.91 -159.662 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 2.6 m -150.59 152.16 11.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 C-N-CA 123.963 0.905 . . . . 3.1 108.647 -178.311 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 20.5 m -62.23 162.68 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 125.998 1.719 . . . . 2.88 113.633 -179.158 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.09 -160.47 3.75 Favored Glycine 0 CA--C 1.537 1.407 0 N-CA-C 111.431 -0.667 . . . . 2.36 111.431 155.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 94.2 mt -140.82 161.66 52.88 Favored Pre-proline 0 N--CA 1.474 0.738 0 CA-C-N 118.055 0.928 . . . . 4.12 111.017 178.02 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -86.52 -158.75 0.09 OUTLIER 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 123.968 3.112 . . . . 2.21 109.152 156.023 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.212 0 CA-C-O 117.239 -1.867 . . . . 3.0 112.546 148.642 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo . . . . . 0 CA--C 1.545 1.042 0 CA-C-O 119.454 -0.311 . . . . 2.74 111.39 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.18 -178.58 8.79 Favored Glycine 0 CA--C 1.541 1.711 0 O-C-N 121.108 -0.995 . . . . 1.34 112.382 128.253 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -74.73 -135.64 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.038 0 C-N-CA 124.789 3.659 . . . . 2.42 108.313 158.514 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 -86.71 -173.17 4.36 Favored 'General case' 0 CA--C 1.541 0.632 0 O-C-N 121.056 -1.027 . . . . 5.61 111.586 172.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.59 158.04 29.37 Favored Glycine 0 CA--C 1.534 1.266 0 O-C-N 121.514 -0.741 . . . . 1.11 112.097 159.689 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 88.2 mt -78.68 154.16 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.076 0 C-N-CA 124.344 1.058 . . . . 4.03 109.799 173.674 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.42 150.39 43.71 Favored 'General case' 0 CA--C 1.547 0.854 0 O-C-N 120.932 -1.105 . . . . 1.59 113.801 177.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -87.46 170.78 41.04 Favored Glycine 0 CA--C 1.526 0.771 0 C-N-CA 125.748 1.642 . . . . 1.93 114.286 -176.517 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -72.41 128.41 35.54 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.646 1.178 . . . . 5.06 111.927 -175.1 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -62.07 153.3 30.23 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 122.586 0.354 . . . . 6.49 111.667 179.266 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.39 158.61 26.69 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 124.209 0.909 . . . . 2.14 115.189 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 13.2 m -84.96 134.68 26.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 N-CA-C 113.645 0.98 . . . . 4.34 113.645 -178.524 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.6 m -88.85 162.02 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 126.151 1.781 . . . . 3.0 113.215 -164.206 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.92 -131.1 7.1 Favored Glycine 0 CA--C 1.529 0.945 0 C-N-CA 124.925 1.25 . . . . 1.83 113.468 177.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.0 pp -172.38 153.83 3.02 Favored Pre-proline 0 CA--C 1.543 0.675 0 C-N-CA 124.302 1.041 . . . . 4.19 112.043 -152.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo . . . . . 0 C--O 1.255 1.359 1 C-N-CA 125.429 4.086 . . . . 2.44 112.548 153.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo . . . . . 0 N--CA 1.488 1.181 0 CA-C-O 118.947 -0.522 . . . . 2.83 112.009 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -72.01 -133.98 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 123.761 2.974 . . . . 2.26 108.107 162.536 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.85 166.16 54.72 Favored Glycine 0 CA--C 1.539 1.578 0 CA-C-N 119.905 1.23 . . . . 1.23 111.107 163.29 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -81.87 -37.64 0.25 Allowed 'Trans proline' 0 CA--C 1.536 0.589 0 C-N-CA 122.919 2.412 . . . . 3.5 113.072 -179.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 31.8 tp60 170.04 134.14 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 127.672 2.389 . . . . 1.94 107.117 -157.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -97.49 178.11 32.48 Favored Glycine 0 CA--C 1.528 0.872 0 C-N-CA 125.119 1.342 . . . . 1.12 113.027 167.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 3.4 mp -63.72 134.75 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 124.152 0.981 . . . . 3.82 111.486 -177.146 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.45 146.46 48.62 Favored 'General case' 0 CA--C 1.541 0.622 0 O-C-N 121.31 -0.869 . . . . 1.37 113.05 -178.582 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.28 87.42 0.5 Allowed Glycine 0 CA--C 1.527 0.788 0 C-N-CA 127.04 2.257 . . . . 2.59 112.748 -173.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -59.21 164.16 3.33 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 124.66 1.184 . . . . 5.52 113.444 -171.189 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 10.5 ttp-105 -46.19 127.75 8.98 Favored 'General case' 0 C--O 1.239 0.525 0 C-N-CA 124.771 1.229 . . . . 6.92 112.809 176.571 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.31 -174.24 8.49 Favored Glycine 0 CA--C 1.524 0.627 0 CA-C-N 113.134 -1.848 . . . . 1.49 113.306 175.647 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.9 t -63.65 143.63 15.44 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 C-N-CA 124.011 0.924 . . . . 2.11 110.237 175.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -89.78 -168.39 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.801 0 C-N-CA 125.787 1.635 . . . . 3.23 110.302 179.063 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.57 -168.49 2.3 Favored Glycine 0 CA--C 1.539 1.567 0 C-N-CA 124.133 0.873 . . . . 1.87 114.385 169.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 14.8 mt . . . . . 0 N--CA 1.483 1.189 0 C-N-CA 124.269 1.028 . . . . 3.95 113.703 176.956 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo . . . . . 0 N--CA 1.453 -0.91 0 N-CA-C 104.867 -2.782 . . . . 3.14 104.867 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 26.7 mm100 -70.76 172.18 9.22 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 125.708 1.603 . . . . 5.73 114.12 -164.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -61.46 145.53 48.68 Favored Glycine 0 C--N 1.335 0.483 0 N-CA-C 110.442 -1.063 . . . . 1.72 110.442 160.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.7 mt -54.47 125.1 8.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 107.068 -1.456 . . . . 2.91 107.068 175.264 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -50.11 150.54 2.34 Favored 'General case' 0 CA--C 1.536 0.435 0 CA-C-O 121.773 0.797 . . . . 2.25 111.897 -176.397 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.81 167.27 34.39 Favored Glycine 0 CA--C 1.527 0.795 0 C-N-CA 124.461 1.029 . . . . 1.55 114.064 -173.139 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 13.5 mp0 -71.49 166.12 22.42 Favored 'General case' 0 CA--C 1.542 0.635 0 O-C-N 122.187 -0.596 . . . . 6.03 111.972 -175.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.8 tpt180 -68.05 132.69 47.71 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 113.94 1.089 . . . . 5.3 113.94 -162.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.78 93.07 1.36 Allowed Glycine 0 C--N 1.336 0.564 0 N-CA-C 109.786 -1.326 . . . . 1.81 109.786 170.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 28.5 m -58.22 140.62 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 123.76 0.824 . . . . 3.47 112.011 -176.439 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.7 t -50.99 142.96 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 126.26 1.824 . . . . 4.56 112.301 -170.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.82 148.28 50.36 Favored Glycine 0 N--CA 1.477 1.373 0 O-C-N 121.507 -0.746 . . . . 1.64 112.304 173.04 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -85.19 156.78 59.95 Favored Pre-proline 0 CA--C 1.541 0.609 0 CA-C-O 118.872 -0.585 . . . . 4.27 110.736 176.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -85.38 -154.09 0.05 OUTLIER 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 123.517 2.811 . . . . 2.06 108.973 157.451 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.344 0 CA-C-O 117.631 -1.649 . . . . 3.09 113.437 148.89 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo . . . . . 0 N--CA 1.482 0.832 0 CA-C-O 119.379 -0.342 . . . . 4.24 112.799 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -79.78 136.83 17.8 Favored Glycine 0 CA--C 1.533 1.175 0 N-CA-C 110.216 -1.154 . . . . 1.36 110.216 157.017 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -76.6 177.23 9.09 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.988 2.459 . . . . 2.27 108.806 160.449 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -41.14 138.41 1.14 Allowed 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.318 1.447 . . . . 5.49 112.366 168.51 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -73.78 168.26 54.15 Favored Glycine 0 CA--C 1.526 0.756 0 C-N-CA 125.782 1.658 . . . . 1.05 115.248 -173.047 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 15.4 mm -61.79 140.14 19.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 CA-C-N 114.673 -0.764 . . . . 3.49 110.038 172.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.04 142.89 58.21 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 123.488 0.715 . . . . 1.98 111.531 173.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.38 -70.24 1.05 Allowed Glycine 0 N--CA 1.472 1.048 0 C-N-CA 123.934 0.778 . . . . 4.8 112.776 -168.399 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 178.48 -170.86 0.11 Allowed 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 128.376 2.67 . . . . 7.11 109.871 162.188 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 2.1 ttt-85 -117.96 152.0 36.34 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.452 1.101 . . . . 6.61 110.965 168.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.07 150.66 52.07 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 113.95 0.34 . . . . 1.97 113.95 -179.44 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 46.3 t -76.5 124.95 35.75 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.389 0 C-N-CA 123.409 0.684 . . . . 3.71 110.583 178.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.4 m -66.34 151.5 10.21 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 C-N-CA 125.451 1.501 . . . . 3.06 113.338 -167.563 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.73 -142.77 10.33 Favored Glycine 0 CA--C 1.527 0.805 0 C-N-CA 123.808 0.718 . . . . 1.76 112.659 169.274 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.2 pp -165.83 154.73 10.49 Favored Pre-proline 0 CA--C 1.54 0.584 0 C-N-CA 123.785 0.834 . . . . 3.91 112.249 -153.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo . . . . . 0 C--O 1.255 1.372 0 C-N-CA 125.3 4.0 . . . . 2.71 112.477 160.58 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo . . . . . 0 N--CA 1.484 0.916 0 CA-C-O 118.569 -0.68 . . . . 2.44 111.073 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -62.38 -151.05 0.02 OUTLIER 'Trans proline' 0 CA--C 1.544 0.984 1 C-N-CA 125.346 4.031 . . . . 2.49 111.998 159.201 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -104.97 167.26 15.01 Favored Glycine 0 CA--C 1.544 1.856 0 N-CA-C 116.954 1.541 . . . . 1.3 116.954 -170.116 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_endo -87.2 55.77 3.06 Favored 'Trans proline' 0 CA--C 1.543 0.942 1 C-N-CA 125.717 4.278 . . . . 3.76 113.145 -171.357 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 70.59 155.31 0.14 Allowed 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 125.467 1.507 . . . . 2.1 112.387 -176.389 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -101.93 176.72 26.15 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 126.68 2.086 . . . . 1.04 114.338 167.355 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 14.9 mt -72.82 126.92 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 O-C-N 121.126 -1.22 . . . . 4.4 112.177 -170.217 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -42.44 132.19 3.58 Favored 'General case' 0 CA--C 1.537 0.481 0 C-N-CA 125.399 1.48 . . . . 1.87 112.656 168.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.46 147.06 32.27 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 110.39 -1.084 . . . . 1.24 110.39 179.191 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -105.67 151.27 24.6 Favored 'General case' 0 C--N 1.327 -0.388 0 O-C-N 122.201 -0.587 . . . . 3.41 110.882 -173.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 12.1 ttp180 -54.71 134.55 47.44 Favored 'General case' 0 N--CA 1.447 -0.602 0 C-N-CA 123.347 0.659 . . . . 6.1 110.369 175.14 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.45 168.93 8.56 Favored Glycine 0 CA--C 1.528 0.846 0 C-N-CA 123.431 0.539 . . . . 1.18 113.094 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.3 t -61.2 143.42 14.9 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 O-C-N 122.039 -0.683 . . . . 1.95 110.162 174.356 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 3.3 p -85.32 176.03 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 C-N-CA 127.736 2.414 . . . . 3.46 110.426 -178.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.27 177.66 2.33 Favored Glycine 0 CA--C 1.54 1.651 0 CA-C-N 118.886 0.766 . . . . 1.82 113.405 161.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 17.9 mt . . . . . 0 C--O 1.253 1.246 0 N-CA-C 115.26 1.578 . . . . 4.02 115.26 -163.861 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo . . . . . 0 N--CA 1.455 -0.793 0 CA-C-O 121.433 0.514 . . . . 2.26 111.306 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -77.49 -177.12 4.56 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.848 1.659 . . . . 3.02 112.16 167.164 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.92 -177.82 40.19 Favored Glycine 0 CA--C 1.529 0.959 0 C-N-CA 123.89 0.757 . . . . 1.3 114.128 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 9.3 mt -67.82 133.59 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 O-C-N 121.911 -0.758 . . . . 2.47 109.795 -174.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.7 131.96 47.9 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 123.881 0.872 . . . . 1.82 110.874 172.281 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.27 152.85 51.13 Favored Glycine 0 CA--C 1.523 0.538 0 C-N-CA 126.405 1.955 . . . . 1.27 113.398 -173.831 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 82.2 mm-40 -74.77 134.65 41.8 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 115.139 -0.531 . . . . 4.36 110.589 -166.195 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 22.9 ttt180 -67.45 140.74 57.12 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-O 121.409 0.624 . . . . 6.2 112.355 -169.018 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -76.12 171.52 54.58 Favored Glycine 0 CA--C 1.522 0.525 0 C-N-CA 125.252 1.406 . . . . 1.47 115.068 -174.125 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 60.4 t -65.89 148.5 12.02 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 125.873 1.669 . . . . 3.94 109.456 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.8 m -51.84 154.7 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.757 0.823 . . . . 2.62 111.828 173.318 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -78.43 132.8 12.01 Favored Glycine 0 C--N 1.336 0.582 0 N-CA-C 107.777 -2.129 . . . . 2.17 107.777 158.146 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . 0.421 HD11 ' HE ' ' C' ' 21' ' ' ARG . 6.6 mp -87.95 -176.58 0.72 Allowed Pre-proline 0 C--N 1.323 -0.578 0 C-N-CA 122.746 0.418 . . . . 3.8 110.368 -174.487 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.515 ' C ' ' H ' ' C' ' 25' ' ' GLY . 85.3 Cg_endo -56.63 -166.66 0.02 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 120.244 0.629 . . . . 3.02 110.79 136.794 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.152 0 CA-C-O 118.019 -1.434 . . . . 5.61 115.543 167.085 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo . . . . . 0 N--CA 1.489 1.246 0 N-CA-C 108.972 -1.203 . . . . 2.92 108.972 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.3 148.76 44.54 Favored Glycine 0 CA--C 1.54 1.655 0 CA-C-O 118.697 -1.057 . . . . 1.39 111.01 164.429 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -76.97 169.08 22.3 Favored 'Trans proline' 0 CA--C 1.538 0.676 0 C-N-CA 124.189 3.26 . . . . 2.27 110.684 166.134 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -53.25 136.94 35.76 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 124.641 1.176 . . . . 4.83 111.273 172.432 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.01 161.38 37.11 Favored Glycine 0 CA--C 1.525 0.669 0 C-N-CA 124.501 1.048 . . . . 1.17 114.696 -170.362 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 32.3 pt -56.48 131.69 20.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 O-C-N 122.172 -0.605 . . . . 4.49 111.341 178.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.02 151.12 45.9 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-O 121.975 0.893 . . . . 1.6 113.198 -171.198 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -70.63 145.38 40.23 Favored Glycine 0 CA--C 1.526 0.759 0 C-N-CA 125.117 1.341 . . . . 1.84 110.712 173.27 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -123.06 159.28 28.79 Favored 'General case' 0 C--N 1.329 -0.295 0 O-C-N 121.634 -0.921 . . . . 3.34 110.81 178.068 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 3.2 ptt180 -54.96 159.75 2.24 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 115.585 1.698 . . . . 5.01 115.585 178.526 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.02 -119.18 0.08 OUTLIER Glycine 0 CA--C 1.535 1.307 0 C-N-CA 127.332 2.396 . . . . 2.94 114.187 -173.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 10.5 m -143.69 142.22 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 C-N-CA 124.701 1.201 . . . . 4.22 112.24 -176.328 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 22.6 m -83.1 161.18 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.151 0 C-N-CA 126.615 1.966 . . . . 2.93 115.679 -159.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.22 -126.11 4.85 Favored Glycine 0 CA--C 1.533 1.171 0 C-N-CA 126.22 1.867 . . . . 1.93 113.636 177.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.418 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.6 pt? -169.36 159.77 7.46 Favored Pre-proline 0 CA--C 1.554 1.12 0 N-CA-C 115.053 1.501 . . . . 3.98 115.053 -148.862 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo . . . . . 0 C--O 1.255 1.343 0 C-N-CA 123.558 2.839 . . . . 3.41 111.565 156.617 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_endo . . . . . 0 CA--C 1.546 1.124 0 CA-C-O 118.729 -0.613 . . . . 2.55 110.923 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -68.34 -155.16 0.03 OUTLIER 'Trans proline' 0 CA--C 1.546 1.093 0 C-N-CA 123.493 2.795 . . . . 2.05 109.618 157.018 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -100.61 -178.68 29.64 Favored Glycine 0 CA--C 1.534 1.251 0 C-N-CA 123.934 0.778 . . . . 1.5 112.775 172.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -75.35 164.83 32.0 Favored 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.446 2.764 . . . . 2.29 112.098 176.054 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -40.81 129.01 2.65 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.296 2.238 . . . . 1.77 113.451 163.226 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.98 152.77 52.71 Favored Glycine 0 CA--C 1.529 0.908 0 C-N-CA 124.641 1.115 . . . . 1.08 113.447 169.642 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 96.7 mt -56.73 148.5 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 124.4 1.08 . . . . 3.7 111.732 179.026 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -77.0 164.37 25.82 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 115.07 1.507 . . . . 1.72 115.07 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -84.7 168.92 44.22 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 124.968 1.27 . . . . 1.1 114.003 -174.401 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 8.9 mp0 -104.98 -179.22 3.88 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.177 1.391 . . . . 3.61 111.043 -166.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . 0.421 ' HE ' HD11 ' A' ' 26' ' ' LEU . 59.3 ttt180 -66.38 148.58 51.65 Favored 'General case' 0 N--CA 1.48 1.054 0 O-C-N 120.938 -1.102 . . . . 4.82 109.437 161.229 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -78.25 -173.58 42.03 Favored Glycine 0 CA--C 1.533 1.19 0 O-C-N 121.119 -0.988 . . . . 1.34 112.067 169.082 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 4.1 t -71.3 139.15 20.35 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 123.693 0.797 . . . . 2.19 109.123 176.551 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 16.0 m -71.47 173.6 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 C-N-CA 126.876 2.07 . . . . 3.5 112.65 176.425 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.515 ' H ' ' C ' ' A' ' 27' ' ' PRO . . . -53.26 172.42 0.52 Allowed Glycine 0 CA--C 1.538 1.509 0 C-N-CA 125.398 1.475 . . . . 1.74 115.895 158.323 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 7.1 mp . . . . . 0 C--O 1.252 1.212 0 C-N-CA 125.831 1.652 . . . . 4.86 114.761 -157.619 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo . . . . . 0 N--CA 1.459 -0.52 0 CA-C-O 120.924 0.302 . . . . 2.56 112.135 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.99 151.68 17.97 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 127.028 2.131 . . . . 4.18 111.567 167.441 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.11 -102.26 0.04 OUTLIER Glycine 0 N--CA 1.471 1.016 0 C-N-CA 125.112 1.339 . . . . 1.94 113.923 -179.355 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.9 mt -123.17 143.51 35.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 O-C-N 121.634 -0.921 . . . . 3.63 108.978 -177.231 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.57 53.05 0.21 Allowed 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 125.403 1.481 . . . . 3.7 111.97 170.056 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 86.11 -164.49 36.98 Favored Glycine 0 C--N 1.335 0.502 0 C-N-CA 127.813 2.625 . . . . 2.3 112.993 172.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 36.1 mm-40 -106.37 124.89 50.29 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 106.162 -1.792 . . . . 3.66 106.162 141.353 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 48.8 ttt85 -63.99 142.43 58.41 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.588 0.755 . . . . 5.66 110.84 -174.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.96 146.33 41.25 Favored Glycine 0 CA--C 1.523 0.59 0 C-N-CA 125.201 1.382 . . . . 1.56 112.272 -173.494 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 14.3 m -73.57 133.44 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 C-N-CA 124.83 1.252 . . . . 3.38 110.989 -174.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.4 p -50.77 147.75 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 C-N-CA 126.386 1.875 . . . . 4.72 114.973 -164.042 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -76.27 -179.95 47.34 Favored Glycine 0 CA--C 1.535 1.31 0 O-C-N 121.969 -0.457 . . . . 1.69 112.338 166.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.8 mt -143.97 158.01 56.55 Favored Pre-proline 0 N--CA 1.477 0.904 0 CA-C-O 118.175 -0.917 . . . . 4.37 112.399 -167.334 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -66.53 -173.45 0.37 Allowed 'Trans proline' 0 CA--C 1.537 0.653 0 C-N-CA 122.017 1.811 . . . . 2.61 110.188 158.119 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.271 0 CA-C-O 117.828 -1.54 . . . . 3.41 113.007 152.384 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo . . . . . 0 CA--C 1.541 0.861 0 CA-C-O 118.621 -0.658 . . . . 2.38 111.486 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -70.84 173.86 40.85 Favored Glycine 0 CA--C 1.54 1.606 0 CA-C-N 119.127 0.876 . . . . 1.38 111.885 143.226 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -71.17 163.03 40.57 Favored 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 123.707 2.938 . . . . 2.63 109.87 158.041 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.22 138.81 54.32 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 124.445 1.098 . . . . 4.69 111.901 179.707 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -57.63 142.79 42.94 Favored Glycine 0 C--N 1.342 0.887 0 C-N-CA 124.497 1.046 . . . . 1.21 114.195 -175.175 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 47.7 mm -73.61 142.72 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 123.893 0.877 . . . . 5.29 110.842 -177.214 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -52.17 139.11 24.37 Favored 'General case' 0 CA--C 1.544 0.717 0 N-CA-C 115.222 1.564 . . . . 1.75 115.222 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -66.32 141.87 41.74 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 126.096 1.807 . . . . 1.62 111.702 176.321 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 6.7 mp0 -79.74 151.85 30.16 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.194 0.598 . . . . 3.92 110.949 -173.388 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 12.7 mtt180 -60.76 150.12 33.51 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 118.857 0.753 . . . . 6.52 112.492 177.297 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.2 153.12 35.8 Favored Glycine 0 CA--C 1.531 1.065 0 CA-C-N 115.955 -0.566 . . . . 2.17 112.736 168.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 22.6 t -75.72 130.43 36.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 N-CA-C 112.613 0.598 . . . . 3.64 112.613 -164.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 m -60.03 157.62 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 N-CA-C 115.41 1.633 . . . . 3.41 115.41 -163.367 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.14 -178.07 45.95 Favored Glycine 0 C--N 1.338 0.652 0 C-N-CA 125.696 1.617 . . . . 2.26 115.548 -167.234 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.7 mp -134.97 130.9 19.68 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 123.78 0.832 . . . . 6.11 112.287 -170.444 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo . . . . . 0 C--O 1.256 1.383 0 C-N-CA 123.826 3.017 . . . . 2.8 112.017 146.947 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo . . . . . 0 N--CA 1.489 1.208 0 CA-C-O 118.73 -0.613 . . . . 2.79 111.511 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.93 -126.63 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.943 0 C-N-CA 124.246 3.298 . . . . 2.11 108.461 167.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -83.47 148.05 24.79 Favored Glycine 0 CA--C 1.538 1.515 0 CA-C-N 119.229 0.922 . . . . 1.4 112.522 172.498 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -74.18 96.76 0.97 Allowed 'Trans proline' 0 N--CA 1.456 -0.703 0 C-N-CA 123.285 2.656 . . . . 2.96 109.329 172.192 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.443 ' HG3' ' H ' ' C' ' 16' ' ' GLY . 16.5 tp60 59.1 -126.27 1.31 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.176 0.99 . . . . 2.98 109.239 179.819 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . 0.443 ' H ' ' HG3' ' C' ' 15' ' ' GLN . . . 174.25 161.78 24.79 Favored Glycine 0 CA--C 1.535 1.33 1 C-N-CA 132.048 4.642 . . . . 2.55 108.763 -179.769 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 3.7 mp -66.69 145.58 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 CA-C-N 119.34 1.57 . . . . 3.96 110.984 -177.576 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -78.56 145.93 34.54 Favored 'General case' 0 CA--C 1.545 0.765 0 O-C-N 120.915 -1.116 . . . . 1.68 113.024 178.311 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -88.84 161.08 30.45 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 125.305 1.431 . . . . 1.36 113.15 -179.603 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 58.7 mt-30 -87.2 160.28 18.54 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 123.95 0.9 . . . . 5.51 113.129 -174.539 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.24 138.42 45.09 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 109.511 -0.552 . . . . 4.35 109.511 163.413 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.9 165.73 52.68 Favored Glycine 0 CA--C 1.523 0.534 0 C-N-CA 123.728 0.68 . . . . 1.02 113.005 -177.096 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 91.2 t -63.67 138.33 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 C-N-CA 123.765 0.826 . . . . 2.23 108.899 173.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 25.6 m -101.89 -175.79 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.802 0 C-N-CA 125.139 1.376 . . . . 3.73 111.057 -177.831 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -58.96 173.75 3.57 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 124.582 1.087 . . . . 1.86 114.744 171.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 22.7 mt . . . . . 0 C--O 1.25 1.102 0 C-N-CA 125.261 1.425 . . . . 3.55 114.434 -168.297 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo . . . . . 0 N--CA 1.458 -0.6 0 CA-C-O 121.306 0.461 . . . . 2.27 111.535 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.43 169.28 16.7 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 127.35 2.26 . . . . 3.2 113.039 170.417 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.84 -174.98 40.8 Favored Glycine 0 CA--C 1.528 0.848 0 C-N-CA 125.21 1.386 . . . . 1.21 113.006 169.619 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 14.6 pt -74.18 155.3 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 O-C-N 121.754 -0.851 . . . . 3.81 111.096 -173.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -57.81 139.84 53.13 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.421 0.688 . . . . 1.84 111.597 172.727 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -57.56 150.65 30.27 Favored Glycine 0 CA--C 1.518 0.244 0 C-N-CA 127.259 2.361 . . . . 1.28 113.492 172.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 10.4 mm100 -64.93 118.26 8.8 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 114.716 -0.742 . . . . 4.54 109.194 -178.076 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.8 ttp180 -58.97 139.67 56.48 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 113.013 0.746 . . . . 5.05 113.013 -170.137 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.04 158.47 53.18 Favored Glycine 0 CA--C 1.519 0.331 0 C-N-CA 125.165 1.364 . . . . 1.54 113.38 -169.436 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 33.3 m -68.13 150.22 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-N 114.858 -0.671 . . . . 3.14 110.72 -175.318 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.5 m -51.05 147.8 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 124.192 0.997 . . . . 2.49 111.883 173.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.77 133.44 19.07 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 109.627 -1.389 . . . . 1.76 109.627 162.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 9.5 mp -77.18 169.92 18.84 Favored Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 122.882 0.473 . . . . 3.89 110.823 177.493 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.444 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 97.7 Cg_endo -77.17 -148.08 0.03 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 121.843 1.695 . . . . 2.24 108.277 154.338 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 1.41 0 CA-C-O 117.365 -1.797 . . . . 3.9 112.98 151.723 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo . . . . . 0 N--CA 1.484 0.938 0 CA-C-O 118.554 -0.686 . . . . 2.4 111.363 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.14 150.46 50.44 Favored Glycine 0 CA--C 1.546 1.994 0 CA-C-O 118.849 -0.973 . . . . 1.55 111.947 157.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -76.74 44.31 1.4 Allowed 'Trans proline' 0 CA--C 1.547 1.148 1 C-N-CA 126.986 5.124 . . . . 3.24 114.127 -172.662 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.1 tp-100 73.19 -175.44 0.16 Allowed 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 125.132 1.373 . . . . 5.86 109.606 -163.476 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -94.4 170.26 29.73 Favored Glycine 0 N--CA 1.473 1.126 0 O-C-N 121.091 -1.006 . . . . 1.17 113.12 166.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 50.1 mt -72.85 125.63 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 C-N-CA 123.564 0.746 . . . . 3.97 110.967 -176.438 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.82 143.75 57.72 Favored 'General case' 0 CA--C 1.545 0.762 0 O-C-N 121.203 -0.935 . . . . 1.62 113.253 -178.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.43 171.24 55.16 Favored Glycine 0 CA--C 1.529 0.919 0 C-N-CA 125.656 1.598 . . . . 1.74 113.578 -177.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -135.34 156.19 49.34 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 125.415 1.486 . . . . 3.48 110.224 -172.269 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.8 ptt-85 -71.99 152.5 42.43 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 114.747 1.388 . . . . 7.48 114.747 -172.48 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.23 176.99 54.53 Favored Glycine 0 CA--C 1.536 1.36 0 C-N-CA 125.317 1.437 . . . . 1.77 113.763 176.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 46.9 t -83.3 142.02 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 124.854 1.261 . . . . 3.61 112.98 -164.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 20.1 m -76.08 163.54 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 126.769 2.028 . . . . 2.91 114.323 -165.612 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -96.27 -127.03 5.3 Favored Glycine 0 CA--C 1.53 1.013 0 C-N-CA 125.107 1.337 . . . . 2.23 113.567 176.054 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.444 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 3.8 pp -171.82 159.04 4.6 Favored Pre-proline 0 CA--C 1.547 0.854 0 C-N-CA 125.769 1.627 . . . . 5.35 111.72 -156.529 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_endo . . . . . 0 C--O 1.256 1.383 0 C-N-CA 123.978 3.119 . . . . 3.23 111.767 153.807 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo . . . . . 0 N--CA 1.487 1.1 0 CA-C-O 119.181 -0.425 . . . . 2.22 111.627 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -71.54 -138.43 0.02 OUTLIER 'Trans proline' 0 CA--C 1.545 1.034 0 C-N-CA 123.317 2.678 . . . . 1.99 108.672 165.075 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -90.21 170.21 35.61 Favored Glycine 0 CA--C 1.538 1.52 0 N-CA-C 110.593 -1.003 . . . . 1.32 110.593 165.112 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.07 -58.63 0.04 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.4 2.067 . . . . 3.82 110.705 173.029 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 23.0 tp60 -174.88 133.51 0.34 Allowed 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 126.316 1.846 . . . . 1.48 106.292 -148.04 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.38 160.52 43.98 Favored Glycine 0 CA--C 1.523 0.575 0 C-N-CA 123.649 0.642 . . . . 1.16 111.658 170.216 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 37.1 mm -66.11 144.08 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 O-C-N 121.817 -0.813 . . . . 4.5 110.089 174.638 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.05 161.18 5.33 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 114.505 1.298 . . . . 1.31 114.505 177.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.44 170.46 52.22 Favored Glycine 0 CA--C 1.528 0.877 0 C-N-CA 124.562 1.077 . . . . 1.21 113.298 179.22 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 8.7 mp0 -95.64 177.88 5.65 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 124.339 1.056 . . . . 4.47 112.064 -168.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 14.6 ttt85 -72.87 141.25 47.93 Favored 'General case' 0 N--CA 1.473 0.692 0 O-C-N 120.369 -1.457 . . . . 4.5 110.329 167.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.95 173.69 34.53 Favored Glycine 0 CA--C 1.534 1.263 0 O-C-N 121.731 -0.606 . . . . 1.37 112.111 167.343 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.2 t -69.94 141.66 16.87 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.657 0 C-N-CA 124.409 1.084 . . . . 2.12 109.636 179.483 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 10.9 m -74.81 178.88 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 C-N-CA 124.432 1.093 . . . . 3.22 111.377 175.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.37 -171.68 0.94 Allowed Glycine 0 CA--C 1.538 1.489 0 C-N-CA 124.735 1.16 . . . . 1.68 114.193 162.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 15.5 mt . . . . . 0 N--CA 1.481 1.088 0 CA-C-O 117.199 -1.381 . . . . 4.07 113.719 -168.858 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo . . . . . 0 CA--C 1.535 0.543 0 CA-C-O 120.838 0.266 . . . . 3.1 111.982 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -78.91 176.96 9.13 Favored 'General case' 0 CA--C 1.553 1.092 0 C-N-CA 129.842 3.257 . . . . 3.7 111.563 -178.044 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -90.85 -172.93 43.97 Favored Glycine 0 N--CA 1.478 1.45 0 C-N-CA 125.189 1.376 . . . . 1.76 113.66 176.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.6 mm -76.45 134.96 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 N-CA-C 108.27 -1.011 . . . . 4.19 108.27 174.217 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.22 71.16 0.26 Allowed 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.074 1.35 . . . . 4.43 111.561 172.271 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 63.98 -146.52 50.4 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 125.021 1.296 . . . . 2.49 111.495 -169.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -142.9 128.7 19.37 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 106.269 -1.752 . . . . 6.67 106.269 150.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -53.02 126.92 22.17 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 118.769 0.713 . . . . 6.63 109.725 -177.362 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.46 -83.59 0.26 Allowed Glycine 0 N--CA 1.471 1.017 0 O-C-N 123.407 0.442 . . . . 3.18 112.088 -165.677 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -148.92 153.94 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 124.562 1.145 . . . . 2.7 112.161 175.813 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.5 m -65.87 161.52 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 C-N-CA 123.972 0.909 . . . . 3.42 111.233 168.196 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -76.24 174.07 53.62 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 123.585 0.612 . . . . 1.39 112.505 168.184 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -101.67 159.82 28.32 Favored Pre-proline 0 CA--C 1.542 0.663 0 C-N-CA 124.352 1.061 . . . . 4.15 110.854 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_endo -78.77 -166.67 0.42 Allowed 'Trans proline' 0 CA--C 1.537 0.675 0 C-N-CA 123.326 2.684 . . . . 2.5 109.324 157.663 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.274 0 CA-C-O 117.834 -1.537 . . . . 3.51 112.826 154.858 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_exo . . . . . 0 CA--C 1.542 0.921 0 N-CA-C 110.308 -0.689 . . . . 3.04 110.308 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.41 -167.91 2.73 Favored Glycine 0 CA--C 1.545 1.958 0 C-N-CA 119.659 -1.257 . . . . 2.16 112.033 124.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_endo -89.51 -138.97 0.02 OUTLIER 'Trans proline' 0 CA--C 1.546 1.077 0 C-N-CA 125.004 3.802 . . . . 2.86 109.287 175.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.82 138.57 32.44 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 127.288 2.235 . . . . 4.82 107.14 162.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -59.27 131.96 51.84 Favored Glycine 0 N--CA 1.468 0.807 0 N-CA-C 111.264 -0.734 . . . . 1.9 111.264 174.188 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 32.2 mm -60.56 150.37 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 O-C-N 122.334 -0.509 . . . . 6.62 110.982 175.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.57 137.5 58.25 Favored 'General case' 0 CA--C 1.55 0.952 0 O-C-N 120.7 -1.25 . . . . 3.01 114.315 176.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -93.13 -162.6 36.69 Favored Glycine 0 CA--C 1.533 1.196 0 C-N-CA 125.79 1.662 . . . . 3.16 112.211 171.123 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -157.73 174.31 15.51 Favored 'General case' 0 CA--C 1.537 0.442 0 O-C-N 121.064 -1.257 . . . . 4.75 113.944 -173.282 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 8.4 ptt180 -58.11 158.46 6.87 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 115.656 1.724 . . . . 5.15 115.656 172.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.17 -161.41 35.36 Favored Glycine 0 CA--C 1.535 1.29 0 C-N-CA 125.462 1.506 . . . . 2.38 111.499 162.283 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 43.8 t -120.3 145.21 26.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.041 0 C-N-CA 124.557 1.143 . . . . 5.41 112.528 -159.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 14.9 p -56.03 159.03 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 128.834 2.854 . . . . 4.59 114.359 -178.548 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.93 -126.7 1.08 Allowed Glycine 0 CA--C 1.53 1.023 0 C-N-CA 124.535 1.064 . . . . 2.57 111.204 166.218 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -167.26 162.76 10.37 Favored Pre-proline 0 CA--C 1.542 0.646 0 C-N-CA 125.343 1.457 . . . . 4.41 110.867 -166.74 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_endo . . . . . 0 CA--C 1.552 1.386 0 C-N-CA 124.47 3.447 . . . . 3.29 112.15 165.844 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 67.2 Cg_endo . . . . . 0 N--CA 1.487 1.122 0 CA-C-O 118.339 -0.775 . . . . 3.53 111.233 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -62.32 -152.38 0.02 OUTLIER 'Trans proline' 0 CA--C 1.542 0.924 0 C-N-CA 124.91 3.74 . . . . 3.14 111.696 163.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.39 168.66 54.4 Favored Glycine 0 CA--C 1.541 1.712 0 N-CA-C 109.985 -1.246 . . . . 1.56 109.985 163.39 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -76.64 176.65 9.83 Favored 'Trans proline' 0 N--CA 1.452 -0.941 0 C-N-CA 123.142 2.561 . . . . 2.66 110.681 170.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 9.5 tp60 -40.38 122.24 1.55 Allowed 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.279 1.432 . . . . 1.91 111.217 148.113 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.94 -169.37 27.54 Favored Glycine 0 CA--C 1.527 0.795 0 CA-C-O 121.993 0.774 . . . . 1.52 112.731 169.021 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 18.9 mt -63.82 124.33 18.33 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 O-C-N 121.638 -0.919 . . . . 3.6 110.833 175.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -65.52 155.85 34.4 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.582 1.153 . . . . 1.46 113.135 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -80.83 -179.24 52.87 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-O 123.23 1.461 . . . . 1.65 111.672 176.289 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.82 -160.48 1.03 Allowed 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.749 1.22 . . . . 3.25 109.149 178.309 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -85.19 152.46 23.33 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.892 1.277 . . . . 6.56 112.342 -179.181 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.26 176.85 43.88 Favored Glycine 0 CA--C 1.533 1.192 0 N-CA-C 111.03 -0.828 . . . . 1.18 111.03 164.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.0 t -59.84 149.39 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 124.042 0.937 . . . . 2.56 110.178 174.28 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 26.9 m -80.83 -173.34 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 C-N-CA 123.866 0.866 . . . . 3.28 111.079 173.227 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -55.98 160.12 7.27 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 124.154 0.883 . . . . 2.04 114.162 173.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 5.3 mt . . . . . 0 C--O 1.25 1.104 0 N-CA-C 114.246 1.202 . . . . 4.65 114.246 -163.079 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo . . . . . 0 N--CA 1.459 -0.533 0 N-CA-C 110.924 -0.452 . . . . 2.8 110.924 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 41.4 tp60 -48.65 151.76 1.09 Allowed 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 127.747 2.419 . . . . 5.71 114.866 -179.69 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.26 176.59 52.9 Favored Glycine 0 N--CA 1.465 0.618 0 C-N-CA 124.676 1.132 . . . . 1.27 115.199 173.957 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 14.4 mt -66.29 134.71 29.56 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 125.107 1.363 . . . . 2.85 110.568 -176.325 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.99 137.35 55.78 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 123.943 0.897 . . . . 1.99 112.267 175.313 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -66.72 157.76 50.33 Favored Glycine 0 CA--C 1.528 0.851 0 C-N-CA 125.485 1.517 . . . . 1.43 113.934 -176.507 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 53.1 mm-40 -62.5 128.98 38.56 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 114.738 -0.731 . . . . 4.32 109.668 -179.169 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 14.8 ttt180 -70.47 143.28 51.79 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 112.291 0.478 . . . . 5.37 112.291 -164.828 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -76.85 138.18 21.79 Favored Glycine 0 CA--C 1.522 0.528 0 C-N-CA 123.844 0.735 . . . . 1.93 111.414 -178.144 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 33.2 m -66.89 162.41 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 124.538 1.135 . . . . 3.01 112.493 -174.628 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.1 m -54.76 160.64 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 C-N-CA 124.527 1.131 . . . . 2.86 112.965 174.373 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.56 168.41 39.2 Favored Glycine 0 CA--C 1.527 0.817 0 CA-C-N 115.448 -0.796 . . . . 1.44 113.285 164.716 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 8.6 mp -99.46 156.63 35.19 Favored Pre-proline 0 CA--C 1.541 0.598 0 C-N-CA 124.004 0.922 . . . . 5.4 109.659 176.835 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -84.58 -164.32 0.24 Allowed 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 123.541 2.827 . . . . 2.91 109.163 162.449 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.239 0 CA-C-O 117.77 -1.572 . . . . 3.64 112.812 158.151 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_exo . . . . . 0 CA--C 1.544 0.998 0 CA-C-O 119.095 -0.46 . . . . 3.12 111.724 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.84 164.46 27.15 Favored Glycine 0 CA--C 1.542 1.752 0 CA-C-N 119.676 1.126 . . . . 1.44 113.153 138.975 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -80.69 63.58 8.79 Favored 'Trans proline' 0 CA--C 1.541 0.827 1 C-N-CA 126.176 4.584 . . . . 3.41 111.278 -179.58 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 22.8 tp60 67.85 173.04 0.27 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.188 1.395 . . . . 5.47 111.698 -172.625 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.15 160.33 29.48 Favored Glycine 0 CA--C 1.531 1.039 0 O-C-N 120.734 -1.229 . . . . 1.05 111.925 155.783 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 48.9 mm -74.65 129.94 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 O-C-N 121.708 -0.878 . . . . 4.04 109.955 176.195 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.73 149.23 50.83 Favored 'General case' 0 CA--C 1.544 0.734 0 N-CA-C 113.945 1.091 . . . . 1.68 113.945 -179.116 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.97 151.74 47.78 Favored Glycine 0 CA--C 1.531 1.073 0 C-N-CA 123.843 0.735 . . . . 1.47 111.557 177.299 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -109.17 156.85 19.38 Favored 'General case' 0 N--CA 1.465 0.307 0 O-C-N 121.644 -0.915 . . . . 3.17 111.649 175.287 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 6.5 ptt180 -64.32 158.31 23.82 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.426 1.89 . . . . 5.69 114.463 178.42 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -90.67 -167.69 41.78 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 126.275 1.893 . . . . 2.31 112.729 170.606 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 11.8 m -100.77 146.52 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 N-CA-C 115.849 1.796 . . . . 3.98 115.849 -162.329 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.6 p -46.35 153.67 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 128.888 2.875 . . . . 4.93 114.938 -178.664 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.33 -127.92 1.09 Allowed Glycine 0 CA--C 1.528 0.893 0 C-N-CA 123.714 0.673 . . . . 2.51 112.165 169.57 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.0 pp -162.67 151.57 12.56 Favored Pre-proline 0 CA--C 1.543 0.675 0 C-N-CA 124.141 0.976 . . . . 5.26 112.135 -164.64 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo . . . . . 0 C--O 1.255 1.367 1 C-N-CA 125.375 4.05 . . . . 3.17 112.397 162.306 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo . . . . . 0 CA--C 1.547 1.153 0 CA-C-O 119.107 -0.455 . . . . 2.15 112.046 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -62.58 -166.81 0.06 OUTLIER 'Trans proline' 0 CA--C 1.54 0.8 0 C-N-CA 124.096 3.197 . . . . 1.83 111.737 166.488 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.53 143.83 34.65 Favored Glycine 0 CA--C 1.54 1.629 0 O-C-N 121.124 -0.985 . . . . 1.1 113.108 -171.753 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -78.52 61.08 7.82 Favored 'Trans proline' 0 CA--C 1.54 0.82 0 C-N-CA 124.847 3.698 . . . . 3.19 112.196 -174.914 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 40.6 tp60 75.66 145.4 0.08 Allowed 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 126.543 1.937 . . . . 2.39 113.643 169.314 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.95 148.57 24.65 Favored Glycine 0 CA--C 1.528 0.848 0 O-C-N 120.875 -1.141 . . . . 1.15 112.838 169.397 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 38.3 mm -65.78 148.08 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 O-C-N 122.201 -0.588 . . . . 4.42 110.786 174.774 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.53 151.76 43.64 Favored 'General case' 0 CA--C 1.543 0.675 0 N-CA-C 113.093 0.775 . . . . 1.25 113.093 176.601 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.76 155.25 35.07 Favored Glycine 0 CA--C 1.529 0.957 0 CA-C-O 122.449 1.027 . . . . 1.0 112.342 174.878 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 18.2 mp0 -91.96 178.27 5.94 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 124.988 1.315 . . . . 3.17 110.556 -179.513 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 15.5 ptp180 -71.11 162.02 30.13 Favored 'General case' 0 N--CA 1.475 0.791 0 O-C-N 121.112 -0.992 . . . . 7.13 112.85 176.931 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.55 -171.82 42.26 Favored Glycine 0 CA--C 1.535 1.327 0 C-N-CA 124.023 0.821 . . . . 1.41 112.876 174.867 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 47.2 t -68.4 139.9 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 124.374 1.069 . . . . 2.32 110.699 -178.721 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 27.8 m -81.68 -176.1 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.705 1.202 . . . . 3.51 111.751 -176.957 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.56 161.82 15.85 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 123.91 0.767 . . . . 1.72 113.707 173.362 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 9.4 mt . . . . . 0 C--O 1.249 1.059 0 N-CA-C 114.717 1.377 . . . . 4.29 114.717 -164.717 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo . . . . . 0 CA--C 1.538 0.686 0 N-CA-C 110.38 -0.661 . . . . 4.19 110.38 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.55 -143.77 0.11 Allowed 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 125.288 1.435 . . . . 2.57 111.073 169.32 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -82.98 -127.91 1.22 Allowed Glycine 0 N--CA 1.472 1.062 0 C-N-CA 125.611 1.577 . . . . 1.23 112.753 170.761 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 10.2 mm -111.59 160.17 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.071 0 C-N-CA 124.504 1.122 . . . . 4.08 110.861 -176.466 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -78.78 81.61 5.07 Favored 'General case' 0 CA--C 1.546 0.807 0 O-C-N 120.47 -1.394 . . . . 3.72 110.237 164.438 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.59 -170.35 42.92 Favored Glycine 0 N--CA 1.466 0.644 0 C-N-CA 126.418 1.961 . . . . 3.45 113.397 -172.288 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -94.39 119.64 33.43 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 105.856 -1.905 . . . . 8.14 105.856 127.773 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 35.7 ttm180 -62.42 136.36 57.87 Favored 'General case' 0 CA--C 1.534 0.361 0 O-C-N 121.109 -0.994 . . . . 6.19 111.377 -178.986 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.32 170.43 53.53 Favored Glycine 0 N--CA 1.465 0.583 0 C-N-CA 125.021 1.296 . . . . 1.9 113.831 -178.082 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.1 m -87.55 156.93 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 CA-C-N 114.043 -1.078 . . . . 3.65 111.614 -175.823 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.1 m -57.16 147.71 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.442 1.097 . . . . 3.02 112.388 -178.807 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -74.44 169.44 54.13 Favored Glycine 0 CA--C 1.529 0.928 0 N-CA-C 110.362 -1.095 . . . . 1.89 110.362 157.773 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 24.0 mt -116.18 172.09 4.1 Favored Pre-proline 0 N--CA 1.471 0.614 0 O-C-N 122.149 -0.618 . . . . 5.37 111.794 170.74 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -69.78 -153.59 0.03 OUTLIER 'Trans proline' 0 CA--C 1.536 0.616 0 C-N-CA 122.717 2.278 . . . . 2.84 108.884 148.029 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.301 0 CA-C-O 116.971 -2.016 . . . . 3.82 113.106 159.693 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo . . . . . 0 N--CA 1.491 1.356 0 N-CA-C 108.774 -1.279 . . . . 3.54 108.774 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.16 147.95 51.16 Favored Glycine 0 CA--C 1.549 2.219 0 CA-C-O 118.27 -1.295 . . . . 2.36 110.635 157.879 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -83.42 -51.41 0.04 OUTLIER 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 124.229 3.286 . . . . 3.42 112.874 -173.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -170.66 -178.99 2.76 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 128.15 2.58 . . . . 5.94 108.358 178.284 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -98.74 157.57 20.24 Favored Glycine 0 CA--C 1.528 0.857 0 CA-C-O 122.16 0.867 . . . . 1.73 113.739 177.744 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 3.5 mp -72.71 157.27 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 124.204 1.002 . . . . 3.74 109.096 175.37 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.41 127.75 32.99 Favored 'General case' 0 CA--C 1.545 0.78 0 O-C-N 120.647 -1.283 . . . . 2.82 112.507 170.125 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -86.59 171.63 43.69 Favored Glycine 0 C--N 1.339 0.7 0 C-N-CA 125.178 1.37 . . . . 2.65 112.608 177.09 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -104.94 147.35 27.87 Favored 'General case' 0 N--CA 1.462 0.174 0 O-C-N 121.855 -0.791 . . . . 3.4 111.259 -179.068 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 6.6 ptt180 -67.99 155.74 38.83 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.167 -0.47 . . . . 5.06 110.796 158.002 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.17 -172.83 43.18 Favored Glycine 0 CA--C 1.533 1.212 0 C-N-CA 123.946 0.784 . . . . 1.97 113.066 178.255 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 15.3 m -93.67 145.59 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 N-CA-C 116.012 1.856 . . . . 4.4 116.012 -155.841 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.8 m -85.84 155.02 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.916 1.687 . . . . 3.11 112.888 -171.373 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.73 -134.15 8.13 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 124.637 1.113 . . . . 2.1 113.25 175.203 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -168.56 163.38 8.26 Favored Pre-proline 0 CA--C 1.551 0.988 0 C-N-CA 126.323 1.849 . . . . 3.85 111.028 -163.475 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo . . . . . 0 C--O 1.255 1.346 0 C-N-CA 124.383 3.389 . . . . 2.79 111.502 159.184 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo . . . . . 0 N--CA 1.486 1.043 0 CA-C-O 118.819 -0.575 . . . . 3.63 111.987 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -64.29 -166.83 0.08 OUTLIER 'Trans proline' 0 CA--C 1.54 0.796 0 C-N-CA 123.616 2.878 . . . . 3.01 110.233 159.413 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -89.87 174.95 41.4 Favored Glycine 0 CA--C 1.534 1.26 0 C-N-CA 124.005 0.812 . . . . 1.63 112.589 175.338 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -70.59 169.31 20.27 Favored 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 123.03 2.487 . . . . 2.47 111.941 170.527 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 26.3 tp60 -34.67 146.28 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 129.066 2.947 . . . . 2.29 114.673 168.601 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.7 171.22 41.13 Favored Glycine 0 CA--C 1.525 0.672 0 C-N-CA 123.427 0.537 . . . . 1.9 112.631 168.346 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 3.3 mp -59.21 130.48 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 123.157 0.583 . . . . 4.48 110.489 178.089 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.32 143.56 50.24 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 125.574 1.55 . . . . 2.5 114.797 -170.514 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -85.16 145.91 21.64 Favored Glycine 0 C--N 1.339 0.736 0 N-CA-C 109.664 -1.374 . . . . 1.62 109.664 171.706 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 5.7 mp0 -85.83 -169.67 2.75 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 123.941 0.896 . . . . 3.42 110.503 179.894 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 16.2 ttt180 -64.88 145.11 56.74 Favored 'General case' 0 N--CA 1.467 0.421 0 O-C-N 121.172 -0.955 . . . . 5.38 109.49 156.297 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.17 162.35 36.19 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 111.414 -0.674 . . . . 1.26 111.414 161.94 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.57 140.15 20.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 C-N-CA 123.445 0.698 . . . . 2.75 109.796 176.221 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 13.4 p -79.67 178.9 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 C-N-CA 127.041 2.136 . . . . 5.06 110.872 178.479 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.34 179.36 2.62 Favored Glycine 0 CA--C 1.537 1.41 0 C-N-CA 124.553 1.073 . . . . 2.28 114.735 169.155 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 10.0 mp . . . . . 0 C--O 1.249 1.078 0 C-N-CA 126.001 1.72 . . . . 4.89 113.296 -162.571 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo . . . . . 0 N--CA 1.459 -0.524 0 N-CA-C 111.318 -0.301 . . . . 2.07 111.318 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -58.58 166.69 1.71 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.774 2.029 . . . . 3.33 114.041 168.871 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.59 -118.45 0.03 OUTLIER Glycine 0 N--CA 1.475 1.287 0 C-N-CA 127.452 2.453 . . . . 2.23 115.798 -176.652 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.2 mp -120.07 137.01 55.3 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 O-C-N 120.916 -1.344 . . . . 3.65 108.874 -179.824 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -52.17 128.41 24.8 Favored 'General case' 0 CA--C 1.542 0.651 0 CA-C-N 118.275 0.489 . . . . 1.9 110.706 170.135 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -62.34 156.7 37.93 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 125.777 1.656 . . . . 1.3 113.713 -177.076 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.9 mm-40 -73.0 116.34 13.39 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 108.734 -0.839 . . . . 3.91 108.734 -171.929 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 7.4 ttt180 -64.22 140.58 58.88 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 122.72 0.408 . . . . 5.8 112.029 -163.283 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.67 158.17 53.62 Favored Glycine 0 C--N 1.335 0.502 0 C-N-CA 123.926 0.774 . . . . 1.77 111.908 -179.644 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 33.3 m -75.97 160.99 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 CA-C-N 115.084 -0.558 . . . . 3.53 111.606 -174.636 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.1 m -51.98 164.76 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 125.531 1.532 . . . . 3.12 112.857 177.283 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.56 124.45 29.26 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.989 -0.844 . . . . 2.18 110.989 163.421 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 9.5 mp -82.31 170.92 13.2 Favored Pre-proline 0 CA--C 1.533 0.321 0 C-N-CA 124.493 1.117 . . . . 4.8 110.856 175.479 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -60.0 -165.77 0.03 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 121.77 1.647 . . . . 4.04 110.821 152.135 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.667 0 CA-C-O 118.647 -1.085 . . . . 6.19 114.984 160.141 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo . . . . . 0 N--CA 1.481 0.776 0 CA-C-O 118.551 -0.687 . . . . 2.42 111.694 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.29 161.44 48.0 Favored Glycine 0 CA--C 1.54 1.628 0 CA-C-O 119.078 -0.845 . . . . 1.27 111.669 152.709 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -76.0 163.68 32.75 Favored 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 124.235 3.29 . . . . 2.47 110.641 165.797 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -53.94 140.17 31.74 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.761 1.224 . . . . 5.38 111.79 170.948 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.23 161.67 53.24 Favored Glycine 0 CA--C 1.529 0.912 0 C-N-CA 124.167 0.889 . . . . 1.42 114.421 -174.512 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 35.6 mm -60.78 119.32 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 O-C-N 121.542 -0.975 . . . . 3.66 111.086 -175.772 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.76 155.04 27.78 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 114.492 1.293 . . . . 1.75 114.492 -172.176 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.24 136.7 28.68 Favored Glycine 0 CA--C 1.527 0.809 0 C-N-CA 126.3 1.905 . . . . 1.62 111.391 -179.534 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -106.3 143.62 34.16 Favored 'General case' 0 N--CA 1.465 0.323 0 O-C-N 121.633 -0.922 . . . . 3.83 110.133 -172.415 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 32.0 ptt180 -72.22 157.6 37.43 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.344 1.058 . . . . 5.01 112.997 175.823 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.86 -174.95 26.77 Favored Glycine 0 CA--C 1.539 1.534 0 N-CA-C 117.061 1.584 . . . . 2.69 117.061 -170.099 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 60.9 t -96.33 136.1 28.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 C-N-CA 124.201 1.001 . . . . 5.19 113.517 -157.873 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.9 p -32.39 143.21 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 131.232 3.813 . . . . 5.27 118.44 -170.32 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.14 -118.79 4.11 Favored Glycine 0 CA--C 1.528 0.905 0 C-N-CA 124.968 1.27 . . . . 2.45 112.211 169.469 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 1.6 pp -168.76 153.39 5.9 Favored Pre-proline 0 CA--C 1.552 1.025 0 N-CA-C 115.565 1.691 . . . . 6.56 115.565 -150.246 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo . . . . . 0 C--O 1.254 1.298 0 C-N-CA 123.739 2.96 . . . . 4.65 111.741 152.935 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo . . . . . 0 N--CA 1.486 1.068 0 CA-C-O 118.582 -0.674 . . . . 2.35 111.096 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -71.12 -150.0 0.03 OUTLIER 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 123.65 2.9 . . . . 2.06 109.581 166.11 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -99.27 -172.77 31.15 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-N 118.688 0.676 . . . . 1.42 112.662 172.232 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.81 167.69 23.46 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 123.248 2.632 . . . . 2.36 112.213 176.608 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 8.7 tp60 -37.23 127.16 1.0 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.696 2.398 . . . . 1.64 113.024 160.583 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -62.5 147.75 49.46 Favored Glycine 0 CA--C 1.527 0.786 0 C-N-CA 124.321 0.962 . . . . 1.01 112.741 168.584 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 47.0 mm -57.9 147.14 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 O-C-N 121.933 -0.745 . . . . 4.35 111.557 -178.952 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -72.4 156.81 38.67 Favored 'General case' 0 CA--C 1.542 0.658 0 O-C-N 121.293 -0.879 . . . . 1.3 112.792 178.72 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -91.94 153.75 22.1 Favored Glycine 0 C--N 1.338 0.644 0 CA-C-O 122.299 0.944 . . . . 1.09 112.046 -178.528 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 25.1 mp0 -92.02 -174.12 3.69 Favored 'General case' 0 CA--C 1.544 0.721 0 CA-C-O 122.024 0.916 . . . . 3.21 111.398 -175.954 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -58.83 139.33 56.56 Favored 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 125.15 1.38 . . . . 5.54 111.653 169.093 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.9 -171.01 6.81 Favored Glycine 0 C--N 1.337 0.628 0 C-N-CA 125.384 1.469 . . . . 1.58 113.481 175.825 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 21.4 t -65.0 127.46 25.95 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.696 0 O-C-N 122.305 -0.527 . . . . 3.17 110.473 -178.833 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 4.3 p -64.31 160.93 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 126.864 2.066 . . . . 5.06 112.133 178.007 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -51.9 176.52 0.1 Allowed Glycine 0 CA--C 1.542 1.728 0 C-N-CA 124.52 1.057 . . . . 1.84 115.236 159.518 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 3.3 mm? . . . . . 0 C--O 1.253 1.248 0 CA-C-O 117.016 -1.469 . . . . 4.07 112.623 -161.156 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo . . . . . 0 CA--C 1.534 0.489 0 CA-C-O 120.661 0.192 . . . . 3.41 111.635 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.01 153.55 36.93 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 127.31 2.244 . . . . 3.14 113.605 178.706 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.7 -122.91 0.05 OUTLIER Glycine 0 CA--C 1.534 1.271 0 C-N-CA 127.146 2.308 . . . . 2.4 115.717 -179.051 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.8 mt -122.42 131.8 72.46 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 O-C-N 121.097 -1.237 . . . . 2.42 109.191 -177.248 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.91 134.33 55.41 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 123.442 0.697 . . . . 2.08 110.81 173.399 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.69 155.18 48.13 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 126.744 2.116 . . . . 1.83 114.33 -173.463 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 72.7 mm-40 -77.76 154.09 32.31 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 114.767 -0.717 . . . . 4.59 112.47 -166.256 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.45 132.16 53.04 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 123.509 0.723 . . . . 7.88 111.759 -177.672 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.9 151.64 44.52 Favored Glycine 0 N--CA 1.467 0.763 0 N-CA-C 115.584 0.994 . . . . 2.01 115.584 -167.879 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 2.5 m -69.1 130.93 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 124.938 1.295 . . . . 3.07 110.893 176.138 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.5 m -55.61 146.07 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 125.062 1.345 . . . . 2.93 114.029 -167.638 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.02 -163.93 7.91 Favored Glycine 0 CA--C 1.534 1.276 0 N-CA-C 111.39 -0.684 . . . . 1.98 111.39 161.032 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.1 mt -143.95 167.02 16.46 Favored Pre-proline 0 N--CA 1.475 0.813 0 C-N-CA 124.551 1.14 . . . . 3.62 111.479 179.951 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . 0.414 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 29.2 Cg_endo -76.73 -152.61 0.04 OUTLIER 'Trans proline' 0 CA--C 1.539 0.736 0 C-N-CA 122.981 2.454 . . . . 2.18 108.584 150.914 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.288 0 CA-C-O 117.017 -1.99 . . . . 3.12 112.774 143.671 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_exo . . . . . 0 CA--C 1.543 0.966 0 N-CA-C 111.512 -0.226 . . . . 3.93 111.512 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.05 176.44 30.06 Favored Glycine 0 CA--C 1.538 1.474 0 C-N-CA 120.284 -0.96 . . . . 1.83 112.935 127.561 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -79.94 156.28 23.56 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 C-N-CA 125.011 3.807 . . . . 2.54 110.795 158.646 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -60.86 140.63 57.62 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 125.158 1.383 . . . . 5.55 110.455 168.24 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.32 162.14 40.83 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 115.508 0.963 . . . . 1.48 115.508 -172.114 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 41.0 pt -55.41 139.19 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 O-C-N 122.376 -0.485 . . . . 5.24 111.213 176.765 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.15 154.04 42.72 Favored 'General case' 0 CA--C 1.54 0.589 0 CA-C-O 121.539 0.685 . . . . 1.81 112.828 -176.638 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.02 161.96 51.71 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 125.094 1.33 . . . . 2.23 113.635 -178.338 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 3.0 tp-100 -90.56 131.06 36.51 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 123.663 0.785 . . . . 4.55 109.709 -174.163 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.28 153.26 3.94 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-O 122.678 1.228 . . . . 9.23 114.161 -177.77 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.91 166.54 54.41 Favored Glycine 0 CA--C 1.531 1.086 0 CA-C-N 113.998 -1.456 . . . . 2.08 112.541 171.298 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 17.6 m -89.71 139.28 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 115.05 1.5 . . . . 4.4 115.05 -162.841 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.1 m -104.22 155.8 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 124.809 1.244 . . . . 3.11 112.708 -163.211 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -107.49 -130.33 6.34 Favored Glycine 0 CA--C 1.529 0.907 0 C-N-CA 125.118 1.342 . . . . 1.68 113.218 177.801 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . 0.414 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.7 pt? -179.14 161.82 1.0 Allowed Pre-proline 0 CA--C 1.547 0.842 0 C-N-CA 126.045 1.738 . . . . 3.76 110.753 -152.996 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo . . . . . 0 C--O 1.257 1.437 0 C-N-CA 124.014 3.143 . . . . 2.91 111.949 156.159 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo . . . . . 0 CA--C 1.547 1.173 0 CA-C-O 119.181 -0.425 . . . . 3.88 112.03 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -66.07 -160.66 0.04 OUTLIER 'Trans proline' 0 CA--C 1.543 0.942 0 C-N-CA 123.066 2.511 . . . . 2.56 110.129 161.67 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -90.89 -177.57 43.74 Favored Glycine 0 CA--C 1.535 1.31 0 O-C-N 121.163 -0.96 . . . . 1.52 111.897 169.043 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -77.77 170.51 18.94 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.946 2.43 . . . . 2.57 111.981 175.405 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.8 tp60 -34.99 127.01 0.53 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 127.557 2.343 . . . . 1.74 113.325 152.499 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.18 155.4 53.16 Favored Glycine 0 CA--C 1.528 0.869 0 C-N-CA 124.944 1.259 . . . . 1.49 112.338 167.304 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 82.3 mt -62.95 139.57 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 O-C-N 121.593 -0.946 . . . . 3.42 110.731 -175.582 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.26 159.15 12.76 Favored 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 122.292 1.044 . . . . 2.28 113.31 178.904 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -61.76 124.99 35.75 Favored Glycine 0 CA--C 1.524 0.638 0 CA-C-O 122.279 0.933 . . . . 2.25 112.679 -170.905 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . 0.527 ' NE2' ' H ' ' C' ' 20' ' ' GLN . 0.0 OUTLIER -60.59 129.76 43.15 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.672 1.589 . . . . 6.1 110.919 -175.982 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.47 129.71 22.51 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.526 0.731 . . . . 3.81 111.862 -174.898 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -62.6 154.98 41.65 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 115.168 -0.924 . . . . 1.12 113.311 -176.466 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.5 t -57.4 146.59 6.76 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 C-N-CA 124.913 1.285 . . . . 1.88 110.288 171.876 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 27.2 m -98.54 -169.87 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.817 0 C-N-CA 125.687 1.595 . . . . 3.06 110.557 179.091 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.6 -168.31 3.94 Favored Glycine 0 CA--C 1.538 1.485 0 C-N-CA 124.339 0.971 . . . . 1.9 113.944 167.356 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 13.5 mt . . . . . 0 N--CA 1.485 1.315 0 N-CA-C 114.329 1.233 . . . . 4.25 114.329 -174.977 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo . . . . . 0 N--CA 1.457 -0.676 0 N-CA-C 111.328 -0.297 . . . . 5.94 111.328 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -64.38 161.71 16.44 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 128.294 2.638 . . . . 5.16 111.451 166.577 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.41 -143.17 0.46 Allowed Glycine 0 CA--C 1.535 1.34 0 C-N-CA 126.66 2.076 . . . . 3.27 114.307 173.367 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.1 mt -101.06 127.92 53.79 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 O-C-N 121.375 -1.074 . . . . 4.8 108.409 179.202 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.89 140.79 56.41 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 118.901 0.773 . . . . 2.63 110.29 168.186 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -61.75 141.95 47.9 Favored Glycine 0 CA--C 1.523 0.58 0 C-N-CA 124.587 1.089 . . . . 1.19 112.291 175.423 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 54.2 mm-40 -68.32 130.22 42.25 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 109.847 -0.427 . . . . 3.79 109.847 -177.516 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -66.69 137.26 56.56 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 121.512 0.672 . . . . 4.56 111.175 -171.765 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.63 126.1 8.33 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-O 122.599 1.11 . . . . 2.48 111.562 176.611 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.8 t -65.28 155.26 6.8 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.835 0 C-N-CA 126.498 1.919 . . . . 5.23 111.822 -178.141 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.3 m -61.62 152.32 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 O-C-N 121.121 -0.987 . . . . 3.96 112.791 173.805 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -97.02 -153.88 29.7 Favored Glycine 0 N--CA 1.468 0.795 0 C-N-CA 124.023 0.821 . . . . 2.19 112.478 167.642 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 89.2 mt -143.26 158.89 57.23 Favored Pre-proline 0 N--CA 1.47 0.536 0 C-N-CA 126.117 1.767 . . . . 6.33 110.246 176.444 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -76.41 -146.21 0.03 OUTLIER 'Trans proline' 0 CA--C 1.54 0.791 0 C-N-CA 122.58 2.186 . . . . 4.73 107.803 154.03 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.169 0 CA-C-O 116.701 -2.166 . . . . 4.72 111.979 151.902 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo . . . . . 0 N--CA 1.481 0.774 0 CA-C-O 118.705 -0.623 . . . . 4.59 111.68 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.6 159.01 50.88 Favored Glycine 0 CA--C 1.539 1.581 0 CA-C-O 118.761 -1.021 . . . . 2.08 111.682 154.443 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_endo -70.8 158.67 54.96 Favored 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 123.782 2.988 . . . . 4.75 109.819 162.134 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -82.34 174.29 11.27 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.909 0.861 . . . . 7.89 113.114 178.593 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.22 154.36 52.53 Favored Glycine 0 CA--C 1.52 0.389 0 CA-C-O 122.615 1.119 . . . . 1.95 114.248 -177.705 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 43.8 pt -61.39 144.69 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 CA-C-N 114.383 -0.909 . . . . 6.69 110.718 161.518 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -85.35 133.4 34.14 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 123.822 0.849 . . . . 2.41 112.495 177.749 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -75.08 125.62 8.32 Favored Glycine 0 CA--C 1.525 0.691 0 C-N-CA 125.653 1.597 . . . . 1.78 110.546 173.272 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -89.71 157.51 17.95 Favored 'General case' 0 CA--C 1.535 0.382 0 O-C-N 121.865 -0.785 . . . . 4.32 110.384 166.321 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.92 162.08 29.92 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 123.235 0.614 . . . . 4.61 111.712 166.029 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -84.19 -141.8 5.1 Favored Glycine 0 CA--C 1.533 1.198 0 N-CA-C 110.991 -0.843 . . . . 3.14 110.991 163.602 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 99.5 t -40.62 131.38 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 126.415 1.886 . . . . 5.75 113.816 -173.944 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 15.3 m -103.78 149.4 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 125.083 1.353 . . . . 4.48 109.02 161.371 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.468 ' H ' HG21 ' C' ' 23' ' ' VAL . . . -102.55 167.63 17.84 Favored Glycine 0 C--N 1.333 0.392 0 C-N-CA 124.843 1.211 . . . . 5.24 115.266 -163.574 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -171.57 158.99 4.83 Favored Pre-proline 0 CA--C 1.544 0.713 0 C-N-CA 127.626 2.37 . . . . 8.04 111.028 -173.824 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo . . . . . 0 C--O 1.255 1.354 0 C-N-CA 124.063 3.175 . . . . 5.61 112.155 152.631 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo . . . . . 0 N--CA 1.486 1.085 0 CA-C-O 118.604 -0.665 . . . . 5.74 111.305 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -69.06 -152.88 0.03 OUTLIER 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 123.394 2.729 . . . . 4.8 109.761 163.632 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -91.45 177.28 40.69 Favored Glycine 0 CA--C 1.535 1.293 0 N-CA-C 111.424 -0.67 . . . . 2.66 111.424 166.684 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -78.26 168.07 22.23 Favored 'Trans proline' 0 N--CA 1.455 -0.772 0 C-N-CA 123.111 2.541 . . . . 4.27 111.858 172.637 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 27.0 tp60 -40.51 121.91 1.52 Allowed 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 128.217 2.607 . . . . 3.04 113.98 160.046 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.74 157.74 51.91 Favored Glycine 0 CA--C 1.527 0.841 0 C-N-CA 124.82 1.2 . . . . 1.71 111.637 163.953 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 51.2 mm -65.56 132.2 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 O-C-N 121.81 -0.818 . . . . 3.95 111.903 -172.458 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.52 145.92 38.77 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 123.77 0.828 . . . . 1.67 111.862 171.731 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -80.44 -173.21 46.19 Favored Glycine 0 C--N 1.338 0.673 0 CA-C-O 122.684 1.158 . . . . 1.08 111.513 -179.959 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 12.5 mp0 -115.95 158.84 22.44 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 108.214 -1.032 . . . . 3.29 108.214 179.367 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 2.8 tmt_? -63.45 134.12 55.1 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 107.611 -1.255 . . . . 7.1 107.611 153.804 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.61 153.66 52.92 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 111.626 -0.589 . . . . 2.79 111.626 -179.249 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . 0.468 HG21 ' H ' ' B' ' 25' ' ' GLY . 15.5 m -67.03 162.66 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 O-C-N 121.429 -1.042 . . . . 5.76 111.95 -176.291 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 16.0 m -90.61 173.93 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 126.889 2.076 . . . . 5.54 110.776 171.552 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.15 -171.87 2.45 Favored Glycine 0 CA--C 1.54 1.632 0 C-N-CA 125.249 1.404 . . . . 3.74 115.132 164.808 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 mm? . . . . . 0 C--O 1.25 1.117 0 C-N-CA 126.69 1.996 . . . . 8.16 112.36 -166.274 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo . . . . . 0 N--CA 1.459 -0.516 0 CA-C-O 121.018 0.341 . . . . 2.31 112.606 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.62 153.47 10.29 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 129.304 3.041 . . . . 3.55 112.464 170.072 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.12 -144.26 3.41 Favored Glycine 0 N--CA 1.475 1.287 0 C-N-CA 126.667 2.079 . . . . 1.67 117.01 -171.8 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 33.2 pt -98.94 139.32 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 O-C-N 121.24 -1.153 . . . . 3.62 108.692 174.848 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.84 146.4 49.77 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-O 121.38 0.609 . . . . 1.78 111.052 179.558 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -45.86 141.64 4.96 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 126.423 1.963 . . . . 1.23 114.017 174.884 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 80.3 mm-40 -63.69 132.82 52.25 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 108.925 -0.768 . . . . 3.95 108.925 -178.54 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.4 tmt_? -64.55 134.31 54.13 Favored 'General case' 0 CA--C 1.536 0.425 0 N-CA-C 112.421 0.526 . . . . 5.9 112.421 -162.481 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.54 160.79 53.7 Favored Glycine 0 N--CA 1.466 0.66 0 CA-C-O 122.823 1.235 . . . . 1.49 115.6 -169.58 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 11.1 t -79.01 145.25 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 126.15 1.78 . . . . 3.11 111.847 -167.272 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.9 m -58.49 147.26 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 C-N-CA 124.965 1.306 . . . . 2.81 113.59 -179.396 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.41 ' H ' ' HB ' ' B' ' 23' ' ' VAL . . . -82.72 -163.88 34.34 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 124.267 0.937 . . . . 2.01 112.263 167.215 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.1 mt -145.9 160.44 43.62 Favored Pre-proline 0 N--CA 1.474 0.768 0 C-N-CA 128.053 2.541 . . . . 3.97 108.177 174.868 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -77.11 -157.12 0.07 OUTLIER 'Trans proline' 0 CA--C 1.541 0.866 0 C-N-CA 122.187 1.925 . . . . 2.29 109.129 164.677 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.205 0 CA-C-O 117.358 -1.801 . . . . 3.39 112.696 154.383 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo . . . . . 0 N--CA 1.481 0.762 0 CA-C-O 118.479 -0.717 . . . . 2.7 111.391 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.49 166.26 30.73 Favored Glycine 0 CA--C 1.543 1.814 0 CA-C-O 119.006 -0.886 . . . . 1.64 112.885 149.724 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -76.62 41.76 0.95 Allowed 'Trans proline' 0 CA--C 1.546 1.078 1 C-N-CA 127.014 5.143 . . . . 3.7 113.176 -179.123 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 66.27 178.17 0.22 Allowed 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 125.274 1.43 . . . . 5.45 112.053 -165.1 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.64 163.54 31.08 Favored Glycine 0 CA--C 1.541 1.696 0 C-N-CA 124.429 1.014 . . . . 0.95 113.447 159.367 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 67.5 mt -77.77 148.71 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 126.05 1.74 . . . . 3.47 111.718 176.469 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -73.58 147.97 43.39 Favored 'General case' 0 CA--C 1.548 0.877 0 N-CA-C 114.362 1.245 . . . . 1.33 114.362 -177.616 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -78.02 169.89 54.72 Favored Glycine 0 CA--C 1.536 1.378 0 C-N-CA 125.52 1.533 . . . . 1.5 112.476 173.188 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.94 170.35 12.35 Favored 'General case' 0 N--CA 1.467 0.408 0 O-C-N 121.321 -1.105 . . . . 3.54 112.06 -177.35 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -59.42 148.4 32.83 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 124.6 1.16 . . . . 5.7 113.328 -176.243 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.6 -54.96 5.22 Favored Glycine 0 N--CA 1.472 1.045 0 N-CA-C 114.418 0.527 . . . . 4.31 114.418 -173.404 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . 0.41 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 11.1 t -146.65 158.91 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 128.478 2.711 . . . . 5.8 107.864 -176.518 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.0 p -121.06 153.58 24.55 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 C-N-CA 127.87 2.468 . . . . 4.32 109.32 178.103 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.02 -168.29 43.73 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-O 121.857 0.698 . . . . 2.18 114.582 177.162 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.9 pp -159.79 150.92 16.07 Favored Pre-proline 0 CA--C 1.543 0.699 0 C-N-CA 125.996 1.718 . . . . 3.64 110.97 -179.265 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo . . . . . 0 C--O 1.254 1.306 1 C-N-CA 125.584 4.189 . . . . 3.1 112.881 167.594 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo . . . . . 0 N--CA 1.485 1.001 0 CA-C-O 118.834 -0.569 . . . . 2.26 111.267 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -71.99 -143.16 0.02 OUTLIER 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 123.943 3.095 . . . . 1.91 109.257 169.091 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.33 146.61 39.45 Favored Glycine 0 CA--C 1.54 1.623 0 CA-C-O 118.713 -1.048 . . . . 1.31 110.506 165.659 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -68.25 -43.04 4.91 Favored 'Trans proline' 0 CA--C 1.534 0.49 0 C-N-CA 123.024 2.483 . . . . 3.28 113.285 178.208 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 16.9 tp60 174.2 115.2 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 126.185 1.794 . . . . 2.06 107.948 -166.201 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.83 164.71 38.77 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 123.663 0.649 . . . . 1.09 112.979 169.616 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 35.0 mm -69.59 128.55 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 O-C-N 121.527 -0.984 . . . . 3.41 110.761 -171.498 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.15 149.98 22.48 Favored 'General case' 0 CA--C 1.543 0.691 0 N-CA-C 113.748 1.018 . . . . 1.36 113.748 176.806 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -73.32 138.46 25.28 Favored Glycine 0 CA--C 1.526 0.746 0 C-N-CA 124.11 0.862 . . . . 1.08 111.36 -177.44 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 -75.81 167.73 21.34 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.138 0.975 . . . . 5.77 111.827 175.529 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.18 147.79 19.75 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 125.619 1.568 . . . . 4.53 112.151 171.374 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -56.32 146.82 32.56 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 125.734 1.635 . . . . 1.28 113.328 166.832 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 34.8 m -75.01 137.89 22.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 107.2 -1.408 . . . . 4.58 107.2 162.698 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 34.9 m -92.19 -152.36 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.799 0 C-N-CA 124.034 0.934 . . . . 3.46 110.991 -168.35 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.98 169.53 1.25 Allowed Glycine 0 CA--C 1.542 1.751 0 C-N-CA 124.033 0.825 . . . . 1.81 114.103 162.189 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 12.8 mt . . . . . 0 C--O 1.249 1.028 0 C-N-CA 124.897 1.279 . . . . 4.36 114.024 -163.845 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo . . . . . 0 CA--C 1.535 0.548 0 N-CA-C 111.331 -0.296 . . . . 2.67 111.331 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? -74.81 165.96 24.4 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 126.739 2.016 . . . . 3.75 113.594 175.534 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.11 -157.58 3.36 Favored Glycine 0 N--CA 1.476 1.365 0 C-N-CA 129.493 3.425 . . . . 1.5 116.915 -170.267 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.9 mt -77.96 125.74 37.78 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 O-C-N 120.403 -1.645 . . . . 2.63 107.942 174.736 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.0 128.41 30.33 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 123.117 0.567 . . . . 1.94 111.274 174.713 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.77 150.23 42.85 Favored Glycine 0 CA--C 1.521 0.466 0 C-N-CA 126.455 1.979 . . . . 1.34 112.856 -174.554 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 76.8 mm-40 -74.46 135.15 42.29 Favored 'General case' 0 C--N 1.332 -0.175 0 O-C-N 122.333 -0.51 . . . . 4.32 110.652 -167.268 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 35.2 ttp180 -54.48 130.96 41.51 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 123.539 0.736 . . . . 6.76 110.908 176.33 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.89 -178.03 29.83 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 124.441 1.02 . . . . 2.2 114.189 -171.646 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -61.11 142.36 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 C-N-CA 123.916 0.886 . . . . 3.32 110.03 174.846 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.7 m -52.22 154.08 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 C-N-CA 124.184 0.994 . . . . 3.39 112.944 173.6 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.404 ' H ' ' HB ' ' B' ' 23' ' ' VAL . . . -83.9 -149.43 9.61 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 123.797 0.713 . . . . 2.43 112.591 166.298 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 82.8 mt -146.73 162.5 33.45 Favored Pre-proline 0 N--CA 1.475 0.789 0 C-N-CA 127.015 2.126 . . . . 4.1 109.687 170.581 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -83.06 -152.92 0.04 OUTLIER 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 123.298 2.665 . . . . 2.62 108.515 154.228 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.207 0 CA-C-O 117.61 -1.661 . . . . 3.83 113.103 156.191 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_exo . . . . . 0 N--CA 1.479 0.676 0 CA-C-O 118.196 -0.835 . . . . 2.36 111.392 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.48 158.21 27.81 Favored Glycine 0 CA--C 1.546 2.01 0 CA-C-N 119.178 0.899 . . . . 1.99 112.816 154.342 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -76.13 47.5 2.03 Favored 'Trans proline' 0 CA--C 1.545 1.071 1 C-N-CA 127.374 5.383 . . . . 3.99 113.419 -175.958 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.464 ' HG3' ' H ' ' B' ' 16' ' ' GLY . 1.4 tp-100 69.88 -169.65 0.17 Allowed 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 124.819 1.248 . . . . 5.04 109.871 -161.33 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . 0.464 ' H ' ' HG3' ' B' ' 15' ' ' GLN . . . -106.93 154.88 16.58 Favored Glycine 0 CA--C 1.533 1.201 0 C-N-CA 126.192 1.853 . . . . 1.15 110.576 158.558 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 18.3 tt -63.58 144.81 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 C-N-CA 124.228 1.011 . . . . 5.59 112.521 177.393 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -75.0 148.36 39.98 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 113.624 0.972 . . . . 1.69 113.624 178.91 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.63 148.39 43.42 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 125.635 1.588 . . . . 1.74 113.8 -177.747 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 19.5 tt0 -80.25 148.34 30.83 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.222 1.009 . . . . 4.44 112.418 -177.86 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.5 mtm180 -63.87 130.75 45.4 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 124.747 1.219 . . . . 5.53 111.829 178.125 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.48 2.72 45.18 Favored Glycine 0 N--CA 1.476 1.34 0 N-CA-C 119.6 2.6 . . . . 4.68 119.6 -155.365 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . 0.404 ' HB ' ' H ' ' A' ' 25' ' ' GLY 0.278 0.9 OUTLIER 173.3 156.92 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 130.302 3.441 . . . . 6.2 108.741 179.214 . . . . . . . . 4 4 . 1 . 027 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 42.1 t -132.54 141.51 44.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 C-N-CA 126.245 1.818 . . . . 5.71 107.911 178.052 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -88.05 -177.69 47.58 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-O 122.496 1.053 . . . . 2.71 114.779 -170.3 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.1 pt? -161.19 156.96 21.55 Favored Pre-proline 0 CA--C 1.542 0.651 0 C-N-CA 126.419 1.888 . . . . 4.43 110.243 -177.734 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo . . . . . 0 C--O 1.255 1.374 0 C-N-CA 124.129 3.219 . . . . 3.48 111.229 164.112 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo . . . . . 0 N--CA 1.487 1.097 0 CA-C-O 119.019 -0.492 . . . . 2.89 111.555 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -70.0 -148.83 0.02 OUTLIER 'Trans proline' 0 CA--C 1.541 0.857 0 C-N-CA 123.616 2.878 . . . . 2.27 109.553 165.768 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -81.95 176.45 53.96 Favored Glycine 0 CA--C 1.537 1.454 0 O-C-N 121.279 -0.888 . . . . 1.13 111.542 168.88 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -79.24 -177.58 4.0 Favored 'Trans proline' 0 N--CA 1.452 -0.952 0 C-N-CA 123.095 2.53 . . . . 2.37 109.792 162.125 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.7 tp60 -41.55 119.29 1.22 Allowed 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 125.981 1.712 . . . . 2.12 113.875 159.363 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.32 161.88 41.22 Favored Glycine 0 CA--C 1.528 0.855 0 C-N-CA 125.772 1.654 . . . . 1.13 112.531 167.518 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 33.4 mm -68.77 142.39 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 O-C-N 121.576 -0.955 . . . . 4.75 110.511 -172.714 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.81 154.63 40.36 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.31 0.856 . . . . 1.62 113.31 177.1 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.59 157.52 53.25 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 124.274 0.94 . . . . 1.15 113.131 -179.095 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 14.4 mp0 -82.31 173.98 11.57 Favored 'General case' 0 CA--C 1.541 0.615 0 O-C-N 121.869 -0.783 . . . . 3.23 111.26 179.024 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.3 135.31 57.13 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 123.287 0.635 . . . . 4.79 110.426 169.15 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -65.35 167.3 32.52 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.93 1.253 . . . . 1.54 113.972 -176.675 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 87.2 t -75.52 148.4 7.49 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 C-N-CA 123.876 0.871 . . . . 2.45 109.458 -176.865 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 98.7 t -97.28 174.69 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.991 0 C-N-CA 127.297 2.239 . . . . 4.07 109.613 -174.891 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -56.3 173.17 1.67 Allowed Glycine 0 CA--C 1.538 1.504 0 C-N-CA 124.974 1.273 . . . . 2.01 114.723 165.25 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 8.8 mt . . . . . 0 C--O 1.25 1.097 0 N-CA-C 113.821 1.045 . . . . 5.05 113.821 -158.143 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo . . . . . 0 CA--C 1.532 0.404 0 N-CA-C 111.491 -0.234 . . . . 2.25 111.491 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.84 177.76 0.71 Allowed 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 127.73 2.412 . . . . 3.73 114.656 -178.227 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.16 173.09 44.25 Favored Glycine 0 CA--C 1.526 0.728 0 C-N-CA 125.904 1.716 . . . . 1.26 113.793 177.323 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.414 ' H ' HD13 ' A' ' 17' ' ' ILE . 3.2 mp -67.42 135.24 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.51 0 N-CA-C 109.292 -0.633 . . . . 3.59 109.292 -173.189 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -53.95 133.0 43.16 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 118.427 0.558 . . . . 1.79 110.482 170.613 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.12 168.68 24.27 Favored Glycine 0 CA--C 1.521 0.417 0 C-N-CA 126.115 1.816 . . . . 1.31 114.778 -167.995 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 85.6 mm-40 -71.46 96.28 1.48 Allowed 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 108.598 -0.89 . . . . 3.86 108.598 179.793 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.2 ttp-105 -62.29 138.63 58.46 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 124.836 1.254 . . . . 6.14 113.23 -165.155 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.7 149.97 39.04 Favored Glycine 0 C--N 1.332 0.355 0 CA-C-O 122.421 1.012 . . . . 2.26 113.704 -171.211 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 32.7 m -76.64 163.11 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 CA-C-N 113.676 -1.262 . . . . 3.46 111.173 -174.624 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.0 m -60.75 167.69 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 124.257 1.023 . . . . 3.97 112.395 177.355 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.72 146.97 39.4 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 110.407 -1.077 . . . . 2.1 110.407 157.957 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 8.5 mp -101.62 169.57 7.53 Favored Pre-proline 0 CA--C 1.538 0.516 0 C-N-CA 124.041 0.936 . . . . 4.33 111.95 -170.833 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -69.11 115.11 3.84 Favored 'Trans proline' 0 N--CA 1.445 -1.337 0 N-CA-C 106.989 -1.966 . . . . 3.29 106.989 151.775 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.147 0 CA-C-O 118.584 -1.12 . . . . 6.8 114.773 -157.294 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo . . . . . 0 CA--C 1.544 0.995 0 N-CA-C 111.313 -0.303 . . . . 2.48 111.313 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.44 167.7 13.23 Favored Glycine 0 CA--C 1.541 1.717 0 C-N-CA 120.13 -1.033 . . . . 1.3 112.902 127.473 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -76.69 -64.4 0.03 OUTLIER 'Trans proline' 0 CA--C 1.538 0.702 0 C-N-CA 124.974 3.782 . . . . 2.85 112.694 175.678 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 8.3 tp-100 -166.6 157.4 12.39 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 127.943 2.497 . . . . 4.31 107.639 -164.711 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.36 159.23 25.02 Favored Glycine 0 CA--C 1.527 0.783 0 C-N-CA 124.324 0.964 . . . . 1.06 113.469 175.549 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 3.8 mp -70.28 127.89 32.82 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 N-CA-C 108.855 -0.795 . . . . 4.37 108.855 176.851 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.62 146.76 38.01 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 118.973 0.806 . . . . 1.38 112.416 178.873 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -78.63 141.27 24.4 Favored Glycine 0 CA--C 1.527 0.8 0 C-N-CA 124.643 1.116 . . . . 1.53 111.668 179.268 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.65 164.77 12.82 Favored 'General case' 0 N--CA 1.468 0.463 0 O-C-N 121.43 -1.041 . . . . 5.06 111.132 166.75 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -82.3 167.12 18.91 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.285 1.034 . . . . 6.01 112.022 167.138 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.71 -174.02 45.65 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 124.609 1.1 . . . . 3.34 112.619 164.945 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 11.0 m -100.9 160.05 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 C-N-CA 125.039 1.336 . . . . 6.22 114.568 -166.243 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.7 p -42.37 150.38 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 C-N-CA 129.016 2.926 . . . . 5.19 115.221 -178.117 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.44 -114.93 1.93 Allowed Glycine 0 CA--C 1.528 0.85 0 CA-C-O 119.154 -0.803 . . . . 2.24 111.343 167.334 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -172.43 177.23 0.83 Allowed Pre-proline 0 CA--C 1.556 1.204 0 C-N-CA 126.977 2.111 . . . . 4.29 110.55 -164.572 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_endo . . . . . 0 C--O 1.255 1.36 0 C-N-CA 123.926 3.084 . . . . 5.29 112.725 174.571 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo . . . . . 0 CA--C 1.546 1.101 0 CA-C-O 118.532 -0.695 . . . . 2.15 111.426 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -61.72 -154.05 0.02 OUTLIER 'Trans proline' 0 CA--C 1.545 1.054 0 C-N-CA 124.934 3.756 . . . . 2.43 111.679 164.682 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -84.21 -177.9 51.45 Favored Glycine 0 CA--C 1.543 1.805 0 O-C-N 121.068 -1.02 . . . . 0.96 113.157 173.53 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -79.54 169.49 18.44 Favored 'Trans proline' 0 CA--C 1.535 0.535 0 C-N-CA 124.219 3.279 . . . . 2.3 111.304 173.865 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 -48.04 116.92 1.68 Allowed 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 124.209 1.004 . . . . 1.73 111.288 160.717 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.58 163.22 36.39 Favored Glycine 0 CA--C 1.529 0.94 0 C-N-CA 124.852 1.215 . . . . 1.02 112.577 172.171 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 3.1 mp -65.96 145.27 14.02 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.667 0 C-N-CA 123.852 0.861 . . . . 3.75 110.673 -168.628 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -68.8 163.72 23.51 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.517 0.932 . . . . 1.32 113.517 179.084 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.11 149.46 17.96 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 109.946 -1.262 . . . . 1.1 109.946 168.6 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 7.2 mm100 -93.39 -167.86 1.8 Allowed 'General case' 0 CA--C 1.541 0.621 0 O-C-N 121.978 -0.719 . . . . 5.95 110.831 -178.07 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 2.6 ttt180 -63.33 154.44 31.76 Favored 'General case' 0 N--CA 1.467 0.41 0 O-C-N 121.272 -0.893 . . . . 4.62 110.898 168.524 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.24 -171.44 45.1 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 123.726 0.679 . . . . 1.22 111.653 165.355 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.0 t -70.3 136.8 25.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 C-N-CA 124.266 1.026 . . . . 2.13 111.855 -170.623 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -44.94 124.58 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 C-N-CA 126.599 1.959 . . . . 4.54 112.671 161.264 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.34 127.45 8.88 Favored Glycine 0 CA--C 1.525 0.698 0 C-N-CA 123.342 0.496 . . . . 3.63 112.823 179.613 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 16.9 mt . . . . . 0 C--O 1.254 1.313 0 CA-C-O 117.107 -1.425 . . . . 8.58 109.623 146.124 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo . . . . . 0 CA--C 1.536 0.614 0 CA-C-O 120.842 0.268 . . . . 3.4 111.96 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -58.46 153.4 15.97 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 128.863 2.865 . . . . 3.08 112.972 173.282 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.46 -135.01 5.01 Favored Glycine 0 N--CA 1.476 1.306 0 C-N-CA 125.996 1.76 . . . . 1.94 115.981 -171.703 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 24.0 pt -102.46 143.35 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 O-C-N 121.751 -0.852 . . . . 4.04 110.863 -178.417 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.34 143.57 28.05 Favored 'General case' 0 CA--C 1.538 0.509 0 CA-C-O 121.845 0.831 . . . . 1.77 112.007 178.612 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.46 152.21 16.39 Favored Glycine 0 CA--C 1.52 0.379 0 C-N-CA 127.637 2.541 . . . . 1.5 115.529 178.367 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 84.8 mm-40 -66.19 152.87 43.91 Favored 'General case' 0 CA--C 1.531 0.236 0 CA-C-N 113.957 -1.121 . . . . 3.88 111.172 -176.424 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -63.95 141.95 58.58 Favored 'General case' 0 N--CA 1.466 0.348 0 O-C-N 122.04 -0.413 . . . . 4.4 111.659 -179.538 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.6 164.27 45.05 Favored Glycine 0 CA--C 1.523 0.591 0 CA-C-N 115.621 -0.718 . . . . 1.53 113.096 176.609 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 2.1 t -64.55 150.07 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 124.565 1.146 . . . . 3.45 112.277 -167.69 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.8 t -53.81 132.51 16.58 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.686 0 C-N-CA 125.497 1.519 . . . . 5.31 111.587 167.88 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -85.42 155.93 30.07 Favored Glycine 0 CA--C 1.528 0.863 0 C-N-CA 124.847 1.213 . . . . 1.5 111.255 165.971 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 94.4 mt -118.16 156.52 50.44 Favored Pre-proline 0 N--CA 1.468 0.456 0 CA-C-O 117.537 -1.22 . . . . 3.59 109.937 -177.12 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -71.22 -158.47 0.06 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.875 0 C-N-CA 121.567 1.512 . . . . 2.08 109.304 161.849 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.307 0 CA-C-O 117.455 -1.747 . . . . 3.14 112.936 154.918 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo . . . . . 0 CA--C 1.544 0.992 0 N-CA-C 111.302 -0.307 . . . . 3.46 111.302 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.55 -173.02 3.19 Favored Glycine 0 CA--C 1.541 1.66 0 C-N-CA 120.097 -1.049 . . . . 1.56 113.339 123.922 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -77.9 -128.97 0.01 OUTLIER 'Trans proline' 0 CA--C 1.546 1.083 0 C-N-CA 124.864 3.709 . . . . 2.47 108.233 161.533 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.469 ' HG2' ' H ' ' B' ' 16' ' ' GLY . 6.5 tt0 -87.01 -171.01 3.31 Favored 'General case' 0 CA--C 1.552 1.038 0 C-N-CA 125.844 1.657 . . . . 5.23 111.304 171.378 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . 0.469 ' H ' ' HG2' ' B' ' 15' ' ' GLN . . . -89.32 166.87 33.63 Favored Glycine 0 CA--C 1.541 1.692 0 O-C-N 121.204 -0.935 . . . . 1.13 111.875 149.412 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 46.8 mm -67.95 143.39 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.02 -1.282 . . . . 4.36 110.212 168.241 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.72 157.89 34.49 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 114.791 1.404 . . . . 1.4 114.791 -173.11 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -78.27 161.2 48.56 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 125.908 1.718 . . . . 1.78 113.561 -175.51 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.41 156.37 18.6 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 121.651 -0.911 . . . . 3.4 111.133 175.431 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.9 155.26 16.84 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 112.208 0.447 . . . . 9.81 112.208 178.177 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.38 -125.45 0.6 Allowed Glycine 0 CA--C 1.529 0.917 0 C-N-CA 123.995 0.807 . . . . 2.65 111.174 172.008 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 82.2 t -64.06 158.34 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 C-N-CA 124.738 1.215 . . . . 6.06 110.715 179.312 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 6.2 m -129.57 157.47 42.26 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 C-N-CA 126.429 1.891 . . . . 3.68 109.362 174.005 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.72 176.74 46.32 Favored Glycine 0 C--N 1.336 0.545 0 C-N-CA 125.395 1.474 . . . . 2.49 115.305 -170.147 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -165.67 157.98 12.85 Favored Pre-proline 0 CA--C 1.549 0.928 0 C-N-CA 125.437 1.495 . . . . 3.6 113.262 -168.805 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_endo . . . . . 0 C--O 1.255 1.343 0 C-N-CA 123.748 2.965 . . . . 2.73 111.786 159.837 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo . . . . . 0 N--CA 1.487 1.119 0 CA-C-O 118.882 -0.549 . . . . 2.78 111.694 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -69.44 -139.37 0.01 OUTLIER 'Trans proline' 0 CA--C 1.542 0.923 0 C-N-CA 123.617 2.878 . . . . 2.02 108.713 163.385 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.1 163.73 53.91 Favored Glycine 0 CA--C 1.54 1.629 0 O-C-N 120.924 -1.11 . . . . 1.26 111.492 165.283 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -79.46 -43.06 0.15 Allowed 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 122.697 2.265 . . . . 3.67 112.511 -178.926 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 17.3 tp60 167.84 133.09 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.81 2.444 . . . . 2.04 105.913 -154.445 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.41 158.96 51.05 Favored Glycine 0 CA--C 1.534 1.225 0 C-N-CA 124.358 0.98 . . . . 1.5 113.654 167.649 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 73.3 mt -62.7 147.28 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 O-C-N 121.495 -1.003 . . . . 2.98 110.394 175.509 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.36 163.91 17.21 Favored 'General case' 0 CA--C 1.545 0.778 0 N-CA-C 114.014 1.116 . . . . 1.8 114.014 -177.148 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.86 154.17 46.46 Favored Glycine 0 CA--C 1.529 0.924 0 CA-C-N 115.443 -0.799 . . . . 1.66 111.66 170.562 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -84.76 168.72 14.92 Favored 'General case' 0 CA--C 1.539 0.54 0 CA-C-O 121.66 0.743 . . . . 3.88 111.909 -174.266 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 1.1 tmt_? -60.79 136.51 58.09 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 123.596 0.758 . . . . 3.8 110.861 -179.492 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.07 138.21 29.26 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.793 -0.923 . . . . 1.28 110.793 175.002 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 18.9 m -61.04 154.62 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 117.931 0.866 . . . . 4.04 111.696 -176.652 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 10.5 p -85.03 177.34 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 C-N-CA 126.876 2.071 . . . . 3.83 110.082 172.908 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.43 -164.72 0.61 Allowed Glycine 0 CA--C 1.54 1.646 0 C-N-CA 125.21 1.385 . . . . 1.58 115.875 169.851 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 16.5 mt . . . . . 0 N--CA 1.481 1.082 0 C-N-CA 125.507 1.523 . . . . 3.73 114.481 -162.439 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo . . . . . 0 N--CA 1.46 -0.458 0 N-CA-C 111.554 -0.21 . . . . 3.0 111.554 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.37 154.29 28.57 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.226 2.21 . . . . 3.19 113.517 178.955 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.08 -116.54 0.04 OUTLIER Glycine 0 CA--C 1.534 1.224 0 C-N-CA 126.937 2.208 . . . . 2.54 115.369 179.481 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.9 mt -134.79 132.95 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 O-C-N 121.211 -1.17 . . . . 2.42 109.739 -174.239 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.11 133.84 55.94 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.644 0.778 . . . . 1.76 112.324 176.44 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.99 163.12 41.73 Favored Glycine 0 CA--C 1.527 0.829 0 C-N-CA 126.885 2.183 . . . . 1.35 113.827 -175.15 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 8.6 mp0 -67.31 130.21 42.35 Favored 'General case' 0 N--CA 1.468 0.438 0 O-C-N 122.527 -0.396 . . . . 5.61 110.851 -164.056 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 42.4 ttt180 -63.09 126.59 27.87 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 118.363 0.529 . . . . 4.82 110.16 179.662 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.74 142.38 36.56 Favored Glycine 0 C--N 1.336 0.575 0 N-CA-C 114.634 0.613 . . . . 1.7 114.634 -160.204 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 35.9 m -64.4 122.93 16.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-N 114.792 -0.704 . . . . 3.27 109.484 -177.199 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 9.8 p -39.16 149.46 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 127.167 2.187 . . . . 4.07 113.566 -176.934 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.92 -155.28 0.61 Allowed Glycine 0 CA--C 1.531 1.054 0 O-C-N 121.405 -0.809 . . . . 1.9 114.296 172.343 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.9 mt -136.66 161.57 61.08 Favored Pre-proline 0 CA--C 1.541 0.6 0 C-N-CA 125.521 1.528 . . . . 3.54 110.751 176.377 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -84.14 -151.65 0.04 OUTLIER 'Trans proline' 0 CA--C 1.539 0.74 0 C-N-CA 123.89 3.06 . . . . 2.07 108.232 159.697 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.153 0 CA-C-O 117.211 -1.883 . . . . 3.16 112.438 141.901 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_exo . . . . . 0 CA--C 1.542 0.907 0 N-CA-C 111.716 -0.148 . . . . 2.87 111.716 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.38 177.19 25.9 Favored Glycine 0 CA--C 1.538 1.492 0 C-N-CA 120.074 -1.06 . . . . 1.35 112.989 128.045 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -82.2 155.93 17.08 Favored 'Trans proline' 0 CA--C 1.539 0.729 1 C-N-CA 125.418 4.079 . . . . 2.7 111.009 159.403 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -59.6 139.86 56.83 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 125.143 1.377 . . . . 5.13 110.757 169.746 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.29 161.94 47.44 Favored Glycine 0 C--N 1.338 0.646 0 C-N-CA 124.052 0.834 . . . . 1.37 114.932 -173.663 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 42.3 pt -57.78 145.71 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 C-N-CA 122.885 0.474 . . . . 5.12 111.892 179.707 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.19 149.31 48.73 Favored 'General case' 0 CA--C 1.543 0.675 0 O-C-N 121.525 -0.735 . . . . 1.49 112.322 175.803 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.61 152.15 51.35 Favored Glycine 0 CA--C 1.53 1.001 0 N-CA-C 110.318 -1.113 . . . . 1.56 110.318 166.942 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.91 151.56 22.25 Favored 'General case' 0 N--CA 1.468 0.456 0 O-C-N 121.356 -1.085 . . . . 3.35 110.449 176.015 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 31.4 ptt180 -61.81 159.57 13.52 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.072 0.949 . . . . 6.34 113.368 -179.566 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.68 160.84 53.82 Favored Glycine 0 CA--C 1.532 1.122 0 C-N-CA 124.825 1.202 . . . . 2.1 114.816 -178.418 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 43.9 t -89.47 131.59 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 124.598 1.159 . . . . 3.39 113.673 -168.424 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 11.5 m -79.46 160.65 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 C-N-CA 126.143 1.777 . . . . 3.07 113.301 -168.381 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.12 -128.31 6.18 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 125.036 1.303 . . . . 1.78 112.812 176.926 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -170.9 156.89 5.0 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 125.359 1.464 . . . . 3.57 112.076 -163.837 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo . . . . . 0 C--O 1.254 1.295 0 C-N-CA 124.571 3.514 . . . . 2.57 112.28 155.584 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo . . . . . 0 CA--C 1.547 1.167 0 CA-C-O 118.964 -0.515 . . . . 3.0 111.517 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -65.91 -157.74 0.03 OUTLIER 'Trans proline' 0 CA--C 1.544 0.975 0 C-N-CA 123.192 2.595 . . . . 2.3 109.967 161.669 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -93.16 -176.73 40.66 Favored Glycine 0 CA--C 1.534 1.26 0 O-C-N 121.171 -0.956 . . . . 1.29 111.859 170.721 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -79.37 170.67 17.09 Favored 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 123.277 2.652 . . . . 2.53 112.295 173.65 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -38.03 135.98 0.64 Allowed 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 127.917 2.487 . . . . 1.96 114.333 154.736 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.81 173.18 54.66 Favored Glycine 0 CA--C 1.529 0.944 0 C-N-CA 126.193 1.854 . . . . 1.1 114.996 174.077 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 96.4 mt -67.57 144.1 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.601 1.161 . . . . 3.57 112.415 -171.133 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.98 132.08 46.18 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.593 1.157 . . . . 2.06 112.967 174.707 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -62.21 122.84 29.6 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 108.293 -1.923 . . . . 1.52 108.293 157.323 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -82.19 160.54 23.02 Favored 'General case' 0 C--N 1.327 -0.407 0 O-C-N 121.736 -0.861 . . . . 3.55 110.9 -173.723 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 9.0 tpp180 -48.31 136.04 12.86 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 124.552 1.141 . . . . 6.04 111.612 173.647 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.1 157.56 52.98 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 115.098 -0.955 . . . . 1.15 112.091 176.119 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.2 t -65.17 155.39 6.66 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 C-N-CA 124.882 1.273 . . . . 2.52 110.58 176.215 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 30.4 m -68.84 -171.18 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.547 0.864 0 C-N-CA 126.392 1.877 . . . . 2.99 112.054 171.42 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.33 -108.24 0.01 OUTLIER Glycine 0 CA--C 1.534 1.273 0 C-N-CA 124.748 1.166 . . . . 2.37 111.884 163.3 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 55.8 mt . . . . . 0 C--O 1.249 1.069 0 CA-C-O 117.647 -1.168 . . . . 4.75 111.563 166.448 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.61 0 CA-C-O 116.417 -2.324 . . . . 3.0 109.524 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -72.05 168.38 24.16 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 122.791 2.328 . . . . 2.86 111.236 179.439 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.49 175.26 6.9 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 127.892 2.477 . . . . 3.28 113.084 -177.472 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.94 173.48 52.43 Favored Glycine 0 N--CA 1.479 1.542 0 N-CA-C 116.595 1.398 . . . . 1.66 116.595 -168.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.2 pt -71.51 145.09 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 O-C-N 120.905 -1.35 . . . . 4.12 110.256 -177.079 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.94 139.9 58.36 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-O 121.441 0.638 . . . . 1.78 112.207 -176.33 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.51 161.14 2.53 Favored Glycine 0 CA--C 1.526 0.744 0 C-N-CA 127.202 2.334 . . . . 1.31 115.682 178.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 22.1 mp0 -68.17 148.9 50.23 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-N 113.708 -1.246 . . . . 4.69 110.042 -174.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.86 130.41 45.57 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.774 -0.579 . . . . 7.92 110.277 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.04 150.38 50.26 Favored Glycine 0 CA--C 1.526 0.723 0 C-N-CA 124.073 0.844 . . . . 1.47 111.841 175.021 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 32.9 m -64.04 145.11 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 123.968 0.907 . . . . 2.87 111.514 -179.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 19.1 m -52.83 149.74 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 124.177 0.991 . . . . 2.54 113.359 -177.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.15 158.64 53.02 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-N 115.985 -0.552 . . . . 1.56 112.091 168.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 9.0 mp -89.2 158.04 47.08 Favored Pre-proline 0 CA--C 1.544 0.72 0 C-N-CA 123.221 0.608 . . . . 5.74 110.813 -176.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -78.19 -166.04 0.37 Allowed 'Trans proline' 0 CA--C 1.537 0.633 0 C-N-CA 123.596 2.864 . . . . 2.98 109.446 160.267 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.153 0 CA-C-O 117.35 -1.806 . . . . 3.58 111.952 150.297 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo . . . . . 0 N--CA 1.481 0.759 0 CA-C-O 118.484 -0.715 . . . . 2.65 111.482 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.02 159.62 51.09 Favored Glycine 0 CA--C 1.539 1.588 0 N-CA-C 110.886 -0.886 . . . . 1.29 110.886 150.245 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -72.09 177.45 7.14 Favored 'Trans proline' 0 CA--C 1.539 0.76 0 C-N-CA 123.244 2.63 . . . . 2.23 108.859 156.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 11.5 tt0 -60.19 172.63 0.78 Allowed 'General case' 0 CA--C 1.544 0.731 0 N-CA-C 114.935 1.457 . . . . 5.59 114.935 -175.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.17 159.48 51.77 Favored Glycine 0 CA--C 1.527 0.811 0 O-C-N 120.995 -1.066 . . . . 1.0 113.563 176.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 29.9 mm -60.25 141.48 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 123.669 0.788 . . . . 4.0 109.578 168.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.42 151.63 31.97 Favored 'General case' 0 CA--C 1.542 0.66 0 CA-C-O 122.756 1.265 . . . . 1.37 113.773 -179.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.19 137.67 38.25 Favored Glycine 0 CA--C 1.523 0.531 0 C-N-CA 125.25 1.405 . . . . 1.67 112.42 -179.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 94.9 mm-40 -81.92 124.84 30.08 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.577 -0.811 . . . . 4.54 109.167 -175.039 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 10.9 ptt180 -55.15 153.64 6.55 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 126.215 1.806 . . . . 7.33 114.064 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.92 173.65 54.69 Favored Glycine 0 CA--C 1.529 0.922 0 C-N-CA 124.133 0.873 . . . . 1.76 113.355 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 59.5 t -93.43 131.64 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 124.503 1.121 . . . . 3.58 112.83 -165.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 19.0 m -60.39 159.99 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 127.61 2.364 . . . . 3.0 114.414 -173.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.81 -136.7 5.25 Favored Glycine 0 CA--C 1.529 0.908 0 C-N-CA 124.191 0.9 . . . . 2.15 112.09 168.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -170.71 160.81 5.88 Favored Pre-proline 0 CA--C 1.543 0.705 0 C-N-CA 124.766 1.226 . . . . 3.98 111.534 -161.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo . . . . . 0 C--O 1.256 1.42 0 C-N-CA 124.586 3.524 . . . . 3.17 112.249 161.422 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo . . . . . 0 N--CA 1.486 1.076 0 CA-C-O 118.989 -0.505 . . . . 2.61 111.251 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -73.18 -130.07 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.939 0 C-N-CA 123.198 2.599 . . . . 2.45 107.778 162.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.29 168.23 48.14 Favored Glycine 0 CA--C 1.536 1.391 0 CA-C-N 119.509 1.049 . . . . 1.35 111.496 164.294 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.99 -44.83 0.31 Allowed 'Trans proline' 0 N--CA 1.458 -0.562 0 C-N-CA 122.578 2.185 . . . . 3.95 112.329 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 30.5 tp60 166.83 137.44 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 127.926 2.49 . . . . 1.73 105.526 -153.169 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.36 160.04 37.67 Favored Glycine 0 N--CA 1.468 0.823 0 C-N-CA 125.958 1.742 . . . . 1.16 112.927 169.228 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 46.7 mt -61.69 143.73 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 124.055 0.942 . . . . 3.15 111.022 -179.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.88 148.14 21.72 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.313 1.045 . . . . 1.44 113.559 174.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.87 149.42 34.61 Favored Glycine 0 C--N 1.339 0.712 0 C-N-CA 123.778 0.704 . . . . 1.14 111.375 -178.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 13.5 mp0 -90.85 -177.84 5.07 Favored 'General case' 0 CA--C 1.539 0.536 0 O-C-N 122.156 -0.614 . . . . 3.33 109.956 177.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 9.6 ptp180 -67.22 164.48 18.15 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-O 122.301 1.048 . . . . 6.27 113.592 -174.2 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.9 165.62 49.5 Favored Glycine 0 CA--C 1.531 1.031 0 C-N-CA 124.77 1.176 . . . . 1.17 111.862 166.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.7 t -64.08 144.99 14.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.282 1.033 . . . . 2.12 110.782 177.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 29.6 m -79.83 -171.67 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.833 0 C-N-CA 125.081 1.353 . . . . 3.59 111.622 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.13 179.42 7.05 Favored Glycine 0 CA--C 1.533 1.174 0 C-N-CA 124.842 1.211 . . . . 2.21 114.775 174.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 7.5 mt . . . . . 0 C--O 1.249 1.057 0 N-CA-C 114.527 1.306 . . . . 4.59 114.527 -169.77 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.555 0 CA-C-O 115.845 -2.642 . . . . 3.17 108.493 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -76.82 169.53 21.54 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 123.133 2.555 . . . . 2.58 111.225 177.276 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -76.32 -166.96 0.69 Allowed 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 127.017 2.127 . . . . 3.05 112.681 167.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.19 174.48 49.59 Favored Glycine 0 N--CA 1.472 1.088 0 O-C-N 121.308 -0.87 . . . . 1.5 114.737 -178.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 33.2 pt -73.15 150.38 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 O-C-N 122.329 -0.512 . . . . 4.27 109.693 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -49.1 131.98 19.26 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-O 121.775 0.798 . . . . 1.9 112.421 177.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.55 148.36 9.49 Favored Glycine 0 CA--C 1.519 0.344 0 C-N-CA 127.305 2.383 . . . . 1.25 112.856 166.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 78.7 mm-40 -80.64 132.61 35.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.081 -0.559 . . . . 4.26 109.534 -166.354 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 60.6 ttp180 -52.88 127.94 25.29 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.76 1.624 . . . . 9.0 113.292 -173.273 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.21 159.83 53.61 Favored Glycine 0 N--CA 1.468 0.78 0 N-CA-C 116.012 1.165 . . . . 1.72 116.012 -170.521 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 27.8 m -72.39 143.13 14.36 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 C-N-CA 124.357 1.063 . . . . 3.27 111.365 176.114 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 31.0 m -50.58 156.48 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 C-N-CA 126.803 2.041 . . . . 2.94 116.116 -168.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -81.27 -173.54 47.94 Favored Glycine 0 CA--C 1.533 1.187 0 C-N-CA 123.804 0.716 . . . . 1.81 113.028 162.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 7.2 mp -120.88 163.09 31.56 Favored Pre-proline 0 CA--C 1.542 0.656 0 C-N-CA 125.745 1.618 . . . . 4.98 111.427 178.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -83.17 -138.11 0.02 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.691 0 C-N-CA 123.738 2.959 . . . . 2.4 107.708 156.285 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.329 0 CA-C-O 116.907 -2.052 . . . . 3.41 113.292 142.836 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo . . . . . 0 N--CA 1.489 1.259 0 N-CA-C 109.306 -1.075 . . . . 2.85 109.306 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.13 147.46 37.87 Favored Glycine 0 CA--C 1.538 1.52 0 CA-C-O 118.546 -1.141 . . . . 1.46 110.718 162.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -72.29 179.89 4.61 Favored 'Trans proline' 0 CA--C 1.54 0.797 0 C-N-CA 123.871 3.047 . . . . 2.5 109.9 163.059 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 12.1 tt0 -53.71 162.82 0.79 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.087 1.355 . . . . 5.43 114.437 178.511 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.25 161.23 51.7 Favored Glycine 0 N--CA 1.47 0.965 0 O-C-N 121.289 -0.882 . . . . 1.11 112.989 -178.415 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.6 pp -65.58 150.13 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 O-C-N 121.944 -0.739 . . . . 5.46 111.117 171.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.47 147.15 49.75 Favored 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 114.431 1.271 . . . . 1.85 114.431 -175.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.58 158.45 53.19 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 124.821 1.2 . . . . 1.77 111.492 170.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 21.2 mp0 -69.1 150.52 47.49 Favored 'General case' 0 CA--C 1.536 0.418 0 O-C-N 121.979 -0.718 . . . . 4.15 111.408 -173.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 17.0 mtt180 -67.55 148.74 51.05 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 109.693 -0.484 . . . . 6.89 109.693 160.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.3 165.53 43.04 Favored Glycine 0 CA--C 1.533 1.165 0 N-CA-C 115.052 0.781 . . . . 2.19 115.052 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 23.3 m -78.97 130.18 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 114.432 1.271 . . . . 4.41 114.432 -168.383 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.7 m -85.23 154.96 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 126.119 1.767 . . . . 3.1 112.113 -170.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.57 -134.4 8.46 Favored Glycine 0 CA--C 1.53 0.994 0 C-N-CA 124.442 1.02 . . . . 1.72 113.273 179.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -166.31 161.04 12.43 Favored Pre-proline 0 CA--C 1.547 0.831 0 C-N-CA 125.498 1.519 . . . . 3.79 112.326 -165.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo . . . . . 0 C--O 1.254 1.323 0 C-N-CA 124.821 3.681 . . . . 2.66 112.249 152.161 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo . . . . . 0 N--CA 1.487 1.097 0 CA-C-O 119.017 -0.493 . . . . 2.42 111.099 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -71.78 -138.87 0.02 OUTLIER 'Trans proline' 0 CA--C 1.546 1.1 0 C-N-CA 123.465 2.776 . . . . 2.06 107.988 157.704 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.87 168.48 37.59 Favored Glycine 0 CA--C 1.54 1.598 0 CA-C-N 119.383 0.992 . . . . 1.12 112.23 166.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -79.28 -43.65 0.14 Allowed 'Trans proline' 0 CA--C 1.535 0.555 0 C-N-CA 123.021 2.481 . . . . 3.65 113.662 -176.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.42 HE21 ' N ' ' C' ' 16' ' ' GLY . 30.4 tp60 171.61 141.12 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 127.452 2.301 . . . . 1.81 105.865 -154.355 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . 0.42 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -91.17 173.37 37.56 Favored Glycine 0 N--CA 1.466 0.634 0 C-N-CA 126.263 1.887 . . . . 1.19 114.474 171.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 3.9 mp -63.03 132.0 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 C-N-CA 124.464 1.106 . . . . 4.36 111.303 -175.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.66 135.05 57.18 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.824 0.85 . . . . 1.4 112.337 175.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -68.06 139.18 33.93 Favored Glycine 0 C--N 1.334 0.446 0 C-N-CA 124.835 1.207 . . . . 1.43 111.014 -173.202 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 98.8 mm-40 -93.19 158.22 15.87 Favored 'General case' 0 C--N 1.324 -0.501 0 O-C-N 122.026 -0.691 . . . . 5.24 111.856 -168.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.51 133.56 46.06 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 115.866 -0.606 . . . . 4.71 110.146 178.208 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.62 163.95 49.12 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 123.328 0.489 . . . . 1.21 113.491 -172.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 1.7 t -64.82 154.9 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 C-N-CA 123.372 0.669 . . . . 2.27 110.517 175.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 30.5 m -75.54 -173.5 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.816 0 C-N-CA 124.704 1.202 . . . . 3.71 110.898 170.611 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.97 -132.66 0.14 Allowed Glycine 0 CA--C 1.536 1.396 0 C-N-CA 125.078 1.323 . . . . 3.43 112.583 167.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 7.7 tt . . . . . 0 C--O 1.251 1.143 0 C-N-CA 126.643 1.977 . . . . 6.26 112.771 178.722 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.564 0 CA-C-O 116.782 -2.121 . . . . 3.39 110.134 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -70.44 167.15 26.16 Favored 'Trans proline' 0 C--N 1.348 0.525 0 C-N-CA 123.241 2.628 . . . . 2.51 110.9 177.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.12 176.45 9.74 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 127.938 2.495 . . . . 2.68 114.357 -172.929 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.9 177.44 44.77 Favored Glycine 0 N--CA 1.48 1.633 0 N-CA-C 116.8 1.48 . . . . 1.3 116.8 -169.404 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 7.8 pt -70.04 147.84 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 O-C-N 121.192 -1.181 . . . . 4.05 110.608 -173.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.14 134.78 44.24 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.77 0.795 . . . . 1.85 112.154 -179.058 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.76 144.85 25.78 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 126.364 1.935 . . . . 1.21 112.814 173.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 84.7 mm-40 -67.91 125.22 25.61 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 108.651 -0.87 . . . . 3.8 108.651 -170.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 32.1 ttt-85 -69.53 145.43 52.63 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-O 121.832 0.825 . . . . 5.54 112.779 -156.016 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.28 144.31 37.34 Favored Glycine 0 CA--C 1.524 0.611 0 CA-C-O 122.296 0.942 . . . . 1.69 113.458 -175.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.3 t -62.79 150.17 9.31 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.521 0 C-N-CA 127.398 2.279 . . . . 3.71 111.444 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.4 m -48.44 158.83 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 C-N-CA 125.809 1.644 . . . . 2.51 113.993 173.154 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.85 174.09 40.52 Favored Glycine 0 CA--C 1.53 1.027 0 CA-C-N 115.999 -0.546 . . . . 1.41 111.931 160.786 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 79.8 mt -113.04 157.3 41.14 Favored Pre-proline 0 CA--C 1.539 0.526 0 C-N-CA 124.219 1.008 . . . . 4.31 110.181 -178.375 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -79.74 -158.26 0.09 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.793 0 C-N-CA 123.395 2.73 . . . . 2.66 108.96 160.13 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.225 0 CA-C-O 118.06 -1.411 . . . . 3.4 113.251 154.182 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo . . . . . 0 CA--C 1.544 1.01 0 CA-C-O 119.493 -0.295 . . . . 2.46 111.769 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.15 170.72 37.2 Favored Glycine 0 CA--C 1.54 1.614 0 CA-C-O 118.86 -0.967 . . . . 1.35 112.175 125.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -72.23 -179.78 4.29 Favored 'Trans proline' 0 CA--C 1.541 0.829 0 C-N-CA 123.439 2.759 . . . . 2.37 108.742 148.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 pm0 -70.39 -175.15 0.95 Allowed 'General case' 0 CA--C 1.546 0.8 0 N-CA-C 113.946 1.091 . . . . 5.2 113.946 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.89 168.12 50.65 Favored Glycine 0 CA--C 1.528 0.901 0 O-C-N 120.347 -1.471 . . . . 0.92 114.187 -178.507 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 79.0 mt -76.01 145.56 10.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 124.569 1.148 . . . . 3.46 108.988 167.465 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -73.65 152.78 40.38 Favored 'General case' 0 CA--C 1.543 0.686 0 N-CA-C 115.161 1.541 . . . . 1.32 115.161 -170.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.36 132.74 21.12 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 125.615 1.579 . . . . 1.5 110.863 173.488 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -95.16 143.68 26.39 Favored 'General case' 0 N--CA 1.465 0.29 0 O-C-N 121.501 -0.999 . . . . 3.76 111.195 -172.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 3.2 mtm180 -55.83 150.89 12.26 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 125.605 1.562 . . . . 6.46 113.802 175.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.79 179.22 44.26 Favored Glycine 0 CA--C 1.538 1.521 0 C-N-CA 124.929 1.252 . . . . 2.05 113.252 165.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 58.4 t -112.43 148.63 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 C-N-CA 125.138 1.375 . . . . 4.61 113.019 -154.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.9 p -53.19 152.56 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 128.92 2.888 . . . . 4.91 115.708 -172.382 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.38 -131.59 3.4 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 125.097 1.332 . . . . 2.16 111.193 165.299 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -172.68 161.57 3.94 Favored Pre-proline 0 CA--C 1.544 0.745 0 C-N-CA 126.153 1.781 . . . . 3.92 111.018 -165.082 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo . . . . . 0 C--O 1.255 1.371 0 C-N-CA 124.644 3.563 . . . . 3.13 112.045 154.05 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo . . . . . 0 CA--C 1.547 1.14 0 CA-C-O 119.265 -0.389 . . . . 2.21 112.302 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -71.37 -132.24 0.01 OUTLIER 'Trans proline' 0 CA--C 1.542 0.893 0 C-N-CA 123.413 2.742 . . . . 2.11 108.121 162.524 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.3 162.09 34.72 Favored Glycine 0 CA--C 1.534 1.242 0 CA-C-N 119.821 1.191 . . . . 1.37 112.532 166.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -73.59 -49.11 0.22 Allowed 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 122.795 2.33 . . . . 3.62 112.079 176.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.456 HE21 ' N ' ' C' ' 16' ' ' GLY . 18.2 tp60 175.26 138.35 0.05 OUTLIER 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.129 1.772 . . . . 1.87 107.392 -152.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . 0.456 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -87.42 166.43 36.36 Favored Glycine 0 CA--C 1.527 0.84 0 C-N-CA 125.807 1.67 . . . . 1.03 112.677 169.256 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 72.6 mt -69.18 138.57 22.0 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 O-C-N 121.84 -0.8 . . . . 2.95 109.335 -179.33 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -65.13 158.72 25.14 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.868 1.062 . . . . 1.18 113.868 177.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -82.51 -168.36 42.07 Favored Glycine 0 CA--C 1.528 0.859 0 CA-C-O 122.384 0.991 . . . . 1.52 111.14 170.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -158.44 179.72 8.87 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 124.265 1.026 . . . . 3.04 109.711 -172.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 5.1 tmm_? -64.95 141.97 58.59 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 125.781 1.632 . . . . 6.29 111.791 -174.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.73 -165.66 35.71 Favored Glycine 0 CA--C 1.532 1.148 0 C-N-CA 125.144 1.354 . . . . 1.4 115.542 -174.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 48.6 t -64.49 147.43 12.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.807 1.643 . . . . 2.35 110.029 176.043 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 33.3 m -102.17 -178.49 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 C-N-CA 125.351 1.46 . . . . 3.31 112.223 -175.126 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.51 171.4 6.84 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 125.061 1.315 . . . . 1.81 115.503 176.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 2.7 mm? . . . . . 0 C--O 1.249 1.072 0 C-N-CA 126.408 1.883 . . . . 4.0 113.116 -166.185 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.645 0 CA-C-O 115.79 -2.672 . . . . 4.95 109.045 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -76.7 179.12 6.77 Favored 'Trans proline' 0 CA--C 1.537 0.647 0 C-N-CA 123.395 2.73 . . . . 3.54 111.29 176.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.95 -152.16 0.35 Allowed 'General case' 0 CA--C 1.548 0.889 0 C-N-CA 126.789 2.036 . . . . 3.17 110.449 175.791 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.37 162.63 44.03 Favored Glycine 0 N--CA 1.473 1.12 0 O-C-N 120.629 -1.295 . . . . 1.47 114.268 -173.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 25.4 pt -69.88 149.03 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 O-C-N 121.226 -1.161 . . . . 3.61 110.525 178.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.98 132.56 50.25 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 123.555 0.742 . . . . 1.81 111.767 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.2 136.69 25.46 Favored Glycine 0 CA--C 1.522 0.498 0 C-N-CA 126.021 1.772 . . . . 2.11 112.13 169.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 77.7 mm-40 -72.48 140.14 48.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.198 -0.501 . . . . 4.01 110.438 -166.806 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 46.8 ttt85 -66.63 134.24 51.91 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-O 121.372 0.606 . . . . 7.22 111.287 -172.625 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.53 146.77 46.33 Favored Glycine 0 CA--C 1.527 0.798 0 CA-C-O 122.08 0.822 . . . . 1.78 113.41 178.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.6 t -67.01 118.61 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 C-N-CA 125.819 1.648 . . . . 3.0 110.475 -171.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 24.3 m -44.84 143.71 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 C-N-CA 125.042 1.337 . . . . 2.94 114.383 -170.093 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -75.08 174.06 52.12 Favored Glycine 0 CA--C 1.533 1.174 0 N-CA-C 111.884 -0.486 . . . . 1.68 111.884 165.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 7.0 mp -122.24 160.32 48.3 Favored Pre-proline 0 CA--C 1.539 0.541 0 C-N-CA 125.273 1.429 . . . . 4.14 109.943 175.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.405 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 41.4 Cg_endo -75.98 -158.22 0.08 OUTLIER 'Trans proline' 0 CA--C 1.537 0.666 0 C-N-CA 122.882 2.388 . . . . 3.43 109.256 157.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.192 0 CA-C-O 116.76 -2.133 . . . . 5.32 112.532 142.762 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo . . . . . 0 N--CA 1.491 1.352 0 N-CA-C 109.089 -1.158 . . . . 3.38 109.089 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.27 144.88 36.74 Favored Glycine 0 CA--C 1.543 1.822 0 CA-C-O 118.697 -1.057 . . . . 1.81 111.415 164.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -77.04 -176.12 3.02 Favored 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 124.675 3.583 . . . . 2.52 110.134 163.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -61.19 173.47 0.84 Allowed 'General case' 0 CA--C 1.546 0.804 0 N-CA-C 116.336 1.976 . . . . 4.83 116.336 -175.247 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -90.01 154.37 23.7 Favored Glycine 0 CA--C 1.526 0.726 0 O-C-N 121.147 -0.971 . . . . 1.18 113.677 -174.062 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 79.7 mt -60.63 134.12 26.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 108.347 -0.983 . . . . 3.68 108.347 168.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.09 152.21 39.97 Favored 'General case' 0 CA--C 1.544 0.719 0 N-CA-C 112.752 0.649 . . . . 1.77 112.752 -177.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -83.81 -168.9 44.43 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 124.076 0.846 . . . . 2.5 111.003 169.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -148.6 176.21 10.53 Favored 'General case' 0 CA--C 1.536 0.431 0 O-C-N 120.961 -1.317 . . . . 4.44 112.231 171.048 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.2 ttm180 -59.65 159.47 8.53 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 125.661 1.585 . . . . 6.64 115.07 -164.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -63.66 157.91 40.94 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-N 116.276 -0.42 . . . . 2.42 114.136 170.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 35.9 t -85.61 121.27 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 C-N-CA 123.742 0.817 . . . . 3.94 111.86 -165.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 6.3 m -69.06 156.51 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 126.154 1.781 . . . . 3.48 113.715 -170.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.29 -142.66 10.99 Favored Glycine 0 N--CA 1.469 0.878 0 C-N-CA 124.17 0.89 . . . . 2.04 112.436 167.059 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.405 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.6 pt? -172.73 160.48 3.87 Favored Pre-proline 0 CA--C 1.545 0.786 0 C-N-CA 124.854 1.262 . . . . 4.8 111.714 -158.428 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo . . . . . 0 C--O 1.255 1.336 0 C-N-CA 124.828 3.686 . . . . 3.02 112.329 155.292 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo . . . . . 0 N--CA 1.487 1.092 0 CA-C-O 119.2 -0.417 . . . . 2.98 111.125 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.56 -131.27 0.01 OUTLIER 'Trans proline' 0 CA--C 1.542 0.895 0 C-N-CA 122.362 2.041 . . . . 2.26 106.859 152.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.99 -179.78 48.74 Favored Glycine 0 CA--C 1.535 1.326 0 CA-C-N 119.558 1.072 . . . . 1.38 113.075 169.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -78.45 -110.0 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.039 0 C-N-CA 124.867 3.712 . . . . 2.59 109.718 161.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.501 HE21 ' N ' ' C' ' 16' ' ' GLY . 8.5 tp60 -146.58 134.51 21.37 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 127.904 2.482 . . . . 2.35 107.676 -159.395 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . 0.501 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -74.34 169.52 54.01 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 124.614 1.102 . . . . 1.45 113.728 170.51 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 65.8 mt -73.16 131.44 34.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 121.745 -0.856 . . . . 3.78 111.221 -174.083 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.37 154.17 35.16 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 113.693 0.997 . . . . 1.74 113.693 178.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -82.99 162.4 40.71 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 124.806 1.193 . . . . 1.66 112.711 177.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 13.9 mp0 -101.69 -175.87 2.97 Favored 'General case' 0 CA--C 1.545 0.753 0 O-C-N 121.425 -1.044 . . . . 3.17 111.189 -178.115 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.46 140.66 54.07 Favored 'General case' 0 CA--C 1.541 0.601 0 O-C-N 121.514 -0.741 . . . . 6.49 111.561 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.57 154.63 36.49 Favored Glycine 0 N--CA 1.47 0.942 0 C-N-CA 125.517 1.532 . . . . 1.76 113.151 179.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 17.7 t -64.0 144.86 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 124.525 1.13 . . . . 3.29 111.02 -179.015 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 78.2 t -101.47 168.58 1.94 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.896 0 C-N-CA 126.603 1.961 . . . . 5.85 109.484 -175.143 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.25 177.43 3.35 Favored Glycine 0 CA--C 1.538 1.516 0 C-N-CA 124.196 0.903 . . . . 3.43 114.181 169.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 11.9 mt . . . . . 0 N--CA 1.484 1.241 0 N-CA-C 114.711 1.374 . . . . 4.79 114.711 -169.401 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.567 0 CA-C-O 116.258 -2.412 . . . . 2.94 109.321 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -67.57 170.02 14.62 Favored 'Trans proline' 0 CA--C 1.535 0.563 0 C-N-CA 123.029 2.486 . . . . 2.37 110.327 170.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 14.8 mm100 -56.51 -177.6 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 129.084 2.953 . . . . 6.07 116.256 -173.221 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -91.35 -173.05 43.26 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 124.309 0.957 . . . . 1.23 112.968 161.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 9.5 mt -72.05 128.09 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 N-CA-C 109.229 -0.656 . . . . 2.58 109.229 -177.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -52.92 135.15 36.99 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.487 0.715 . . . . 1.8 110.727 174.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.65 154.55 48.61 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 125.327 1.441 . . . . 1.27 113.387 -170.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 71.4 mm-40 -69.91 106.55 3.21 Favored 'General case' 0 CA--C 1.532 0.258 0 N-CA-C 109.877 -0.416 . . . . 3.77 109.877 -171.11 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.0 ttp180 -61.49 143.17 56.37 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 125.069 1.348 . . . . 4.93 114.186 -163.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.26 136.96 30.73 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 124.839 1.209 . . . . 1.57 113.517 -167.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 8.8 p -60.9 134.88 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 C-N-CA 125.493 1.517 . . . . 4.55 111.005 177.112 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 30.0 m -46.13 157.96 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.984 0 C-N-CA 127.148 2.179 . . . . 2.77 115.616 -171.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.42 171.6 43.36 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-N 115.424 -0.807 . . . . 1.35 113.476 168.315 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 87.6 mt -120.36 159.68 46.81 Favored Pre-proline 0 CA--C 1.54 0.566 0 C-N-CA 124.952 1.301 . . . . 3.31 110.776 -173.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -76.42 -169.56 0.72 Allowed 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 123.208 2.605 . . . . 2.16 109.797 161.006 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.182 0 CA-C-O 117.837 -1.535 . . . . 3.14 113.189 155.143 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo . . . . . 0 CA--C 1.545 1.073 0 CA-C-O 119.209 -0.413 . . . . 2.47 111.317 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.25 171.42 10.35 Favored Glycine 0 CA--C 1.54 1.613 0 C-N-CA 119.259 -1.448 . . . . 1.36 112.634 123.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -75.73 -57.89 0.05 OUTLIER 'Trans proline' 0 CA--C 1.535 0.554 0 C-N-CA 123.974 3.116 . . . . 2.7 111.042 170.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 175.55 152.38 0.14 Allowed 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 127.464 2.306 . . . . 5.67 107.702 -164.309 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.66 153.88 35.39 Favored Glycine 0 CA--C 1.527 0.785 0 C-N-CA 123.817 0.722 . . . . 0.92 112.695 174.793 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 4.7 mp -67.36 136.1 27.29 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 108.657 -0.868 . . . . 3.58 108.657 173.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.24 153.85 41.43 Favored 'General case' 0 CA--C 1.541 0.634 0 N-CA-C 113.277 0.843 . . . . 1.63 113.277 -179.154 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -66.98 141.73 40.29 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 111.312 -0.715 . . . . 1.63 111.312 172.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -81.04 164.96 22.1 Favored 'General case' 0 CA--C 1.54 0.576 0 O-C-N 120.899 -1.354 . . . . 3.39 112.218 173.86 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -63.6 146.15 54.3 Favored 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 125.926 1.69 . . . . 5.29 112.586 173.231 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.55 157.97 53.4 Favored Glycine 0 CA--C 1.533 1.216 0 N-CA-C 115.087 0.795 . . . . 2.25 115.087 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 17.9 m -91.65 133.08 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 N-CA-C 114.708 1.373 . . . . 4.69 114.708 -164.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -56.36 150.81 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 C-N-CA 127.791 2.436 . . . . 4.13 115.164 -165.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -84.72 -122.49 1.05 Allowed Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.217 0.913 . . . . 2.12 111.182 165.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.3 pt? -170.8 156.65 5.04 Favored Pre-proline 0 CA--C 1.543 0.696 0 C-N-CA 124.756 1.223 . . . . 3.76 112.014 -161.291 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo . . . . . 0 CA--C 1.552 1.379 0 C-N-CA 124.123 3.215 . . . . 2.58 111.767 159.1 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo . . . . . 0 N--CA 1.488 1.168 0 CA-C-O 118.779 -0.592 . . . . 3.12 111.591 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 80.0 Cg_exo -50.6 177.41 0.03 OUTLIER 'Trans proline' 0 CA--C 1.537 0.656 1 C-N-CA 125.565 4.177 . . . . 2.64 113.568 162.599 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.26 178.85 53.69 Favored Glycine 0 CA--C 1.541 1.711 0 C-N-CA 123.575 0.607 . . . . 1.22 112.6 167.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_endo -70.18 156.78 61.47 Favored 'Trans proline' 0 N--CA 1.457 -0.628 0 C-N-CA 123.319 2.679 . . . . 2.49 111.571 171.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.0 tp60 -39.25 126.21 1.69 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 127.609 2.363 . . . . 1.52 113.046 164.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.9 168.48 49.92 Favored Glycine 0 CA--C 1.529 0.922 0 C-N-CA 124.75 1.167 . . . . 0.99 112.67 170.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 29.7 mt -67.51 143.26 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 O-C-N 121.228 -1.16 . . . . 3.2 110.747 -172.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.77 151.82 28.62 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 112.891 0.7 . . . . 1.17 112.891 172.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.0 169.64 52.13 Favored Glycine 0 CA--C 1.527 0.816 0 CA-C-O 122.823 1.235 . . . . 1.12 113.519 178.532 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 40.0 mt-30 -95.84 154.29 17.3 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.355 -1.085 . . . . 4.66 111.767 -170.029 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -62.72 135.17 57.22 Favored 'General case' 0 C--O 1.234 0.253 0 N-CA-C 109.207 -0.664 . . . . 6.05 109.207 168.501 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -66.65 173.07 26.97 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 116.204 1.242 . . . . 1.11 116.204 -165.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 61.0 t -66.95 136.88 25.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 C-N-CA 124.443 1.097 . . . . 2.19 109.013 173.264 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 33.9 m -100.82 -169.68 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 C-N-CA 124.53 1.132 . . . . 2.97 110.845 -169.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.33 155.22 4.91 Favored Glycine 0 CA--C 1.532 1.154 0 C-N-CA 124.657 1.122 . . . . 1.58 114.27 172.39 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 8.8 mt . . . . . 0 C--O 1.249 1.079 0 CA-C-O 117.637 -1.173 . . . . 4.46 113.998 -162.871 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.52 0 CA-C-O 116.317 -2.379 . . . . 3.23 109.063 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -63.17 161.7 29.28 Favored 'Trans proline' 0 C--N 1.348 0.526 0 C-N-CA 122.83 2.353 . . . . 2.41 110.534 173.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.72 -179.14 0.35 Allowed 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.931 2.493 . . . . 3.34 113.978 176.559 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.98 -178.74 44.64 Favored Glycine 0 CA--C 1.527 0.797 0 C-N-CA 125.556 1.551 . . . . 1.29 114.686 174.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.8 mt -65.63 134.0 30.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 123.951 0.9 . . . . 2.96 109.922 -172.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.93 129.76 38.84 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 123.703 0.801 . . . . 2.34 111.471 173.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.78 166.77 54.18 Favored Glycine 0 CA--C 1.522 0.477 0 C-N-CA 127.44 2.447 . . . . 1.69 113.069 -177.396 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 14.0 mp0 -82.38 113.58 20.25 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 108.591 -0.892 . . . . 4.9 108.591 -162.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 73.8 ttt180 -49.56 130.66 20.71 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 124.2 1.0 . . . . 4.69 112.199 -173.368 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.26 145.58 39.5 Favored Glycine 0 N--CA 1.464 0.523 0 C-N-CA 124.75 1.167 . . . . 1.66 113.102 -173.544 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 28.2 m -63.89 161.28 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 124.566 1.147 . . . . 3.04 111.615 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.8 m -47.97 157.22 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 125.443 1.497 . . . . 2.6 113.667 177.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.29 173.33 39.87 Favored Glycine 0 CA--C 1.527 0.812 0 CA-C-N 115.391 -0.822 . . . . 1.42 112.171 162.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 87.6 mt -111.57 158.19 37.1 Favored Pre-proline 0 CA--C 1.537 0.451 0 C-N-CA 123.687 0.795 . . . . 4.58 110.523 -178.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -81.39 -160.56 0.13 Allowed 'Trans proline' 0 N--CA 1.454 -0.829 0 C-N-CA 123.302 2.668 . . . . 3.1 108.889 158.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.135 0 CA-C-O 117.75 -1.583 . . . . 3.91 113.021 152.076 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo . . . . . 0 CA--C 1.543 0.927 0 CA-C-O 119.157 -0.435 . . . . 2.44 111.664 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.57 162.99 43.93 Favored Glycine 0 CA--C 1.543 1.834 0 C-N-CA 119.516 -1.326 . . . . 1.38 111.766 130.018 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -76.49 -53.54 0.08 OUTLIER 'Trans proline' 0 CA--C 1.536 0.618 0 C-N-CA 124.876 3.717 . . . . 3.22 113.055 177.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -177.13 159.16 1.6 Allowed 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 128.45 2.7 . . . . 4.8 106.8 -162.471 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.11 155.26 22.88 Favored Glycine 0 N--CA 1.468 0.817 0 C-N-CA 124.189 0.899 . . . . 1.03 113.039 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 34.4 mm -67.94 130.37 33.1 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 N-CA-C 109.107 -0.701 . . . . 3.4 109.107 172.601 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -73.28 166.76 22.57 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 113.866 1.062 . . . . 2.12 113.866 -174.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -73.93 113.63 4.25 Favored Glycine 0 CA--C 1.53 1.027 0 C-N-CA 124.313 0.958 . . . . 2.21 112.516 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 -66.23 141.51 58.02 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 123.683 0.793 . . . . 4.88 112.769 178.44 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 9.2 mtt85 -62.05 159.44 14.43 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 115.096 1.517 . . . . 6.59 115.096 -176.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.99 -179.29 44.46 Favored Glycine 0 CA--C 1.538 1.474 0 C-N-CA 125.453 1.501 . . . . 2.0 113.151 163.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 15.6 m -112.03 146.97 16.2 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 N-CA-C 115.015 1.487 . . . . 3.83 115.015 -158.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 8.9 p -54.36 152.42 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 127.973 2.509 . . . . 4.8 115.351 -170.332 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -85.72 -129.23 2.24 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 124.599 1.095 . . . . 1.99 111.062 162.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -170.79 159.94 5.71 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 125.252 1.421 . . . . 3.76 111.777 -168.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo . . . . . 0 C--O 1.256 1.397 1 C-N-CA 125.306 4.004 . . . . 2.69 111.931 155.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo . . . . . 0 CA--C 1.547 1.149 0 CA-C-O 118.318 -0.784 . . . . 2.82 111.433 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -54.04 -169.49 0.02 OUTLIER 'Trans proline' 0 CA--C 1.541 0.864 1 C-N-CA 126.043 4.495 . . . . 2.16 113.595 164.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -83.83 175.03 51.76 Favored Glycine 0 CA--C 1.542 1.779 0 O-C-N 121.769 -0.582 . . . . 1.15 112.345 165.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -69.47 157.91 59.26 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 122.996 2.464 . . . . 2.53 111.166 170.076 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 tp60 -41.09 124.87 2.32 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.82 2.048 . . . . 1.61 113.439 165.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.65 154.65 53.01 Favored Glycine 0 CA--C 1.53 0.974 0 C-N-CA 124.391 0.996 . . . . 1.03 112.382 171.135 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 1.8 mp -67.87 146.1 13.21 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 C-N-CA 124.524 1.129 . . . . 3.73 110.99 -168.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.95 142.0 54.54 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 125.216 1.406 . . . . 1.48 113.197 178.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -76.07 134.04 15.21 Favored Glycine 0 C--N 1.333 0.366 0 N-CA-C 110.384 -1.086 . . . . 1.41 110.384 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -88.09 171.9 9.92 Favored 'General case' 0 CA--C 1.542 0.644 0 CA-C-N 115.088 -0.556 . . . . 3.1 109.524 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -61.12 155.27 20.95 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.711 0.767 . . . . 5.65 112.279 179.544 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.44 -176.62 25.09 Favored Glycine 0 CA--C 1.53 1.012 0 C-N-CA 124.995 1.283 . . . . 1.45 113.512 179.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 49.0 t -59.13 143.5 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.879 1.272 . . . . 2.74 110.279 176.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 30.9 m -97.76 -175.75 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.056 1.342 . . . . 4.11 112.024 -173.665 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.43 167.35 19.02 Favored Glycine 0 CA--C 1.532 1.127 0 C-N-CA 124.984 1.278 . . . . 2.23 114.867 175.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 9.6 mp . . . . . 0 C--O 1.249 1.046 0 C-N-CA 126.516 1.927 . . . . 4.7 113.463 -166.9 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.731 0 CA-C-O 116.337 -2.368 . . . . 5.59 108.929 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -77.37 -172.43 1.45 Allowed 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 122.943 2.429 . . . . 4.8 109.981 171.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.9 -137.18 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 124.583 1.153 . . . . 3.38 110.188 157.295 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.52 -148.78 17.59 Favored Glycine 0 N--CA 1.468 0.83 0 CA-C-O 122.827 1.237 . . . . 1.87 114.75 172.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.9 mt -84.1 158.38 3.6 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.506 0 C-N-CA 124.131 0.972 . . . . 4.03 108.435 177.371 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.65 46.69 0.09 Allowed 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 126.807 2.043 . . . . 4.24 112.599 170.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 61.56 -155.09 37.51 Favored Glycine 0 C--N 1.337 0.609 0 C-N-CA 125.289 1.424 . . . . 2.09 112.627 -171.122 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -105.56 160.92 14.8 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.935 0.874 . . . . 6.42 110.408 158.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.4 tpt180 -66.0 141.24 58.25 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.203 -0.908 . . . . 4.58 109.828 163.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -93.29 -167.18 38.39 Favored Glycine 0 C--O 1.227 -0.308 0 C-N-CA 125.324 1.44 . . . . 2.45 112.787 177.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 52.8 t -82.61 132.93 30.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 124.524 1.13 . . . . 3.75 109.035 -176.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.8 m -56.37 145.61 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 C-N-CA 124.47 1.108 . . . . 3.3 112.926 -178.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.402 ' H ' ' HB ' ' B' ' 23' ' ' VAL . . . -90.96 145.13 17.64 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 109.951 -1.26 . . . . 1.75 109.951 165.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 85.3 mt -91.18 156.43 43.86 Favored Pre-proline 0 N--CA 1.472 0.662 0 CA-C-O 117.161 -1.4 . . . . 4.86 110.444 171.202 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -80.24 -158.04 0.09 OUTLIER 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 123.645 2.897 . . . . 4.01 109.23 166.393 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.24 0 CA-C-O 117.549 -1.695 . . . . 5.43 113.458 154.643 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo . . . . . 0 N--CA 1.491 1.364 0 N-CA-C 109.165 -1.129 . . . . 4.5 109.165 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.04 140.92 30.72 Favored Glycine 0 CA--C 1.539 1.55 0 CA-C-O 118.044 -1.42 . . . . 2.46 110.003 158.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -68.62 -175.01 0.79 Allowed 'Trans proline' 0 CA--C 1.538 0.695 0 C-N-CA 123.787 2.991 . . . . 2.43 109.878 162.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 4.7 tp-100 -50.47 148.79 3.5 Favored 'General case' 0 CA--C 1.541 0.599 0 N-CA-C 114.734 1.383 . . . . 5.83 114.734 -174.476 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.15 165.83 48.62 Favored Glycine 0 C--N 1.339 0.736 0 CA-C-O 123.285 1.492 . . . . 1.97 112.854 169.145 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 8.2 mm -71.67 160.84 5.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 123.279 1.514 . . . . 4.81 110.722 178.336 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -46.35 147.67 1.09 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.854 1.261 . . . . 3.12 112.975 153.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -82.55 169.16 48.79 Favored Glycine 0 C--N 1.336 0.574 0 CA-C-O 122.626 1.125 . . . . 2.97 112.681 178.726 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -118.41 123.59 45.61 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 123.487 0.715 . . . . 4.73 111.014 -166.247 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 14.9 ptt180 -55.16 134.21 49.42 Favored 'General case' 0 N--CA 1.47 0.546 0 O-C-N 122.056 -0.403 . . . . 6.08 110.703 179.112 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.18 -45.4 93.76 Favored Glycine 0 N--CA 1.477 1.407 0 N-CA-C 114.825 0.69 . . . . 4.28 114.825 -150.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . 0.402 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 55.3 t -158.99 164.37 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.877 1 C-N-CA 132.117 4.167 . . . . 4.6 105.613 179.699 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 23.0 m -134.34 156.25 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 C-N-CA 125.989 1.716 . . . . 4.47 109.051 168.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -79.62 -175.28 47.54 Favored Glycine 0 C--N 1.335 0.515 0 CA-C-O 122.189 0.883 . . . . 2.9 114.263 179.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -159.08 158.11 28.5 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 126.982 2.113 . . . . 6.72 109.921 175.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.256 1.381 0 C-N-CA 125.293 3.996 . . . . 5.34 111.831 164.375 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo . . . . . 0 N--CA 1.486 1.04 0 CA-C-O 118.616 -0.66 . . . . 3.92 111.097 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -68.73 -163.78 0.1 OUTLIER 'Trans proline' 0 CA--C 1.544 0.987 0 C-N-CA 123.469 2.779 . . . . 3.34 109.466 157.182 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.91 154.09 52.72 Favored Glycine 0 CA--C 1.541 1.706 0 O-C-N 121.751 -0.593 . . . . 1.64 113.8 172.102 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -79.83 87.15 1.56 Allowed 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 124.504 3.469 . . . . 2.97 111.664 -173.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 30.4 tp60 67.8 -124.12 0.19 Allowed 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.615 1.166 . . . . 2.82 108.777 -176.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.63 -179.4 41.07 Favored Glycine 0 CA--C 1.534 1.256 1 C-N-CA 131.956 4.598 . . . . 2.81 107.523 -171.58 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -74.69 156.44 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 O-C-N 120.726 -1.455 . . . . 3.06 110.223 176.232 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.26 159.03 30.99 Favored 'General case' 0 CA--C 1.543 0.675 0 O-C-N 120.215 -1.553 . . . . 1.98 112.165 173.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -97.93 160.75 20.9 Favored Glycine 0 CA--C 1.53 0.988 0 C-N-CA 124.502 1.049 . . . . 1.9 112.124 177.576 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 22.9 mp0 -101.87 -179.79 4.11 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 124.376 1.071 . . . . 3.45 111.862 -170.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 6.2 tpt85 -66.8 138.62 57.49 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.908 0.883 . . . . 4.33 110.103 162.713 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.83 172.07 30.78 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 124.175 0.893 . . . . 1.9 112.009 172.214 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 1.9 t -57.15 144.64 9.07 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 124.914 1.285 . . . . 2.43 110.872 -179.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 7.5 p -75.9 -169.32 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.189 0 C-N-CA 124.557 1.143 . . . . 4.97 109.129 164.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.5 168.29 0.83 Allowed Glycine 0 CA--C 1.541 1.656 0 CA-C-N 119.858 1.208 . . . . 1.99 113.913 161.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 10.2 mp . . . . . 0 C--O 1.249 1.03 0 C-N-CA 125.72 1.608 . . . . 5.4 112.723 -171.784 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.588 0 CA-C-O 116.864 -2.076 . . . . 2.89 110.148 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -73.66 166.9 28.61 Favored 'Trans proline' 0 N--CA 1.458 -0.596 0 C-N-CA 123.268 2.645 . . . . 2.23 111.312 -177.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -60.92 167.07 3.04 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 126.473 1.909 . . . . 3.12 113.627 173.654 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -78.48 166.52 52.43 Favored Glycine 0 CA--C 1.518 0.247 0 CA-C-N 114.986 -1.007 . . . . 1.39 113.587 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 21.2 mt -51.93 124.76 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 C-N-CA 125.698 1.599 . . . . 2.91 109.557 178.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -42.9 132.45 3.91 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.715 1.206 . . . . 1.97 112.597 178.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.43 149.78 51.67 Favored Glycine 0 CA--C 1.517 0.195 0 C-N-CA 125.129 1.347 . . . . 1.33 111.673 -178.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 7.3 mp0 -62.68 114.53 3.64 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 114.962 -0.619 . . . . 4.66 109.636 -173.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 48.6 ttt85 -54.56 139.75 37.08 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.686 1.195 . . . . 5.51 112.435 -173.673 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.41 142.62 32.91 Favored Glycine 0 CA--C 1.525 0.698 0 C-N-CA 124.242 0.925 . . . . 1.73 112.71 -175.525 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -60.37 153.42 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 C-N-CA 126.4 1.88 . . . . 2.81 113.231 178.035 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 m -66.99 150.61 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 124.85 1.26 . . . . 2.81 112.924 -175.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.58 153.34 51.51 Favored Glycine 0 CA--C 1.531 1.037 0 CA-C-N 115.899 -0.591 . . . . 1.48 112.436 170.44 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 10.1 mp -83.62 160.25 59.29 Favored Pre-proline 0 CA--C 1.544 0.723 0 C-N-CA 123.882 0.873 . . . . 4.25 111.166 176.608 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -81.9 -158.71 0.1 OUTLIER 'Trans proline' 0 CA--C 1.537 0.649 0 C-N-CA 123.997 3.131 . . . . 2.01 109.127 158.228 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.169 0 CA-C-O 117.336 -1.813 . . . . 3.09 112.843 155.802 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo . . . . . 0 CA--C 1.545 1.056 0 CA-C-O 119.289 -0.38 . . . . 2.29 111.143 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.08 -178.49 10.44 Favored Glycine 0 CA--C 1.544 1.882 0 CA-C-O 119.035 -0.869 . . . . 1.59 112.625 125.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -77.83 -134.99 0.02 OUTLIER 'Trans proline' 0 CA--C 1.546 1.1 1 C-N-CA 125.642 4.228 . . . . 2.18 109.071 160.535 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.37 176.44 9.68 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 124.986 1.314 . . . . 4.75 110.99 166.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.14 157.85 39.49 Favored Glycine 0 N--CA 1.472 1.047 0 O-C-N 121.357 -0.839 . . . . 0.93 112.698 154.318 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 28.3 mm -77.88 131.49 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 108.596 -0.89 . . . . 4.09 108.596 173.647 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -77.4 157.67 30.46 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 114.078 1.14 . . . . 1.88 114.078 -173.063 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.01 121.31 8.39 Favored Glycine 0 CA--C 1.529 0.957 0 C-N-CA 124.298 0.951 . . . . 1.68 111.687 -179.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.96 155.54 40.7 Favored 'General case' 0 CA--C 1.54 0.58 0 O-C-N 121.496 -1.003 . . . . 3.2 111.759 174.344 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.7 ptt-85 -66.14 161.47 21.83 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 122.297 1.046 . . . . 5.22 113.045 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.75 -179.18 49.12 Favored Glycine 0 CA--C 1.529 0.91 0 C-N-CA 125.59 1.567 . . . . 1.89 111.865 172.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 7.0 m -100.89 139.79 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 N-CA-C 114.253 1.205 . . . . 4.06 114.253 -160.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 26.5 m -64.49 160.27 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 C-N-CA 126.292 1.837 . . . . 2.98 113.502 -174.386 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -88.92 -135.82 5.53 Favored Glycine 0 CA--C 1.529 0.914 0 C-N-CA 124.147 0.879 . . . . 1.78 111.84 171.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -167.29 163.65 9.94 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 125.576 1.55 . . . . 3.76 110.745 -167.031 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo . . . . . 0 C--O 1.257 1.445 0 C-N-CA 124.264 3.309 . . . . 2.61 112.163 167.177 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo . . . . . 0 N--CA 1.487 1.102 0 CA-C-O 119.059 -0.476 . . . . 2.39 111.837 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.28 -137.78 0.02 OUTLIER 'Trans proline' 0 CA--C 1.54 0.825 0 C-N-CA 123.298 2.665 . . . . 1.83 108.226 163.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -79.0 151.7 35.65 Favored Glycine 0 CA--C 1.542 1.753 0 CA-C-N 119.557 1.071 . . . . 1.2 112.758 173.431 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -85.19 64.08 6.08 Favored 'Trans proline' 0 CA--C 1.541 0.849 0 C-N-CA 124.556 3.504 . . . . 3.17 111.34 -176.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 71.89 151.52 0.11 Allowed 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 125.343 1.457 . . . . 2.55 112.716 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.03 153.74 22.05 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 124.769 1.176 . . . . 1.25 111.416 166.152 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 66.0 mt -71.62 144.77 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.8 0 O-C-N 121.805 -0.821 . . . . 2.89 111.193 -177.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.17 149.02 48.68 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.97 1.308 . . . . 1.39 113.205 175.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -88.7 140.95 16.23 Favored Glycine 0 CA--C 1.532 1.138 0 C-N-CA 125.106 1.336 . . . . 1.27 114.686 -175.124 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -71.51 157.15 38.52 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 126.641 1.976 . . . . 4.39 112.059 168.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 46.3 ttp180 -62.07 158.12 17.35 Favored 'General case' 0 CA--C 1.54 0.581 0 N-CA-C 114.331 1.234 . . . . 4.91 114.331 176.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -66.14 168.96 32.66 Favored Glycine 0 CA--C 1.537 1.434 0 CA-C-O 122.112 0.84 . . . . 1.13 113.237 158.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.2 t -68.03 160.85 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 125.86 1.664 . . . . 2.42 111.097 179.111 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 28.6 m -83.17 -175.19 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 125.896 1.678 . . . . 2.86 111.774 175.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.37 173.5 5.38 Favored Glycine 0 CA--C 1.537 1.409 0 C-N-CA 125.164 1.364 . . . . 1.61 114.55 169.073 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 5.7 mt . . . . . 0 C--O 1.25 1.113 0 N-CA-C 114.136 1.162 . . . . 4.15 114.136 -159.072 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.354 0 CA-C-O 116.197 -2.446 . . . . 3.08 107.782 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -69.16 -170.03 0.33 Allowed 'Trans proline' 0 CA--C 1.541 0.848 0 C-N-CA 122.256 1.971 . . . . 2.23 109.571 156.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -87.07 -168.68 2.33 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 127.414 2.286 . . . . 3.02 111.909 168.142 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.91 177.98 45.0 Favored Glycine 0 N--CA 1.474 1.209 0 C-N-CA 125.978 1.752 . . . . 1.63 112.957 161.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.483 ' H ' HD13 ' A' ' 17' ' ' ILE . 2.8 mp -61.98 141.44 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 O-C-N 121.813 -0.816 . . . . 3.82 110.372 -174.544 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.88 133.88 56.52 Favored 'General case' 0 CA--C 1.537 0.469 0 CA-C-N 119.039 0.836 . . . . 1.74 110.946 170.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.57 146.53 41.08 Favored Glycine 0 CA--C 1.523 0.581 0 C-N-CA 126.569 2.033 . . . . 1.43 114.603 -178.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 73.1 mm-40 -77.56 134.89 38.16 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 114.604 -0.798 . . . . 4.32 110.816 -166.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 31.6 mtt180 -59.21 137.46 57.96 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 121.642 0.734 . . . . 5.09 112.529 -171.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -78.35 -179.41 50.77 Favored Glycine 0 CA--C 1.523 0.581 0 CA-C-O 123.271 1.484 . . . . 1.87 115.363 -168.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -71.6 156.56 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 CA-C-N 113.489 -1.356 . . . . 3.09 111.826 -169.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 p -56.4 143.06 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 125.263 1.425 . . . . 6.49 111.967 168.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.433 ' H ' ' HB ' ' B' ' 23' ' ' VAL . . . -93.62 -162.78 36.25 Favored Glycine 0 N--CA 1.472 1.059 0 C-N-CA 124.426 1.013 . . . . 2.42 113.873 170.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 93.0 mt -142.43 153.47 62.46 Favored Pre-proline 0 N--CA 1.471 0.59 0 C-N-CA 126.044 1.738 . . . . 4.24 109.823 172.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -79.21 -155.6 0.06 OUTLIER 'Trans proline' 0 CA--C 1.539 0.752 0 C-N-CA 123.138 2.559 . . . . 2.58 108.909 159.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.291 0 CA-C-O 118.002 -1.443 . . . . 3.84 113.51 158.225 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo . . . . . 0 CA--C 1.544 0.994 0 CA-C-O 118.791 -0.587 . . . . 2.72 111.773 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.0 159.66 49.28 Favored Glycine 0 CA--C 1.548 2.147 0 C-N-CA 118.977 -1.582 . . . . 1.23 110.886 127.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . 0.422 ' HG2' ' H ' ' B' ' 15' ' ' GLN . 59.3 Cg_endo -75.84 -66.84 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.617 1 C-N-CA 125.349 4.033 . . . . 3.04 111.809 177.061 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.422 ' H ' ' HG2' ' B' ' 14' ' ' PRO . 0.0 OUTLIER -155.16 161.64 41.18 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 128.892 2.877 . . . . 5.39 107.182 -176.812 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.42 160.44 31.72 Favored Glycine 0 N--CA 1.464 0.555 0 C-N-CA 123.629 0.633 . . . . 1.04 112.922 174.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.3 pp -78.23 149.37 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 O-C-N 122.313 -0.522 . . . . 5.1 111.215 176.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.8 153.12 38.89 Favored 'General case' 0 CA--C 1.543 0.698 0 N-CA-C 113.528 0.936 . . . . 1.35 113.528 -174.777 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.81 147.7 26.7 Favored Glycine 0 CA--C 1.528 0.866 0 C-N-CA 125.947 1.737 . . . . 1.59 114.572 -172.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 37.4 tt0 -77.95 148.08 34.65 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 126.386 1.874 . . . . 4.86 111.599 172.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 31.6 mtt180 -64.86 164.37 12.57 Favored 'General case' 0 N--CA 1.473 0.702 0 O-C-N 121.306 -0.871 . . . . 4.99 112.299 174.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.3 -144.1 3.47 Favored Glycine 0 CA--C 1.534 1.222 0 CA-C-N 114.959 -1.018 . . . . 2.6 110.96 161.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . 0.433 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 49.8 t -53.26 137.52 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 C-N-CA 124.3 1.04 . . . . 6.39 112.687 -176.44 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 26.4 m -103.12 162.41 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 125.651 1.58 . . . . 4.08 111.23 172.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.14 171.7 24.75 Favored Glycine 0 C--N 1.338 0.656 0 C-N-CA 125.412 1.482 . . . . 2.83 113.507 -176.18 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -169.38 157.59 6.92 Favored Pre-proline 0 CA--C 1.545 0.754 0 C-N-CA 126.105 1.762 . . . . 4.43 111.521 -168.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo . . . . . 0 C--O 1.256 1.39 0 C-N-CA 124.611 3.541 . . . . 3.62 111.803 159.363 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo . . . . . 0 CA--C 1.548 1.178 0 CA-C-O 118.951 -0.521 . . . . 2.71 111.667 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -56.18 -174.4 0.04 OUTLIER 'Trans proline' 0 CA--C 1.539 0.756 0 C-N-CA 124.994 3.796 . . . . 2.39 112.863 164.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.71 178.13 54.1 Favored Glycine 0 CA--C 1.541 1.682 0 C-N-CA 123.628 0.633 . . . . 1.02 112.145 165.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -67.91 155.96 67.75 Favored 'Trans proline' 0 N--CA 1.457 -0.62 0 C-N-CA 122.904 2.403 . . . . 2.59 111.001 171.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 22.0 tp60 -40.55 121.36 1.42 Allowed 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 127.384 2.274 . . . . 1.53 112.946 169.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.4 157.08 44.72 Favored Glycine 0 CA--C 1.527 0.814 0 C-N-CA 124.29 0.948 . . . . 1.05 112.091 170.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 2.2 mp -65.22 140.55 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 123.548 0.739 . . . . 3.23 110.486 -169.129 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.51 156.57 15.98 Favored 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 123.065 1.412 . . . . 1.12 114.748 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.83 145.85 39.04 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 108.994 -1.643 . . . . 1.19 108.994 174.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 7.2 mp0 -82.99 -179.46 7.45 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.884 0.85 . . . . 4.02 110.441 -170.077 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 1.9 tmt_? -57.63 138.39 55.39 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-O 121.618 0.723 . . . . 3.96 110.095 169.119 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.46 148.25 51.09 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 124.367 0.985 . . . . 2.25 112.04 178.299 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 91.2 t -64.86 148.43 11.96 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.603 0 C-N-CA 124.246 1.018 . . . . 2.67 110.447 -173.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 12.3 p -97.24 171.79 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.995 0 C-N-CA 127.982 2.513 . . . . 3.9 111.059 -178.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.5 -168.66 0.61 Allowed Glycine 0 CA--C 1.54 1.614 0 C-N-CA 125.203 1.382 . . . . 2.08 116.083 171.102 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 15.5 mt . . . . . 0 C--O 1.249 1.047 0 C-N-CA 125.736 1.614 . . . . 4.14 115.12 -170.544 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.511 0 CA-C-O 116.915 -2.047 . . . . 3.38 110.172 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -71.62 162.02 43.46 Favored 'Trans proline' 0 N--CA 1.458 -0.575 0 C-N-CA 123.611 2.874 . . . . 2.63 111.39 -177.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 31.2 tp60 -46.07 163.73 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 129.228 3.011 . . . . 5.34 115.53 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.56 172.47 42.82 Favored Glycine 0 CA--C 1.524 0.638 0 C-N-CA 124.388 0.994 . . . . 1.21 114.616 168.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.481 ' H ' HD13 ' A' ' 17' ' ' ILE . 3.0 mp -60.41 140.53 18.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 C-N-CA 124.975 1.31 . . . . 4.08 109.858 -179.369 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.41 130.01 37.82 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 123.318 0.647 . . . . 2.58 111.291 170.512 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.59 161.49 54.22 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 126.122 1.82 . . . . 1.62 113.58 176.447 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 11.0 mm100 -74.33 115.35 13.74 Favored 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 109.675 -0.491 . . . . 4.43 109.675 -168.248 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -58.46 139.26 55.86 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.564 0.746 . . . . 4.54 112.219 -175.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.38 147.3 35.65 Favored Glycine 0 CA--C 1.522 0.527 0 C-N-CA 125.848 1.689 . . . . 1.59 113.542 -173.093 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.0 p -66.6 144.82 14.32 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 125.465 1.506 . . . . 4.88 110.573 176.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -50.69 157.61 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 126.09 1.756 . . . . 2.63 114.716 -175.257 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.5 175.4 53.49 Favored Glycine 0 N--CA 1.474 1.207 0 N-CA-C 110.787 -0.925 . . . . 1.69 110.787 158.311 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 17.6 mt -149.84 157.04 38.46 Favored Pre-proline 0 N--CA 1.471 0.621 0 N-CA-C 115.884 1.809 . . . . 4.01 115.884 -152.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -68.2 104.66 1.09 Allowed 'Trans proline' 0 N--CA 1.449 -1.09 0 N-CA-C 106.529 -2.143 . . . . 2.62 106.529 154.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.231 0 CA-C-O 118.923 -0.932 . . . . 6.39 114.218 -160.405 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo . . . . . 0 CA--C 1.544 0.987 0 N-CA-C 110.993 -0.426 . . . . 3.11 110.993 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.63 -170.4 0.41 Allowed Glycine 0 CA--C 1.538 1.488 0 C-N-CA 120.457 -0.878 . . . . 1.86 113.875 125.537 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -74.38 -123.39 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 0.998 0 C-N-CA 124.069 3.179 . . . . 2.17 107.545 157.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -100.29 178.7 4.68 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.309 1.443 . . . . 7.4 112.218 175.137 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.46 145.72 25.46 Favored Glycine 0 N--CA 1.472 1.047 0 O-C-N 121.202 -0.936 . . . . 1.22 112.684 164.215 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 96.7 mt -63.38 132.77 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 O-C-N 121.079 -1.248 . . . . 4.22 108.659 170.375 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -77.55 157.05 30.53 Favored 'General case' 0 CA--C 1.542 0.65 0 N-CA-C 114.151 1.167 . . . . 2.13 114.151 -169.382 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.54 140.27 40.64 Favored Glycine 0 CA--C 1.524 0.634 0 C-N-CA 126.229 1.871 . . . . 2.06 110.5 169.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 10.4 mp0 -95.95 147.86 23.24 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 123.308 0.643 . . . . 4.59 110.84 -165.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 3.8 ttt180 -64.12 154.76 33.61 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 124.525 1.13 . . . . 5.97 113.722 -176.229 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.68 155.86 52.35 Favored Glycine 0 CA--C 1.531 1.05 0 C-N-CA 124.042 0.83 . . . . 1.99 115.115 176.053 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 27.7 m -75.58 136.8 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 114.677 1.362 . . . . 4.08 114.677 -174.023 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.6 m -56.43 156.5 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.002 0 N-CA-C 116.729 2.122 . . . . 3.34 116.729 -162.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.56 -177.06 42.93 Favored Glycine 0 C--N 1.34 0.753 0 C-N-CA 125.864 1.697 . . . . 2.75 115.8 -167.087 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.6 mp -147.72 158.37 42.92 Favored Pre-proline 0 CA--C 1.546 0.813 0 C-N-CA 125.453 1.501 . . . . 5.93 113.031 -165.428 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo . . . . . 0 C--O 1.255 1.343 0 C-N-CA 123.843 3.029 . . . . 3.42 112.635 148.585 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo . . . . . 0 CA--C 1.547 1.151 0 CA-C-O 118.323 -0.782 . . . . 2.52 111.855 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_exo -49.58 -179.35 0.02 OUTLIER 'Trans proline' 0 C--N 1.35 0.655 1 C-N-CA 126.571 4.847 . . . . 2.67 114.402 166.549 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.26 148.55 51.41 Favored Glycine 0 CA--C 1.547 2.035 0 CA-C-O 119.368 -0.685 . . . . 1.46 112.059 162.327 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -81.55 61.95 8.17 Favored 'Trans proline' 0 CA--C 1.542 0.899 0 C-N-CA 125.036 3.824 . . . . 3.6 113.058 -169.056 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 74.7 147.32 0.09 Allowed 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.402 1.881 . . . . 2.48 112.774 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -85.85 146.08 21.17 Favored Glycine 0 CA--C 1.527 0.842 0 O-C-N 121.299 -0.875 . . . . 1.43 112.145 170.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 97.5 mt -63.46 148.77 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 124.607 1.163 . . . . 2.97 110.883 175.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.97 150.43 39.02 Favored 'General case' 0 CA--C 1.548 0.887 0 N-CA-C 114.383 1.253 . . . . 1.19 114.383 177.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -80.63 152.79 34.1 Favored Glycine 0 C--N 1.338 0.679 0 C-N-CA 125.44 1.495 . . . . 1.06 111.176 177.211 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 10.5 mp0 -101.18 161.0 13.92 Favored 'General case' 0 C--N 1.326 -0.419 0 O-C-N 121.726 -0.867 . . . . 3.42 110.095 -172.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -53.34 134.85 39.71 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 123.483 0.713 . . . . 4.74 109.804 172.62 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.25 177.19 29.4 Favored Glycine 0 CA--C 1.522 0.483 0 CA-C-N 115.713 -0.676 . . . . 1.06 112.105 -175.281 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 45.2 t -58.58 131.74 23.0 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 CA-C-O 121.464 0.65 . . . . 2.16 110.564 -177.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 8.7 p -70.23 158.68 5.99 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.394 0 C-N-CA 129.374 3.069 . . . . 4.51 112.774 177.322 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.72 167.1 1.09 Allowed Glycine 0 CA--C 1.538 1.53 0 N-CA-C 115.288 0.875 . . . . 1.81 115.288 159.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 2.8 mm? . . . . . 0 C--O 1.25 1.094 0 C-N-CA 125.595 1.558 . . . . 4.72 113.683 -164.968 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.558 0 CA-C-O 117.175 -1.903 . . . . 3.12 109.31 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -71.82 -168.65 0.38 Allowed 'Trans proline' 0 CA--C 1.54 0.821 0 C-N-CA 123.384 2.722 . . . . 2.21 109.927 165.185 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -87.74 -173.14 4.18 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.074 1.75 . . . . 3.21 112.187 169.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -93.37 -171.61 39.69 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 125.884 1.707 . . . . 1.32 113.881 163.603 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.2 mt -62.24 139.88 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.103 0 O-C-N 121.784 -0.833 . . . . 2.71 110.481 -173.477 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -57.32 133.35 55.04 Favored 'General case' 0 CA--C 1.536 0.426 0 CA-C-N 118.692 0.678 . . . . 1.82 110.509 168.712 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.46 147.14 18.88 Favored Glycine 0 CA--C 1.52 0.405 0 C-N-CA 127.546 2.498 . . . . 1.23 113.665 177.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 87.3 mm-40 -71.57 125.72 27.8 Favored 'General case' 0 CA--C 1.535 0.403 0 N-CA-C 108.159 -1.052 . . . . 3.8 108.159 -177.182 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.9 ttt180 -57.97 137.07 57.11 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 123.639 0.776 . . . . 5.85 111.54 -169.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -65.8 163.33 40.72 Favored Glycine 0 C--N 1.338 0.679 0 C-N-CA 124.985 1.279 . . . . 1.54 115.577 -169.623 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 45.3 t -66.88 132.17 32.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 C-N-CA 126.617 1.967 . . . . 3.79 109.5 -175.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 1.7 t -56.26 145.78 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 124.974 1.31 . . . . 3.58 112.224 -173.526 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.11 175.33 42.46 Favored Glycine 0 CA--C 1.535 1.286 0 N-CA-C 112.019 -0.432 . . . . 1.46 112.019 163.408 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 6.4 mp -129.68 156.71 78.36 Favored Pre-proline 0 CA--C 1.538 0.505 0 C-N-CA 124.636 1.174 . . . . 3.61 109.447 178.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -77.74 -165.03 0.3 Allowed 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.951 2.434 . . . . 2.0 109.44 161.264 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.259 0 CA-C-O 117.67 -1.628 . . . . 3.38 112.588 153.863 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo . . . . . 0 CA--C 1.54 0.81 0 CA-C-O 118.047 -0.897 . . . . 3.01 110.573 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.77 162.87 25.32 Favored Glycine 0 CA--C 1.551 2.299 0 C-N-CA 118.882 -1.628 . . . . 1.57 111.144 126.414 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -79.0 -51.8 0.06 OUTLIER 'Trans proline' 0 CA--C 1.536 0.599 0 C-N-CA 124.746 3.631 . . . . 3.21 112.302 178.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 177.93 160.58 0.53 Allowed 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 129.731 3.213 . . . . 5.05 105.443 -165.381 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.07 -173.78 46.48 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 116.873 1.509 . . . . 1.31 116.873 -168.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 4.0 mp -71.78 121.31 21.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 108.473 -0.936 . . . . 4.49 108.473 168.284 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -68.5 137.63 54.55 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-O 121.542 0.686 . . . . 1.62 111.419 176.611 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.09 147.2 40.81 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 124.698 1.142 . . . . 1.64 112.826 -170.717 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . 0.426 ' H ' ' NE2' ' B' ' 20' ' ' GLN . 0.0 OUTLIER -82.08 147.79 28.92 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 123.764 0.826 . . . . 4.4 111.327 169.541 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 6.0 ptt180 -52.27 157.17 1.47 Allowed 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 114.63 1.344 . . . . 6.1 114.63 168.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.03 179.1 53.16 Favored Glycine 0 CA--C 1.532 1.111 0 C-N-CA 124.331 0.967 . . . . 1.88 114.035 177.131 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 24.2 t -91.93 122.33 43.28 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 N-CA-C 113.648 0.981 . . . . 3.59 113.648 -152.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.1 m -58.89 154.28 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 127.06 2.144 . . . . 3.12 114.272 -173.096 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.63 -146.71 16.91 Favored Glycine 0 CA--C 1.53 0.996 0 C-N-CA 124.196 0.903 . . . . 1.71 112.026 163.069 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -171.12 161.06 5.42 Favored Pre-proline 0 CA--C 1.546 0.823 0 C-N-CA 126.097 1.759 . . . . 4.12 111.568 -164.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo . . . . . 0 CA--C 1.552 1.386 0 C-N-CA 125.292 3.995 . . . . 2.83 112.595 153.901 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 CA--C 1.547 1.125 0 CA-C-O 118.765 -0.598 . . . . 3.67 111.467 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -55.94 -179.4 0.08 OUTLIER 'Trans proline' 0 CA--C 1.537 0.652 0 C-N-CA 124.477 3.452 . . . . 2.96 112.583 164.071 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.84 179.54 47.27 Favored Glycine 0 CA--C 1.54 1.615 0 C-N-CA 124.662 1.125 . . . . 1.52 114.028 176.227 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_endo -70.61 156.69 60.62 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 123.383 2.722 . . . . 2.39 111.116 172.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 22.2 tp60 -32.22 120.34 0.29 Allowed 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 127.648 2.379 . . . . 1.63 113.546 167.055 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.62 158.35 53.63 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.345 -0.702 . . . . 1.05 111.345 166.376 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 68.1 mt -61.84 143.55 15.0 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 C-N-CA 123.203 0.601 . . . . 3.05 111.528 -169.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -67.7 158.44 32.28 Favored 'General case' 0 CA--C 1.545 0.754 0 CA-C-O 122.722 1.248 . . . . 1.12 114.234 177.177 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.28 163.18 54.44 Favored Glycine 0 CA--C 1.527 0.782 0 C-N-CA 124.625 1.107 . . . . 1.2 112.909 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 9.8 mp0 -96.38 -178.83 4.42 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 124.264 1.026 . . . . 4.06 111.491 -171.193 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.49 142.91 46.78 Favored 'General case' 0 N--CA 1.473 0.686 0 O-C-N 121.06 -1.025 . . . . 4.26 110.868 172.438 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.41 173.26 55.21 Favored Glycine 0 N--CA 1.47 0.919 0 C-N-CA 124.895 1.236 . . . . 1.04 112.817 177.121 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 38.1 t -71.3 138.45 21.71 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 C-N-CA 123.803 0.841 . . . . 2.34 110.164 179.206 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -91.81 173.45 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 C-N-CA 127.277 2.231 . . . . 3.61 109.763 -179.301 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -50.99 149.13 7.34 Favored Glycine 0 CA--C 1.533 1.182 0 CA-C-N 119.076 0.853 . . . . 1.79 113.13 170.71 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 8.6 tt . . . . . 0 C--O 1.25 1.097 0 C-N-CA 127.322 2.249 . . . . 5.27 113.766 -167.205 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.756 0 CA-C-O 115.971 -2.572 . . . . 4.12 108.813 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -77.68 178.3 7.77 Favored 'Trans proline' 0 CA--C 1.534 0.515 0 C-N-CA 123.162 2.575 . . . . 2.9 110.965 177.386 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.58 -155.44 0.15 Allowed 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.933 1.693 . . . . 2.81 111.034 165.586 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -85.67 173.0 47.09 Favored Glycine 0 N--CA 1.47 0.943 0 N-CA-C 115.701 1.041 . . . . 1.47 115.701 -173.29 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.449 ' H ' HD13 ' A' ' 17' ' ' ILE . 2.8 mp -66.16 137.49 24.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 108.468 -0.938 . . . . 3.79 108.468 177.517 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.73 131.26 50.35 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 121.569 0.699 . . . . 1.71 110.632 170.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.78 153.17 30.07 Favored Glycine 0 CA--C 1.519 0.301 0 C-N-CA 126.651 2.072 . . . . 1.62 113.004 174.135 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 5.4 mp0 -74.37 143.66 44.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 114.78 -0.71 . . . . 4.76 110.738 -164.173 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 16.8 tpp85 -52.22 135.55 31.97 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 123.553 0.741 . . . . 5.32 110.992 173.101 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.84 167.54 54.44 Favored Glycine 0 CA--C 1.522 0.485 0 CA-C-O 122.587 1.104 . . . . 1.51 113.819 -173.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 15.4 t -66.06 129.2 30.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 C-N-CA 125.78 1.632 . . . . 3.36 109.392 -178.497 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 31.4 m -58.69 146.98 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 N-CA-C 114.355 1.243 . . . . 2.51 114.355 -172.268 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.11 159.48 53.52 Favored Glycine 0 CA--C 1.536 1.358 0 CA-C-O 121.903 0.724 . . . . 1.37 112.051 161.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 11.0 mp -120.05 136.82 25.25 Favored Pre-proline 0 CA--C 1.532 0.262 0 C-N-CA 126.314 1.846 . . . . 3.74 109.815 -177.152 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -74.42 -172.05 1.08 Allowed 'Trans proline' 0 N--CA 1.456 -0.679 0 C-N-CA 122.729 2.286 . . . . 2.68 109.861 169.666 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.245 0 CA-C-O 117.659 -1.634 . . . . 4.58 113.095 151.359 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo . . . . . 0 N--CA 1.491 1.347 0 N-CA-C 109.248 -1.097 . . . . 2.88 109.248 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.64 147.38 49.65 Favored Glycine 0 CA--C 1.541 1.678 0 CA-C-O 118.898 -0.946 . . . . 1.35 111.308 162.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -77.42 176.94 9.46 Favored 'Trans proline' 0 CA--C 1.538 0.707 0 C-N-CA 124.116 3.211 . . . . 2.28 110.315 164.041 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.1 tp-100 -38.91 143.61 0.15 Allowed 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 127.743 2.417 . . . . 4.91 115.594 176.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.14 163.36 53.11 Favored Glycine 0 CA--C 1.529 0.949 0 C-N-CA 124.031 0.824 . . . . 1.02 113.028 175.298 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . 0.407 ' H ' HD13 ' B' ' 17' ' ' ILE . 2.9 mp -65.28 134.7 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 O-C-N 121.733 -0.863 . . . . 3.61 109.328 175.118 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.68 148.76 51.47 Favored 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 119.093 0.86 . . . . 1.56 112.196 176.427 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -68.41 153.2 52.85 Favored Glycine 0 CA--C 1.527 0.826 0 C-N-CA 124.57 1.081 . . . . 1.75 111.746 174.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.59 155.26 25.77 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.999 0.92 . . . . 3.45 111.332 -176.64 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 41.0 mtt-85 -53.53 148.1 9.92 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 125.204 1.402 . . . . 6.85 113.905 -169.076 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.78 166.43 54.3 Favored Glycine 0 CA--C 1.535 1.299 0 CA-C-N 116.133 -0.485 . . . . 1.92 113.813 175.445 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 27.6 t -72.59 121.77 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 N-CA-C 113.56 0.948 . . . . 3.49 113.56 -161.114 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -65.95 161.37 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 125.481 1.512 . . . . 3.16 114.758 -165.615 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -85.0 -155.91 24.91 Favored Glycine 0 CA--C 1.528 0.903 0 C-N-CA 125.776 1.655 . . . . 1.7 113.461 175.294 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.1 pp -161.9 145.86 9.55 Favored Pre-proline 0 CA--C 1.541 0.63 0 C-N-CA 124.628 1.171 . . . . 3.49 111.499 -177.113 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo . . . . . 0 C--O 1.255 1.367 1 C-N-CA 126.087 4.524 . . . . 3.28 112.765 158.012 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo . . . . . 0 CA--C 1.543 0.93 0 CA-C-O 118.607 -0.664 . . . . 2.42 111.959 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -70.98 -150.23 0.03 OUTLIER 'Trans proline' 0 CA--C 1.541 0.869 0 C-N-CA 123.95 3.1 . . . . 1.93 108.523 164.515 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.66 169.49 40.98 Favored Glycine 0 CA--C 1.531 1.072 0 O-C-N 121.575 -0.703 . . . . 1.05 113.29 172.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -72.49 160.88 45.68 Favored 'Trans proline' 0 N--CA 1.454 -0.794 0 C-N-CA 123.081 2.521 . . . . 2.46 110.674 171.137 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 34.0 tp60 -52.77 120.13 5.38 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 126.249 1.82 . . . . 1.75 112.798 170.642 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -60.06 150.28 40.29 Favored Glycine 0 CA--C 1.53 1.028 0 C-N-CA 123.876 0.751 . . . . 1.05 111.639 168.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 78.0 mt -67.14 145.86 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.409 1.084 . . . . 3.65 110.676 -176.037 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.13 154.89 29.65 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 114.824 1.416 . . . . 1.25 114.824 178.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -76.75 148.24 34.84 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 124.739 1.162 . . . . 1.04 112.596 176.151 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -83.33 171.11 13.87 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.475 1.11 . . . . 5.28 112.294 -177.159 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.29 138.49 58.24 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 121.398 -0.814 . . . . 4.2 111.97 178.672 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.84 159.0 51.26 Favored Glycine 0 CA--C 1.528 0.857 0 C-N-CA 125.657 1.598 . . . . 0.99 112.933 177.183 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 23.7 t -68.76 136.43 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 124.054 0.941 . . . . 2.04 109.095 171.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 31.0 m -87.9 -165.54 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.843 0 C-N-CA 125.053 1.341 . . . . 3.34 111.623 -179.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.51 -138.79 0.15 Allowed Glycine 0 CA--C 1.54 1.628 0 C-N-CA 125.109 1.338 . . . . 1.69 113.562 164.365 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.251 1.162 0 C-N-CA 126.413 1.885 . . . . 7.78 114.682 -177.017 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.641 0 CA-C-O 116.849 -2.084 . . . . 2.62 110.072 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -72.28 167.97 25.45 Favored 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 123.458 2.772 . . . . 2.1 111.229 179.362 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.99 162.68 8.85 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 126.253 1.821 . . . . 3.58 113.695 172.744 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.71 -179.54 47.92 Favored Glycine 0 CA--C 1.525 0.693 0 C-N-CA 124.639 1.114 . . . . 1.29 112.547 171.42 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.3 mt -61.28 138.01 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 C-N-CA 123.488 0.715 . . . . 2.73 109.506 -172.402 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.93 135.62 56.67 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-O 120.961 0.41 . . . . 2.04 110.727 170.85 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.26 151.79 49.84 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 126.286 1.898 . . . . 1.52 112.876 179.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 57.7 mm-40 -69.86 155.71 40.15 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 114.744 -0.728 . . . . 4.57 111.336 -174.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -68.0 145.8 54.16 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 121.028 0.442 . . . . 6.32 111.961 -177.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.45 141.48 28.81 Favored Glycine 0 C--N 1.333 0.413 0 CA-C-N 115.52 -0.764 . . . . 1.59 112.1 -178.156 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 27.2 m -61.4 141.42 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 CA-C-O 121.173 0.511 . . . . 3.18 111.248 -179.615 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.1 m -48.89 150.9 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 125.585 1.554 . . . . 2.92 113.878 -172.14 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.83 -153.8 26.16 Favored Glycine 0 N--CA 1.471 1.0 0 C-N-CA 123.165 0.412 . . . . 1.94 112.556 165.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 85.7 mt -149.48 155.47 39.13 Favored Pre-proline 0 N--CA 1.472 0.631 0 C-N-CA 125.677 1.591 . . . . 4.09 109.532 178.186 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -80.04 -162.1 0.17 Allowed 'Trans proline' 0 CA--C 1.539 0.747 0 C-N-CA 122.641 2.227 . . . . 2.71 109.392 158.08 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.239 0 CA-C-O 117.071 -1.961 . . . . 4.47 112.069 142.241 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_exo . . . . . 0 CA--C 1.544 1.015 0 N-CA-C 111.154 -0.364 . . . . 3.44 111.154 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -63.66 -177.49 4.49 Favored Glycine 0 CA--C 1.542 1.728 0 C-N-CA 120.187 -1.006 . . . . 2.52 112.446 126.217 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -74.64 -135.7 0.01 OUTLIER 'Trans proline' 0 CA--C 1.546 1.113 0 C-N-CA 124.571 3.514 . . . . 2.76 108.19 155.623 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 -87.33 -176.88 5.8 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 124.903 1.281 . . . . 4.91 111.454 171.812 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -84.75 158.97 34.13 Favored Glycine 0 CA--C 1.528 0.899 0 O-C-N 121.86 -0.525 . . . . 1.05 111.955 161.183 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 53.5 mt -72.77 133.26 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 123.389 0.676 . . . . 4.6 109.291 179.116 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.52 145.41 52.68 Favored 'General case' 0 CA--C 1.547 0.834 0 CA-C-N 119.39 0.995 . . . . 1.53 113.387 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.72 140.5 29.18 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 125.328 1.442 . . . . 1.52 111.694 173.591 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -95.37 153.09 17.85 Favored 'General case' 0 CA--C 1.532 0.257 0 O-C-N 121.729 -0.865 . . . . 3.5 111.604 -175.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 5.7 ttt85 -62.94 149.57 44.33 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.086 1.355 . . . . 7.49 112.221 -172.195 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.73 -174.86 26.61 Favored Glycine 0 CA--C 1.532 1.14 0 N-CA-C 114.463 0.545 . . . . 1.95 114.463 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 75.8 t -44.66 142.17 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 C-N-CA 128.016 2.526 . . . . 5.24 114.057 -172.501 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -93.1 156.95 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 124.13 0.972 . . . . 3.73 113.613 178.059 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.18 -162.62 29.57 Favored Glycine 0 C--N 1.341 0.828 0 C-N-CA 125.535 1.541 . . . . 2.38 114.23 -178.251 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.8 pp -153.76 141.83 13.98 Favored Pre-proline 0 CA--C 1.542 0.656 0 C-N-CA 124.287 1.035 . . . . 4.41 110.904 174.241 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo . . . . . 0 C--O 1.254 1.292 1 C-N-CA 126.282 4.654 . . . . 4.75 113.147 160.135 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo . . . . . 0 CA--C 1.547 1.152 0 CA-C-O 119.178 -0.426 . . . . 3.69 111.917 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -72.5 -135.59 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.075 0 C-N-CA 123.502 2.802 . . . . 2.3 108.351 162.447 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -81.04 175.42 54.78 Favored Glycine 0 CA--C 1.543 1.786 0 CA-C-N 119.303 0.956 . . . . 1.54 111.552 163.355 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -80.14 170.64 16.13 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 123.676 2.917 . . . . 2.42 110.46 161.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 28.7 tp60 -43.31 117.58 1.14 Allowed 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 125.33 1.452 . . . . 1.63 112.133 161.005 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.5 145.98 49.96 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.331 -1.108 . . . . 1.07 110.331 166.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 36.2 mm -66.51 145.33 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 O-C-N 122.367 -0.49 . . . . 5.18 110.567 -174.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -68.52 166.56 16.72 Favored 'General case' 0 CA--C 1.543 0.687 0 N-CA-C 114.394 1.257 . . . . 1.91 114.394 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.58 155.17 43.0 Favored Glycine 0 CA--C 1.527 0.81 0 C-N-CA 125.007 1.289 . . . . 1.05 112.6 -179.384 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -95.92 167.73 11.06 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.1 0.96 . . . . 4.89 111.164 -176.671 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.69 134.5 51.37 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.243 0.617 . . . . 4.94 111.038 178.501 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -63.72 178.49 7.12 Favored Glycine 0 N--CA 1.469 0.868 0 C-N-CA 126.41 1.957 . . . . 1.24 114.667 -175.773 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 93.1 t -74.83 138.09 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 108.969 -0.752 . . . . 2.54 108.969 -179.023 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 13.9 m -99.93 174.35 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 C-N-CA 126.305 1.842 . . . . 3.19 110.335 -178.386 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.92 -178.16 9.6 Favored Glycine 0 CA--C 1.534 1.227 0 C-N-CA 123.615 0.626 . . . . 1.81 113.673 167.308 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.479 0.987 0 N-CA-C 114.649 1.351 . . . . 6.67 114.649 173.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.689 0 CA-C-O 116.827 -2.096 . . . . 3.15 109.604 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -70.11 177.15 6.11 Favored 'Trans proline' 0 CA--C 1.538 0.716 0 C-N-CA 123.153 2.568 . . . . 2.6 110.249 166.08 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . 0.253 0.0 OUTLIER -89.99 -156.65 0.43 Allowed 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 125.984 1.714 . . . . 3.18 111.699 173.435 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.03 178.47 45.03 Favored Glycine 0 N--CA 1.475 1.257 0 C-N-CA 124.95 1.262 . . . . 1.39 114.535 178.354 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.9 mt -76.06 130.41 36.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 O-C-N 121.261 -1.14 . . . . 3.17 108.579 -176.724 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.66 127.65 30.93 Favored 'General case' 0 CA--C 1.539 0.554 0 CA-C-N 119.318 0.963 . . . . 2.02 111.571 178.73 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.86 164.29 35.68 Favored Glycine 0 CA--C 1.528 0.869 0 C-N-CA 126.097 1.808 . . . . 1.33 112.803 -176.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -71.95 112.3 7.92 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 121.894 -0.768 . . . . 5.99 110.574 -169.431 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 67.4 ttt-85 -60.9 127.04 29.63 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 123.425 0.69 . . . . 4.58 109.402 177.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -78.57 171.99 55.19 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 125.002 1.287 . . . . 1.55 115.318 -166.7 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -64.38 147.52 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 CA-C-N 113.78 -1.21 . . . . 3.42 110.538 -173.875 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.0 m -54.14 150.58 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 123.146 0.578 . . . . 3.06 111.491 167.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.2 148.98 46.71 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 110.538 -1.025 . . . . 1.98 110.538 159.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 7.4 mp -101.35 167.04 11.27 Favored Pre-proline 0 C--N 1.328 -0.337 0 C-N-CA 124.027 0.931 . . . . 4.31 110.748 174.512 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.416 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 44.3 Cg_endo -69.94 -155.38 0.04 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 121.789 1.659 . . . . 2.07 108.55 155.113 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.259 0 CA-C-O 117.019 -1.989 . . . . 3.31 112.683 152.373 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_exo . . . . . 0 N--CA 1.481 0.765 0 CA-C-O 117.618 -1.076 . . . . 2.61 110.268 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -63.97 153.08 48.15 Favored Glycine 0 CA--C 1.548 2.131 0 C-N-CA 119.758 -1.211 . . . . 1.32 111.06 144.055 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -78.88 -47.96 0.09 OUTLIER 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 124.461 3.44 . . . . 2.88 114.628 -179.417 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.8 tp-100 -170.8 146.76 2.64 Favored 'General case' 0 N--CA 1.463 0.204 0 C-N-CA 124.285 1.034 . . . . 4.51 110.722 -161.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -86.51 149.8 22.94 Favored Glycine 0 CA--C 1.527 0.792 0 CA-C-O 121.822 0.679 . . . . 1.05 113.149 -178.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 65.7 mt -69.31 122.45 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 108.481 -0.933 . . . . 3.9 108.481 175.592 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.92 136.65 58.06 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 113.126 0.788 . . . . 1.28 113.126 -174.008 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -67.81 129.38 27.21 Favored Glycine 0 CA--C 1.523 0.533 0 C-N-CA 125.287 1.422 . . . . 1.65 110.183 169.429 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 8.8 tp-100 -96.89 150.34 20.86 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 123.685 0.794 . . . . 7.25 110.195 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.96 157.17 10.33 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 112.912 0.708 . . . . 5.38 112.912 171.461 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.46 -174.65 49.43 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 124.417 1.008 . . . . 2.05 112.455 170.701 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 13.4 m -93.31 141.9 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 115.133 1.531 . . . . 4.53 115.133 -156.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 12.9 m -69.5 154.17 8.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 125.796 1.638 . . . . 3.07 113.274 -166.816 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.72 -136.66 9.45 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 123.931 0.777 . . . . 1.77 113.117 170.802 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.416 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.6 pt? -172.18 158.57 4.18 Favored Pre-proline 0 CA--C 1.546 0.804 0 C-N-CA 126.085 1.754 . . . . 3.56 110.788 -157.41 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo . . . . . 0 C--O 1.256 1.424 0 C-N-CA 122.294 1.996 . . . . 2.79 111.013 160.851 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo . . . . . 0 CA--C 1.544 1.015 0 CA-C-O 118.783 -0.59 . . . . 3.05 111.939 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -55.39 -176.1 0.04 OUTLIER 'Trans proline' 0 CA--C 1.536 0.625 0 C-N-CA 124.707 3.605 . . . . 2.46 112.582 162.14 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -89.64 -172.85 45.55 Favored Glycine 0 CA--C 1.537 1.425 0 C-N-CA 124.882 1.23 . . . . 1.31 113.202 171.047 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -72.96 159.13 48.68 Favored 'Trans proline' 0 N--CA 1.456 -0.703 0 C-N-CA 123.211 2.607 . . . . 2.57 111.858 178.443 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -45.7 130.02 9.1 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.461 1.904 . . . . 1.75 112.947 161.916 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -79.15 174.77 55.26 Favored Glycine 0 CA--C 1.53 0.981 0 C-N-CA 125.471 1.51 . . . . 1.17 114.06 174.521 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 97.0 mt -63.98 145.87 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 124.958 1.303 . . . . 3.63 111.76 -174.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -85.44 157.24 20.52 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 125.609 1.563 . . . . 1.55 114.115 177.189 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -98.02 138.06 13.66 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 124.945 1.26 . . . . 1.43 112.605 178.269 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -70.73 -179.07 2.04 Favored 'General case' 0 CA--C 1.543 0.709 0 CA-C-O 122.479 1.133 . . . . 5.2 111.797 170.199 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 17.8 ttt85 -55.41 149.34 13.43 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 124.588 1.155 . . . . 4.85 110.917 161.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.45 171.54 46.58 Favored Glycine 0 CA--C 1.533 1.17 0 N-CA-C 111.423 -0.671 . . . . 1.11 111.423 161.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 6.3 t -66.53 144.02 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 C-N-CA 124.13 0.972 . . . . 2.17 110.972 -179.457 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 12.4 m -85.77 175.0 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 C-N-CA 127.342 2.257 . . . . 3.39 112.497 179.384 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.26 173.71 10.53 Favored Glycine 0 CA--C 1.537 1.419 0 C-N-CA 124.619 1.104 . . . . 2.15 114.809 162.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 21.7 mt . . . . . 0 N--CA 1.484 1.242 0 N-CA-C 115.474 1.657 . . . . 3.98 115.474 -155.556 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.582 0 CA-C-O 116.953 -2.026 . . . . 3.47 110.13 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -75.02 167.22 27.5 Favored 'Trans proline' 0 N--CA 1.459 -0.553 0 C-N-CA 123.294 2.663 . . . . 2.77 111.477 -177.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.1 161.96 23.36 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 127.269 2.228 . . . . 3.04 113.257 175.29 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.26 -152.02 21.94 Favored Glycine 0 N--CA 1.472 1.053 0 C-N-CA 125.454 1.502 . . . . 1.55 115.457 -170.515 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -66.92 132.18 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 O-C-N 121.09 -1.241 . . . . 3.03 109.796 -176.384 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -72.39 64.49 0.59 Allowed 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 125.797 1.639 . . . . 3.43 112.435 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.35 -175.35 32.99 Favored Glycine 0 CA--C 1.527 0.784 0 C-N-CA 125.722 1.629 . . . . 2.06 112.402 -174.064 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 80.4 mm-40 -106.92 154.94 20.33 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.222 -0.658 . . . . 4.2 109.222 145.371 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 24.0 ttt180 -70.89 107.54 4.08 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 108.673 -0.862 . . . . 5.85 108.673 169.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -76.81 -81.81 0.57 Allowed Glycine 0 N--CA 1.472 1.083 0 C-N-CA 124.696 1.141 . . . . 4.36 112.91 -159.662 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 2.6 m -150.59 152.16 11.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 C-N-CA 123.963 0.905 . . . . 3.1 108.647 -178.311 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 20.5 m -62.23 162.68 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 125.998 1.719 . . . . 2.88 113.633 -179.158 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.09 -160.47 3.75 Favored Glycine 0 CA--C 1.537 1.407 0 N-CA-C 111.431 -0.667 . . . . 2.36 111.431 155.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 94.2 mt -140.82 161.66 52.88 Favored Pre-proline 0 N--CA 1.474 0.738 0 CA-C-N 118.055 0.928 . . . . 4.12 111.017 178.02 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -86.52 -158.75 0.09 OUTLIER 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 123.968 3.112 . . . . 2.21 109.152 156.023 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.212 0 CA-C-O 117.239 -1.867 . . . . 3.0 112.546 148.642 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo . . . . . 0 CA--C 1.545 1.042 0 CA-C-O 119.454 -0.311 . . . . 2.74 111.39 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.18 -178.58 8.79 Favored Glycine 0 CA--C 1.541 1.711 0 O-C-N 121.108 -0.995 . . . . 1.34 112.382 128.253 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -74.73 -135.64 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.038 0 C-N-CA 124.789 3.659 . . . . 2.42 108.313 158.514 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 -86.71 -173.17 4.36 Favored 'General case' 0 CA--C 1.541 0.632 0 O-C-N 121.056 -1.027 . . . . 5.61 111.586 172.577 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.59 158.04 29.37 Favored Glycine 0 CA--C 1.534 1.266 0 O-C-N 121.514 -0.741 . . . . 1.11 112.097 159.689 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 88.2 mt -78.68 154.16 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.076 0 C-N-CA 124.344 1.058 . . . . 4.03 109.799 173.674 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.42 150.39 43.71 Favored 'General case' 0 CA--C 1.547 0.854 0 O-C-N 120.932 -1.105 . . . . 1.59 113.801 177.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -87.46 170.78 41.04 Favored Glycine 0 CA--C 1.526 0.771 0 C-N-CA 125.748 1.642 . . . . 1.93 114.286 -176.517 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -72.41 128.41 35.54 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.646 1.178 . . . . 5.06 111.927 -175.1 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -62.07 153.3 30.23 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 122.586 0.354 . . . . 6.49 111.667 179.266 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.39 158.61 26.69 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 124.209 0.909 . . . . 2.14 115.189 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 13.2 m -84.96 134.68 26.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 N-CA-C 113.645 0.98 . . . . 4.34 113.645 -178.524 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.6 m -88.85 162.02 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 126.151 1.781 . . . . 3.0 113.215 -164.206 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.92 -131.1 7.1 Favored Glycine 0 CA--C 1.529 0.945 0 C-N-CA 124.925 1.25 . . . . 1.83 113.468 177.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.0 pp -172.38 153.83 3.02 Favored Pre-proline 0 CA--C 1.543 0.675 0 C-N-CA 124.302 1.041 . . . . 4.19 112.043 -152.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo . . . . . 0 C--O 1.255 1.359 1 C-N-CA 125.429 4.086 . . . . 2.44 112.548 153.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo . . . . . 0 N--CA 1.488 1.181 0 CA-C-O 118.947 -0.522 . . . . 2.83 112.009 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -72.01 -133.98 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 123.761 2.974 . . . . 2.26 108.107 162.536 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.85 166.16 54.72 Favored Glycine 0 CA--C 1.539 1.578 0 CA-C-N 119.905 1.23 . . . . 1.23 111.107 163.29 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -81.87 -37.64 0.25 Allowed 'Trans proline' 0 CA--C 1.536 0.589 0 C-N-CA 122.919 2.412 . . . . 3.5 113.072 -179.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 31.8 tp60 170.04 134.14 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 127.672 2.389 . . . . 1.94 107.117 -157.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -97.49 178.11 32.48 Favored Glycine 0 CA--C 1.528 0.872 0 C-N-CA 125.119 1.342 . . . . 1.12 113.027 167.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 3.4 mp -63.72 134.75 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 124.152 0.981 . . . . 3.82 111.486 -177.146 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.45 146.46 48.62 Favored 'General case' 0 CA--C 1.541 0.622 0 O-C-N 121.31 -0.869 . . . . 1.37 113.05 -178.582 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.28 87.42 0.5 Allowed Glycine 0 CA--C 1.527 0.788 0 C-N-CA 127.04 2.257 . . . . 2.59 112.748 -173.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -59.21 164.16 3.33 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 124.66 1.184 . . . . 5.52 113.444 -171.189 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 10.5 ttp-105 -46.19 127.75 8.98 Favored 'General case' 0 C--O 1.239 0.525 0 C-N-CA 124.771 1.229 . . . . 6.92 112.809 176.571 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.31 -174.24 8.49 Favored Glycine 0 CA--C 1.524 0.627 0 CA-C-N 113.134 -1.848 . . . . 1.49 113.306 175.647 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.9 t -63.65 143.63 15.44 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 C-N-CA 124.011 0.924 . . . . 2.11 110.237 175.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -89.78 -168.39 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.801 0 C-N-CA 125.787 1.635 . . . . 3.23 110.302 179.063 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.57 -168.49 2.3 Favored Glycine 0 CA--C 1.539 1.567 0 C-N-CA 124.133 0.873 . . . . 1.87 114.385 169.748 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 14.8 mt . . . . . 0 N--CA 1.483 1.189 0 C-N-CA 124.269 1.028 . . . . 3.95 113.703 176.956 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.855 0 CA-C-O 117.153 -1.915 . . . . 5.77 108.801 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -64.34 111.35 1.6 Allowed 'Trans proline' 0 N--CA 1.453 -0.91 0 N-CA-C 104.867 -2.782 . . . . 3.14 104.867 151.61 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 26.7 mm100 -70.76 172.18 9.22 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 125.708 1.603 . . . . 5.73 114.12 -164.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -61.46 145.53 48.68 Favored Glycine 0 C--N 1.335 0.483 0 N-CA-C 110.442 -1.063 . . . . 1.72 110.442 160.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.7 mt -54.47 125.1 8.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 107.068 -1.456 . . . . 2.91 107.068 175.264 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -50.11 150.54 2.34 Favored 'General case' 0 CA--C 1.536 0.435 0 CA-C-O 121.773 0.797 . . . . 2.25 111.897 -176.397 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.81 167.27 34.39 Favored Glycine 0 CA--C 1.527 0.795 0 C-N-CA 124.461 1.029 . . . . 1.55 114.064 -173.139 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 13.5 mp0 -71.49 166.12 22.42 Favored 'General case' 0 CA--C 1.542 0.635 0 O-C-N 122.187 -0.596 . . . . 6.03 111.972 -175.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.8 tpt180 -68.05 132.69 47.71 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 113.94 1.089 . . . . 5.3 113.94 -162.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.78 93.07 1.36 Allowed Glycine 0 C--N 1.336 0.564 0 N-CA-C 109.786 -1.326 . . . . 1.81 109.786 170.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 28.5 m -58.22 140.62 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 123.76 0.824 . . . . 3.47 112.011 -176.439 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.7 t -50.99 142.96 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 126.26 1.824 . . . . 4.56 112.301 -170.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.82 148.28 50.36 Favored Glycine 0 N--CA 1.477 1.373 0 O-C-N 121.507 -0.746 . . . . 1.64 112.304 173.04 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -85.19 156.78 59.95 Favored Pre-proline 0 CA--C 1.541 0.609 0 CA-C-O 118.872 -0.585 . . . . 4.27 110.736 176.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -85.38 -154.09 0.05 OUTLIER 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 123.517 2.811 . . . . 2.06 108.973 157.451 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.344 0 CA-C-O 117.631 -1.649 . . . . 3.09 113.437 148.89 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo . . . . . 0 N--CA 1.482 0.832 0 CA-C-O 119.379 -0.342 . . . . 4.24 112.799 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -79.78 136.83 17.8 Favored Glycine 0 CA--C 1.533 1.175 0 N-CA-C 110.216 -1.154 . . . . 1.36 110.216 157.017 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -76.6 177.23 9.09 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.988 2.459 . . . . 2.27 108.806 160.449 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -41.14 138.41 1.14 Allowed 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.318 1.447 . . . . 5.49 112.366 168.51 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -73.78 168.26 54.15 Favored Glycine 0 CA--C 1.526 0.756 0 C-N-CA 125.782 1.658 . . . . 1.05 115.248 -173.047 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 15.4 mm -61.79 140.14 19.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 CA-C-N 114.673 -0.764 . . . . 3.49 110.038 172.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.04 142.89 58.21 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 123.488 0.715 . . . . 1.98 111.531 173.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.38 -70.24 1.05 Allowed Glycine 0 N--CA 1.472 1.048 0 C-N-CA 123.934 0.778 . . . . 4.8 112.776 -168.399 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 178.48 -170.86 0.11 Allowed 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 128.376 2.67 . . . . 7.11 109.871 162.188 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 2.1 ttt-85 -117.96 152.0 36.34 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.452 1.101 . . . . 6.61 110.965 168.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.07 150.66 52.07 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 113.95 0.34 . . . . 1.97 113.95 -179.44 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 46.3 t -76.5 124.95 35.75 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.389 0 C-N-CA 123.409 0.684 . . . . 3.71 110.583 178.761 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.4 m -66.34 151.5 10.21 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 C-N-CA 125.451 1.501 . . . . 3.06 113.338 -167.563 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.73 -142.77 10.33 Favored Glycine 0 CA--C 1.527 0.805 0 C-N-CA 123.808 0.718 . . . . 1.76 112.659 169.274 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.2 pp -165.83 154.73 10.49 Favored Pre-proline 0 CA--C 1.54 0.584 0 C-N-CA 123.785 0.834 . . . . 3.91 112.249 -153.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo . . . . . 0 C--O 1.255 1.372 0 C-N-CA 125.3 4.0 . . . . 2.71 112.477 160.58 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo . . . . . 0 N--CA 1.484 0.916 0 CA-C-O 118.569 -0.68 . . . . 2.44 111.073 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -62.38 -151.05 0.02 OUTLIER 'Trans proline' 0 CA--C 1.544 0.984 1 C-N-CA 125.346 4.031 . . . . 2.49 111.998 159.201 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -104.97 167.26 15.01 Favored Glycine 0 CA--C 1.544 1.856 0 N-CA-C 116.954 1.541 . . . . 1.3 116.954 -170.116 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_endo -87.2 55.77 3.06 Favored 'Trans proline' 0 CA--C 1.543 0.942 1 C-N-CA 125.717 4.278 . . . . 3.76 113.145 -171.357 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 70.59 155.31 0.14 Allowed 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 125.467 1.507 . . . . 2.1 112.387 -176.389 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -101.93 176.72 26.15 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 126.68 2.086 . . . . 1.04 114.338 167.355 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 14.9 mt -72.82 126.92 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 O-C-N 121.126 -1.22 . . . . 4.4 112.177 -170.217 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -42.44 132.19 3.58 Favored 'General case' 0 CA--C 1.537 0.481 0 C-N-CA 125.399 1.48 . . . . 1.87 112.656 168.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.46 147.06 32.27 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 110.39 -1.084 . . . . 1.24 110.39 179.191 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -105.67 151.27 24.6 Favored 'General case' 0 C--N 1.327 -0.388 0 O-C-N 122.201 -0.587 . . . . 3.41 110.882 -173.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 12.1 ttp180 -54.71 134.55 47.44 Favored 'General case' 0 N--CA 1.447 -0.602 0 C-N-CA 123.347 0.659 . . . . 6.1 110.369 175.14 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.45 168.93 8.56 Favored Glycine 0 CA--C 1.528 0.846 0 C-N-CA 123.431 0.539 . . . . 1.18 113.094 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.3 t -61.2 143.42 14.9 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 O-C-N 122.039 -0.683 . . . . 1.95 110.162 174.356 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 3.3 p -85.32 176.03 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 C-N-CA 127.736 2.414 . . . . 3.46 110.426 -178.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.27 177.66 2.33 Favored Glycine 0 CA--C 1.54 1.651 0 CA-C-N 118.886 0.766 . . . . 1.82 113.405 161.77 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 17.9 mt . . . . . 0 C--O 1.253 1.246 0 N-CA-C 115.26 1.578 . . . . 4.02 115.26 -163.861 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.56 0 CA-C-O 115.779 -2.678 . . . . 3.43 108.527 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -76.01 164.18 31.93 Favored 'Trans proline' 0 N--CA 1.455 -0.793 0 C-N-CA 122.636 2.224 . . . . 2.26 111.306 -178.085 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -77.49 -177.12 4.56 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.848 1.659 . . . . 3.02 112.16 167.164 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.92 -177.82 40.19 Favored Glycine 0 CA--C 1.529 0.959 0 C-N-CA 123.89 0.757 . . . . 1.3 114.128 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 9.3 mt -67.82 133.59 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 O-C-N 121.911 -0.758 . . . . 2.47 109.795 -174.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.7 131.96 47.9 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 123.881 0.872 . . . . 1.82 110.874 172.281 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.27 152.85 51.13 Favored Glycine 0 CA--C 1.523 0.538 0 C-N-CA 126.405 1.955 . . . . 1.27 113.398 -173.831 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 82.2 mm-40 -74.77 134.65 41.8 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 115.139 -0.531 . . . . 4.36 110.589 -166.195 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 22.9 ttt180 -67.45 140.74 57.12 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-O 121.409 0.624 . . . . 6.2 112.355 -169.018 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -76.12 171.52 54.58 Favored Glycine 0 CA--C 1.522 0.525 0 C-N-CA 125.252 1.406 . . . . 1.47 115.068 -174.125 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 60.4 t -65.89 148.5 12.02 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 125.873 1.669 . . . . 3.94 109.456 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.8 m -51.84 154.7 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.757 0.823 . . . . 2.62 111.828 173.318 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -78.43 132.8 12.01 Favored Glycine 0 C--N 1.336 0.582 0 N-CA-C 107.777 -2.129 . . . . 2.17 107.777 158.146 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . 0.421 HD11 ' HE ' ' C' ' 21' ' ' ARG . 6.6 mp -87.95 -176.58 0.72 Allowed Pre-proline 0 C--N 1.323 -0.578 0 C-N-CA 122.746 0.418 . . . . 3.8 110.368 -174.487 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.515 ' C ' ' H ' ' C' ' 25' ' ' GLY . 85.3 Cg_endo -56.63 -166.66 0.02 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 120.244 0.629 . . . . 3.02 110.79 136.794 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.152 0 CA-C-O 118.019 -1.434 . . . . 5.61 115.543 167.085 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo . . . . . 0 N--CA 1.489 1.246 0 N-CA-C 108.972 -1.203 . . . . 2.92 108.972 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.3 148.76 44.54 Favored Glycine 0 CA--C 1.54 1.655 0 CA-C-O 118.697 -1.057 . . . . 1.39 111.01 164.429 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -76.97 169.08 22.3 Favored 'Trans proline' 0 CA--C 1.538 0.676 0 C-N-CA 124.189 3.26 . . . . 2.27 110.684 166.134 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -53.25 136.94 35.76 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 124.641 1.176 . . . . 4.83 111.273 172.432 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.01 161.38 37.11 Favored Glycine 0 CA--C 1.525 0.669 0 C-N-CA 124.501 1.048 . . . . 1.17 114.696 -170.362 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 32.3 pt -56.48 131.69 20.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 O-C-N 122.172 -0.605 . . . . 4.49 111.341 178.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.02 151.12 45.9 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-O 121.975 0.893 . . . . 1.6 113.198 -171.198 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -70.63 145.38 40.23 Favored Glycine 0 CA--C 1.526 0.759 0 C-N-CA 125.117 1.341 . . . . 1.84 110.712 173.27 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -123.06 159.28 28.79 Favored 'General case' 0 C--N 1.329 -0.295 0 O-C-N 121.634 -0.921 . . . . 3.34 110.81 178.068 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 3.2 ptt180 -54.96 159.75 2.24 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 115.585 1.698 . . . . 5.01 115.585 178.526 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.02 -119.18 0.08 OUTLIER Glycine 0 CA--C 1.535 1.307 0 C-N-CA 127.332 2.396 . . . . 2.94 114.187 -173.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 10.5 m -143.69 142.22 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 C-N-CA 124.701 1.201 . . . . 4.22 112.24 -176.328 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 22.6 m -83.1 161.18 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.151 0 C-N-CA 126.615 1.966 . . . . 2.93 115.679 -159.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.22 -126.11 4.85 Favored Glycine 0 CA--C 1.533 1.171 0 C-N-CA 126.22 1.867 . . . . 1.93 113.636 177.852 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.418 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.6 pt? -169.36 159.77 7.46 Favored Pre-proline 0 CA--C 1.554 1.12 0 N-CA-C 115.053 1.501 . . . . 3.98 115.053 -148.862 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo . . . . . 0 C--O 1.255 1.343 0 C-N-CA 123.558 2.839 . . . . 3.41 111.565 156.617 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_endo . . . . . 0 CA--C 1.546 1.124 0 CA-C-O 118.729 -0.613 . . . . 2.55 110.923 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -68.34 -155.16 0.03 OUTLIER 'Trans proline' 0 CA--C 1.546 1.093 0 C-N-CA 123.493 2.795 . . . . 2.05 109.618 157.018 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -100.61 -178.68 29.64 Favored Glycine 0 CA--C 1.534 1.251 0 C-N-CA 123.934 0.778 . . . . 1.5 112.775 172.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -75.35 164.83 32.0 Favored 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.446 2.764 . . . . 2.29 112.098 176.054 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -40.81 129.01 2.65 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.296 2.238 . . . . 1.77 113.451 163.226 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.98 152.77 52.71 Favored Glycine 0 CA--C 1.529 0.908 0 C-N-CA 124.641 1.115 . . . . 1.08 113.447 169.642 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 96.7 mt -56.73 148.5 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 124.4 1.08 . . . . 3.7 111.732 179.026 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -77.0 164.37 25.82 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 115.07 1.507 . . . . 1.72 115.07 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -84.7 168.92 44.22 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 124.968 1.27 . . . . 1.1 114.003 -174.401 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 8.9 mp0 -104.98 -179.22 3.88 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.177 1.391 . . . . 3.61 111.043 -166.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . 0.421 ' HE ' HD11 ' A' ' 26' ' ' LEU . 59.3 ttt180 -66.38 148.58 51.65 Favored 'General case' 0 N--CA 1.48 1.054 0 O-C-N 120.938 -1.102 . . . . 4.82 109.437 161.229 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -78.25 -173.58 42.03 Favored Glycine 0 CA--C 1.533 1.19 0 O-C-N 121.119 -0.988 . . . . 1.34 112.067 169.082 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 4.1 t -71.3 139.15 20.35 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 123.693 0.797 . . . . 2.19 109.123 176.551 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 16.0 m -71.47 173.6 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 C-N-CA 126.876 2.07 . . . . 3.5 112.65 176.425 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.515 ' H ' ' C ' ' A' ' 27' ' ' PRO . . . -53.26 172.42 0.52 Allowed Glycine 0 CA--C 1.538 1.509 0 C-N-CA 125.398 1.475 . . . . 1.74 115.895 158.323 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 7.1 mp . . . . . 0 C--O 1.252 1.212 0 C-N-CA 125.831 1.652 . . . . 4.86 114.761 -157.619 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.614 0 CA-C-O 116.662 -2.188 . . . . 2.92 109.511 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -77.05 164.27 29.79 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 123.234 2.623 . . . . 2.56 112.135 -171.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.99 151.68 17.97 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 127.028 2.131 . . . . 4.18 111.567 167.441 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.11 -102.26 0.04 OUTLIER Glycine 0 N--CA 1.471 1.016 0 C-N-CA 125.112 1.339 . . . . 1.94 113.923 -179.355 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.9 mt -123.17 143.51 35.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 O-C-N 121.634 -0.921 . . . . 3.63 108.978 -177.231 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.57 53.05 0.21 Allowed 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 125.403 1.481 . . . . 3.7 111.97 170.056 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 86.11 -164.49 36.98 Favored Glycine 0 C--N 1.335 0.502 0 C-N-CA 127.813 2.625 . . . . 2.3 112.993 172.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 36.1 mm-40 -106.37 124.89 50.29 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 106.162 -1.792 . . . . 3.66 106.162 141.353 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 48.8 ttt85 -63.99 142.43 58.41 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.588 0.755 . . . . 5.66 110.84 -174.848 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.96 146.33 41.25 Favored Glycine 0 CA--C 1.523 0.59 0 C-N-CA 125.201 1.382 . . . . 1.56 112.272 -173.494 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 14.3 m -73.57 133.44 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 C-N-CA 124.83 1.252 . . . . 3.38 110.989 -174.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.4 p -50.77 147.75 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 C-N-CA 126.386 1.875 . . . . 4.72 114.973 -164.042 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -76.27 -179.95 47.34 Favored Glycine 0 CA--C 1.535 1.31 0 O-C-N 121.969 -0.457 . . . . 1.69 112.338 166.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.8 mt -143.97 158.01 56.55 Favored Pre-proline 0 N--CA 1.477 0.904 0 CA-C-O 118.175 -0.917 . . . . 4.37 112.399 -167.334 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -66.53 -173.45 0.37 Allowed 'Trans proline' 0 CA--C 1.537 0.653 0 C-N-CA 122.017 1.811 . . . . 2.61 110.188 158.119 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.271 0 CA-C-O 117.828 -1.54 . . . . 3.41 113.007 152.384 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo . . . . . 0 CA--C 1.541 0.861 0 CA-C-O 118.621 -0.658 . . . . 2.38 111.486 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -70.84 173.86 40.85 Favored Glycine 0 CA--C 1.54 1.606 0 CA-C-N 119.127 0.876 . . . . 1.38 111.885 143.226 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -71.17 163.03 40.57 Favored 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 123.707 2.938 . . . . 2.63 109.87 158.041 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.22 138.81 54.32 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 124.445 1.098 . . . . 4.69 111.901 179.707 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -57.63 142.79 42.94 Favored Glycine 0 C--N 1.342 0.887 0 C-N-CA 124.497 1.046 . . . . 1.21 114.195 -175.175 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 47.7 mm -73.61 142.72 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 123.893 0.877 . . . . 5.29 110.842 -177.214 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -52.17 139.11 24.37 Favored 'General case' 0 CA--C 1.544 0.717 0 N-CA-C 115.222 1.564 . . . . 1.75 115.222 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -66.32 141.87 41.74 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 126.096 1.807 . . . . 1.62 111.702 176.321 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 6.7 mp0 -79.74 151.85 30.16 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.194 0.598 . . . . 3.92 110.949 -173.388 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 12.7 mtt180 -60.76 150.12 33.51 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 118.857 0.753 . . . . 6.52 112.492 177.297 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.2 153.12 35.8 Favored Glycine 0 CA--C 1.531 1.065 0 CA-C-N 115.955 -0.566 . . . . 2.17 112.736 168.194 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 22.6 t -75.72 130.43 36.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 N-CA-C 112.613 0.598 . . . . 3.64 112.613 -164.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 m -60.03 157.62 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 N-CA-C 115.41 1.633 . . . . 3.41 115.41 -163.367 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.14 -178.07 45.95 Favored Glycine 0 C--N 1.338 0.652 0 C-N-CA 125.696 1.617 . . . . 2.26 115.548 -167.234 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.7 mp -134.97 130.9 19.68 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 123.78 0.832 . . . . 6.11 112.287 -170.444 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo . . . . . 0 C--O 1.256 1.383 0 C-N-CA 123.826 3.017 . . . . 2.8 112.017 146.947 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo . . . . . 0 N--CA 1.489 1.208 0 CA-C-O 118.73 -0.613 . . . . 2.79 111.511 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.93 -126.63 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.943 0 C-N-CA 124.246 3.298 . . . . 2.11 108.461 167.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -83.47 148.05 24.79 Favored Glycine 0 CA--C 1.538 1.515 0 CA-C-N 119.229 0.922 . . . . 1.4 112.522 172.498 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -74.18 96.76 0.97 Allowed 'Trans proline' 0 N--CA 1.456 -0.703 0 C-N-CA 123.285 2.656 . . . . 2.96 109.329 172.192 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.443 ' HG3' ' H ' ' C' ' 16' ' ' GLY . 16.5 tp60 59.1 -126.27 1.31 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.176 0.99 . . . . 2.98 109.239 179.819 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . 0.443 ' H ' ' HG3' ' C' ' 15' ' ' GLN . . . 174.25 161.78 24.79 Favored Glycine 0 CA--C 1.535 1.33 1 C-N-CA 132.048 4.642 . . . . 2.55 108.763 -179.769 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 3.7 mp -66.69 145.58 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 CA-C-N 119.34 1.57 . . . . 3.96 110.984 -177.576 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -78.56 145.93 34.54 Favored 'General case' 0 CA--C 1.545 0.765 0 O-C-N 120.915 -1.116 . . . . 1.68 113.024 178.311 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -88.84 161.08 30.45 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 125.305 1.431 . . . . 1.36 113.15 -179.603 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 58.7 mt-30 -87.2 160.28 18.54 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 123.95 0.9 . . . . 5.51 113.129 -174.539 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.24 138.42 45.09 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 109.511 -0.552 . . . . 4.35 109.511 163.413 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.9 165.73 52.68 Favored Glycine 0 CA--C 1.523 0.534 0 C-N-CA 123.728 0.68 . . . . 1.02 113.005 -177.096 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 91.2 t -63.67 138.33 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 C-N-CA 123.765 0.826 . . . . 2.23 108.899 173.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 25.6 m -101.89 -175.79 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.802 0 C-N-CA 125.139 1.376 . . . . 3.73 111.057 -177.831 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -58.96 173.75 3.57 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 124.582 1.087 . . . . 1.86 114.744 171.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 22.7 mt . . . . . 0 C--O 1.25 1.102 0 C-N-CA 125.261 1.425 . . . . 3.55 114.434 -168.297 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.62 0 CA-C-O 116.009 -2.55 . . . . 2.86 108.799 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -72.99 167.96 25.99 Favored 'Trans proline' 0 N--CA 1.458 -0.6 0 C-N-CA 122.991 2.461 . . . . 2.27 111.535 -179.413 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.43 169.28 16.7 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 127.35 2.26 . . . . 3.2 113.039 170.417 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.84 -174.98 40.8 Favored Glycine 0 CA--C 1.528 0.848 0 C-N-CA 125.21 1.386 . . . . 1.21 113.006 169.619 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 14.6 pt -74.18 155.3 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 O-C-N 121.754 -0.851 . . . . 3.81 111.096 -173.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -57.81 139.84 53.13 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.421 0.688 . . . . 1.84 111.597 172.727 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -57.56 150.65 30.27 Favored Glycine 0 CA--C 1.518 0.244 0 C-N-CA 127.259 2.361 . . . . 1.28 113.492 172.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 10.4 mm100 -64.93 118.26 8.8 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 114.716 -0.742 . . . . 4.54 109.194 -178.076 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.8 ttp180 -58.97 139.67 56.48 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 113.013 0.746 . . . . 5.05 113.013 -170.137 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.04 158.47 53.18 Favored Glycine 0 CA--C 1.519 0.331 0 C-N-CA 125.165 1.364 . . . . 1.54 113.38 -169.436 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 33.3 m -68.13 150.22 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-N 114.858 -0.671 . . . . 3.14 110.72 -175.318 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.5 m -51.05 147.8 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 124.192 0.997 . . . . 2.49 111.883 173.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.77 133.44 19.07 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 109.627 -1.389 . . . . 1.76 109.627 162.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 9.5 mp -77.18 169.92 18.84 Favored Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 122.882 0.473 . . . . 3.89 110.823 177.493 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.444 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 97.7 Cg_endo -77.17 -148.08 0.03 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 121.843 1.695 . . . . 2.24 108.277 154.338 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 1.41 0 CA-C-O 117.365 -1.797 . . . . 3.9 112.98 151.723 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo . . . . . 0 N--CA 1.484 0.938 0 CA-C-O 118.554 -0.686 . . . . 2.4 111.363 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.14 150.46 50.44 Favored Glycine 0 CA--C 1.546 1.994 0 CA-C-O 118.849 -0.973 . . . . 1.55 111.947 157.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -76.74 44.31 1.4 Allowed 'Trans proline' 0 CA--C 1.547 1.148 1 C-N-CA 126.986 5.124 . . . . 3.24 114.127 -172.662 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.1 tp-100 73.19 -175.44 0.16 Allowed 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 125.132 1.373 . . . . 5.86 109.606 -163.476 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -94.4 170.26 29.73 Favored Glycine 0 N--CA 1.473 1.126 0 O-C-N 121.091 -1.006 . . . . 1.17 113.12 166.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 50.1 mt -72.85 125.63 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 C-N-CA 123.564 0.746 . . . . 3.97 110.967 -176.438 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.82 143.75 57.72 Favored 'General case' 0 CA--C 1.545 0.762 0 O-C-N 121.203 -0.935 . . . . 1.62 113.253 -178.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.43 171.24 55.16 Favored Glycine 0 CA--C 1.529 0.919 0 C-N-CA 125.656 1.598 . . . . 1.74 113.578 -177.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -135.34 156.19 49.34 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 125.415 1.486 . . . . 3.48 110.224 -172.269 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.8 ptt-85 -71.99 152.5 42.43 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 114.747 1.388 . . . . 7.48 114.747 -172.48 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.23 176.99 54.53 Favored Glycine 0 CA--C 1.536 1.36 0 C-N-CA 125.317 1.437 . . . . 1.77 113.763 176.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 46.9 t -83.3 142.02 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 124.854 1.261 . . . . 3.61 112.98 -164.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 20.1 m -76.08 163.54 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 126.769 2.028 . . . . 2.91 114.323 -165.612 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -96.27 -127.03 5.3 Favored Glycine 0 CA--C 1.53 1.013 0 C-N-CA 125.107 1.337 . . . . 2.23 113.567 176.054 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.444 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 3.8 pp -171.82 159.04 4.6 Favored Pre-proline 0 CA--C 1.547 0.854 0 C-N-CA 125.769 1.627 . . . . 5.35 111.72 -156.529 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_endo . . . . . 0 C--O 1.256 1.383 0 C-N-CA 123.978 3.119 . . . . 3.23 111.767 153.807 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo . . . . . 0 N--CA 1.487 1.1 0 CA-C-O 119.181 -0.425 . . . . 2.22 111.627 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -71.54 -138.43 0.02 OUTLIER 'Trans proline' 0 CA--C 1.545 1.034 0 C-N-CA 123.317 2.678 . . . . 1.99 108.672 165.075 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -90.21 170.21 35.61 Favored Glycine 0 CA--C 1.538 1.52 0 N-CA-C 110.593 -1.003 . . . . 1.32 110.593 165.112 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.07 -58.63 0.04 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.4 2.067 . . . . 3.82 110.705 173.029 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 23.0 tp60 -174.88 133.51 0.34 Allowed 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 126.316 1.846 . . . . 1.48 106.292 -148.04 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.38 160.52 43.98 Favored Glycine 0 CA--C 1.523 0.575 0 C-N-CA 123.649 0.642 . . . . 1.16 111.658 170.216 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 37.1 mm -66.11 144.08 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 O-C-N 121.817 -0.813 . . . . 4.5 110.089 174.638 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.05 161.18 5.33 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 114.505 1.298 . . . . 1.31 114.505 177.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.44 170.46 52.22 Favored Glycine 0 CA--C 1.528 0.877 0 C-N-CA 124.562 1.077 . . . . 1.21 113.298 179.22 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 8.7 mp0 -95.64 177.88 5.65 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 124.339 1.056 . . . . 4.47 112.064 -168.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 14.6 ttt85 -72.87 141.25 47.93 Favored 'General case' 0 N--CA 1.473 0.692 0 O-C-N 120.369 -1.457 . . . . 4.5 110.329 167.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.95 173.69 34.53 Favored Glycine 0 CA--C 1.534 1.263 0 O-C-N 121.731 -0.606 . . . . 1.37 112.111 167.343 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.2 t -69.94 141.66 16.87 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.657 0 C-N-CA 124.409 1.084 . . . . 2.12 109.636 179.483 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 10.9 m -74.81 178.88 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 C-N-CA 124.432 1.093 . . . . 3.22 111.377 175.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.37 -171.68 0.94 Allowed Glycine 0 CA--C 1.538 1.489 0 C-N-CA 124.735 1.16 . . . . 1.68 114.193 162.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 15.5 mt . . . . . 0 N--CA 1.481 1.088 0 CA-C-O 117.199 -1.381 . . . . 4.07 113.719 -168.858 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.598 0 CA-C-O 117.035 -1.981 . . . . 3.25 110.153 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -70.02 154.5 66.64 Favored 'Trans proline' 0 CA--C 1.535 0.543 0 C-N-CA 123.631 2.887 . . . . 3.1 111.982 179.332 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -78.91 176.96 9.13 Favored 'General case' 0 CA--C 1.553 1.092 0 C-N-CA 129.842 3.257 . . . . 3.7 111.563 -178.044 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -90.85 -172.93 43.97 Favored Glycine 0 N--CA 1.478 1.45 0 C-N-CA 125.189 1.376 . . . . 1.76 113.66 176.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.6 mm -76.45 134.96 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 N-CA-C 108.27 -1.011 . . . . 4.19 108.27 174.217 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.22 71.16 0.26 Allowed 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.074 1.35 . . . . 4.43 111.561 172.271 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 63.98 -146.52 50.4 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 125.021 1.296 . . . . 2.49 111.495 -169.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -142.9 128.7 19.37 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 106.269 -1.752 . . . . 6.67 106.269 150.964 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -53.02 126.92 22.17 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 118.769 0.713 . . . . 6.63 109.725 -177.362 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.46 -83.59 0.26 Allowed Glycine 0 N--CA 1.471 1.017 0 O-C-N 123.407 0.442 . . . . 3.18 112.088 -165.677 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -148.92 153.94 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 124.562 1.145 . . . . 2.7 112.161 175.813 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.5 m -65.87 161.52 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 C-N-CA 123.972 0.909 . . . . 3.42 111.233 168.196 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -76.24 174.07 53.62 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 123.585 0.612 . . . . 1.39 112.505 168.184 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -101.67 159.82 28.32 Favored Pre-proline 0 CA--C 1.542 0.663 0 C-N-CA 124.352 1.061 . . . . 4.15 110.854 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_endo -78.77 -166.67 0.42 Allowed 'Trans proline' 0 CA--C 1.537 0.675 0 C-N-CA 123.326 2.684 . . . . 2.5 109.324 157.663 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.274 0 CA-C-O 117.834 -1.537 . . . . 3.51 112.826 154.858 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_exo . . . . . 0 CA--C 1.542 0.921 0 N-CA-C 110.308 -0.689 . . . . 3.04 110.308 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.41 -167.91 2.73 Favored Glycine 0 CA--C 1.545 1.958 0 C-N-CA 119.659 -1.257 . . . . 2.16 112.033 124.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_endo -89.51 -138.97 0.02 OUTLIER 'Trans proline' 0 CA--C 1.546 1.077 0 C-N-CA 125.004 3.802 . . . . 2.86 109.287 175.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.82 138.57 32.44 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 127.288 2.235 . . . . 4.82 107.14 162.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -59.27 131.96 51.84 Favored Glycine 0 N--CA 1.468 0.807 0 N-CA-C 111.264 -0.734 . . . . 1.9 111.264 174.188 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 32.2 mm -60.56 150.37 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 O-C-N 122.334 -0.509 . . . . 6.62 110.982 175.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.57 137.5 58.25 Favored 'General case' 0 CA--C 1.55 0.952 0 O-C-N 120.7 -1.25 . . . . 3.01 114.315 176.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -93.13 -162.6 36.69 Favored Glycine 0 CA--C 1.533 1.196 0 C-N-CA 125.79 1.662 . . . . 3.16 112.211 171.123 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -157.73 174.31 15.51 Favored 'General case' 0 CA--C 1.537 0.442 0 O-C-N 121.064 -1.257 . . . . 4.75 113.944 -173.282 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 8.4 ptt180 -58.11 158.46 6.87 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 115.656 1.724 . . . . 5.15 115.656 172.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.17 -161.41 35.36 Favored Glycine 0 CA--C 1.535 1.29 0 C-N-CA 125.462 1.506 . . . . 2.38 111.499 162.283 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 43.8 t -120.3 145.21 26.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.041 0 C-N-CA 124.557 1.143 . . . . 5.41 112.528 -159.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 14.9 p -56.03 159.03 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 128.834 2.854 . . . . 4.59 114.359 -178.548 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.93 -126.7 1.08 Allowed Glycine 0 CA--C 1.53 1.023 0 C-N-CA 124.535 1.064 . . . . 2.57 111.204 166.218 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -167.26 162.76 10.37 Favored Pre-proline 0 CA--C 1.542 0.646 0 C-N-CA 125.343 1.457 . . . . 4.41 110.867 -166.74 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_endo . . . . . 0 CA--C 1.552 1.386 0 C-N-CA 124.47 3.447 . . . . 3.29 112.15 165.844 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 67.2 Cg_endo . . . . . 0 N--CA 1.487 1.122 0 CA-C-O 118.339 -0.775 . . . . 3.53 111.233 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -62.32 -152.38 0.02 OUTLIER 'Trans proline' 0 CA--C 1.542 0.924 0 C-N-CA 124.91 3.74 . . . . 3.14 111.696 163.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.39 168.66 54.4 Favored Glycine 0 CA--C 1.541 1.712 0 N-CA-C 109.985 -1.246 . . . . 1.56 109.985 163.39 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -76.64 176.65 9.83 Favored 'Trans proline' 0 N--CA 1.452 -0.941 0 C-N-CA 123.142 2.561 . . . . 2.66 110.681 170.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 9.5 tp60 -40.38 122.24 1.55 Allowed 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.279 1.432 . . . . 1.91 111.217 148.113 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.94 -169.37 27.54 Favored Glycine 0 CA--C 1.527 0.795 0 CA-C-O 121.993 0.774 . . . . 1.52 112.731 169.021 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 18.9 mt -63.82 124.33 18.33 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 O-C-N 121.638 -0.919 . . . . 3.6 110.833 175.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -65.52 155.85 34.4 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.582 1.153 . . . . 1.46 113.135 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -80.83 -179.24 52.87 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-O 123.23 1.461 . . . . 1.65 111.672 176.289 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.82 -160.48 1.03 Allowed 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.749 1.22 . . . . 3.25 109.149 178.309 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -85.19 152.46 23.33 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.892 1.277 . . . . 6.56 112.342 -179.181 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.26 176.85 43.88 Favored Glycine 0 CA--C 1.533 1.192 0 N-CA-C 111.03 -0.828 . . . . 1.18 111.03 164.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.0 t -59.84 149.39 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 124.042 0.937 . . . . 2.56 110.178 174.28 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 26.9 m -80.83 -173.34 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 C-N-CA 123.866 0.866 . . . . 3.28 111.079 173.227 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -55.98 160.12 7.27 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 124.154 0.883 . . . . 2.04 114.162 173.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 5.3 mt . . . . . 0 C--O 1.25 1.104 0 N-CA-C 114.246 1.202 . . . . 4.65 114.246 -163.079 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.738 0 CA-C-O 116.517 -2.268 . . . . 3.68 109.755 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -73.53 160.86 43.51 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 122.685 2.256 . . . . 2.8 110.924 -177.103 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 41.4 tp60 -48.65 151.76 1.09 Allowed 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 127.747 2.419 . . . . 5.71 114.866 -179.69 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.26 176.59 52.9 Favored Glycine 0 N--CA 1.465 0.618 0 C-N-CA 124.676 1.132 . . . . 1.27 115.199 173.957 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 14.4 mt -66.29 134.71 29.56 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 125.107 1.363 . . . . 2.85 110.568 -176.325 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.99 137.35 55.78 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 123.943 0.897 . . . . 1.99 112.267 175.313 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -66.72 157.76 50.33 Favored Glycine 0 CA--C 1.528 0.851 0 C-N-CA 125.485 1.517 . . . . 1.43 113.934 -176.507 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 53.1 mm-40 -62.5 128.98 38.56 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 114.738 -0.731 . . . . 4.32 109.668 -179.169 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 14.8 ttt180 -70.47 143.28 51.79 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 112.291 0.478 . . . . 5.37 112.291 -164.828 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -76.85 138.18 21.79 Favored Glycine 0 CA--C 1.522 0.528 0 C-N-CA 123.844 0.735 . . . . 1.93 111.414 -178.144 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 33.2 m -66.89 162.41 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 124.538 1.135 . . . . 3.01 112.493 -174.628 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.1 m -54.76 160.64 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 C-N-CA 124.527 1.131 . . . . 2.86 112.965 174.373 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.56 168.41 39.2 Favored Glycine 0 CA--C 1.527 0.817 0 CA-C-N 115.448 -0.796 . . . . 1.44 113.285 164.716 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 8.6 mp -99.46 156.63 35.19 Favored Pre-proline 0 CA--C 1.541 0.598 0 C-N-CA 124.004 0.922 . . . . 5.4 109.659 176.835 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -84.58 -164.32 0.24 Allowed 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 123.541 2.827 . . . . 2.91 109.163 162.449 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.239 0 CA-C-O 117.77 -1.572 . . . . 3.64 112.812 158.151 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_exo . . . . . 0 CA--C 1.544 0.998 0 CA-C-O 119.095 -0.46 . . . . 3.12 111.724 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.84 164.46 27.15 Favored Glycine 0 CA--C 1.542 1.752 0 CA-C-N 119.676 1.126 . . . . 1.44 113.153 138.975 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -80.69 63.58 8.79 Favored 'Trans proline' 0 CA--C 1.541 0.827 1 C-N-CA 126.176 4.584 . . . . 3.41 111.278 -179.58 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 22.8 tp60 67.85 173.04 0.27 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.188 1.395 . . . . 5.47 111.698 -172.625 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.15 160.33 29.48 Favored Glycine 0 CA--C 1.531 1.039 0 O-C-N 120.734 -1.229 . . . . 1.05 111.925 155.783 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 48.9 mm -74.65 129.94 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 O-C-N 121.708 -0.878 . . . . 4.04 109.955 176.195 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.73 149.23 50.83 Favored 'General case' 0 CA--C 1.544 0.734 0 N-CA-C 113.945 1.091 . . . . 1.68 113.945 -179.116 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.97 151.74 47.78 Favored Glycine 0 CA--C 1.531 1.073 0 C-N-CA 123.843 0.735 . . . . 1.47 111.557 177.299 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -109.17 156.85 19.38 Favored 'General case' 0 N--CA 1.465 0.307 0 O-C-N 121.644 -0.915 . . . . 3.17 111.649 175.287 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 6.5 ptt180 -64.32 158.31 23.82 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.426 1.89 . . . . 5.69 114.463 178.42 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -90.67 -167.69 41.78 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 126.275 1.893 . . . . 2.31 112.729 170.606 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 11.8 m -100.77 146.52 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 N-CA-C 115.849 1.796 . . . . 3.98 115.849 -162.329 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.6 p -46.35 153.67 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 128.888 2.875 . . . . 4.93 114.938 -178.664 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.33 -127.92 1.09 Allowed Glycine 0 CA--C 1.528 0.893 0 C-N-CA 123.714 0.673 . . . . 2.51 112.165 169.57 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.0 pp -162.67 151.57 12.56 Favored Pre-proline 0 CA--C 1.543 0.675 0 C-N-CA 124.141 0.976 . . . . 5.26 112.135 -164.64 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo . . . . . 0 C--O 1.255 1.367 1 C-N-CA 125.375 4.05 . . . . 3.17 112.397 162.306 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo . . . . . 0 CA--C 1.547 1.153 0 CA-C-O 119.107 -0.455 . . . . 2.15 112.046 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -62.58 -166.81 0.06 OUTLIER 'Trans proline' 0 CA--C 1.54 0.8 0 C-N-CA 124.096 3.197 . . . . 1.83 111.737 166.488 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.53 143.83 34.65 Favored Glycine 0 CA--C 1.54 1.629 0 O-C-N 121.124 -0.985 . . . . 1.1 113.108 -171.753 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -78.52 61.08 7.82 Favored 'Trans proline' 0 CA--C 1.54 0.82 0 C-N-CA 124.847 3.698 . . . . 3.19 112.196 -174.914 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 40.6 tp60 75.66 145.4 0.08 Allowed 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 126.543 1.937 . . . . 2.39 113.643 169.314 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.95 148.57 24.65 Favored Glycine 0 CA--C 1.528 0.848 0 O-C-N 120.875 -1.141 . . . . 1.15 112.838 169.397 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 38.3 mm -65.78 148.08 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 O-C-N 122.201 -0.588 . . . . 4.42 110.786 174.774 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.53 151.76 43.64 Favored 'General case' 0 CA--C 1.543 0.675 0 N-CA-C 113.093 0.775 . . . . 1.25 113.093 176.601 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.76 155.25 35.07 Favored Glycine 0 CA--C 1.529 0.957 0 CA-C-O 122.449 1.027 . . . . 1.0 112.342 174.878 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 18.2 mp0 -91.96 178.27 5.94 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 124.988 1.315 . . . . 3.17 110.556 -179.513 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 15.5 ptp180 -71.11 162.02 30.13 Favored 'General case' 0 N--CA 1.475 0.791 0 O-C-N 121.112 -0.992 . . . . 7.13 112.85 176.931 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.55 -171.82 42.26 Favored Glycine 0 CA--C 1.535 1.327 0 C-N-CA 124.023 0.821 . . . . 1.41 112.876 174.867 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 47.2 t -68.4 139.9 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 124.374 1.069 . . . . 2.32 110.699 -178.721 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 27.8 m -81.68 -176.1 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.705 1.202 . . . . 3.51 111.751 -176.957 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.56 161.82 15.85 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 123.91 0.767 . . . . 1.72 113.707 173.362 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 9.4 mt . . . . . 0 C--O 1.249 1.059 0 N-CA-C 114.717 1.377 . . . . 4.29 114.717 -164.717 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.846 0 CA-C-O 116.061 -2.522 . . . . 5.48 108.935 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -80.15 -174.99 2.48 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 122.829 2.352 . . . . 4.19 110.38 176.831 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.55 -143.77 0.11 Allowed 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 125.288 1.435 . . . . 2.57 111.073 169.32 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -82.98 -127.91 1.22 Allowed Glycine 0 N--CA 1.472 1.062 0 C-N-CA 125.611 1.577 . . . . 1.23 112.753 170.761 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 10.2 mm -111.59 160.17 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.071 0 C-N-CA 124.504 1.122 . . . . 4.08 110.861 -176.466 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -78.78 81.61 5.07 Favored 'General case' 0 CA--C 1.546 0.807 0 O-C-N 120.47 -1.394 . . . . 3.72 110.237 164.438 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.59 -170.35 42.92 Favored Glycine 0 N--CA 1.466 0.644 0 C-N-CA 126.418 1.961 . . . . 3.45 113.397 -172.288 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -94.39 119.64 33.43 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 105.856 -1.905 . . . . 8.14 105.856 127.773 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 35.7 ttm180 -62.42 136.36 57.87 Favored 'General case' 0 CA--C 1.534 0.361 0 O-C-N 121.109 -0.994 . . . . 6.19 111.377 -178.986 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.32 170.43 53.53 Favored Glycine 0 N--CA 1.465 0.583 0 C-N-CA 125.021 1.296 . . . . 1.9 113.831 -178.082 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.1 m -87.55 156.93 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 CA-C-N 114.043 -1.078 . . . . 3.65 111.614 -175.823 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.1 m -57.16 147.71 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.442 1.097 . . . . 3.02 112.388 -178.807 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -74.44 169.44 54.13 Favored Glycine 0 CA--C 1.529 0.928 0 N-CA-C 110.362 -1.095 . . . . 1.89 110.362 157.773 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 24.0 mt -116.18 172.09 4.1 Favored Pre-proline 0 N--CA 1.471 0.614 0 O-C-N 122.149 -0.618 . . . . 5.37 111.794 170.74 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -69.78 -153.59 0.03 OUTLIER 'Trans proline' 0 CA--C 1.536 0.616 0 C-N-CA 122.717 2.278 . . . . 2.84 108.884 148.029 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.301 0 CA-C-O 116.971 -2.016 . . . . 3.82 113.106 159.693 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo . . . . . 0 N--CA 1.491 1.356 0 N-CA-C 108.774 -1.279 . . . . 3.54 108.774 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.16 147.95 51.16 Favored Glycine 0 CA--C 1.549 2.219 0 CA-C-O 118.27 -1.295 . . . . 2.36 110.635 157.879 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -83.42 -51.41 0.04 OUTLIER 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 124.229 3.286 . . . . 3.42 112.874 -173.969 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -170.66 -178.99 2.76 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 128.15 2.58 . . . . 5.94 108.358 178.284 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -98.74 157.57 20.24 Favored Glycine 0 CA--C 1.528 0.857 0 CA-C-O 122.16 0.867 . . . . 1.73 113.739 177.744 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 3.5 mp -72.71 157.27 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 124.204 1.002 . . . . 3.74 109.096 175.37 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.41 127.75 32.99 Favored 'General case' 0 CA--C 1.545 0.78 0 O-C-N 120.647 -1.283 . . . . 2.82 112.507 170.125 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -86.59 171.63 43.69 Favored Glycine 0 C--N 1.339 0.7 0 C-N-CA 125.178 1.37 . . . . 2.65 112.608 177.09 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -104.94 147.35 27.87 Favored 'General case' 0 N--CA 1.462 0.174 0 O-C-N 121.855 -0.791 . . . . 3.4 111.259 -179.068 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 6.6 ptt180 -67.99 155.74 38.83 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.167 -0.47 . . . . 5.06 110.796 158.002 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.17 -172.83 43.18 Favored Glycine 0 CA--C 1.533 1.212 0 C-N-CA 123.946 0.784 . . . . 1.97 113.066 178.255 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 15.3 m -93.67 145.59 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 N-CA-C 116.012 1.856 . . . . 4.4 116.012 -155.841 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.8 m -85.84 155.02 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.916 1.687 . . . . 3.11 112.888 -171.373 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.73 -134.15 8.13 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 124.637 1.113 . . . . 2.1 113.25 175.203 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -168.56 163.38 8.26 Favored Pre-proline 0 CA--C 1.551 0.988 0 C-N-CA 126.323 1.849 . . . . 3.85 111.028 -163.475 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo . . . . . 0 C--O 1.255 1.346 0 C-N-CA 124.383 3.389 . . . . 2.79 111.502 159.184 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo . . . . . 0 N--CA 1.486 1.043 0 CA-C-O 118.819 -0.575 . . . . 3.63 111.987 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -64.29 -166.83 0.08 OUTLIER 'Trans proline' 0 CA--C 1.54 0.796 0 C-N-CA 123.616 2.878 . . . . 3.01 110.233 159.413 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -89.87 174.95 41.4 Favored Glycine 0 CA--C 1.534 1.26 0 C-N-CA 124.005 0.812 . . . . 1.63 112.589 175.338 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -70.59 169.31 20.27 Favored 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 123.03 2.487 . . . . 2.47 111.941 170.527 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 26.3 tp60 -34.67 146.28 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 129.066 2.947 . . . . 2.29 114.673 168.601 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.7 171.22 41.13 Favored Glycine 0 CA--C 1.525 0.672 0 C-N-CA 123.427 0.537 . . . . 1.9 112.631 168.346 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 3.3 mp -59.21 130.48 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 123.157 0.583 . . . . 4.48 110.489 178.089 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.32 143.56 50.24 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 125.574 1.55 . . . . 2.5 114.797 -170.514 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -85.16 145.91 21.64 Favored Glycine 0 C--N 1.339 0.736 0 N-CA-C 109.664 -1.374 . . . . 1.62 109.664 171.706 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 5.7 mp0 -85.83 -169.67 2.75 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 123.941 0.896 . . . . 3.42 110.503 179.894 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 16.2 ttt180 -64.88 145.11 56.74 Favored 'General case' 0 N--CA 1.467 0.421 0 O-C-N 121.172 -0.955 . . . . 5.38 109.49 156.297 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.17 162.35 36.19 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 111.414 -0.674 . . . . 1.26 111.414 161.94 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.57 140.15 20.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 C-N-CA 123.445 0.698 . . . . 2.75 109.796 176.221 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 13.4 p -79.67 178.9 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 C-N-CA 127.041 2.136 . . . . 5.06 110.872 178.479 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.34 179.36 2.62 Favored Glycine 0 CA--C 1.537 1.41 0 C-N-CA 124.553 1.073 . . . . 2.28 114.735 169.155 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 10.0 mp . . . . . 0 C--O 1.249 1.078 0 C-N-CA 126.001 1.72 . . . . 4.89 113.296 -162.571 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.791 0 CA-C-O 116.154 -2.47 . . . . 2.68 109.216 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -79.04 163.95 25.22 Favored 'Trans proline' 0 N--CA 1.459 -0.524 0 C-N-CA 123.0 2.466 . . . . 2.07 111.318 -174.941 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -58.58 166.69 1.71 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.774 2.029 . . . . 3.33 114.041 168.871 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.59 -118.45 0.03 OUTLIER Glycine 0 N--CA 1.475 1.287 0 C-N-CA 127.452 2.453 . . . . 2.23 115.798 -176.652 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.2 mp -120.07 137.01 55.3 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 O-C-N 120.916 -1.344 . . . . 3.65 108.874 -179.824 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -52.17 128.41 24.8 Favored 'General case' 0 CA--C 1.542 0.651 0 CA-C-N 118.275 0.489 . . . . 1.9 110.706 170.135 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -62.34 156.7 37.93 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 125.777 1.656 . . . . 1.3 113.713 -177.076 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.9 mm-40 -73.0 116.34 13.39 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 108.734 -0.839 . . . . 3.91 108.734 -171.929 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 7.4 ttt180 -64.22 140.58 58.88 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 122.72 0.408 . . . . 5.8 112.029 -163.283 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.67 158.17 53.62 Favored Glycine 0 C--N 1.335 0.502 0 C-N-CA 123.926 0.774 . . . . 1.77 111.908 -179.644 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 33.3 m -75.97 160.99 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 CA-C-N 115.084 -0.558 . . . . 3.53 111.606 -174.636 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.1 m -51.98 164.76 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 125.531 1.532 . . . . 3.12 112.857 177.283 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.56 124.45 29.26 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.989 -0.844 . . . . 2.18 110.989 163.421 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 9.5 mp -82.31 170.92 13.2 Favored Pre-proline 0 CA--C 1.533 0.321 0 C-N-CA 124.493 1.117 . . . . 4.8 110.856 175.479 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -60.0 -165.77 0.03 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 121.77 1.647 . . . . 4.04 110.821 152.135 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.667 0 CA-C-O 118.647 -1.085 . . . . 6.19 114.984 160.141 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo . . . . . 0 N--CA 1.481 0.776 0 CA-C-O 118.551 -0.687 . . . . 2.42 111.694 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.29 161.44 48.0 Favored Glycine 0 CA--C 1.54 1.628 0 CA-C-O 119.078 -0.845 . . . . 1.27 111.669 152.709 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -76.0 163.68 32.75 Favored 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 124.235 3.29 . . . . 2.47 110.641 165.797 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -53.94 140.17 31.74 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.761 1.224 . . . . 5.38 111.79 170.948 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.23 161.67 53.24 Favored Glycine 0 CA--C 1.529 0.912 0 C-N-CA 124.167 0.889 . . . . 1.42 114.421 -174.512 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 35.6 mm -60.78 119.32 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 O-C-N 121.542 -0.975 . . . . 3.66 111.086 -175.772 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.76 155.04 27.78 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 114.492 1.293 . . . . 1.75 114.492 -172.176 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.24 136.7 28.68 Favored Glycine 0 CA--C 1.527 0.809 0 C-N-CA 126.3 1.905 . . . . 1.62 111.391 -179.534 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -106.3 143.62 34.16 Favored 'General case' 0 N--CA 1.465 0.323 0 O-C-N 121.633 -0.922 . . . . 3.83 110.133 -172.415 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 32.0 ptt180 -72.22 157.6 37.43 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.344 1.058 . . . . 5.01 112.997 175.823 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.86 -174.95 26.77 Favored Glycine 0 CA--C 1.539 1.534 0 N-CA-C 117.061 1.584 . . . . 2.69 117.061 -170.099 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 60.9 t -96.33 136.1 28.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 C-N-CA 124.201 1.001 . . . . 5.19 113.517 -157.873 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.9 p -32.39 143.21 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 131.232 3.813 . . . . 5.27 118.44 -170.32 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.14 -118.79 4.11 Favored Glycine 0 CA--C 1.528 0.905 0 C-N-CA 124.968 1.27 . . . . 2.45 112.211 169.469 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 1.6 pp -168.76 153.39 5.9 Favored Pre-proline 0 CA--C 1.552 1.025 0 N-CA-C 115.565 1.691 . . . . 6.56 115.565 -150.246 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo . . . . . 0 C--O 1.254 1.298 0 C-N-CA 123.739 2.96 . . . . 4.65 111.741 152.935 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo . . . . . 0 N--CA 1.486 1.068 0 CA-C-O 118.582 -0.674 . . . . 2.35 111.096 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -71.12 -150.0 0.03 OUTLIER 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 123.65 2.9 . . . . 2.06 109.581 166.11 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -99.27 -172.77 31.15 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-N 118.688 0.676 . . . . 1.42 112.662 172.232 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.81 167.69 23.46 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 123.248 2.632 . . . . 2.36 112.213 176.608 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 8.7 tp60 -37.23 127.16 1.0 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.696 2.398 . . . . 1.64 113.024 160.583 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -62.5 147.75 49.46 Favored Glycine 0 CA--C 1.527 0.786 0 C-N-CA 124.321 0.962 . . . . 1.01 112.741 168.584 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 47.0 mm -57.9 147.14 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 O-C-N 121.933 -0.745 . . . . 4.35 111.557 -178.952 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -72.4 156.81 38.67 Favored 'General case' 0 CA--C 1.542 0.658 0 O-C-N 121.293 -0.879 . . . . 1.3 112.792 178.72 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -91.94 153.75 22.1 Favored Glycine 0 C--N 1.338 0.644 0 CA-C-O 122.299 0.944 . . . . 1.09 112.046 -178.528 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 25.1 mp0 -92.02 -174.12 3.69 Favored 'General case' 0 CA--C 1.544 0.721 0 CA-C-O 122.024 0.916 . . . . 3.21 111.398 -175.954 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -58.83 139.33 56.56 Favored 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 125.15 1.38 . . . . 5.54 111.653 169.093 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.9 -171.01 6.81 Favored Glycine 0 C--N 1.337 0.628 0 C-N-CA 125.384 1.469 . . . . 1.58 113.481 175.825 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 21.4 t -65.0 127.46 25.95 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.696 0 O-C-N 122.305 -0.527 . . . . 3.17 110.473 -178.833 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 4.3 p -64.31 160.93 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 126.864 2.066 . . . . 5.06 112.133 178.007 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -51.9 176.52 0.1 Allowed Glycine 0 CA--C 1.542 1.728 0 C-N-CA 124.52 1.057 . . . . 1.84 115.236 159.518 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 3.3 mm? . . . . . 0 C--O 1.253 1.248 0 CA-C-O 117.016 -1.469 . . . . 4.07 112.623 -161.156 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.784 0 CA-C-O 116.837 -2.09 . . . . 4.05 110.139 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 83.5 Cg_endo -76.27 162.11 34.24 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 123.436 2.758 . . . . 3.41 111.635 -174.989 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.01 153.55 36.93 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 127.31 2.244 . . . . 3.14 113.605 178.706 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.7 -122.91 0.05 OUTLIER Glycine 0 CA--C 1.534 1.271 0 C-N-CA 127.146 2.308 . . . . 2.4 115.717 -179.051 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.8 mt -122.42 131.8 72.46 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 O-C-N 121.097 -1.237 . . . . 2.42 109.191 -177.248 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.91 134.33 55.41 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 123.442 0.697 . . . . 2.08 110.81 173.399 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.69 155.18 48.13 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 126.744 2.116 . . . . 1.83 114.33 -173.463 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 72.7 mm-40 -77.76 154.09 32.31 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 114.767 -0.717 . . . . 4.59 112.47 -166.256 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.45 132.16 53.04 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 123.509 0.723 . . . . 7.88 111.759 -177.672 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.9 151.64 44.52 Favored Glycine 0 N--CA 1.467 0.763 0 N-CA-C 115.584 0.994 . . . . 2.01 115.584 -167.879 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 2.5 m -69.1 130.93 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 124.938 1.295 . . . . 3.07 110.893 176.138 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.5 m -55.61 146.07 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 125.062 1.345 . . . . 2.93 114.029 -167.638 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.02 -163.93 7.91 Favored Glycine 0 CA--C 1.534 1.276 0 N-CA-C 111.39 -0.684 . . . . 1.98 111.39 161.032 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.1 mt -143.95 167.02 16.46 Favored Pre-proline 0 N--CA 1.475 0.813 0 C-N-CA 124.551 1.14 . . . . 3.62 111.479 179.951 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . 0.414 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 29.2 Cg_endo -76.73 -152.61 0.04 OUTLIER 'Trans proline' 0 CA--C 1.539 0.736 0 C-N-CA 122.981 2.454 . . . . 2.18 108.584 150.914 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.288 0 CA-C-O 117.017 -1.99 . . . . 3.12 112.774 143.671 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_exo . . . . . 0 CA--C 1.543 0.966 0 N-CA-C 111.512 -0.226 . . . . 3.93 111.512 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.05 176.44 30.06 Favored Glycine 0 CA--C 1.538 1.474 0 C-N-CA 120.284 -0.96 . . . . 1.83 112.935 127.561 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -79.94 156.28 23.56 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 C-N-CA 125.011 3.807 . . . . 2.54 110.795 158.646 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -60.86 140.63 57.62 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 125.158 1.383 . . . . 5.55 110.455 168.24 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.32 162.14 40.83 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 115.508 0.963 . . . . 1.48 115.508 -172.114 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 41.0 pt -55.41 139.19 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 O-C-N 122.376 -0.485 . . . . 5.24 111.213 176.765 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.15 154.04 42.72 Favored 'General case' 0 CA--C 1.54 0.589 0 CA-C-O 121.539 0.685 . . . . 1.81 112.828 -176.638 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.02 161.96 51.71 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 125.094 1.33 . . . . 2.23 113.635 -178.338 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 3.0 tp-100 -90.56 131.06 36.51 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 123.663 0.785 . . . . 4.55 109.709 -174.163 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.28 153.26 3.94 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-O 122.678 1.228 . . . . 9.23 114.161 -177.77 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.91 166.54 54.41 Favored Glycine 0 CA--C 1.531 1.086 0 CA-C-N 113.998 -1.456 . . . . 2.08 112.541 171.298 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 17.6 m -89.71 139.28 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 115.05 1.5 . . . . 4.4 115.05 -162.841 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.1 m -104.22 155.8 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 124.809 1.244 . . . . 3.11 112.708 -163.211 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -107.49 -130.33 6.34 Favored Glycine 0 CA--C 1.529 0.907 0 C-N-CA 125.118 1.342 . . . . 1.68 113.218 177.801 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . 0.414 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.7 pt? -179.14 161.82 1.0 Allowed Pre-proline 0 CA--C 1.547 0.842 0 C-N-CA 126.045 1.738 . . . . 3.76 110.753 -152.996 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo . . . . . 0 C--O 1.257 1.437 0 C-N-CA 124.014 3.143 . . . . 2.91 111.949 156.159 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo . . . . . 0 CA--C 1.547 1.173 0 CA-C-O 119.181 -0.425 . . . . 3.88 112.03 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -66.07 -160.66 0.04 OUTLIER 'Trans proline' 0 CA--C 1.543 0.942 0 C-N-CA 123.066 2.511 . . . . 2.56 110.129 161.67 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -90.89 -177.57 43.74 Favored Glycine 0 CA--C 1.535 1.31 0 O-C-N 121.163 -0.96 . . . . 1.52 111.897 169.043 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -77.77 170.51 18.94 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.946 2.43 . . . . 2.57 111.981 175.405 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.8 tp60 -34.99 127.01 0.53 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 127.557 2.343 . . . . 1.74 113.325 152.499 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.18 155.4 53.16 Favored Glycine 0 CA--C 1.528 0.869 0 C-N-CA 124.944 1.259 . . . . 1.49 112.338 167.304 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 82.3 mt -62.95 139.57 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 O-C-N 121.593 -0.946 . . . . 3.42 110.731 -175.582 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.26 159.15 12.76 Favored 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 122.292 1.044 . . . . 2.28 113.31 178.904 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -61.76 124.99 35.75 Favored Glycine 0 CA--C 1.524 0.638 0 CA-C-O 122.279 0.933 . . . . 2.25 112.679 -170.905 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . 0.527 ' NE2' ' H ' ' C' ' 20' ' ' GLN . 0.0 OUTLIER -60.59 129.76 43.15 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.672 1.589 . . . . 6.1 110.919 -175.982 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.47 129.71 22.51 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.526 0.731 . . . . 3.81 111.862 -174.898 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -62.6 154.98 41.65 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 115.168 -0.924 . . . . 1.12 113.311 -176.466 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.5 t -57.4 146.59 6.76 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 C-N-CA 124.913 1.285 . . . . 1.88 110.288 171.876 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 27.2 m -98.54 -169.87 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.817 0 C-N-CA 125.687 1.595 . . . . 3.06 110.557 179.091 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.6 -168.31 3.94 Favored Glycine 0 CA--C 1.538 1.485 0 C-N-CA 124.339 0.971 . . . . 1.9 113.944 167.356 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 13.5 mt . . . . . 0 N--CA 1.485 1.315 0 N-CA-C 114.329 1.233 . . . . 4.25 114.329 -174.977 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.558 0 CA-C-O 116.121 -2.488 . . . . 4.87 108.856 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -76.57 162.52 32.99 Favored 'Trans proline' 0 N--CA 1.457 -0.676 0 C-N-CA 122.593 2.195 . . . . 5.94 111.328 -176.841 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -64.38 161.71 16.44 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 128.294 2.638 . . . . 5.16 111.451 166.577 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.41 -143.17 0.46 Allowed Glycine 0 CA--C 1.535 1.34 0 C-N-CA 126.66 2.076 . . . . 3.27 114.307 173.367 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.1 mt -101.06 127.92 53.79 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 O-C-N 121.375 -1.074 . . . . 4.8 108.409 179.202 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.89 140.79 56.41 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 118.901 0.773 . . . . 2.63 110.29 168.186 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -61.75 141.95 47.9 Favored Glycine 0 CA--C 1.523 0.58 0 C-N-CA 124.587 1.089 . . . . 1.19 112.291 175.423 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 54.2 mm-40 -68.32 130.22 42.25 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 109.847 -0.427 . . . . 3.79 109.847 -177.516 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -66.69 137.26 56.56 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 121.512 0.672 . . . . 4.56 111.175 -171.765 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.63 126.1 8.33 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-O 122.599 1.11 . . . . 2.48 111.562 176.611 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.8 t -65.28 155.26 6.8 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.835 0 C-N-CA 126.498 1.919 . . . . 5.23 111.822 -178.141 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.3 m -61.62 152.32 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 O-C-N 121.121 -0.987 . . . . 3.96 112.791 173.805 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -97.02 -153.88 29.7 Favored Glycine 0 N--CA 1.468 0.795 0 C-N-CA 124.023 0.821 . . . . 2.19 112.478 167.642 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 89.2 mt -143.26 158.89 57.23 Favored Pre-proline 0 N--CA 1.47 0.536 0 C-N-CA 126.117 1.767 . . . . 6.33 110.246 176.444 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -76.41 -146.21 0.03 OUTLIER 'Trans proline' 0 CA--C 1.54 0.791 0 C-N-CA 122.58 2.186 . . . . 4.73 107.803 154.03 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.169 0 CA-C-O 116.701 -2.166 . . . . 4.72 111.979 151.902 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo . . . . . 0 N--CA 1.481 0.774 0 CA-C-O 118.705 -0.623 . . . . 4.59 111.68 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.6 159.01 50.88 Favored Glycine 0 CA--C 1.539 1.581 0 CA-C-O 118.761 -1.021 . . . . 2.08 111.682 154.443 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_endo -70.8 158.67 54.96 Favored 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 123.782 2.988 . . . . 4.75 109.819 162.134 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -82.34 174.29 11.27 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.909 0.861 . . . . 7.89 113.114 178.593 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.22 154.36 52.53 Favored Glycine 0 CA--C 1.52 0.389 0 CA-C-O 122.615 1.119 . . . . 1.95 114.248 -177.705 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 43.8 pt -61.39 144.69 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 CA-C-N 114.383 -0.909 . . . . 6.69 110.718 161.518 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -85.35 133.4 34.14 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 123.822 0.849 . . . . 2.41 112.495 177.749 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -75.08 125.62 8.32 Favored Glycine 0 CA--C 1.525 0.691 0 C-N-CA 125.653 1.597 . . . . 1.78 110.546 173.272 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -89.71 157.51 17.95 Favored 'General case' 0 CA--C 1.535 0.382 0 O-C-N 121.865 -0.785 . . . . 4.32 110.384 166.321 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.92 162.08 29.92 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 123.235 0.614 . . . . 4.61 111.712 166.029 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -84.19 -141.8 5.1 Favored Glycine 0 CA--C 1.533 1.198 0 N-CA-C 110.991 -0.843 . . . . 3.14 110.991 163.602 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 99.5 t -40.62 131.38 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 126.415 1.886 . . . . 5.75 113.816 -173.944 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 15.3 m -103.78 149.4 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 125.083 1.353 . . . . 4.48 109.02 161.371 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.468 ' H ' HG21 ' C' ' 23' ' ' VAL . . . -102.55 167.63 17.84 Favored Glycine 0 C--N 1.333 0.392 0 C-N-CA 124.843 1.211 . . . . 5.24 115.266 -163.574 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -171.57 158.99 4.83 Favored Pre-proline 0 CA--C 1.544 0.713 0 C-N-CA 127.626 2.37 . . . . 8.04 111.028 -173.824 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo . . . . . 0 C--O 1.255 1.354 0 C-N-CA 124.063 3.175 . . . . 5.61 112.155 152.631 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo . . . . . 0 N--CA 1.486 1.085 0 CA-C-O 118.604 -0.665 . . . . 5.74 111.305 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -69.06 -152.88 0.03 OUTLIER 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 123.394 2.729 . . . . 4.8 109.761 163.632 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -91.45 177.28 40.69 Favored Glycine 0 CA--C 1.535 1.293 0 N-CA-C 111.424 -0.67 . . . . 2.66 111.424 166.684 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -78.26 168.07 22.23 Favored 'Trans proline' 0 N--CA 1.455 -0.772 0 C-N-CA 123.111 2.541 . . . . 4.27 111.858 172.637 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 27.0 tp60 -40.51 121.91 1.52 Allowed 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 128.217 2.607 . . . . 3.04 113.98 160.046 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.74 157.74 51.91 Favored Glycine 0 CA--C 1.527 0.841 0 C-N-CA 124.82 1.2 . . . . 1.71 111.637 163.953 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 51.2 mm -65.56 132.2 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 O-C-N 121.81 -0.818 . . . . 3.95 111.903 -172.458 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.52 145.92 38.77 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 123.77 0.828 . . . . 1.67 111.862 171.731 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -80.44 -173.21 46.19 Favored Glycine 0 C--N 1.338 0.673 0 CA-C-O 122.684 1.158 . . . . 1.08 111.513 -179.959 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 12.5 mp0 -115.95 158.84 22.44 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 108.214 -1.032 . . . . 3.29 108.214 179.367 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 2.8 tmt_? -63.45 134.12 55.1 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 107.611 -1.255 . . . . 7.1 107.611 153.804 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.61 153.66 52.92 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 111.626 -0.589 . . . . 2.79 111.626 -179.249 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . 0.468 HG21 ' H ' ' B' ' 25' ' ' GLY . 15.5 m -67.03 162.66 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 O-C-N 121.429 -1.042 . . . . 5.76 111.95 -176.291 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 16.0 m -90.61 173.93 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 126.889 2.076 . . . . 5.54 110.776 171.552 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.15 -171.87 2.45 Favored Glycine 0 CA--C 1.54 1.632 0 C-N-CA 125.249 1.404 . . . . 3.74 115.132 164.808 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 mm? . . . . . 0 C--O 1.25 1.117 0 C-N-CA 126.69 1.996 . . . . 8.16 112.36 -166.274 . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.69 0 CA-C-O 116.307 -2.385 . . . . 2.85 109.047 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -78.43 164.85 25.96 Favored 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 123.144 2.562 . . . . 2.31 112.606 -170.612 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.62 153.47 10.29 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 129.304 3.041 . . . . 3.55 112.464 170.072 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.12 -144.26 3.41 Favored Glycine 0 N--CA 1.475 1.287 0 C-N-CA 126.667 2.079 . . . . 1.67 117.01 -171.8 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 33.2 pt -98.94 139.32 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 O-C-N 121.24 -1.153 . . . . 3.62 108.692 174.848 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.84 146.4 49.77 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-O 121.38 0.609 . . . . 1.78 111.052 179.558 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -45.86 141.64 4.96 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 126.423 1.963 . . . . 1.23 114.017 174.884 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 80.3 mm-40 -63.69 132.82 52.25 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 108.925 -0.768 . . . . 3.95 108.925 -178.54 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.4 tmt_? -64.55 134.31 54.13 Favored 'General case' 0 CA--C 1.536 0.425 0 N-CA-C 112.421 0.526 . . . . 5.9 112.421 -162.481 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.54 160.79 53.7 Favored Glycine 0 N--CA 1.466 0.66 0 CA-C-O 122.823 1.235 . . . . 1.49 115.6 -169.58 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 11.1 t -79.01 145.25 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 126.15 1.78 . . . . 3.11 111.847 -167.272 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.9 m -58.49 147.26 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 C-N-CA 124.965 1.306 . . . . 2.81 113.59 -179.396 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.41 ' H ' ' HB ' ' B' ' 23' ' ' VAL . . . -82.72 -163.88 34.34 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 124.267 0.937 . . . . 2.01 112.263 167.215 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.1 mt -145.9 160.44 43.62 Favored Pre-proline 0 N--CA 1.474 0.768 0 C-N-CA 128.053 2.541 . . . . 3.97 108.177 174.868 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -77.11 -157.12 0.07 OUTLIER 'Trans proline' 0 CA--C 1.541 0.866 0 C-N-CA 122.187 1.925 . . . . 2.29 109.129 164.677 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.205 0 CA-C-O 117.358 -1.801 . . . . 3.39 112.696 154.383 . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo . . . . . 0 N--CA 1.481 0.762 0 CA-C-O 118.479 -0.717 . . . . 2.7 111.391 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.49 166.26 30.73 Favored Glycine 0 CA--C 1.543 1.814 0 CA-C-O 119.006 -0.886 . . . . 1.64 112.885 149.724 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -76.62 41.76 0.95 Allowed 'Trans proline' 0 CA--C 1.546 1.078 1 C-N-CA 127.014 5.143 . . . . 3.7 113.176 -179.123 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 66.27 178.17 0.22 Allowed 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 125.274 1.43 . . . . 5.45 112.053 -165.1 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.64 163.54 31.08 Favored Glycine 0 CA--C 1.541 1.696 0 C-N-CA 124.429 1.014 . . . . 0.95 113.447 159.367 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 67.5 mt -77.77 148.71 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 126.05 1.74 . . . . 3.47 111.718 176.469 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -73.58 147.97 43.39 Favored 'General case' 0 CA--C 1.548 0.877 0 N-CA-C 114.362 1.245 . . . . 1.33 114.362 -177.616 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -78.02 169.89 54.72 Favored Glycine 0 CA--C 1.536 1.378 0 C-N-CA 125.52 1.533 . . . . 1.5 112.476 173.188 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.94 170.35 12.35 Favored 'General case' 0 N--CA 1.467 0.408 0 O-C-N 121.321 -1.105 . . . . 3.54 112.06 -177.35 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -59.42 148.4 32.83 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 124.6 1.16 . . . . 5.7 113.328 -176.243 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.6 -54.96 5.22 Favored Glycine 0 N--CA 1.472 1.045 0 N-CA-C 114.418 0.527 . . . . 4.31 114.418 -173.404 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . 0.41 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 11.1 t -146.65 158.91 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 128.478 2.711 . . . . 5.8 107.864 -176.518 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.0 p -121.06 153.58 24.55 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 C-N-CA 127.87 2.468 . . . . 4.32 109.32 178.103 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.02 -168.29 43.73 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-O 121.857 0.698 . . . . 2.18 114.582 177.162 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.9 pp -159.79 150.92 16.07 Favored Pre-proline 0 CA--C 1.543 0.699 0 C-N-CA 125.996 1.718 . . . . 3.64 110.97 -179.265 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo . . . . . 0 C--O 1.254 1.306 1 C-N-CA 125.584 4.189 . . . . 3.1 112.881 167.594 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo . . . . . 0 N--CA 1.485 1.001 0 CA-C-O 118.834 -0.569 . . . . 2.26 111.267 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -71.99 -143.16 0.02 OUTLIER 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 123.943 3.095 . . . . 1.91 109.257 169.091 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.33 146.61 39.45 Favored Glycine 0 CA--C 1.54 1.623 0 CA-C-O 118.713 -1.048 . . . . 1.31 110.506 165.659 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -68.25 -43.04 4.91 Favored 'Trans proline' 0 CA--C 1.534 0.49 0 C-N-CA 123.024 2.483 . . . . 3.28 113.285 178.208 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 16.9 tp60 174.2 115.2 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 126.185 1.794 . . . . 2.06 107.948 -166.201 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.83 164.71 38.77 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 123.663 0.649 . . . . 1.09 112.979 169.616 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 35.0 mm -69.59 128.55 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 O-C-N 121.527 -0.984 . . . . 3.41 110.761 -171.498 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.15 149.98 22.48 Favored 'General case' 0 CA--C 1.543 0.691 0 N-CA-C 113.748 1.018 . . . . 1.36 113.748 176.806 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -73.32 138.46 25.28 Favored Glycine 0 CA--C 1.526 0.746 0 C-N-CA 124.11 0.862 . . . . 1.08 111.36 -177.44 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 -75.81 167.73 21.34 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.138 0.975 . . . . 5.77 111.827 175.529 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.18 147.79 19.75 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 125.619 1.568 . . . . 4.53 112.151 171.374 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -56.32 146.82 32.56 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 125.734 1.635 . . . . 1.28 113.328 166.832 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 34.8 m -75.01 137.89 22.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 107.2 -1.408 . . . . 4.58 107.2 162.698 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 34.9 m -92.19 -152.36 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.799 0 C-N-CA 124.034 0.934 . . . . 3.46 110.991 -168.35 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.98 169.53 1.25 Allowed Glycine 0 CA--C 1.542 1.751 0 C-N-CA 124.033 0.825 . . . . 1.81 114.103 162.189 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 12.8 mt . . . . . 0 C--O 1.249 1.028 0 C-N-CA 124.897 1.279 . . . . 4.36 114.024 -163.845 . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.647 0 CA-C-O 116.042 -2.532 . . . . 3.24 108.965 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -76.38 166.1 28.1 Favored 'Trans proline' 0 CA--C 1.535 0.548 0 C-N-CA 122.839 2.36 . . . . 2.67 111.331 -177.79 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? -74.81 165.96 24.4 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 126.739 2.016 . . . . 3.75 113.594 175.534 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.11 -157.58 3.36 Favored Glycine 0 N--CA 1.476 1.365 0 C-N-CA 129.493 3.425 . . . . 1.5 116.915 -170.267 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.9 mt -77.96 125.74 37.78 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 O-C-N 120.403 -1.645 . . . . 2.63 107.942 174.736 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.0 128.41 30.33 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 123.117 0.567 . . . . 1.94 111.274 174.713 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.77 150.23 42.85 Favored Glycine 0 CA--C 1.521 0.466 0 C-N-CA 126.455 1.979 . . . . 1.34 112.856 -174.554 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 76.8 mm-40 -74.46 135.15 42.29 Favored 'General case' 0 C--N 1.332 -0.175 0 O-C-N 122.333 -0.51 . . . . 4.32 110.652 -167.268 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 35.2 ttp180 -54.48 130.96 41.51 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 123.539 0.736 . . . . 6.76 110.908 176.33 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.89 -178.03 29.83 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 124.441 1.02 . . . . 2.2 114.189 -171.646 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -61.11 142.36 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 C-N-CA 123.916 0.886 . . . . 3.32 110.03 174.846 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.7 m -52.22 154.08 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 C-N-CA 124.184 0.994 . . . . 3.39 112.944 173.6 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.404 ' H ' ' HB ' ' B' ' 23' ' ' VAL . . . -83.9 -149.43 9.61 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 123.797 0.713 . . . . 2.43 112.591 166.298 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 82.8 mt -146.73 162.5 33.45 Favored Pre-proline 0 N--CA 1.475 0.789 0 C-N-CA 127.015 2.126 . . . . 4.1 109.687 170.581 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -83.06 -152.92 0.04 OUTLIER 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 123.298 2.665 . . . . 2.62 108.515 154.228 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.207 0 CA-C-O 117.61 -1.661 . . . . 3.83 113.103 156.191 . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_exo . . . . . 0 N--CA 1.479 0.676 0 CA-C-O 118.196 -0.835 . . . . 2.36 111.392 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.48 158.21 27.81 Favored Glycine 0 CA--C 1.546 2.01 0 CA-C-N 119.178 0.899 . . . . 1.99 112.816 154.342 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -76.13 47.5 2.03 Favored 'Trans proline' 0 CA--C 1.545 1.071 1 C-N-CA 127.374 5.383 . . . . 3.99 113.419 -175.958 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.464 ' HG3' ' H ' ' B' ' 16' ' ' GLY . 1.4 tp-100 69.88 -169.65 0.17 Allowed 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 124.819 1.248 . . . . 5.04 109.871 -161.33 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . 0.464 ' H ' ' HG3' ' B' ' 15' ' ' GLN . . . -106.93 154.88 16.58 Favored Glycine 0 CA--C 1.533 1.201 0 C-N-CA 126.192 1.853 . . . . 1.15 110.576 158.558 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 18.3 tt -63.58 144.81 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 C-N-CA 124.228 1.011 . . . . 5.59 112.521 177.393 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -75.0 148.36 39.98 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 113.624 0.972 . . . . 1.69 113.624 178.91 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.63 148.39 43.42 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 125.635 1.588 . . . . 1.74 113.8 -177.747 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 19.5 tt0 -80.25 148.34 30.83 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.222 1.009 . . . . 4.44 112.418 -177.86 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.5 mtm180 -63.87 130.75 45.4 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 124.747 1.219 . . . . 5.53 111.829 178.125 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.48 2.72 45.18 Favored Glycine 0 N--CA 1.476 1.34 0 N-CA-C 119.6 2.6 . . . . 4.68 119.6 -155.365 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . 0.404 ' HB ' ' H ' ' A' ' 25' ' ' GLY 0.278 0.9 OUTLIER 173.3 156.92 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 130.302 3.441 . . . . 6.2 108.741 179.214 . . . . . . . . 4 4 . 1 . 027 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 42.1 t -132.54 141.51 44.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 C-N-CA 126.245 1.818 . . . . 5.71 107.911 178.052 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -88.05 -177.69 47.58 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-O 122.496 1.053 . . . . 2.71 114.779 -170.3 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.1 pt? -161.19 156.96 21.55 Favored Pre-proline 0 CA--C 1.542 0.651 0 C-N-CA 126.419 1.888 . . . . 4.43 110.243 -177.734 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo . . . . . 0 C--O 1.255 1.374 0 C-N-CA 124.129 3.219 . . . . 3.48 111.229 164.112 . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo . . . . . 0 N--CA 1.487 1.097 0 CA-C-O 119.019 -0.492 . . . . 2.89 111.555 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -70.0 -148.83 0.02 OUTLIER 'Trans proline' 0 CA--C 1.541 0.857 0 C-N-CA 123.616 2.878 . . . . 2.27 109.553 165.768 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -81.95 176.45 53.96 Favored Glycine 0 CA--C 1.537 1.454 0 O-C-N 121.279 -0.888 . . . . 1.13 111.542 168.88 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -79.24 -177.58 4.0 Favored 'Trans proline' 0 N--CA 1.452 -0.952 0 C-N-CA 123.095 2.53 . . . . 2.37 109.792 162.125 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.7 tp60 -41.55 119.29 1.22 Allowed 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 125.981 1.712 . . . . 2.12 113.875 159.363 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.32 161.88 41.22 Favored Glycine 0 CA--C 1.528 0.855 0 C-N-CA 125.772 1.654 . . . . 1.13 112.531 167.518 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 33.4 mm -68.77 142.39 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 O-C-N 121.576 -0.955 . . . . 4.75 110.511 -172.714 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.81 154.63 40.36 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.31 0.856 . . . . 1.62 113.31 177.1 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.59 157.52 53.25 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 124.274 0.94 . . . . 1.15 113.131 -179.095 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 14.4 mp0 -82.31 173.98 11.57 Favored 'General case' 0 CA--C 1.541 0.615 0 O-C-N 121.869 -0.783 . . . . 3.23 111.26 179.024 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.3 135.31 57.13 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 123.287 0.635 . . . . 4.79 110.426 169.15 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -65.35 167.3 32.52 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.93 1.253 . . . . 1.54 113.972 -176.675 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 87.2 t -75.52 148.4 7.49 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 C-N-CA 123.876 0.871 . . . . 2.45 109.458 -176.865 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 98.7 t -97.28 174.69 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.991 0 C-N-CA 127.297 2.239 . . . . 4.07 109.613 -174.891 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -56.3 173.17 1.67 Allowed Glycine 0 CA--C 1.538 1.504 0 C-N-CA 124.974 1.273 . . . . 2.01 114.723 165.25 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 8.8 mt . . . . . 0 C--O 1.25 1.097 0 N-CA-C 113.821 1.045 . . . . 5.05 113.821 -158.143 . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.647 0 CA-C-O 116.623 -2.209 . . . . 3.49 110.08 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -63.39 159.86 38.04 Favored 'Trans proline' 0 C--N 1.349 0.585 0 C-N-CA 123.849 3.033 . . . . 2.25 111.491 179.79 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.84 177.76 0.71 Allowed 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 127.73 2.412 . . . . 3.73 114.656 -178.227 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.16 173.09 44.25 Favored Glycine 0 CA--C 1.526 0.728 0 C-N-CA 125.904 1.716 . . . . 1.26 113.793 177.323 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.414 ' H ' HD13 ' A' ' 17' ' ' ILE . 3.2 mp -67.42 135.24 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.51 0 N-CA-C 109.292 -0.633 . . . . 3.59 109.292 -173.189 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -53.95 133.0 43.16 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 118.427 0.558 . . . . 1.79 110.482 170.613 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.12 168.68 24.27 Favored Glycine 0 CA--C 1.521 0.417 0 C-N-CA 126.115 1.816 . . . . 1.31 114.778 -167.995 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 85.6 mm-40 -71.46 96.28 1.48 Allowed 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 108.598 -0.89 . . . . 3.86 108.598 179.793 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.2 ttp-105 -62.29 138.63 58.46 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 124.836 1.254 . . . . 6.14 113.23 -165.155 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.7 149.97 39.04 Favored Glycine 0 C--N 1.332 0.355 0 CA-C-O 122.421 1.012 . . . . 2.26 113.704 -171.211 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 32.7 m -76.64 163.11 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 CA-C-N 113.676 -1.262 . . . . 3.46 111.173 -174.624 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.0 m -60.75 167.69 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 124.257 1.023 . . . . 3.97 112.395 177.355 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.72 146.97 39.4 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 110.407 -1.077 . . . . 2.1 110.407 157.957 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 8.5 mp -101.62 169.57 7.53 Favored Pre-proline 0 CA--C 1.538 0.516 0 C-N-CA 124.041 0.936 . . . . 4.33 111.95 -170.833 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -69.11 115.11 3.84 Favored 'Trans proline' 0 N--CA 1.445 -1.337 0 N-CA-C 106.989 -1.966 . . . . 3.29 106.989 151.775 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.147 0 CA-C-O 118.584 -1.12 . . . . 6.8 114.773 -157.294 . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo . . . . . 0 CA--C 1.544 0.995 0 N-CA-C 111.313 -0.303 . . . . 2.48 111.313 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.44 167.7 13.23 Favored Glycine 0 CA--C 1.541 1.717 0 C-N-CA 120.13 -1.033 . . . . 1.3 112.902 127.473 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -76.69 -64.4 0.03 OUTLIER 'Trans proline' 0 CA--C 1.538 0.702 0 C-N-CA 124.974 3.782 . . . . 2.85 112.694 175.678 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 8.3 tp-100 -166.6 157.4 12.39 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 127.943 2.497 . . . . 4.31 107.639 -164.711 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.36 159.23 25.02 Favored Glycine 0 CA--C 1.527 0.783 0 C-N-CA 124.324 0.964 . . . . 1.06 113.469 175.549 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 3.8 mp -70.28 127.89 32.82 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 N-CA-C 108.855 -0.795 . . . . 4.37 108.855 176.851 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.62 146.76 38.01 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 118.973 0.806 . . . . 1.38 112.416 178.873 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -78.63 141.27 24.4 Favored Glycine 0 CA--C 1.527 0.8 0 C-N-CA 124.643 1.116 . . . . 1.53 111.668 179.268 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.65 164.77 12.82 Favored 'General case' 0 N--CA 1.468 0.463 0 O-C-N 121.43 -1.041 . . . . 5.06 111.132 166.75 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -82.3 167.12 18.91 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.285 1.034 . . . . 6.01 112.022 167.138 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.71 -174.02 45.65 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 124.609 1.1 . . . . 3.34 112.619 164.945 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 11.0 m -100.9 160.05 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 C-N-CA 125.039 1.336 . . . . 6.22 114.568 -166.243 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.7 p -42.37 150.38 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 C-N-CA 129.016 2.926 . . . . 5.19 115.221 -178.117 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.44 -114.93 1.93 Allowed Glycine 0 CA--C 1.528 0.85 0 CA-C-O 119.154 -0.803 . . . . 2.24 111.343 167.334 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -172.43 177.23 0.83 Allowed Pre-proline 0 CA--C 1.556 1.204 0 C-N-CA 126.977 2.111 . . . . 4.29 110.55 -164.572 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_endo . . . . . 0 C--O 1.255 1.36 0 C-N-CA 123.926 3.084 . . . . 5.29 112.725 174.571 . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo . . . . . 0 CA--C 1.546 1.101 0 CA-C-O 118.532 -0.695 . . . . 2.15 111.426 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -61.72 -154.05 0.02 OUTLIER 'Trans proline' 0 CA--C 1.545 1.054 0 C-N-CA 124.934 3.756 . . . . 2.43 111.679 164.682 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -84.21 -177.9 51.45 Favored Glycine 0 CA--C 1.543 1.805 0 O-C-N 121.068 -1.02 . . . . 0.96 113.157 173.53 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -79.54 169.49 18.44 Favored 'Trans proline' 0 CA--C 1.535 0.535 0 C-N-CA 124.219 3.279 . . . . 2.3 111.304 173.865 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 -48.04 116.92 1.68 Allowed 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 124.209 1.004 . . . . 1.73 111.288 160.717 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.58 163.22 36.39 Favored Glycine 0 CA--C 1.529 0.94 0 C-N-CA 124.852 1.215 . . . . 1.02 112.577 172.171 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 3.1 mp -65.96 145.27 14.02 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.667 0 C-N-CA 123.852 0.861 . . . . 3.75 110.673 -168.628 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -68.8 163.72 23.51 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.517 0.932 . . . . 1.32 113.517 179.084 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.11 149.46 17.96 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 109.946 -1.262 . . . . 1.1 109.946 168.6 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 7.2 mm100 -93.39 -167.86 1.8 Allowed 'General case' 0 CA--C 1.541 0.621 0 O-C-N 121.978 -0.719 . . . . 5.95 110.831 -178.07 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 2.6 ttt180 -63.33 154.44 31.76 Favored 'General case' 0 N--CA 1.467 0.41 0 O-C-N 121.272 -0.893 . . . . 4.62 110.898 168.524 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.24 -171.44 45.1 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 123.726 0.679 . . . . 1.22 111.653 165.355 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.0 t -70.3 136.8 25.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 C-N-CA 124.266 1.026 . . . . 2.13 111.855 -170.623 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -44.94 124.58 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 C-N-CA 126.599 1.959 . . . . 4.54 112.671 161.264 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.34 127.45 8.88 Favored Glycine 0 CA--C 1.525 0.698 0 C-N-CA 123.342 0.496 . . . . 3.63 112.823 179.613 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 16.9 mt . . . . . 0 C--O 1.254 1.313 0 CA-C-O 117.107 -1.425 . . . . 8.58 109.623 146.124 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.645 0 CA-C-O 117.014 -1.992 . . . . 4.3 110.063 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.68 168.37 19.58 Favored 'Trans proline' 0 CA--C 1.536 0.614 0 C-N-CA 123.473 2.782 . . . . 3.4 111.96 -176.073 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -58.46 153.4 15.97 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 128.863 2.865 . . . . 3.08 112.972 173.282 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.46 -135.01 5.01 Favored Glycine 0 N--CA 1.476 1.306 0 C-N-CA 125.996 1.76 . . . . 1.94 115.981 -171.703 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 24.0 pt -102.46 143.35 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 O-C-N 121.751 -0.852 . . . . 4.04 110.863 -178.417 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.34 143.57 28.05 Favored 'General case' 0 CA--C 1.538 0.509 0 CA-C-O 121.845 0.831 . . . . 1.77 112.007 178.612 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.46 152.21 16.39 Favored Glycine 0 CA--C 1.52 0.379 0 C-N-CA 127.637 2.541 . . . . 1.5 115.529 178.367 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 84.8 mm-40 -66.19 152.87 43.91 Favored 'General case' 0 CA--C 1.531 0.236 0 CA-C-N 113.957 -1.121 . . . . 3.88 111.172 -176.424 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -63.95 141.95 58.58 Favored 'General case' 0 N--CA 1.466 0.348 0 O-C-N 122.04 -0.413 . . . . 4.4 111.659 -179.538 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.6 164.27 45.05 Favored Glycine 0 CA--C 1.523 0.591 0 CA-C-N 115.621 -0.718 . . . . 1.53 113.096 176.609 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 2.1 t -64.55 150.07 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 124.565 1.146 . . . . 3.45 112.277 -167.69 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.8 t -53.81 132.51 16.58 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.686 0 C-N-CA 125.497 1.519 . . . . 5.31 111.587 167.88 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -85.42 155.93 30.07 Favored Glycine 0 CA--C 1.528 0.863 0 C-N-CA 124.847 1.213 . . . . 1.5 111.255 165.971 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 94.4 mt -118.16 156.52 50.44 Favored Pre-proline 0 N--CA 1.468 0.456 0 CA-C-O 117.537 -1.22 . . . . 3.59 109.937 -177.12 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -71.22 -158.47 0.06 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.875 0 C-N-CA 121.567 1.512 . . . . 2.08 109.304 161.849 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.307 0 CA-C-O 117.455 -1.747 . . . . 3.14 112.936 154.918 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo . . . . . 0 CA--C 1.544 0.992 0 N-CA-C 111.302 -0.307 . . . . 3.46 111.302 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.55 -173.02 3.19 Favored Glycine 0 CA--C 1.541 1.66 0 C-N-CA 120.097 -1.049 . . . . 1.56 113.339 123.922 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -77.9 -128.97 0.01 OUTLIER 'Trans proline' 0 CA--C 1.546 1.083 0 C-N-CA 124.864 3.709 . . . . 2.47 108.233 161.533 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.469 ' HG2' ' H ' ' B' ' 16' ' ' GLY . 6.5 tt0 -87.01 -171.01 3.31 Favored 'General case' 0 CA--C 1.552 1.038 0 C-N-CA 125.844 1.657 . . . . 5.23 111.304 171.378 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . 0.469 ' H ' ' HG2' ' B' ' 15' ' ' GLN . . . -89.32 166.87 33.63 Favored Glycine 0 CA--C 1.541 1.692 0 O-C-N 121.204 -0.935 . . . . 1.13 111.875 149.412 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 46.8 mm -67.95 143.39 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.02 -1.282 . . . . 4.36 110.212 168.241 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.72 157.89 34.49 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 114.791 1.404 . . . . 1.4 114.791 -173.11 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -78.27 161.2 48.56 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 125.908 1.718 . . . . 1.78 113.561 -175.51 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.41 156.37 18.6 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 121.651 -0.911 . . . . 3.4 111.133 175.431 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.9 155.26 16.84 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 112.208 0.447 . . . . 9.81 112.208 178.177 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.38 -125.45 0.6 Allowed Glycine 0 CA--C 1.529 0.917 0 C-N-CA 123.995 0.807 . . . . 2.65 111.174 172.008 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 82.2 t -64.06 158.34 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 C-N-CA 124.738 1.215 . . . . 6.06 110.715 179.312 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 6.2 m -129.57 157.47 42.26 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 C-N-CA 126.429 1.891 . . . . 3.68 109.362 174.005 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.72 176.74 46.32 Favored Glycine 0 C--N 1.336 0.545 0 C-N-CA 125.395 1.474 . . . . 2.49 115.305 -170.147 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -165.67 157.98 12.85 Favored Pre-proline 0 CA--C 1.549 0.928 0 C-N-CA 125.437 1.495 . . . . 3.6 113.262 -168.805 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_endo . . . . . 0 C--O 1.255 1.343 0 C-N-CA 123.748 2.965 . . . . 2.73 111.786 159.837 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo . . . . . 0 N--CA 1.487 1.119 0 CA-C-O 118.882 -0.549 . . . . 2.78 111.694 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -69.44 -139.37 0.01 OUTLIER 'Trans proline' 0 CA--C 1.542 0.923 0 C-N-CA 123.617 2.878 . . . . 2.02 108.713 163.385 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.1 163.73 53.91 Favored Glycine 0 CA--C 1.54 1.629 0 O-C-N 120.924 -1.11 . . . . 1.26 111.492 165.283 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -79.46 -43.06 0.15 Allowed 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 122.697 2.265 . . . . 3.67 112.511 -178.926 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 17.3 tp60 167.84 133.09 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.81 2.444 . . . . 2.04 105.913 -154.445 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.41 158.96 51.05 Favored Glycine 0 CA--C 1.534 1.225 0 C-N-CA 124.358 0.98 . . . . 1.5 113.654 167.649 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 73.3 mt -62.7 147.28 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 O-C-N 121.495 -1.003 . . . . 2.98 110.394 175.509 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.36 163.91 17.21 Favored 'General case' 0 CA--C 1.545 0.778 0 N-CA-C 114.014 1.116 . . . . 1.8 114.014 -177.148 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.86 154.17 46.46 Favored Glycine 0 CA--C 1.529 0.924 0 CA-C-N 115.443 -0.799 . . . . 1.66 111.66 170.562 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -84.76 168.72 14.92 Favored 'General case' 0 CA--C 1.539 0.54 0 CA-C-O 121.66 0.743 . . . . 3.88 111.909 -174.266 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 1.1 tmt_? -60.79 136.51 58.09 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 123.596 0.758 . . . . 3.8 110.861 -179.492 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.07 138.21 29.26 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.793 -0.923 . . . . 1.28 110.793 175.002 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 18.9 m -61.04 154.62 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 117.931 0.866 . . . . 4.04 111.696 -176.652 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 10.5 p -85.03 177.34 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 C-N-CA 126.876 2.071 . . . . 3.83 110.082 172.908 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.43 -164.72 0.61 Allowed Glycine 0 CA--C 1.54 1.646 0 C-N-CA 125.21 1.385 . . . . 1.58 115.875 169.851 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 16.5 mt . . . . . 0 N--CA 1.481 1.082 0 C-N-CA 125.507 1.523 . . . . 3.73 114.481 -162.439 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.756 0 CA-C-O 116.838 -2.09 . . . . 3.63 110.108 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -76.47 161.74 34.11 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 123.395 2.73 . . . . 3.0 111.554 -175.278 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.37 154.29 28.57 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.226 2.21 . . . . 3.19 113.517 178.955 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.08 -116.54 0.04 OUTLIER Glycine 0 CA--C 1.534 1.224 0 C-N-CA 126.937 2.208 . . . . 2.54 115.369 179.481 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.9 mt -134.79 132.95 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 O-C-N 121.211 -1.17 . . . . 2.42 109.739 -174.239 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.11 133.84 55.94 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.644 0.778 . . . . 1.76 112.324 176.44 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.99 163.12 41.73 Favored Glycine 0 CA--C 1.527 0.829 0 C-N-CA 126.885 2.183 . . . . 1.35 113.827 -175.15 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 8.6 mp0 -67.31 130.21 42.35 Favored 'General case' 0 N--CA 1.468 0.438 0 O-C-N 122.527 -0.396 . . . . 5.61 110.851 -164.056 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 42.4 ttt180 -63.09 126.59 27.87 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 118.363 0.529 . . . . 4.82 110.16 179.662 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.74 142.38 36.56 Favored Glycine 0 C--N 1.336 0.575 0 N-CA-C 114.634 0.613 . . . . 1.7 114.634 -160.204 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 35.9 m -64.4 122.93 16.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-N 114.792 -0.704 . . . . 3.27 109.484 -177.199 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 9.8 p -39.16 149.46 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 127.167 2.187 . . . . 4.07 113.566 -176.934 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.92 -155.28 0.61 Allowed Glycine 0 CA--C 1.531 1.054 0 O-C-N 121.405 -0.809 . . . . 1.9 114.296 172.343 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.9 mt -136.66 161.57 61.08 Favored Pre-proline 0 CA--C 1.541 0.6 0 C-N-CA 125.521 1.528 . . . . 3.54 110.751 176.377 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -84.14 -151.65 0.04 OUTLIER 'Trans proline' 0 CA--C 1.539 0.74 0 C-N-CA 123.89 3.06 . . . . 2.07 108.232 159.697 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.153 0 CA-C-O 117.211 -1.883 . . . . 3.16 112.438 141.901 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_exo . . . . . 0 CA--C 1.542 0.907 0 N-CA-C 111.716 -0.148 . . . . 2.87 111.716 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.38 177.19 25.9 Favored Glycine 0 CA--C 1.538 1.492 0 C-N-CA 120.074 -1.06 . . . . 1.35 112.989 128.045 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -82.2 155.93 17.08 Favored 'Trans proline' 0 CA--C 1.539 0.729 1 C-N-CA 125.418 4.079 . . . . 2.7 111.009 159.403 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -59.6 139.86 56.83 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 125.143 1.377 . . . . 5.13 110.757 169.746 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.29 161.94 47.44 Favored Glycine 0 C--N 1.338 0.646 0 C-N-CA 124.052 0.834 . . . . 1.37 114.932 -173.663 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 42.3 pt -57.78 145.71 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 C-N-CA 122.885 0.474 . . . . 5.12 111.892 179.707 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.19 149.31 48.73 Favored 'General case' 0 CA--C 1.543 0.675 0 O-C-N 121.525 -0.735 . . . . 1.49 112.322 175.803 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.61 152.15 51.35 Favored Glycine 0 CA--C 1.53 1.001 0 N-CA-C 110.318 -1.113 . . . . 1.56 110.318 166.942 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.91 151.56 22.25 Favored 'General case' 0 N--CA 1.468 0.456 0 O-C-N 121.356 -1.085 . . . . 3.35 110.449 176.015 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 31.4 ptt180 -61.81 159.57 13.52 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.072 0.949 . . . . 6.34 113.368 -179.566 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.68 160.84 53.82 Favored Glycine 0 CA--C 1.532 1.122 0 C-N-CA 124.825 1.202 . . . . 2.1 114.816 -178.418 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 43.9 t -89.47 131.59 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 124.598 1.159 . . . . 3.39 113.673 -168.424 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 11.5 m -79.46 160.65 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 C-N-CA 126.143 1.777 . . . . 3.07 113.301 -168.381 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.12 -128.31 6.18 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 125.036 1.303 . . . . 1.78 112.812 176.926 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -170.9 156.89 5.0 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 125.359 1.464 . . . . 3.57 112.076 -163.837 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo . . . . . 0 C--O 1.254 1.295 0 C-N-CA 124.571 3.514 . . . . 2.57 112.28 155.584 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo . . . . . 0 CA--C 1.547 1.167 0 CA-C-O 118.964 -0.515 . . . . 3.0 111.517 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -65.91 -157.74 0.03 OUTLIER 'Trans proline' 0 CA--C 1.544 0.975 0 C-N-CA 123.192 2.595 . . . . 2.3 109.967 161.669 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -93.16 -176.73 40.66 Favored Glycine 0 CA--C 1.534 1.26 0 O-C-N 121.171 -0.956 . . . . 1.29 111.859 170.721 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -79.37 170.67 17.09 Favored 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 123.277 2.652 . . . . 2.53 112.295 173.65 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -38.03 135.98 0.64 Allowed 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 127.917 2.487 . . . . 1.96 114.333 154.736 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.81 173.18 54.66 Favored Glycine 0 CA--C 1.529 0.944 0 C-N-CA 126.193 1.854 . . . . 1.1 114.996 174.077 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 96.4 mt -67.57 144.1 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.601 1.161 . . . . 3.57 112.415 -171.133 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.98 132.08 46.18 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.593 1.157 . . . . 2.06 112.967 174.707 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -62.21 122.84 29.6 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 108.293 -1.923 . . . . 1.52 108.293 157.323 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -82.19 160.54 23.02 Favored 'General case' 0 C--N 1.327 -0.407 0 O-C-N 121.736 -0.861 . . . . 3.55 110.9 -173.723 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 9.0 tpp180 -48.31 136.04 12.86 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 124.552 1.141 . . . . 6.04 111.612 173.647 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.1 157.56 52.98 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 115.098 -0.955 . . . . 1.15 112.091 176.119 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.2 t -65.17 155.39 6.66 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 C-N-CA 124.882 1.273 . . . . 2.52 110.58 176.215 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 30.4 m -68.84 -171.18 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.547 0.864 0 C-N-CA 126.392 1.877 . . . . 2.99 112.054 171.42 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.33 -108.24 0.01 OUTLIER Glycine 0 CA--C 1.534 1.273 0 C-N-CA 124.748 1.166 . . . . 2.37 111.884 163.3 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 55.8 mt . . . . . 0 C--O 1.249 1.069 0 CA-C-O 117.647 -1.168 . . . . 4.75 111.563 166.448 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo . . . . . 0 N--CA 1.457 -0.644 0 CA-C-O 121.136 0.39 . . . . 2.37 111.236 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 4.3 pp0? -92.49 175.26 6.9 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 127.892 2.477 . . . . 2.81 113.084 -177.472 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.94 173.48 52.43 Favored Glycine 0 N--CA 1.479 1.542 0 N-CA-C 116.595 1.398 . . . . 1.66 116.595 -168.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.2 pt -71.51 145.09 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 O-C-N 120.905 -1.35 . . . . 3.03 110.256 -177.079 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.94 139.9 58.36 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-O 121.441 0.638 . . . . 1.78 112.207 -176.33 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.51 161.14 2.53 Favored Glycine 0 CA--C 1.526 0.744 0 C-N-CA 127.202 2.334 . . . . 1.31 115.682 178.734 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 22.1 mp0 -68.17 148.9 50.23 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-N 113.708 -1.246 . . . . 4.11 110.042 -174.681 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.86 130.41 45.57 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.774 -0.579 . . . . 6.82 110.277 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.04 150.38 50.26 Favored Glycine 0 CA--C 1.526 0.723 0 C-N-CA 124.073 0.844 . . . . 1.47 111.841 175.021 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 32.9 m -64.04 145.11 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 123.968 0.907 . . . . 2.24 111.514 -179.648 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 19.1 m -52.83 149.74 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 124.177 0.991 . . . . 2.16 113.359 -177.86 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.15 158.64 53.02 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-N 115.985 -0.552 . . . . 1.56 112.091 168.646 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 9.0 mp -89.2 158.04 47.08 Favored Pre-proline 0 CA--C 1.544 0.72 0 C-N-CA 123.221 0.608 . . . . 4.9 110.813 -176.046 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -78.19 -166.04 0.37 Allowed 'Trans proline' 0 CA--C 1.537 0.633 0 C-N-CA 123.596 2.864 . . . . 2.52 109.446 160.267 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.153 0 CA-C-O 117.35 -1.806 . . . . 3.58 111.952 150.297 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo . . . . . 0 N--CA 1.481 0.759 0 CA-C-O 118.484 -0.715 . . . . 2.2 111.482 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.02 159.62 51.09 Favored Glycine 0 CA--C 1.539 1.588 0 N-CA-C 110.886 -0.886 . . . . 1.29 110.886 150.245 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -72.09 177.45 7.14 Favored 'Trans proline' 0 CA--C 1.539 0.76 0 C-N-CA 123.244 2.63 . . . . 2.18 108.859 156.893 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 11.5 tt0 -60.19 172.63 0.78 Allowed 'General case' 0 CA--C 1.544 0.731 0 N-CA-C 114.935 1.457 . . . . 4.66 114.935 -175.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.17 159.48 51.77 Favored Glycine 0 CA--C 1.527 0.811 0 O-C-N 120.995 -1.066 . . . . 1.0 113.563 176.625 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 29.9 mm -60.25 141.48 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 123.669 0.788 . . . . 3.24 109.578 168.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.42 151.63 31.97 Favored 'General case' 0 CA--C 1.542 0.66 0 CA-C-O 122.756 1.265 . . . . 1.35 113.773 -179.521 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.19 137.67 38.25 Favored Glycine 0 CA--C 1.523 0.531 0 C-N-CA 125.25 1.405 . . . . 1.55 112.42 -179.067 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 94.9 mm-40 -81.92 124.84 30.08 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.577 -0.811 . . . . 3.96 109.167 -175.039 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 10.9 ptt180 -55.15 153.64 6.55 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 126.215 1.806 . . . . 6.64 114.064 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.92 173.65 54.69 Favored Glycine 0 CA--C 1.529 0.922 0 C-N-CA 124.133 0.873 . . . . 1.73 113.355 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 59.5 t -93.43 131.64 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 124.503 1.121 . . . . 2.98 112.83 -165.483 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 19.0 m -60.39 159.99 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 127.61 2.364 . . . . 2.5 114.414 -173.594 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.81 -136.7 5.25 Favored Glycine 0 CA--C 1.529 0.908 0 C-N-CA 124.191 0.9 . . . . 2.15 112.09 168.462 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -170.71 160.81 5.88 Favored Pre-proline 0 CA--C 1.543 0.705 0 C-N-CA 124.766 1.226 . . . . 3.48 111.534 -161.359 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo . . . . . 0 C--O 1.256 1.42 0 C-N-CA 124.586 3.524 . . . . 2.84 112.249 161.422 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo . . . . . 0 N--CA 1.486 1.076 0 CA-C-O 118.989 -0.505 . . . . 2.2 111.251 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -73.18 -130.07 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.939 0 C-N-CA 123.198 2.599 . . . . 2.01 107.778 162.686 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.29 168.23 48.14 Favored Glycine 0 CA--C 1.536 1.391 0 CA-C-N 119.509 1.049 . . . . 1.35 111.496 164.294 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.99 -44.83 0.31 Allowed 'Trans proline' 0 N--CA 1.458 -0.562 0 C-N-CA 122.578 2.185 . . . . 3.95 112.329 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 166.83 137.44 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 127.926 2.49 . . . . 1.65 105.526 -153.169 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.36 160.04 37.67 Favored Glycine 0 N--CA 1.468 0.823 0 C-N-CA 125.958 1.742 . . . . 1.07 112.927 169.228 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 46.7 mt -61.69 143.73 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 124.055 0.942 . . . . 2.2 111.022 -179.181 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.88 148.14 21.72 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.313 1.045 . . . . 1.24 113.559 174.878 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.87 149.42 34.61 Favored Glycine 0 C--N 1.339 0.712 0 C-N-CA 123.778 0.704 . . . . 0.97 111.375 -178.654 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 13.5 mp0 -90.85 -177.84 5.07 Favored 'General case' 0 CA--C 1.539 0.536 0 O-C-N 122.156 -0.614 . . . . 3.33 109.956 177.521 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 9.6 ptp180 -67.22 164.48 18.15 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-O 122.301 1.048 . . . . 5.6 113.592 -174.2 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.9 165.62 49.5 Favored Glycine 0 CA--C 1.531 1.031 0 C-N-CA 124.77 1.176 . . . . 1.17 111.862 166.676 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.7 t -64.08 144.99 14.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.282 1.033 . . . . 1.9 110.782 177.876 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 29.6 m -79.83 -171.67 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.833 0 C-N-CA 125.081 1.353 . . . . 2.98 111.622 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.13 179.42 7.05 Favored Glycine 0 CA--C 1.533 1.174 0 C-N-CA 124.842 1.211 . . . . 2.21 114.775 174.362 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 7.5 mt . . . . . 0 C--O 1.249 1.057 0 N-CA-C 114.527 1.306 . . . . 4.09 114.527 -169.77 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo . . . . . 0 N--CA 1.456 -0.697 0 CA-C-O 121.351 0.479 . . . . 2.21 111.225 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -76.32 -166.96 0.69 Allowed 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 127.017 2.127 . . . . 2.97 112.681 167.669 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.19 174.48 49.59 Favored Glycine 0 N--CA 1.472 1.088 0 O-C-N 121.308 -0.87 . . . . 1.5 114.737 -178.77 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 33.2 pt -73.15 150.38 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 O-C-N 122.329 -0.512 . . . . 3.12 109.693 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -49.1 131.98 19.26 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-O 121.775 0.798 . . . . 1.9 112.421 177.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.55 148.36 9.49 Favored Glycine 0 CA--C 1.519 0.344 0 C-N-CA 127.305 2.383 . . . . 1.25 112.856 166.803 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -80.64 132.61 35.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.081 -0.559 . . . . 3.69 109.534 -166.354 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 60.6 ttp180 -52.88 127.94 25.29 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.76 1.624 . . . . 7.94 113.292 -173.273 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.21 159.83 53.61 Favored Glycine 0 N--CA 1.468 0.78 0 N-CA-C 116.012 1.165 . . . . 1.72 116.012 -170.521 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 27.8 m -72.39 143.13 14.36 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 C-N-CA 124.357 1.063 . . . . 2.57 111.365 176.114 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 31.0 m -50.58 156.48 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 C-N-CA 126.803 2.041 . . . . 2.59 116.116 -168.45 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -81.27 -173.54 47.94 Favored Glycine 0 CA--C 1.533 1.187 0 C-N-CA 123.804 0.716 . . . . 1.81 113.028 162.215 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 7.2 mp -120.88 163.09 31.56 Favored Pre-proline 0 CA--C 1.542 0.656 0 C-N-CA 125.745 1.618 . . . . 4.18 111.427 178.707 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -83.17 -138.11 0.02 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.691 0 C-N-CA 123.738 2.959 . . . . 2.38 107.708 156.285 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.329 0 CA-C-O 116.907 -2.052 . . . . 3.41 113.292 142.836 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo . . . . . 0 N--CA 1.489 1.259 0 N-CA-C 109.306 -1.075 . . . . 2.44 109.306 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.13 147.46 37.87 Favored Glycine 0 CA--C 1.538 1.52 0 CA-C-O 118.546 -1.141 . . . . 1.41 110.718 162.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -72.29 179.89 4.61 Favored 'Trans proline' 0 CA--C 1.54 0.797 0 C-N-CA 123.871 3.047 . . . . 2.15 109.9 163.059 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 12.1 tt0 -53.71 162.82 0.79 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.087 1.355 . . . . 4.42 114.437 178.511 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.25 161.23 51.7 Favored Glycine 0 N--CA 1.47 0.965 0 O-C-N 121.289 -0.882 . . . . 1.11 112.989 -178.415 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.6 pp -65.58 150.13 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 O-C-N 121.944 -0.739 . . . . 4.39 111.117 171.628 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.47 147.15 49.75 Favored 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 114.431 1.271 . . . . 1.71 114.431 -175.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.58 158.45 53.19 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 124.821 1.2 . . . . 1.77 111.492 170.065 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 21.2 mp0 -69.1 150.52 47.49 Favored 'General case' 0 CA--C 1.536 0.418 0 O-C-N 121.979 -0.718 . . . . 3.69 111.408 -173.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 17.0 mtt180 -67.55 148.74 51.05 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 109.693 -0.484 . . . . 6.03 109.693 160.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.3 165.53 43.04 Favored Glycine 0 CA--C 1.533 1.165 0 N-CA-C 115.052 0.781 . . . . 1.95 115.052 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 23.3 m -78.97 130.18 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 114.432 1.271 . . . . 3.64 114.432 -168.383 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.7 m -85.23 154.96 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 126.119 1.767 . . . . 2.52 112.113 -170.547 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.57 -134.4 8.46 Favored Glycine 0 CA--C 1.53 0.994 0 C-N-CA 124.442 1.02 . . . . 1.64 113.273 179.321 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -166.31 161.04 12.43 Favored Pre-proline 0 CA--C 1.547 0.831 0 C-N-CA 125.498 1.519 . . . . 3.25 112.326 -165.712 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo . . . . . 0 C--O 1.254 1.323 0 C-N-CA 124.821 3.681 . . . . 2.66 112.249 152.161 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo . . . . . 0 N--CA 1.487 1.097 0 CA-C-O 119.017 -0.493 . . . . 2.2 111.099 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -71.78 -138.87 0.02 OUTLIER 'Trans proline' 0 CA--C 1.546 1.1 0 C-N-CA 123.465 2.776 . . . . 1.76 107.988 157.704 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.87 168.48 37.59 Favored Glycine 0 CA--C 1.54 1.598 0 CA-C-N 119.383 0.992 . . . . 1.12 112.23 166.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -79.28 -43.65 0.14 Allowed 'Trans proline' 0 CA--C 1.535 0.555 0 C-N-CA 123.021 2.481 . . . . 3.65 113.662 -176.719 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 171.61 141.12 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 127.452 2.301 . . . . 1.35 105.865 -154.355 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -91.17 173.37 37.56 Favored Glycine 0 N--CA 1.466 0.634 0 C-N-CA 126.263 1.887 . . . . 0.89 114.474 171.766 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 17' ' ' ILE . . . . . 0.521 ' H ' HD12 ' C' ' 17' ' ' ILE . 3.9 mp -63.03 132.0 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 C-N-CA 124.464 1.106 . . . . 3.13 111.303 -175.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.66 135.05 57.18 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.824 0.85 . . . . 1.26 112.337 175.719 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -68.06 139.18 33.93 Favored Glycine 0 C--N 1.334 0.446 0 C-N-CA 124.835 1.207 . . . . 1.29 111.014 -173.202 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 98.8 mm-40 -93.19 158.22 15.87 Favored 'General case' 0 C--N 1.324 -0.501 0 O-C-N 122.026 -0.691 . . . . 4.69 111.856 -168.264 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.51 133.56 46.06 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 115.866 -0.606 . . . . 4.01 110.146 178.208 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.62 163.95 49.12 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 123.328 0.489 . . . . 1.11 113.491 -172.545 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 1.7 t -64.82 154.9 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 C-N-CA 123.372 0.669 . . . . 2.03 110.517 175.838 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 30.5 m -75.54 -173.5 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.816 0 C-N-CA 124.704 1.202 . . . . 3.08 110.898 170.611 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.97 -132.66 0.14 Allowed Glycine 0 CA--C 1.536 1.396 0 C-N-CA 125.078 1.323 . . . . 3.43 112.583 167.303 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 7.7 tt . . . . . 0 C--O 1.251 1.143 0 C-N-CA 126.643 1.977 . . . . 4.87 112.771 178.722 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo . . . . . 0 N--CA 1.46 -0.491 0 N-CA-C 110.9 -0.461 . . . . 2.06 110.9 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.12 176.45 9.74 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 127.938 2.495 . . . . 2.56 114.357 -172.929 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.9 177.44 44.77 Favored Glycine 0 N--CA 1.48 1.633 0 N-CA-C 116.8 1.48 . . . . 1.3 116.8 -169.404 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 7.8 pt -70.04 147.84 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 O-C-N 121.192 -1.181 . . . . 2.85 110.608 -173.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.14 134.78 44.24 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.77 0.795 . . . . 1.85 112.154 -179.058 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.76 144.85 25.78 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 126.364 1.935 . . . . 1.21 112.814 173.779 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 19.6 mm100 -67.91 125.22 25.61 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 108.651 -0.87 . . . . 3.13 108.651 -170.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 32.1 ttt-85 -69.53 145.43 52.63 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-O 121.832 0.825 . . . . 4.76 112.779 -156.016 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.28 144.31 37.34 Favored Glycine 0 CA--C 1.524 0.611 0 CA-C-O 122.296 0.942 . . . . 1.69 113.458 -175.007 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.3 t -62.79 150.17 9.31 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.521 0 C-N-CA 127.398 2.279 . . . . 2.65 111.444 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.4 m -48.44 158.83 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 C-N-CA 125.809 1.644 . . . . 2.01 113.993 173.154 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.85 174.09 40.52 Favored Glycine 0 CA--C 1.53 1.027 0 CA-C-N 115.999 -0.546 . . . . 1.41 111.931 160.786 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 79.8 mt -113.04 157.3 41.14 Favored Pre-proline 0 CA--C 1.539 0.526 0 C-N-CA 124.219 1.008 . . . . 3.61 110.181 -178.375 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.402 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 29.1 Cg_endo -79.74 -158.26 0.09 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.793 0 C-N-CA 123.395 2.73 . . . . 2.28 108.96 160.13 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.225 0 CA-C-O 118.06 -1.411 . . . . 3.4 113.251 154.182 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo . . . . . 0 CA--C 1.544 1.01 0 CA-C-O 119.493 -0.295 . . . . 2.06 111.769 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.15 170.72 37.2 Favored Glycine 0 CA--C 1.54 1.614 0 CA-C-O 118.86 -0.967 . . . . 1.35 112.175 125.557 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -72.23 -179.78 4.29 Favored 'Trans proline' 0 CA--C 1.541 0.829 0 C-N-CA 123.439 2.759 . . . . 2.37 108.742 148.715 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 pm0 -70.39 -175.15 0.95 Allowed 'General case' 0 CA--C 1.546 0.8 0 N-CA-C 113.946 1.091 . . . . 4.31 113.946 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.89 168.12 50.65 Favored Glycine 0 CA--C 1.528 0.901 0 O-C-N 120.347 -1.471 . . . . 0.92 114.187 -178.507 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 79.0 mt -76.01 145.56 10.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 124.569 1.148 . . . . 2.82 108.988 167.465 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -73.65 152.78 40.38 Favored 'General case' 0 CA--C 1.543 0.686 0 N-CA-C 115.161 1.541 . . . . 1.31 115.161 -170.51 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.36 132.74 21.12 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 125.615 1.579 . . . . 1.5 110.863 173.488 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -95.16 143.68 26.39 Favored 'General case' 0 N--CA 1.465 0.29 0 O-C-N 121.501 -0.999 . . . . 3.25 111.195 -172.575 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 3.2 mtm180 -55.83 150.89 12.26 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 125.605 1.562 . . . . 5.57 113.802 175.138 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.79 179.22 44.26 Favored Glycine 0 CA--C 1.538 1.521 0 C-N-CA 124.929 1.252 . . . . 1.96 113.252 165.812 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 58.4 t -112.43 148.63 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 C-N-CA 125.138 1.375 . . . . 3.91 113.019 -154.34 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.9 p -53.19 152.56 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 128.92 2.888 . . . . 3.75 115.708 -172.382 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.38 -131.59 3.4 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 125.097 1.332 . . . . 2.16 111.193 165.299 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.402 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.5 pt? -172.68 161.57 3.94 Favored Pre-proline 0 CA--C 1.544 0.745 0 C-N-CA 126.153 1.781 . . . . 3.46 111.018 -165.082 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo . . . . . 0 C--O 1.255 1.371 0 C-N-CA 124.644 3.563 . . . . 3.1 112.045 154.05 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo . . . . . 0 CA--C 1.547 1.14 0 CA-C-O 119.265 -0.389 . . . . 1.9 112.302 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -71.37 -132.24 0.01 OUTLIER 'Trans proline' 0 CA--C 1.542 0.893 0 C-N-CA 123.413 2.742 . . . . 1.69 108.121 162.524 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.3 162.09 34.72 Favored Glycine 0 CA--C 1.534 1.242 0 CA-C-N 119.821 1.191 . . . . 1.37 112.532 166.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -73.59 -49.11 0.22 Allowed 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 122.795 2.33 . . . . 3.62 112.079 176.293 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.4 tp-100 175.26 138.35 0.05 OUTLIER 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.129 1.772 . . . . 1.48 107.392 -152.823 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.42 166.43 36.36 Favored Glycine 0 CA--C 1.527 0.84 0 C-N-CA 125.807 1.67 . . . . 0.93 112.677 169.256 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 72.6 mt -69.18 138.57 22.0 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 O-C-N 121.84 -0.8 . . . . 2.2 109.335 -179.33 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -65.13 158.72 25.14 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.868 1.062 . . . . 1.11 113.868 177.82 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -82.51 -168.36 42.07 Favored Glycine 0 CA--C 1.528 0.859 0 CA-C-O 122.384 0.991 . . . . 1.52 111.14 170.52 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -158.44 179.72 8.87 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 124.265 1.026 . . . . 3.0 109.711 -172.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 5.1 tmm_? -64.95 141.97 58.59 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 125.781 1.632 . . . . 5.27 111.791 -174.643 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.73 -165.66 35.71 Favored Glycine 0 CA--C 1.532 1.148 0 C-N-CA 125.144 1.354 . . . . 1.4 115.542 -174.538 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 48.6 t -64.49 147.43 12.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.807 1.643 . . . . 2.06 110.029 176.043 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 33.3 m -102.17 -178.49 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 C-N-CA 125.351 1.46 . . . . 2.71 112.223 -175.126 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.51 171.4 6.84 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 125.061 1.315 . . . . 1.81 115.503 176.903 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 2.7 mm? . . . . . 0 C--O 1.249 1.072 0 C-N-CA 126.408 1.883 . . . . 3.48 113.116 -166.185 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo . . . . . 0 CA--C 1.537 0.647 0 CA-C-O 121.14 0.391 . . . . 3.01 111.29 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.95 -152.16 0.35 Allowed 'General case' 0 CA--C 1.548 0.889 0 C-N-CA 126.789 2.036 . . . . 2.73 110.449 175.791 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.37 162.63 44.03 Favored Glycine 0 N--CA 1.473 1.12 0 O-C-N 120.629 -1.295 . . . . 1.47 114.268 -173.875 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 25.4 pt -69.88 149.03 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 O-C-N 121.226 -1.161 . . . . 2.51 110.525 178.789 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.98 132.56 50.25 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 123.555 0.742 . . . . 1.81 111.767 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.2 136.69 25.46 Favored Glycine 0 CA--C 1.522 0.498 0 C-N-CA 126.021 1.772 . . . . 2.11 112.13 169.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 14.8 mm100 -72.48 140.14 48.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.198 -0.501 . . . . 3.47 110.438 -166.806 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 46.8 ttt85 -66.63 134.24 51.91 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-O 121.372 0.606 . . . . 6.12 111.287 -172.625 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.53 146.77 46.33 Favored Glycine 0 CA--C 1.527 0.798 0 CA-C-O 122.08 0.822 . . . . 1.78 113.41 178.57 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.6 t -67.01 118.61 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 C-N-CA 125.819 1.648 . . . . 2.22 110.475 -171.815 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 24.3 m -44.84 143.71 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 C-N-CA 125.042 1.337 . . . . 2.55 114.383 -170.093 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -75.08 174.06 52.12 Favored Glycine 0 CA--C 1.533 1.174 0 N-CA-C 111.884 -0.486 . . . . 1.68 111.884 165.354 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 7.0 mp -122.24 160.32 48.3 Favored Pre-proline 0 CA--C 1.539 0.541 0 C-N-CA 125.273 1.429 . . . . 3.45 109.943 175.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.414 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 41.4 Cg_endo -75.98 -158.22 0.08 OUTLIER 'Trans proline' 0 CA--C 1.537 0.666 0 C-N-CA 122.882 2.388 . . . . 3.08 109.256 157.527 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.192 0 CA-C-O 116.76 -2.133 . . . . 5.32 112.532 142.762 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo . . . . . 0 N--CA 1.491 1.352 0 N-CA-C 109.089 -1.158 . . . . 3.24 109.089 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.27 144.88 36.74 Favored Glycine 0 CA--C 1.543 1.822 0 CA-C-O 118.697 -1.057 . . . . 1.81 111.415 164.652 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -77.04 -176.12 3.02 Favored 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 124.675 3.583 . . . . 2.52 110.134 163.471 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -61.19 173.47 0.84 Allowed 'General case' 0 CA--C 1.546 0.804 0 N-CA-C 116.336 1.976 . . . . 4.16 116.336 -175.247 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -90.01 154.37 23.7 Favored Glycine 0 CA--C 1.526 0.726 0 O-C-N 121.147 -0.971 . . . . 1.18 113.677 -174.062 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 79.7 mt -60.63 134.12 26.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 108.347 -0.983 . . . . 3.08 108.347 168.324 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.09 152.21 39.97 Favored 'General case' 0 CA--C 1.544 0.719 0 N-CA-C 112.752 0.649 . . . . 1.77 112.752 -177.708 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -83.81 -168.9 44.43 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 124.076 0.846 . . . . 2.5 111.003 169.629 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -148.6 176.21 10.53 Favored 'General case' 0 CA--C 1.536 0.431 0 O-C-N 120.961 -1.317 . . . . 3.82 112.231 171.048 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.2 ttm180 -59.65 159.47 8.53 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 125.661 1.585 . . . . 6.03 115.07 -164.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -63.66 157.91 40.94 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-N 116.276 -0.42 . . . . 2.42 114.136 170.203 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 35.9 t -85.61 121.27 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 C-N-CA 123.742 0.817 . . . . 3.41 111.86 -165.876 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.445 HG12 ' H ' ' C' ' 23' ' ' VAL . 6.3 m -69.06 156.51 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 126.154 1.781 . . . . 3.01 113.715 -170.675 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.29 -142.66 10.99 Favored Glycine 0 N--CA 1.469 0.878 0 C-N-CA 124.17 0.89 . . . . 2.04 112.436 167.059 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.414 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.6 pt? -172.73 160.48 3.87 Favored Pre-proline 0 CA--C 1.545 0.786 0 C-N-CA 124.854 1.262 . . . . 4.34 111.714 -158.428 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo . . . . . 0 C--O 1.255 1.336 0 C-N-CA 124.828 3.686 . . . . 3.02 112.329 155.292 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo . . . . . 0 N--CA 1.487 1.092 0 CA-C-O 119.2 -0.417 . . . . 2.5 111.125 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.56 -131.27 0.01 OUTLIER 'Trans proline' 0 CA--C 1.542 0.895 0 C-N-CA 122.362 2.041 . . . . 1.72 106.859 152.626 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.99 -179.78 48.74 Favored Glycine 0 CA--C 1.535 1.326 0 CA-C-N 119.558 1.072 . . . . 1.38 113.075 169.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -78.45 -110.0 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.039 0 C-N-CA 124.867 3.712 . . . . 2.59 109.718 161.752 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -146.58 134.51 21.37 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 127.904 2.482 . . . . 1.89 107.676 -159.395 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.34 169.52 54.01 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 124.614 1.102 . . . . 1.45 113.728 170.51 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 65.8 mt -73.16 131.44 34.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 121.745 -0.856 . . . . 2.94 111.221 -174.083 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.37 154.17 35.16 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 113.693 0.997 . . . . 1.52 113.693 178.483 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -82.99 162.4 40.71 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 124.806 1.193 . . . . 1.47 112.711 177.762 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 13.9 mp0 -101.69 -175.87 2.97 Favored 'General case' 0 CA--C 1.545 0.753 0 O-C-N 121.425 -1.044 . . . . 3.12 111.189 -178.115 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.46 140.66 54.07 Favored 'General case' 0 CA--C 1.541 0.601 0 O-C-N 121.514 -0.741 . . . . 5.16 111.561 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.57 154.63 36.49 Favored Glycine 0 N--CA 1.47 0.942 0 C-N-CA 125.517 1.532 . . . . 1.76 113.151 179.327 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 23' ' ' VAL . . . . . 0.445 ' H ' HG12 ' B' ' 24' ' ' VAL . 17.7 t -64.0 144.86 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 124.525 1.13 . . . . 2.8 111.02 -179.015 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 78.2 t -101.47 168.58 1.94 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.896 0 C-N-CA 126.603 1.961 . . . . 4.58 109.484 -175.143 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.25 177.43 3.35 Favored Glycine 0 CA--C 1.538 1.516 0 C-N-CA 124.196 0.903 . . . . 3.43 114.181 169.212 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 11.9 mt . . . . . 0 N--CA 1.484 1.241 0 N-CA-C 114.711 1.374 . . . . 4.45 114.711 -169.401 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo . . . . . 0 CA--C 1.535 0.563 0 N-CA-C 110.327 -0.682 . . . . 1.99 110.327 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 14.8 mm100 -56.51 -177.6 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 129.084 2.953 . . . . 4.59 116.256 -173.221 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -91.35 -173.05 43.26 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 124.309 0.957 . . . . 1.23 112.968 161.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 9.5 mt -72.05 128.09 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 N-CA-C 109.229 -0.656 . . . . 1.97 109.229 -177.387 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -52.92 135.15 36.99 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.487 0.715 . . . . 1.8 110.727 174.063 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.65 154.55 48.61 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 125.327 1.441 . . . . 1.27 113.387 -170.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 71.4 mm-40 -69.91 106.55 3.21 Favored 'General case' 0 CA--C 1.532 0.258 0 N-CA-C 109.877 -0.416 . . . . 3.04 109.877 -171.11 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.0 ttp180 -61.49 143.17 56.37 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 125.069 1.348 . . . . 4.3 114.186 -163.111 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.26 136.96 30.73 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 124.839 1.209 . . . . 1.57 113.517 -167.599 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 8.8 p -60.9 134.88 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 C-N-CA 125.493 1.517 . . . . 3.23 111.005 177.112 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 30.0 m -46.13 157.96 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.984 0 C-N-CA 127.148 2.179 . . . . 2.3 115.616 -171.8 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.42 171.6 43.36 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-N 115.424 -0.807 . . . . 1.35 113.476 168.315 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 87.6 mt -120.36 159.68 46.81 Favored Pre-proline 0 CA--C 1.54 0.566 0 C-N-CA 124.952 1.301 . . . . 2.64 110.776 -173.579 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -76.42 -169.56 0.72 Allowed 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 123.208 2.605 . . . . 1.83 109.797 161.006 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.182 0 CA-C-O 117.837 -1.535 . . . . 3.14 113.189 155.143 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo . . . . . 0 CA--C 1.545 1.073 0 CA-C-O 119.209 -0.413 . . . . 2.18 111.317 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.25 171.42 10.35 Favored Glycine 0 CA--C 1.54 1.613 0 C-N-CA 119.259 -1.448 . . . . 1.28 112.634 123.926 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -75.73 -57.89 0.05 OUTLIER 'Trans proline' 0 CA--C 1.535 0.554 0 C-N-CA 123.974 3.116 . . . . 2.7 111.042 170.763 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 175.55 152.38 0.14 Allowed 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 127.464 2.306 . . . . 4.43 107.702 -164.309 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.66 153.88 35.39 Favored Glycine 0 CA--C 1.527 0.785 0 C-N-CA 123.817 0.722 . . . . 0.91 112.695 174.793 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.49 ' H ' HD12 ' B' ' 17' ' ' ILE . 4.7 mp -67.36 136.1 27.29 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 108.657 -0.868 . . . . 2.69 108.657 173.503 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.24 153.85 41.43 Favored 'General case' 0 CA--C 1.541 0.634 0 N-CA-C 113.277 0.843 . . . . 1.52 113.277 -179.154 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -66.98 141.73 40.29 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 111.312 -0.715 . . . . 1.63 111.312 172.795 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -81.04 164.96 22.1 Favored 'General case' 0 CA--C 1.54 0.576 0 O-C-N 120.899 -1.354 . . . . 2.85 112.218 173.86 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -63.6 146.15 54.3 Favored 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 125.926 1.69 . . . . 4.69 112.586 173.231 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.55 157.97 53.4 Favored Glycine 0 CA--C 1.533 1.216 0 N-CA-C 115.087 0.795 . . . . 2.25 115.087 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 17.9 m -91.65 133.08 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 N-CA-C 114.708 1.373 . . . . 3.99 114.708 -164.776 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -56.36 150.81 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 C-N-CA 127.791 2.436 . . . . 3.12 115.164 -165.822 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -84.72 -122.49 1.05 Allowed Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.217 0.913 . . . . 2.12 111.182 165.525 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.3 pt? -170.8 156.65 5.04 Favored Pre-proline 0 CA--C 1.543 0.696 0 C-N-CA 124.756 1.223 . . . . 3.31 112.014 -161.291 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo . . . . . 0 CA--C 1.552 1.379 0 C-N-CA 124.123 3.215 . . . . 2.57 111.767 159.1 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo . . . . . 0 N--CA 1.488 1.168 0 CA-C-O 118.779 -0.592 . . . . 2.73 111.591 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 80.0 Cg_exo -50.6 177.41 0.03 OUTLIER 'Trans proline' 0 CA--C 1.537 0.656 1 C-N-CA 125.565 4.177 . . . . 1.87 113.568 162.599 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.26 178.85 53.69 Favored Glycine 0 CA--C 1.541 1.711 0 C-N-CA 123.575 0.607 . . . . 0.95 112.6 167.662 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_endo -70.18 156.78 61.47 Favored 'Trans proline' 0 N--CA 1.457 -0.628 0 C-N-CA 123.319 2.679 . . . . 2.49 111.571 171.747 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.0 tp60 -39.25 126.21 1.69 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 127.609 2.363 . . . . 1.4 113.046 164.182 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.9 168.48 49.92 Favored Glycine 0 CA--C 1.529 0.922 0 C-N-CA 124.75 1.167 . . . . 0.89 112.67 170.058 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 29.7 mt -67.51 143.26 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 O-C-N 121.228 -1.16 . . . . 2.33 110.747 -172.512 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.77 151.82 28.62 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 112.891 0.7 . . . . 1.08 112.891 172.349 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.0 169.64 52.13 Favored Glycine 0 CA--C 1.527 0.816 0 CA-C-O 122.823 1.235 . . . . 1.12 113.519 178.532 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 40.0 mt-30 -95.84 154.29 17.3 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.355 -1.085 . . . . 3.88 111.767 -170.029 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -62.72 135.17 57.22 Favored 'General case' 0 C--O 1.234 0.253 0 N-CA-C 109.207 -0.664 . . . . 5.08 109.207 168.501 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -66.65 173.07 26.97 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 116.204 1.242 . . . . 1.06 116.204 -165.732 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 61.0 t -66.95 136.88 25.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 C-N-CA 124.443 1.097 . . . . 1.82 109.013 173.264 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 33.9 m -100.82 -169.68 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 C-N-CA 124.53 1.132 . . . . 2.41 110.845 -169.47 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.33 155.22 4.91 Favored Glycine 0 CA--C 1.532 1.154 0 C-N-CA 124.657 1.122 . . . . 1.58 114.27 172.39 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 8.8 mt . . . . . 0 C--O 1.249 1.079 0 CA-C-O 117.637 -1.173 . . . . 3.94 113.998 -162.871 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo . . . . . 0 N--CA 1.461 -0.436 0 N-CA-C 110.534 -0.602 . . . . 2.08 110.534 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.72 -179.14 0.35 Allowed 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.931 2.493 . . . . 3.32 113.978 176.559 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.98 -178.74 44.64 Favored Glycine 0 CA--C 1.527 0.797 0 C-N-CA 125.556 1.551 . . . . 1.29 114.686 174.155 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.8 mt -65.63 134.0 30.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 123.951 0.9 . . . . 2.43 109.922 -172.667 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.93 129.76 38.84 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 123.703 0.801 . . . . 2.34 111.471 173.654 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.78 166.77 54.18 Favored Glycine 0 CA--C 1.522 0.477 0 C-N-CA 127.44 2.447 . . . . 1.47 113.069 -177.396 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 14.0 mp0 -82.38 113.58 20.25 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 108.591 -0.892 . . . . 4.13 108.591 -162.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 73.8 ttt180 -49.56 130.66 20.71 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 124.2 1.0 . . . . 4.05 112.199 -173.368 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.26 145.58 39.5 Favored Glycine 0 N--CA 1.464 0.523 0 C-N-CA 124.75 1.167 . . . . 1.66 113.102 -173.544 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 28.2 m -63.89 161.28 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 124.566 1.147 . . . . 2.2 111.615 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.8 m -47.97 157.22 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 125.443 1.497 . . . . 2.1 113.667 177.727 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.29 173.33 39.87 Favored Glycine 0 CA--C 1.527 0.812 0 CA-C-N 115.391 -0.822 . . . . 1.42 112.171 162.165 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 87.6 mt -111.57 158.19 37.1 Favored Pre-proline 0 CA--C 1.537 0.451 0 C-N-CA 123.687 0.795 . . . . 3.89 110.523 -178.24 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -81.39 -160.56 0.13 Allowed 'Trans proline' 0 N--CA 1.454 -0.829 0 C-N-CA 123.302 2.668 . . . . 2.74 108.889 158.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.135 0 CA-C-O 117.75 -1.583 . . . . 3.91 113.021 152.076 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo . . . . . 0 CA--C 1.543 0.927 0 CA-C-O 119.157 -0.435 . . . . 2.17 111.664 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.57 162.99 43.93 Favored Glycine 0 CA--C 1.543 1.834 0 C-N-CA 119.516 -1.326 . . . . 1.38 111.766 130.018 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -76.49 -53.54 0.08 OUTLIER 'Trans proline' 0 CA--C 1.536 0.618 0 C-N-CA 124.876 3.717 . . . . 3.22 113.055 177.822 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -177.13 159.16 1.6 Allowed 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 128.45 2.7 . . . . 3.69 106.8 -162.471 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.11 155.26 22.88 Favored Glycine 0 N--CA 1.468 0.817 0 C-N-CA 124.189 0.899 . . . . 1.03 113.039 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 34.4 mm -67.94 130.37 33.1 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 N-CA-C 109.107 -0.701 . . . . 2.69 109.107 172.601 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -73.28 166.76 22.57 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 113.866 1.062 . . . . 2.12 113.866 -174.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -73.93 113.63 4.25 Favored Glycine 0 CA--C 1.53 1.027 0 C-N-CA 124.313 0.958 . . . . 2.21 112.516 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 -66.23 141.51 58.02 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 123.683 0.793 . . . . 4.61 112.769 178.44 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 9.2 mtt85 -62.05 159.44 14.43 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 115.096 1.517 . . . . 5.66 115.096 -176.345 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.99 -179.29 44.46 Favored Glycine 0 CA--C 1.538 1.474 0 C-N-CA 125.453 1.501 . . . . 1.74 113.151 163.822 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 15.6 m -112.03 146.97 16.2 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 N-CA-C 115.015 1.487 . . . . 3.15 115.015 -158.565 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 8.9 p -54.36 152.42 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 127.973 2.509 . . . . 3.71 115.351 -170.332 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -85.72 -129.23 2.24 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 124.599 1.095 . . . . 1.99 111.062 162.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -170.79 159.94 5.71 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 125.252 1.421 . . . . 3.36 111.777 -168.594 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo . . . . . 0 C--O 1.256 1.397 1 C-N-CA 125.306 4.004 . . . . 2.69 111.931 155.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo . . . . . 0 CA--C 1.547 1.149 0 CA-C-O 118.318 -0.784 . . . . 2.47 111.433 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -54.04 -169.49 0.02 OUTLIER 'Trans proline' 0 CA--C 1.541 0.864 1 C-N-CA 126.043 4.495 . . . . 1.55 113.595 164.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -83.83 175.03 51.76 Favored Glycine 0 CA--C 1.542 1.779 0 O-C-N 121.769 -0.582 . . . . 1.12 112.345 165.378 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -69.47 157.91 59.26 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 122.996 2.464 . . . . 2.53 111.166 170.076 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 tp60 -41.09 124.87 2.32 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.82 2.048 . . . . 1.48 113.439 165.355 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.65 154.65 53.01 Favored Glycine 0 CA--C 1.53 0.974 0 C-N-CA 124.391 0.996 . . . . 1.03 112.382 171.135 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 1.8 mp -67.87 146.1 13.21 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 C-N-CA 124.524 1.129 . . . . 2.51 110.99 -168.807 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.95 142.0 54.54 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 125.216 1.406 . . . . 1.4 113.197 178.311 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -76.07 134.04 15.21 Favored Glycine 0 C--N 1.333 0.366 0 N-CA-C 110.384 -1.086 . . . . 1.41 110.384 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -88.09 171.9 9.92 Favored 'General case' 0 CA--C 1.542 0.644 0 CA-C-N 115.088 -0.556 . . . . 2.96 109.524 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -61.12 155.27 20.95 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.711 0.767 . . . . 4.98 112.279 179.544 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.44 -176.62 25.09 Favored Glycine 0 CA--C 1.53 1.012 0 C-N-CA 124.995 1.283 . . . . 1.45 113.512 179.395 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 49.0 t -59.13 143.5 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.879 1.272 . . . . 2.42 110.279 176.12 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 30.9 m -97.76 -175.75 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.056 1.342 . . . . 3.44 112.024 -173.665 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.43 167.35 19.02 Favored Glycine 0 CA--C 1.532 1.127 0 C-N-CA 124.984 1.278 . . . . 2.23 114.867 175.778 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 9.6 mp . . . . . 0 C--O 1.249 1.046 0 C-N-CA 126.516 1.927 . . . . 3.83 113.463 -166.9 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo . . . . . 0 CA--C 1.538 0.704 0 N-CA-C 109.981 -0.815 . . . . 4.07 109.981 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.9 -137.18 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 124.583 1.153 . . . . 2.88 110.188 157.295 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.52 -148.78 17.59 Favored Glycine 0 N--CA 1.468 0.83 0 CA-C-O 122.827 1.237 . . . . 1.87 114.75 172.496 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.9 mt -84.1 158.38 3.6 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.506 0 C-N-CA 124.131 0.972 . . . . 3.52 108.435 177.371 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.65 46.69 0.09 Allowed 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 126.807 2.043 . . . . 4.24 112.599 170.239 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 61.56 -155.09 37.51 Favored Glycine 0 C--N 1.337 0.609 0 C-N-CA 125.289 1.424 . . . . 2.07 112.627 -171.122 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 7.1 mp0 -105.56 160.92 14.8 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.935 0.874 . . . . 4.99 110.408 158.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.4 tpt180 -66.0 141.24 58.25 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.203 -0.908 . . . . 4.01 109.828 163.346 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -93.29 -167.18 38.39 Favored Glycine 0 C--O 1.227 -0.308 0 C-N-CA 125.324 1.44 . . . . 2.45 112.787 177.885 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 52.8 t -82.61 132.93 30.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 124.524 1.13 . . . . 2.95 109.035 -176.85 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.8 m -56.37 145.61 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 C-N-CA 124.47 1.108 . . . . 2.88 112.926 -178.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.96 145.13 17.64 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 109.951 -1.26 . . . . 1.75 109.951 165.829 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 85.3 mt -91.18 156.43 43.86 Favored Pre-proline 0 N--CA 1.472 0.662 0 CA-C-O 117.161 -1.4 . . . . 3.94 110.444 171.202 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -80.24 -158.04 0.09 OUTLIER 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 123.645 2.897 . . . . 3.46 109.23 166.393 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.24 0 CA-C-O 117.549 -1.695 . . . . 5.43 113.458 154.643 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo . . . . . 0 N--CA 1.491 1.364 0 N-CA-C 109.165 -1.129 . . . . 4.26 109.165 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.04 140.92 30.72 Favored Glycine 0 CA--C 1.539 1.55 0 CA-C-O 118.044 -1.42 . . . . 2.31 110.003 158.541 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -68.62 -175.01 0.79 Allowed 'Trans proline' 0 CA--C 1.538 0.695 0 C-N-CA 123.787 2.991 . . . . 2.43 109.878 162.407 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 4.7 tp-100 -50.47 148.79 3.5 Favored 'General case' 0 CA--C 1.541 0.599 0 N-CA-C 114.734 1.383 . . . . 4.64 114.734 -174.476 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.15 165.83 48.62 Favored Glycine 0 C--N 1.339 0.736 0 CA-C-O 123.285 1.492 . . . . 1.97 112.854 169.145 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 8.2 mm -71.67 160.84 5.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 123.279 1.514 . . . . 4.01 110.722 178.336 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -46.35 147.67 1.09 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.854 1.261 . . . . 2.82 112.975 153.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -82.55 169.16 48.79 Favored Glycine 0 C--N 1.336 0.574 0 CA-C-O 122.626 1.125 . . . . 2.78 112.681 178.726 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -118.41 123.59 45.61 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 123.487 0.715 . . . . 3.58 111.014 -166.247 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 14.9 ptt180 -55.16 134.21 49.42 Favored 'General case' 0 N--CA 1.47 0.546 0 O-C-N 122.056 -0.403 . . . . 5.37 110.703 179.112 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.18 -45.4 93.76 Favored Glycine 0 N--CA 1.477 1.407 0 N-CA-C 114.825 0.69 . . . . 4.28 114.825 -150.059 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 55.3 t -158.99 164.37 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.877 1 C-N-CA 132.117 4.167 . . . . 3.77 105.613 179.699 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 23.0 m -134.34 156.25 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 C-N-CA 125.989 1.716 . . . . 3.74 109.051 168.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -79.62 -175.28 47.54 Favored Glycine 0 C--N 1.335 0.515 0 CA-C-O 122.189 0.883 . . . . 2.9 114.263 179.517 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -159.08 158.11 28.5 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 126.982 2.113 . . . . 6.11 109.921 175.407 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.256 1.381 0 C-N-CA 125.293 3.996 . . . . 5.34 111.831 164.375 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo . . . . . 0 N--CA 1.486 1.04 0 CA-C-O 118.616 -0.66 . . . . 3.57 111.097 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -68.73 -163.78 0.1 OUTLIER 'Trans proline' 0 CA--C 1.544 0.987 0 C-N-CA 123.469 2.779 . . . . 2.93 109.466 157.182 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.91 154.09 52.72 Favored Glycine 0 CA--C 1.541 1.706 0 O-C-N 121.751 -0.593 . . . . 1.64 113.8 172.102 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -79.83 87.15 1.56 Allowed 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 124.504 3.469 . . . . 2.97 111.664 -173.876 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 30.4 tp60 67.8 -124.12 0.19 Allowed 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.615 1.166 . . . . 2.82 108.777 -176.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.63 -179.4 41.07 Favored Glycine 0 CA--C 1.534 1.256 1 C-N-CA 131.956 4.598 . . . . 1.89 107.523 -171.58 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -74.69 156.44 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 O-C-N 120.726 -1.455 . . . . 2.27 110.223 176.232 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.26 159.03 30.99 Favored 'General case' 0 CA--C 1.543 0.675 0 O-C-N 120.215 -1.553 . . . . 1.86 112.165 173.792 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -97.93 160.75 20.9 Favored Glycine 0 CA--C 1.53 0.988 0 C-N-CA 124.502 1.049 . . . . 1.73 112.124 177.576 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 22.9 mp0 -101.87 -179.79 4.11 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 124.376 1.071 . . . . 3.0 111.862 -170.815 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 6.2 tpt85 -66.8 138.62 57.49 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.908 0.883 . . . . 3.73 110.103 162.713 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.83 172.07 30.78 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 124.175 0.893 . . . . 1.43 112.009 172.214 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 23' ' ' VAL . . . . . 0.414 HG23 ' H ' ' C' ' 23' ' ' VAL . 1.9 t -57.15 144.64 9.07 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 124.914 1.285 . . . . 2.18 110.872 -179.733 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.446 HG22 ' H ' ' C' ' 25' ' ' GLY . 7.5 p -75.9 -169.32 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.189 0 C-N-CA 124.557 1.143 . . . . 4.13 109.129 164.716 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.446 ' H ' HG22 ' C' ' 24' ' ' VAL . . . -52.5 168.29 0.83 Allowed Glycine 0 CA--C 1.541 1.656 0 CA-C-N 119.858 1.208 . . . . 1.98 113.913 161.414 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 10.2 mp . . . . . 0 C--O 1.249 1.03 0 C-N-CA 125.72 1.608 . . . . 4.69 112.723 -171.784 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo . . . . . 0 N--CA 1.458 -0.596 0 CA-C-O 121.035 0.348 . . . . 1.86 111.312 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -60.92 167.07 3.04 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 126.473 1.909 . . . . 3.12 113.627 173.654 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -78.48 166.52 52.43 Favored Glycine 0 CA--C 1.518 0.247 0 CA-C-N 114.986 -1.007 . . . . 1.39 113.587 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 21.2 mt -51.93 124.76 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 C-N-CA 125.698 1.599 . . . . 2.43 109.557 178.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -42.9 132.45 3.91 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.715 1.206 . . . . 1.97 112.597 178.449 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.43 149.78 51.67 Favored Glycine 0 CA--C 1.517 0.195 0 C-N-CA 125.129 1.347 . . . . 1.17 111.673 -178.295 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 7.3 mp0 -62.68 114.53 3.64 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 114.962 -0.619 . . . . 4.3 109.636 -173.482 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 48.6 ttt85 -54.56 139.75 37.08 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.686 1.195 . . . . 4.45 112.435 -173.673 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.41 142.62 32.91 Favored Glycine 0 CA--C 1.525 0.698 0 C-N-CA 124.242 0.925 . . . . 1.73 112.71 -175.525 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -60.37 153.42 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 C-N-CA 126.4 1.88 . . . . 2.15 113.231 178.035 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 m -66.99 150.61 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 124.85 1.26 . . . . 2.33 112.924 -175.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.58 153.34 51.51 Favored Glycine 0 CA--C 1.531 1.037 0 CA-C-N 115.899 -0.591 . . . . 1.48 112.436 170.44 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 10.1 mp -83.62 160.25 59.29 Favored Pre-proline 0 CA--C 1.544 0.723 0 C-N-CA 123.882 0.873 . . . . 3.45 111.166 176.608 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -81.9 -158.71 0.1 OUTLIER 'Trans proline' 0 CA--C 1.537 0.649 0 C-N-CA 123.997 3.131 . . . . 1.75 109.127 158.228 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.169 0 CA-C-O 117.336 -1.813 . . . . 3.09 112.843 155.802 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo . . . . . 0 CA--C 1.545 1.056 0 CA-C-O 119.289 -0.38 . . . . 2.02 111.143 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.08 -178.49 10.44 Favored Glycine 0 CA--C 1.544 1.882 0 CA-C-O 119.035 -0.869 . . . . 1.59 112.625 125.512 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -77.83 -134.99 0.02 OUTLIER 'Trans proline' 0 CA--C 1.546 1.1 1 C-N-CA 125.642 4.228 . . . . 2.18 109.071 160.535 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.37 176.44 9.68 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 124.986 1.314 . . . . 3.66 110.99 166.87 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.14 157.85 39.49 Favored Glycine 0 N--CA 1.472 1.047 0 O-C-N 121.357 -0.839 . . . . 0.93 112.698 154.318 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 28.3 mm -77.88 131.49 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 108.596 -0.89 . . . . 3.25 108.596 173.647 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -77.4 157.67 30.46 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 114.078 1.14 . . . . 1.72 114.078 -173.063 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.01 121.31 8.39 Favored Glycine 0 CA--C 1.529 0.957 0 C-N-CA 124.298 0.951 . . . . 1.68 111.687 -179.473 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.96 155.54 40.7 Favored 'General case' 0 CA--C 1.54 0.58 0 O-C-N 121.496 -1.003 . . . . 2.72 111.759 174.344 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.7 ptt-85 -66.14 161.47 21.83 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 122.297 1.046 . . . . 4.54 113.045 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.75 -179.18 49.12 Favored Glycine 0 CA--C 1.529 0.91 0 C-N-CA 125.59 1.567 . . . . 1.89 111.865 172.885 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 7.0 m -100.89 139.79 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 N-CA-C 114.253 1.205 . . . . 3.37 114.253 -160.401 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 26.5 m -64.49 160.27 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 C-N-CA 126.292 1.837 . . . . 2.52 113.502 -174.386 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -88.92 -135.82 5.53 Favored Glycine 0 CA--C 1.529 0.914 0 C-N-CA 124.147 0.879 . . . . 1.71 111.84 171.654 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -167.29 163.65 9.94 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 125.576 1.55 . . . . 3.21 110.745 -167.031 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo . . . . . 0 C--O 1.257 1.445 0 C-N-CA 124.264 3.309 . . . . 2.61 112.163 167.177 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo . . . . . 0 N--CA 1.487 1.102 0 CA-C-O 119.059 -0.476 . . . . 2.04 111.837 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.28 -137.78 0.02 OUTLIER 'Trans proline' 0 CA--C 1.54 0.825 0 C-N-CA 123.298 2.665 . . . . 1.45 108.226 163.668 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -79.0 151.7 35.65 Favored Glycine 0 CA--C 1.542 1.753 0 CA-C-N 119.557 1.071 . . . . 0.95 112.758 173.431 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -85.19 64.08 6.08 Favored 'Trans proline' 0 CA--C 1.541 0.849 0 C-N-CA 124.556 3.504 . . . . 3.17 111.34 -176.845 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 71.89 151.52 0.11 Allowed 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 125.343 1.457 . . . . 2.55 112.716 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.03 153.74 22.05 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 124.769 1.176 . . . . 1.17 111.416 166.152 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 66.0 mt -71.62 144.77 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.8 0 O-C-N 121.805 -0.821 . . . . 2.06 111.193 -177.327 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.17 149.02 48.68 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.97 1.308 . . . . 1.3 113.205 175.413 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -88.7 140.95 16.23 Favored Glycine 0 CA--C 1.532 1.138 0 C-N-CA 125.106 1.336 . . . . 1.11 114.686 -175.124 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 20' ' ' GLN . . . . . 0.572 HE21 ' N ' ' C' ' 20' ' ' GLN . 0.0 OUTLIER -71.51 157.15 38.52 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 126.641 1.976 . . . . 3.89 112.059 168.628 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 46.3 ttp180 -62.07 158.12 17.35 Favored 'General case' 0 CA--C 1.54 0.581 0 N-CA-C 114.331 1.234 . . . . 3.87 114.331 176.941 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -66.14 168.96 32.66 Favored Glycine 0 CA--C 1.537 1.434 0 CA-C-O 122.112 0.84 . . . . 1.04 113.237 158.149 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.2 t -68.03 160.85 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 125.86 1.664 . . . . 2.15 111.097 179.111 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 28.6 m -83.17 -175.19 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 125.896 1.678 . . . . 2.28 111.774 175.781 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.37 173.5 5.38 Favored Glycine 0 CA--C 1.537 1.409 0 C-N-CA 125.164 1.364 . . . . 1.61 114.55 169.073 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 5.7 mt . . . . . 0 C--O 1.25 1.113 0 N-CA-C 114.136 1.162 . . . . 3.63 114.136 -159.072 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo . . . . . 0 CA--C 1.541 0.848 0 N-CA-C 109.571 -0.973 . . . . 2.19 109.571 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.435 ' CD ' ' H ' ' A' ' 15' ' ' GLN . 0.0 OUTLIER -87.07 -168.68 2.33 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 127.414 2.286 . . . . 3.02 111.909 168.142 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.91 177.98 45.0 Favored Glycine 0 N--CA 1.474 1.209 0 C-N-CA 125.978 1.752 . . . . 1.63 112.957 161.382 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.588 ' H ' HD12 ' A' ' 17' ' ' ILE . 2.8 mp -61.98 141.44 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 O-C-N 121.813 -0.816 . . . . 2.59 110.372 -174.544 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.88 133.88 56.52 Favored 'General case' 0 CA--C 1.537 0.469 0 CA-C-N 119.039 0.836 . . . . 1.74 110.946 170.582 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.57 146.53 41.08 Favored Glycine 0 CA--C 1.523 0.581 0 C-N-CA 126.569 2.033 . . . . 1.43 114.603 -178.144 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 73.1 mm-40 -77.56 134.89 38.16 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 114.604 -0.798 . . . . 3.69 110.816 -166.405 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 31.6 mtt180 -59.21 137.46 57.96 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 121.642 0.734 . . . . 4.41 112.529 -171.258 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -78.35 -179.41 50.77 Favored Glycine 0 CA--C 1.523 0.581 0 CA-C-O 123.271 1.484 . . . . 1.87 115.363 -168.282 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -71.6 156.56 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 CA-C-N 113.489 -1.356 . . . . 2.38 111.826 -169.927 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 p -56.4 143.06 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 125.263 1.425 . . . . 5.25 111.967 168.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.48 ' H ' ' HB ' ' B' ' 23' ' ' VAL . . . -93.62 -162.78 36.25 Favored Glycine 0 N--CA 1.472 1.059 0 C-N-CA 124.426 1.013 . . . . 2.42 113.873 170.657 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 93.0 mt -142.43 153.47 62.46 Favored Pre-proline 0 N--CA 1.471 0.59 0 C-N-CA 126.044 1.738 . . . . 3.52 109.823 172.761 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -79.21 -155.6 0.06 OUTLIER 'Trans proline' 0 CA--C 1.539 0.752 0 C-N-CA 123.138 2.559 . . . . 2.21 108.909 159.454 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.291 0 CA-C-O 118.002 -1.443 . . . . 3.84 113.51 158.225 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo . . . . . 0 CA--C 1.544 0.994 0 CA-C-O 118.791 -0.587 . . . . 2.24 111.773 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.0 159.66 49.28 Favored Glycine 0 CA--C 1.548 2.147 0 C-N-CA 118.977 -1.582 . . . . 1.23 110.886 127.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -75.84 -66.84 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.617 1 C-N-CA 125.349 4.033 . . . . 3.04 111.809 177.061 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.16 161.64 41.18 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 128.892 2.877 . . . . 4.23 107.182 -176.812 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.42 160.44 31.72 Favored Glycine 0 N--CA 1.464 0.555 0 C-N-CA 123.629 0.633 . . . . 1.04 112.922 174.855 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.3 pp -78.23 149.37 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 O-C-N 122.313 -0.522 . . . . 4.05 111.215 176.423 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.8 153.12 38.89 Favored 'General case' 0 CA--C 1.543 0.698 0 N-CA-C 113.528 0.936 . . . . 1.29 113.528 -174.777 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.81 147.7 26.7 Favored Glycine 0 CA--C 1.528 0.866 0 C-N-CA 125.947 1.737 . . . . 1.59 114.572 -172.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 37.4 tt0 -77.95 148.08 34.65 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 126.386 1.874 . . . . 4.15 111.599 172.434 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 31.6 mtt180 -64.86 164.37 12.57 Favored 'General case' 0 N--CA 1.473 0.702 0 O-C-N 121.306 -0.871 . . . . 4.15 112.299 174.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.3 -144.1 3.47 Favored Glycine 0 CA--C 1.534 1.222 0 CA-C-N 114.959 -1.018 . . . . 2.51 110.96 161.475 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 23' ' ' VAL . . . . . 0.48 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 49.8 t -53.26 137.52 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 C-N-CA 124.3 1.04 . . . . 5.26 112.687 -176.44 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 26.4 m -103.12 162.41 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 125.651 1.58 . . . . 3.4 111.23 172.442 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.14 171.7 24.75 Favored Glycine 0 C--N 1.338 0.656 0 C-N-CA 125.412 1.482 . . . . 2.54 113.507 -176.18 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -169.38 157.59 6.92 Favored Pre-proline 0 CA--C 1.545 0.754 0 C-N-CA 126.105 1.762 . . . . 3.94 111.521 -168.73 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo . . . . . 0 C--O 1.256 1.39 0 C-N-CA 124.611 3.541 . . . . 3.49 111.803 159.363 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo . . . . . 0 CA--C 1.548 1.178 0 CA-C-O 118.951 -0.521 . . . . 2.43 111.667 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -56.18 -174.4 0.04 OUTLIER 'Trans proline' 0 CA--C 1.539 0.756 0 C-N-CA 124.994 3.796 . . . . 1.72 112.863 164.258 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.71 178.13 54.1 Favored Glycine 0 CA--C 1.541 1.682 0 C-N-CA 123.628 0.633 . . . . 1.01 112.145 165.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -67.91 155.96 67.75 Favored 'Trans proline' 0 N--CA 1.457 -0.62 0 C-N-CA 122.904 2.403 . . . . 2.59 111.001 171.721 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 22.0 tp60 -40.55 121.36 1.42 Allowed 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 127.384 2.274 . . . . 1.51 112.946 169.828 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.4 157.08 44.72 Favored Glycine 0 CA--C 1.527 0.814 0 C-N-CA 124.29 0.948 . . . . 0.91 112.091 170.757 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 2.2 mp -65.22 140.55 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 123.548 0.739 . . . . 2.18 110.486 -169.129 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.51 156.57 15.98 Favored 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 123.065 1.412 . . . . 1.05 114.748 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.83 145.85 39.04 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 108.994 -1.643 . . . . 1.0 108.994 174.668 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 7.2 mp0 -82.99 -179.46 7.45 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.884 0.85 . . . . 3.63 110.441 -170.077 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 1.9 tmt_? -57.63 138.39 55.39 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-O 121.618 0.723 . . . . 3.4 110.095 169.119 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.46 148.25 51.09 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 124.367 0.985 . . . . 1.82 112.04 178.299 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 91.2 t -64.86 148.43 11.96 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.603 0 C-N-CA 124.246 1.018 . . . . 2.3 110.447 -173.172 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 12.3 p -97.24 171.79 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.995 0 C-N-CA 127.982 2.513 . . . . 2.97 111.059 -178.88 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.5 -168.66 0.61 Allowed Glycine 0 CA--C 1.54 1.614 0 C-N-CA 125.203 1.382 . . . . 2.08 116.083 171.102 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 15.5 mt . . . . . 0 C--O 1.249 1.047 0 C-N-CA 125.736 1.614 . . . . 3.55 115.12 -170.544 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo . . . . . 0 N--CA 1.458 -0.575 0 N-CA-C 111.39 -0.273 . . . . 2.21 111.39 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 31.2 tp60 -46.07 163.73 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 129.228 3.011 . . . . 3.66 115.53 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.56 172.47 42.82 Favored Glycine 0 CA--C 1.524 0.638 0 C-N-CA 124.388 0.994 . . . . 1.21 114.616 168.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.558 ' H ' HD12 ' A' ' 17' ' ' ILE . 3.0 mp -60.41 140.53 18.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 C-N-CA 124.975 1.31 . . . . 3.02 109.858 -179.369 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.41 130.01 37.82 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 123.318 0.647 . . . . 2.4 111.291 170.512 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.59 161.49 54.22 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 126.122 1.82 . . . . 1.43 113.58 176.447 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 11.0 mm100 -74.33 115.35 13.74 Favored 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 109.675 -0.491 . . . . 3.6 109.675 -168.248 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -58.46 139.26 55.86 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.564 0.746 . . . . 3.93 112.219 -175.348 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.38 147.3 35.65 Favored Glycine 0 CA--C 1.522 0.527 0 C-N-CA 125.848 1.689 . . . . 1.59 113.542 -173.093 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.0 p -66.6 144.82 14.32 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 125.465 1.506 . . . . 3.63 110.573 176.458 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -50.69 157.61 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 126.09 1.756 . . . . 2.15 114.716 -175.257 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.5 175.4 53.49 Favored Glycine 0 N--CA 1.474 1.207 0 N-CA-C 110.787 -0.925 . . . . 1.69 110.787 158.311 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 17.6 mt -149.84 157.04 38.46 Favored Pre-proline 0 N--CA 1.471 0.621 0 N-CA-C 115.884 1.809 . . . . 3.41 115.884 -152.383 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -68.2 104.66 1.09 Allowed 'Trans proline' 0 N--CA 1.449 -1.09 0 N-CA-C 106.529 -2.143 . . . . 2.5 106.529 154.637 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.231 0 CA-C-O 118.923 -0.932 . . . . 6.39 114.218 -160.405 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo . . . . . 0 CA--C 1.544 0.987 0 N-CA-C 110.993 -0.426 . . . . 2.73 110.993 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.63 -170.4 0.41 Allowed Glycine 0 CA--C 1.538 1.488 0 C-N-CA 120.457 -0.878 . . . . 1.86 113.875 125.537 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -74.38 -123.39 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 0.998 0 C-N-CA 124.069 3.179 . . . . 2.07 107.545 157.489 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -100.29 178.7 4.68 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.309 1.443 . . . . 6.16 112.218 175.137 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.46 145.72 25.46 Favored Glycine 0 N--CA 1.472 1.047 0 O-C-N 121.202 -0.936 . . . . 1.22 112.684 164.215 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 96.7 mt -63.38 132.77 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 O-C-N 121.079 -1.248 . . . . 3.24 108.659 170.375 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -77.55 157.05 30.53 Favored 'General case' 0 CA--C 1.542 0.65 0 N-CA-C 114.151 1.167 . . . . 2.13 114.151 -169.382 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.54 140.27 40.64 Favored Glycine 0 CA--C 1.524 0.634 0 C-N-CA 126.229 1.871 . . . . 1.8 110.5 169.522 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 10.4 mp0 -95.95 147.86 23.24 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 123.308 0.643 . . . . 3.91 110.84 -165.845 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 3.8 ttt180 -64.12 154.76 33.61 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 124.525 1.13 . . . . 5.09 113.722 -176.229 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.68 155.86 52.35 Favored Glycine 0 CA--C 1.531 1.05 0 C-N-CA 124.042 0.83 . . . . 1.99 115.115 176.053 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 27.7 m -75.58 136.8 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 114.677 1.362 . . . . 3.22 114.677 -174.023 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.6 m -56.43 156.5 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.002 0 N-CA-C 116.729 2.122 . . . . 2.82 116.729 -162.168 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.56 -177.06 42.93 Favored Glycine 0 C--N 1.34 0.753 0 C-N-CA 125.864 1.697 . . . . 2.08 115.8 -167.087 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.6 mp -147.72 158.37 42.92 Favored Pre-proline 0 CA--C 1.546 0.813 0 C-N-CA 125.453 1.501 . . . . 4.63 113.031 -165.428 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo . . . . . 0 C--O 1.255 1.343 0 C-N-CA 123.843 3.029 . . . . 3.42 112.635 148.585 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo . . . . . 0 CA--C 1.547 1.151 0 CA-C-O 118.323 -0.782 . . . . 2.26 111.855 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_exo -49.58 -179.35 0.02 OUTLIER 'Trans proline' 0 C--N 1.35 0.655 1 C-N-CA 126.571 4.847 . . . . 1.9 114.402 166.549 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.26 148.55 51.41 Favored Glycine 0 CA--C 1.547 2.035 0 CA-C-O 119.368 -0.685 . . . . 1.38 112.059 162.327 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -81.55 61.95 8.17 Favored 'Trans proline' 0 CA--C 1.542 0.899 0 C-N-CA 125.036 3.824 . . . . 3.6 113.058 -169.056 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 9.0 tp-100 74.7 147.32 0.09 Allowed 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.402 1.881 . . . . 2.48 112.774 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -85.85 146.08 21.17 Favored Glycine 0 CA--C 1.527 0.842 0 O-C-N 121.299 -0.875 . . . . 1.08 112.145 170.695 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 97.5 mt -63.46 148.77 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 124.607 1.163 . . . . 2.18 110.883 175.597 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.97 150.43 39.02 Favored 'General case' 0 CA--C 1.548 0.887 0 N-CA-C 114.383 1.253 . . . . 1.1 114.383 177.426 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -80.63 152.79 34.1 Favored Glycine 0 C--N 1.338 0.679 0 C-N-CA 125.44 1.495 . . . . 1.03 111.176 177.211 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 10.5 mp0 -101.18 161.0 13.92 Favored 'General case' 0 C--N 1.326 -0.419 0 O-C-N 121.726 -0.867 . . . . 3.27 110.095 -172.876 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -53.34 134.85 39.71 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 123.483 0.713 . . . . 3.83 109.804 172.62 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.25 177.19 29.4 Favored Glycine 0 CA--C 1.522 0.483 0 CA-C-N 115.713 -0.676 . . . . 1.06 112.105 -175.281 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 45.2 t -58.58 131.74 23.0 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 CA-C-O 121.464 0.65 . . . . 1.87 110.564 -177.743 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 8.7 p -70.23 158.68 5.99 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.394 0 C-N-CA 129.374 3.069 . . . . 3.53 112.774 177.322 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.72 167.1 1.09 Allowed Glycine 0 CA--C 1.538 1.53 0 N-CA-C 115.288 0.875 . . . . 1.81 115.288 159.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 2.8 mm? . . . . . 0 C--O 1.25 1.094 0 C-N-CA 125.595 1.558 . . . . 3.95 113.683 -164.968 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo . . . . . 0 CA--C 1.54 0.821 0 N-CA-C 109.927 -0.836 . . . . 2.09 109.927 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -87.74 -173.14 4.18 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.074 1.75 . . . . 3.14 112.187 169.652 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -93.37 -171.61 39.69 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 125.884 1.707 . . . . 1.32 113.881 163.603 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.2 mt -62.24 139.88 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.103 0 O-C-N 121.784 -0.833 . . . . 2.06 110.481 -173.477 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -57.32 133.35 55.04 Favored 'General case' 0 CA--C 1.536 0.426 0 CA-C-N 118.692 0.678 . . . . 1.82 110.509 168.712 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.46 147.14 18.88 Favored Glycine 0 CA--C 1.52 0.405 0 C-N-CA 127.546 2.498 . . . . 1.23 113.665 177.844 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 87.3 mm-40 -71.57 125.72 27.8 Favored 'General case' 0 CA--C 1.535 0.403 0 N-CA-C 108.159 -1.052 . . . . 3.2 108.159 -177.182 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.9 ttt180 -57.97 137.07 57.11 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 123.639 0.776 . . . . 5.19 111.54 -169.781 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -65.8 163.33 40.72 Favored Glycine 0 C--N 1.338 0.679 0 C-N-CA 124.985 1.279 . . . . 1.54 115.577 -169.623 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 45.3 t -66.88 132.17 32.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 C-N-CA 126.617 1.967 . . . . 2.83 109.5 -175.71 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.415 HG23 ' H ' ' A' ' 24' ' ' VAL . 1.7 t -56.26 145.78 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 124.974 1.31 . . . . 2.58 112.224 -173.526 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.11 175.33 42.46 Favored Glycine 0 CA--C 1.535 1.286 0 N-CA-C 112.019 -0.432 . . . . 1.46 112.019 163.408 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 6.4 mp -129.68 156.71 78.36 Favored Pre-proline 0 CA--C 1.538 0.505 0 C-N-CA 124.636 1.174 . . . . 2.9 109.447 178.85 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.401 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 30.4 Cg_endo -77.74 -165.03 0.3 Allowed 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.951 2.434 . . . . 1.77 109.44 161.264 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.259 0 CA-C-O 117.67 -1.628 . . . . 3.38 112.588 153.863 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo . . . . . 0 CA--C 1.54 0.81 0 CA-C-O 118.047 -0.897 . . . . 2.61 110.573 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.77 162.87 25.32 Favored Glycine 0 CA--C 1.551 2.299 0 C-N-CA 118.882 -1.628 . . . . 1.57 111.144 126.414 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -79.0 -51.8 0.06 OUTLIER 'Trans proline' 0 CA--C 1.536 0.599 0 C-N-CA 124.746 3.631 . . . . 3.21 112.302 178.732 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 177.93 160.58 0.53 Allowed 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 129.731 3.213 . . . . 3.74 105.443 -165.381 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.07 -173.78 46.48 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 116.873 1.509 . . . . 1.31 116.873 -168.8 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.513 ' H ' HD12 ' B' ' 17' ' ' ILE . 4.0 mp -71.78 121.31 21.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 108.473 -0.936 . . . . 3.64 108.473 168.284 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -68.5 137.63 54.55 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-O 121.542 0.686 . . . . 1.5 111.419 176.611 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.09 147.2 40.81 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 124.698 1.142 . . . . 1.64 112.826 -170.717 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -82.08 147.79 28.92 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 123.764 0.826 . . . . 3.63 111.327 169.541 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 6.0 ptt180 -52.27 157.17 1.47 Allowed 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 114.63 1.344 . . . . 5.38 114.63 168.633 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.03 179.1 53.16 Favored Glycine 0 CA--C 1.532 1.111 0 C-N-CA 124.331 0.967 . . . . 1.87 114.035 177.131 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 24.2 t -91.93 122.33 43.28 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 N-CA-C 113.648 0.981 . . . . 3.05 113.648 -152.901 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.1 m -58.89 154.28 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 127.06 2.144 . . . . 2.48 114.272 -173.096 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.63 -146.71 16.91 Favored Glycine 0 CA--C 1.53 0.996 0 C-N-CA 124.196 0.903 . . . . 1.62 112.026 163.069 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.401 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.5 pt? -171.12 161.06 5.42 Favored Pre-proline 0 CA--C 1.546 0.823 0 C-N-CA 126.097 1.759 . . . . 3.59 111.568 -164.868 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo . . . . . 0 CA--C 1.552 1.386 0 C-N-CA 125.292 3.995 . . . . 2.83 112.595 153.901 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 CA--C 1.547 1.125 0 CA-C-O 118.765 -0.598 . . . . 3.18 111.467 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -55.94 -179.4 0.08 OUTLIER 'Trans proline' 0 CA--C 1.537 0.652 0 C-N-CA 124.477 3.452 . . . . 2.18 112.583 164.071 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.84 179.54 47.27 Favored Glycine 0 CA--C 1.54 1.615 0 C-N-CA 124.662 1.125 . . . . 1.13 114.028 176.227 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_endo -70.61 156.69 60.62 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 123.383 2.722 . . . . 2.39 111.116 172.322 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 22.2 tp60 -32.22 120.34 0.29 Allowed 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 127.648 2.379 . . . . 1.33 113.546 167.055 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.62 158.35 53.63 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.345 -0.702 . . . . 0.9 111.345 166.376 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 68.1 mt -61.84 143.55 15.0 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 C-N-CA 123.203 0.601 . . . . 2.2 111.528 -169.721 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -67.7 158.44 32.28 Favored 'General case' 0 CA--C 1.545 0.754 0 CA-C-O 122.722 1.248 . . . . 1.04 114.234 177.177 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.28 163.18 54.44 Favored Glycine 0 CA--C 1.527 0.782 0 C-N-CA 124.625 1.107 . . . . 1.2 112.909 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 9.8 mp0 -96.38 -178.83 4.42 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 124.264 1.026 . . . . 3.95 111.491 -171.193 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.49 142.91 46.78 Favored 'General case' 0 N--CA 1.473 0.686 0 O-C-N 121.06 -1.025 . . . . 3.41 110.868 172.438 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.41 173.26 55.21 Favored Glycine 0 N--CA 1.47 0.919 0 C-N-CA 124.895 1.236 . . . . 1.01 112.817 177.121 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 38.1 t -71.3 138.45 21.71 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 C-N-CA 123.803 0.841 . . . . 1.99 110.164 179.206 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -91.81 173.45 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 C-N-CA 127.277 2.231 . . . . 2.64 109.763 -179.301 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -50.99 149.13 7.34 Favored Glycine 0 CA--C 1.533 1.182 0 CA-C-N 119.076 0.853 . . . . 1.79 113.13 170.71 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 8.6 tt . . . . . 0 C--O 1.25 1.097 0 C-N-CA 127.322 2.249 . . . . 4.15 113.766 -167.205 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo . . . . . 0 CA--C 1.534 0.515 0 N-CA-C 110.965 -0.436 . . . . 2.35 110.965 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.58 -155.44 0.15 Allowed 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.933 1.693 . . . . 2.71 111.034 165.586 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -85.67 173.0 47.09 Favored Glycine 0 N--CA 1.47 0.943 0 N-CA-C 115.701 1.041 . . . . 1.47 115.701 -173.29 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.558 ' H ' HD12 ' A' ' 17' ' ' ILE . 2.8 mp -66.16 137.49 24.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 108.468 -0.938 . . . . 2.52 108.468 177.517 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.73 131.26 50.35 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 121.569 0.699 . . . . 1.71 110.632 170.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.78 153.17 30.07 Favored Glycine 0 CA--C 1.519 0.301 0 C-N-CA 126.651 2.072 . . . . 1.62 113.004 174.135 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 5.4 mp0 -74.37 143.66 44.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 114.78 -0.71 . . . . 3.87 110.738 -164.173 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 16.8 tpp85 -52.22 135.55 31.97 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 123.553 0.741 . . . . 4.51 110.992 173.101 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.84 167.54 54.44 Favored Glycine 0 CA--C 1.522 0.485 0 CA-C-O 122.587 1.104 . . . . 1.51 113.819 -173.757 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 15.4 t -66.06 129.2 30.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 C-N-CA 125.78 1.632 . . . . 2.45 109.392 -178.497 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 31.4 m -58.69 146.98 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 N-CA-C 114.355 1.243 . . . . 2.13 114.355 -172.268 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.11 159.48 53.52 Favored Glycine 0 CA--C 1.536 1.358 0 CA-C-O 121.903 0.724 . . . . 1.37 112.051 161.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.544 HD13 HH21 ' C' ' 21' ' ' ARG . 11.0 mp -120.05 136.82 25.25 Favored Pre-proline 0 CA--C 1.532 0.262 0 C-N-CA 126.314 1.846 . . . . 2.8 109.815 -177.152 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -74.42 -172.05 1.08 Allowed 'Trans proline' 0 N--CA 1.456 -0.679 0 C-N-CA 122.729 2.286 . . . . 2.49 109.861 169.666 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.245 0 CA-C-O 117.659 -1.634 . . . . 4.58 113.095 151.359 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo . . . . . 0 N--CA 1.491 1.347 0 N-CA-C 109.248 -1.097 . . . . 2.59 109.248 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.64 147.38 49.65 Favored Glycine 0 CA--C 1.541 1.678 0 CA-C-O 118.898 -0.946 . . . . 1.35 111.308 162.888 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -77.42 176.94 9.46 Favored 'Trans proline' 0 CA--C 1.538 0.707 0 C-N-CA 124.116 3.211 . . . . 2.28 110.315 164.041 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.1 tp-100 -38.91 143.61 0.15 Allowed 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 127.743 2.417 . . . . 3.74 115.594 176.69 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.14 163.36 53.11 Favored Glycine 0 CA--C 1.529 0.949 0 C-N-CA 124.031 0.824 . . . . 1.02 113.028 175.298 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.511 ' H ' HD12 ' B' ' 17' ' ' ILE . 2.9 mp -65.28 134.7 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 O-C-N 121.733 -0.863 . . . . 2.75 109.328 175.118 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.68 148.76 51.47 Favored 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 119.093 0.86 . . . . 1.46 112.196 176.427 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -68.41 153.2 52.85 Favored Glycine 0 CA--C 1.527 0.826 0 C-N-CA 124.57 1.081 . . . . 1.75 111.746 174.938 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.59 155.26 25.77 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.999 0.92 . . . . 2.87 111.332 -176.64 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 41.0 mtt-85 -53.53 148.1 9.92 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 125.204 1.402 . . . . 5.84 113.905 -169.076 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.78 166.43 54.3 Favored Glycine 0 CA--C 1.535 1.299 0 CA-C-N 116.133 -0.485 . . . . 1.92 113.813 175.445 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 27.6 t -72.59 121.77 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 N-CA-C 113.56 0.948 . . . . 2.93 113.56 -161.114 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -65.95 161.37 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 125.481 1.512 . . . . 2.51 114.758 -165.615 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -85.0 -155.91 24.91 Favored Glycine 0 CA--C 1.528 0.903 0 C-N-CA 125.776 1.655 . . . . 1.7 113.461 175.294 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.1 pp -161.9 145.86 9.55 Favored Pre-proline 0 CA--C 1.541 0.63 0 C-N-CA 124.628 1.171 . . . . 2.99 111.499 -177.113 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo . . . . . 0 C--O 1.255 1.367 1 C-N-CA 126.087 4.524 . . . . 3.14 112.765 158.012 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo . . . . . 0 CA--C 1.543 0.93 0 CA-C-O 118.607 -0.664 . . . . 2.14 111.959 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -70.98 -150.23 0.03 OUTLIER 'Trans proline' 0 CA--C 1.541 0.869 0 C-N-CA 123.95 3.1 . . . . 1.52 108.523 164.515 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.66 169.49 40.98 Favored Glycine 0 CA--C 1.531 1.072 0 O-C-N 121.575 -0.703 . . . . 0.93 113.29 172.876 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -72.49 160.88 45.68 Favored 'Trans proline' 0 N--CA 1.454 -0.794 0 C-N-CA 123.081 2.521 . . . . 2.46 110.674 171.137 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 34.0 tp60 -52.77 120.13 5.38 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 126.249 1.82 . . . . 1.75 112.798 170.642 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -60.06 150.28 40.29 Favored Glycine 0 CA--C 1.53 1.028 0 C-N-CA 123.876 0.751 . . . . 0.89 111.639 168.599 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 78.0 mt -67.14 145.86 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.409 1.084 . . . . 2.7 110.676 -176.037 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.13 154.89 29.65 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 114.824 1.416 . . . . 1.12 114.824 178.225 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -76.75 148.24 34.84 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 124.739 1.162 . . . . 0.94 112.596 176.151 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -83.33 171.11 13.87 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.475 1.11 . . . . 5.28 112.294 -177.159 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' C' C ' 21' ' ' ARG . . . . . 0.544 HH21 HD13 ' A' ' 26' ' ' LEU . 0.0 OUTLIER -61.29 138.49 58.24 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 121.398 -0.814 . . . . 3.52 111.97 178.672 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.84 159.0 51.26 Favored Glycine 0 CA--C 1.528 0.857 0 C-N-CA 125.657 1.598 . . . . 0.98 112.933 177.183 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 23.7 t -68.76 136.43 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 124.054 0.941 . . . . 1.74 109.095 171.767 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 31.0 m -87.9 -165.54 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.843 0 C-N-CA 125.053 1.341 . . . . 2.71 111.623 -179.455 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.51 -138.79 0.15 Allowed Glycine 0 CA--C 1.54 1.628 0 C-N-CA 125.109 1.338 . . . . 1.69 113.562 164.365 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.251 1.162 0 C-N-CA 126.413 1.885 . . . . 6.5 114.682 -177.017 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo . . . . . 0 N--CA 1.459 -0.534 0 N-CA-C 111.229 -0.335 . . . . 1.76 111.229 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.99 162.68 8.85 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 126.253 1.821 . . . . 3.58 113.695 172.744 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.71 -179.54 47.92 Favored Glycine 0 CA--C 1.525 0.693 0 C-N-CA 124.639 1.114 . . . . 1.29 112.547 171.42 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.401 HG13 ' H ' ' A' ' 17' ' ' ILE . 3.3 mt -61.28 138.01 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 C-N-CA 123.488 0.715 . . . . 2.14 109.506 -172.402 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.93 135.62 56.67 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-O 120.961 0.41 . . . . 2.04 110.727 170.85 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.26 151.79 49.84 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 126.286 1.898 . . . . 1.31 112.876 179.234 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 57.7 mm-40 -69.86 155.71 40.15 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 114.744 -0.728 . . . . 3.93 111.336 -174.788 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -68.0 145.8 54.16 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 121.028 0.442 . . . . 5.47 111.961 -177.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.45 141.48 28.81 Favored Glycine 0 C--N 1.333 0.413 0 CA-C-N 115.52 -0.764 . . . . 1.59 112.1 -178.156 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 27.2 m -61.4 141.42 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 CA-C-O 121.173 0.511 . . . . 2.43 111.248 -179.615 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.1 m -48.89 150.9 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 125.585 1.554 . . . . 2.54 113.878 -172.14 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.83 -153.8 26.16 Favored Glycine 0 N--CA 1.471 1.0 0 C-N-CA 123.165 0.412 . . . . 1.94 112.556 165.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 85.7 mt -149.48 155.47 39.13 Favored Pre-proline 0 N--CA 1.472 0.631 0 C-N-CA 125.677 1.591 . . . . 3.28 109.532 178.186 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -80.04 -162.1 0.17 Allowed 'Trans proline' 0 CA--C 1.539 0.747 0 C-N-CA 122.641 2.227 . . . . 2.41 109.392 158.08 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.239 0 CA-C-O 117.071 -1.961 . . . . 4.47 112.069 142.241 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_exo . . . . . 0 CA--C 1.544 1.015 0 N-CA-C 111.154 -0.364 . . . . 3.1 111.154 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -63.66 -177.49 4.49 Favored Glycine 0 CA--C 1.542 1.728 0 C-N-CA 120.187 -1.006 . . . . 2.52 112.446 126.217 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -74.64 -135.7 0.01 OUTLIER 'Trans proline' 0 CA--C 1.546 1.113 0 C-N-CA 124.571 3.514 . . . . 2.29 108.19 155.623 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 -87.33 -176.88 5.8 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 124.903 1.281 . . . . 3.98 111.454 171.812 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -84.75 158.97 34.13 Favored Glycine 0 CA--C 1.528 0.899 0 O-C-N 121.86 -0.525 . . . . 1.03 111.955 161.183 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 53.5 mt -72.77 133.26 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 123.389 0.676 . . . . 3.62 109.291 179.116 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.52 145.41 52.68 Favored 'General case' 0 CA--C 1.547 0.834 0 CA-C-N 119.39 0.995 . . . . 1.45 113.387 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.72 140.5 29.18 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 125.328 1.442 . . . . 1.52 111.694 173.591 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -95.37 153.09 17.85 Favored 'General case' 0 CA--C 1.532 0.257 0 O-C-N 121.729 -0.865 . . . . 3.15 111.604 -175.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 5.7 ttt85 -62.94 149.57 44.33 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.086 1.355 . . . . 6.68 112.221 -172.195 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.73 -174.86 26.61 Favored Glycine 0 CA--C 1.532 1.14 0 N-CA-C 114.463 0.545 . . . . 1.8 114.463 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 75.8 t -44.66 142.17 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 C-N-CA 128.016 2.526 . . . . 4.29 114.057 -172.501 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -93.1 156.95 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 124.13 0.972 . . . . 3.17 113.613 178.059 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.18 -162.62 29.57 Favored Glycine 0 C--N 1.341 0.828 0 C-N-CA 125.535 1.541 . . . . 1.89 114.23 -178.251 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.8 pp -153.76 141.83 13.98 Favored Pre-proline 0 CA--C 1.542 0.656 0 C-N-CA 124.287 1.035 . . . . 3.85 110.904 174.241 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo . . . . . 0 C--O 1.254 1.292 1 C-N-CA 126.282 4.654 . . . . 4.59 113.147 160.135 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo . . . . . 0 CA--C 1.547 1.152 0 CA-C-O 119.178 -0.426 . . . . 3.11 111.917 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -72.5 -135.59 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.075 0 C-N-CA 123.502 2.802 . . . . 1.97 108.351 162.447 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -81.04 175.42 54.78 Favored Glycine 0 CA--C 1.543 1.786 0 CA-C-N 119.303 0.956 . . . . 1.34 111.552 163.355 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -80.14 170.64 16.13 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 123.676 2.917 . . . . 2.42 110.46 161.771 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 28.7 tp60 -43.31 117.58 1.14 Allowed 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 125.33 1.452 . . . . 1.51 112.133 161.005 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.5 145.98 49.96 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.331 -1.108 . . . . 1.07 110.331 166.558 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 36.2 mm -66.51 145.33 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 O-C-N 122.367 -0.49 . . . . 4.11 110.567 -174.889 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -68.52 166.56 16.72 Favored 'General case' 0 CA--C 1.543 0.687 0 N-CA-C 114.394 1.257 . . . . 1.71 114.394 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.58 155.17 43.0 Favored Glycine 0 CA--C 1.527 0.81 0 C-N-CA 125.007 1.289 . . . . 1.04 112.6 -179.384 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -95.92 167.73 11.06 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.1 0.96 . . . . 4.89 111.164 -176.671 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.69 134.5 51.37 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.243 0.617 . . . . 3.87 111.038 178.501 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -63.72 178.49 7.12 Favored Glycine 0 N--CA 1.469 0.868 0 C-N-CA 126.41 1.957 . . . . 1.07 114.667 -175.773 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 93.1 t -74.83 138.09 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 108.969 -0.752 . . . . 2.14 108.969 -179.023 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 13.9 m -99.93 174.35 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 C-N-CA 126.305 1.842 . . . . 2.49 110.335 -178.386 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.92 -178.16 9.6 Favored Glycine 0 CA--C 1.534 1.227 0 C-N-CA 123.615 0.626 . . . . 1.81 113.673 167.308 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.479 0.987 0 N-CA-C 114.649 1.351 . . . . 5.57 114.649 173.766 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo . . . . . 0 CA--C 1.538 0.716 0 N-CA-C 110.249 -0.712 . . . . 2.06 110.249 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.427 ' HA ' ' HD2' ' B' ' 14' ' ' PRO 0.253 0.0 OUTLIER -89.99 -156.65 0.43 Allowed 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 125.984 1.714 . . . . 3.18 111.699 173.435 . . . . . . . . 4 4 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.03 178.47 45.03 Favored Glycine 0 N--CA 1.475 1.257 0 C-N-CA 124.95 1.262 . . . . 1.33 114.535 178.354 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.9 mt -76.06 130.41 36.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 O-C-N 121.261 -1.14 . . . . 2.54 108.579 -176.724 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.66 127.65 30.93 Favored 'General case' 0 CA--C 1.539 0.554 0 CA-C-N 119.318 0.963 . . . . 2.02 111.571 178.73 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.86 164.29 35.68 Favored Glycine 0 CA--C 1.528 0.869 0 C-N-CA 126.097 1.808 . . . . 1.28 112.803 -176.837 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -71.95 112.3 7.92 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 121.894 -0.768 . . . . 5.28 110.574 -169.431 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 67.4 ttt-85 -60.9 127.04 29.63 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 123.425 0.69 . . . . 4.0 109.402 177.587 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -78.57 171.99 55.19 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 125.002 1.287 . . . . 1.55 115.318 -166.7 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -64.38 147.52 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 CA-C-N 113.78 -1.21 . . . . 2.69 110.538 -173.875 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.0 m -54.14 150.58 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 123.146 0.578 . . . . 2.59 111.491 167.98 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.2 148.98 46.71 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 110.538 -1.025 . . . . 1.98 110.538 159.807 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 7.4 mp -101.35 167.04 11.27 Favored Pre-proline 0 C--N 1.328 -0.337 0 C-N-CA 124.027 0.931 . . . . 3.53 110.748 174.512 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.421 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 44.3 Cg_endo -69.94 -155.38 0.04 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 121.789 1.659 . . . . 1.81 108.55 155.113 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.259 0 CA-C-O 117.019 -1.989 . . . . 3.31 112.683 152.373 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_exo . . . . . 0 N--CA 1.481 0.765 0 CA-C-O 117.618 -1.076 . . . . 2.31 110.268 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -63.97 153.08 48.15 Favored Glycine 0 CA--C 1.548 2.131 0 C-N-CA 119.758 -1.211 . . . . 1.32 111.06 144.055 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 14' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 15' ' ' GLN . 57.8 Cg_endo -78.88 -47.96 0.09 OUTLIER 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 124.461 3.44 . . . . 2.88 114.628 -179.417 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.8 tp-100 -170.8 146.76 2.64 Favored 'General case' 0 N--CA 1.463 0.204 0 C-N-CA 124.285 1.034 . . . . 3.52 110.722 -161.76 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -86.51 149.8 22.94 Favored Glycine 0 CA--C 1.527 0.792 0 CA-C-O 121.822 0.679 . . . . 0.95 113.149 -178.936 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 65.7 mt -69.31 122.45 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 108.481 -0.933 . . . . 3.02 108.481 175.592 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.92 136.65 58.06 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 113.126 0.788 . . . . 1.21 113.126 -174.008 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -67.81 129.38 27.21 Favored Glycine 0 CA--C 1.523 0.533 0 C-N-CA 125.287 1.422 . . . . 1.65 110.183 169.429 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 8.8 tp-100 -96.89 150.34 20.86 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 123.685 0.794 . . . . 7.25 110.195 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.96 157.17 10.33 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 112.912 0.708 . . . . 4.62 112.912 171.461 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.46 -174.65 49.43 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 124.417 1.008 . . . . 1.83 112.455 170.701 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 13.4 m -93.31 141.9 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 115.133 1.531 . . . . 3.76 115.133 -156.659 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 12.9 m -69.5 154.17 8.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 125.796 1.638 . . . . 2.47 113.274 -166.816 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.72 -136.66 9.45 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 123.931 0.777 . . . . 1.77 113.117 170.802 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.421 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.6 pt? -172.18 158.57 4.18 Favored Pre-proline 0 CA--C 1.546 0.804 0 C-N-CA 126.085 1.754 . . . . 3.16 110.788 -157.41 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo . . . . . 0 C--O 1.256 1.424 0 C-N-CA 122.294 1.996 . . . . 2.56 111.013 160.851 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo . . . . . 0 CA--C 1.544 1.015 0 CA-C-O 118.783 -0.59 . . . . 2.64 111.939 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -55.39 -176.1 0.04 OUTLIER 'Trans proline' 0 CA--C 1.536 0.625 0 C-N-CA 124.707 3.605 . . . . 1.74 112.582 162.14 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -89.64 -172.85 45.55 Favored Glycine 0 CA--C 1.537 1.425 0 C-N-CA 124.882 1.23 . . . . 1.06 113.202 171.047 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -72.96 159.13 48.68 Favored 'Trans proline' 0 N--CA 1.456 -0.703 0 C-N-CA 123.211 2.607 . . . . 2.57 111.858 178.443 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.481 ' HA ' HE21 ' C' ' 15' ' ' GLN . 0.0 OUTLIER -45.7 130.02 9.1 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.461 1.904 . . . . 1.75 112.947 161.916 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -79.15 174.77 55.26 Favored Glycine 0 CA--C 1.53 0.981 0 C-N-CA 125.471 1.51 . . . . 1.17 114.06 174.521 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 97.0 mt -63.98 145.87 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 124.958 1.303 . . . . 2.82 111.76 -174.872 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -85.44 157.24 20.52 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 125.609 1.563 . . . . 1.34 114.115 177.189 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -98.02 138.06 13.66 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 124.945 1.26 . . . . 1.19 112.605 178.269 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -70.73 -179.07 2.04 Favored 'General case' 0 CA--C 1.543 0.709 0 CA-C-O 122.479 1.133 . . . . 5.2 111.797 170.199 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 17.8 ttt85 -55.41 149.34 13.43 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 124.588 1.155 . . . . 4.11 110.917 161.572 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.45 171.54 46.58 Favored Glycine 0 CA--C 1.533 1.17 0 N-CA-C 111.423 -0.671 . . . . 1.05 111.423 161.87 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 6.3 t -66.53 144.02 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 C-N-CA 124.13 0.972 . . . . 1.91 110.972 -179.457 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 12.4 m -85.77 175.0 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 C-N-CA 127.342 2.257 . . . . 2.71 112.497 179.384 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.26 173.71 10.53 Favored Glycine 0 CA--C 1.537 1.419 0 C-N-CA 124.619 1.104 . . . . 2.15 114.809 162.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 21.7 mt . . . . . 0 N--CA 1.484 1.242 0 N-CA-C 115.474 1.657 . . . . 3.41 115.474 -155.556 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo . . . . . 0 N--CA 1.459 -0.553 0 CA-C-O 120.897 0.29 . . . . 2.31 111.477 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 5.2 pp0? -67.1 161.96 23.36 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 127.269 2.228 . . . . 2.87 113.257 175.29 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.26 -152.02 21.94 Favored Glycine 0 N--CA 1.472 1.053 0 C-N-CA 125.454 1.502 . . . . 1.55 115.457 -170.515 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -66.92 132.18 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 O-C-N 121.09 -1.241 . . . . 2.55 109.796 -176.384 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -72.39 64.49 0.59 Allowed 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 125.797 1.639 . . . . 3.43 112.435 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.35 -175.35 32.99 Favored Glycine 0 CA--C 1.527 0.784 0 C-N-CA 125.722 1.629 . . . . 2.06 112.402 -174.064 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 18.7 mm100 -106.92 154.94 20.33 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.222 -0.658 . . . . 3.73 109.222 145.371 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 24.0 ttt180 -70.89 107.54 4.08 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 108.673 -0.862 . . . . 5.09 108.673 169.823 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -76.81 -81.81 0.57 Allowed Glycine 0 N--CA 1.472 1.083 0 C-N-CA 124.696 1.141 . . . . 4.36 112.91 -159.662 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 2.6 m -150.59 152.16 11.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 C-N-CA 123.963 0.905 . . . . 2.52 108.647 -178.311 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 20.5 m -62.23 162.68 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 125.998 1.719 . . . . 2.51 113.633 -179.158 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.09 -160.47 3.75 Favored Glycine 0 CA--C 1.537 1.407 0 N-CA-C 111.431 -0.667 . . . . 2.36 111.431 155.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 94.2 mt -140.82 161.66 52.88 Favored Pre-proline 0 N--CA 1.474 0.738 0 CA-C-N 118.055 0.928 . . . . 3.44 111.017 178.02 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -86.52 -158.75 0.09 OUTLIER 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 123.968 3.112 . . . . 1.95 109.152 156.023 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.212 0 CA-C-O 117.239 -1.867 . . . . 3.0 112.546 148.642 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo . . . . . 0 CA--C 1.545 1.042 0 CA-C-O 119.454 -0.311 . . . . 2.33 111.39 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.18 -178.58 8.79 Favored Glycine 0 CA--C 1.541 1.711 0 O-C-N 121.108 -0.995 . . . . 1.34 112.382 128.253 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -74.73 -135.64 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.038 0 C-N-CA 124.789 3.659 . . . . 2.42 108.313 158.514 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 -86.71 -173.17 4.36 Favored 'General case' 0 CA--C 1.541 0.632 0 O-C-N 121.056 -1.027 . . . . 4.57 111.586 172.577 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.59 158.04 29.37 Favored Glycine 0 CA--C 1.534 1.266 0 O-C-N 121.514 -0.741 . . . . 1.11 112.097 159.689 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 88.2 mt -78.68 154.16 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.076 0 C-N-CA 124.344 1.058 . . . . 3.27 109.799 173.674 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.42 150.39 43.71 Favored 'General case' 0 CA--C 1.547 0.854 0 O-C-N 120.932 -1.105 . . . . 1.44 113.801 177.802 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -87.46 170.78 41.04 Favored Glycine 0 CA--C 1.526 0.771 0 C-N-CA 125.748 1.642 . . . . 1.93 114.286 -176.517 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -72.41 128.41 35.54 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.646 1.178 . . . . 4.63 111.927 -175.1 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -62.07 153.3 30.23 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 122.586 0.354 . . . . 5.62 111.667 179.266 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.39 158.61 26.69 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 124.209 0.909 . . . . 1.73 115.189 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 13.2 m -84.96 134.68 26.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 N-CA-C 113.645 0.98 . . . . 3.7 113.645 -178.524 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.6 m -88.85 162.02 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 126.151 1.781 . . . . 2.38 113.215 -164.206 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.92 -131.1 7.1 Favored Glycine 0 CA--C 1.529 0.945 0 C-N-CA 124.925 1.25 . . . . 1.83 113.468 177.386 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.0 pp -172.38 153.83 3.02 Favored Pre-proline 0 CA--C 1.543 0.675 0 C-N-CA 124.302 1.041 . . . . 3.64 112.043 -152.927 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo . . . . . 0 C--O 1.255 1.359 1 C-N-CA 125.429 4.086 . . . . 2.42 112.548 153.764 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo . . . . . 0 N--CA 1.488 1.181 0 CA-C-O 118.947 -0.522 . . . . 2.52 112.009 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -72.01 -133.98 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 123.761 2.974 . . . . 1.94 108.107 162.536 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.85 166.16 54.72 Favored Glycine 0 CA--C 1.539 1.578 0 CA-C-N 119.905 1.23 . . . . 1.2 111.107 163.29 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -81.87 -37.64 0.25 Allowed 'Trans proline' 0 CA--C 1.536 0.589 0 C-N-CA 122.919 2.412 . . . . 3.5 113.072 -179.456 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 6.8 tp-100 170.04 134.14 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 127.672 2.389 . . . . 1.37 107.117 -157.825 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -97.49 178.11 32.48 Favored Glycine 0 CA--C 1.528 0.872 0 C-N-CA 125.119 1.342 . . . . 0.97 113.027 167.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 17' ' ' ILE . . . . . 0.463 ' H ' HD12 ' C' ' 17' ' ' ILE . 3.4 mp -63.72 134.75 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 124.152 0.981 . . . . 2.55 111.486 -177.146 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.45 146.46 48.62 Favored 'General case' 0 CA--C 1.541 0.622 0 O-C-N 121.31 -0.869 . . . . 1.31 113.05 -178.582 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.28 87.42 0.5 Allowed Glycine 0 CA--C 1.527 0.788 0 C-N-CA 127.04 2.257 . . . . 2.59 112.748 -173.532 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -59.21 164.16 3.33 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 124.66 1.184 . . . . 5.07 113.444 -171.189 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 10.5 ttp-105 -46.19 127.75 8.98 Favored 'General case' 0 C--O 1.239 0.525 0 C-N-CA 124.771 1.229 . . . . 5.86 112.809 176.571 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.31 -174.24 8.49 Favored Glycine 0 CA--C 1.524 0.627 0 CA-C-N 113.134 -1.848 . . . . 1.49 113.306 175.647 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.9 t -63.65 143.63 15.44 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 C-N-CA 124.011 0.924 . . . . 1.88 110.237 175.869 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -89.78 -168.39 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.801 0 C-N-CA 125.787 1.635 . . . . 2.52 110.302 179.063 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.57 -168.49 2.3 Favored Glycine 0 CA--C 1.539 1.567 0 C-N-CA 124.133 0.873 . . . . 1.87 114.385 169.748 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 14.8 mt . . . . . 0 N--CA 1.483 1.189 0 C-N-CA 124.269 1.028 . . . . 3.45 113.703 176.956 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo . . . . . 0 N--CA 1.453 -0.91 0 N-CA-C 104.867 -2.782 . . . . 2.35 104.867 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 26.7 mm100 -70.76 172.18 9.22 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 125.708 1.603 . . . . 4.41 114.12 -164.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -61.46 145.53 48.68 Favored Glycine 0 C--N 1.335 0.483 0 N-CA-C 110.442 -1.063 . . . . 1.72 110.442 160.784 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.416 HG13 ' H ' ' A' ' 17' ' ' ILE . 2.7 mt -54.47 125.1 8.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 107.068 -1.456 . . . . 2.38 107.068 175.264 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -50.11 150.54 2.34 Favored 'General case' 0 CA--C 1.536 0.435 0 CA-C-O 121.773 0.797 . . . . 2.25 111.897 -176.397 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.81 167.27 34.39 Favored Glycine 0 CA--C 1.527 0.795 0 C-N-CA 124.461 1.029 . . . . 1.55 114.064 -173.139 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 13.5 mp0 -71.49 166.12 22.42 Favored 'General case' 0 CA--C 1.542 0.635 0 O-C-N 122.187 -0.596 . . . . 5.15 111.972 -175.703 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.8 tpt180 -68.05 132.69 47.71 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 113.94 1.089 . . . . 4.67 113.94 -162.261 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.78 93.07 1.36 Allowed Glycine 0 C--N 1.336 0.564 0 N-CA-C 109.786 -1.326 . . . . 1.81 109.786 170.769 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 28.5 m -58.22 140.62 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 123.76 0.824 . . . . 2.64 112.011 -176.439 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.7 t -50.99 142.96 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 126.26 1.824 . . . . 3.57 112.301 -170.777 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.82 148.28 50.36 Favored Glycine 0 N--CA 1.477 1.373 0 O-C-N 121.507 -0.746 . . . . 1.64 112.304 173.04 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -85.19 156.78 59.95 Favored Pre-proline 0 CA--C 1.541 0.609 0 CA-C-O 118.872 -0.585 . . . . 3.26 110.736 176.673 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.417 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 30.3 Cg_endo -85.38 -154.09 0.05 OUTLIER 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 123.517 2.811 . . . . 1.78 108.973 157.451 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.344 0 CA-C-O 117.631 -1.649 . . . . 3.09 113.437 148.89 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo . . . . . 0 N--CA 1.482 0.832 0 CA-C-O 119.379 -0.342 . . . . 3.5 112.799 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -79.78 136.83 17.8 Favored Glycine 0 CA--C 1.533 1.175 0 N-CA-C 110.216 -1.154 . . . . 1.31 110.216 157.017 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -76.6 177.23 9.09 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.988 2.459 . . . . 2.27 108.806 160.449 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -41.14 138.41 1.14 Allowed 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.318 1.447 . . . . 4.38 112.366 168.51 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -73.78 168.26 54.15 Favored Glycine 0 CA--C 1.526 0.756 0 C-N-CA 125.782 1.658 . . . . 1.05 115.248 -173.047 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 15.4 mm -61.79 140.14 19.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 CA-C-N 114.673 -0.764 . . . . 2.79 110.038 172.011 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.04 142.89 58.21 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 123.488 0.715 . . . . 1.76 111.531 173.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.38 -70.24 1.05 Allowed Glycine 0 N--CA 1.472 1.048 0 C-N-CA 123.934 0.778 . . . . 4.8 112.776 -168.399 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 178.48 -170.86 0.11 Allowed 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 128.376 2.67 . . . . 5.76 109.871 162.188 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 2.1 ttt-85 -117.96 152.0 36.34 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.452 1.101 . . . . 5.71 110.965 168.832 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.07 150.66 52.07 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 113.95 0.34 . . . . 1.97 113.95 -179.44 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 46.3 t -76.5 124.95 35.75 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.389 0 C-N-CA 123.409 0.684 . . . . 3.22 110.583 178.761 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.4 m -66.34 151.5 10.21 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 C-N-CA 125.451 1.501 . . . . 2.45 113.338 -167.563 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.73 -142.77 10.33 Favored Glycine 0 CA--C 1.527 0.805 0 C-N-CA 123.808 0.718 . . . . 1.76 112.659 169.274 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.417 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 3.2 pp -165.83 154.73 10.49 Favored Pre-proline 0 CA--C 1.54 0.584 0 C-N-CA 123.785 0.834 . . . . 3.31 112.249 -153.857 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo . . . . . 0 C--O 1.255 1.372 0 C-N-CA 125.3 4.0 . . . . 2.71 112.477 160.58 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo . . . . . 0 N--CA 1.484 0.916 0 CA-C-O 118.569 -0.68 . . . . 2.15 111.073 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -62.38 -151.05 0.02 OUTLIER 'Trans proline' 0 CA--C 1.544 0.984 1 C-N-CA 125.346 4.031 . . . . 1.75 111.998 159.201 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -104.97 167.26 15.01 Favored Glycine 0 CA--C 1.544 1.856 0 N-CA-C 116.954 1.541 . . . . 1.3 116.954 -170.116 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_endo -87.2 55.77 3.06 Favored 'Trans proline' 0 CA--C 1.543 0.942 1 C-N-CA 125.717 4.278 . . . . 3.76 113.145 -171.357 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 70.59 155.31 0.14 Allowed 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 125.467 1.507 . . . . 2.1 112.387 -176.389 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -101.93 176.72 26.15 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 126.68 2.086 . . . . 1.01 114.338 167.355 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 14.9 mt -72.82 126.92 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 O-C-N 121.126 -1.22 . . . . 3.58 112.177 -170.217 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -42.44 132.19 3.58 Favored 'General case' 0 CA--C 1.537 0.481 0 C-N-CA 125.399 1.48 . . . . 1.57 112.656 168.764 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.46 147.06 32.27 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 110.39 -1.084 . . . . 1.05 110.39 179.191 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -105.67 151.27 24.6 Favored 'General case' 0 C--N 1.327 -0.388 0 O-C-N 122.201 -0.587 . . . . 3.21 110.882 -173.901 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 12.1 ttp180 -54.71 134.55 47.44 Favored 'General case' 0 N--CA 1.447 -0.602 0 C-N-CA 123.347 0.659 . . . . 5.12 110.369 175.14 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.45 168.93 8.56 Favored Glycine 0 CA--C 1.528 0.846 0 C-N-CA 123.431 0.539 . . . . 1.01 113.094 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.3 t -61.2 143.42 14.9 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 O-C-N 122.039 -0.683 . . . . 1.71 110.162 174.356 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 3.3 p -85.32 176.03 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 C-N-CA 127.736 2.414 . . . . 2.5 110.426 -178.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.27 177.66 2.33 Favored Glycine 0 CA--C 1.54 1.651 0 CA-C-N 118.886 0.766 . . . . 1.82 113.405 161.77 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 17.9 mt . . . . . 0 C--O 1.253 1.246 0 N-CA-C 115.26 1.578 . . . . 3.38 115.26 -163.861 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo . . . . . 0 N--CA 1.455 -0.793 0 CA-C-O 121.433 0.514 . . . . 1.87 111.306 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -77.49 -177.12 4.56 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.848 1.659 . . . . 2.75 112.16 167.164 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.92 -177.82 40.19 Favored Glycine 0 CA--C 1.529 0.959 0 C-N-CA 123.89 0.757 . . . . 1.3 114.128 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 9.3 mt -67.82 133.59 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 O-C-N 121.911 -0.758 . . . . 2.04 109.795 -174.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.7 131.96 47.9 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 123.881 0.872 . . . . 1.82 110.874 172.281 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.27 152.85 51.13 Favored Glycine 0 CA--C 1.523 0.538 0 C-N-CA 126.405 1.955 . . . . 1.27 113.398 -173.831 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 82.2 mm-40 -74.77 134.65 41.8 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 115.139 -0.531 . . . . 3.8 110.589 -166.195 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 22.9 ttt180 -67.45 140.74 57.12 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-O 121.409 0.624 . . . . 5.21 112.355 -169.018 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -76.12 171.52 54.58 Favored Glycine 0 CA--C 1.522 0.525 0 C-N-CA 125.252 1.406 . . . . 1.47 115.068 -174.125 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 60.4 t -65.89 148.5 12.02 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 125.873 1.669 . . . . 2.98 109.456 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.8 m -51.84 154.7 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.757 0.823 . . . . 2.12 111.828 173.318 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -78.43 132.8 12.01 Favored Glycine 0 C--N 1.336 0.582 0 N-CA-C 107.777 -2.129 . . . . 2.17 107.777 158.146 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' LEU . . . . . 0.481 HD13 ' HE ' ' C' ' 21' ' ' ARG . 6.6 mp -87.95 -176.58 0.72 Allowed Pre-proline 0 C--N 1.323 -0.578 0 C-N-CA 122.746 0.418 . . . . 3.1 110.368 -174.487 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.563 ' C ' ' H ' ' C' ' 25' ' ' GLY . 85.3 Cg_endo -56.63 -166.66 0.02 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 120.244 0.629 . . . . 2.39 110.79 136.794 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.152 0 CA-C-O 118.019 -1.434 . . . . 5.61 115.543 167.085 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo . . . . . 0 N--CA 1.489 1.246 0 N-CA-C 108.972 -1.203 . . . . 2.53 108.972 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.3 148.76 44.54 Favored Glycine 0 CA--C 1.54 1.655 0 CA-C-O 118.697 -1.057 . . . . 1.28 111.01 164.429 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -76.97 169.08 22.3 Favored 'Trans proline' 0 CA--C 1.538 0.676 0 C-N-CA 124.189 3.26 . . . . 2.27 110.684 166.134 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -53.25 136.94 35.76 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 124.641 1.176 . . . . 4.06 111.273 172.432 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.01 161.38 37.11 Favored Glycine 0 CA--C 1.525 0.669 0 C-N-CA 124.501 1.048 . . . . 1.1 114.696 -170.362 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 32.3 pt -56.48 131.69 20.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 O-C-N 122.172 -0.605 . . . . 3.32 111.341 178.872 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.02 151.12 45.9 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-O 121.975 0.893 . . . . 1.47 113.198 -171.198 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -70.63 145.38 40.23 Favored Glycine 0 CA--C 1.526 0.759 0 C-N-CA 125.117 1.341 . . . . 1.84 110.712 173.27 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -123.06 159.28 28.79 Favored 'General case' 0 C--N 1.329 -0.295 0 O-C-N 121.634 -0.921 . . . . 2.68 110.81 178.068 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 3.2 ptt180 -54.96 159.75 2.24 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 115.585 1.698 . . . . 4.31 115.585 178.526 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.02 -119.18 0.08 OUTLIER Glycine 0 CA--C 1.535 1.307 0 C-N-CA 127.332 2.396 . . . . 2.94 114.187 -173.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 10.5 m -143.69 142.22 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 C-N-CA 124.701 1.201 . . . . 3.54 112.24 -176.328 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 22.6 m -83.1 161.18 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.151 0 C-N-CA 126.615 1.966 . . . . 2.35 115.679 -159.828 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.22 -126.11 4.85 Favored Glycine 0 CA--C 1.533 1.171 0 C-N-CA 126.22 1.867 . . . . 1.88 113.636 177.852 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.44 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.6 pt? -169.36 159.77 7.46 Favored Pre-proline 0 CA--C 1.554 1.12 0 N-CA-C 115.053 1.501 . . . . 3.58 115.053 -148.862 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo . . . . . 0 C--O 1.255 1.343 0 C-N-CA 123.558 2.839 . . . . 3.41 111.565 156.617 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_endo . . . . . 0 CA--C 1.546 1.124 0 CA-C-O 118.729 -0.613 . . . . 2.29 110.923 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -68.34 -155.16 0.03 OUTLIER 'Trans proline' 0 CA--C 1.546 1.093 0 C-N-CA 123.493 2.795 . . . . 1.7 109.618 157.018 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -100.61 -178.68 29.64 Favored Glycine 0 CA--C 1.534 1.251 0 C-N-CA 123.934 0.778 . . . . 1.25 112.775 172.088 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -75.35 164.83 32.0 Favored 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.446 2.764 . . . . 2.29 112.098 176.054 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -40.81 129.01 2.65 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.296 2.238 . . . . 1.63 113.451 163.226 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.98 152.77 52.71 Favored Glycine 0 CA--C 1.529 0.908 0 C-N-CA 124.641 1.115 . . . . 1.08 113.447 169.642 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 96.7 mt -56.73 148.5 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 124.4 1.08 . . . . 2.82 111.732 179.026 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -77.0 164.37 25.82 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 115.07 1.507 . . . . 1.49 115.07 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -84.7 168.92 44.22 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 124.968 1.27 . . . . 1.05 114.003 -174.401 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 8.9 mp0 -104.98 -179.22 3.88 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.177 1.391 . . . . 3.61 111.043 -166.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 21' ' ' ARG . . . . . 0.481 ' HE ' HD13 ' A' ' 26' ' ' LEU . 59.3 ttt180 -66.38 148.58 51.65 Favored 'General case' 0 N--CA 1.48 1.054 0 O-C-N 120.938 -1.102 . . . . 4.19 109.437 161.229 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -78.25 -173.58 42.03 Favored Glycine 0 CA--C 1.533 1.19 0 O-C-N 121.119 -0.988 . . . . 1.34 112.067 169.082 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 4.1 t -71.3 139.15 20.35 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 123.693 0.797 . . . . 1.94 109.123 176.551 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 16.0 m -71.47 173.6 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 C-N-CA 126.876 2.07 . . . . 2.82 112.65 176.425 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.563 ' H ' ' C ' ' A' ' 27' ' ' PRO . . . -53.26 172.42 0.52 Allowed Glycine 0 CA--C 1.538 1.509 0 C-N-CA 125.398 1.475 . . . . 1.74 115.895 158.323 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 7.1 mp . . . . . 0 C--O 1.252 1.212 0 C-N-CA 125.831 1.652 . . . . 3.98 114.761 -157.619 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo . . . . . 0 N--CA 1.459 -0.52 0 CA-C-O 120.924 0.302 . . . . 2.2 112.135 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.99 151.68 17.97 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 127.028 2.131 . . . . 4.18 111.567 167.441 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.11 -102.26 0.04 OUTLIER Glycine 0 N--CA 1.471 1.016 0 C-N-CA 125.112 1.339 . . . . 1.94 113.923 -179.355 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.9 mt -123.17 143.51 35.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 O-C-N 121.634 -0.921 . . . . 3.14 108.978 -177.231 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.57 53.05 0.21 Allowed 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 125.403 1.481 . . . . 3.7 111.97 170.056 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 86.11 -164.49 36.98 Favored Glycine 0 C--N 1.335 0.502 0 C-N-CA 127.813 2.625 . . . . 2.3 112.993 172.403 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 36.1 mm-40 -106.37 124.89 50.29 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 106.162 -1.792 . . . . 3.0 106.162 141.353 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 48.8 ttt85 -63.99 142.43 58.41 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.588 0.755 . . . . 4.59 110.84 -174.848 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.96 146.33 41.25 Favored Glycine 0 CA--C 1.523 0.59 0 C-N-CA 125.201 1.382 . . . . 1.56 112.272 -173.494 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 14.3 m -73.57 133.44 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 C-N-CA 124.83 1.252 . . . . 2.64 110.989 -174.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.4 p -50.77 147.75 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 C-N-CA 126.386 1.875 . . . . 3.33 114.973 -164.042 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -76.27 -179.95 47.34 Favored Glycine 0 CA--C 1.535 1.31 0 O-C-N 121.969 -0.457 . . . . 1.69 112.338 166.767 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.8 mt -143.97 158.01 56.55 Favored Pre-proline 0 N--CA 1.477 0.904 0 CA-C-O 118.175 -0.917 . . . . 3.72 112.399 -167.334 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -66.53 -173.45 0.37 Allowed 'Trans proline' 0 CA--C 1.537 0.653 0 C-N-CA 122.017 1.811 . . . . 2.3 110.188 158.119 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.271 0 CA-C-O 117.828 -1.54 . . . . 3.41 113.007 152.384 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo . . . . . 0 CA--C 1.541 0.861 0 CA-C-O 118.621 -0.658 . . . . 2.09 111.486 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -70.84 173.86 40.85 Favored Glycine 0 CA--C 1.54 1.606 0 CA-C-N 119.127 0.876 . . . . 1.38 111.885 143.226 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -71.17 163.03 40.57 Favored 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 123.707 2.938 . . . . 2.63 109.87 158.041 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -69.22 138.81 54.32 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 124.445 1.098 . . . . 3.63 111.901 179.707 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -57.63 142.79 42.94 Favored Glycine 0 C--N 1.342 0.887 0 C-N-CA 124.497 1.046 . . . . 1.21 114.195 -175.175 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 47.7 mm -73.61 142.72 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 123.893 0.877 . . . . 4.56 110.842 -177.214 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -52.17 139.11 24.37 Favored 'General case' 0 CA--C 1.544 0.717 0 N-CA-C 115.222 1.564 . . . . 1.58 115.222 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -66.32 141.87 41.74 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 126.096 1.807 . . . . 1.62 111.702 176.321 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 6.7 mp0 -79.74 151.85 30.16 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.194 0.598 . . . . 3.29 110.949 -173.388 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 12.7 mtt180 -60.76 150.12 33.51 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 118.857 0.753 . . . . 5.78 112.492 177.297 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.2 153.12 35.8 Favored Glycine 0 CA--C 1.531 1.065 0 CA-C-N 115.955 -0.566 . . . . 2.06 112.736 168.194 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 22.6 t -75.72 130.43 36.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 N-CA-C 112.613 0.598 . . . . 3.16 112.613 -164.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 m -60.03 157.62 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 N-CA-C 115.41 1.633 . . . . 2.78 115.41 -163.367 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.14 -178.07 45.95 Favored Glycine 0 C--N 1.338 0.652 0 C-N-CA 125.696 1.617 . . . . 1.77 115.548 -167.234 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.7 mp -134.97 130.9 19.68 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 123.78 0.832 . . . . 4.89 112.287 -170.444 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo . . . . . 0 C--O 1.256 1.383 0 C-N-CA 123.826 3.017 . . . . 2.67 112.017 146.947 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo . . . . . 0 N--CA 1.489 1.208 0 CA-C-O 118.73 -0.613 . . . . 2.43 111.511 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.93 -126.63 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.943 0 C-N-CA 124.246 3.298 . . . . 1.86 108.461 167.779 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -83.47 148.05 24.79 Favored Glycine 0 CA--C 1.538 1.515 0 CA-C-N 119.229 0.922 . . . . 1.22 112.522 172.498 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -74.18 96.76 0.97 Allowed 'Trans proline' 0 N--CA 1.456 -0.703 0 C-N-CA 123.285 2.656 . . . . 2.96 109.329 172.192 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.455 ' HG3' ' H ' ' C' ' 16' ' ' GLY . 16.5 tp60 59.1 -126.27 1.31 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.176 0.99 . . . . 2.98 109.239 179.819 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' C' C ' 16' ' ' GLY . . . . . 0.455 ' H ' ' HG3' ' C' ' 15' ' ' GLN . . . 174.25 161.78 24.79 Favored Glycine 0 CA--C 1.535 1.33 1 C-N-CA 132.048 4.642 . . . . 1.15 108.763 -179.769 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' C' C ' 17' ' ' ILE . . . . . 0.426 ' H ' HD12 ' C' ' 17' ' ' ILE . 3.7 mp -66.69 145.58 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 CA-C-N 119.34 1.57 . . . . 3.02 110.984 -177.576 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -78.56 145.93 34.54 Favored 'General case' 0 CA--C 1.545 0.765 0 O-C-N 120.915 -1.116 . . . . 1.58 113.024 178.311 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -88.84 161.08 30.45 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 125.305 1.431 . . . . 1.25 113.15 -179.603 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 58.7 mt-30 -87.2 160.28 18.54 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 123.95 0.9 . . . . 4.31 113.129 -174.539 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.24 138.42 45.09 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 109.511 -0.552 . . . . 3.62 109.511 163.413 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.9 165.73 52.68 Favored Glycine 0 CA--C 1.523 0.534 0 C-N-CA 123.728 0.68 . . . . 1.02 113.005 -177.096 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 91.2 t -63.67 138.33 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 C-N-CA 123.765 0.826 . . . . 1.78 108.899 173.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 25.6 m -101.89 -175.79 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.802 0 C-N-CA 125.139 1.376 . . . . 3.12 111.057 -177.831 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -58.96 173.75 3.57 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 124.582 1.087 . . . . 1.86 114.744 171.731 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 22.7 mt . . . . . 0 C--O 1.25 1.102 0 C-N-CA 125.261 1.425 . . . . 3.07 114.434 -168.297 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo . . . . . 0 N--CA 1.458 -0.6 0 CA-C-O 121.306 0.461 . . . . 1.9 111.535 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.43 169.28 16.7 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 127.35 2.26 . . . . 3.13 113.039 170.417 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.84 -174.98 40.8 Favored Glycine 0 CA--C 1.528 0.848 0 C-N-CA 125.21 1.386 . . . . 1.2 113.006 169.619 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 14.6 pt -74.18 155.3 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 O-C-N 121.754 -0.851 . . . . 2.7 111.096 -173.626 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -57.81 139.84 53.13 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.421 0.688 . . . . 1.84 111.597 172.727 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -57.56 150.65 30.27 Favored Glycine 0 CA--C 1.518 0.244 0 C-N-CA 127.259 2.361 . . . . 1.27 113.492 172.592 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 10.4 mm100 -64.93 118.26 8.8 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 114.716 -0.742 . . . . 3.75 109.194 -178.076 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.8 ttp180 -58.97 139.67 56.48 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 113.013 0.746 . . . . 4.34 113.013 -170.137 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.04 158.47 53.18 Favored Glycine 0 CA--C 1.519 0.331 0 C-N-CA 125.165 1.364 . . . . 1.54 113.38 -169.436 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 33.3 m -68.13 150.22 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-N 114.858 -0.671 . . . . 2.44 110.72 -175.318 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.5 m -51.05 147.8 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 124.192 0.997 . . . . 1.99 111.883 173.785 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.77 133.44 19.07 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 109.627 -1.389 . . . . 1.76 109.627 162.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 9.5 mp -77.18 169.92 18.84 Favored Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 122.882 0.473 . . . . 2.98 110.823 177.493 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.463 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 97.7 Cg_endo -77.17 -148.08 0.03 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 121.843 1.695 . . . . 2.02 108.277 154.338 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 1.41 0 CA-C-O 117.365 -1.797 . . . . 3.9 112.98 151.723 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo . . . . . 0 N--CA 1.484 0.938 0 CA-C-O 118.554 -0.686 . . . . 2.07 111.363 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.14 150.46 50.44 Favored Glycine 0 CA--C 1.546 1.994 0 CA-C-O 118.849 -0.973 . . . . 1.55 111.947 157.844 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -76.74 44.31 1.4 Allowed 'Trans proline' 0 CA--C 1.547 1.148 1 C-N-CA 126.986 5.124 . . . . 3.24 114.127 -172.662 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.1 tp-100 73.19 -175.44 0.16 Allowed 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 125.132 1.373 . . . . 4.95 109.606 -163.476 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -94.4 170.26 29.73 Favored Glycine 0 N--CA 1.473 1.126 0 O-C-N 121.091 -1.006 . . . . 1.16 113.12 166.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 50.1 mt -72.85 125.63 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 C-N-CA 123.564 0.746 . . . . 3.08 110.967 -176.438 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.82 143.75 57.72 Favored 'General case' 0 CA--C 1.545 0.762 0 O-C-N 121.203 -0.935 . . . . 1.48 113.253 -178.894 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.43 171.24 55.16 Favored Glycine 0 CA--C 1.529 0.919 0 C-N-CA 125.656 1.598 . . . . 1.74 113.578 -177.726 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -135.34 156.19 49.34 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 125.415 1.486 . . . . 2.97 110.224 -172.269 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.8 ptt-85 -71.99 152.5 42.43 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 114.747 1.388 . . . . 6.41 114.747 -172.48 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.23 176.99 54.53 Favored Glycine 0 CA--C 1.536 1.36 0 C-N-CA 125.317 1.437 . . . . 1.77 113.763 176.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 46.9 t -83.3 142.02 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 124.854 1.261 . . . . 3.11 112.98 -164.867 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 20.1 m -76.08 163.54 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 126.769 2.028 . . . . 2.43 114.323 -165.612 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -96.27 -127.03 5.3 Favored Glycine 0 CA--C 1.53 1.013 0 C-N-CA 125.107 1.337 . . . . 2.23 113.567 176.054 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.463 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 3.8 pp -171.82 159.04 4.6 Favored Pre-proline 0 CA--C 1.547 0.854 0 C-N-CA 125.769 1.627 . . . . 4.67 111.72 -156.529 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_endo . . . . . 0 C--O 1.256 1.383 0 C-N-CA 123.978 3.119 . . . . 3.23 111.767 153.807 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo . . . . . 0 N--CA 1.487 1.1 0 CA-C-O 119.181 -0.425 . . . . 1.98 111.627 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -71.54 -138.43 0.02 OUTLIER 'Trans proline' 0 CA--C 1.545 1.034 0 C-N-CA 123.317 2.678 . . . . 1.66 108.672 165.075 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -90.21 170.21 35.61 Favored Glycine 0 CA--C 1.538 1.52 0 N-CA-C 110.593 -1.003 . . . . 1.32 110.593 165.112 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.07 -58.63 0.04 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.4 2.067 . . . . 3.82 110.705 173.029 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -174.88 133.51 0.34 Allowed 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 126.316 1.846 . . . . 1.28 106.292 -148.04 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.38 160.52 43.98 Favored Glycine 0 CA--C 1.523 0.575 0 C-N-CA 123.649 0.642 . . . . 1.0 111.658 170.216 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 37.1 mm -66.11 144.08 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 O-C-N 121.817 -0.813 . . . . 3.49 110.089 174.638 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.05 161.18 5.33 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 114.505 1.298 . . . . 1.19 114.505 177.881 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.44 170.46 52.22 Favored Glycine 0 CA--C 1.528 0.877 0 C-N-CA 124.562 1.077 . . . . 1.21 113.298 179.22 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 8.7 mp0 -95.64 177.88 5.65 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 124.339 1.056 . . . . 4.41 112.064 -168.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 14.6 ttt85 -72.87 141.25 47.93 Favored 'General case' 0 N--CA 1.473 0.692 0 O-C-N 120.369 -1.457 . . . . 3.5 110.329 167.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.95 173.69 34.53 Favored Glycine 0 CA--C 1.534 1.263 0 O-C-N 121.731 -0.606 . . . . 1.32 112.111 167.343 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.2 t -69.94 141.66 16.87 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.657 0 C-N-CA 124.409 1.084 . . . . 1.89 109.636 179.483 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 10.9 m -74.81 178.88 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 C-N-CA 124.432 1.093 . . . . 2.57 111.377 175.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.37 -171.68 0.94 Allowed Glycine 0 CA--C 1.538 1.489 0 C-N-CA 124.735 1.16 . . . . 1.68 114.193 162.84 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 15.5 mt . . . . . 0 N--CA 1.481 1.088 0 CA-C-O 117.199 -1.381 . . . . 3.58 113.719 -168.858 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo . . . . . 0 CA--C 1.535 0.543 0 CA-C-O 120.838 0.266 . . . . 2.69 111.982 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -78.91 176.96 9.13 Favored 'General case' 0 CA--C 1.553 1.092 0 C-N-CA 129.842 3.257 . . . . 3.7 111.563 -178.044 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -90.85 -172.93 43.97 Favored Glycine 0 N--CA 1.478 1.45 0 C-N-CA 125.189 1.376 . . . . 1.76 113.66 176.601 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.6 mm -76.45 134.96 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 N-CA-C 108.27 -1.011 . . . . 3.72 108.27 174.217 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.22 71.16 0.26 Allowed 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.074 1.35 . . . . 4.43 111.561 172.271 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 63.98 -146.52 50.4 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 125.021 1.296 . . . . 2.47 111.495 -169.262 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -142.9 128.7 19.37 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 106.269 -1.752 . . . . 5.48 106.269 150.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -53.02 126.92 22.17 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 118.769 0.713 . . . . 5.81 109.725 -177.362 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.46 -83.59 0.26 Allowed Glycine 0 N--CA 1.471 1.017 0 O-C-N 123.407 0.442 . . . . 3.18 112.088 -165.677 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -148.92 153.94 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 124.562 1.145 . . . . 2.06 112.161 175.813 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.5 m -65.87 161.52 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 C-N-CA 123.972 0.909 . . . . 2.99 111.233 168.196 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -76.24 174.07 53.62 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 123.585 0.612 . . . . 1.39 112.505 168.184 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -101.67 159.82 28.32 Favored Pre-proline 0 CA--C 1.542 0.663 0 C-N-CA 124.352 1.061 . . . . 3.14 110.854 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_endo -78.77 -166.67 0.42 Allowed 'Trans proline' 0 CA--C 1.537 0.675 0 C-N-CA 123.326 2.684 . . . . 2.19 109.324 157.663 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.274 0 CA-C-O 117.834 -1.537 . . . . 3.51 112.826 154.858 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_exo . . . . . 0 CA--C 1.542 0.921 0 N-CA-C 110.308 -0.689 . . . . 2.96 110.308 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.41 -167.91 2.73 Favored Glycine 0 CA--C 1.545 1.958 0 C-N-CA 119.659 -1.257 . . . . 2.16 112.033 124.763 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_endo -89.51 -138.97 0.02 OUTLIER 'Trans proline' 0 CA--C 1.546 1.077 0 C-N-CA 125.004 3.802 . . . . 2.86 109.287 175.955 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.82 138.57 32.44 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 127.288 2.235 . . . . 4.0 107.14 162.951 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -59.27 131.96 51.84 Favored Glycine 0 N--CA 1.468 0.807 0 N-CA-C 111.264 -0.734 . . . . 1.9 111.264 174.188 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 32.2 mm -60.56 150.37 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 O-C-N 122.334 -0.509 . . . . 5.87 110.982 175.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.57 137.5 58.25 Favored 'General case' 0 CA--C 1.55 0.952 0 O-C-N 120.7 -1.25 . . . . 3.01 114.315 176.971 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -93.13 -162.6 36.69 Favored Glycine 0 CA--C 1.533 1.196 0 C-N-CA 125.79 1.662 . . . . 2.9 112.211 171.123 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -157.73 174.31 15.51 Favored 'General case' 0 CA--C 1.537 0.442 0 O-C-N 121.064 -1.257 . . . . 3.98 113.944 -173.282 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 8.4 ptt180 -58.11 158.46 6.87 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 115.656 1.724 . . . . 4.54 115.656 172.698 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.17 -161.41 35.36 Favored Glycine 0 CA--C 1.535 1.29 0 C-N-CA 125.462 1.506 . . . . 2.34 111.499 162.283 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 43.8 t -120.3 145.21 26.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.041 0 C-N-CA 124.557 1.143 . . . . 4.62 112.528 -159.825 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 14.9 p -56.03 159.03 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 128.834 2.854 . . . . 3.72 114.359 -178.548 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.93 -126.7 1.08 Allowed Glycine 0 CA--C 1.53 1.023 0 C-N-CA 124.535 1.064 . . . . 2.23 111.204 166.218 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -167.26 162.76 10.37 Favored Pre-proline 0 CA--C 1.542 0.646 0 C-N-CA 125.343 1.457 . . . . 3.85 110.867 -166.74 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_endo . . . . . 0 CA--C 1.552 1.386 0 C-N-CA 124.47 3.447 . . . . 3.29 112.15 165.844 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 67.2 Cg_endo . . . . . 0 N--CA 1.487 1.122 0 CA-C-O 118.339 -0.775 . . . . 3.23 111.233 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -62.32 -152.38 0.02 OUTLIER 'Trans proline' 0 CA--C 1.542 0.924 0 C-N-CA 124.91 3.74 . . . . 2.5 111.696 163.899 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.39 168.66 54.4 Favored Glycine 0 CA--C 1.541 1.712 0 N-CA-C 109.985 -1.246 . . . . 1.56 109.985 163.39 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -76.64 176.65 9.83 Favored 'Trans proline' 0 N--CA 1.452 -0.941 0 C-N-CA 123.142 2.561 . . . . 2.66 110.681 170.854 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 9.5 tp60 -40.38 122.24 1.55 Allowed 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.279 1.432 . . . . 1.6 111.217 148.113 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.94 -169.37 27.54 Favored Glycine 0 CA--C 1.527 0.795 0 CA-C-O 121.993 0.774 . . . . 1.52 112.731 169.021 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 18.9 mt -63.82 124.33 18.33 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 O-C-N 121.638 -0.919 . . . . 2.87 110.833 175.388 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -65.52 155.85 34.4 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.582 1.153 . . . . 1.36 113.135 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -80.83 -179.24 52.87 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-O 123.23 1.461 . . . . 1.65 111.672 176.289 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.82 -160.48 1.03 Allowed 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.749 1.22 . . . . 3.25 109.149 178.309 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -85.19 152.46 23.33 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.892 1.277 . . . . 5.72 112.342 -179.181 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.26 176.85 43.88 Favored Glycine 0 CA--C 1.533 1.192 0 N-CA-C 111.03 -0.828 . . . . 1.01 111.03 164.955 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.0 t -59.84 149.39 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 124.042 0.937 . . . . 2.24 110.178 174.28 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 26.9 m -80.83 -173.34 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 C-N-CA 123.866 0.866 . . . . 2.65 111.079 173.227 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -55.98 160.12 7.27 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 124.154 0.883 . . . . 2.04 114.162 173.909 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 5.3 mt . . . . . 0 C--O 1.25 1.104 0 N-CA-C 114.246 1.202 . . . . 4.07 114.246 -163.079 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo . . . . . 0 N--CA 1.459 -0.533 0 N-CA-C 110.924 -0.452 . . . . 2.25 110.924 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 41.4 tp60 -48.65 151.76 1.09 Allowed 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 127.747 2.419 . . . . 4.14 114.866 -179.69 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.26 176.59 52.9 Favored Glycine 0 N--CA 1.465 0.618 0 C-N-CA 124.676 1.132 . . . . 1.27 115.199 173.957 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 14.4 mt -66.29 134.71 29.56 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 125.107 1.363 . . . . 2.34 110.568 -176.325 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.99 137.35 55.78 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 123.943 0.897 . . . . 1.99 112.267 175.313 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -66.72 157.76 50.33 Favored Glycine 0 CA--C 1.528 0.851 0 C-N-CA 125.485 1.517 . . . . 1.26 113.934 -176.507 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 53.1 mm-40 -62.5 128.98 38.56 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 114.738 -0.731 . . . . 3.36 109.668 -179.169 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 14.8 ttt180 -70.47 143.28 51.79 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 112.291 0.478 . . . . 4.73 112.291 -164.828 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -76.85 138.18 21.79 Favored Glycine 0 CA--C 1.522 0.528 0 C-N-CA 123.844 0.735 . . . . 1.93 111.414 -178.144 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 33.2 m -66.89 162.41 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 124.538 1.135 . . . . 2.24 112.493 -174.628 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.1 m -54.76 160.64 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 C-N-CA 124.527 1.131 . . . . 2.33 112.965 174.373 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.56 168.41 39.2 Favored Glycine 0 CA--C 1.527 0.817 0 CA-C-N 115.448 -0.796 . . . . 1.44 113.285 164.716 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 8.6 mp -99.46 156.63 35.19 Favored Pre-proline 0 CA--C 1.541 0.598 0 C-N-CA 124.004 0.922 . . . . 4.45 109.659 176.835 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -84.58 -164.32 0.24 Allowed 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 123.541 2.827 . . . . 2.55 109.163 162.449 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.239 0 CA-C-O 117.77 -1.572 . . . . 3.64 112.812 158.151 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_exo . . . . . 0 CA--C 1.544 0.998 0 CA-C-O 119.095 -0.46 . . . . 2.77 111.724 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.84 164.46 27.15 Favored Glycine 0 CA--C 1.542 1.752 0 CA-C-N 119.676 1.126 . . . . 1.44 113.153 138.975 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -80.69 63.58 8.79 Favored 'Trans proline' 0 CA--C 1.541 0.827 1 C-N-CA 126.176 4.584 . . . . 3.41 111.278 -179.58 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 22.8 tp60 67.85 173.04 0.27 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.188 1.395 . . . . 4.28 111.698 -172.625 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.15 160.33 29.48 Favored Glycine 0 CA--C 1.531 1.039 0 O-C-N 120.734 -1.229 . . . . 1.05 111.925 155.783 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 48.9 mm -74.65 129.94 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 O-C-N 121.708 -0.878 . . . . 3.18 109.955 176.195 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.73 149.23 50.83 Favored 'General case' 0 CA--C 1.544 0.734 0 N-CA-C 113.945 1.091 . . . . 1.52 113.945 -179.116 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.97 151.74 47.78 Favored Glycine 0 CA--C 1.531 1.073 0 C-N-CA 123.843 0.735 . . . . 1.47 111.557 177.299 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -109.17 156.85 19.38 Favored 'General case' 0 N--CA 1.465 0.307 0 O-C-N 121.644 -0.915 . . . . 2.71 111.649 175.287 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 6.5 ptt180 -64.32 158.31 23.82 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.426 1.89 . . . . 4.97 114.463 178.42 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -90.67 -167.69 41.78 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 126.275 1.893 . . . . 1.92 112.729 170.606 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 11.8 m -100.77 146.52 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 N-CA-C 115.849 1.796 . . . . 3.33 115.849 -162.329 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.6 p -46.35 153.67 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 128.888 2.875 . . . . 3.84 114.938 -178.664 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.33 -127.92 1.09 Allowed Glycine 0 CA--C 1.528 0.893 0 C-N-CA 123.714 0.673 . . . . 2.51 112.165 169.57 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.0 pp -162.67 151.57 12.56 Favored Pre-proline 0 CA--C 1.543 0.675 0 C-N-CA 124.141 0.976 . . . . 4.78 112.135 -164.64 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo . . . . . 0 C--O 1.255 1.367 1 C-N-CA 125.375 4.05 . . . . 3.17 112.397 162.306 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo . . . . . 0 CA--C 1.547 1.153 0 CA-C-O 119.107 -0.455 . . . . 1.88 112.046 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -62.58 -166.81 0.06 OUTLIER 'Trans proline' 0 CA--C 1.54 0.8 0 C-N-CA 124.096 3.197 . . . . 1.59 111.737 166.488 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.53 143.83 34.65 Favored Glycine 0 CA--C 1.54 1.629 0 O-C-N 121.124 -0.985 . . . . 1.03 113.108 -171.753 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -78.52 61.08 7.82 Favored 'Trans proline' 0 CA--C 1.54 0.82 0 C-N-CA 124.847 3.698 . . . . 3.19 112.196 -174.914 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 40.6 tp60 75.66 145.4 0.08 Allowed 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 126.543 1.937 . . . . 2.39 113.643 169.314 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.95 148.57 24.65 Favored Glycine 0 CA--C 1.528 0.848 0 O-C-N 120.875 -1.141 . . . . 1.1 112.838 169.397 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 38.3 mm -65.78 148.08 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 O-C-N 122.201 -0.588 . . . . 3.33 110.786 174.774 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.53 151.76 43.64 Favored 'General case' 0 CA--C 1.543 0.675 0 N-CA-C 113.093 0.775 . . . . 1.12 113.093 176.601 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.76 155.25 35.07 Favored Glycine 0 CA--C 1.529 0.957 0 CA-C-O 122.449 1.027 . . . . 0.95 112.342 174.878 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 18.2 mp0 -91.96 178.27 5.94 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 124.988 1.315 . . . . 3.16 110.556 -179.513 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 15.5 ptp180 -71.11 162.02 30.13 Favored 'General case' 0 N--CA 1.475 0.791 0 O-C-N 121.112 -0.992 . . . . 6.29 112.85 176.931 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.55 -171.82 42.26 Favored Glycine 0 CA--C 1.535 1.327 0 C-N-CA 124.023 0.821 . . . . 1.41 112.876 174.867 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 47.2 t -68.4 139.9 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 124.374 1.069 . . . . 2.05 110.699 -178.721 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 27.8 m -81.68 -176.1 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.705 1.202 . . . . 2.89 111.751 -176.957 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.56 161.82 15.85 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 123.91 0.767 . . . . 1.72 113.707 173.362 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 9.4 mt . . . . . 0 C--O 1.249 1.059 0 N-CA-C 114.717 1.377 . . . . 3.68 114.717 -164.717 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo . . . . . 0 CA--C 1.538 0.686 0 N-CA-C 110.38 -0.661 . . . . 3.47 110.38 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.409 ' HA ' ' HD2' ' B' ' 14' ' ' PRO . 0.0 OUTLIER -86.55 -143.77 0.11 Allowed 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 125.288 1.435 . . . . 2.57 111.073 169.32 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -82.98 -127.91 1.22 Allowed Glycine 0 N--CA 1.472 1.062 0 C-N-CA 125.611 1.577 . . . . 1.18 112.753 170.761 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 10.2 mm -111.59 160.17 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.071 0 C-N-CA 124.504 1.122 . . . . 3.58 110.861 -176.466 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -78.78 81.61 5.07 Favored 'General case' 0 CA--C 1.546 0.807 0 O-C-N 120.47 -1.394 . . . . 3.72 110.237 164.438 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.59 -170.35 42.92 Favored Glycine 0 N--CA 1.466 0.644 0 C-N-CA 126.418 1.961 . . . . 3.08 113.397 -172.288 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -94.39 119.64 33.43 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 105.856 -1.905 . . . . 6.55 105.856 127.773 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 35.7 ttm180 -62.42 136.36 57.87 Favored 'General case' 0 CA--C 1.534 0.361 0 O-C-N 121.109 -0.994 . . . . 5.57 111.377 -178.986 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.32 170.43 53.53 Favored Glycine 0 N--CA 1.465 0.583 0 C-N-CA 125.021 1.296 . . . . 1.9 113.831 -178.082 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.1 m -87.55 156.93 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 CA-C-N 114.043 -1.078 . . . . 2.71 111.614 -175.823 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.1 m -57.16 147.71 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.442 1.097 . . . . 2.59 112.388 -178.807 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -74.44 169.44 54.13 Favored Glycine 0 CA--C 1.529 0.928 0 N-CA-C 110.362 -1.095 . . . . 1.89 110.362 157.773 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 24.0 mt -116.18 172.09 4.1 Favored Pre-proline 0 N--CA 1.471 0.614 0 O-C-N 122.149 -0.618 . . . . 4.5 111.794 170.74 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.433 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 47.4 Cg_endo -69.78 -153.59 0.03 OUTLIER 'Trans proline' 0 CA--C 1.536 0.616 0 C-N-CA 122.717 2.278 . . . . 2.43 108.884 148.029 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.301 0 CA-C-O 116.971 -2.016 . . . . 3.82 113.106 159.693 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo . . . . . 0 N--CA 1.491 1.356 0 N-CA-C 108.774 -1.279 . . . . 3.52 108.774 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.16 147.95 51.16 Favored Glycine 0 CA--C 1.549 2.219 0 CA-C-O 118.27 -1.295 . . . . 2.36 110.635 157.879 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 14' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 15' ' ' GLN . 87.5 Cg_endo -83.42 -51.41 0.04 OUTLIER 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 124.229 3.286 . . . . 3.42 112.874 -173.969 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -170.66 -178.99 2.76 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 128.15 2.58 . . . . 4.9 108.358 178.284 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -98.74 157.57 20.24 Favored Glycine 0 CA--C 1.528 0.857 0 CA-C-O 122.16 0.867 . . . . 1.73 113.739 177.744 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.515 ' H ' HD12 ' B' ' 17' ' ' ILE . 3.5 mp -72.71 157.27 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 124.204 1.002 . . . . 3.17 109.096 175.37 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.41 127.75 32.99 Favored 'General case' 0 CA--C 1.545 0.78 0 O-C-N 120.647 -1.283 . . . . 2.68 112.507 170.125 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -86.59 171.63 43.69 Favored Glycine 0 C--N 1.339 0.7 0 C-N-CA 125.178 1.37 . . . . 2.31 112.608 177.09 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -104.94 147.35 27.87 Favored 'General case' 0 N--CA 1.462 0.174 0 O-C-N 121.855 -0.791 . . . . 2.94 111.259 -179.068 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 6.6 ptt180 -67.99 155.74 38.83 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.167 -0.47 . . . . 4.41 110.796 158.002 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.17 -172.83 43.18 Favored Glycine 0 CA--C 1.533 1.212 0 C-N-CA 123.946 0.784 . . . . 1.93 113.066 178.255 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 15.3 m -93.67 145.59 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 N-CA-C 116.012 1.856 . . . . 3.66 116.012 -155.841 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.8 m -85.84 155.02 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.916 1.687 . . . . 2.6 112.888 -171.373 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.73 -134.15 8.13 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 124.637 1.113 . . . . 1.67 113.25 175.203 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.433 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.4 pt? -168.56 163.38 8.26 Favored Pre-proline 0 CA--C 1.551 0.988 0 C-N-CA 126.323 1.849 . . . . 3.47 111.028 -163.475 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo . . . . . 0 C--O 1.255 1.346 0 C-N-CA 124.383 3.389 . . . . 2.49 111.502 159.184 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo . . . . . 0 N--CA 1.486 1.043 0 CA-C-O 118.819 -0.575 . . . . 3.27 111.987 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -64.29 -166.83 0.08 OUTLIER 'Trans proline' 0 CA--C 1.54 0.796 0 C-N-CA 123.616 2.878 . . . . 2.52 110.233 159.413 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -89.87 174.95 41.4 Favored Glycine 0 CA--C 1.534 1.26 0 C-N-CA 124.005 0.812 . . . . 1.49 112.589 175.338 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -70.59 169.31 20.27 Favored 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 123.03 2.487 . . . . 2.47 111.941 170.527 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 26.3 tp60 -34.67 146.28 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 129.066 2.947 . . . . 1.92 114.673 168.601 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.7 171.22 41.13 Favored Glycine 0 CA--C 1.525 0.672 0 C-N-CA 123.427 0.537 . . . . 1.9 112.631 168.346 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' C' C ' 17' ' ' ILE . . . . . 0.612 ' H ' HD12 ' C' ' 17' ' ' ILE . 3.3 mp -59.21 130.48 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 123.157 0.583 . . . . 3.3 110.489 178.089 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.32 143.56 50.24 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 125.574 1.55 . . . . 2.34 114.797 -170.514 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -85.16 145.91 21.64 Favored Glycine 0 C--N 1.339 0.736 0 N-CA-C 109.664 -1.374 . . . . 1.56 109.664 171.706 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 5.7 mp0 -85.83 -169.67 2.75 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 123.941 0.896 . . . . 3.42 110.503 179.894 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 16.2 ttt180 -64.88 145.11 56.74 Favored 'General case' 0 N--CA 1.467 0.421 0 O-C-N 121.172 -0.955 . . . . 4.57 109.49 156.297 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.17 162.35 36.19 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 111.414 -0.674 . . . . 1.26 111.414 161.94 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.57 140.15 20.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 C-N-CA 123.445 0.698 . . . . 2.41 109.796 176.221 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 13.4 p -79.67 178.9 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 C-N-CA 127.041 2.136 . . . . 4.12 110.872 178.479 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.34 179.36 2.62 Favored Glycine 0 CA--C 1.537 1.41 0 C-N-CA 124.553 1.073 . . . . 2.28 114.735 169.155 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 10.0 mp . . . . . 0 C--O 1.249 1.078 0 C-N-CA 126.001 1.72 . . . . 3.87 113.296 -162.571 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo . . . . . 0 N--CA 1.459 -0.524 0 N-CA-C 111.318 -0.301 . . . . 1.75 111.318 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -58.58 166.69 1.71 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.774 2.029 . . . . 3.33 114.041 168.871 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.59 -118.45 0.03 OUTLIER Glycine 0 N--CA 1.475 1.287 0 C-N-CA 127.452 2.453 . . . . 2.23 115.798 -176.652 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.2 mp -120.07 137.01 55.3 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 O-C-N 120.916 -1.344 . . . . 2.47 108.874 -179.824 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -52.17 128.41 24.8 Favored 'General case' 0 CA--C 1.542 0.651 0 CA-C-N 118.275 0.489 . . . . 1.9 110.706 170.135 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -62.34 156.7 37.93 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 125.777 1.656 . . . . 1.26 113.713 -177.076 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.9 mm-40 -73.0 116.34 13.39 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 108.734 -0.839 . . . . 3.33 108.734 -171.929 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 7.4 ttt180 -64.22 140.58 58.88 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 122.72 0.408 . . . . 5.14 112.029 -163.283 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.67 158.17 53.62 Favored Glycine 0 C--N 1.335 0.502 0 C-N-CA 123.926 0.774 . . . . 1.77 111.908 -179.644 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 33.3 m -75.97 160.99 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 CA-C-N 115.084 -0.558 . . . . 2.73 111.606 -174.636 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.1 m -51.98 164.76 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 125.531 1.532 . . . . 2.61 112.857 177.283 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.56 124.45 29.26 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.989 -0.844 . . . . 2.06 110.989 163.421 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 9.5 mp -82.31 170.92 13.2 Favored Pre-proline 0 CA--C 1.533 0.321 0 C-N-CA 124.493 1.117 . . . . 3.74 110.856 175.479 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -60.0 -165.77 0.03 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 121.77 1.647 . . . . 3.42 110.821 152.135 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.667 0 CA-C-O 118.647 -1.085 . . . . 6.19 114.984 160.141 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo . . . . . 0 N--CA 1.481 0.776 0 CA-C-O 118.551 -0.687 . . . . 2.1 111.694 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.29 161.44 48.0 Favored Glycine 0 CA--C 1.54 1.628 0 CA-C-O 119.078 -0.845 . . . . 1.26 111.669 152.709 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -76.0 163.68 32.75 Favored 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 124.235 3.29 . . . . 2.47 110.641 165.797 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -53.94 140.17 31.74 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.761 1.224 . . . . 4.27 111.79 170.948 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.23 161.67 53.24 Favored Glycine 0 CA--C 1.529 0.912 0 C-N-CA 124.167 0.889 . . . . 1.42 114.421 -174.512 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 35.6 mm -60.78 119.32 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 O-C-N 121.542 -0.975 . . . . 2.9 111.086 -175.772 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.76 155.04 27.78 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 114.492 1.293 . . . . 1.59 114.492 -172.176 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.24 136.7 28.68 Favored Glycine 0 CA--C 1.527 0.809 0 C-N-CA 126.3 1.905 . . . . 1.62 111.391 -179.534 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -106.3 143.62 34.16 Favored 'General case' 0 N--CA 1.465 0.323 0 O-C-N 121.633 -0.922 . . . . 3.2 110.133 -172.415 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 32.0 ptt180 -72.22 157.6 37.43 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.344 1.058 . . . . 4.41 112.997 175.823 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.86 -174.95 26.77 Favored Glycine 0 CA--C 1.539 1.534 0 N-CA-C 117.061 1.584 . . . . 2.27 117.061 -170.099 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 60.9 t -96.33 136.1 28.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 C-N-CA 124.201 1.001 . . . . 4.49 113.517 -157.873 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.9 p -32.39 143.21 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 131.232 3.813 . . . . 4.33 118.44 -170.32 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.14 -118.79 4.11 Favored Glycine 0 CA--C 1.528 0.905 0 C-N-CA 124.968 1.27 . . . . 2.45 112.211 169.469 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 1.6 pp -168.76 153.39 5.9 Favored Pre-proline 0 CA--C 1.552 1.025 0 N-CA-C 115.565 1.691 . . . . 5.91 115.565 -150.246 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo . . . . . 0 C--O 1.254 1.298 0 C-N-CA 123.739 2.96 . . . . 4.65 111.741 152.935 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo . . . . . 0 N--CA 1.486 1.068 0 CA-C-O 118.582 -0.674 . . . . 2.13 111.096 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -71.12 -150.0 0.03 OUTLIER 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 123.65 2.9 . . . . 1.61 109.581 166.11 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -99.27 -172.77 31.15 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-N 118.688 0.676 . . . . 1.21 112.662 172.232 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.81 167.69 23.46 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 123.248 2.632 . . . . 2.36 112.213 176.608 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 8.7 tp60 -37.23 127.16 1.0 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.696 2.398 . . . . 1.39 113.024 160.583 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -62.5 147.75 49.46 Favored Glycine 0 CA--C 1.527 0.786 0 C-N-CA 124.321 0.962 . . . . 1.01 112.741 168.584 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 47.0 mm -57.9 147.14 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 O-C-N 121.933 -0.745 . . . . 3.35 111.557 -178.952 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -72.4 156.81 38.67 Favored 'General case' 0 CA--C 1.542 0.658 0 O-C-N 121.293 -0.879 . . . . 1.2 112.792 178.72 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -91.94 153.75 22.1 Favored Glycine 0 C--N 1.338 0.644 0 CA-C-O 122.299 0.944 . . . . 1.09 112.046 -178.528 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 25.1 mp0 -92.02 -174.12 3.69 Favored 'General case' 0 CA--C 1.544 0.721 0 CA-C-O 122.024 0.916 . . . . 2.92 111.398 -175.954 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -58.83 139.33 56.56 Favored 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 125.15 1.38 . . . . 4.65 111.653 169.093 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.9 -171.01 6.81 Favored Glycine 0 C--N 1.337 0.628 0 C-N-CA 125.384 1.469 . . . . 1.58 113.481 175.825 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 21.4 t -65.0 127.46 25.95 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.696 0 O-C-N 122.305 -0.527 . . . . 2.77 110.473 -178.833 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 4.3 p -64.31 160.93 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 126.864 2.066 . . . . 4.17 112.133 178.007 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -51.9 176.52 0.1 Allowed Glycine 0 CA--C 1.542 1.728 0 C-N-CA 124.52 1.057 . . . . 1.84 115.236 159.518 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 3.3 mm? . . . . . 0 C--O 1.253 1.248 0 CA-C-O 117.016 -1.469 . . . . 3.57 112.623 -161.156 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.406 ' O ' ' HA3' ' B' ' 13' ' ' GLY . 83.5 Cg_endo . . . . . 0 CA--C 1.534 0.489 0 CA-C-O 120.661 0.192 . . . . 2.88 111.635 . . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.01 153.55 36.93 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 127.31 2.244 . . . . 3.14 113.605 178.706 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.7 -122.91 0.05 OUTLIER Glycine 0 CA--C 1.534 1.271 0 C-N-CA 127.146 2.308 . . . . 2.4 115.717 -179.051 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.8 mt -122.42 131.8 72.46 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 O-C-N 121.097 -1.237 . . . . 1.97 109.191 -177.248 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.91 134.33 55.41 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 123.442 0.697 . . . . 2.08 110.81 173.399 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.69 155.18 48.13 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 126.744 2.116 . . . . 1.83 114.33 -173.463 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 72.7 mm-40 -77.76 154.09 32.31 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 114.767 -0.717 . . . . 4.14 112.47 -166.256 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.45 132.16 53.04 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 123.509 0.723 . . . . 6.85 111.759 -177.672 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.9 151.64 44.52 Favored Glycine 0 N--CA 1.467 0.763 0 N-CA-C 115.584 0.994 . . . . 1.74 115.584 -167.879 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 2.5 m -69.1 130.93 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 124.938 1.295 . . . . 2.57 110.893 176.138 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.5 m -55.61 146.07 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 125.062 1.345 . . . . 2.58 114.029 -167.638 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.02 -163.93 7.91 Favored Glycine 0 CA--C 1.534 1.276 0 N-CA-C 111.39 -0.684 . . . . 1.98 111.39 161.032 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.1 mt -143.95 167.02 16.46 Favored Pre-proline 0 N--CA 1.475 0.813 0 C-N-CA 124.551 1.14 . . . . 2.95 111.479 179.951 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 27' ' ' PRO . . . . . 0.426 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 29.2 Cg_endo -76.73 -152.61 0.04 OUTLIER 'Trans proline' 0 CA--C 1.539 0.736 0 C-N-CA 122.981 2.454 . . . . 1.92 108.584 150.914 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.288 0 CA-C-O 117.017 -1.99 . . . . 3.12 112.774 143.671 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_exo . . . . . 0 CA--C 1.543 0.966 0 N-CA-C 111.512 -0.226 . . . . 3.51 111.512 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' B' B ' 13' ' ' GLY . . . . . 0.406 ' HA3' ' O ' ' A' ' 14' ' ' PRO . . . -69.05 176.44 30.06 Favored Glycine 0 CA--C 1.538 1.474 0 C-N-CA 120.284 -0.96 . . . . 1.72 112.935 127.561 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -79.94 156.28 23.56 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 C-N-CA 125.011 3.807 . . . . 2.54 110.795 158.646 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -60.86 140.63 57.62 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 125.158 1.383 . . . . 4.33 110.455 168.24 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.32 162.14 40.83 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 115.508 0.963 . . . . 1.45 115.508 -172.114 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 41.0 pt -55.41 139.19 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 O-C-N 122.376 -0.485 . . . . 4.12 111.213 176.765 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.15 154.04 42.72 Favored 'General case' 0 CA--C 1.54 0.589 0 CA-C-O 121.539 0.685 . . . . 1.73 112.828 -176.638 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.02 161.96 51.71 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 125.094 1.33 . . . . 2.23 113.635 -178.338 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 3.0 tp-100 -90.56 131.06 36.51 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 123.663 0.785 . . . . 3.83 109.709 -174.163 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.28 153.26 3.94 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-O 122.678 1.228 . . . . 8.13 114.161 -177.77 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.91 166.54 54.41 Favored Glycine 0 CA--C 1.531 1.086 0 CA-C-N 113.998 -1.456 . . . . 1.78 112.541 171.298 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 17.6 m -89.71 139.28 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 115.05 1.5 . . . . 3.7 115.05 -162.841 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.1 m -104.22 155.8 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 124.809 1.244 . . . . 2.62 112.708 -163.211 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -107.49 -130.33 6.34 Favored Glycine 0 CA--C 1.529 0.907 0 C-N-CA 125.118 1.342 . . . . 1.66 113.218 177.801 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' B' B ' 26' ' ' LEU . . . . . 0.426 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.7 pt? -179.14 161.82 1.0 Allowed Pre-proline 0 CA--C 1.547 0.842 0 C-N-CA 126.045 1.738 . . . . 3.33 110.753 -152.996 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo . . . . . 0 C--O 1.257 1.437 0 C-N-CA 124.014 3.143 . . . . 2.89 111.949 156.159 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo . . . . . 0 CA--C 1.547 1.173 0 CA-C-O 119.181 -0.425 . . . . 3.22 112.03 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -66.07 -160.66 0.04 OUTLIER 'Trans proline' 0 CA--C 1.543 0.942 0 C-N-CA 123.066 2.511 . . . . 2.28 110.129 161.67 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -90.89 -177.57 43.74 Favored Glycine 0 CA--C 1.535 1.31 0 O-C-N 121.163 -0.96 . . . . 1.5 111.897 169.043 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -77.77 170.51 18.94 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.946 2.43 . . . . 2.57 111.981 175.405 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.8 tp60 -34.99 127.01 0.53 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 127.557 2.343 . . . . 1.74 113.325 152.499 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.18 155.4 53.16 Favored Glycine 0 CA--C 1.528 0.869 0 C-N-CA 124.944 1.259 . . . . 1.49 112.338 167.304 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 82.3 mt -62.95 139.57 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 O-C-N 121.593 -0.946 . . . . 2.56 110.731 -175.582 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.26 159.15 12.76 Favored 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 122.292 1.044 . . . . 2.15 113.31 178.904 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -61.76 124.99 35.75 Favored Glycine 0 CA--C 1.524 0.638 0 CA-C-O 122.279 0.933 . . . . 1.95 112.679 -170.905 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' C' C ' 20' ' ' GLN . . . . . 0.567 ' NE2' ' H ' ' C' ' 20' ' ' GLN . 0.0 OUTLIER -60.59 129.76 43.15 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.672 1.589 . . . . 6.1 110.919 -175.982 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.47 129.71 22.51 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.526 0.731 . . . . 3.13 111.862 -174.898 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -62.6 154.98 41.65 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 115.168 -0.924 . . . . 1.03 113.311 -176.466 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.5 t -57.4 146.59 6.76 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 C-N-CA 124.913 1.285 . . . . 1.61 110.288 171.876 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 27.2 m -98.54 -169.87 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.817 0 C-N-CA 125.687 1.595 . . . . 2.39 110.557 179.091 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.6 -168.31 3.94 Favored Glycine 0 CA--C 1.538 1.485 0 C-N-CA 124.339 0.971 . . . . 1.9 113.944 167.356 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 13.5 mt . . . . . 0 N--CA 1.485 1.315 0 N-CA-C 114.329 1.233 . . . . 3.61 114.329 -174.977 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo . . . . . 0 N--CA 1.457 -0.676 0 N-CA-C 111.328 -0.297 . . . . 5.17 111.328 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -64.38 161.71 16.44 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 128.294 2.638 . . . . 4.46 111.451 166.577 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.41 -143.17 0.46 Allowed Glycine 0 CA--C 1.535 1.34 0 C-N-CA 126.66 2.076 . . . . 3.27 114.307 173.367 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.1 mt -101.06 127.92 53.79 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 O-C-N 121.375 -1.074 . . . . 4.24 108.409 179.202 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.89 140.79 56.41 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 118.901 0.773 . . . . 2.45 110.29 168.186 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -61.75 141.95 47.9 Favored Glycine 0 CA--C 1.523 0.58 0 C-N-CA 124.587 1.089 . . . . 1.18 112.291 175.423 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 54.2 mm-40 -68.32 130.22 42.25 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 109.847 -0.427 . . . . 3.08 109.847 -177.516 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -66.69 137.26 56.56 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 121.512 0.672 . . . . 3.96 111.175 -171.765 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.63 126.1 8.33 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-O 122.599 1.11 . . . . 2.48 111.562 176.611 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.8 t -65.28 155.26 6.8 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.835 0 C-N-CA 126.498 1.919 . . . . 4.27 111.822 -178.141 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.3 m -61.62 152.32 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 O-C-N 121.121 -0.987 . . . . 3.57 112.791 173.805 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -97.02 -153.88 29.7 Favored Glycine 0 N--CA 1.468 0.795 0 C-N-CA 124.023 0.821 . . . . 2.03 112.478 167.642 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 89.2 mt -143.26 158.89 57.23 Favored Pre-proline 0 N--CA 1.47 0.536 0 C-N-CA 126.117 1.767 . . . . 5.58 110.246 176.444 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -76.41 -146.21 0.03 OUTLIER 'Trans proline' 0 CA--C 1.54 0.791 0 C-N-CA 122.58 2.186 . . . . 3.93 107.803 154.03 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.169 0 CA-C-O 116.701 -2.166 . . . . 4.72 111.979 151.902 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo . . . . . 0 N--CA 1.481 0.774 0 CA-C-O 118.705 -0.623 . . . . 4.03 111.68 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.6 159.01 50.88 Favored Glycine 0 CA--C 1.539 1.581 0 CA-C-O 118.761 -1.021 . . . . 2.08 111.682 154.443 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_endo -70.8 158.67 54.96 Favored 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 123.782 2.988 . . . . 4.16 109.819 162.134 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -82.34 174.29 11.27 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.909 0.861 . . . . 6.66 113.114 178.593 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.22 154.36 52.53 Favored Glycine 0 CA--C 1.52 0.389 0 CA-C-O 122.615 1.119 . . . . 1.95 114.248 -177.705 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 43.8 pt -61.39 144.69 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 CA-C-N 114.383 -0.909 . . . . 5.38 110.718 161.518 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -85.35 133.4 34.14 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 123.822 0.849 . . . . 2.1 112.495 177.749 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -75.08 125.62 8.32 Favored Glycine 0 CA--C 1.525 0.691 0 C-N-CA 125.653 1.597 . . . . 1.58 110.546 173.272 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -89.71 157.51 17.95 Favored 'General case' 0 CA--C 1.535 0.382 0 O-C-N 121.865 -0.785 . . . . 4.32 110.384 166.321 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.92 162.08 29.92 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 123.235 0.614 . . . . 4.03 111.712 166.029 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -84.19 -141.8 5.1 Favored Glycine 0 CA--C 1.533 1.198 0 N-CA-C 110.991 -0.843 . . . . 2.52 110.991 163.602 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 99.5 t -40.62 131.38 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 126.415 1.886 . . . . 4.88 113.816 -173.944 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 15.3 m -103.78 149.4 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 125.083 1.353 . . . . 3.96 109.02 161.371 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.515 ' H ' HG23 ' C' ' 23' ' ' VAL . . . -102.55 167.63 17.84 Favored Glycine 0 C--N 1.333 0.392 0 C-N-CA 124.843 1.211 . . . . 5.24 115.266 -163.574 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -171.57 158.99 4.83 Favored Pre-proline 0 CA--C 1.544 0.713 0 C-N-CA 127.626 2.37 . . . . 7.26 111.028 -173.824 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo . . . . . 0 C--O 1.255 1.354 0 C-N-CA 124.063 3.175 . . . . 4.97 112.155 152.631 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo . . . . . 0 N--CA 1.486 1.085 0 CA-C-O 118.604 -0.665 . . . . 5.14 111.305 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -69.06 -152.88 0.03 OUTLIER 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 123.394 2.729 . . . . 4.32 109.761 163.632 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -91.45 177.28 40.69 Favored Glycine 0 CA--C 1.535 1.293 0 N-CA-C 111.424 -0.67 . . . . 2.66 111.424 166.684 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -78.26 168.07 22.23 Favored 'Trans proline' 0 N--CA 1.455 -0.772 0 C-N-CA 123.111 2.541 . . . . 3.85 111.858 172.637 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 27.0 tp60 -40.51 121.91 1.52 Allowed 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 128.217 2.607 . . . . 2.8 113.98 160.046 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.74 157.74 51.91 Favored Glycine 0 CA--C 1.527 0.841 0 C-N-CA 124.82 1.2 . . . . 1.53 111.637 163.953 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 51.2 mm -65.56 132.2 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 O-C-N 121.81 -0.818 . . . . 2.89 111.903 -172.458 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.52 145.92 38.77 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 123.77 0.828 . . . . 1.46 111.862 171.731 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -80.44 -173.21 46.19 Favored Glycine 0 C--N 1.338 0.673 0 CA-C-O 122.684 1.158 . . . . 1.02 111.513 -179.959 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 12.5 mp0 -115.95 158.84 22.44 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 108.214 -1.032 . . . . 3.29 108.214 179.367 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 2.8 tmt_? -63.45 134.12 55.1 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 107.611 -1.255 . . . . 6.43 107.611 153.804 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.61 153.66 52.92 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 111.626 -0.589 . . . . 2.79 111.626 -179.249 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' C' C ' 23' ' ' VAL . . . . . 0.515 HG23 ' H ' ' B' ' 25' ' ' GLY . 15.5 m -67.03 162.66 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 O-C-N 121.429 -1.042 . . . . 4.62 111.95 -176.291 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 16.0 m -90.61 173.93 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 126.889 2.076 . . . . 4.88 110.776 171.552 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.15 -171.87 2.45 Favored Glycine 0 CA--C 1.54 1.632 0 C-N-CA 125.249 1.404 . . . . 3.74 115.132 164.808 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 mm? . . . . . 0 C--O 1.25 1.117 0 C-N-CA 126.69 1.996 . . . . 7.44 112.36 -166.274 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo . . . . . 0 N--CA 1.459 -0.516 0 CA-C-O 121.018 0.341 . . . . 1.92 112.606 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.62 153.47 10.29 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 129.304 3.041 . . . . 3.55 112.464 170.072 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.12 -144.26 3.41 Favored Glycine 0 N--CA 1.475 1.287 0 C-N-CA 126.667 2.079 . . . . 1.67 117.01 -171.8 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 33.2 pt -98.94 139.32 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 O-C-N 121.24 -1.153 . . . . 2.59 108.692 174.848 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.84 146.4 49.77 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-O 121.38 0.609 . . . . 1.78 111.052 179.558 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -45.86 141.64 4.96 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 126.423 1.963 . . . . 1.23 114.017 174.884 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 80.3 mm-40 -63.69 132.82 52.25 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 108.925 -0.768 . . . . 3.3 108.925 -178.54 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.4 tmt_? -64.55 134.31 54.13 Favored 'General case' 0 CA--C 1.536 0.425 0 N-CA-C 112.421 0.526 . . . . 4.83 112.421 -162.481 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.54 160.79 53.7 Favored Glycine 0 N--CA 1.466 0.66 0 CA-C-O 122.823 1.235 . . . . 1.49 115.6 -169.58 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 11.1 t -79.01 145.25 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 126.15 1.78 . . . . 2.24 111.847 -167.272 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.9 m -58.49 147.26 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 C-N-CA 124.965 1.306 . . . . 2.51 113.59 -179.396 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.72 -163.88 34.34 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 124.267 0.937 . . . . 2.01 112.263 167.215 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.1 mt -145.9 160.44 43.62 Favored Pre-proline 0 N--CA 1.474 0.768 0 C-N-CA 128.053 2.541 . . . . 3.14 108.177 174.868 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -77.11 -157.12 0.07 OUTLIER 'Trans proline' 0 CA--C 1.541 0.866 0 C-N-CA 122.187 1.925 . . . . 2.0 109.129 164.677 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.205 0 CA-C-O 117.358 -1.801 . . . . 3.39 112.696 154.383 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo . . . . . 0 N--CA 1.481 0.762 0 CA-C-O 118.479 -0.717 . . . . 2.46 111.391 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.49 166.26 30.73 Favored Glycine 0 CA--C 1.543 1.814 0 CA-C-O 119.006 -0.886 . . . . 1.64 112.885 149.724 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -76.62 41.76 0.95 Allowed 'Trans proline' 0 CA--C 1.546 1.078 1 C-N-CA 127.014 5.143 . . . . 3.7 113.176 -179.123 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 66.27 178.17 0.22 Allowed 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 125.274 1.43 . . . . 4.4 112.053 -165.1 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.64 163.54 31.08 Favored Glycine 0 CA--C 1.541 1.696 0 C-N-CA 124.429 1.014 . . . . 0.95 113.447 159.367 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 67.5 mt -77.77 148.71 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 126.05 1.74 . . . . 2.87 111.718 176.469 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -73.58 147.97 43.39 Favored 'General case' 0 CA--C 1.548 0.877 0 N-CA-C 114.362 1.245 . . . . 1.29 114.362 -177.616 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -78.02 169.89 54.72 Favored Glycine 0 CA--C 1.536 1.378 0 C-N-CA 125.52 1.533 . . . . 1.5 112.476 173.188 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.94 170.35 12.35 Favored 'General case' 0 N--CA 1.467 0.408 0 O-C-N 121.321 -1.105 . . . . 3.26 112.06 -177.35 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -59.42 148.4 32.83 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 124.6 1.16 . . . . 4.97 113.328 -176.243 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.6 -54.96 5.22 Favored Glycine 0 N--CA 1.472 1.045 0 N-CA-C 114.418 0.527 . . . . 4.31 114.418 -173.404 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 11.1 t -146.65 158.91 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 128.478 2.711 . . . . 4.73 107.864 -176.518 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.0 p -121.06 153.58 24.55 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 C-N-CA 127.87 2.468 . . . . 3.32 109.32 178.103 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.02 -168.29 43.73 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-O 121.857 0.698 . . . . 1.74 114.582 177.162 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.9 pp -159.79 150.92 16.07 Favored Pre-proline 0 CA--C 1.543 0.699 0 C-N-CA 125.996 1.718 . . . . 3.16 110.97 -179.265 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo . . . . . 0 C--O 1.254 1.306 1 C-N-CA 125.584 4.189 . . . . 3.09 112.881 167.594 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo . . . . . 0 N--CA 1.485 1.001 0 CA-C-O 118.834 -0.569 . . . . 2.06 111.267 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -71.99 -143.16 0.02 OUTLIER 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 123.943 3.095 . . . . 1.55 109.257 169.091 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.33 146.61 39.45 Favored Glycine 0 CA--C 1.54 1.623 0 CA-C-O 118.713 -1.048 . . . . 1.07 110.506 165.659 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -68.25 -43.04 4.91 Favored 'Trans proline' 0 CA--C 1.534 0.49 0 C-N-CA 123.024 2.483 . . . . 3.28 113.285 178.208 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.427 HE21 ' N ' ' C' ' 16' ' ' GLY . 16.9 tp60 174.2 115.2 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 126.185 1.794 . . . . 1.32 107.948 -166.201 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' C' C ' 16' ' ' GLY . . . . . 0.427 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -65.83 164.71 38.77 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 123.663 0.649 . . . . 0.92 112.979 169.616 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 35.0 mm -69.59 128.55 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 O-C-N 121.527 -0.984 . . . . 2.25 110.761 -171.498 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.15 149.98 22.48 Favored 'General case' 0 CA--C 1.543 0.691 0 N-CA-C 113.748 1.018 . . . . 1.25 113.748 176.806 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -73.32 138.46 25.28 Favored Glycine 0 CA--C 1.526 0.746 0 C-N-CA 124.11 0.862 . . . . 1.04 111.36 -177.44 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 -75.81 167.73 21.34 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.138 0.975 . . . . 5.45 111.827 175.529 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.18 147.79 19.75 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 125.619 1.568 . . . . 3.78 112.151 171.374 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -56.32 146.82 32.56 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 125.734 1.635 . . . . 1.08 113.328 166.832 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 34.8 m -75.01 137.89 22.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 107.2 -1.408 . . . . 3.38 107.2 162.698 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 34.9 m -92.19 -152.36 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.799 0 C-N-CA 124.034 0.934 . . . . 2.87 110.991 -168.35 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.98 169.53 1.25 Allowed Glycine 0 CA--C 1.542 1.751 0 C-N-CA 124.033 0.825 . . . . 1.81 114.103 162.189 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 12.8 mt . . . . . 0 C--O 1.249 1.028 0 C-N-CA 124.897 1.279 . . . . 3.65 114.024 -163.845 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo . . . . . 0 CA--C 1.535 0.548 0 N-CA-C 111.331 -0.296 . . . . 2.29 111.331 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? -74.81 165.96 24.4 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 126.739 2.016 . . . . 3.75 113.594 175.534 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.11 -157.58 3.36 Favored Glycine 0 N--CA 1.476 1.365 0 C-N-CA 129.493 3.425 . . . . 1.5 116.915 -170.267 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.9 mt -77.96 125.74 37.78 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 O-C-N 120.403 -1.645 . . . . 2.15 107.942 174.736 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.0 128.41 30.33 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 123.117 0.567 . . . . 1.94 111.274 174.713 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.77 150.23 42.85 Favored Glycine 0 CA--C 1.521 0.466 0 C-N-CA 126.455 1.979 . . . . 1.26 112.856 -174.554 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 76.8 mm-40 -74.46 135.15 42.29 Favored 'General case' 0 C--N 1.332 -0.175 0 O-C-N 122.333 -0.51 . . . . 3.7 110.652 -167.268 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 35.2 ttp180 -54.48 130.96 41.51 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 123.539 0.736 . . . . 5.99 110.908 176.33 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.89 -178.03 29.83 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 124.441 1.02 . . . . 2.2 114.189 -171.646 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.412 HG23 ' H ' ' A' ' 23' ' ' VAL . 0.9 OUTLIER -61.11 142.36 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 C-N-CA 123.916 0.886 . . . . 2.76 110.03 174.846 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.7 m -52.22 154.08 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 C-N-CA 124.184 0.994 . . . . 3.03 112.944 173.6 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -83.9 -149.43 9.61 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 123.797 0.713 . . . . 2.43 112.591 166.298 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 82.8 mt -146.73 162.5 33.45 Favored Pre-proline 0 N--CA 1.475 0.789 0 C-N-CA 127.015 2.126 . . . . 3.46 109.687 170.581 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -83.06 -152.92 0.04 OUTLIER 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 123.298 2.665 . . . . 2.17 108.515 154.228 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.207 0 CA-C-O 117.61 -1.661 . . . . 3.83 113.103 156.191 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_exo . . . . . 0 N--CA 1.479 0.676 0 CA-C-O 118.196 -0.835 . . . . 2.24 111.392 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.48 158.21 27.81 Favored Glycine 0 CA--C 1.546 2.01 0 CA-C-N 119.178 0.899 . . . . 1.99 112.816 154.342 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -76.13 47.5 2.03 Favored 'Trans proline' 0 CA--C 1.545 1.071 1 C-N-CA 127.374 5.383 . . . . 3.99 113.419 -175.958 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.4 tp-100 69.88 -169.65 0.17 Allowed 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 124.819 1.248 . . . . 4.22 109.871 -161.33 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -106.93 154.88 16.58 Favored Glycine 0 CA--C 1.533 1.201 0 C-N-CA 126.192 1.853 . . . . 1.15 110.576 158.558 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 18.3 tt -63.58 144.81 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 C-N-CA 124.228 1.011 . . . . 4.05 112.521 177.393 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -75.0 148.36 39.98 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 113.624 0.972 . . . . 1.61 113.624 178.91 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.63 148.39 43.42 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 125.635 1.588 . . . . 1.74 113.8 -177.747 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 19.5 tt0 -80.25 148.34 30.83 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.222 1.009 . . . . 3.88 112.418 -177.86 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.5 mtm180 -63.87 130.75 45.4 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 124.747 1.219 . . . . 4.61 111.829 178.125 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.48 2.72 45.18 Favored Glycine 0 N--CA 1.476 1.34 0 N-CA-C 119.6 2.6 . . . . 4.68 119.6 -155.365 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . 0.278 0.9 OUTLIER 173.3 156.92 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 130.302 3.441 . . . . 4.96 108.741 179.214 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 42.1 t -132.54 141.51 44.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 C-N-CA 126.245 1.818 . . . . 4.46 107.911 178.052 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -88.05 -177.69 47.58 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-O 122.496 1.053 . . . . 2.53 114.779 -170.3 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.1 pt? -161.19 156.96 21.55 Favored Pre-proline 0 CA--C 1.542 0.651 0 C-N-CA 126.419 1.888 . . . . 3.98 110.243 -177.734 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo . . . . . 0 C--O 1.255 1.374 0 C-N-CA 124.129 3.219 . . . . 3.32 111.229 164.112 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo . . . . . 0 N--CA 1.487 1.097 0 CA-C-O 119.019 -0.492 . . . . 2.55 111.555 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -70.0 -148.83 0.02 OUTLIER 'Trans proline' 0 CA--C 1.541 0.857 0 C-N-CA 123.616 2.878 . . . . 1.98 109.553 165.768 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -81.95 176.45 53.96 Favored Glycine 0 CA--C 1.537 1.454 0 O-C-N 121.279 -0.888 . . . . 1.13 111.542 168.88 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -79.24 -177.58 4.0 Favored 'Trans proline' 0 N--CA 1.452 -0.952 0 C-N-CA 123.095 2.53 . . . . 2.37 109.792 162.125 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.7 tp60 -41.55 119.29 1.22 Allowed 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 125.981 1.712 . . . . 1.8 113.875 159.363 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.32 161.88 41.22 Favored Glycine 0 CA--C 1.528 0.855 0 C-N-CA 125.772 1.654 . . . . 1.13 112.531 167.518 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 33.4 mm -68.77 142.39 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 O-C-N 121.576 -0.955 . . . . 3.72 110.511 -172.714 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.81 154.63 40.36 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.31 0.856 . . . . 1.42 113.31 177.1 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.59 157.52 53.25 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 124.274 0.94 . . . . 1.15 113.131 -179.095 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 14.4 mp0 -82.31 173.98 11.57 Favored 'General case' 0 CA--C 1.541 0.615 0 O-C-N 121.869 -0.783 . . . . 3.0 111.26 179.024 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.3 135.31 57.13 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 123.287 0.635 . . . . 3.69 110.426 169.15 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -65.35 167.3 32.52 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.93 1.253 . . . . 1.34 113.972 -176.675 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 87.2 t -75.52 148.4 7.49 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 C-N-CA 123.876 0.871 . . . . 2.06 109.458 -176.865 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 98.7 t -97.28 174.69 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.991 0 C-N-CA 127.297 2.239 . . . . 2.83 109.613 -174.891 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -56.3 173.17 1.67 Allowed Glycine 0 CA--C 1.538 1.504 0 C-N-CA 124.974 1.273 . . . . 2.01 114.723 165.25 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 8.8 mt . . . . . 0 C--O 1.25 1.097 0 N-CA-C 113.821 1.045 . . . . 4.43 113.821 -158.143 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo . . . . . 0 CA--C 1.532 0.404 0 N-CA-C 111.491 -0.234 . . . . 1.92 111.491 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.84 177.76 0.71 Allowed 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 127.73 2.412 . . . . 3.73 114.656 -178.227 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.16 173.09 44.25 Favored Glycine 0 CA--C 1.526 0.728 0 C-N-CA 125.904 1.716 . . . . 1.26 113.793 177.323 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.546 ' H ' HD12 ' A' ' 17' ' ' ILE . 3.2 mp -67.42 135.24 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.51 0 N-CA-C 109.292 -0.633 . . . . 2.37 109.292 -173.189 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -53.95 133.0 43.16 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 118.427 0.558 . . . . 1.79 110.482 170.613 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.12 168.68 24.27 Favored Glycine 0 CA--C 1.521 0.417 0 C-N-CA 126.115 1.816 . . . . 1.31 114.778 -167.995 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 85.6 mm-40 -71.46 96.28 1.48 Allowed 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 108.598 -0.89 . . . . 3.19 108.598 179.793 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.2 ttp-105 -62.29 138.63 58.46 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 124.836 1.254 . . . . 4.96 113.23 -165.155 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.7 149.97 39.04 Favored Glycine 0 C--N 1.332 0.355 0 CA-C-O 122.421 1.012 . . . . 2.26 113.704 -171.211 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 32.7 m -76.64 163.11 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 CA-C-N 113.676 -1.262 . . . . 2.74 111.173 -174.624 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.0 m -60.75 167.69 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 124.257 1.023 . . . . 3.54 112.395 177.355 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.72 146.97 39.4 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 110.407 -1.077 . . . . 2.1 110.407 157.957 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 8.5 mp -101.62 169.57 7.53 Favored Pre-proline 0 CA--C 1.538 0.516 0 C-N-CA 124.041 0.936 . . . . 3.64 111.95 -170.833 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -69.11 115.11 3.84 Favored 'Trans proline' 0 N--CA 1.445 -1.337 0 N-CA-C 106.989 -1.966 . . . . 2.98 106.989 151.775 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.147 0 CA-C-O 118.584 -1.12 . . . . 6.8 114.773 -157.294 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo . . . . . 0 CA--C 1.544 0.995 0 N-CA-C 111.313 -0.303 . . . . 2.1 111.313 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.44 167.7 13.23 Favored Glycine 0 CA--C 1.541 1.717 0 C-N-CA 120.13 -1.033 . . . . 1.3 112.902 127.473 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -76.69 -64.4 0.03 OUTLIER 'Trans proline' 0 CA--C 1.538 0.702 0 C-N-CA 124.974 3.782 . . . . 2.85 112.694 175.678 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 8.3 tp-100 -166.6 157.4 12.39 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 127.943 2.497 . . . . 3.25 107.639 -164.711 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.36 159.23 25.02 Favored Glycine 0 CA--C 1.527 0.783 0 C-N-CA 124.324 0.964 . . . . 0.97 113.469 175.549 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 17' ' ' ILE . . . . . 0.53 ' H ' HD12 ' B' ' 17' ' ' ILE . 3.8 mp -70.28 127.89 32.82 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 N-CA-C 108.855 -0.795 . . . . 3.49 108.855 176.851 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.62 146.76 38.01 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 118.973 0.806 . . . . 1.27 112.416 178.873 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -78.63 141.27 24.4 Favored Glycine 0 CA--C 1.527 0.8 0 C-N-CA 124.643 1.116 . . . . 1.53 111.668 179.268 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.65 164.77 12.82 Favored 'General case' 0 N--CA 1.468 0.463 0 O-C-N 121.43 -1.041 . . . . 4.14 111.132 166.75 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -82.3 167.12 18.91 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.285 1.034 . . . . 5.24 112.022 167.138 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.71 -174.02 45.65 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 124.609 1.1 . . . . 2.68 112.619 164.945 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 11.0 m -100.9 160.05 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 C-N-CA 125.039 1.336 . . . . 5.2 114.568 -166.243 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.7 p -42.37 150.38 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 C-N-CA 129.016 2.926 . . . . 4.1 115.221 -178.117 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.44 -114.93 1.93 Allowed Glycine 0 CA--C 1.528 0.85 0 CA-C-O 119.154 -0.803 . . . . 2.24 111.343 167.334 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -172.43 177.23 0.83 Allowed Pre-proline 0 CA--C 1.556 1.204 0 C-N-CA 126.977 2.111 . . . . 3.81 110.55 -164.572 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_endo . . . . . 0 C--O 1.255 1.36 0 C-N-CA 123.926 3.084 . . . . 5.26 112.725 174.571 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo . . . . . 0 CA--C 1.546 1.101 0 CA-C-O 118.532 -0.695 . . . . 1.89 111.426 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -61.72 -154.05 0.02 OUTLIER 'Trans proline' 0 CA--C 1.545 1.054 0 C-N-CA 124.934 3.756 . . . . 1.72 111.679 164.682 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -84.21 -177.9 51.45 Favored Glycine 0 CA--C 1.543 1.805 0 O-C-N 121.068 -1.02 . . . . 0.96 113.157 173.53 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -79.54 169.49 18.44 Favored 'Trans proline' 0 CA--C 1.535 0.535 0 C-N-CA 124.219 3.279 . . . . 2.3 111.304 173.865 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 -48.04 116.92 1.68 Allowed 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 124.209 1.004 . . . . 1.47 111.288 160.717 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.58 163.22 36.39 Favored Glycine 0 CA--C 1.529 0.94 0 C-N-CA 124.852 1.215 . . . . 0.87 112.577 172.171 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 3.1 mp -65.96 145.27 14.02 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.667 0 C-N-CA 123.852 0.861 . . . . 2.67 110.673 -168.628 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -68.8 163.72 23.51 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.517 0.932 . . . . 1.2 113.517 179.084 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.11 149.46 17.96 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 109.946 -1.262 . . . . 1.01 109.946 168.6 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 7.2 mm100 -93.39 -167.86 1.8 Allowed 'General case' 0 CA--C 1.541 0.621 0 O-C-N 121.978 -0.719 . . . . 4.77 110.831 -178.07 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 2.6 ttt180 -63.33 154.44 31.76 Favored 'General case' 0 N--CA 1.467 0.41 0 O-C-N 121.272 -0.893 . . . . 3.8 110.898 168.524 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.24 -171.44 45.1 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 123.726 0.679 . . . . 1.04 111.653 165.355 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.0 t -70.3 136.8 25.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 C-N-CA 124.266 1.026 . . . . 1.79 111.855 -170.623 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -44.94 124.58 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 C-N-CA 126.599 1.959 . . . . 3.78 112.671 161.264 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.34 127.45 8.88 Favored Glycine 0 CA--C 1.525 0.698 0 C-N-CA 123.342 0.496 . . . . 3.63 112.823 179.613 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 16.9 mt . . . . . 0 C--O 1.254 1.313 0 CA-C-O 117.107 -1.425 . . . . 7.05 109.623 146.124 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo . . . . . 0 CA--C 1.536 0.614 0 CA-C-O 120.842 0.268 . . . . 2.74 111.96 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -58.46 153.4 15.97 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 128.863 2.865 . . . . 3.06 112.972 173.282 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.46 -135.01 5.01 Favored Glycine 0 N--CA 1.476 1.306 0 C-N-CA 125.996 1.76 . . . . 1.94 115.981 -171.703 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 24.0 pt -102.46 143.35 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 O-C-N 121.751 -0.852 . . . . 2.85 110.863 -178.417 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.34 143.57 28.05 Favored 'General case' 0 CA--C 1.538 0.509 0 CA-C-O 121.845 0.831 . . . . 1.77 112.007 178.612 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.46 152.21 16.39 Favored Glycine 0 CA--C 1.52 0.379 0 C-N-CA 127.637 2.541 . . . . 1.5 115.529 178.367 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 84.8 mm-40 -66.19 152.87 43.91 Favored 'General case' 0 CA--C 1.531 0.236 0 CA-C-N 113.957 -1.121 . . . . 3.21 111.172 -176.424 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -63.95 141.95 58.58 Favored 'General case' 0 N--CA 1.466 0.348 0 O-C-N 122.04 -0.413 . . . . 3.83 111.659 -179.538 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.6 164.27 45.05 Favored Glycine 0 CA--C 1.523 0.591 0 CA-C-N 115.621 -0.718 . . . . 1.53 113.096 176.609 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 2.1 t -64.55 150.07 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 124.565 1.146 . . . . 2.76 112.277 -167.69 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.8 t -53.81 132.51 16.58 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.686 0 C-N-CA 125.497 1.519 . . . . 3.83 111.587 167.88 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -85.42 155.93 30.07 Favored Glycine 0 CA--C 1.528 0.863 0 C-N-CA 124.847 1.213 . . . . 1.42 111.255 165.971 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 94.4 mt -118.16 156.52 50.44 Favored Pre-proline 0 N--CA 1.468 0.456 0 CA-C-O 117.537 -1.22 . . . . 2.86 109.937 -177.12 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -71.22 -158.47 0.06 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.875 0 C-N-CA 121.567 1.512 . . . . 1.86 109.304 161.849 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.307 0 CA-C-O 117.455 -1.747 . . . . 3.14 112.936 154.918 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo . . . . . 0 CA--C 1.544 0.992 0 N-CA-C 111.302 -0.307 . . . . 3.06 111.302 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.55 -173.02 3.19 Favored Glycine 0 CA--C 1.541 1.66 0 C-N-CA 120.097 -1.049 . . . . 1.56 113.339 123.922 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -77.9 -128.97 0.01 OUTLIER 'Trans proline' 0 CA--C 1.546 1.083 0 C-N-CA 124.864 3.709 . . . . 2.47 108.233 161.533 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -87.01 -171.01 3.31 Favored 'General case' 0 CA--C 1.552 1.038 0 C-N-CA 125.844 1.657 . . . . 4.25 111.304 171.378 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.32 166.87 33.63 Favored Glycine 0 CA--C 1.541 1.692 0 O-C-N 121.204 -0.935 . . . . 1.08 111.875 149.412 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 46.8 mm -67.95 143.39 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.02 -1.282 . . . . 3.67 110.212 168.241 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.72 157.89 34.49 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 114.791 1.404 . . . . 1.39 114.791 -173.11 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -78.27 161.2 48.56 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 125.908 1.718 . . . . 1.78 113.561 -175.51 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.41 156.37 18.6 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 121.651 -0.911 . . . . 3.27 111.133 175.431 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.9 155.26 16.84 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 112.208 0.447 . . . . 8.19 112.208 178.177 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.38 -125.45 0.6 Allowed Glycine 0 CA--C 1.529 0.917 0 C-N-CA 123.995 0.807 . . . . 2.65 111.174 172.008 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 82.2 t -64.06 158.34 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 C-N-CA 124.738 1.215 . . . . 4.93 110.715 179.312 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 6.2 m -129.57 157.47 42.26 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 C-N-CA 126.429 1.891 . . . . 2.99 109.362 174.005 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.478 ' H ' HG23 ' C' ' 23' ' ' VAL . . . -87.72 176.74 46.32 Favored Glycine 0 C--N 1.336 0.545 0 C-N-CA 125.395 1.474 . . . . 1.89 115.305 -170.147 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -165.67 157.98 12.85 Favored Pre-proline 0 CA--C 1.549 0.928 0 C-N-CA 125.437 1.495 . . . . 3.22 113.262 -168.805 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_endo . . . . . 0 C--O 1.255 1.343 0 C-N-CA 123.748 2.965 . . . . 2.72 111.786 159.837 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo . . . . . 0 N--CA 1.487 1.119 0 CA-C-O 118.882 -0.549 . . . . 2.47 111.694 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -69.44 -139.37 0.01 OUTLIER 'Trans proline' 0 CA--C 1.542 0.923 0 C-N-CA 123.617 2.878 . . . . 1.54 108.713 163.385 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.1 163.73 53.91 Favored Glycine 0 CA--C 1.54 1.629 0 O-C-N 120.924 -1.11 . . . . 1.26 111.492 165.283 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -79.46 -43.06 0.15 Allowed 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 122.697 2.265 . . . . 3.67 112.511 -178.926 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.452 HE21 ' N ' ' C' ' 16' ' ' GLY . 17.3 tp60 167.84 133.09 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.81 2.444 . . . . 1.6 105.913 -154.445 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' C' C ' 16' ' ' GLY . . . . . 0.452 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -75.41 158.96 51.05 Favored Glycine 0 CA--C 1.534 1.225 0 C-N-CA 124.358 0.98 . . . . 1.19 113.654 167.649 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 73.3 mt -62.7 147.28 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 O-C-N 121.495 -1.003 . . . . 2.2 110.394 175.509 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.36 163.91 17.21 Favored 'General case' 0 CA--C 1.545 0.778 0 N-CA-C 114.014 1.116 . . . . 1.8 114.014 -177.148 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.86 154.17 46.46 Favored Glycine 0 CA--C 1.529 0.924 0 CA-C-N 115.443 -0.799 . . . . 1.62 111.66 170.562 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -84.76 168.72 14.92 Favored 'General case' 0 CA--C 1.539 0.54 0 CA-C-O 121.66 0.743 . . . . 3.38 111.909 -174.266 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 1.1 tmt_? -60.79 136.51 58.09 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 123.596 0.758 . . . . 3.15 110.861 -179.492 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.07 138.21 29.26 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.793 -0.923 . . . . 1.12 110.793 175.002 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' C' C ' 23' ' ' VAL . . . . . 0.478 HG23 ' H ' ' B' ' 25' ' ' GLY . 18.9 m -61.04 154.62 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 117.931 0.866 . . . . 2.76 111.696 -176.652 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 10.5 p -85.03 177.34 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 C-N-CA 126.876 2.071 . . . . 2.87 110.082 172.908 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.43 -164.72 0.61 Allowed Glycine 0 CA--C 1.54 1.646 0 C-N-CA 125.21 1.385 . . . . 1.58 115.875 169.851 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 16.5 mt . . . . . 0 N--CA 1.481 1.082 0 C-N-CA 125.507 1.523 . . . . 3.27 114.481 -162.439 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo . . . . . 0 N--CA 1.46 -0.458 0 N-CA-C 111.554 -0.21 . . . . 2.55 111.554 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.37 154.29 28.57 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.226 2.21 . . . . 3.17 113.517 178.955 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.08 -116.54 0.04 OUTLIER Glycine 0 CA--C 1.534 1.224 0 C-N-CA 126.937 2.208 . . . . 2.54 115.369 179.481 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.9 mt -134.79 132.95 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 O-C-N 121.211 -1.17 . . . . 1.92 109.739 -174.239 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.11 133.84 55.94 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.644 0.778 . . . . 1.76 112.324 176.44 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.99 163.12 41.73 Favored Glycine 0 CA--C 1.527 0.829 0 C-N-CA 126.885 2.183 . . . . 1.35 113.827 -175.15 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 8.6 mp0 -67.31 130.21 42.35 Favored 'General case' 0 N--CA 1.468 0.438 0 O-C-N 122.527 -0.396 . . . . 4.94 110.851 -164.056 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 42.4 ttt180 -63.09 126.59 27.87 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 118.363 0.529 . . . . 4.24 110.16 179.662 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.74 142.38 36.56 Favored Glycine 0 C--N 1.336 0.575 0 N-CA-C 114.634 0.613 . . . . 1.7 114.634 -160.204 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 35.9 m -64.4 122.93 16.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-N 114.792 -0.704 . . . . 2.53 109.484 -177.199 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 9.8 p -39.16 149.46 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 127.167 2.187 . . . . 2.86 113.566 -176.934 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.92 -155.28 0.61 Allowed Glycine 0 CA--C 1.531 1.054 0 O-C-N 121.405 -0.809 . . . . 1.9 114.296 172.343 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.9 mt -136.66 161.57 61.08 Favored Pre-proline 0 CA--C 1.541 0.6 0 C-N-CA 125.521 1.528 . . . . 2.9 110.751 176.377 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -84.14 -151.65 0.04 OUTLIER 'Trans proline' 0 CA--C 1.539 0.74 0 C-N-CA 123.89 3.06 . . . . 1.82 108.232 159.697 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.153 0 CA-C-O 117.211 -1.883 . . . . 3.16 112.438 141.901 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_exo . . . . . 0 CA--C 1.542 0.907 0 N-CA-C 111.716 -0.148 . . . . 2.53 111.716 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.38 177.19 25.9 Favored Glycine 0 CA--C 1.538 1.492 0 C-N-CA 120.074 -1.06 . . . . 1.28 112.989 128.045 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -82.2 155.93 17.08 Favored 'Trans proline' 0 CA--C 1.539 0.729 1 C-N-CA 125.418 4.079 . . . . 2.7 111.009 159.403 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -59.6 139.86 56.83 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 125.143 1.377 . . . . 3.95 110.757 169.746 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.29 161.94 47.44 Favored Glycine 0 C--N 1.338 0.646 0 C-N-CA 124.052 0.834 . . . . 1.12 114.932 -173.663 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 42.3 pt -57.78 145.71 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 C-N-CA 122.885 0.474 . . . . 3.9 111.892 179.707 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.19 149.31 48.73 Favored 'General case' 0 CA--C 1.543 0.675 0 O-C-N 121.525 -0.735 . . . . 1.42 112.322 175.803 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.61 152.15 51.35 Favored Glycine 0 CA--C 1.53 1.001 0 N-CA-C 110.318 -1.113 . . . . 1.56 110.318 166.942 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.91 151.56 22.25 Favored 'General case' 0 N--CA 1.468 0.456 0 O-C-N 121.356 -1.085 . . . . 3.25 110.449 176.015 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 31.4 ptt180 -61.81 159.57 13.52 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.072 0.949 . . . . 5.68 113.368 -179.566 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.68 160.84 53.82 Favored Glycine 0 CA--C 1.532 1.122 0 C-N-CA 124.825 1.202 . . . . 2.1 114.816 -178.418 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 43.9 t -89.47 131.59 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 124.598 1.159 . . . . 2.88 113.673 -168.424 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 11.5 m -79.46 160.65 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 C-N-CA 126.143 1.777 . . . . 2.6 113.301 -168.381 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.12 -128.31 6.18 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 125.036 1.303 . . . . 1.69 112.812 176.926 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -170.9 156.89 5.0 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 125.359 1.464 . . . . 3.11 112.076 -163.837 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo . . . . . 0 C--O 1.254 1.295 0 C-N-CA 124.571 3.514 . . . . 2.57 112.28 155.584 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo . . . . . 0 CA--C 1.547 1.167 0 CA-C-O 118.964 -0.515 . . . . 2.49 111.517 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -65.91 -157.74 0.03 OUTLIER 'Trans proline' 0 CA--C 1.544 0.975 0 C-N-CA 123.192 2.595 . . . . 1.93 109.967 161.669 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -93.16 -176.73 40.66 Favored Glycine 0 CA--C 1.534 1.26 0 O-C-N 121.171 -0.956 . . . . 1.22 111.859 170.721 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -79.37 170.67 17.09 Favored 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 123.277 2.652 . . . . 2.53 112.295 173.65 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.442 ' HA ' HE21 ' C' ' 15' ' ' GLN . 0.0 OUTLIER -38.03 135.98 0.64 Allowed 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 127.917 2.487 . . . . 1.96 114.333 154.736 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.81 173.18 54.66 Favored Glycine 0 CA--C 1.529 0.944 0 C-N-CA 126.193 1.854 . . . . 1.01 114.996 174.077 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 96.4 mt -67.57 144.1 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.601 1.161 . . . . 2.74 112.415 -171.133 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.98 132.08 46.18 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.593 1.157 . . . . 1.75 112.967 174.707 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -62.21 122.84 29.6 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 108.293 -1.923 . . . . 1.43 108.293 157.323 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -82.19 160.54 23.02 Favored 'General case' 0 C--N 1.327 -0.407 0 O-C-N 121.736 -0.861 . . . . 3.48 110.9 -173.723 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 9.0 tpp180 -48.31 136.04 12.86 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 124.552 1.141 . . . . 5.17 111.612 173.647 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.1 157.56 52.98 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 115.098 -0.955 . . . . 1.15 112.091 176.119 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.2 t -65.17 155.39 6.66 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 C-N-CA 124.882 1.273 . . . . 2.25 110.58 176.215 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 30.4 m -68.84 -171.18 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.547 0.864 0 C-N-CA 126.392 1.877 . . . . 2.33 112.054 171.42 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.33 -108.24 0.01 OUTLIER Glycine 0 CA--C 1.534 1.273 0 C-N-CA 124.748 1.166 . . . . 2.37 111.884 163.3 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 55.8 mt . . . . . 0 C--O 1.249 1.069 0 CA-C-O 117.647 -1.168 . . . . 4.16 111.563 166.448 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.61 0 CA-C-O 116.417 -2.324 . . . . 3.0 109.524 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -72.05 168.38 24.16 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 122.791 2.328 . . . . 2.37 111.236 179.439 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 4.3 pp0? -92.49 175.26 6.9 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 127.892 2.477 . . . . 2.81 113.084 -177.472 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.94 173.48 52.43 Favored Glycine 0 N--CA 1.479 1.542 0 N-CA-C 116.595 1.398 . . . . 1.66 116.595 -168.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.2 pt -71.51 145.09 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 O-C-N 120.905 -1.35 . . . . 3.03 110.256 -177.079 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.94 139.9 58.36 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-O 121.441 0.638 . . . . 1.78 112.207 -176.33 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.51 161.14 2.53 Favored Glycine 0 CA--C 1.526 0.744 0 C-N-CA 127.202 2.334 . . . . 1.31 115.682 178.734 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 22.1 mp0 -68.17 148.9 50.23 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-N 113.708 -1.246 . . . . 4.11 110.042 -174.681 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.86 130.41 45.57 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.774 -0.579 . . . . 6.82 110.277 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.04 150.38 50.26 Favored Glycine 0 CA--C 1.526 0.723 0 C-N-CA 124.073 0.844 . . . . 1.47 111.841 175.021 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 32.9 m -64.04 145.11 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 123.968 0.907 . . . . 2.24 111.514 -179.648 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 19.1 m -52.83 149.74 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 124.177 0.991 . . . . 2.16 113.359 -177.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.15 158.64 53.02 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-N 115.985 -0.552 . . . . 1.56 112.091 168.646 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 9.0 mp -89.2 158.04 47.08 Favored Pre-proline 0 CA--C 1.544 0.72 0 C-N-CA 123.221 0.608 . . . . 4.9 110.813 -176.046 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -78.19 -166.04 0.37 Allowed 'Trans proline' 0 CA--C 1.537 0.633 0 C-N-CA 123.596 2.864 . . . . 2.52 109.446 160.267 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.153 0 CA-C-O 117.35 -1.806 . . . . 3.58 111.952 150.297 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo . . . . . 0 N--CA 1.481 0.759 0 CA-C-O 118.484 -0.715 . . . . 2.2 111.482 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.02 159.62 51.09 Favored Glycine 0 CA--C 1.539 1.588 0 N-CA-C 110.886 -0.886 . . . . 1.29 110.886 150.245 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -72.09 177.45 7.14 Favored 'Trans proline' 0 CA--C 1.539 0.76 0 C-N-CA 123.244 2.63 . . . . 2.18 108.859 156.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 11.5 tt0 -60.19 172.63 0.78 Allowed 'General case' 0 CA--C 1.544 0.731 0 N-CA-C 114.935 1.457 . . . . 4.66 114.935 -175.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.17 159.48 51.77 Favored Glycine 0 CA--C 1.527 0.811 0 O-C-N 120.995 -1.066 . . . . 1.0 113.563 176.625 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 29.9 mm -60.25 141.48 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 123.669 0.788 . . . . 3.24 109.578 168.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.42 151.63 31.97 Favored 'General case' 0 CA--C 1.542 0.66 0 CA-C-O 122.756 1.265 . . . . 1.35 113.773 -179.521 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.19 137.67 38.25 Favored Glycine 0 CA--C 1.523 0.531 0 C-N-CA 125.25 1.405 . . . . 1.55 112.42 -179.067 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 94.9 mm-40 -81.92 124.84 30.08 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.577 -0.811 . . . . 3.96 109.167 -175.039 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 10.9 ptt180 -55.15 153.64 6.55 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 126.215 1.806 . . . . 6.64 114.064 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.92 173.65 54.69 Favored Glycine 0 CA--C 1.529 0.922 0 C-N-CA 124.133 0.873 . . . . 1.73 113.355 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 59.5 t -93.43 131.64 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 124.503 1.121 . . . . 2.98 112.83 -165.483 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 19.0 m -60.39 159.99 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 127.61 2.364 . . . . 2.5 114.414 -173.594 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.81 -136.7 5.25 Favored Glycine 0 CA--C 1.529 0.908 0 C-N-CA 124.191 0.9 . . . . 2.15 112.09 168.462 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -170.71 160.81 5.88 Favored Pre-proline 0 CA--C 1.543 0.705 0 C-N-CA 124.766 1.226 . . . . 3.48 111.534 -161.359 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo . . . . . 0 C--O 1.256 1.42 0 C-N-CA 124.586 3.524 . . . . 2.84 112.249 161.422 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo . . . . . 0 N--CA 1.486 1.076 0 CA-C-O 118.989 -0.505 . . . . 2.2 111.251 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -73.18 -130.07 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.939 0 C-N-CA 123.198 2.599 . . . . 2.01 107.778 162.686 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.29 168.23 48.14 Favored Glycine 0 CA--C 1.536 1.391 0 CA-C-N 119.509 1.049 . . . . 1.35 111.496 164.294 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.99 -44.83 0.31 Allowed 'Trans proline' 0 N--CA 1.458 -0.562 0 C-N-CA 122.578 2.185 . . . . 3.95 112.329 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 166.83 137.44 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 127.926 2.49 . . . . 1.65 105.526 -153.169 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.36 160.04 37.67 Favored Glycine 0 N--CA 1.468 0.823 0 C-N-CA 125.958 1.742 . . . . 1.07 112.927 169.228 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 46.7 mt -61.69 143.73 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 124.055 0.942 . . . . 2.2 111.022 -179.181 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.88 148.14 21.72 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.313 1.045 . . . . 1.24 113.559 174.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.87 149.42 34.61 Favored Glycine 0 C--N 1.339 0.712 0 C-N-CA 123.778 0.704 . . . . 0.97 111.375 -178.654 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 13.5 mp0 -90.85 -177.84 5.07 Favored 'General case' 0 CA--C 1.539 0.536 0 O-C-N 122.156 -0.614 . . . . 3.33 109.956 177.521 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 9.6 ptp180 -67.22 164.48 18.15 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-O 122.301 1.048 . . . . 5.6 113.592 -174.2 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.9 165.62 49.5 Favored Glycine 0 CA--C 1.531 1.031 0 C-N-CA 124.77 1.176 . . . . 1.17 111.862 166.676 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.7 t -64.08 144.99 14.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.282 1.033 . . . . 1.9 110.782 177.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 29.6 m -79.83 -171.67 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.833 0 C-N-CA 125.081 1.353 . . . . 2.98 111.622 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.13 179.42 7.05 Favored Glycine 0 CA--C 1.533 1.174 0 C-N-CA 124.842 1.211 . . . . 2.21 114.775 174.362 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 7.5 mt . . . . . 0 C--O 1.249 1.057 0 N-CA-C 114.527 1.306 . . . . 4.09 114.527 -169.77 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.555 0 CA-C-O 115.845 -2.642 . . . . 3.17 108.493 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -76.82 169.53 21.54 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 123.133 2.555 . . . . 2.21 111.225 177.276 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -76.32 -166.96 0.69 Allowed 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 127.017 2.127 . . . . 2.97 112.681 167.669 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.19 174.48 49.59 Favored Glycine 0 N--CA 1.472 1.088 0 O-C-N 121.308 -0.87 . . . . 1.5 114.737 -178.77 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 33.2 pt -73.15 150.38 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 O-C-N 122.329 -0.512 . . . . 3.12 109.693 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -49.1 131.98 19.26 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-O 121.775 0.798 . . . . 1.9 112.421 177.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.55 148.36 9.49 Favored Glycine 0 CA--C 1.519 0.344 0 C-N-CA 127.305 2.383 . . . . 1.25 112.856 166.803 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 11.8 mm100 -80.64 132.61 35.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.081 -0.559 . . . . 3.69 109.534 -166.354 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 60.6 ttp180 -52.88 127.94 25.29 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.76 1.624 . . . . 7.94 113.292 -173.273 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.21 159.83 53.61 Favored Glycine 0 N--CA 1.468 0.78 0 N-CA-C 116.012 1.165 . . . . 1.72 116.012 -170.521 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 27.8 m -72.39 143.13 14.36 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 C-N-CA 124.357 1.063 . . . . 2.57 111.365 176.114 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 31.0 m -50.58 156.48 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 C-N-CA 126.803 2.041 . . . . 2.59 116.116 -168.45 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -81.27 -173.54 47.94 Favored Glycine 0 CA--C 1.533 1.187 0 C-N-CA 123.804 0.716 . . . . 1.81 113.028 162.215 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 7.2 mp -120.88 163.09 31.56 Favored Pre-proline 0 CA--C 1.542 0.656 0 C-N-CA 125.745 1.618 . . . . 4.18 111.427 178.707 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -83.17 -138.11 0.02 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.691 0 C-N-CA 123.738 2.959 . . . . 2.38 107.708 156.285 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.329 0 CA-C-O 116.907 -2.052 . . . . 3.41 113.292 142.836 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo . . . . . 0 N--CA 1.489 1.259 0 N-CA-C 109.306 -1.075 . . . . 2.44 109.306 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.13 147.46 37.87 Favored Glycine 0 CA--C 1.538 1.52 0 CA-C-O 118.546 -1.141 . . . . 1.41 110.718 162.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -72.29 179.89 4.61 Favored 'Trans proline' 0 CA--C 1.54 0.797 0 C-N-CA 123.871 3.047 . . . . 2.15 109.9 163.059 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 12.1 tt0 -53.71 162.82 0.79 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.087 1.355 . . . . 4.42 114.437 178.511 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.25 161.23 51.7 Favored Glycine 0 N--CA 1.47 0.965 0 O-C-N 121.289 -0.882 . . . . 1.11 112.989 -178.415 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.6 pp -65.58 150.13 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 O-C-N 121.944 -0.739 . . . . 4.39 111.117 171.628 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.47 147.15 49.75 Favored 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 114.431 1.271 . . . . 1.71 114.431 -175.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.58 158.45 53.19 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 124.821 1.2 . . . . 1.77 111.492 170.065 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 21.2 mp0 -69.1 150.52 47.49 Favored 'General case' 0 CA--C 1.536 0.418 0 O-C-N 121.979 -0.718 . . . . 3.69 111.408 -173.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 17.0 mtt180 -67.55 148.74 51.05 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 109.693 -0.484 . . . . 6.03 109.693 160.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.3 165.53 43.04 Favored Glycine 0 CA--C 1.533 1.165 0 N-CA-C 115.052 0.781 . . . . 1.95 115.052 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 23.3 m -78.97 130.18 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 114.432 1.271 . . . . 3.64 114.432 -168.383 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.7 m -85.23 154.96 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 126.119 1.767 . . . . 2.52 112.113 -170.547 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.57 -134.4 8.46 Favored Glycine 0 CA--C 1.53 0.994 0 C-N-CA 124.442 1.02 . . . . 1.64 113.273 179.321 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -166.31 161.04 12.43 Favored Pre-proline 0 CA--C 1.547 0.831 0 C-N-CA 125.498 1.519 . . . . 3.25 112.326 -165.712 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo . . . . . 0 C--O 1.254 1.323 0 C-N-CA 124.821 3.681 . . . . 2.66 112.249 152.161 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo . . . . . 0 N--CA 1.487 1.097 0 CA-C-O 119.017 -0.493 . . . . 2.2 111.099 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -71.78 -138.87 0.02 OUTLIER 'Trans proline' 0 CA--C 1.546 1.1 0 C-N-CA 123.465 2.776 . . . . 1.76 107.988 157.704 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.87 168.48 37.59 Favored Glycine 0 CA--C 1.54 1.598 0 CA-C-N 119.383 0.992 . . . . 1.12 112.23 166.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -79.28 -43.65 0.14 Allowed 'Trans proline' 0 CA--C 1.535 0.555 0 C-N-CA 123.021 2.481 . . . . 3.65 113.662 -176.719 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 171.61 141.12 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 127.452 2.301 . . . . 1.35 105.865 -154.355 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -91.17 173.37 37.56 Favored Glycine 0 N--CA 1.466 0.634 0 C-N-CA 126.263 1.887 . . . . 0.89 114.474 171.766 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 17' ' ' ILE . . . . . 0.521 ' H ' HD12 ' C' ' 17' ' ' ILE . 3.9 mp -63.03 132.0 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 C-N-CA 124.464 1.106 . . . . 3.13 111.303 -175.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.66 135.05 57.18 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.824 0.85 . . . . 1.26 112.337 175.719 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -68.06 139.18 33.93 Favored Glycine 0 C--N 1.334 0.446 0 C-N-CA 124.835 1.207 . . . . 1.29 111.014 -173.202 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 98.8 mm-40 -93.19 158.22 15.87 Favored 'General case' 0 C--N 1.324 -0.501 0 O-C-N 122.026 -0.691 . . . . 4.69 111.856 -168.264 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.51 133.56 46.06 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 115.866 -0.606 . . . . 4.01 110.146 178.208 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.62 163.95 49.12 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 123.328 0.489 . . . . 1.11 113.491 -172.545 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 1.7 t -64.82 154.9 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 C-N-CA 123.372 0.669 . . . . 2.03 110.517 175.838 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 30.5 m -75.54 -173.5 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.816 0 C-N-CA 124.704 1.202 . . . . 3.08 110.898 170.611 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.97 -132.66 0.14 Allowed Glycine 0 CA--C 1.536 1.396 0 C-N-CA 125.078 1.323 . . . . 3.43 112.583 167.303 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 7.7 tt . . . . . 0 C--O 1.251 1.143 0 C-N-CA 126.643 1.977 . . . . 4.87 112.771 178.722 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.564 0 CA-C-O 116.782 -2.121 . . . . 3.18 110.134 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -70.44 167.15 26.16 Favored 'Trans proline' 0 C--N 1.348 0.525 0 C-N-CA 123.241 2.628 . . . . 2.06 110.9 177.756 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.12 176.45 9.74 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 127.938 2.495 . . . . 2.56 114.357 -172.929 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.9 177.44 44.77 Favored Glycine 0 N--CA 1.48 1.633 0 N-CA-C 116.8 1.48 . . . . 1.3 116.8 -169.404 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 7.8 pt -70.04 147.84 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 O-C-N 121.192 -1.181 . . . . 2.85 110.608 -173.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.14 134.78 44.24 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.77 0.795 . . . . 1.85 112.154 -179.058 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.76 144.85 25.78 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 126.364 1.935 . . . . 1.21 112.814 173.779 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 19.6 mm100 -67.91 125.22 25.61 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 108.651 -0.87 . . . . 3.13 108.651 -170.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 32.1 ttt-85 -69.53 145.43 52.63 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-O 121.832 0.825 . . . . 4.76 112.779 -156.016 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.28 144.31 37.34 Favored Glycine 0 CA--C 1.524 0.611 0 CA-C-O 122.296 0.942 . . . . 1.69 113.458 -175.007 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.3 t -62.79 150.17 9.31 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.521 0 C-N-CA 127.398 2.279 . . . . 2.65 111.444 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.4 m -48.44 158.83 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 C-N-CA 125.809 1.644 . . . . 2.01 113.993 173.154 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.85 174.09 40.52 Favored Glycine 0 CA--C 1.53 1.027 0 CA-C-N 115.999 -0.546 . . . . 1.41 111.931 160.786 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 79.8 mt -113.04 157.3 41.14 Favored Pre-proline 0 CA--C 1.539 0.526 0 C-N-CA 124.219 1.008 . . . . 3.61 110.181 -178.375 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.402 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 29.1 Cg_endo -79.74 -158.26 0.09 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.793 0 C-N-CA 123.395 2.73 . . . . 2.28 108.96 160.13 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.225 0 CA-C-O 118.06 -1.411 . . . . 3.4 113.251 154.182 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo . . . . . 0 CA--C 1.544 1.01 0 CA-C-O 119.493 -0.295 . . . . 2.06 111.769 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.15 170.72 37.2 Favored Glycine 0 CA--C 1.54 1.614 0 CA-C-O 118.86 -0.967 . . . . 1.35 112.175 125.557 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -72.23 -179.78 4.29 Favored 'Trans proline' 0 CA--C 1.541 0.829 0 C-N-CA 123.439 2.759 . . . . 2.37 108.742 148.715 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 pm0 -70.39 -175.15 0.95 Allowed 'General case' 0 CA--C 1.546 0.8 0 N-CA-C 113.946 1.091 . . . . 4.31 113.946 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.89 168.12 50.65 Favored Glycine 0 CA--C 1.528 0.901 0 O-C-N 120.347 -1.471 . . . . 0.92 114.187 -178.507 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 79.0 mt -76.01 145.56 10.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 124.569 1.148 . . . . 2.82 108.988 167.465 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -73.65 152.78 40.38 Favored 'General case' 0 CA--C 1.543 0.686 0 N-CA-C 115.161 1.541 . . . . 1.31 115.161 -170.51 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.36 132.74 21.12 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 125.615 1.579 . . . . 1.5 110.863 173.488 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -95.16 143.68 26.39 Favored 'General case' 0 N--CA 1.465 0.29 0 O-C-N 121.501 -0.999 . . . . 3.25 111.195 -172.575 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 3.2 mtm180 -55.83 150.89 12.26 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 125.605 1.562 . . . . 5.57 113.802 175.138 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.79 179.22 44.26 Favored Glycine 0 CA--C 1.538 1.521 0 C-N-CA 124.929 1.252 . . . . 1.96 113.252 165.812 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 58.4 t -112.43 148.63 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 C-N-CA 125.138 1.375 . . . . 3.91 113.019 -154.34 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.9 p -53.19 152.56 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 128.92 2.888 . . . . 3.75 115.708 -172.382 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.38 -131.59 3.4 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 125.097 1.332 . . . . 2.16 111.193 165.299 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.402 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.5 pt? -172.68 161.57 3.94 Favored Pre-proline 0 CA--C 1.544 0.745 0 C-N-CA 126.153 1.781 . . . . 3.46 111.018 -165.082 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo . . . . . 0 C--O 1.255 1.371 0 C-N-CA 124.644 3.563 . . . . 3.1 112.045 154.05 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo . . . . . 0 CA--C 1.547 1.14 0 CA-C-O 119.265 -0.389 . . . . 1.9 112.302 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -71.37 -132.24 0.01 OUTLIER 'Trans proline' 0 CA--C 1.542 0.893 0 C-N-CA 123.413 2.742 . . . . 1.69 108.121 162.524 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.3 162.09 34.72 Favored Glycine 0 CA--C 1.534 1.242 0 CA-C-N 119.821 1.191 . . . . 1.37 112.532 166.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -73.59 -49.11 0.22 Allowed 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 122.795 2.33 . . . . 3.62 112.079 176.293 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.4 tp-100 175.26 138.35 0.05 OUTLIER 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.129 1.772 . . . . 1.48 107.392 -152.823 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.42 166.43 36.36 Favored Glycine 0 CA--C 1.527 0.84 0 C-N-CA 125.807 1.67 . . . . 0.93 112.677 169.256 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 72.6 mt -69.18 138.57 22.0 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 O-C-N 121.84 -0.8 . . . . 2.2 109.335 -179.33 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -65.13 158.72 25.14 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.868 1.062 . . . . 1.11 113.868 177.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -82.51 -168.36 42.07 Favored Glycine 0 CA--C 1.528 0.859 0 CA-C-O 122.384 0.991 . . . . 1.52 111.14 170.52 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -158.44 179.72 8.87 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 124.265 1.026 . . . . 3.0 109.711 -172.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 5.1 tmm_? -64.95 141.97 58.59 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 125.781 1.632 . . . . 5.27 111.791 -174.643 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.73 -165.66 35.71 Favored Glycine 0 CA--C 1.532 1.148 0 C-N-CA 125.144 1.354 . . . . 1.4 115.542 -174.538 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 48.6 t -64.49 147.43 12.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.807 1.643 . . . . 2.06 110.029 176.043 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 33.3 m -102.17 -178.49 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 C-N-CA 125.351 1.46 . . . . 2.71 112.223 -175.126 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.51 171.4 6.84 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 125.061 1.315 . . . . 1.81 115.503 176.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 2.7 mm? . . . . . 0 C--O 1.249 1.072 0 C-N-CA 126.408 1.883 . . . . 3.48 113.116 -166.185 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.645 0 CA-C-O 115.79 -2.672 . . . . 4.95 109.045 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -76.7 179.12 6.77 Favored 'Trans proline' 0 CA--C 1.537 0.647 0 C-N-CA 123.395 2.73 . . . . 3.01 111.29 176.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.95 -152.16 0.35 Allowed 'General case' 0 CA--C 1.548 0.889 0 C-N-CA 126.789 2.036 . . . . 2.73 110.449 175.791 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.37 162.63 44.03 Favored Glycine 0 N--CA 1.473 1.12 0 O-C-N 120.629 -1.295 . . . . 1.47 114.268 -173.875 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 25.4 pt -69.88 149.03 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 O-C-N 121.226 -1.161 . . . . 2.51 110.525 178.789 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.98 132.56 50.25 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 123.555 0.742 . . . . 1.81 111.767 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.2 136.69 25.46 Favored Glycine 0 CA--C 1.522 0.498 0 C-N-CA 126.021 1.772 . . . . 2.11 112.13 169.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 14.8 mm100 -72.48 140.14 48.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.198 -0.501 . . . . 3.47 110.438 -166.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 46.8 ttt85 -66.63 134.24 51.91 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-O 121.372 0.606 . . . . 6.12 111.287 -172.625 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.53 146.77 46.33 Favored Glycine 0 CA--C 1.527 0.798 0 CA-C-O 122.08 0.822 . . . . 1.78 113.41 178.57 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.6 t -67.01 118.61 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 C-N-CA 125.819 1.648 . . . . 2.22 110.475 -171.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 24.3 m -44.84 143.71 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 C-N-CA 125.042 1.337 . . . . 2.55 114.383 -170.093 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -75.08 174.06 52.12 Favored Glycine 0 CA--C 1.533 1.174 0 N-CA-C 111.884 -0.486 . . . . 1.68 111.884 165.354 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 7.0 mp -122.24 160.32 48.3 Favored Pre-proline 0 CA--C 1.539 0.541 0 C-N-CA 125.273 1.429 . . . . 3.45 109.943 175.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.414 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 41.4 Cg_endo -75.98 -158.22 0.08 OUTLIER 'Trans proline' 0 CA--C 1.537 0.666 0 C-N-CA 122.882 2.388 . . . . 3.08 109.256 157.527 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.192 0 CA-C-O 116.76 -2.133 . . . . 5.32 112.532 142.762 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo . . . . . 0 N--CA 1.491 1.352 0 N-CA-C 109.089 -1.158 . . . . 3.24 109.089 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.27 144.88 36.74 Favored Glycine 0 CA--C 1.543 1.822 0 CA-C-O 118.697 -1.057 . . . . 1.81 111.415 164.652 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -77.04 -176.12 3.02 Favored 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 124.675 3.583 . . . . 2.52 110.134 163.471 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -61.19 173.47 0.84 Allowed 'General case' 0 CA--C 1.546 0.804 0 N-CA-C 116.336 1.976 . . . . 4.16 116.336 -175.247 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -90.01 154.37 23.7 Favored Glycine 0 CA--C 1.526 0.726 0 O-C-N 121.147 -0.971 . . . . 1.18 113.677 -174.062 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 79.7 mt -60.63 134.12 26.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 108.347 -0.983 . . . . 3.08 108.347 168.324 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.09 152.21 39.97 Favored 'General case' 0 CA--C 1.544 0.719 0 N-CA-C 112.752 0.649 . . . . 1.77 112.752 -177.708 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -83.81 -168.9 44.43 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 124.076 0.846 . . . . 2.5 111.003 169.629 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -148.6 176.21 10.53 Favored 'General case' 0 CA--C 1.536 0.431 0 O-C-N 120.961 -1.317 . . . . 3.82 112.231 171.048 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.2 ttm180 -59.65 159.47 8.53 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 125.661 1.585 . . . . 6.03 115.07 -164.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -63.66 157.91 40.94 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-N 116.276 -0.42 . . . . 2.42 114.136 170.203 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 35.9 t -85.61 121.27 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 C-N-CA 123.742 0.817 . . . . 3.41 111.86 -165.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.445 HG12 ' H ' ' C' ' 23' ' ' VAL . 6.3 m -69.06 156.51 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 126.154 1.781 . . . . 3.01 113.715 -170.675 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.29 -142.66 10.99 Favored Glycine 0 N--CA 1.469 0.878 0 C-N-CA 124.17 0.89 . . . . 2.04 112.436 167.059 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.414 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.6 pt? -172.73 160.48 3.87 Favored Pre-proline 0 CA--C 1.545 0.786 0 C-N-CA 124.854 1.262 . . . . 4.34 111.714 -158.428 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo . . . . . 0 C--O 1.255 1.336 0 C-N-CA 124.828 3.686 . . . . 3.02 112.329 155.292 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo . . . . . 0 N--CA 1.487 1.092 0 CA-C-O 119.2 -0.417 . . . . 2.5 111.125 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.56 -131.27 0.01 OUTLIER 'Trans proline' 0 CA--C 1.542 0.895 0 C-N-CA 122.362 2.041 . . . . 1.72 106.859 152.626 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.99 -179.78 48.74 Favored Glycine 0 CA--C 1.535 1.326 0 CA-C-N 119.558 1.072 . . . . 1.38 113.075 169.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -78.45 -110.0 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.039 0 C-N-CA 124.867 3.712 . . . . 2.59 109.718 161.752 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -146.58 134.51 21.37 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 127.904 2.482 . . . . 1.89 107.676 -159.395 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.34 169.52 54.01 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 124.614 1.102 . . . . 1.45 113.728 170.51 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 65.8 mt -73.16 131.44 34.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 121.745 -0.856 . . . . 2.94 111.221 -174.083 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.37 154.17 35.16 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 113.693 0.997 . . . . 1.52 113.693 178.483 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -82.99 162.4 40.71 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 124.806 1.193 . . . . 1.47 112.711 177.762 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 13.9 mp0 -101.69 -175.87 2.97 Favored 'General case' 0 CA--C 1.545 0.753 0 O-C-N 121.425 -1.044 . . . . 3.12 111.189 -178.115 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.46 140.66 54.07 Favored 'General case' 0 CA--C 1.541 0.601 0 O-C-N 121.514 -0.741 . . . . 5.16 111.561 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.57 154.63 36.49 Favored Glycine 0 N--CA 1.47 0.942 0 C-N-CA 125.517 1.532 . . . . 1.76 113.151 179.327 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 23' ' ' VAL . . . . . 0.445 ' H ' HG12 ' B' ' 24' ' ' VAL . 17.7 t -64.0 144.86 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 124.525 1.13 . . . . 2.8 111.02 -179.015 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 78.2 t -101.47 168.58 1.94 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.896 0 C-N-CA 126.603 1.961 . . . . 4.58 109.484 -175.143 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.25 177.43 3.35 Favored Glycine 0 CA--C 1.538 1.516 0 C-N-CA 124.196 0.903 . . . . 3.43 114.181 169.212 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 11.9 mt . . . . . 0 N--CA 1.484 1.241 0 N-CA-C 114.711 1.374 . . . . 4.45 114.711 -169.401 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.567 0 CA-C-O 116.258 -2.412 . . . . 2.79 109.321 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -67.57 170.02 14.62 Favored 'Trans proline' 0 CA--C 1.535 0.563 0 C-N-CA 123.029 2.486 . . . . 1.99 110.327 170.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 14.8 mm100 -56.51 -177.6 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 129.084 2.953 . . . . 4.59 116.256 -173.221 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -91.35 -173.05 43.26 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 124.309 0.957 . . . . 1.23 112.968 161.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 9.5 mt -72.05 128.09 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 N-CA-C 109.229 -0.656 . . . . 1.97 109.229 -177.387 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -52.92 135.15 36.99 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.487 0.715 . . . . 1.8 110.727 174.063 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.65 154.55 48.61 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 125.327 1.441 . . . . 1.27 113.387 -170.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 71.4 mm-40 -69.91 106.55 3.21 Favored 'General case' 0 CA--C 1.532 0.258 0 N-CA-C 109.877 -0.416 . . . . 3.04 109.877 -171.11 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.0 ttp180 -61.49 143.17 56.37 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 125.069 1.348 . . . . 4.3 114.186 -163.111 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.26 136.96 30.73 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 124.839 1.209 . . . . 1.57 113.517 -167.599 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 8.8 p -60.9 134.88 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 C-N-CA 125.493 1.517 . . . . 3.23 111.005 177.112 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 30.0 m -46.13 157.96 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.984 0 C-N-CA 127.148 2.179 . . . . 2.3 115.616 -171.8 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.42 171.6 43.36 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-N 115.424 -0.807 . . . . 1.35 113.476 168.315 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 87.6 mt -120.36 159.68 46.81 Favored Pre-proline 0 CA--C 1.54 0.566 0 C-N-CA 124.952 1.301 . . . . 2.64 110.776 -173.579 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -76.42 -169.56 0.72 Allowed 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 123.208 2.605 . . . . 1.83 109.797 161.006 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.182 0 CA-C-O 117.837 -1.535 . . . . 3.14 113.189 155.143 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo . . . . . 0 CA--C 1.545 1.073 0 CA-C-O 119.209 -0.413 . . . . 2.18 111.317 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.25 171.42 10.35 Favored Glycine 0 CA--C 1.54 1.613 0 C-N-CA 119.259 -1.448 . . . . 1.28 112.634 123.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -75.73 -57.89 0.05 OUTLIER 'Trans proline' 0 CA--C 1.535 0.554 0 C-N-CA 123.974 3.116 . . . . 2.7 111.042 170.763 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 175.55 152.38 0.14 Allowed 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 127.464 2.306 . . . . 4.43 107.702 -164.309 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.66 153.88 35.39 Favored Glycine 0 CA--C 1.527 0.785 0 C-N-CA 123.817 0.722 . . . . 0.91 112.695 174.793 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.49 ' H ' HD12 ' B' ' 17' ' ' ILE . 4.7 mp -67.36 136.1 27.29 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 108.657 -0.868 . . . . 2.69 108.657 173.503 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.24 153.85 41.43 Favored 'General case' 0 CA--C 1.541 0.634 0 N-CA-C 113.277 0.843 . . . . 1.52 113.277 -179.154 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -66.98 141.73 40.29 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 111.312 -0.715 . . . . 1.63 111.312 172.795 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -81.04 164.96 22.1 Favored 'General case' 0 CA--C 1.54 0.576 0 O-C-N 120.899 -1.354 . . . . 2.85 112.218 173.86 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -63.6 146.15 54.3 Favored 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 125.926 1.69 . . . . 4.69 112.586 173.231 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.55 157.97 53.4 Favored Glycine 0 CA--C 1.533 1.216 0 N-CA-C 115.087 0.795 . . . . 2.25 115.087 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 17.9 m -91.65 133.08 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 N-CA-C 114.708 1.373 . . . . 3.99 114.708 -164.776 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -56.36 150.81 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 C-N-CA 127.791 2.436 . . . . 3.12 115.164 -165.822 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -84.72 -122.49 1.05 Allowed Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.217 0.913 . . . . 2.12 111.182 165.525 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.3 pt? -170.8 156.65 5.04 Favored Pre-proline 0 CA--C 1.543 0.696 0 C-N-CA 124.756 1.223 . . . . 3.31 112.014 -161.291 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo . . . . . 0 CA--C 1.552 1.379 0 C-N-CA 124.123 3.215 . . . . 2.57 111.767 159.1 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo . . . . . 0 N--CA 1.488 1.168 0 CA-C-O 118.779 -0.592 . . . . 2.73 111.591 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 80.0 Cg_exo -50.6 177.41 0.03 OUTLIER 'Trans proline' 0 CA--C 1.537 0.656 1 C-N-CA 125.565 4.177 . . . . 1.87 113.568 162.599 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.26 178.85 53.69 Favored Glycine 0 CA--C 1.541 1.711 0 C-N-CA 123.575 0.607 . . . . 0.95 112.6 167.662 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_endo -70.18 156.78 61.47 Favored 'Trans proline' 0 N--CA 1.457 -0.628 0 C-N-CA 123.319 2.679 . . . . 2.49 111.571 171.747 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.0 tp60 -39.25 126.21 1.69 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 127.609 2.363 . . . . 1.4 113.046 164.182 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.9 168.48 49.92 Favored Glycine 0 CA--C 1.529 0.922 0 C-N-CA 124.75 1.167 . . . . 0.89 112.67 170.058 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 29.7 mt -67.51 143.26 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 O-C-N 121.228 -1.16 . . . . 2.33 110.747 -172.512 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.77 151.82 28.62 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 112.891 0.7 . . . . 1.08 112.891 172.349 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.0 169.64 52.13 Favored Glycine 0 CA--C 1.527 0.816 0 CA-C-O 122.823 1.235 . . . . 1.12 113.519 178.532 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 40.0 mt-30 -95.84 154.29 17.3 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.355 -1.085 . . . . 3.88 111.767 -170.029 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -62.72 135.17 57.22 Favored 'General case' 0 C--O 1.234 0.253 0 N-CA-C 109.207 -0.664 . . . . 5.08 109.207 168.501 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -66.65 173.07 26.97 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 116.204 1.242 . . . . 1.06 116.204 -165.732 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 61.0 t -66.95 136.88 25.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 C-N-CA 124.443 1.097 . . . . 1.82 109.013 173.264 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 33.9 m -100.82 -169.68 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 C-N-CA 124.53 1.132 . . . . 2.41 110.845 -169.47 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.33 155.22 4.91 Favored Glycine 0 CA--C 1.532 1.154 0 C-N-CA 124.657 1.122 . . . . 1.58 114.27 172.39 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 8.8 mt . . . . . 0 C--O 1.249 1.079 0 CA-C-O 117.637 -1.173 . . . . 3.94 113.998 -162.871 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.52 0 CA-C-O 116.317 -2.379 . . . . 3.23 109.063 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -63.17 161.7 29.28 Favored 'Trans proline' 0 C--N 1.348 0.526 0 C-N-CA 122.83 2.353 . . . . 2.08 110.534 173.485 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.72 -179.14 0.35 Allowed 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.931 2.493 . . . . 3.32 113.978 176.559 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.98 -178.74 44.64 Favored Glycine 0 CA--C 1.527 0.797 0 C-N-CA 125.556 1.551 . . . . 1.29 114.686 174.155 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.8 mt -65.63 134.0 30.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 123.951 0.9 . . . . 2.43 109.922 -172.667 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.93 129.76 38.84 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 123.703 0.801 . . . . 2.34 111.471 173.654 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.78 166.77 54.18 Favored Glycine 0 CA--C 1.522 0.477 0 C-N-CA 127.44 2.447 . . . . 1.47 113.069 -177.396 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 14.0 mp0 -82.38 113.58 20.25 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 108.591 -0.892 . . . . 4.13 108.591 -162.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 73.8 ttt180 -49.56 130.66 20.71 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 124.2 1.0 . . . . 4.05 112.199 -173.368 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.26 145.58 39.5 Favored Glycine 0 N--CA 1.464 0.523 0 C-N-CA 124.75 1.167 . . . . 1.66 113.102 -173.544 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 28.2 m -63.89 161.28 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 124.566 1.147 . . . . 2.2 111.615 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.8 m -47.97 157.22 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 125.443 1.497 . . . . 2.1 113.667 177.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.29 173.33 39.87 Favored Glycine 0 CA--C 1.527 0.812 0 CA-C-N 115.391 -0.822 . . . . 1.42 112.171 162.165 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 87.6 mt -111.57 158.19 37.1 Favored Pre-proline 0 CA--C 1.537 0.451 0 C-N-CA 123.687 0.795 . . . . 3.89 110.523 -178.24 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -81.39 -160.56 0.13 Allowed 'Trans proline' 0 N--CA 1.454 -0.829 0 C-N-CA 123.302 2.668 . . . . 2.74 108.889 158.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.135 0 CA-C-O 117.75 -1.583 . . . . 3.91 113.021 152.076 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo . . . . . 0 CA--C 1.543 0.927 0 CA-C-O 119.157 -0.435 . . . . 2.17 111.664 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.57 162.99 43.93 Favored Glycine 0 CA--C 1.543 1.834 0 C-N-CA 119.516 -1.326 . . . . 1.38 111.766 130.018 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -76.49 -53.54 0.08 OUTLIER 'Trans proline' 0 CA--C 1.536 0.618 0 C-N-CA 124.876 3.717 . . . . 3.22 113.055 177.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -177.13 159.16 1.6 Allowed 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 128.45 2.7 . . . . 3.69 106.8 -162.471 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.11 155.26 22.88 Favored Glycine 0 N--CA 1.468 0.817 0 C-N-CA 124.189 0.899 . . . . 1.03 113.039 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 34.4 mm -67.94 130.37 33.1 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 N-CA-C 109.107 -0.701 . . . . 2.69 109.107 172.601 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -73.28 166.76 22.57 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 113.866 1.062 . . . . 2.12 113.866 -174.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -73.93 113.63 4.25 Favored Glycine 0 CA--C 1.53 1.027 0 C-N-CA 124.313 0.958 . . . . 2.21 112.516 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 -66.23 141.51 58.02 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 123.683 0.793 . . . . 4.61 112.769 178.44 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 9.2 mtt85 -62.05 159.44 14.43 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 115.096 1.517 . . . . 5.66 115.096 -176.345 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.99 -179.29 44.46 Favored Glycine 0 CA--C 1.538 1.474 0 C-N-CA 125.453 1.501 . . . . 1.74 113.151 163.822 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 15.6 m -112.03 146.97 16.2 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 N-CA-C 115.015 1.487 . . . . 3.15 115.015 -158.565 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 8.9 p -54.36 152.42 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 127.973 2.509 . . . . 3.71 115.351 -170.332 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -85.72 -129.23 2.24 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 124.599 1.095 . . . . 1.99 111.062 162.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -170.79 159.94 5.71 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 125.252 1.421 . . . . 3.36 111.777 -168.594 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo . . . . . 0 C--O 1.256 1.397 1 C-N-CA 125.306 4.004 . . . . 2.69 111.931 155.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo . . . . . 0 CA--C 1.547 1.149 0 CA-C-O 118.318 -0.784 . . . . 2.47 111.433 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -54.04 -169.49 0.02 OUTLIER 'Trans proline' 0 CA--C 1.541 0.864 1 C-N-CA 126.043 4.495 . . . . 1.55 113.595 164.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -83.83 175.03 51.76 Favored Glycine 0 CA--C 1.542 1.779 0 O-C-N 121.769 -0.582 . . . . 1.12 112.345 165.378 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -69.47 157.91 59.26 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 122.996 2.464 . . . . 2.53 111.166 170.076 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 tp60 -41.09 124.87 2.32 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.82 2.048 . . . . 1.48 113.439 165.355 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.65 154.65 53.01 Favored Glycine 0 CA--C 1.53 0.974 0 C-N-CA 124.391 0.996 . . . . 1.03 112.382 171.135 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 1.8 mp -67.87 146.1 13.21 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 C-N-CA 124.524 1.129 . . . . 2.51 110.99 -168.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.95 142.0 54.54 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 125.216 1.406 . . . . 1.4 113.197 178.311 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -76.07 134.04 15.21 Favored Glycine 0 C--N 1.333 0.366 0 N-CA-C 110.384 -1.086 . . . . 1.41 110.384 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -88.09 171.9 9.92 Favored 'General case' 0 CA--C 1.542 0.644 0 CA-C-N 115.088 -0.556 . . . . 2.96 109.524 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -61.12 155.27 20.95 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.711 0.767 . . . . 4.98 112.279 179.544 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.44 -176.62 25.09 Favored Glycine 0 CA--C 1.53 1.012 0 C-N-CA 124.995 1.283 . . . . 1.45 113.512 179.395 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 49.0 t -59.13 143.5 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.879 1.272 . . . . 2.42 110.279 176.12 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 30.9 m -97.76 -175.75 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.056 1.342 . . . . 3.44 112.024 -173.665 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.43 167.35 19.02 Favored Glycine 0 CA--C 1.532 1.127 0 C-N-CA 124.984 1.278 . . . . 2.23 114.867 175.778 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 9.6 mp . . . . . 0 C--O 1.249 1.046 0 C-N-CA 126.516 1.927 . . . . 3.83 113.463 -166.9 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.731 0 CA-C-O 116.337 -2.368 . . . . 5.59 108.929 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -77.37 -172.43 1.45 Allowed 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 122.943 2.429 . . . . 4.07 109.981 171.78 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.9 -137.18 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 124.583 1.153 . . . . 2.88 110.188 157.295 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.52 -148.78 17.59 Favored Glycine 0 N--CA 1.468 0.83 0 CA-C-O 122.827 1.237 . . . . 1.87 114.75 172.496 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.9 mt -84.1 158.38 3.6 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.506 0 C-N-CA 124.131 0.972 . . . . 3.52 108.435 177.371 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.65 46.69 0.09 Allowed 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 126.807 2.043 . . . . 4.24 112.599 170.239 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 61.56 -155.09 37.51 Favored Glycine 0 C--N 1.337 0.609 0 C-N-CA 125.289 1.424 . . . . 2.07 112.627 -171.122 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 7.1 mp0 -105.56 160.92 14.8 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.935 0.874 . . . . 4.99 110.408 158.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.4 tpt180 -66.0 141.24 58.25 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.203 -0.908 . . . . 4.01 109.828 163.346 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -93.29 -167.18 38.39 Favored Glycine 0 C--O 1.227 -0.308 0 C-N-CA 125.324 1.44 . . . . 2.45 112.787 177.885 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 52.8 t -82.61 132.93 30.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 124.524 1.13 . . . . 2.95 109.035 -176.85 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.8 m -56.37 145.61 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 C-N-CA 124.47 1.108 . . . . 2.88 112.926 -178.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.96 145.13 17.64 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 109.951 -1.26 . . . . 1.75 109.951 165.829 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 85.3 mt -91.18 156.43 43.86 Favored Pre-proline 0 N--CA 1.472 0.662 0 CA-C-O 117.161 -1.4 . . . . 3.94 110.444 171.202 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -80.24 -158.04 0.09 OUTLIER 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 123.645 2.897 . . . . 3.46 109.23 166.393 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.24 0 CA-C-O 117.549 -1.695 . . . . 5.43 113.458 154.643 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo . . . . . 0 N--CA 1.491 1.364 0 N-CA-C 109.165 -1.129 . . . . 4.26 109.165 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.04 140.92 30.72 Favored Glycine 0 CA--C 1.539 1.55 0 CA-C-O 118.044 -1.42 . . . . 2.31 110.003 158.541 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -68.62 -175.01 0.79 Allowed 'Trans proline' 0 CA--C 1.538 0.695 0 C-N-CA 123.787 2.991 . . . . 2.43 109.878 162.407 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 4.7 tp-100 -50.47 148.79 3.5 Favored 'General case' 0 CA--C 1.541 0.599 0 N-CA-C 114.734 1.383 . . . . 4.64 114.734 -174.476 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.15 165.83 48.62 Favored Glycine 0 C--N 1.339 0.736 0 CA-C-O 123.285 1.492 . . . . 1.97 112.854 169.145 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 8.2 mm -71.67 160.84 5.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 123.279 1.514 . . . . 4.01 110.722 178.336 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -46.35 147.67 1.09 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.854 1.261 . . . . 2.82 112.975 153.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -82.55 169.16 48.79 Favored Glycine 0 C--N 1.336 0.574 0 CA-C-O 122.626 1.125 . . . . 2.78 112.681 178.726 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -118.41 123.59 45.61 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 123.487 0.715 . . . . 3.58 111.014 -166.247 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 14.9 ptt180 -55.16 134.21 49.42 Favored 'General case' 0 N--CA 1.47 0.546 0 O-C-N 122.056 -0.403 . . . . 5.37 110.703 179.112 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.18 -45.4 93.76 Favored Glycine 0 N--CA 1.477 1.407 0 N-CA-C 114.825 0.69 . . . . 4.28 114.825 -150.059 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 55.3 t -158.99 164.37 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.877 1 C-N-CA 132.117 4.167 . . . . 3.77 105.613 179.699 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 23.0 m -134.34 156.25 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 C-N-CA 125.989 1.716 . . . . 3.74 109.051 168.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -79.62 -175.28 47.54 Favored Glycine 0 C--N 1.335 0.515 0 CA-C-O 122.189 0.883 . . . . 2.9 114.263 179.517 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -159.08 158.11 28.5 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 126.982 2.113 . . . . 6.11 109.921 175.407 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.256 1.381 0 C-N-CA 125.293 3.996 . . . . 5.34 111.831 164.375 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo . . . . . 0 N--CA 1.486 1.04 0 CA-C-O 118.616 -0.66 . . . . 3.57 111.097 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -68.73 -163.78 0.1 OUTLIER 'Trans proline' 0 CA--C 1.544 0.987 0 C-N-CA 123.469 2.779 . . . . 2.93 109.466 157.182 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.91 154.09 52.72 Favored Glycine 0 CA--C 1.541 1.706 0 O-C-N 121.751 -0.593 . . . . 1.64 113.8 172.102 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -79.83 87.15 1.56 Allowed 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 124.504 3.469 . . . . 2.97 111.664 -173.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 30.4 tp60 67.8 -124.12 0.19 Allowed 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.615 1.166 . . . . 2.82 108.777 -176.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.63 -179.4 41.07 Favored Glycine 0 CA--C 1.534 1.256 1 C-N-CA 131.956 4.598 . . . . 1.89 107.523 -171.58 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -74.69 156.44 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 O-C-N 120.726 -1.455 . . . . 2.27 110.223 176.232 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.26 159.03 30.99 Favored 'General case' 0 CA--C 1.543 0.675 0 O-C-N 120.215 -1.553 . . . . 1.86 112.165 173.792 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -97.93 160.75 20.9 Favored Glycine 0 CA--C 1.53 0.988 0 C-N-CA 124.502 1.049 . . . . 1.73 112.124 177.576 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 22.9 mp0 -101.87 -179.79 4.11 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 124.376 1.071 . . . . 3.0 111.862 -170.815 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 6.2 tpt85 -66.8 138.62 57.49 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.908 0.883 . . . . 3.73 110.103 162.713 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.83 172.07 30.78 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 124.175 0.893 . . . . 1.43 112.009 172.214 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 23' ' ' VAL . . . . . 0.414 HG23 ' H ' ' C' ' 23' ' ' VAL . 1.9 t -57.15 144.64 9.07 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 124.914 1.285 . . . . 2.18 110.872 -179.733 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.446 HG22 ' H ' ' C' ' 25' ' ' GLY . 7.5 p -75.9 -169.32 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.189 0 C-N-CA 124.557 1.143 . . . . 4.13 109.129 164.716 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.446 ' H ' HG22 ' C' ' 24' ' ' VAL . . . -52.5 168.29 0.83 Allowed Glycine 0 CA--C 1.541 1.656 0 CA-C-N 119.858 1.208 . . . . 1.98 113.913 161.414 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 10.2 mp . . . . . 0 C--O 1.249 1.03 0 C-N-CA 125.72 1.608 . . . . 4.69 112.723 -171.784 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.588 0 CA-C-O 116.864 -2.076 . . . . 2.71 110.148 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -73.66 166.9 28.61 Favored 'Trans proline' 0 N--CA 1.458 -0.596 0 C-N-CA 123.268 2.645 . . . . 1.86 111.312 -177.533 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -60.92 167.07 3.04 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 126.473 1.909 . . . . 3.12 113.627 173.654 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -78.48 166.52 52.43 Favored Glycine 0 CA--C 1.518 0.247 0 CA-C-N 114.986 -1.007 . . . . 1.39 113.587 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 21.2 mt -51.93 124.76 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 C-N-CA 125.698 1.599 . . . . 2.43 109.557 178.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -42.9 132.45 3.91 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.715 1.206 . . . . 1.97 112.597 178.449 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.43 149.78 51.67 Favored Glycine 0 CA--C 1.517 0.195 0 C-N-CA 125.129 1.347 . . . . 1.17 111.673 -178.295 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 7.3 mp0 -62.68 114.53 3.64 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 114.962 -0.619 . . . . 4.3 109.636 -173.482 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 48.6 ttt85 -54.56 139.75 37.08 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.686 1.195 . . . . 4.45 112.435 -173.673 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.41 142.62 32.91 Favored Glycine 0 CA--C 1.525 0.698 0 C-N-CA 124.242 0.925 . . . . 1.73 112.71 -175.525 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -60.37 153.42 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 C-N-CA 126.4 1.88 . . . . 2.15 113.231 178.035 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 m -66.99 150.61 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 124.85 1.26 . . . . 2.33 112.924 -175.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.58 153.34 51.51 Favored Glycine 0 CA--C 1.531 1.037 0 CA-C-N 115.899 -0.591 . . . . 1.48 112.436 170.44 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 10.1 mp -83.62 160.25 59.29 Favored Pre-proline 0 CA--C 1.544 0.723 0 C-N-CA 123.882 0.873 . . . . 3.45 111.166 176.608 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -81.9 -158.71 0.1 OUTLIER 'Trans proline' 0 CA--C 1.537 0.649 0 C-N-CA 123.997 3.131 . . . . 1.75 109.127 158.228 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.169 0 CA-C-O 117.336 -1.813 . . . . 3.09 112.843 155.802 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo . . . . . 0 CA--C 1.545 1.056 0 CA-C-O 119.289 -0.38 . . . . 2.02 111.143 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.08 -178.49 10.44 Favored Glycine 0 CA--C 1.544 1.882 0 CA-C-O 119.035 -0.869 . . . . 1.59 112.625 125.512 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -77.83 -134.99 0.02 OUTLIER 'Trans proline' 0 CA--C 1.546 1.1 1 C-N-CA 125.642 4.228 . . . . 2.18 109.071 160.535 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.37 176.44 9.68 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 124.986 1.314 . . . . 3.66 110.99 166.87 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.14 157.85 39.49 Favored Glycine 0 N--CA 1.472 1.047 0 O-C-N 121.357 -0.839 . . . . 0.93 112.698 154.318 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 28.3 mm -77.88 131.49 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 108.596 -0.89 . . . . 3.25 108.596 173.647 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -77.4 157.67 30.46 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 114.078 1.14 . . . . 1.72 114.078 -173.063 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.01 121.31 8.39 Favored Glycine 0 CA--C 1.529 0.957 0 C-N-CA 124.298 0.951 . . . . 1.68 111.687 -179.473 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.96 155.54 40.7 Favored 'General case' 0 CA--C 1.54 0.58 0 O-C-N 121.496 -1.003 . . . . 2.72 111.759 174.344 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.7 ptt-85 -66.14 161.47 21.83 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 122.297 1.046 . . . . 4.54 113.045 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.75 -179.18 49.12 Favored Glycine 0 CA--C 1.529 0.91 0 C-N-CA 125.59 1.567 . . . . 1.89 111.865 172.885 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 7.0 m -100.89 139.79 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 N-CA-C 114.253 1.205 . . . . 3.37 114.253 -160.401 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 26.5 m -64.49 160.27 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 C-N-CA 126.292 1.837 . . . . 2.52 113.502 -174.386 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -88.92 -135.82 5.53 Favored Glycine 0 CA--C 1.529 0.914 0 C-N-CA 124.147 0.879 . . . . 1.71 111.84 171.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -167.29 163.65 9.94 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 125.576 1.55 . . . . 3.21 110.745 -167.031 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo . . . . . 0 C--O 1.257 1.445 0 C-N-CA 124.264 3.309 . . . . 2.61 112.163 167.177 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo . . . . . 0 N--CA 1.487 1.102 0 CA-C-O 119.059 -0.476 . . . . 2.04 111.837 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.28 -137.78 0.02 OUTLIER 'Trans proline' 0 CA--C 1.54 0.825 0 C-N-CA 123.298 2.665 . . . . 1.45 108.226 163.668 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -79.0 151.7 35.65 Favored Glycine 0 CA--C 1.542 1.753 0 CA-C-N 119.557 1.071 . . . . 0.95 112.758 173.431 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -85.19 64.08 6.08 Favored 'Trans proline' 0 CA--C 1.541 0.849 0 C-N-CA 124.556 3.504 . . . . 3.17 111.34 -176.845 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 71.89 151.52 0.11 Allowed 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 125.343 1.457 . . . . 2.55 112.716 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.03 153.74 22.05 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 124.769 1.176 . . . . 1.17 111.416 166.152 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 66.0 mt -71.62 144.77 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.8 0 O-C-N 121.805 -0.821 . . . . 2.06 111.193 -177.327 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.17 149.02 48.68 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.97 1.308 . . . . 1.3 113.205 175.413 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -88.7 140.95 16.23 Favored Glycine 0 CA--C 1.532 1.138 0 C-N-CA 125.106 1.336 . . . . 1.11 114.686 -175.124 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 20' ' ' GLN . . . . . 0.572 HE21 ' N ' ' C' ' 20' ' ' GLN . 0.0 OUTLIER -71.51 157.15 38.52 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 126.641 1.976 . . . . 3.89 112.059 168.628 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 46.3 ttp180 -62.07 158.12 17.35 Favored 'General case' 0 CA--C 1.54 0.581 0 N-CA-C 114.331 1.234 . . . . 3.87 114.331 176.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -66.14 168.96 32.66 Favored Glycine 0 CA--C 1.537 1.434 0 CA-C-O 122.112 0.84 . . . . 1.04 113.237 158.149 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.2 t -68.03 160.85 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 125.86 1.664 . . . . 2.15 111.097 179.111 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 28.6 m -83.17 -175.19 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 125.896 1.678 . . . . 2.28 111.774 175.781 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.37 173.5 5.38 Favored Glycine 0 CA--C 1.537 1.409 0 C-N-CA 125.164 1.364 . . . . 1.61 114.55 169.073 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 5.7 mt . . . . . 0 C--O 1.25 1.113 0 N-CA-C 114.136 1.162 . . . . 3.63 114.136 -159.072 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.354 0 CA-C-O 116.197 -2.446 . . . . 3.02 107.782 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -69.16 -170.03 0.33 Allowed 'Trans proline' 0 CA--C 1.541 0.848 0 C-N-CA 122.256 1.971 . . . . 2.19 109.571 156.635 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.435 ' CD ' ' H ' ' A' ' 15' ' ' GLN . 0.0 OUTLIER -87.07 -168.68 2.33 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 127.414 2.286 . . . . 3.02 111.909 168.142 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.91 177.98 45.0 Favored Glycine 0 N--CA 1.474 1.209 0 C-N-CA 125.978 1.752 . . . . 1.63 112.957 161.382 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.588 ' H ' HD12 ' A' ' 17' ' ' ILE . 2.8 mp -61.98 141.44 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 O-C-N 121.813 -0.816 . . . . 2.59 110.372 -174.544 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.88 133.88 56.52 Favored 'General case' 0 CA--C 1.537 0.469 0 CA-C-N 119.039 0.836 . . . . 1.74 110.946 170.582 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.57 146.53 41.08 Favored Glycine 0 CA--C 1.523 0.581 0 C-N-CA 126.569 2.033 . . . . 1.43 114.603 -178.144 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 73.1 mm-40 -77.56 134.89 38.16 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 114.604 -0.798 . . . . 3.69 110.816 -166.405 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 31.6 mtt180 -59.21 137.46 57.96 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 121.642 0.734 . . . . 4.41 112.529 -171.258 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -78.35 -179.41 50.77 Favored Glycine 0 CA--C 1.523 0.581 0 CA-C-O 123.271 1.484 . . . . 1.87 115.363 -168.282 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -71.6 156.56 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 CA-C-N 113.489 -1.356 . . . . 2.38 111.826 -169.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 p -56.4 143.06 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 125.263 1.425 . . . . 5.25 111.967 168.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.48 ' H ' ' HB ' ' B' ' 23' ' ' VAL . . . -93.62 -162.78 36.25 Favored Glycine 0 N--CA 1.472 1.059 0 C-N-CA 124.426 1.013 . . . . 2.42 113.873 170.657 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 93.0 mt -142.43 153.47 62.46 Favored Pre-proline 0 N--CA 1.471 0.59 0 C-N-CA 126.044 1.738 . . . . 3.52 109.823 172.761 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -79.21 -155.6 0.06 OUTLIER 'Trans proline' 0 CA--C 1.539 0.752 0 C-N-CA 123.138 2.559 . . . . 2.21 108.909 159.454 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.291 0 CA-C-O 118.002 -1.443 . . . . 3.84 113.51 158.225 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo . . . . . 0 CA--C 1.544 0.994 0 CA-C-O 118.791 -0.587 . . . . 2.24 111.773 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.0 159.66 49.28 Favored Glycine 0 CA--C 1.548 2.147 0 C-N-CA 118.977 -1.582 . . . . 1.23 110.886 127.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -75.84 -66.84 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.617 1 C-N-CA 125.349 4.033 . . . . 3.04 111.809 177.061 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.16 161.64 41.18 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 128.892 2.877 . . . . 4.23 107.182 -176.812 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.42 160.44 31.72 Favored Glycine 0 N--CA 1.464 0.555 0 C-N-CA 123.629 0.633 . . . . 1.04 112.922 174.855 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.3 pp -78.23 149.37 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 O-C-N 122.313 -0.522 . . . . 4.05 111.215 176.423 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.8 153.12 38.89 Favored 'General case' 0 CA--C 1.543 0.698 0 N-CA-C 113.528 0.936 . . . . 1.29 113.528 -174.777 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.81 147.7 26.7 Favored Glycine 0 CA--C 1.528 0.866 0 C-N-CA 125.947 1.737 . . . . 1.59 114.572 -172.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 37.4 tt0 -77.95 148.08 34.65 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 126.386 1.874 . . . . 4.15 111.599 172.434 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 31.6 mtt180 -64.86 164.37 12.57 Favored 'General case' 0 N--CA 1.473 0.702 0 O-C-N 121.306 -0.871 . . . . 4.15 112.299 174.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.3 -144.1 3.47 Favored Glycine 0 CA--C 1.534 1.222 0 CA-C-N 114.959 -1.018 . . . . 2.51 110.96 161.475 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 23' ' ' VAL . . . . . 0.48 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 49.8 t -53.26 137.52 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 C-N-CA 124.3 1.04 . . . . 5.26 112.687 -176.44 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 26.4 m -103.12 162.41 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 125.651 1.58 . . . . 3.4 111.23 172.442 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.14 171.7 24.75 Favored Glycine 0 C--N 1.338 0.656 0 C-N-CA 125.412 1.482 . . . . 2.54 113.507 -176.18 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -169.38 157.59 6.92 Favored Pre-proline 0 CA--C 1.545 0.754 0 C-N-CA 126.105 1.762 . . . . 3.94 111.521 -168.73 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo . . . . . 0 C--O 1.256 1.39 0 C-N-CA 124.611 3.541 . . . . 3.49 111.803 159.363 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo . . . . . 0 CA--C 1.548 1.178 0 CA-C-O 118.951 -0.521 . . . . 2.43 111.667 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -56.18 -174.4 0.04 OUTLIER 'Trans proline' 0 CA--C 1.539 0.756 0 C-N-CA 124.994 3.796 . . . . 1.72 112.863 164.258 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.71 178.13 54.1 Favored Glycine 0 CA--C 1.541 1.682 0 C-N-CA 123.628 0.633 . . . . 1.01 112.145 165.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -67.91 155.96 67.75 Favored 'Trans proline' 0 N--CA 1.457 -0.62 0 C-N-CA 122.904 2.403 . . . . 2.59 111.001 171.721 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 22.0 tp60 -40.55 121.36 1.42 Allowed 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 127.384 2.274 . . . . 1.51 112.946 169.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.4 157.08 44.72 Favored Glycine 0 CA--C 1.527 0.814 0 C-N-CA 124.29 0.948 . . . . 0.91 112.091 170.757 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 2.2 mp -65.22 140.55 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 123.548 0.739 . . . . 2.18 110.486 -169.129 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.51 156.57 15.98 Favored 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 123.065 1.412 . . . . 1.05 114.748 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.83 145.85 39.04 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 108.994 -1.643 . . . . 1.0 108.994 174.668 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 7.2 mp0 -82.99 -179.46 7.45 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.884 0.85 . . . . 3.63 110.441 -170.077 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 1.9 tmt_? -57.63 138.39 55.39 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-O 121.618 0.723 . . . . 3.4 110.095 169.119 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.46 148.25 51.09 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 124.367 0.985 . . . . 1.82 112.04 178.299 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 91.2 t -64.86 148.43 11.96 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.603 0 C-N-CA 124.246 1.018 . . . . 2.3 110.447 -173.172 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 12.3 p -97.24 171.79 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.995 0 C-N-CA 127.982 2.513 . . . . 2.97 111.059 -178.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.5 -168.66 0.61 Allowed Glycine 0 CA--C 1.54 1.614 0 C-N-CA 125.203 1.382 . . . . 2.08 116.083 171.102 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 15.5 mt . . . . . 0 C--O 1.249 1.047 0 C-N-CA 125.736 1.614 . . . . 3.55 115.12 -170.544 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.511 0 CA-C-O 116.915 -2.047 . . . . 3.38 110.172 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -71.62 162.02 43.46 Favored 'Trans proline' 0 N--CA 1.458 -0.575 0 C-N-CA 123.611 2.874 . . . . 2.21 111.39 -177.722 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 31.2 tp60 -46.07 163.73 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 129.228 3.011 . . . . 3.66 115.53 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.56 172.47 42.82 Favored Glycine 0 CA--C 1.524 0.638 0 C-N-CA 124.388 0.994 . . . . 1.21 114.616 168.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.558 ' H ' HD12 ' A' ' 17' ' ' ILE . 3.0 mp -60.41 140.53 18.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 C-N-CA 124.975 1.31 . . . . 3.02 109.858 -179.369 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.41 130.01 37.82 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 123.318 0.647 . . . . 2.4 111.291 170.512 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.59 161.49 54.22 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 126.122 1.82 . . . . 1.43 113.58 176.447 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 11.0 mm100 -74.33 115.35 13.74 Favored 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 109.675 -0.491 . . . . 3.6 109.675 -168.248 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -58.46 139.26 55.86 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.564 0.746 . . . . 3.93 112.219 -175.348 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.38 147.3 35.65 Favored Glycine 0 CA--C 1.522 0.527 0 C-N-CA 125.848 1.689 . . . . 1.59 113.542 -173.093 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.0 p -66.6 144.82 14.32 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 125.465 1.506 . . . . 3.63 110.573 176.458 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -50.69 157.61 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 126.09 1.756 . . . . 2.15 114.716 -175.257 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.5 175.4 53.49 Favored Glycine 0 N--CA 1.474 1.207 0 N-CA-C 110.787 -0.925 . . . . 1.69 110.787 158.311 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 17.6 mt -149.84 157.04 38.46 Favored Pre-proline 0 N--CA 1.471 0.621 0 N-CA-C 115.884 1.809 . . . . 3.41 115.884 -152.383 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -68.2 104.66 1.09 Allowed 'Trans proline' 0 N--CA 1.449 -1.09 0 N-CA-C 106.529 -2.143 . . . . 2.5 106.529 154.637 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.231 0 CA-C-O 118.923 -0.932 . . . . 6.39 114.218 -160.405 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo . . . . . 0 CA--C 1.544 0.987 0 N-CA-C 110.993 -0.426 . . . . 2.73 110.993 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.63 -170.4 0.41 Allowed Glycine 0 CA--C 1.538 1.488 0 C-N-CA 120.457 -0.878 . . . . 1.86 113.875 125.537 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -74.38 -123.39 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 0.998 0 C-N-CA 124.069 3.179 . . . . 2.07 107.545 157.489 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -100.29 178.7 4.68 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.309 1.443 . . . . 6.16 112.218 175.137 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.46 145.72 25.46 Favored Glycine 0 N--CA 1.472 1.047 0 O-C-N 121.202 -0.936 . . . . 1.22 112.684 164.215 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 96.7 mt -63.38 132.77 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 O-C-N 121.079 -1.248 . . . . 3.24 108.659 170.375 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -77.55 157.05 30.53 Favored 'General case' 0 CA--C 1.542 0.65 0 N-CA-C 114.151 1.167 . . . . 2.13 114.151 -169.382 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.54 140.27 40.64 Favored Glycine 0 CA--C 1.524 0.634 0 C-N-CA 126.229 1.871 . . . . 1.8 110.5 169.522 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 10.4 mp0 -95.95 147.86 23.24 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 123.308 0.643 . . . . 3.91 110.84 -165.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 3.8 ttt180 -64.12 154.76 33.61 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 124.525 1.13 . . . . 5.09 113.722 -176.229 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.68 155.86 52.35 Favored Glycine 0 CA--C 1.531 1.05 0 C-N-CA 124.042 0.83 . . . . 1.99 115.115 176.053 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 27.7 m -75.58 136.8 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 114.677 1.362 . . . . 3.22 114.677 -174.023 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.6 m -56.43 156.5 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.002 0 N-CA-C 116.729 2.122 . . . . 2.82 116.729 -162.168 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.56 -177.06 42.93 Favored Glycine 0 C--N 1.34 0.753 0 C-N-CA 125.864 1.697 . . . . 2.08 115.8 -167.087 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.6 mp -147.72 158.37 42.92 Favored Pre-proline 0 CA--C 1.546 0.813 0 C-N-CA 125.453 1.501 . . . . 4.63 113.031 -165.428 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo . . . . . 0 C--O 1.255 1.343 0 C-N-CA 123.843 3.029 . . . . 3.42 112.635 148.585 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo . . . . . 0 CA--C 1.547 1.151 0 CA-C-O 118.323 -0.782 . . . . 2.26 111.855 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_exo -49.58 -179.35 0.02 OUTLIER 'Trans proline' 0 C--N 1.35 0.655 1 C-N-CA 126.571 4.847 . . . . 1.9 114.402 166.549 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.26 148.55 51.41 Favored Glycine 0 CA--C 1.547 2.035 0 CA-C-O 119.368 -0.685 . . . . 1.38 112.059 162.327 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -81.55 61.95 8.17 Favored 'Trans proline' 0 CA--C 1.542 0.899 0 C-N-CA 125.036 3.824 . . . . 3.6 113.058 -169.056 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 9.0 tp-100 74.7 147.32 0.09 Allowed 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.402 1.881 . . . . 2.48 112.774 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -85.85 146.08 21.17 Favored Glycine 0 CA--C 1.527 0.842 0 O-C-N 121.299 -0.875 . . . . 1.08 112.145 170.695 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 97.5 mt -63.46 148.77 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 124.607 1.163 . . . . 2.18 110.883 175.597 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.97 150.43 39.02 Favored 'General case' 0 CA--C 1.548 0.887 0 N-CA-C 114.383 1.253 . . . . 1.1 114.383 177.426 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -80.63 152.79 34.1 Favored Glycine 0 C--N 1.338 0.679 0 C-N-CA 125.44 1.495 . . . . 1.03 111.176 177.211 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 10.5 mp0 -101.18 161.0 13.92 Favored 'General case' 0 C--N 1.326 -0.419 0 O-C-N 121.726 -0.867 . . . . 3.27 110.095 -172.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -53.34 134.85 39.71 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 123.483 0.713 . . . . 3.83 109.804 172.62 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.25 177.19 29.4 Favored Glycine 0 CA--C 1.522 0.483 0 CA-C-N 115.713 -0.676 . . . . 1.06 112.105 -175.281 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 45.2 t -58.58 131.74 23.0 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 CA-C-O 121.464 0.65 . . . . 1.87 110.564 -177.743 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 8.7 p -70.23 158.68 5.99 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.394 0 C-N-CA 129.374 3.069 . . . . 3.53 112.774 177.322 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.72 167.1 1.09 Allowed Glycine 0 CA--C 1.538 1.53 0 N-CA-C 115.288 0.875 . . . . 1.81 115.288 159.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 2.8 mm? . . . . . 0 C--O 1.25 1.094 0 C-N-CA 125.595 1.558 . . . . 3.95 113.683 -164.968 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.558 0 CA-C-O 117.175 -1.903 . . . . 3.11 109.31 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -71.82 -168.65 0.38 Allowed 'Trans proline' 0 CA--C 1.54 0.821 0 C-N-CA 123.384 2.722 . . . . 2.09 109.927 165.185 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -87.74 -173.14 4.18 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.074 1.75 . . . . 3.14 112.187 169.652 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -93.37 -171.61 39.69 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 125.884 1.707 . . . . 1.32 113.881 163.603 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.2 mt -62.24 139.88 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.103 0 O-C-N 121.784 -0.833 . . . . 2.06 110.481 -173.477 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -57.32 133.35 55.04 Favored 'General case' 0 CA--C 1.536 0.426 0 CA-C-N 118.692 0.678 . . . . 1.82 110.509 168.712 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.46 147.14 18.88 Favored Glycine 0 CA--C 1.52 0.405 0 C-N-CA 127.546 2.498 . . . . 1.23 113.665 177.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 87.3 mm-40 -71.57 125.72 27.8 Favored 'General case' 0 CA--C 1.535 0.403 0 N-CA-C 108.159 -1.052 . . . . 3.2 108.159 -177.182 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.9 ttt180 -57.97 137.07 57.11 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 123.639 0.776 . . . . 5.19 111.54 -169.781 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -65.8 163.33 40.72 Favored Glycine 0 C--N 1.338 0.679 0 C-N-CA 124.985 1.279 . . . . 1.54 115.577 -169.623 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 45.3 t -66.88 132.17 32.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 C-N-CA 126.617 1.967 . . . . 2.83 109.5 -175.71 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.415 HG23 ' H ' ' A' ' 24' ' ' VAL . 1.7 t -56.26 145.78 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 124.974 1.31 . . . . 2.58 112.224 -173.526 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.11 175.33 42.46 Favored Glycine 0 CA--C 1.535 1.286 0 N-CA-C 112.019 -0.432 . . . . 1.46 112.019 163.408 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 6.4 mp -129.68 156.71 78.36 Favored Pre-proline 0 CA--C 1.538 0.505 0 C-N-CA 124.636 1.174 . . . . 2.9 109.447 178.85 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.401 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 30.4 Cg_endo -77.74 -165.03 0.3 Allowed 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.951 2.434 . . . . 1.77 109.44 161.264 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.259 0 CA-C-O 117.67 -1.628 . . . . 3.38 112.588 153.863 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo . . . . . 0 CA--C 1.54 0.81 0 CA-C-O 118.047 -0.897 . . . . 2.61 110.573 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.77 162.87 25.32 Favored Glycine 0 CA--C 1.551 2.299 0 C-N-CA 118.882 -1.628 . . . . 1.57 111.144 126.414 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -79.0 -51.8 0.06 OUTLIER 'Trans proline' 0 CA--C 1.536 0.599 0 C-N-CA 124.746 3.631 . . . . 3.21 112.302 178.732 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 177.93 160.58 0.53 Allowed 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 129.731 3.213 . . . . 3.74 105.443 -165.381 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.07 -173.78 46.48 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 116.873 1.509 . . . . 1.31 116.873 -168.8 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.513 ' H ' HD12 ' B' ' 17' ' ' ILE . 4.0 mp -71.78 121.31 21.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 108.473 -0.936 . . . . 3.64 108.473 168.284 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -68.5 137.63 54.55 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-O 121.542 0.686 . . . . 1.5 111.419 176.611 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.09 147.2 40.81 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 124.698 1.142 . . . . 1.64 112.826 -170.717 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 1.2 pm0 -82.08 147.79 28.92 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 123.764 0.826 . . . . 3.63 111.327 169.541 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 6.0 ptt180 -52.27 157.17 1.47 Allowed 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 114.63 1.344 . . . . 5.38 114.63 168.633 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.03 179.1 53.16 Favored Glycine 0 CA--C 1.532 1.111 0 C-N-CA 124.331 0.967 . . . . 1.87 114.035 177.131 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 24.2 t -91.93 122.33 43.28 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 N-CA-C 113.648 0.981 . . . . 3.05 113.648 -152.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.1 m -58.89 154.28 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 127.06 2.144 . . . . 2.48 114.272 -173.096 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.63 -146.71 16.91 Favored Glycine 0 CA--C 1.53 0.996 0 C-N-CA 124.196 0.903 . . . . 1.62 112.026 163.069 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.401 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.5 pt? -171.12 161.06 5.42 Favored Pre-proline 0 CA--C 1.546 0.823 0 C-N-CA 126.097 1.759 . . . . 3.59 111.568 -164.868 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo . . . . . 0 CA--C 1.552 1.386 0 C-N-CA 125.292 3.995 . . . . 2.83 112.595 153.901 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 CA--C 1.547 1.125 0 CA-C-O 118.765 -0.598 . . . . 3.18 111.467 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -55.94 -179.4 0.08 OUTLIER 'Trans proline' 0 CA--C 1.537 0.652 0 C-N-CA 124.477 3.452 . . . . 2.18 112.583 164.071 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.84 179.54 47.27 Favored Glycine 0 CA--C 1.54 1.615 0 C-N-CA 124.662 1.125 . . . . 1.13 114.028 176.227 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_endo -70.61 156.69 60.62 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 123.383 2.722 . . . . 2.39 111.116 172.322 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 22.2 tp60 -32.22 120.34 0.29 Allowed 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 127.648 2.379 . . . . 1.33 113.546 167.055 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.62 158.35 53.63 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.345 -0.702 . . . . 0.9 111.345 166.376 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 68.1 mt -61.84 143.55 15.0 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 C-N-CA 123.203 0.601 . . . . 2.2 111.528 -169.721 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -67.7 158.44 32.28 Favored 'General case' 0 CA--C 1.545 0.754 0 CA-C-O 122.722 1.248 . . . . 1.04 114.234 177.177 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.28 163.18 54.44 Favored Glycine 0 CA--C 1.527 0.782 0 C-N-CA 124.625 1.107 . . . . 1.2 112.909 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 9.8 mp0 -96.38 -178.83 4.42 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 124.264 1.026 . . . . 3.95 111.491 -171.193 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.49 142.91 46.78 Favored 'General case' 0 N--CA 1.473 0.686 0 O-C-N 121.06 -1.025 . . . . 3.41 110.868 172.438 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.41 173.26 55.21 Favored Glycine 0 N--CA 1.47 0.919 0 C-N-CA 124.895 1.236 . . . . 1.01 112.817 177.121 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 38.1 t -71.3 138.45 21.71 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 C-N-CA 123.803 0.841 . . . . 1.99 110.164 179.206 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -91.81 173.45 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 C-N-CA 127.277 2.231 . . . . 2.64 109.763 -179.301 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -50.99 149.13 7.34 Favored Glycine 0 CA--C 1.533 1.182 0 CA-C-N 119.076 0.853 . . . . 1.79 113.13 170.71 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 8.6 tt . . . . . 0 C--O 1.25 1.097 0 C-N-CA 127.322 2.249 . . . . 4.15 113.766 -167.205 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.756 0 CA-C-O 115.971 -2.572 . . . . 4.12 108.813 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -77.68 178.3 7.77 Favored 'Trans proline' 0 CA--C 1.534 0.515 0 C-N-CA 123.162 2.575 . . . . 2.35 110.965 177.386 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.58 -155.44 0.15 Allowed 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.933 1.693 . . . . 2.71 111.034 165.586 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -85.67 173.0 47.09 Favored Glycine 0 N--CA 1.47 0.943 0 N-CA-C 115.701 1.041 . . . . 1.47 115.701 -173.29 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.558 ' H ' HD12 ' A' ' 17' ' ' ILE . 2.8 mp -66.16 137.49 24.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 108.468 -0.938 . . . . 2.52 108.468 177.517 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.73 131.26 50.35 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 121.569 0.699 . . . . 1.71 110.632 170.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.78 153.17 30.07 Favored Glycine 0 CA--C 1.519 0.301 0 C-N-CA 126.651 2.072 . . . . 1.62 113.004 174.135 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 5.4 mp0 -74.37 143.66 44.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 114.78 -0.71 . . . . 3.87 110.738 -164.173 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 16.8 tpp85 -52.22 135.55 31.97 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 123.553 0.741 . . . . 4.51 110.992 173.101 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.84 167.54 54.44 Favored Glycine 0 CA--C 1.522 0.485 0 CA-C-O 122.587 1.104 . . . . 1.51 113.819 -173.757 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 15.4 t -66.06 129.2 30.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 C-N-CA 125.78 1.632 . . . . 2.45 109.392 -178.497 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 31.4 m -58.69 146.98 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 N-CA-C 114.355 1.243 . . . . 2.13 114.355 -172.268 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.11 159.48 53.52 Favored Glycine 0 CA--C 1.536 1.358 0 CA-C-O 121.903 0.724 . . . . 1.37 112.051 161.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.544 HD13 HH21 ' C' ' 21' ' ' ARG . 11.0 mp -120.05 136.82 25.25 Favored Pre-proline 0 CA--C 1.532 0.262 0 C-N-CA 126.314 1.846 . . . . 2.8 109.815 -177.152 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -74.42 -172.05 1.08 Allowed 'Trans proline' 0 N--CA 1.456 -0.679 0 C-N-CA 122.729 2.286 . . . . 2.49 109.861 169.666 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.245 0 CA-C-O 117.659 -1.634 . . . . 4.58 113.095 151.359 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo . . . . . 0 N--CA 1.491 1.347 0 N-CA-C 109.248 -1.097 . . . . 2.59 109.248 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.64 147.38 49.65 Favored Glycine 0 CA--C 1.541 1.678 0 CA-C-O 118.898 -0.946 . . . . 1.35 111.308 162.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -77.42 176.94 9.46 Favored 'Trans proline' 0 CA--C 1.538 0.707 0 C-N-CA 124.116 3.211 . . . . 2.28 110.315 164.041 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.1 tp-100 -38.91 143.61 0.15 Allowed 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 127.743 2.417 . . . . 3.74 115.594 176.69 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.14 163.36 53.11 Favored Glycine 0 CA--C 1.529 0.949 0 C-N-CA 124.031 0.824 . . . . 1.02 113.028 175.298 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.511 ' H ' HD12 ' B' ' 17' ' ' ILE . 2.9 mp -65.28 134.7 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 O-C-N 121.733 -0.863 . . . . 2.75 109.328 175.118 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.68 148.76 51.47 Favored 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 119.093 0.86 . . . . 1.46 112.196 176.427 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -68.41 153.2 52.85 Favored Glycine 0 CA--C 1.527 0.826 0 C-N-CA 124.57 1.081 . . . . 1.75 111.746 174.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.59 155.26 25.77 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.999 0.92 . . . . 2.87 111.332 -176.64 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 41.0 mtt-85 -53.53 148.1 9.92 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 125.204 1.402 . . . . 5.84 113.905 -169.076 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.78 166.43 54.3 Favored Glycine 0 CA--C 1.535 1.299 0 CA-C-N 116.133 -0.485 . . . . 1.92 113.813 175.445 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 27.6 t -72.59 121.77 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 N-CA-C 113.56 0.948 . . . . 2.93 113.56 -161.114 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -65.95 161.37 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 125.481 1.512 . . . . 2.51 114.758 -165.615 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -85.0 -155.91 24.91 Favored Glycine 0 CA--C 1.528 0.903 0 C-N-CA 125.776 1.655 . . . . 1.7 113.461 175.294 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.1 pp -161.9 145.86 9.55 Favored Pre-proline 0 CA--C 1.541 0.63 0 C-N-CA 124.628 1.171 . . . . 2.99 111.499 -177.113 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo . . . . . 0 C--O 1.255 1.367 1 C-N-CA 126.087 4.524 . . . . 3.14 112.765 158.012 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo . . . . . 0 CA--C 1.543 0.93 0 CA-C-O 118.607 -0.664 . . . . 2.14 111.959 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -70.98 -150.23 0.03 OUTLIER 'Trans proline' 0 CA--C 1.541 0.869 0 C-N-CA 123.95 3.1 . . . . 1.52 108.523 164.515 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.66 169.49 40.98 Favored Glycine 0 CA--C 1.531 1.072 0 O-C-N 121.575 -0.703 . . . . 0.93 113.29 172.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -72.49 160.88 45.68 Favored 'Trans proline' 0 N--CA 1.454 -0.794 0 C-N-CA 123.081 2.521 . . . . 2.46 110.674 171.137 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 34.0 tp60 -52.77 120.13 5.38 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 126.249 1.82 . . . . 1.75 112.798 170.642 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -60.06 150.28 40.29 Favored Glycine 0 CA--C 1.53 1.028 0 C-N-CA 123.876 0.751 . . . . 0.89 111.639 168.599 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 78.0 mt -67.14 145.86 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.409 1.084 . . . . 2.7 110.676 -176.037 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.13 154.89 29.65 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 114.824 1.416 . . . . 1.12 114.824 178.225 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -76.75 148.24 34.84 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 124.739 1.162 . . . . 0.94 112.596 176.151 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -83.33 171.11 13.87 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.475 1.11 . . . . 5.28 112.294 -177.159 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' C' C ' 21' ' ' ARG . . . . . 0.544 HH21 HD13 ' A' ' 26' ' ' LEU . 0.0 OUTLIER -61.29 138.49 58.24 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 121.398 -0.814 . . . . 3.52 111.97 178.672 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.84 159.0 51.26 Favored Glycine 0 CA--C 1.528 0.857 0 C-N-CA 125.657 1.598 . . . . 0.98 112.933 177.183 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 23.7 t -68.76 136.43 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 124.054 0.941 . . . . 1.74 109.095 171.767 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 31.0 m -87.9 -165.54 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.843 0 C-N-CA 125.053 1.341 . . . . 2.71 111.623 -179.455 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.51 -138.79 0.15 Allowed Glycine 0 CA--C 1.54 1.628 0 C-N-CA 125.109 1.338 . . . . 1.69 113.562 164.365 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.251 1.162 0 C-N-CA 126.413 1.885 . . . . 6.5 114.682 -177.017 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.641 0 CA-C-O 116.849 -2.084 . . . . 2.57 110.072 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -72.28 167.97 25.45 Favored 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 123.458 2.772 . . . . 1.76 111.229 179.362 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.99 162.68 8.85 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 126.253 1.821 . . . . 3.58 113.695 172.744 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.71 -179.54 47.92 Favored Glycine 0 CA--C 1.525 0.693 0 C-N-CA 124.639 1.114 . . . . 1.29 112.547 171.42 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.401 HG13 ' H ' ' A' ' 17' ' ' ILE . 3.3 mt -61.28 138.01 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 C-N-CA 123.488 0.715 . . . . 2.14 109.506 -172.402 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.93 135.62 56.67 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-O 120.961 0.41 . . . . 2.04 110.727 170.85 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.26 151.79 49.84 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 126.286 1.898 . . . . 1.31 112.876 179.234 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 57.7 mm-40 -69.86 155.71 40.15 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 114.744 -0.728 . . . . 3.93 111.336 -174.788 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -68.0 145.8 54.16 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 121.028 0.442 . . . . 5.47 111.961 -177.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.45 141.48 28.81 Favored Glycine 0 C--N 1.333 0.413 0 CA-C-N 115.52 -0.764 . . . . 1.59 112.1 -178.156 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 27.2 m -61.4 141.42 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 CA-C-O 121.173 0.511 . . . . 2.43 111.248 -179.615 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.1 m -48.89 150.9 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 125.585 1.554 . . . . 2.54 113.878 -172.14 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.83 -153.8 26.16 Favored Glycine 0 N--CA 1.471 1.0 0 C-N-CA 123.165 0.412 . . . . 1.94 112.556 165.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 85.7 mt -149.48 155.47 39.13 Favored Pre-proline 0 N--CA 1.472 0.631 0 C-N-CA 125.677 1.591 . . . . 3.28 109.532 178.186 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -80.04 -162.1 0.17 Allowed 'Trans proline' 0 CA--C 1.539 0.747 0 C-N-CA 122.641 2.227 . . . . 2.41 109.392 158.08 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.239 0 CA-C-O 117.071 -1.961 . . . . 4.47 112.069 142.241 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_exo . . . . . 0 CA--C 1.544 1.015 0 N-CA-C 111.154 -0.364 . . . . 3.1 111.154 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -63.66 -177.49 4.49 Favored Glycine 0 CA--C 1.542 1.728 0 C-N-CA 120.187 -1.006 . . . . 2.52 112.446 126.217 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -74.64 -135.7 0.01 OUTLIER 'Trans proline' 0 CA--C 1.546 1.113 0 C-N-CA 124.571 3.514 . . . . 2.29 108.19 155.623 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 -87.33 -176.88 5.8 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 124.903 1.281 . . . . 3.98 111.454 171.812 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -84.75 158.97 34.13 Favored Glycine 0 CA--C 1.528 0.899 0 O-C-N 121.86 -0.525 . . . . 1.03 111.955 161.183 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 53.5 mt -72.77 133.26 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 123.389 0.676 . . . . 3.62 109.291 179.116 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.52 145.41 52.68 Favored 'General case' 0 CA--C 1.547 0.834 0 CA-C-N 119.39 0.995 . . . . 1.45 113.387 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.72 140.5 29.18 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 125.328 1.442 . . . . 1.52 111.694 173.591 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -95.37 153.09 17.85 Favored 'General case' 0 CA--C 1.532 0.257 0 O-C-N 121.729 -0.865 . . . . 3.15 111.604 -175.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 5.7 ttt85 -62.94 149.57 44.33 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.086 1.355 . . . . 6.68 112.221 -172.195 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.73 -174.86 26.61 Favored Glycine 0 CA--C 1.532 1.14 0 N-CA-C 114.463 0.545 . . . . 1.8 114.463 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 75.8 t -44.66 142.17 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 C-N-CA 128.016 2.526 . . . . 4.29 114.057 -172.501 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -93.1 156.95 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 124.13 0.972 . . . . 3.17 113.613 178.059 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.18 -162.62 29.57 Favored Glycine 0 C--N 1.341 0.828 0 C-N-CA 125.535 1.541 . . . . 1.89 114.23 -178.251 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.8 pp -153.76 141.83 13.98 Favored Pre-proline 0 CA--C 1.542 0.656 0 C-N-CA 124.287 1.035 . . . . 3.85 110.904 174.241 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo . . . . . 0 C--O 1.254 1.292 1 C-N-CA 126.282 4.654 . . . . 4.59 113.147 160.135 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo . . . . . 0 CA--C 1.547 1.152 0 CA-C-O 119.178 -0.426 . . . . 3.11 111.917 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -72.5 -135.59 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.075 0 C-N-CA 123.502 2.802 . . . . 1.97 108.351 162.447 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -81.04 175.42 54.78 Favored Glycine 0 CA--C 1.543 1.786 0 CA-C-N 119.303 0.956 . . . . 1.34 111.552 163.355 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -80.14 170.64 16.13 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 123.676 2.917 . . . . 2.42 110.46 161.771 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 28.7 tp60 -43.31 117.58 1.14 Allowed 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 125.33 1.452 . . . . 1.51 112.133 161.005 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.5 145.98 49.96 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.331 -1.108 . . . . 1.07 110.331 166.558 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 36.2 mm -66.51 145.33 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 O-C-N 122.367 -0.49 . . . . 4.11 110.567 -174.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -68.52 166.56 16.72 Favored 'General case' 0 CA--C 1.543 0.687 0 N-CA-C 114.394 1.257 . . . . 1.71 114.394 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.58 155.17 43.0 Favored Glycine 0 CA--C 1.527 0.81 0 C-N-CA 125.007 1.289 . . . . 1.04 112.6 -179.384 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -95.92 167.73 11.06 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.1 0.96 . . . . 4.89 111.164 -176.671 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.69 134.5 51.37 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.243 0.617 . . . . 3.87 111.038 178.501 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -63.72 178.49 7.12 Favored Glycine 0 N--CA 1.469 0.868 0 C-N-CA 126.41 1.957 . . . . 1.07 114.667 -175.773 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 93.1 t -74.83 138.09 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 108.969 -0.752 . . . . 2.14 108.969 -179.023 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 13.9 m -99.93 174.35 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 C-N-CA 126.305 1.842 . . . . 2.49 110.335 -178.386 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.92 -178.16 9.6 Favored Glycine 0 CA--C 1.534 1.227 0 C-N-CA 123.615 0.626 . . . . 1.81 113.673 167.308 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.479 0.987 0 N-CA-C 114.649 1.351 . . . . 5.57 114.649 173.766 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.689 0 CA-C-O 116.827 -2.096 . . . . 3.15 109.604 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -70.11 177.15 6.11 Favored 'Trans proline' 0 CA--C 1.538 0.716 0 C-N-CA 123.153 2.568 . . . . 2.06 110.249 166.08 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.427 ' HA ' ' HD2' ' B' ' 14' ' ' PRO 0.253 0.0 OUTLIER -89.99 -156.65 0.43 Allowed 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 125.984 1.714 . . . . 3.18 111.699 173.435 . . . . . . . . 4 4 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.03 178.47 45.03 Favored Glycine 0 N--CA 1.475 1.257 0 C-N-CA 124.95 1.262 . . . . 1.33 114.535 178.354 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.9 mt -76.06 130.41 36.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 O-C-N 121.261 -1.14 . . . . 2.54 108.579 -176.724 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.66 127.65 30.93 Favored 'General case' 0 CA--C 1.539 0.554 0 CA-C-N 119.318 0.963 . . . . 2.02 111.571 178.73 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.86 164.29 35.68 Favored Glycine 0 CA--C 1.528 0.869 0 C-N-CA 126.097 1.808 . . . . 1.28 112.803 -176.837 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -71.95 112.3 7.92 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 121.894 -0.768 . . . . 5.28 110.574 -169.431 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 67.4 ttt-85 -60.9 127.04 29.63 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 123.425 0.69 . . . . 4.0 109.402 177.587 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -78.57 171.99 55.19 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 125.002 1.287 . . . . 1.55 115.318 -166.7 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -64.38 147.52 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 CA-C-N 113.78 -1.21 . . . . 2.69 110.538 -173.875 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.0 m -54.14 150.58 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 123.146 0.578 . . . . 2.59 111.491 167.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.2 148.98 46.71 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 110.538 -1.025 . . . . 1.98 110.538 159.807 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 7.4 mp -101.35 167.04 11.27 Favored Pre-proline 0 C--N 1.328 -0.337 0 C-N-CA 124.027 0.931 . . . . 3.53 110.748 174.512 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.421 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 44.3 Cg_endo -69.94 -155.38 0.04 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 121.789 1.659 . . . . 1.81 108.55 155.113 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.259 0 CA-C-O 117.019 -1.989 . . . . 3.31 112.683 152.373 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_exo . . . . . 0 N--CA 1.481 0.765 0 CA-C-O 117.618 -1.076 . . . . 2.31 110.268 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -63.97 153.08 48.15 Favored Glycine 0 CA--C 1.548 2.131 0 C-N-CA 119.758 -1.211 . . . . 1.32 111.06 144.055 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 14' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 15' ' ' GLN . 57.8 Cg_endo -78.88 -47.96 0.09 OUTLIER 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 124.461 3.44 . . . . 2.88 114.628 -179.417 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.8 tp-100 -170.8 146.76 2.64 Favored 'General case' 0 N--CA 1.463 0.204 0 C-N-CA 124.285 1.034 . . . . 3.52 110.722 -161.76 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -86.51 149.8 22.94 Favored Glycine 0 CA--C 1.527 0.792 0 CA-C-O 121.822 0.679 . . . . 0.95 113.149 -178.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 65.7 mt -69.31 122.45 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 108.481 -0.933 . . . . 3.02 108.481 175.592 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.92 136.65 58.06 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 113.126 0.788 . . . . 1.21 113.126 -174.008 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -67.81 129.38 27.21 Favored Glycine 0 CA--C 1.523 0.533 0 C-N-CA 125.287 1.422 . . . . 1.65 110.183 169.429 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 8.8 tp-100 -96.89 150.34 20.86 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 123.685 0.794 . . . . 7.25 110.195 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.96 157.17 10.33 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 112.912 0.708 . . . . 4.62 112.912 171.461 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.46 -174.65 49.43 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 124.417 1.008 . . . . 1.83 112.455 170.701 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 13.4 m -93.31 141.9 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 115.133 1.531 . . . . 3.76 115.133 -156.659 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 12.9 m -69.5 154.17 8.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 125.796 1.638 . . . . 2.47 113.274 -166.816 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.72 -136.66 9.45 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 123.931 0.777 . . . . 1.77 113.117 170.802 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.421 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.6 pt? -172.18 158.57 4.18 Favored Pre-proline 0 CA--C 1.546 0.804 0 C-N-CA 126.085 1.754 . . . . 3.16 110.788 -157.41 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo . . . . . 0 C--O 1.256 1.424 0 C-N-CA 122.294 1.996 . . . . 2.56 111.013 160.851 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo . . . . . 0 CA--C 1.544 1.015 0 CA-C-O 118.783 -0.59 . . . . 2.64 111.939 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -55.39 -176.1 0.04 OUTLIER 'Trans proline' 0 CA--C 1.536 0.625 0 C-N-CA 124.707 3.605 . . . . 1.74 112.582 162.14 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -89.64 -172.85 45.55 Favored Glycine 0 CA--C 1.537 1.425 0 C-N-CA 124.882 1.23 . . . . 1.06 113.202 171.047 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -72.96 159.13 48.68 Favored 'Trans proline' 0 N--CA 1.456 -0.703 0 C-N-CA 123.211 2.607 . . . . 2.57 111.858 178.443 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.481 ' HA ' HE21 ' C' ' 15' ' ' GLN . 0.0 OUTLIER -45.7 130.02 9.1 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.461 1.904 . . . . 1.75 112.947 161.916 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -79.15 174.77 55.26 Favored Glycine 0 CA--C 1.53 0.981 0 C-N-CA 125.471 1.51 . . . . 1.17 114.06 174.521 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 97.0 mt -63.98 145.87 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 124.958 1.303 . . . . 2.82 111.76 -174.872 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -85.44 157.24 20.52 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 125.609 1.563 . . . . 1.34 114.115 177.189 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -98.02 138.06 13.66 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 124.945 1.26 . . . . 1.19 112.605 178.269 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -70.73 -179.07 2.04 Favored 'General case' 0 CA--C 1.543 0.709 0 CA-C-O 122.479 1.133 . . . . 5.2 111.797 170.199 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 17.8 ttt85 -55.41 149.34 13.43 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 124.588 1.155 . . . . 4.11 110.917 161.572 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.45 171.54 46.58 Favored Glycine 0 CA--C 1.533 1.17 0 N-CA-C 111.423 -0.671 . . . . 1.05 111.423 161.87 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 6.3 t -66.53 144.02 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 C-N-CA 124.13 0.972 . . . . 1.91 110.972 -179.457 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 12.4 m -85.77 175.0 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 C-N-CA 127.342 2.257 . . . . 2.71 112.497 179.384 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.26 173.71 10.53 Favored Glycine 0 CA--C 1.537 1.419 0 C-N-CA 124.619 1.104 . . . . 2.15 114.809 162.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 21.7 mt . . . . . 0 N--CA 1.484 1.242 0 N-CA-C 115.474 1.657 . . . . 3.41 115.474 -155.556 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.582 0 CA-C-O 116.953 -2.026 . . . . 3.13 110.13 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -75.02 167.22 27.5 Favored 'Trans proline' 0 N--CA 1.459 -0.553 0 C-N-CA 123.294 2.663 . . . . 2.31 111.477 -177.86 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 5.2 pp0? -67.1 161.96 23.36 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 127.269 2.228 . . . . 2.87 113.257 175.29 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.26 -152.02 21.94 Favored Glycine 0 N--CA 1.472 1.053 0 C-N-CA 125.454 1.502 . . . . 1.55 115.457 -170.515 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -66.92 132.18 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 O-C-N 121.09 -1.241 . . . . 2.55 109.796 -176.384 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -72.39 64.49 0.59 Allowed 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 125.797 1.639 . . . . 3.43 112.435 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.35 -175.35 32.99 Favored Glycine 0 CA--C 1.527 0.784 0 C-N-CA 125.722 1.629 . . . . 2.06 112.402 -174.064 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 18.7 mm100 -106.92 154.94 20.33 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.222 -0.658 . . . . 3.73 109.222 145.371 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 24.0 ttt180 -70.89 107.54 4.08 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 108.673 -0.862 . . . . 5.09 108.673 169.823 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -76.81 -81.81 0.57 Allowed Glycine 0 N--CA 1.472 1.083 0 C-N-CA 124.696 1.141 . . . . 4.36 112.91 -159.662 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 2.6 m -150.59 152.16 11.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 C-N-CA 123.963 0.905 . . . . 2.52 108.647 -178.311 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 20.5 m -62.23 162.68 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 125.998 1.719 . . . . 2.51 113.633 -179.158 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.09 -160.47 3.75 Favored Glycine 0 CA--C 1.537 1.407 0 N-CA-C 111.431 -0.667 . . . . 2.36 111.431 155.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 94.2 mt -140.82 161.66 52.88 Favored Pre-proline 0 N--CA 1.474 0.738 0 CA-C-N 118.055 0.928 . . . . 3.44 111.017 178.02 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -86.52 -158.75 0.09 OUTLIER 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 123.968 3.112 . . . . 1.95 109.152 156.023 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.212 0 CA-C-O 117.239 -1.867 . . . . 3.0 112.546 148.642 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo . . . . . 0 CA--C 1.545 1.042 0 CA-C-O 119.454 -0.311 . . . . 2.33 111.39 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.18 -178.58 8.79 Favored Glycine 0 CA--C 1.541 1.711 0 O-C-N 121.108 -0.995 . . . . 1.34 112.382 128.253 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -74.73 -135.64 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.038 0 C-N-CA 124.789 3.659 . . . . 2.42 108.313 158.514 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 -86.71 -173.17 4.36 Favored 'General case' 0 CA--C 1.541 0.632 0 O-C-N 121.056 -1.027 . . . . 4.57 111.586 172.577 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.59 158.04 29.37 Favored Glycine 0 CA--C 1.534 1.266 0 O-C-N 121.514 -0.741 . . . . 1.11 112.097 159.689 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 88.2 mt -78.68 154.16 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.076 0 C-N-CA 124.344 1.058 . . . . 3.27 109.799 173.674 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.42 150.39 43.71 Favored 'General case' 0 CA--C 1.547 0.854 0 O-C-N 120.932 -1.105 . . . . 1.44 113.801 177.802 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -87.46 170.78 41.04 Favored Glycine 0 CA--C 1.526 0.771 0 C-N-CA 125.748 1.642 . . . . 1.93 114.286 -176.517 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -72.41 128.41 35.54 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.646 1.178 . . . . 4.63 111.927 -175.1 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -62.07 153.3 30.23 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 122.586 0.354 . . . . 5.62 111.667 179.266 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.39 158.61 26.69 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 124.209 0.909 . . . . 1.73 115.189 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 13.2 m -84.96 134.68 26.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 N-CA-C 113.645 0.98 . . . . 3.7 113.645 -178.524 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.6 m -88.85 162.02 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 126.151 1.781 . . . . 2.38 113.215 -164.206 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.92 -131.1 7.1 Favored Glycine 0 CA--C 1.529 0.945 0 C-N-CA 124.925 1.25 . . . . 1.83 113.468 177.386 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.0 pp -172.38 153.83 3.02 Favored Pre-proline 0 CA--C 1.543 0.675 0 C-N-CA 124.302 1.041 . . . . 3.64 112.043 -152.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo . . . . . 0 C--O 1.255 1.359 1 C-N-CA 125.429 4.086 . . . . 2.42 112.548 153.764 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo . . . . . 0 N--CA 1.488 1.181 0 CA-C-O 118.947 -0.522 . . . . 2.52 112.009 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -72.01 -133.98 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 123.761 2.974 . . . . 1.94 108.107 162.536 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.85 166.16 54.72 Favored Glycine 0 CA--C 1.539 1.578 0 CA-C-N 119.905 1.23 . . . . 1.2 111.107 163.29 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -81.87 -37.64 0.25 Allowed 'Trans proline' 0 CA--C 1.536 0.589 0 C-N-CA 122.919 2.412 . . . . 3.5 113.072 -179.456 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 6.8 tp-100 170.04 134.14 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 127.672 2.389 . . . . 1.37 107.117 -157.825 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -97.49 178.11 32.48 Favored Glycine 0 CA--C 1.528 0.872 0 C-N-CA 125.119 1.342 . . . . 0.97 113.027 167.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 17' ' ' ILE . . . . . 0.463 ' H ' HD12 ' C' ' 17' ' ' ILE . 3.4 mp -63.72 134.75 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 124.152 0.981 . . . . 2.55 111.486 -177.146 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.45 146.46 48.62 Favored 'General case' 0 CA--C 1.541 0.622 0 O-C-N 121.31 -0.869 . . . . 1.31 113.05 -178.582 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.28 87.42 0.5 Allowed Glycine 0 CA--C 1.527 0.788 0 C-N-CA 127.04 2.257 . . . . 2.59 112.748 -173.532 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -59.21 164.16 3.33 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 124.66 1.184 . . . . 5.07 113.444 -171.189 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 10.5 ttp-105 -46.19 127.75 8.98 Favored 'General case' 0 C--O 1.239 0.525 0 C-N-CA 124.771 1.229 . . . . 5.86 112.809 176.571 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.31 -174.24 8.49 Favored Glycine 0 CA--C 1.524 0.627 0 CA-C-N 113.134 -1.848 . . . . 1.49 113.306 175.647 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.9 t -63.65 143.63 15.44 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 C-N-CA 124.011 0.924 . . . . 1.88 110.237 175.869 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -89.78 -168.39 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.801 0 C-N-CA 125.787 1.635 . . . . 2.52 110.302 179.063 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.57 -168.49 2.3 Favored Glycine 0 CA--C 1.539 1.567 0 C-N-CA 124.133 0.873 . . . . 1.87 114.385 169.748 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 14.8 mt . . . . . 0 N--CA 1.483 1.189 0 C-N-CA 124.269 1.028 . . . . 3.45 113.703 176.956 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.855 0 CA-C-O 117.153 -1.915 . . . . 5.61 108.801 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -64.34 111.35 1.6 Allowed 'Trans proline' 0 N--CA 1.453 -0.91 0 N-CA-C 104.867 -2.782 . . . . 2.35 104.867 151.61 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 85.3 mm-40 -70.76 172.18 9.22 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 125.708 1.603 . . . . 4.41 114.12 -164.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -61.46 145.53 48.68 Favored Glycine 0 C--N 1.335 0.483 0 N-CA-C 110.442 -1.063 . . . . 1.72 110.442 160.784 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.416 HG13 ' H ' ' A' ' 17' ' ' ILE . 2.7 mt -54.47 125.1 8.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 107.068 -1.456 . . . . 2.38 107.068 175.264 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -50.11 150.54 2.34 Favored 'General case' 0 CA--C 1.536 0.435 0 CA-C-O 121.773 0.797 . . . . 2.25 111.897 -176.397 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.81 167.27 34.39 Favored Glycine 0 CA--C 1.527 0.795 0 C-N-CA 124.461 1.029 . . . . 1.55 114.064 -173.139 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 13.5 mp0 -71.49 166.12 22.42 Favored 'General case' 0 CA--C 1.542 0.635 0 O-C-N 122.187 -0.596 . . . . 5.15 111.972 -175.703 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.8 tpt180 -68.05 132.69 47.71 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 113.94 1.089 . . . . 4.67 113.94 -162.261 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.78 93.07 1.36 Allowed Glycine 0 C--N 1.336 0.564 0 N-CA-C 109.786 -1.326 . . . . 1.81 109.786 170.769 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 28.5 m -58.22 140.62 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 123.76 0.824 . . . . 2.64 112.011 -176.439 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.7 t -50.99 142.96 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 126.26 1.824 . . . . 3.57 112.301 -170.777 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.82 148.28 50.36 Favored Glycine 0 N--CA 1.477 1.373 0 O-C-N 121.507 -0.746 . . . . 1.64 112.304 173.04 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -85.19 156.78 59.95 Favored Pre-proline 0 CA--C 1.541 0.609 0 CA-C-O 118.872 -0.585 . . . . 3.26 110.736 176.673 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.417 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 30.3 Cg_endo -85.38 -154.09 0.05 OUTLIER 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 123.517 2.811 . . . . 1.78 108.973 157.451 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.344 0 CA-C-O 117.631 -1.649 . . . . 3.09 113.437 148.89 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo . . . . . 0 N--CA 1.482 0.832 0 CA-C-O 119.379 -0.342 . . . . 3.5 112.799 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -79.78 136.83 17.8 Favored Glycine 0 CA--C 1.533 1.175 0 N-CA-C 110.216 -1.154 . . . . 1.31 110.216 157.017 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -76.6 177.23 9.09 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.988 2.459 . . . . 2.27 108.806 160.449 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -41.14 138.41 1.14 Allowed 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.318 1.447 . . . . 4.38 112.366 168.51 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -73.78 168.26 54.15 Favored Glycine 0 CA--C 1.526 0.756 0 C-N-CA 125.782 1.658 . . . . 1.05 115.248 -173.047 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 15.4 mm -61.79 140.14 19.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 CA-C-N 114.673 -0.764 . . . . 2.79 110.038 172.011 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.04 142.89 58.21 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 123.488 0.715 . . . . 1.76 111.531 173.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.38 -70.24 1.05 Allowed Glycine 0 N--CA 1.472 1.048 0 C-N-CA 123.934 0.778 . . . . 4.8 112.776 -168.399 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 178.48 -170.86 0.11 Allowed 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 128.376 2.67 . . . . 5.76 109.871 162.188 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 2.1 ttt-85 -117.96 152.0 36.34 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.452 1.101 . . . . 5.71 110.965 168.832 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.07 150.66 52.07 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 113.95 0.34 . . . . 1.97 113.95 -179.44 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 46.3 t -76.5 124.95 35.75 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.389 0 C-N-CA 123.409 0.684 . . . . 3.22 110.583 178.761 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.4 m -66.34 151.5 10.21 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 C-N-CA 125.451 1.501 . . . . 2.45 113.338 -167.563 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.73 -142.77 10.33 Favored Glycine 0 CA--C 1.527 0.805 0 C-N-CA 123.808 0.718 . . . . 1.76 112.659 169.274 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.417 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 3.2 pp -165.83 154.73 10.49 Favored Pre-proline 0 CA--C 1.54 0.584 0 C-N-CA 123.785 0.834 . . . . 3.31 112.249 -153.857 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo . . . . . 0 C--O 1.255 1.372 0 C-N-CA 125.3 4.0 . . . . 2.71 112.477 160.58 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo . . . . . 0 N--CA 1.484 0.916 0 CA-C-O 118.569 -0.68 . . . . 2.15 111.073 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -62.38 -151.05 0.02 OUTLIER 'Trans proline' 0 CA--C 1.544 0.984 1 C-N-CA 125.346 4.031 . . . . 1.75 111.998 159.201 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -104.97 167.26 15.01 Favored Glycine 0 CA--C 1.544 1.856 0 N-CA-C 116.954 1.541 . . . . 1.3 116.954 -170.116 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_endo -87.2 55.77 3.06 Favored 'Trans proline' 0 CA--C 1.543 0.942 1 C-N-CA 125.717 4.278 . . . . 3.76 113.145 -171.357 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 70.59 155.31 0.14 Allowed 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 125.467 1.507 . . . . 2.1 112.387 -176.389 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -101.93 176.72 26.15 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 126.68 2.086 . . . . 1.01 114.338 167.355 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 14.9 mt -72.82 126.92 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 O-C-N 121.126 -1.22 . . . . 3.58 112.177 -170.217 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -42.44 132.19 3.58 Favored 'General case' 0 CA--C 1.537 0.481 0 C-N-CA 125.399 1.48 . . . . 1.57 112.656 168.764 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.46 147.06 32.27 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 110.39 -1.084 . . . . 1.05 110.39 179.191 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -105.67 151.27 24.6 Favored 'General case' 0 C--N 1.327 -0.388 0 O-C-N 122.201 -0.587 . . . . 3.21 110.882 -173.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 12.1 ttp180 -54.71 134.55 47.44 Favored 'General case' 0 N--CA 1.447 -0.602 0 C-N-CA 123.347 0.659 . . . . 5.12 110.369 175.14 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.45 168.93 8.56 Favored Glycine 0 CA--C 1.528 0.846 0 C-N-CA 123.431 0.539 . . . . 1.01 113.094 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.3 t -61.2 143.42 14.9 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 O-C-N 122.039 -0.683 . . . . 1.71 110.162 174.356 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 3.3 p -85.32 176.03 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 C-N-CA 127.736 2.414 . . . . 2.5 110.426 -178.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.27 177.66 2.33 Favored Glycine 0 CA--C 1.54 1.651 0 CA-C-N 118.886 0.766 . . . . 1.82 113.405 161.77 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 17.9 mt . . . . . 0 C--O 1.253 1.246 0 N-CA-C 115.26 1.578 . . . . 3.38 115.26 -163.861 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.56 0 CA-C-O 115.779 -2.678 . . . . 3.43 108.527 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -76.01 164.18 31.93 Favored 'Trans proline' 0 N--CA 1.455 -0.793 0 C-N-CA 122.636 2.224 . . . . 1.87 111.306 -178.085 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -77.49 -177.12 4.56 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.848 1.659 . . . . 2.75 112.16 167.164 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.92 -177.82 40.19 Favored Glycine 0 CA--C 1.529 0.959 0 C-N-CA 123.89 0.757 . . . . 1.3 114.128 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 9.3 mt -67.82 133.59 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 O-C-N 121.911 -0.758 . . . . 2.04 109.795 -174.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.7 131.96 47.9 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 123.881 0.872 . . . . 1.82 110.874 172.281 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.27 152.85 51.13 Favored Glycine 0 CA--C 1.523 0.538 0 C-N-CA 126.405 1.955 . . . . 1.27 113.398 -173.831 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 82.2 mm-40 -74.77 134.65 41.8 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 115.139 -0.531 . . . . 3.8 110.589 -166.195 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 22.9 ttt180 -67.45 140.74 57.12 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-O 121.409 0.624 . . . . 5.21 112.355 -169.018 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -76.12 171.52 54.58 Favored Glycine 0 CA--C 1.522 0.525 0 C-N-CA 125.252 1.406 . . . . 1.47 115.068 -174.125 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 60.4 t -65.89 148.5 12.02 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 125.873 1.669 . . . . 2.98 109.456 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.8 m -51.84 154.7 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.757 0.823 . . . . 2.12 111.828 173.318 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -78.43 132.8 12.01 Favored Glycine 0 C--N 1.336 0.582 0 N-CA-C 107.777 -2.129 . . . . 2.17 107.777 158.146 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LEU . . . . . 0.481 HD13 ' HE ' ' C' ' 21' ' ' ARG . 6.6 mp -87.95 -176.58 0.72 Allowed Pre-proline 0 C--N 1.323 -0.578 0 C-N-CA 122.746 0.418 . . . . 3.1 110.368 -174.487 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.563 ' C ' ' H ' ' C' ' 25' ' ' GLY . 85.3 Cg_endo -56.63 -166.66 0.02 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 120.244 0.629 . . . . 2.39 110.79 136.794 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.152 0 CA-C-O 118.019 -1.434 . . . . 5.61 115.543 167.085 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo . . . . . 0 N--CA 1.489 1.246 0 N-CA-C 108.972 -1.203 . . . . 2.53 108.972 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.3 148.76 44.54 Favored Glycine 0 CA--C 1.54 1.655 0 CA-C-O 118.697 -1.057 . . . . 1.28 111.01 164.429 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -76.97 169.08 22.3 Favored 'Trans proline' 0 CA--C 1.538 0.676 0 C-N-CA 124.189 3.26 . . . . 2.27 110.684 166.134 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -53.25 136.94 35.76 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 124.641 1.176 . . . . 4.06 111.273 172.432 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.01 161.38 37.11 Favored Glycine 0 CA--C 1.525 0.669 0 C-N-CA 124.501 1.048 . . . . 1.1 114.696 -170.362 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 32.3 pt -56.48 131.69 20.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 O-C-N 122.172 -0.605 . . . . 3.32 111.341 178.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.02 151.12 45.9 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-O 121.975 0.893 . . . . 1.47 113.198 -171.198 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -70.63 145.38 40.23 Favored Glycine 0 CA--C 1.526 0.759 0 C-N-CA 125.117 1.341 . . . . 1.84 110.712 173.27 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -123.06 159.28 28.79 Favored 'General case' 0 C--N 1.329 -0.295 0 O-C-N 121.634 -0.921 . . . . 2.68 110.81 178.068 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 3.2 ptt180 -54.96 159.75 2.24 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 115.585 1.698 . . . . 4.31 115.585 178.526 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.02 -119.18 0.08 OUTLIER Glycine 0 CA--C 1.535 1.307 0 C-N-CA 127.332 2.396 . . . . 2.94 114.187 -173.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 10.5 m -143.69 142.22 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 C-N-CA 124.701 1.201 . . . . 3.54 112.24 -176.328 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 22.6 m -83.1 161.18 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.151 0 C-N-CA 126.615 1.966 . . . . 2.35 115.679 -159.828 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.22 -126.11 4.85 Favored Glycine 0 CA--C 1.533 1.171 0 C-N-CA 126.22 1.867 . . . . 1.88 113.636 177.852 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.44 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.6 pt? -169.36 159.77 7.46 Favored Pre-proline 0 CA--C 1.554 1.12 0 N-CA-C 115.053 1.501 . . . . 3.58 115.053 -148.862 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo . . . . . 0 C--O 1.255 1.343 0 C-N-CA 123.558 2.839 . . . . 3.41 111.565 156.617 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_endo . . . . . 0 CA--C 1.546 1.124 0 CA-C-O 118.729 -0.613 . . . . 2.29 110.923 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -68.34 -155.16 0.03 OUTLIER 'Trans proline' 0 CA--C 1.546 1.093 0 C-N-CA 123.493 2.795 . . . . 1.7 109.618 157.018 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -100.61 -178.68 29.64 Favored Glycine 0 CA--C 1.534 1.251 0 C-N-CA 123.934 0.778 . . . . 1.25 112.775 172.088 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -75.35 164.83 32.0 Favored 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.446 2.764 . . . . 2.29 112.098 176.054 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -40.81 129.01 2.65 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.296 2.238 . . . . 1.63 113.451 163.226 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.98 152.77 52.71 Favored Glycine 0 CA--C 1.529 0.908 0 C-N-CA 124.641 1.115 . . . . 1.08 113.447 169.642 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 96.7 mt -56.73 148.5 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 124.4 1.08 . . . . 2.82 111.732 179.026 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -77.0 164.37 25.82 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 115.07 1.507 . . . . 1.49 115.07 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -84.7 168.92 44.22 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 124.968 1.27 . . . . 1.05 114.003 -174.401 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 8.9 mp0 -104.98 -179.22 3.88 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.177 1.391 . . . . 3.61 111.043 -166.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 21' ' ' ARG . . . . . 0.481 ' HE ' HD13 ' A' ' 26' ' ' LEU . 59.3 ttt180 -66.38 148.58 51.65 Favored 'General case' 0 N--CA 1.48 1.054 0 O-C-N 120.938 -1.102 . . . . 4.19 109.437 161.229 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -78.25 -173.58 42.03 Favored Glycine 0 CA--C 1.533 1.19 0 O-C-N 121.119 -0.988 . . . . 1.34 112.067 169.082 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 4.1 t -71.3 139.15 20.35 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 123.693 0.797 . . . . 1.94 109.123 176.551 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 16.0 m -71.47 173.6 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 C-N-CA 126.876 2.07 . . . . 2.82 112.65 176.425 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.563 ' H ' ' C ' ' A' ' 27' ' ' PRO . . . -53.26 172.42 0.52 Allowed Glycine 0 CA--C 1.538 1.509 0 C-N-CA 125.398 1.475 . . . . 1.74 115.895 158.323 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 7.1 mp . . . . . 0 C--O 1.252 1.212 0 C-N-CA 125.831 1.652 . . . . 3.98 114.761 -157.619 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.614 0 CA-C-O 116.662 -2.188 . . . . 2.92 109.511 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -77.05 164.27 29.79 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 123.234 2.623 . . . . 2.2 112.135 -171.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.99 151.68 17.97 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 127.028 2.131 . . . . 4.18 111.567 167.441 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.11 -102.26 0.04 OUTLIER Glycine 0 N--CA 1.471 1.016 0 C-N-CA 125.112 1.339 . . . . 1.94 113.923 -179.355 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.9 mt -123.17 143.51 35.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 O-C-N 121.634 -0.921 . . . . 3.14 108.978 -177.231 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.57 53.05 0.21 Allowed 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 125.403 1.481 . . . . 3.7 111.97 170.056 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 86.11 -164.49 36.98 Favored Glycine 0 C--N 1.335 0.502 0 C-N-CA 127.813 2.625 . . . . 2.3 112.993 172.403 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 36.1 mm-40 -106.37 124.89 50.29 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 106.162 -1.792 . . . . 3.0 106.162 141.353 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 48.8 ttt85 -63.99 142.43 58.41 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.588 0.755 . . . . 4.59 110.84 -174.848 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.96 146.33 41.25 Favored Glycine 0 CA--C 1.523 0.59 0 C-N-CA 125.201 1.382 . . . . 1.56 112.272 -173.494 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 14.3 m -73.57 133.44 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 C-N-CA 124.83 1.252 . . . . 2.64 110.989 -174.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.4 p -50.77 147.75 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 C-N-CA 126.386 1.875 . . . . 3.33 114.973 -164.042 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -76.27 -179.95 47.34 Favored Glycine 0 CA--C 1.535 1.31 0 O-C-N 121.969 -0.457 . . . . 1.69 112.338 166.767 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.8 mt -143.97 158.01 56.55 Favored Pre-proline 0 N--CA 1.477 0.904 0 CA-C-O 118.175 -0.917 . . . . 3.72 112.399 -167.334 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -66.53 -173.45 0.37 Allowed 'Trans proline' 0 CA--C 1.537 0.653 0 C-N-CA 122.017 1.811 . . . . 2.3 110.188 158.119 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.271 0 CA-C-O 117.828 -1.54 . . . . 3.41 113.007 152.384 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo . . . . . 0 CA--C 1.541 0.861 0 CA-C-O 118.621 -0.658 . . . . 2.09 111.486 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -70.84 173.86 40.85 Favored Glycine 0 CA--C 1.54 1.606 0 CA-C-N 119.127 0.876 . . . . 1.38 111.885 143.226 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -71.17 163.03 40.57 Favored 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 123.707 2.938 . . . . 2.63 109.87 158.041 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -69.22 138.81 54.32 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 124.445 1.098 . . . . 3.63 111.901 179.707 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -57.63 142.79 42.94 Favored Glycine 0 C--N 1.342 0.887 0 C-N-CA 124.497 1.046 . . . . 1.21 114.195 -175.175 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 47.7 mm -73.61 142.72 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 123.893 0.877 . . . . 4.56 110.842 -177.214 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -52.17 139.11 24.37 Favored 'General case' 0 CA--C 1.544 0.717 0 N-CA-C 115.222 1.564 . . . . 1.58 115.222 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -66.32 141.87 41.74 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 126.096 1.807 . . . . 1.62 111.702 176.321 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 6.7 mp0 -79.74 151.85 30.16 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.194 0.598 . . . . 3.29 110.949 -173.388 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 12.7 mtt180 -60.76 150.12 33.51 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 118.857 0.753 . . . . 5.78 112.492 177.297 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.2 153.12 35.8 Favored Glycine 0 CA--C 1.531 1.065 0 CA-C-N 115.955 -0.566 . . . . 2.06 112.736 168.194 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 22.6 t -75.72 130.43 36.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 N-CA-C 112.613 0.598 . . . . 3.16 112.613 -164.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 m -60.03 157.62 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 N-CA-C 115.41 1.633 . . . . 2.78 115.41 -163.367 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.14 -178.07 45.95 Favored Glycine 0 C--N 1.338 0.652 0 C-N-CA 125.696 1.617 . . . . 1.77 115.548 -167.234 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.7 mp -134.97 130.9 19.68 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 123.78 0.832 . . . . 4.89 112.287 -170.444 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo . . . . . 0 C--O 1.256 1.383 0 C-N-CA 123.826 3.017 . . . . 2.67 112.017 146.947 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo . . . . . 0 N--CA 1.489 1.208 0 CA-C-O 118.73 -0.613 . . . . 2.43 111.511 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.93 -126.63 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.943 0 C-N-CA 124.246 3.298 . . . . 1.86 108.461 167.779 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -83.47 148.05 24.79 Favored Glycine 0 CA--C 1.538 1.515 0 CA-C-N 119.229 0.922 . . . . 1.22 112.522 172.498 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -74.18 96.76 0.97 Allowed 'Trans proline' 0 N--CA 1.456 -0.703 0 C-N-CA 123.285 2.656 . . . . 2.96 109.329 172.192 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.455 ' HG3' ' H ' ' C' ' 16' ' ' GLY . 16.5 tp60 59.1 -126.27 1.31 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.176 0.99 . . . . 2.98 109.239 179.819 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' C' C ' 16' ' ' GLY . . . . . 0.455 ' H ' ' HG3' ' C' ' 15' ' ' GLN . . . 174.25 161.78 24.79 Favored Glycine 0 CA--C 1.535 1.33 1 C-N-CA 132.048 4.642 . . . . 1.15 108.763 -179.769 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' C' C ' 17' ' ' ILE . . . . . 0.426 ' H ' HD12 ' C' ' 17' ' ' ILE . 3.7 mp -66.69 145.58 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 CA-C-N 119.34 1.57 . . . . 3.02 110.984 -177.576 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -78.56 145.93 34.54 Favored 'General case' 0 CA--C 1.545 0.765 0 O-C-N 120.915 -1.116 . . . . 1.58 113.024 178.311 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -88.84 161.08 30.45 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 125.305 1.431 . . . . 1.25 113.15 -179.603 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 58.7 mt-30 -87.2 160.28 18.54 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 123.95 0.9 . . . . 4.31 113.129 -174.539 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.24 138.42 45.09 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 109.511 -0.552 . . . . 3.62 109.511 163.413 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.9 165.73 52.68 Favored Glycine 0 CA--C 1.523 0.534 0 C-N-CA 123.728 0.68 . . . . 1.02 113.005 -177.096 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 91.2 t -63.67 138.33 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 C-N-CA 123.765 0.826 . . . . 1.78 108.899 173.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 25.6 m -101.89 -175.79 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.802 0 C-N-CA 125.139 1.376 . . . . 3.12 111.057 -177.831 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -58.96 173.75 3.57 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 124.582 1.087 . . . . 1.86 114.744 171.731 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 22.7 mt . . . . . 0 C--O 1.25 1.102 0 C-N-CA 125.261 1.425 . . . . 3.07 114.434 -168.297 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.62 0 CA-C-O 116.009 -2.55 . . . . 2.86 108.799 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -72.99 167.96 25.99 Favored 'Trans proline' 0 N--CA 1.458 -0.6 0 C-N-CA 122.991 2.461 . . . . 1.9 111.535 -179.413 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.43 169.28 16.7 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 127.35 2.26 . . . . 3.13 113.039 170.417 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.84 -174.98 40.8 Favored Glycine 0 CA--C 1.528 0.848 0 C-N-CA 125.21 1.386 . . . . 1.2 113.006 169.619 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 14.6 pt -74.18 155.3 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 O-C-N 121.754 -0.851 . . . . 2.7 111.096 -173.626 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -57.81 139.84 53.13 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.421 0.688 . . . . 1.84 111.597 172.727 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -57.56 150.65 30.27 Favored Glycine 0 CA--C 1.518 0.244 0 C-N-CA 127.259 2.361 . . . . 1.27 113.492 172.592 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 10.4 mm100 -64.93 118.26 8.8 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 114.716 -0.742 . . . . 3.75 109.194 -178.076 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.8 ttp180 -58.97 139.67 56.48 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 113.013 0.746 . . . . 4.34 113.013 -170.137 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.04 158.47 53.18 Favored Glycine 0 CA--C 1.519 0.331 0 C-N-CA 125.165 1.364 . . . . 1.54 113.38 -169.436 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 33.3 m -68.13 150.22 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-N 114.858 -0.671 . . . . 2.44 110.72 -175.318 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.5 m -51.05 147.8 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 124.192 0.997 . . . . 1.99 111.883 173.785 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.77 133.44 19.07 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 109.627 -1.389 . . . . 1.76 109.627 162.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 9.5 mp -77.18 169.92 18.84 Favored Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 122.882 0.473 . . . . 2.98 110.823 177.493 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.463 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 97.7 Cg_endo -77.17 -148.08 0.03 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 121.843 1.695 . . . . 2.02 108.277 154.338 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 1.41 0 CA-C-O 117.365 -1.797 . . . . 3.9 112.98 151.723 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo . . . . . 0 N--CA 1.484 0.938 0 CA-C-O 118.554 -0.686 . . . . 2.07 111.363 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.14 150.46 50.44 Favored Glycine 0 CA--C 1.546 1.994 0 CA-C-O 118.849 -0.973 . . . . 1.55 111.947 157.844 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -76.74 44.31 1.4 Allowed 'Trans proline' 0 CA--C 1.547 1.148 1 C-N-CA 126.986 5.124 . . . . 3.24 114.127 -172.662 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.1 tp-100 73.19 -175.44 0.16 Allowed 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 125.132 1.373 . . . . 4.95 109.606 -163.476 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -94.4 170.26 29.73 Favored Glycine 0 N--CA 1.473 1.126 0 O-C-N 121.091 -1.006 . . . . 1.16 113.12 166.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 50.1 mt -72.85 125.63 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 C-N-CA 123.564 0.746 . . . . 3.08 110.967 -176.438 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.82 143.75 57.72 Favored 'General case' 0 CA--C 1.545 0.762 0 O-C-N 121.203 -0.935 . . . . 1.48 113.253 -178.894 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.43 171.24 55.16 Favored Glycine 0 CA--C 1.529 0.919 0 C-N-CA 125.656 1.598 . . . . 1.74 113.578 -177.726 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -135.34 156.19 49.34 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 125.415 1.486 . . . . 2.97 110.224 -172.269 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.8 ptt-85 -71.99 152.5 42.43 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 114.747 1.388 . . . . 6.41 114.747 -172.48 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.23 176.99 54.53 Favored Glycine 0 CA--C 1.536 1.36 0 C-N-CA 125.317 1.437 . . . . 1.77 113.763 176.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 46.9 t -83.3 142.02 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 124.854 1.261 . . . . 3.11 112.98 -164.867 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 20.1 m -76.08 163.54 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 126.769 2.028 . . . . 2.43 114.323 -165.612 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -96.27 -127.03 5.3 Favored Glycine 0 CA--C 1.53 1.013 0 C-N-CA 125.107 1.337 . . . . 2.23 113.567 176.054 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.463 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 3.8 pp -171.82 159.04 4.6 Favored Pre-proline 0 CA--C 1.547 0.854 0 C-N-CA 125.769 1.627 . . . . 4.67 111.72 -156.529 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_endo . . . . . 0 C--O 1.256 1.383 0 C-N-CA 123.978 3.119 . . . . 3.23 111.767 153.807 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo . . . . . 0 N--CA 1.487 1.1 0 CA-C-O 119.181 -0.425 . . . . 1.98 111.627 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -71.54 -138.43 0.02 OUTLIER 'Trans proline' 0 CA--C 1.545 1.034 0 C-N-CA 123.317 2.678 . . . . 1.66 108.672 165.075 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -90.21 170.21 35.61 Favored Glycine 0 CA--C 1.538 1.52 0 N-CA-C 110.593 -1.003 . . . . 1.32 110.593 165.112 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.07 -58.63 0.04 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.4 2.067 . . . . 3.82 110.705 173.029 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -174.88 133.51 0.34 Allowed 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 126.316 1.846 . . . . 1.28 106.292 -148.04 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.38 160.52 43.98 Favored Glycine 0 CA--C 1.523 0.575 0 C-N-CA 123.649 0.642 . . . . 1.0 111.658 170.216 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 37.1 mm -66.11 144.08 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 O-C-N 121.817 -0.813 . . . . 3.49 110.089 174.638 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.05 161.18 5.33 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 114.505 1.298 . . . . 1.19 114.505 177.881 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.44 170.46 52.22 Favored Glycine 0 CA--C 1.528 0.877 0 C-N-CA 124.562 1.077 . . . . 1.21 113.298 179.22 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 8.7 mp0 -95.64 177.88 5.65 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 124.339 1.056 . . . . 4.41 112.064 -168.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 14.6 ttt85 -72.87 141.25 47.93 Favored 'General case' 0 N--CA 1.473 0.692 0 O-C-N 120.369 -1.457 . . . . 3.5 110.329 167.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.95 173.69 34.53 Favored Glycine 0 CA--C 1.534 1.263 0 O-C-N 121.731 -0.606 . . . . 1.32 112.111 167.343 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.2 t -69.94 141.66 16.87 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.657 0 C-N-CA 124.409 1.084 . . . . 1.89 109.636 179.483 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 10.9 m -74.81 178.88 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 C-N-CA 124.432 1.093 . . . . 2.57 111.377 175.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.37 -171.68 0.94 Allowed Glycine 0 CA--C 1.538 1.489 0 C-N-CA 124.735 1.16 . . . . 1.68 114.193 162.84 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 15.5 mt . . . . . 0 N--CA 1.481 1.088 0 CA-C-O 117.199 -1.381 . . . . 3.58 113.719 -168.858 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.598 0 CA-C-O 117.035 -1.981 . . . . 3.25 110.153 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -70.02 154.5 66.64 Favored 'Trans proline' 0 CA--C 1.535 0.543 0 C-N-CA 123.631 2.887 . . . . 2.69 111.982 179.332 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -78.91 176.96 9.13 Favored 'General case' 0 CA--C 1.553 1.092 0 C-N-CA 129.842 3.257 . . . . 3.7 111.563 -178.044 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -90.85 -172.93 43.97 Favored Glycine 0 N--CA 1.478 1.45 0 C-N-CA 125.189 1.376 . . . . 1.76 113.66 176.601 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.6 mm -76.45 134.96 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 N-CA-C 108.27 -1.011 . . . . 3.72 108.27 174.217 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.22 71.16 0.26 Allowed 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.074 1.35 . . . . 4.43 111.561 172.271 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 63.98 -146.52 50.4 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 125.021 1.296 . . . . 2.47 111.495 -169.262 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -142.9 128.7 19.37 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 106.269 -1.752 . . . . 5.48 106.269 150.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -53.02 126.92 22.17 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 118.769 0.713 . . . . 5.81 109.725 -177.362 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.46 -83.59 0.26 Allowed Glycine 0 N--CA 1.471 1.017 0 O-C-N 123.407 0.442 . . . . 3.18 112.088 -165.677 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -148.92 153.94 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 124.562 1.145 . . . . 2.06 112.161 175.813 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.5 m -65.87 161.52 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 C-N-CA 123.972 0.909 . . . . 2.99 111.233 168.196 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -76.24 174.07 53.62 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 123.585 0.612 . . . . 1.39 112.505 168.184 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -101.67 159.82 28.32 Favored Pre-proline 0 CA--C 1.542 0.663 0 C-N-CA 124.352 1.061 . . . . 3.14 110.854 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_endo -78.77 -166.67 0.42 Allowed 'Trans proline' 0 CA--C 1.537 0.675 0 C-N-CA 123.326 2.684 . . . . 2.19 109.324 157.663 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.274 0 CA-C-O 117.834 -1.537 . . . . 3.51 112.826 154.858 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_exo . . . . . 0 CA--C 1.542 0.921 0 N-CA-C 110.308 -0.689 . . . . 2.96 110.308 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.41 -167.91 2.73 Favored Glycine 0 CA--C 1.545 1.958 0 C-N-CA 119.659 -1.257 . . . . 2.16 112.033 124.763 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_endo -89.51 -138.97 0.02 OUTLIER 'Trans proline' 0 CA--C 1.546 1.077 0 C-N-CA 125.004 3.802 . . . . 2.86 109.287 175.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.82 138.57 32.44 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 127.288 2.235 . . . . 4.0 107.14 162.951 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -59.27 131.96 51.84 Favored Glycine 0 N--CA 1.468 0.807 0 N-CA-C 111.264 -0.734 . . . . 1.9 111.264 174.188 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 32.2 mm -60.56 150.37 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 O-C-N 122.334 -0.509 . . . . 5.87 110.982 175.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.57 137.5 58.25 Favored 'General case' 0 CA--C 1.55 0.952 0 O-C-N 120.7 -1.25 . . . . 3.01 114.315 176.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -93.13 -162.6 36.69 Favored Glycine 0 CA--C 1.533 1.196 0 C-N-CA 125.79 1.662 . . . . 2.9 112.211 171.123 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -157.73 174.31 15.51 Favored 'General case' 0 CA--C 1.537 0.442 0 O-C-N 121.064 -1.257 . . . . 3.98 113.944 -173.282 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 8.4 ptt180 -58.11 158.46 6.87 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 115.656 1.724 . . . . 4.54 115.656 172.698 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.17 -161.41 35.36 Favored Glycine 0 CA--C 1.535 1.29 0 C-N-CA 125.462 1.506 . . . . 2.34 111.499 162.283 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 43.8 t -120.3 145.21 26.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.041 0 C-N-CA 124.557 1.143 . . . . 4.62 112.528 -159.825 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 14.9 p -56.03 159.03 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 128.834 2.854 . . . . 3.72 114.359 -178.548 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.93 -126.7 1.08 Allowed Glycine 0 CA--C 1.53 1.023 0 C-N-CA 124.535 1.064 . . . . 2.23 111.204 166.218 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -167.26 162.76 10.37 Favored Pre-proline 0 CA--C 1.542 0.646 0 C-N-CA 125.343 1.457 . . . . 3.85 110.867 -166.74 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_endo . . . . . 0 CA--C 1.552 1.386 0 C-N-CA 124.47 3.447 . . . . 3.29 112.15 165.844 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 67.2 Cg_endo . . . . . 0 N--CA 1.487 1.122 0 CA-C-O 118.339 -0.775 . . . . 3.23 111.233 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -62.32 -152.38 0.02 OUTLIER 'Trans proline' 0 CA--C 1.542 0.924 0 C-N-CA 124.91 3.74 . . . . 2.5 111.696 163.899 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.39 168.66 54.4 Favored Glycine 0 CA--C 1.541 1.712 0 N-CA-C 109.985 -1.246 . . . . 1.56 109.985 163.39 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -76.64 176.65 9.83 Favored 'Trans proline' 0 N--CA 1.452 -0.941 0 C-N-CA 123.142 2.561 . . . . 2.66 110.681 170.854 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 9.5 tp60 -40.38 122.24 1.55 Allowed 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.279 1.432 . . . . 1.6 111.217 148.113 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.94 -169.37 27.54 Favored Glycine 0 CA--C 1.527 0.795 0 CA-C-O 121.993 0.774 . . . . 1.52 112.731 169.021 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 18.9 mt -63.82 124.33 18.33 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 O-C-N 121.638 -0.919 . . . . 2.87 110.833 175.388 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -65.52 155.85 34.4 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.582 1.153 . . . . 1.36 113.135 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -80.83 -179.24 52.87 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-O 123.23 1.461 . . . . 1.65 111.672 176.289 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.82 -160.48 1.03 Allowed 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.749 1.22 . . . . 3.25 109.149 178.309 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -85.19 152.46 23.33 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.892 1.277 . . . . 5.72 112.342 -179.181 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.26 176.85 43.88 Favored Glycine 0 CA--C 1.533 1.192 0 N-CA-C 111.03 -0.828 . . . . 1.01 111.03 164.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.0 t -59.84 149.39 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 124.042 0.937 . . . . 2.24 110.178 174.28 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 26.9 m -80.83 -173.34 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 C-N-CA 123.866 0.866 . . . . 2.65 111.079 173.227 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -55.98 160.12 7.27 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 124.154 0.883 . . . . 2.04 114.162 173.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 5.3 mt . . . . . 0 C--O 1.25 1.104 0 N-CA-C 114.246 1.202 . . . . 4.07 114.246 -163.079 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.738 0 CA-C-O 116.517 -2.268 . . . . 3.68 109.755 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -73.53 160.86 43.51 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 122.685 2.256 . . . . 2.25 110.924 -177.103 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 41.4 tp60 -48.65 151.76 1.09 Allowed 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 127.747 2.419 . . . . 4.14 114.866 -179.69 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.26 176.59 52.9 Favored Glycine 0 N--CA 1.465 0.618 0 C-N-CA 124.676 1.132 . . . . 1.27 115.199 173.957 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 14.4 mt -66.29 134.71 29.56 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 125.107 1.363 . . . . 2.34 110.568 -176.325 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.99 137.35 55.78 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 123.943 0.897 . . . . 1.99 112.267 175.313 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -66.72 157.76 50.33 Favored Glycine 0 CA--C 1.528 0.851 0 C-N-CA 125.485 1.517 . . . . 1.26 113.934 -176.507 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 53.1 mm-40 -62.5 128.98 38.56 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 114.738 -0.731 . . . . 3.36 109.668 -179.169 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 14.8 ttt180 -70.47 143.28 51.79 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 112.291 0.478 . . . . 4.73 112.291 -164.828 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -76.85 138.18 21.79 Favored Glycine 0 CA--C 1.522 0.528 0 C-N-CA 123.844 0.735 . . . . 1.93 111.414 -178.144 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 33.2 m -66.89 162.41 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 124.538 1.135 . . . . 2.24 112.493 -174.628 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.1 m -54.76 160.64 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 C-N-CA 124.527 1.131 . . . . 2.33 112.965 174.373 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.56 168.41 39.2 Favored Glycine 0 CA--C 1.527 0.817 0 CA-C-N 115.448 -0.796 . . . . 1.44 113.285 164.716 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 8.6 mp -99.46 156.63 35.19 Favored Pre-proline 0 CA--C 1.541 0.598 0 C-N-CA 124.004 0.922 . . . . 4.45 109.659 176.835 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -84.58 -164.32 0.24 Allowed 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 123.541 2.827 . . . . 2.55 109.163 162.449 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.239 0 CA-C-O 117.77 -1.572 . . . . 3.64 112.812 158.151 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_exo . . . . . 0 CA--C 1.544 0.998 0 CA-C-O 119.095 -0.46 . . . . 2.77 111.724 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.84 164.46 27.15 Favored Glycine 0 CA--C 1.542 1.752 0 CA-C-N 119.676 1.126 . . . . 1.44 113.153 138.975 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -80.69 63.58 8.79 Favored 'Trans proline' 0 CA--C 1.541 0.827 1 C-N-CA 126.176 4.584 . . . . 3.41 111.278 -179.58 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 22.8 tp60 67.85 173.04 0.27 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.188 1.395 . . . . 4.28 111.698 -172.625 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.15 160.33 29.48 Favored Glycine 0 CA--C 1.531 1.039 0 O-C-N 120.734 -1.229 . . . . 1.05 111.925 155.783 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 48.9 mm -74.65 129.94 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 O-C-N 121.708 -0.878 . . . . 3.18 109.955 176.195 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.73 149.23 50.83 Favored 'General case' 0 CA--C 1.544 0.734 0 N-CA-C 113.945 1.091 . . . . 1.52 113.945 -179.116 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.97 151.74 47.78 Favored Glycine 0 CA--C 1.531 1.073 0 C-N-CA 123.843 0.735 . . . . 1.47 111.557 177.299 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -109.17 156.85 19.38 Favored 'General case' 0 N--CA 1.465 0.307 0 O-C-N 121.644 -0.915 . . . . 2.71 111.649 175.287 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 6.5 ptt180 -64.32 158.31 23.82 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.426 1.89 . . . . 4.97 114.463 178.42 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -90.67 -167.69 41.78 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 126.275 1.893 . . . . 1.92 112.729 170.606 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 11.8 m -100.77 146.52 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 N-CA-C 115.849 1.796 . . . . 3.33 115.849 -162.329 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.6 p -46.35 153.67 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 128.888 2.875 . . . . 3.84 114.938 -178.664 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.33 -127.92 1.09 Allowed Glycine 0 CA--C 1.528 0.893 0 C-N-CA 123.714 0.673 . . . . 2.51 112.165 169.57 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.0 pp -162.67 151.57 12.56 Favored Pre-proline 0 CA--C 1.543 0.675 0 C-N-CA 124.141 0.976 . . . . 4.78 112.135 -164.64 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo . . . . . 0 C--O 1.255 1.367 1 C-N-CA 125.375 4.05 . . . . 3.17 112.397 162.306 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo . . . . . 0 CA--C 1.547 1.153 0 CA-C-O 119.107 -0.455 . . . . 1.88 112.046 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -62.58 -166.81 0.06 OUTLIER 'Trans proline' 0 CA--C 1.54 0.8 0 C-N-CA 124.096 3.197 . . . . 1.59 111.737 166.488 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.53 143.83 34.65 Favored Glycine 0 CA--C 1.54 1.629 0 O-C-N 121.124 -0.985 . . . . 1.03 113.108 -171.753 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -78.52 61.08 7.82 Favored 'Trans proline' 0 CA--C 1.54 0.82 0 C-N-CA 124.847 3.698 . . . . 3.19 112.196 -174.914 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 40.6 tp60 75.66 145.4 0.08 Allowed 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 126.543 1.937 . . . . 2.39 113.643 169.314 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.95 148.57 24.65 Favored Glycine 0 CA--C 1.528 0.848 0 O-C-N 120.875 -1.141 . . . . 1.1 112.838 169.397 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 38.3 mm -65.78 148.08 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 O-C-N 122.201 -0.588 . . . . 3.33 110.786 174.774 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.53 151.76 43.64 Favored 'General case' 0 CA--C 1.543 0.675 0 N-CA-C 113.093 0.775 . . . . 1.12 113.093 176.601 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.76 155.25 35.07 Favored Glycine 0 CA--C 1.529 0.957 0 CA-C-O 122.449 1.027 . . . . 0.95 112.342 174.878 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 18.2 mp0 -91.96 178.27 5.94 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 124.988 1.315 . . . . 3.16 110.556 -179.513 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 15.5 ptp180 -71.11 162.02 30.13 Favored 'General case' 0 N--CA 1.475 0.791 0 O-C-N 121.112 -0.992 . . . . 6.29 112.85 176.931 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.55 -171.82 42.26 Favored Glycine 0 CA--C 1.535 1.327 0 C-N-CA 124.023 0.821 . . . . 1.41 112.876 174.867 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 47.2 t -68.4 139.9 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 124.374 1.069 . . . . 2.05 110.699 -178.721 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 27.8 m -81.68 -176.1 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.705 1.202 . . . . 2.89 111.751 -176.957 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.56 161.82 15.85 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 123.91 0.767 . . . . 1.72 113.707 173.362 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 9.4 mt . . . . . 0 C--O 1.249 1.059 0 N-CA-C 114.717 1.377 . . . . 3.68 114.717 -164.717 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.846 0 CA-C-O 116.061 -2.522 . . . . 5.48 108.935 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -80.15 -174.99 2.48 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 122.829 2.352 . . . . 3.47 110.38 176.831 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.409 ' HA ' ' HD2' ' B' ' 14' ' ' PRO . 0.0 OUTLIER -86.55 -143.77 0.11 Allowed 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 125.288 1.435 . . . . 2.57 111.073 169.32 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -82.98 -127.91 1.22 Allowed Glycine 0 N--CA 1.472 1.062 0 C-N-CA 125.611 1.577 . . . . 1.18 112.753 170.761 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 10.2 mm -111.59 160.17 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.071 0 C-N-CA 124.504 1.122 . . . . 3.58 110.861 -176.466 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -78.78 81.61 5.07 Favored 'General case' 0 CA--C 1.546 0.807 0 O-C-N 120.47 -1.394 . . . . 3.72 110.237 164.438 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.59 -170.35 42.92 Favored Glycine 0 N--CA 1.466 0.644 0 C-N-CA 126.418 1.961 . . . . 3.08 113.397 -172.288 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -94.39 119.64 33.43 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 105.856 -1.905 . . . . 6.55 105.856 127.773 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 35.7 ttm180 -62.42 136.36 57.87 Favored 'General case' 0 CA--C 1.534 0.361 0 O-C-N 121.109 -0.994 . . . . 5.57 111.377 -178.986 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.32 170.43 53.53 Favored Glycine 0 N--CA 1.465 0.583 0 C-N-CA 125.021 1.296 . . . . 1.9 113.831 -178.082 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.1 m -87.55 156.93 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 CA-C-N 114.043 -1.078 . . . . 2.71 111.614 -175.823 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.1 m -57.16 147.71 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.442 1.097 . . . . 2.59 112.388 -178.807 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -74.44 169.44 54.13 Favored Glycine 0 CA--C 1.529 0.928 0 N-CA-C 110.362 -1.095 . . . . 1.89 110.362 157.773 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 24.0 mt -116.18 172.09 4.1 Favored Pre-proline 0 N--CA 1.471 0.614 0 O-C-N 122.149 -0.618 . . . . 4.5 111.794 170.74 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.433 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 47.4 Cg_endo -69.78 -153.59 0.03 OUTLIER 'Trans proline' 0 CA--C 1.536 0.616 0 C-N-CA 122.717 2.278 . . . . 2.43 108.884 148.029 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.301 0 CA-C-O 116.971 -2.016 . . . . 3.82 113.106 159.693 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo . . . . . 0 N--CA 1.491 1.356 0 N-CA-C 108.774 -1.279 . . . . 3.52 108.774 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.16 147.95 51.16 Favored Glycine 0 CA--C 1.549 2.219 0 CA-C-O 118.27 -1.295 . . . . 2.36 110.635 157.879 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 14' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 15' ' ' GLN . 87.5 Cg_endo -83.42 -51.41 0.04 OUTLIER 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 124.229 3.286 . . . . 3.42 112.874 -173.969 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -170.66 -178.99 2.76 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 128.15 2.58 . . . . 4.9 108.358 178.284 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -98.74 157.57 20.24 Favored Glycine 0 CA--C 1.528 0.857 0 CA-C-O 122.16 0.867 . . . . 1.73 113.739 177.744 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.515 ' H ' HD12 ' B' ' 17' ' ' ILE . 3.5 mp -72.71 157.27 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 124.204 1.002 . . . . 3.17 109.096 175.37 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.41 127.75 32.99 Favored 'General case' 0 CA--C 1.545 0.78 0 O-C-N 120.647 -1.283 . . . . 2.68 112.507 170.125 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -86.59 171.63 43.69 Favored Glycine 0 C--N 1.339 0.7 0 C-N-CA 125.178 1.37 . . . . 2.31 112.608 177.09 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -104.94 147.35 27.87 Favored 'General case' 0 N--CA 1.462 0.174 0 O-C-N 121.855 -0.791 . . . . 2.94 111.259 -179.068 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 6.6 ptt180 -67.99 155.74 38.83 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.167 -0.47 . . . . 4.41 110.796 158.002 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.17 -172.83 43.18 Favored Glycine 0 CA--C 1.533 1.212 0 C-N-CA 123.946 0.784 . . . . 1.93 113.066 178.255 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 15.3 m -93.67 145.59 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 N-CA-C 116.012 1.856 . . . . 3.66 116.012 -155.841 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.8 m -85.84 155.02 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.916 1.687 . . . . 2.6 112.888 -171.373 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.73 -134.15 8.13 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 124.637 1.113 . . . . 1.67 113.25 175.203 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.433 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.4 pt? -168.56 163.38 8.26 Favored Pre-proline 0 CA--C 1.551 0.988 0 C-N-CA 126.323 1.849 . . . . 3.47 111.028 -163.475 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo . . . . . 0 C--O 1.255 1.346 0 C-N-CA 124.383 3.389 . . . . 2.49 111.502 159.184 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo . . . . . 0 N--CA 1.486 1.043 0 CA-C-O 118.819 -0.575 . . . . 3.27 111.987 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -64.29 -166.83 0.08 OUTLIER 'Trans proline' 0 CA--C 1.54 0.796 0 C-N-CA 123.616 2.878 . . . . 2.52 110.233 159.413 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -89.87 174.95 41.4 Favored Glycine 0 CA--C 1.534 1.26 0 C-N-CA 124.005 0.812 . . . . 1.49 112.589 175.338 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -70.59 169.31 20.27 Favored 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 123.03 2.487 . . . . 2.47 111.941 170.527 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 26.3 tp60 -34.67 146.28 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 129.066 2.947 . . . . 1.92 114.673 168.601 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.7 171.22 41.13 Favored Glycine 0 CA--C 1.525 0.672 0 C-N-CA 123.427 0.537 . . . . 1.9 112.631 168.346 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' C' C ' 17' ' ' ILE . . . . . 0.612 ' H ' HD12 ' C' ' 17' ' ' ILE . 3.3 mp -59.21 130.48 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 123.157 0.583 . . . . 3.3 110.489 178.089 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.32 143.56 50.24 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 125.574 1.55 . . . . 2.34 114.797 -170.514 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -85.16 145.91 21.64 Favored Glycine 0 C--N 1.339 0.736 0 N-CA-C 109.664 -1.374 . . . . 1.56 109.664 171.706 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 5.7 mp0 -85.83 -169.67 2.75 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 123.941 0.896 . . . . 3.42 110.503 179.894 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 16.2 ttt180 -64.88 145.11 56.74 Favored 'General case' 0 N--CA 1.467 0.421 0 O-C-N 121.172 -0.955 . . . . 4.57 109.49 156.297 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.17 162.35 36.19 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 111.414 -0.674 . . . . 1.26 111.414 161.94 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.57 140.15 20.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 C-N-CA 123.445 0.698 . . . . 2.41 109.796 176.221 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 13.4 p -79.67 178.9 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 C-N-CA 127.041 2.136 . . . . 4.12 110.872 178.479 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.34 179.36 2.62 Favored Glycine 0 CA--C 1.537 1.41 0 C-N-CA 124.553 1.073 . . . . 2.28 114.735 169.155 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 10.0 mp . . . . . 0 C--O 1.249 1.078 0 C-N-CA 126.001 1.72 . . . . 3.87 113.296 -162.571 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.791 0 CA-C-O 116.154 -2.47 . . . . 2.68 109.216 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -79.04 163.95 25.22 Favored 'Trans proline' 0 N--CA 1.459 -0.524 0 C-N-CA 123.0 2.466 . . . . 1.75 111.318 -174.941 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -58.58 166.69 1.71 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.774 2.029 . . . . 3.33 114.041 168.871 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.59 -118.45 0.03 OUTLIER Glycine 0 N--CA 1.475 1.287 0 C-N-CA 127.452 2.453 . . . . 2.23 115.798 -176.652 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.2 mp -120.07 137.01 55.3 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 O-C-N 120.916 -1.344 . . . . 2.47 108.874 -179.824 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -52.17 128.41 24.8 Favored 'General case' 0 CA--C 1.542 0.651 0 CA-C-N 118.275 0.489 . . . . 1.9 110.706 170.135 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -62.34 156.7 37.93 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 125.777 1.656 . . . . 1.26 113.713 -177.076 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.9 mm-40 -73.0 116.34 13.39 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 108.734 -0.839 . . . . 3.33 108.734 -171.929 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 7.4 ttt180 -64.22 140.58 58.88 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 122.72 0.408 . . . . 5.14 112.029 -163.283 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.67 158.17 53.62 Favored Glycine 0 C--N 1.335 0.502 0 C-N-CA 123.926 0.774 . . . . 1.77 111.908 -179.644 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 33.3 m -75.97 160.99 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 CA-C-N 115.084 -0.558 . . . . 2.73 111.606 -174.636 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.1 m -51.98 164.76 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 125.531 1.532 . . . . 2.61 112.857 177.283 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.56 124.45 29.26 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.989 -0.844 . . . . 2.06 110.989 163.421 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 9.5 mp -82.31 170.92 13.2 Favored Pre-proline 0 CA--C 1.533 0.321 0 C-N-CA 124.493 1.117 . . . . 3.74 110.856 175.479 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -60.0 -165.77 0.03 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 121.77 1.647 . . . . 3.42 110.821 152.135 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.667 0 CA-C-O 118.647 -1.085 . . . . 6.19 114.984 160.141 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo . . . . . 0 N--CA 1.481 0.776 0 CA-C-O 118.551 -0.687 . . . . 2.1 111.694 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.29 161.44 48.0 Favored Glycine 0 CA--C 1.54 1.628 0 CA-C-O 119.078 -0.845 . . . . 1.26 111.669 152.709 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -76.0 163.68 32.75 Favored 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 124.235 3.29 . . . . 2.47 110.641 165.797 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -53.94 140.17 31.74 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.761 1.224 . . . . 4.27 111.79 170.948 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.23 161.67 53.24 Favored Glycine 0 CA--C 1.529 0.912 0 C-N-CA 124.167 0.889 . . . . 1.42 114.421 -174.512 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 35.6 mm -60.78 119.32 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 O-C-N 121.542 -0.975 . . . . 2.9 111.086 -175.772 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.76 155.04 27.78 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 114.492 1.293 . . . . 1.59 114.492 -172.176 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.24 136.7 28.68 Favored Glycine 0 CA--C 1.527 0.809 0 C-N-CA 126.3 1.905 . . . . 1.62 111.391 -179.534 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -106.3 143.62 34.16 Favored 'General case' 0 N--CA 1.465 0.323 0 O-C-N 121.633 -0.922 . . . . 3.2 110.133 -172.415 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 32.0 ptt180 -72.22 157.6 37.43 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.344 1.058 . . . . 4.41 112.997 175.823 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.86 -174.95 26.77 Favored Glycine 0 CA--C 1.539 1.534 0 N-CA-C 117.061 1.584 . . . . 2.27 117.061 -170.099 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 60.9 t -96.33 136.1 28.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 C-N-CA 124.201 1.001 . . . . 4.49 113.517 -157.873 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.9 p -32.39 143.21 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 131.232 3.813 . . . . 4.33 118.44 -170.32 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.14 -118.79 4.11 Favored Glycine 0 CA--C 1.528 0.905 0 C-N-CA 124.968 1.27 . . . . 2.45 112.211 169.469 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 1.6 pp -168.76 153.39 5.9 Favored Pre-proline 0 CA--C 1.552 1.025 0 N-CA-C 115.565 1.691 . . . . 5.91 115.565 -150.246 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo . . . . . 0 C--O 1.254 1.298 0 C-N-CA 123.739 2.96 . . . . 4.65 111.741 152.935 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo . . . . . 0 N--CA 1.486 1.068 0 CA-C-O 118.582 -0.674 . . . . 2.13 111.096 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -71.12 -150.0 0.03 OUTLIER 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 123.65 2.9 . . . . 1.61 109.581 166.11 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -99.27 -172.77 31.15 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-N 118.688 0.676 . . . . 1.21 112.662 172.232 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.81 167.69 23.46 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 123.248 2.632 . . . . 2.36 112.213 176.608 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 8.7 tp60 -37.23 127.16 1.0 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.696 2.398 . . . . 1.39 113.024 160.583 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -62.5 147.75 49.46 Favored Glycine 0 CA--C 1.527 0.786 0 C-N-CA 124.321 0.962 . . . . 1.01 112.741 168.584 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 47.0 mm -57.9 147.14 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 O-C-N 121.933 -0.745 . . . . 3.35 111.557 -178.952 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -72.4 156.81 38.67 Favored 'General case' 0 CA--C 1.542 0.658 0 O-C-N 121.293 -0.879 . . . . 1.2 112.792 178.72 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -91.94 153.75 22.1 Favored Glycine 0 C--N 1.338 0.644 0 CA-C-O 122.299 0.944 . . . . 1.09 112.046 -178.528 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 25.1 mp0 -92.02 -174.12 3.69 Favored 'General case' 0 CA--C 1.544 0.721 0 CA-C-O 122.024 0.916 . . . . 2.92 111.398 -175.954 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -58.83 139.33 56.56 Favored 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 125.15 1.38 . . . . 4.65 111.653 169.093 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.9 -171.01 6.81 Favored Glycine 0 C--N 1.337 0.628 0 C-N-CA 125.384 1.469 . . . . 1.58 113.481 175.825 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 21.4 t -65.0 127.46 25.95 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.696 0 O-C-N 122.305 -0.527 . . . . 2.77 110.473 -178.833 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 4.3 p -64.31 160.93 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 126.864 2.066 . . . . 4.17 112.133 178.007 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -51.9 176.52 0.1 Allowed Glycine 0 CA--C 1.542 1.728 0 C-N-CA 124.52 1.057 . . . . 1.84 115.236 159.518 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 3.3 mm? . . . . . 0 C--O 1.253 1.248 0 CA-C-O 117.016 -1.469 . . . . 3.57 112.623 -161.156 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.784 0 CA-C-O 116.837 -2.09 . . . . 3.93 110.139 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.406 ' O ' ' HA3' ' B' ' 13' ' ' GLY . 83.5 Cg_endo -76.27 162.11 34.24 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 123.436 2.758 . . . . 2.88 111.635 -174.989 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.01 153.55 36.93 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 127.31 2.244 . . . . 3.14 113.605 178.706 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.7 -122.91 0.05 OUTLIER Glycine 0 CA--C 1.534 1.271 0 C-N-CA 127.146 2.308 . . . . 2.4 115.717 -179.051 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.8 mt -122.42 131.8 72.46 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 O-C-N 121.097 -1.237 . . . . 1.97 109.191 -177.248 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.91 134.33 55.41 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 123.442 0.697 . . . . 2.08 110.81 173.399 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.69 155.18 48.13 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 126.744 2.116 . . . . 1.83 114.33 -173.463 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 72.7 mm-40 -77.76 154.09 32.31 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 114.767 -0.717 . . . . 4.14 112.47 -166.256 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.45 132.16 53.04 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 123.509 0.723 . . . . 6.85 111.759 -177.672 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.9 151.64 44.52 Favored Glycine 0 N--CA 1.467 0.763 0 N-CA-C 115.584 0.994 . . . . 1.74 115.584 -167.879 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 2.5 m -69.1 130.93 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 124.938 1.295 . . . . 2.57 110.893 176.138 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.5 m -55.61 146.07 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 125.062 1.345 . . . . 2.58 114.029 -167.638 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.02 -163.93 7.91 Favored Glycine 0 CA--C 1.534 1.276 0 N-CA-C 111.39 -0.684 . . . . 1.98 111.39 161.032 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.1 mt -143.95 167.02 16.46 Favored Pre-proline 0 N--CA 1.475 0.813 0 C-N-CA 124.551 1.14 . . . . 2.95 111.479 179.951 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 27' ' ' PRO . . . . . 0.426 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 29.2 Cg_endo -76.73 -152.61 0.04 OUTLIER 'Trans proline' 0 CA--C 1.539 0.736 0 C-N-CA 122.981 2.454 . . . . 1.92 108.584 150.914 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.288 0 CA-C-O 117.017 -1.99 . . . . 3.12 112.774 143.671 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_exo . . . . . 0 CA--C 1.543 0.966 0 N-CA-C 111.512 -0.226 . . . . 3.51 111.512 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' B' B ' 13' ' ' GLY . . . . . 0.406 ' HA3' ' O ' ' A' ' 14' ' ' PRO . . . -69.05 176.44 30.06 Favored Glycine 0 CA--C 1.538 1.474 0 C-N-CA 120.284 -0.96 . . . . 1.72 112.935 127.561 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -79.94 156.28 23.56 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 C-N-CA 125.011 3.807 . . . . 2.54 110.795 158.646 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -60.86 140.63 57.62 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 125.158 1.383 . . . . 4.33 110.455 168.24 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.32 162.14 40.83 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 115.508 0.963 . . . . 1.45 115.508 -172.114 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 41.0 pt -55.41 139.19 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 O-C-N 122.376 -0.485 . . . . 4.12 111.213 176.765 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.15 154.04 42.72 Favored 'General case' 0 CA--C 1.54 0.589 0 CA-C-O 121.539 0.685 . . . . 1.73 112.828 -176.638 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.02 161.96 51.71 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 125.094 1.33 . . . . 2.23 113.635 -178.338 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 3.0 tp-100 -90.56 131.06 36.51 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 123.663 0.785 . . . . 3.83 109.709 -174.163 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.28 153.26 3.94 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-O 122.678 1.228 . . . . 8.13 114.161 -177.77 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.91 166.54 54.41 Favored Glycine 0 CA--C 1.531 1.086 0 CA-C-N 113.998 -1.456 . . . . 1.78 112.541 171.298 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 17.6 m -89.71 139.28 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 115.05 1.5 . . . . 3.7 115.05 -162.841 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.1 m -104.22 155.8 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 124.809 1.244 . . . . 2.62 112.708 -163.211 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -107.49 -130.33 6.34 Favored Glycine 0 CA--C 1.529 0.907 0 C-N-CA 125.118 1.342 . . . . 1.66 113.218 177.801 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' B' B ' 26' ' ' LEU . . . . . 0.426 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.7 pt? -179.14 161.82 1.0 Allowed Pre-proline 0 CA--C 1.547 0.842 0 C-N-CA 126.045 1.738 . . . . 3.33 110.753 -152.996 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo . . . . . 0 C--O 1.257 1.437 0 C-N-CA 124.014 3.143 . . . . 2.89 111.949 156.159 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo . . . . . 0 CA--C 1.547 1.173 0 CA-C-O 119.181 -0.425 . . . . 3.22 112.03 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -66.07 -160.66 0.04 OUTLIER 'Trans proline' 0 CA--C 1.543 0.942 0 C-N-CA 123.066 2.511 . . . . 2.28 110.129 161.67 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -90.89 -177.57 43.74 Favored Glycine 0 CA--C 1.535 1.31 0 O-C-N 121.163 -0.96 . . . . 1.5 111.897 169.043 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -77.77 170.51 18.94 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.946 2.43 . . . . 2.57 111.981 175.405 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.8 tp60 -34.99 127.01 0.53 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 127.557 2.343 . . . . 1.74 113.325 152.499 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.18 155.4 53.16 Favored Glycine 0 CA--C 1.528 0.869 0 C-N-CA 124.944 1.259 . . . . 1.49 112.338 167.304 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 82.3 mt -62.95 139.57 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 O-C-N 121.593 -0.946 . . . . 2.56 110.731 -175.582 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.26 159.15 12.76 Favored 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 122.292 1.044 . . . . 2.15 113.31 178.904 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -61.76 124.99 35.75 Favored Glycine 0 CA--C 1.524 0.638 0 CA-C-O 122.279 0.933 . . . . 1.95 112.679 -170.905 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' C' C ' 20' ' ' GLN . . . . . 0.567 ' NE2' ' H ' ' C' ' 20' ' ' GLN . 0.0 OUTLIER -60.59 129.76 43.15 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.672 1.589 . . . . 6.1 110.919 -175.982 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.47 129.71 22.51 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.526 0.731 . . . . 3.13 111.862 -174.898 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -62.6 154.98 41.65 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 115.168 -0.924 . . . . 1.03 113.311 -176.466 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.5 t -57.4 146.59 6.76 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 C-N-CA 124.913 1.285 . . . . 1.61 110.288 171.876 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 27.2 m -98.54 -169.87 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.817 0 C-N-CA 125.687 1.595 . . . . 2.39 110.557 179.091 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.6 -168.31 3.94 Favored Glycine 0 CA--C 1.538 1.485 0 C-N-CA 124.339 0.971 . . . . 1.9 113.944 167.356 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 13.5 mt . . . . . 0 N--CA 1.485 1.315 0 N-CA-C 114.329 1.233 . . . . 3.61 114.329 -174.977 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.558 0 CA-C-O 116.121 -2.488 . . . . 4.67 108.856 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -76.57 162.52 32.99 Favored 'Trans proline' 0 N--CA 1.457 -0.676 0 C-N-CA 122.593 2.195 . . . . 5.17 111.328 -176.841 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -64.38 161.71 16.44 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 128.294 2.638 . . . . 4.46 111.451 166.577 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.41 -143.17 0.46 Allowed Glycine 0 CA--C 1.535 1.34 0 C-N-CA 126.66 2.076 . . . . 3.27 114.307 173.367 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.1 mt -101.06 127.92 53.79 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 O-C-N 121.375 -1.074 . . . . 4.24 108.409 179.202 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.89 140.79 56.41 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 118.901 0.773 . . . . 2.45 110.29 168.186 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -61.75 141.95 47.9 Favored Glycine 0 CA--C 1.523 0.58 0 C-N-CA 124.587 1.089 . . . . 1.18 112.291 175.423 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 54.2 mm-40 -68.32 130.22 42.25 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 109.847 -0.427 . . . . 3.08 109.847 -177.516 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -66.69 137.26 56.56 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 121.512 0.672 . . . . 3.96 111.175 -171.765 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.63 126.1 8.33 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-O 122.599 1.11 . . . . 2.48 111.562 176.611 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.8 t -65.28 155.26 6.8 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.835 0 C-N-CA 126.498 1.919 . . . . 4.27 111.822 -178.141 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.3 m -61.62 152.32 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 O-C-N 121.121 -0.987 . . . . 3.57 112.791 173.805 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -97.02 -153.88 29.7 Favored Glycine 0 N--CA 1.468 0.795 0 C-N-CA 124.023 0.821 . . . . 2.03 112.478 167.642 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 89.2 mt -143.26 158.89 57.23 Favored Pre-proline 0 N--CA 1.47 0.536 0 C-N-CA 126.117 1.767 . . . . 5.58 110.246 176.444 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -76.41 -146.21 0.03 OUTLIER 'Trans proline' 0 CA--C 1.54 0.791 0 C-N-CA 122.58 2.186 . . . . 3.93 107.803 154.03 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.169 0 CA-C-O 116.701 -2.166 . . . . 4.72 111.979 151.902 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo . . . . . 0 N--CA 1.481 0.774 0 CA-C-O 118.705 -0.623 . . . . 4.03 111.68 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.6 159.01 50.88 Favored Glycine 0 CA--C 1.539 1.581 0 CA-C-O 118.761 -1.021 . . . . 2.08 111.682 154.443 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_endo -70.8 158.67 54.96 Favored 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 123.782 2.988 . . . . 4.16 109.819 162.134 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -82.34 174.29 11.27 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.909 0.861 . . . . 6.66 113.114 178.593 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.22 154.36 52.53 Favored Glycine 0 CA--C 1.52 0.389 0 CA-C-O 122.615 1.119 . . . . 1.95 114.248 -177.705 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 43.8 pt -61.39 144.69 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 CA-C-N 114.383 -0.909 . . . . 5.38 110.718 161.518 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -85.35 133.4 34.14 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 123.822 0.849 . . . . 2.1 112.495 177.749 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -75.08 125.62 8.32 Favored Glycine 0 CA--C 1.525 0.691 0 C-N-CA 125.653 1.597 . . . . 1.58 110.546 173.272 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -89.71 157.51 17.95 Favored 'General case' 0 CA--C 1.535 0.382 0 O-C-N 121.865 -0.785 . . . . 4.32 110.384 166.321 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.92 162.08 29.92 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 123.235 0.614 . . . . 4.03 111.712 166.029 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -84.19 -141.8 5.1 Favored Glycine 0 CA--C 1.533 1.198 0 N-CA-C 110.991 -0.843 . . . . 2.52 110.991 163.602 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 99.5 t -40.62 131.38 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 126.415 1.886 . . . . 4.88 113.816 -173.944 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 15.3 m -103.78 149.4 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 125.083 1.353 . . . . 3.96 109.02 161.371 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.515 ' H ' HG23 ' C' ' 23' ' ' VAL . . . -102.55 167.63 17.84 Favored Glycine 0 C--N 1.333 0.392 0 C-N-CA 124.843 1.211 . . . . 5.24 115.266 -163.574 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -171.57 158.99 4.83 Favored Pre-proline 0 CA--C 1.544 0.713 0 C-N-CA 127.626 2.37 . . . . 7.26 111.028 -173.824 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo . . . . . 0 C--O 1.255 1.354 0 C-N-CA 124.063 3.175 . . . . 4.97 112.155 152.631 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo . . . . . 0 N--CA 1.486 1.085 0 CA-C-O 118.604 -0.665 . . . . 5.14 111.305 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -69.06 -152.88 0.03 OUTLIER 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 123.394 2.729 . . . . 4.32 109.761 163.632 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -91.45 177.28 40.69 Favored Glycine 0 CA--C 1.535 1.293 0 N-CA-C 111.424 -0.67 . . . . 2.66 111.424 166.684 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -78.26 168.07 22.23 Favored 'Trans proline' 0 N--CA 1.455 -0.772 0 C-N-CA 123.111 2.541 . . . . 3.85 111.858 172.637 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 27.0 tp60 -40.51 121.91 1.52 Allowed 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 128.217 2.607 . . . . 2.8 113.98 160.046 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.74 157.74 51.91 Favored Glycine 0 CA--C 1.527 0.841 0 C-N-CA 124.82 1.2 . . . . 1.53 111.637 163.953 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 51.2 mm -65.56 132.2 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 O-C-N 121.81 -0.818 . . . . 2.89 111.903 -172.458 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.52 145.92 38.77 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 123.77 0.828 . . . . 1.46 111.862 171.731 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -80.44 -173.21 46.19 Favored Glycine 0 C--N 1.338 0.673 0 CA-C-O 122.684 1.158 . . . . 1.02 111.513 -179.959 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 12.5 mp0 -115.95 158.84 22.44 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 108.214 -1.032 . . . . 3.29 108.214 179.367 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 2.8 tmt_? -63.45 134.12 55.1 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 107.611 -1.255 . . . . 6.43 107.611 153.804 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.61 153.66 52.92 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 111.626 -0.589 . . . . 2.79 111.626 -179.249 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' C' C ' 23' ' ' VAL . . . . . 0.515 HG23 ' H ' ' B' ' 25' ' ' GLY . 15.5 m -67.03 162.66 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 O-C-N 121.429 -1.042 . . . . 4.62 111.95 -176.291 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 16.0 m -90.61 173.93 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 126.889 2.076 . . . . 4.88 110.776 171.552 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.15 -171.87 2.45 Favored Glycine 0 CA--C 1.54 1.632 0 C-N-CA 125.249 1.404 . . . . 3.74 115.132 164.808 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 mm? . . . . . 0 C--O 1.25 1.117 0 C-N-CA 126.69 1.996 . . . . 7.44 112.36 -166.274 . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.69 0 CA-C-O 116.307 -2.385 . . . . 2.84 109.047 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -78.43 164.85 25.96 Favored 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 123.144 2.562 . . . . 1.92 112.606 -170.612 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.62 153.47 10.29 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 129.304 3.041 . . . . 3.55 112.464 170.072 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.12 -144.26 3.41 Favored Glycine 0 N--CA 1.475 1.287 0 C-N-CA 126.667 2.079 . . . . 1.67 117.01 -171.8 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 33.2 pt -98.94 139.32 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 O-C-N 121.24 -1.153 . . . . 2.59 108.692 174.848 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.84 146.4 49.77 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-O 121.38 0.609 . . . . 1.78 111.052 179.558 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -45.86 141.64 4.96 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 126.423 1.963 . . . . 1.23 114.017 174.884 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 80.3 mm-40 -63.69 132.82 52.25 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 108.925 -0.768 . . . . 3.3 108.925 -178.54 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.4 tmt_? -64.55 134.31 54.13 Favored 'General case' 0 CA--C 1.536 0.425 0 N-CA-C 112.421 0.526 . . . . 4.83 112.421 -162.481 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.54 160.79 53.7 Favored Glycine 0 N--CA 1.466 0.66 0 CA-C-O 122.823 1.235 . . . . 1.49 115.6 -169.58 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 11.1 t -79.01 145.25 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 126.15 1.78 . . . . 2.24 111.847 -167.272 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.9 m -58.49 147.26 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 C-N-CA 124.965 1.306 . . . . 2.51 113.59 -179.396 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.72 -163.88 34.34 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 124.267 0.937 . . . . 2.01 112.263 167.215 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.1 mt -145.9 160.44 43.62 Favored Pre-proline 0 N--CA 1.474 0.768 0 C-N-CA 128.053 2.541 . . . . 3.14 108.177 174.868 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -77.11 -157.12 0.07 OUTLIER 'Trans proline' 0 CA--C 1.541 0.866 0 C-N-CA 122.187 1.925 . . . . 2.0 109.129 164.677 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.205 0 CA-C-O 117.358 -1.801 . . . . 3.39 112.696 154.383 . . . . . . . . 0 0 . 1 . 026 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo . . . . . 0 N--CA 1.481 0.762 0 CA-C-O 118.479 -0.717 . . . . 2.46 111.391 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.49 166.26 30.73 Favored Glycine 0 CA--C 1.543 1.814 0 CA-C-O 119.006 -0.886 . . . . 1.64 112.885 149.724 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -76.62 41.76 0.95 Allowed 'Trans proline' 0 CA--C 1.546 1.078 1 C-N-CA 127.014 5.143 . . . . 3.7 113.176 -179.123 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 66.27 178.17 0.22 Allowed 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 125.274 1.43 . . . . 4.4 112.053 -165.1 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.64 163.54 31.08 Favored Glycine 0 CA--C 1.541 1.696 0 C-N-CA 124.429 1.014 . . . . 0.95 113.447 159.367 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 67.5 mt -77.77 148.71 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 126.05 1.74 . . . . 2.87 111.718 176.469 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -73.58 147.97 43.39 Favored 'General case' 0 CA--C 1.548 0.877 0 N-CA-C 114.362 1.245 . . . . 1.29 114.362 -177.616 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -78.02 169.89 54.72 Favored Glycine 0 CA--C 1.536 1.378 0 C-N-CA 125.52 1.533 . . . . 1.5 112.476 173.188 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.94 170.35 12.35 Favored 'General case' 0 N--CA 1.467 0.408 0 O-C-N 121.321 -1.105 . . . . 3.26 112.06 -177.35 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -59.42 148.4 32.83 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 124.6 1.16 . . . . 4.97 113.328 -176.243 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.6 -54.96 5.22 Favored Glycine 0 N--CA 1.472 1.045 0 N-CA-C 114.418 0.527 . . . . 4.31 114.418 -173.404 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 11.1 t -146.65 158.91 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 128.478 2.711 . . . . 4.73 107.864 -176.518 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.0 p -121.06 153.58 24.55 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 C-N-CA 127.87 2.468 . . . . 3.32 109.32 178.103 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.02 -168.29 43.73 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-O 121.857 0.698 . . . . 1.74 114.582 177.162 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.9 pp -159.79 150.92 16.07 Favored Pre-proline 0 CA--C 1.543 0.699 0 C-N-CA 125.996 1.718 . . . . 3.16 110.97 -179.265 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo . . . . . 0 C--O 1.254 1.306 1 C-N-CA 125.584 4.189 . . . . 3.09 112.881 167.594 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo . . . . . 0 N--CA 1.485 1.001 0 CA-C-O 118.834 -0.569 . . . . 2.06 111.267 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -71.99 -143.16 0.02 OUTLIER 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 123.943 3.095 . . . . 1.55 109.257 169.091 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.33 146.61 39.45 Favored Glycine 0 CA--C 1.54 1.623 0 CA-C-O 118.713 -1.048 . . . . 1.07 110.506 165.659 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -68.25 -43.04 4.91 Favored 'Trans proline' 0 CA--C 1.534 0.49 0 C-N-CA 123.024 2.483 . . . . 3.28 113.285 178.208 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.427 HE21 ' N ' ' C' ' 16' ' ' GLY . 16.9 tp60 174.2 115.2 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 126.185 1.794 . . . . 1.32 107.948 -166.201 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' C' C ' 16' ' ' GLY . . . . . 0.427 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -65.83 164.71 38.77 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 123.663 0.649 . . . . 0.92 112.979 169.616 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 35.0 mm -69.59 128.55 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 O-C-N 121.527 -0.984 . . . . 2.25 110.761 -171.498 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.15 149.98 22.48 Favored 'General case' 0 CA--C 1.543 0.691 0 N-CA-C 113.748 1.018 . . . . 1.25 113.748 176.806 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -73.32 138.46 25.28 Favored Glycine 0 CA--C 1.526 0.746 0 C-N-CA 124.11 0.862 . . . . 1.04 111.36 -177.44 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 -75.81 167.73 21.34 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.138 0.975 . . . . 5.45 111.827 175.529 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.18 147.79 19.75 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 125.619 1.568 . . . . 3.78 112.151 171.374 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -56.32 146.82 32.56 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 125.734 1.635 . . . . 1.08 113.328 166.832 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 34.8 m -75.01 137.89 22.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 107.2 -1.408 . . . . 3.38 107.2 162.698 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 34.9 m -92.19 -152.36 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.799 0 C-N-CA 124.034 0.934 . . . . 2.87 110.991 -168.35 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.98 169.53 1.25 Allowed Glycine 0 CA--C 1.542 1.751 0 C-N-CA 124.033 0.825 . . . . 1.81 114.103 162.189 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 12.8 mt . . . . . 0 C--O 1.249 1.028 0 C-N-CA 124.897 1.279 . . . . 3.65 114.024 -163.845 . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.647 0 CA-C-O 116.042 -2.532 . . . . 3.24 108.965 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -76.38 166.1 28.1 Favored 'Trans proline' 0 CA--C 1.535 0.548 0 C-N-CA 122.839 2.36 . . . . 2.29 111.331 -177.79 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? -74.81 165.96 24.4 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 126.739 2.016 . . . . 3.75 113.594 175.534 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.11 -157.58 3.36 Favored Glycine 0 N--CA 1.476 1.365 0 C-N-CA 129.493 3.425 . . . . 1.5 116.915 -170.267 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.9 mt -77.96 125.74 37.78 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 O-C-N 120.403 -1.645 . . . . 2.15 107.942 174.736 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.0 128.41 30.33 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 123.117 0.567 . . . . 1.94 111.274 174.713 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.77 150.23 42.85 Favored Glycine 0 CA--C 1.521 0.466 0 C-N-CA 126.455 1.979 . . . . 1.26 112.856 -174.554 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 76.8 mm-40 -74.46 135.15 42.29 Favored 'General case' 0 C--N 1.332 -0.175 0 O-C-N 122.333 -0.51 . . . . 3.7 110.652 -167.268 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 35.2 ttp180 -54.48 130.96 41.51 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 123.539 0.736 . . . . 5.99 110.908 176.33 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.89 -178.03 29.83 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 124.441 1.02 . . . . 2.2 114.189 -171.646 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.412 HG23 ' H ' ' A' ' 23' ' ' VAL . 0.9 OUTLIER -61.11 142.36 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 C-N-CA 123.916 0.886 . . . . 2.76 110.03 174.846 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.7 m -52.22 154.08 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 C-N-CA 124.184 0.994 . . . . 3.03 112.944 173.6 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -83.9 -149.43 9.61 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 123.797 0.713 . . . . 2.43 112.591 166.298 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 82.8 mt -146.73 162.5 33.45 Favored Pre-proline 0 N--CA 1.475 0.789 0 C-N-CA 127.015 2.126 . . . . 3.46 109.687 170.581 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -83.06 -152.92 0.04 OUTLIER 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 123.298 2.665 . . . . 2.17 108.515 154.228 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.207 0 CA-C-O 117.61 -1.661 . . . . 3.83 113.103 156.191 . . . . . . . . 0 0 . 1 . 027 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_exo . . . . . 0 N--CA 1.479 0.676 0 CA-C-O 118.196 -0.835 . . . . 2.24 111.392 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.48 158.21 27.81 Favored Glycine 0 CA--C 1.546 2.01 0 CA-C-N 119.178 0.899 . . . . 1.99 112.816 154.342 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -76.13 47.5 2.03 Favored 'Trans proline' 0 CA--C 1.545 1.071 1 C-N-CA 127.374 5.383 . . . . 3.99 113.419 -175.958 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.4 tp-100 69.88 -169.65 0.17 Allowed 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 124.819 1.248 . . . . 4.22 109.871 -161.33 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -106.93 154.88 16.58 Favored Glycine 0 CA--C 1.533 1.201 0 C-N-CA 126.192 1.853 . . . . 1.15 110.576 158.558 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 18.3 tt -63.58 144.81 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 C-N-CA 124.228 1.011 . . . . 4.05 112.521 177.393 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -75.0 148.36 39.98 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 113.624 0.972 . . . . 1.61 113.624 178.91 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.63 148.39 43.42 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 125.635 1.588 . . . . 1.74 113.8 -177.747 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 19.5 tt0 -80.25 148.34 30.83 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.222 1.009 . . . . 3.88 112.418 -177.86 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.5 mtm180 -63.87 130.75 45.4 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 124.747 1.219 . . . . 4.61 111.829 178.125 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.48 2.72 45.18 Favored Glycine 0 N--CA 1.476 1.34 0 N-CA-C 119.6 2.6 . . . . 4.68 119.6 -155.365 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . 0.278 0.9 OUTLIER 173.3 156.92 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 130.302 3.441 . . . . 4.96 108.741 179.214 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 42.1 t -132.54 141.51 44.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 C-N-CA 126.245 1.818 . . . . 4.46 107.911 178.052 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -88.05 -177.69 47.58 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-O 122.496 1.053 . . . . 2.53 114.779 -170.3 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.1 pt? -161.19 156.96 21.55 Favored Pre-proline 0 CA--C 1.542 0.651 0 C-N-CA 126.419 1.888 . . . . 3.98 110.243 -177.734 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo . . . . . 0 C--O 1.255 1.374 0 C-N-CA 124.129 3.219 . . . . 3.32 111.229 164.112 . . . . . . . . 0 0 . 1 . 027 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo . . . . . 0 N--CA 1.487 1.097 0 CA-C-O 119.019 -0.492 . . . . 2.55 111.555 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -70.0 -148.83 0.02 OUTLIER 'Trans proline' 0 CA--C 1.541 0.857 0 C-N-CA 123.616 2.878 . . . . 1.98 109.553 165.768 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -81.95 176.45 53.96 Favored Glycine 0 CA--C 1.537 1.454 0 O-C-N 121.279 -0.888 . . . . 1.13 111.542 168.88 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -79.24 -177.58 4.0 Favored 'Trans proline' 0 N--CA 1.452 -0.952 0 C-N-CA 123.095 2.53 . . . . 2.37 109.792 162.125 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.7 tp60 -41.55 119.29 1.22 Allowed 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 125.981 1.712 . . . . 1.8 113.875 159.363 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.32 161.88 41.22 Favored Glycine 0 CA--C 1.528 0.855 0 C-N-CA 125.772 1.654 . . . . 1.13 112.531 167.518 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 33.4 mm -68.77 142.39 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 O-C-N 121.576 -0.955 . . . . 3.72 110.511 -172.714 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.81 154.63 40.36 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.31 0.856 . . . . 1.42 113.31 177.1 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.59 157.52 53.25 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 124.274 0.94 . . . . 1.15 113.131 -179.095 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 14.4 mp0 -82.31 173.98 11.57 Favored 'General case' 0 CA--C 1.541 0.615 0 O-C-N 121.869 -0.783 . . . . 3.0 111.26 179.024 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.3 135.31 57.13 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 123.287 0.635 . . . . 3.69 110.426 169.15 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -65.35 167.3 32.52 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.93 1.253 . . . . 1.34 113.972 -176.675 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 87.2 t -75.52 148.4 7.49 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 C-N-CA 123.876 0.871 . . . . 2.06 109.458 -176.865 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 98.7 t -97.28 174.69 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.991 0 C-N-CA 127.297 2.239 . . . . 2.83 109.613 -174.891 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -56.3 173.17 1.67 Allowed Glycine 0 CA--C 1.538 1.504 0 C-N-CA 124.974 1.273 . . . . 2.01 114.723 165.25 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 8.8 mt . . . . . 0 C--O 1.25 1.097 0 N-CA-C 113.821 1.045 . . . . 4.43 113.821 -158.143 . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.647 0 CA-C-O 116.623 -2.209 . . . . 3.13 110.08 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -63.39 159.86 38.04 Favored 'Trans proline' 0 C--N 1.349 0.585 0 C-N-CA 123.849 3.033 . . . . 1.92 111.491 179.79 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.84 177.76 0.71 Allowed 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 127.73 2.412 . . . . 3.73 114.656 -178.227 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.16 173.09 44.25 Favored Glycine 0 CA--C 1.526 0.728 0 C-N-CA 125.904 1.716 . . . . 1.26 113.793 177.323 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.546 ' H ' HD12 ' A' ' 17' ' ' ILE . 3.2 mp -67.42 135.24 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.51 0 N-CA-C 109.292 -0.633 . . . . 2.37 109.292 -173.189 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -53.95 133.0 43.16 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 118.427 0.558 . . . . 1.79 110.482 170.613 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.12 168.68 24.27 Favored Glycine 0 CA--C 1.521 0.417 0 C-N-CA 126.115 1.816 . . . . 1.31 114.778 -167.995 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 85.6 mm-40 -71.46 96.28 1.48 Allowed 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 108.598 -0.89 . . . . 3.19 108.598 179.793 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.2 ttp-105 -62.29 138.63 58.46 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 124.836 1.254 . . . . 4.96 113.23 -165.155 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.7 149.97 39.04 Favored Glycine 0 C--N 1.332 0.355 0 CA-C-O 122.421 1.012 . . . . 2.26 113.704 -171.211 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 32.7 m -76.64 163.11 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 CA-C-N 113.676 -1.262 . . . . 2.74 111.173 -174.624 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.0 m -60.75 167.69 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 124.257 1.023 . . . . 3.54 112.395 177.355 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.72 146.97 39.4 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 110.407 -1.077 . . . . 2.1 110.407 157.957 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 8.5 mp -101.62 169.57 7.53 Favored Pre-proline 0 CA--C 1.538 0.516 0 C-N-CA 124.041 0.936 . . . . 3.64 111.95 -170.833 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -69.11 115.11 3.84 Favored 'Trans proline' 0 N--CA 1.445 -1.337 0 N-CA-C 106.989 -1.966 . . . . 2.98 106.989 151.775 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.147 0 CA-C-O 118.584 -1.12 . . . . 6.8 114.773 -157.294 . . . . . . . . 0 0 . 1 . 028 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo . . . . . 0 CA--C 1.544 0.995 0 N-CA-C 111.313 -0.303 . . . . 2.1 111.313 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.44 167.7 13.23 Favored Glycine 0 CA--C 1.541 1.717 0 C-N-CA 120.13 -1.033 . . . . 1.3 112.902 127.473 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -76.69 -64.4 0.03 OUTLIER 'Trans proline' 0 CA--C 1.538 0.702 0 C-N-CA 124.974 3.782 . . . . 2.85 112.694 175.678 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 8.3 tp-100 -166.6 157.4 12.39 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 127.943 2.497 . . . . 3.25 107.639 -164.711 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.36 159.23 25.02 Favored Glycine 0 CA--C 1.527 0.783 0 C-N-CA 124.324 0.964 . . . . 0.97 113.469 175.549 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 17' ' ' ILE . . . . . 0.53 ' H ' HD12 ' B' ' 17' ' ' ILE . 3.8 mp -70.28 127.89 32.82 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 N-CA-C 108.855 -0.795 . . . . 3.49 108.855 176.851 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.62 146.76 38.01 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 118.973 0.806 . . . . 1.27 112.416 178.873 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -78.63 141.27 24.4 Favored Glycine 0 CA--C 1.527 0.8 0 C-N-CA 124.643 1.116 . . . . 1.53 111.668 179.268 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.65 164.77 12.82 Favored 'General case' 0 N--CA 1.468 0.463 0 O-C-N 121.43 -1.041 . . . . 4.14 111.132 166.75 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -82.3 167.12 18.91 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.285 1.034 . . . . 5.24 112.022 167.138 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.71 -174.02 45.65 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 124.609 1.1 . . . . 2.68 112.619 164.945 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 11.0 m -100.9 160.05 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 C-N-CA 125.039 1.336 . . . . 5.2 114.568 -166.243 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.7 p -42.37 150.38 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 C-N-CA 129.016 2.926 . . . . 4.1 115.221 -178.117 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.44 -114.93 1.93 Allowed Glycine 0 CA--C 1.528 0.85 0 CA-C-O 119.154 -0.803 . . . . 2.24 111.343 167.334 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -172.43 177.23 0.83 Allowed Pre-proline 0 CA--C 1.556 1.204 0 C-N-CA 126.977 2.111 . . . . 3.81 110.55 -164.572 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_endo . . . . . 0 C--O 1.255 1.36 0 C-N-CA 123.926 3.084 . . . . 5.26 112.725 174.571 . . . . . . . . 0 0 . 1 . 028 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo . . . . . 0 CA--C 1.546 1.101 0 CA-C-O 118.532 -0.695 . . . . 1.89 111.426 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -61.72 -154.05 0.02 OUTLIER 'Trans proline' 0 CA--C 1.545 1.054 0 C-N-CA 124.934 3.756 . . . . 1.72 111.679 164.682 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -84.21 -177.9 51.45 Favored Glycine 0 CA--C 1.543 1.805 0 O-C-N 121.068 -1.02 . . . . 0.96 113.157 173.53 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -79.54 169.49 18.44 Favored 'Trans proline' 0 CA--C 1.535 0.535 0 C-N-CA 124.219 3.279 . . . . 2.3 111.304 173.865 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 -48.04 116.92 1.68 Allowed 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 124.209 1.004 . . . . 1.47 111.288 160.717 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.58 163.22 36.39 Favored Glycine 0 CA--C 1.529 0.94 0 C-N-CA 124.852 1.215 . . . . 0.87 112.577 172.171 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 3.1 mp -65.96 145.27 14.02 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.667 0 C-N-CA 123.852 0.861 . . . . 2.67 110.673 -168.628 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -68.8 163.72 23.51 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.517 0.932 . . . . 1.2 113.517 179.084 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.11 149.46 17.96 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 109.946 -1.262 . . . . 1.01 109.946 168.6 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 7.2 mm100 -93.39 -167.86 1.8 Allowed 'General case' 0 CA--C 1.541 0.621 0 O-C-N 121.978 -0.719 . . . . 4.77 110.831 -178.07 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 2.6 ttt180 -63.33 154.44 31.76 Favored 'General case' 0 N--CA 1.467 0.41 0 O-C-N 121.272 -0.893 . . . . 3.8 110.898 168.524 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.24 -171.44 45.1 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 123.726 0.679 . . . . 1.04 111.653 165.355 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.0 t -70.3 136.8 25.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 C-N-CA 124.266 1.026 . . . . 1.79 111.855 -170.623 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -44.94 124.58 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 C-N-CA 126.599 1.959 . . . . 3.78 112.671 161.264 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.34 127.45 8.88 Favored Glycine 0 CA--C 1.525 0.698 0 C-N-CA 123.342 0.496 . . . . 3.63 112.823 179.613 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 16.9 mt . . . . . 0 C--O 1.254 1.313 0 CA-C-O 117.107 -1.425 . . . . 7.05 109.623 146.124 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.645 0 CA-C-O 117.014 -1.992 . . . . 4.3 110.063 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.68 168.37 19.58 Favored 'Trans proline' 0 CA--C 1.536 0.614 0 C-N-CA 123.473 2.782 . . . . 2.74 111.96 -176.073 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -58.46 153.4 15.97 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 128.863 2.865 . . . . 3.06 112.972 173.282 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.46 -135.01 5.01 Favored Glycine 0 N--CA 1.476 1.306 0 C-N-CA 125.996 1.76 . . . . 1.94 115.981 -171.703 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 24.0 pt -102.46 143.35 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 O-C-N 121.751 -0.852 . . . . 2.85 110.863 -178.417 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.34 143.57 28.05 Favored 'General case' 0 CA--C 1.538 0.509 0 CA-C-O 121.845 0.831 . . . . 1.77 112.007 178.612 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.46 152.21 16.39 Favored Glycine 0 CA--C 1.52 0.379 0 C-N-CA 127.637 2.541 . . . . 1.5 115.529 178.367 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 84.8 mm-40 -66.19 152.87 43.91 Favored 'General case' 0 CA--C 1.531 0.236 0 CA-C-N 113.957 -1.121 . . . . 3.21 111.172 -176.424 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -63.95 141.95 58.58 Favored 'General case' 0 N--CA 1.466 0.348 0 O-C-N 122.04 -0.413 . . . . 3.83 111.659 -179.538 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.6 164.27 45.05 Favored Glycine 0 CA--C 1.523 0.591 0 CA-C-N 115.621 -0.718 . . . . 1.53 113.096 176.609 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 2.1 t -64.55 150.07 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 124.565 1.146 . . . . 2.76 112.277 -167.69 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.8 t -53.81 132.51 16.58 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.686 0 C-N-CA 125.497 1.519 . . . . 3.83 111.587 167.88 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -85.42 155.93 30.07 Favored Glycine 0 CA--C 1.528 0.863 0 C-N-CA 124.847 1.213 . . . . 1.42 111.255 165.971 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 94.4 mt -118.16 156.52 50.44 Favored Pre-proline 0 N--CA 1.468 0.456 0 CA-C-O 117.537 -1.22 . . . . 2.86 109.937 -177.12 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -71.22 -158.47 0.06 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.875 0 C-N-CA 121.567 1.512 . . . . 1.86 109.304 161.849 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.307 0 CA-C-O 117.455 -1.747 . . . . 3.14 112.936 154.918 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo . . . . . 0 CA--C 1.544 0.992 0 N-CA-C 111.302 -0.307 . . . . 3.06 111.302 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.55 -173.02 3.19 Favored Glycine 0 CA--C 1.541 1.66 0 C-N-CA 120.097 -1.049 . . . . 1.56 113.339 123.922 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -77.9 -128.97 0.01 OUTLIER 'Trans proline' 0 CA--C 1.546 1.083 0 C-N-CA 124.864 3.709 . . . . 2.47 108.233 161.533 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -87.01 -171.01 3.31 Favored 'General case' 0 CA--C 1.552 1.038 0 C-N-CA 125.844 1.657 . . . . 4.25 111.304 171.378 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.32 166.87 33.63 Favored Glycine 0 CA--C 1.541 1.692 0 O-C-N 121.204 -0.935 . . . . 1.08 111.875 149.412 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 46.8 mm -67.95 143.39 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.02 -1.282 . . . . 3.67 110.212 168.241 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.72 157.89 34.49 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 114.791 1.404 . . . . 1.39 114.791 -173.11 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -78.27 161.2 48.56 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 125.908 1.718 . . . . 1.78 113.561 -175.51 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.41 156.37 18.6 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 121.651 -0.911 . . . . 3.27 111.133 175.431 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.9 155.26 16.84 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 112.208 0.447 . . . . 8.19 112.208 178.177 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.38 -125.45 0.6 Allowed Glycine 0 CA--C 1.529 0.917 0 C-N-CA 123.995 0.807 . . . . 2.65 111.174 172.008 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 82.2 t -64.06 158.34 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 C-N-CA 124.738 1.215 . . . . 4.93 110.715 179.312 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 6.2 m -129.57 157.47 42.26 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 C-N-CA 126.429 1.891 . . . . 2.99 109.362 174.005 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.478 ' H ' HG23 ' C' ' 23' ' ' VAL . . . -87.72 176.74 46.32 Favored Glycine 0 C--N 1.336 0.545 0 C-N-CA 125.395 1.474 . . . . 1.89 115.305 -170.147 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -165.67 157.98 12.85 Favored Pre-proline 0 CA--C 1.549 0.928 0 C-N-CA 125.437 1.495 . . . . 3.22 113.262 -168.805 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_endo . . . . . 0 C--O 1.255 1.343 0 C-N-CA 123.748 2.965 . . . . 2.72 111.786 159.837 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo . . . . . 0 N--CA 1.487 1.119 0 CA-C-O 118.882 -0.549 . . . . 2.47 111.694 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -69.44 -139.37 0.01 OUTLIER 'Trans proline' 0 CA--C 1.542 0.923 0 C-N-CA 123.617 2.878 . . . . 1.54 108.713 163.385 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.1 163.73 53.91 Favored Glycine 0 CA--C 1.54 1.629 0 O-C-N 120.924 -1.11 . . . . 1.26 111.492 165.283 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -79.46 -43.06 0.15 Allowed 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 122.697 2.265 . . . . 3.67 112.511 -178.926 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.452 HE21 ' N ' ' C' ' 16' ' ' GLY . 17.3 tp60 167.84 133.09 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.81 2.444 . . . . 1.6 105.913 -154.445 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' C' C ' 16' ' ' GLY . . . . . 0.452 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -75.41 158.96 51.05 Favored Glycine 0 CA--C 1.534 1.225 0 C-N-CA 124.358 0.98 . . . . 1.19 113.654 167.649 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 73.3 mt -62.7 147.28 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 O-C-N 121.495 -1.003 . . . . 2.2 110.394 175.509 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.36 163.91 17.21 Favored 'General case' 0 CA--C 1.545 0.778 0 N-CA-C 114.014 1.116 . . . . 1.8 114.014 -177.148 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.86 154.17 46.46 Favored Glycine 0 CA--C 1.529 0.924 0 CA-C-N 115.443 -0.799 . . . . 1.62 111.66 170.562 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -84.76 168.72 14.92 Favored 'General case' 0 CA--C 1.539 0.54 0 CA-C-O 121.66 0.743 . . . . 3.38 111.909 -174.266 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 1.1 tmt_? -60.79 136.51 58.09 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 123.596 0.758 . . . . 3.15 110.861 -179.492 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.07 138.21 29.26 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.793 -0.923 . . . . 1.12 110.793 175.002 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' C' C ' 23' ' ' VAL . . . . . 0.478 HG23 ' H ' ' B' ' 25' ' ' GLY . 18.9 m -61.04 154.62 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 117.931 0.866 . . . . 2.76 111.696 -176.652 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 10.5 p -85.03 177.34 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 C-N-CA 126.876 2.071 . . . . 2.87 110.082 172.908 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.43 -164.72 0.61 Allowed Glycine 0 CA--C 1.54 1.646 0 C-N-CA 125.21 1.385 . . . . 1.58 115.875 169.851 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 16.5 mt . . . . . 0 N--CA 1.481 1.082 0 C-N-CA 125.507 1.523 . . . . 3.27 114.481 -162.439 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.756 0 CA-C-O 116.838 -2.09 . . . . 3.44 110.108 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -76.47 161.74 34.11 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 123.395 2.73 . . . . 2.55 111.554 -175.278 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.37 154.29 28.57 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.226 2.21 . . . . 3.17 113.517 178.955 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.08 -116.54 0.04 OUTLIER Glycine 0 CA--C 1.534 1.224 0 C-N-CA 126.937 2.208 . . . . 2.54 115.369 179.481 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.9 mt -134.79 132.95 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 O-C-N 121.211 -1.17 . . . . 1.92 109.739 -174.239 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.11 133.84 55.94 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.644 0.778 . . . . 1.76 112.324 176.44 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.99 163.12 41.73 Favored Glycine 0 CA--C 1.527 0.829 0 C-N-CA 126.885 2.183 . . . . 1.35 113.827 -175.15 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 8.6 mp0 -67.31 130.21 42.35 Favored 'General case' 0 N--CA 1.468 0.438 0 O-C-N 122.527 -0.396 . . . . 4.94 110.851 -164.056 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 42.4 ttt180 -63.09 126.59 27.87 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 118.363 0.529 . . . . 4.24 110.16 179.662 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.74 142.38 36.56 Favored Glycine 0 C--N 1.336 0.575 0 N-CA-C 114.634 0.613 . . . . 1.7 114.634 -160.204 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 35.9 m -64.4 122.93 16.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-N 114.792 -0.704 . . . . 2.53 109.484 -177.199 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 9.8 p -39.16 149.46 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 127.167 2.187 . . . . 2.86 113.566 -176.934 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.92 -155.28 0.61 Allowed Glycine 0 CA--C 1.531 1.054 0 O-C-N 121.405 -0.809 . . . . 1.9 114.296 172.343 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.9 mt -136.66 161.57 61.08 Favored Pre-proline 0 CA--C 1.541 0.6 0 C-N-CA 125.521 1.528 . . . . 2.9 110.751 176.377 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -84.14 -151.65 0.04 OUTLIER 'Trans proline' 0 CA--C 1.539 0.74 0 C-N-CA 123.89 3.06 . . . . 1.82 108.232 159.697 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.153 0 CA-C-O 117.211 -1.883 . . . . 3.16 112.438 141.901 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_exo . . . . . 0 CA--C 1.542 0.907 0 N-CA-C 111.716 -0.148 . . . . 2.53 111.716 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.38 177.19 25.9 Favored Glycine 0 CA--C 1.538 1.492 0 C-N-CA 120.074 -1.06 . . . . 1.28 112.989 128.045 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -82.2 155.93 17.08 Favored 'Trans proline' 0 CA--C 1.539 0.729 1 C-N-CA 125.418 4.079 . . . . 2.7 111.009 159.403 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -59.6 139.86 56.83 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 125.143 1.377 . . . . 3.95 110.757 169.746 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.29 161.94 47.44 Favored Glycine 0 C--N 1.338 0.646 0 C-N-CA 124.052 0.834 . . . . 1.12 114.932 -173.663 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 42.3 pt -57.78 145.71 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 C-N-CA 122.885 0.474 . . . . 3.9 111.892 179.707 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.19 149.31 48.73 Favored 'General case' 0 CA--C 1.543 0.675 0 O-C-N 121.525 -0.735 . . . . 1.42 112.322 175.803 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.61 152.15 51.35 Favored Glycine 0 CA--C 1.53 1.001 0 N-CA-C 110.318 -1.113 . . . . 1.56 110.318 166.942 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.91 151.56 22.25 Favored 'General case' 0 N--CA 1.468 0.456 0 O-C-N 121.356 -1.085 . . . . 3.25 110.449 176.015 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 31.4 ptt180 -61.81 159.57 13.52 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.072 0.949 . . . . 5.68 113.368 -179.566 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.68 160.84 53.82 Favored Glycine 0 CA--C 1.532 1.122 0 C-N-CA 124.825 1.202 . . . . 2.1 114.816 -178.418 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 43.9 t -89.47 131.59 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 124.598 1.159 . . . . 2.88 113.673 -168.424 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 11.5 m -79.46 160.65 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 C-N-CA 126.143 1.777 . . . . 2.6 113.301 -168.381 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.12 -128.31 6.18 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 125.036 1.303 . . . . 1.69 112.812 176.926 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -170.9 156.89 5.0 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 125.359 1.464 . . . . 3.11 112.076 -163.837 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo . . . . . 0 C--O 1.254 1.295 0 C-N-CA 124.571 3.514 . . . . 2.57 112.28 155.584 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo . . . . . 0 CA--C 1.547 1.167 0 CA-C-O 118.964 -0.515 . . . . 2.49 111.517 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -65.91 -157.74 0.03 OUTLIER 'Trans proline' 0 CA--C 1.544 0.975 0 C-N-CA 123.192 2.595 . . . . 1.93 109.967 161.669 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -93.16 -176.73 40.66 Favored Glycine 0 CA--C 1.534 1.26 0 O-C-N 121.171 -0.956 . . . . 1.22 111.859 170.721 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -79.37 170.67 17.09 Favored 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 123.277 2.652 . . . . 2.53 112.295 173.65 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.442 ' HA ' HE21 ' C' ' 15' ' ' GLN . 0.0 OUTLIER -38.03 135.98 0.64 Allowed 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 127.917 2.487 . . . . 1.96 114.333 154.736 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.81 173.18 54.66 Favored Glycine 0 CA--C 1.529 0.944 0 C-N-CA 126.193 1.854 . . . . 1.01 114.996 174.077 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 96.4 mt -67.57 144.1 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.601 1.161 . . . . 2.74 112.415 -171.133 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.98 132.08 46.18 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.593 1.157 . . . . 1.75 112.967 174.707 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -62.21 122.84 29.6 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 108.293 -1.923 . . . . 1.43 108.293 157.323 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -82.19 160.54 23.02 Favored 'General case' 0 C--N 1.327 -0.407 0 O-C-N 121.736 -0.861 . . . . 3.48 110.9 -173.723 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 9.0 tpp180 -48.31 136.04 12.86 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 124.552 1.141 . . . . 5.17 111.612 173.647 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.1 157.56 52.98 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 115.098 -0.955 . . . . 1.15 112.091 176.119 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.2 t -65.17 155.39 6.66 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 C-N-CA 124.882 1.273 . . . . 2.25 110.58 176.215 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 30.4 m -68.84 -171.18 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.547 0.864 0 C-N-CA 126.392 1.877 . . . . 2.33 112.054 171.42 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.33 -108.24 0.01 OUTLIER Glycine 0 CA--C 1.534 1.273 0 C-N-CA 124.748 1.166 . . . . 2.37 111.884 163.3 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 55.8 mt . . . . . 0 C--O 1.249 1.069 0 CA-C-O 117.647 -1.168 . . . . 4.16 111.563 166.448 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo . . . . . 0 N--CA 1.457 -0.644 0 CA-C-O 121.136 0.39 . . . . 2.37 111.236 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.49 175.26 6.9 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 127.892 2.477 . . . . 2.81 113.084 -177.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.94 173.48 52.43 Favored Glycine 0 N--CA 1.479 1.542 0 N-CA-C 116.595 1.398 . . . . 1.66 116.595 -168.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.2 pt -71.51 145.09 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 O-C-N 120.905 -1.35 . . . . 3.03 110.256 -177.079 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.94 139.9 58.36 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-O 121.441 0.638 . . . . 1.78 112.207 -176.33 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.51 161.14 2.53 Favored Glycine 0 CA--C 1.526 0.744 0 C-N-CA 127.202 2.334 . . . . 1.31 115.682 178.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 22.1 mp0 -68.17 148.9 50.23 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-N 113.708 -1.246 . . . . 4.11 110.042 -174.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.86 130.41 45.57 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.774 -0.579 . . . . 6.82 110.277 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.04 150.38 50.26 Favored Glycine 0 CA--C 1.526 0.723 0 C-N-CA 124.073 0.844 . . . . 1.47 111.841 175.021 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 32.9 m -64.04 145.11 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 123.968 0.907 . . . . 2.24 111.514 -179.648 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 19.1 m -52.83 149.74 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 124.177 0.991 . . . . 2.16 113.359 -177.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.15 158.64 53.02 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-N 115.985 -0.552 . . . . 1.56 112.091 168.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 9.0 mp -89.2 158.04 47.08 Favored Pre-proline 0 CA--C 1.544 0.72 0 C-N-CA 123.221 0.608 . . . . 4.9 110.813 -176.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -78.19 -166.04 0.37 Allowed 'Trans proline' 0 CA--C 1.537 0.633 0 C-N-CA 123.596 2.864 . . . . 2.52 109.446 160.267 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.153 0 CA-C-O 117.35 -1.806 . . . . 3.58 111.952 150.297 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo . . . . . 0 N--CA 1.481 0.759 0 CA-C-O 118.484 -0.715 . . . . 2.2 111.482 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.02 159.62 51.09 Favored Glycine 0 CA--C 1.539 1.588 0 N-CA-C 110.886 -0.886 . . . . 1.29 110.886 150.245 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -72.09 177.45 7.14 Favored 'Trans proline' 0 CA--C 1.539 0.76 0 C-N-CA 123.244 2.63 . . . . 2.18 108.859 156.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 11.5 tt0 -60.19 172.63 0.78 Allowed 'General case' 0 CA--C 1.544 0.731 0 N-CA-C 114.935 1.457 . . . . 4.66 114.935 -175.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.17 159.48 51.77 Favored Glycine 0 CA--C 1.527 0.811 0 O-C-N 120.995 -1.066 . . . . 1.0 113.563 176.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 29.9 mm -60.25 141.48 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 123.669 0.788 . . . . 3.24 109.578 168.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.42 151.63 31.97 Favored 'General case' 0 CA--C 1.542 0.66 0 CA-C-O 122.756 1.265 . . . . 1.35 113.773 -179.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.19 137.67 38.25 Favored Glycine 0 CA--C 1.523 0.531 0 C-N-CA 125.25 1.405 . . . . 1.55 112.42 -179.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 94.9 mm-40 -81.92 124.84 30.08 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.577 -0.811 . . . . 3.96 109.167 -175.039 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 10.9 ptt180 -55.15 153.64 6.55 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 126.215 1.806 . . . . 6.64 114.064 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.92 173.65 54.69 Favored Glycine 0 CA--C 1.529 0.922 0 C-N-CA 124.133 0.873 . . . . 1.73 113.355 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 59.5 t -93.43 131.64 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 124.503 1.121 . . . . 2.98 112.83 -165.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 19.0 m -60.39 159.99 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 127.61 2.364 . . . . 2.5 114.414 -173.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.81 -136.7 5.25 Favored Glycine 0 CA--C 1.529 0.908 0 C-N-CA 124.191 0.9 . . . . 2.15 112.09 168.462 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -170.71 160.81 5.88 Favored Pre-proline 0 CA--C 1.543 0.705 0 C-N-CA 124.766 1.226 . . . . 3.48 111.534 -161.359 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo . . . . . 0 C--O 1.256 1.42 0 C-N-CA 124.586 3.524 . . . . 2.84 112.249 161.422 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo . . . . . 0 N--CA 1.486 1.076 0 CA-C-O 118.989 -0.505 . . . . 2.2 111.251 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -73.18 -130.07 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.939 0 C-N-CA 123.198 2.599 . . . . 2.01 107.778 162.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.29 168.23 48.14 Favored Glycine 0 CA--C 1.536 1.391 0 CA-C-N 119.509 1.049 . . . . 1.35 111.496 164.294 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.99 -44.83 0.31 Allowed 'Trans proline' 0 N--CA 1.458 -0.562 0 C-N-CA 122.578 2.185 . . . . 3.95 112.329 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.423 HE21 ' N ' ' C' ' 16' ' ' GLY . 30.5 tp60 166.83 137.44 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 127.926 2.49 . . . . 1.65 105.526 -153.169 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . 0.423 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -83.36 160.04 37.67 Favored Glycine 0 N--CA 1.468 0.823 0 C-N-CA 125.958 1.742 . . . . 1.07 112.927 169.228 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 46.7 mt -61.69 143.73 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 124.055 0.942 . . . . 2.2 111.022 -179.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.88 148.14 21.72 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.313 1.045 . . . . 1.24 113.559 174.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.87 149.42 34.61 Favored Glycine 0 C--N 1.339 0.712 0 C-N-CA 123.778 0.704 . . . . 0.97 111.375 -178.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 13.5 mp0 -90.85 -177.84 5.07 Favored 'General case' 0 CA--C 1.539 0.536 0 O-C-N 122.156 -0.614 . . . . 3.33 109.956 177.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 9.6 ptp180 -67.22 164.48 18.15 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-O 122.301 1.048 . . . . 5.6 113.592 -174.2 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.9 165.62 49.5 Favored Glycine 0 CA--C 1.531 1.031 0 C-N-CA 124.77 1.176 . . . . 1.17 111.862 166.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.7 t -64.08 144.99 14.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.282 1.033 . . . . 1.9 110.782 177.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 29.6 m -79.83 -171.67 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.833 0 C-N-CA 125.081 1.353 . . . . 2.98 111.622 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.13 179.42 7.05 Favored Glycine 0 CA--C 1.533 1.174 0 C-N-CA 124.842 1.211 . . . . 2.21 114.775 174.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 7.5 mt . . . . . 0 C--O 1.249 1.057 0 N-CA-C 114.527 1.306 . . . . 4.09 114.527 -169.77 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo . . . . . 0 N--CA 1.456 -0.697 0 CA-C-O 121.351 0.479 . . . . 2.21 111.225 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -76.32 -166.96 0.69 Allowed 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 127.017 2.127 . . . . 2.97 112.681 167.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.19 174.48 49.59 Favored Glycine 0 N--CA 1.472 1.088 0 O-C-N 121.308 -0.87 . . . . 1.5 114.737 -178.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 33.2 pt -73.15 150.38 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 O-C-N 122.329 -0.512 . . . . 3.12 109.693 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -49.1 131.98 19.26 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-O 121.775 0.798 . . . . 1.9 112.421 177.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.55 148.36 9.49 Favored Glycine 0 CA--C 1.519 0.344 0 C-N-CA 127.305 2.383 . . . . 1.25 112.856 166.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 78.7 mm-40 -80.64 132.61 35.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.081 -0.559 . . . . 3.69 109.534 -166.354 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 60.6 ttp180 -52.88 127.94 25.29 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.76 1.624 . . . . 7.94 113.292 -173.273 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.21 159.83 53.61 Favored Glycine 0 N--CA 1.468 0.78 0 N-CA-C 116.012 1.165 . . . . 1.72 116.012 -170.521 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 27.8 m -72.39 143.13 14.36 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 C-N-CA 124.357 1.063 . . . . 2.57 111.365 176.114 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 31.0 m -50.58 156.48 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 C-N-CA 126.803 2.041 . . . . 2.59 116.116 -168.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -81.27 -173.54 47.94 Favored Glycine 0 CA--C 1.533 1.187 0 C-N-CA 123.804 0.716 . . . . 1.81 113.028 162.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 7.2 mp -120.88 163.09 31.56 Favored Pre-proline 0 CA--C 1.542 0.656 0 C-N-CA 125.745 1.618 . . . . 4.18 111.427 178.707 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -83.17 -138.11 0.02 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.691 0 C-N-CA 123.738 2.959 . . . . 2.38 107.708 156.285 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.329 0 CA-C-O 116.907 -2.052 . . . . 3.41 113.292 142.836 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo . . . . . 0 N--CA 1.489 1.259 0 N-CA-C 109.306 -1.075 . . . . 2.44 109.306 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.13 147.46 37.87 Favored Glycine 0 CA--C 1.538 1.52 0 CA-C-O 118.546 -1.141 . . . . 1.41 110.718 162.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -72.29 179.89 4.61 Favored 'Trans proline' 0 CA--C 1.54 0.797 0 C-N-CA 123.871 3.047 . . . . 2.15 109.9 163.059 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 12.1 tt0 -53.71 162.82 0.79 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.087 1.355 . . . . 4.42 114.437 178.511 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.25 161.23 51.7 Favored Glycine 0 N--CA 1.47 0.965 0 O-C-N 121.289 -0.882 . . . . 1.11 112.989 -178.415 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.6 pp -65.58 150.13 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 O-C-N 121.944 -0.739 . . . . 4.39 111.117 171.628 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.47 147.15 49.75 Favored 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 114.431 1.271 . . . . 1.71 114.431 -175.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.58 158.45 53.19 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 124.821 1.2 . . . . 1.77 111.492 170.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 21.2 mp0 -69.1 150.52 47.49 Favored 'General case' 0 CA--C 1.536 0.418 0 O-C-N 121.979 -0.718 . . . . 3.69 111.408 -173.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 17.0 mtt180 -67.55 148.74 51.05 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 109.693 -0.484 . . . . 6.03 109.693 160.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.3 165.53 43.04 Favored Glycine 0 CA--C 1.533 1.165 0 N-CA-C 115.052 0.781 . . . . 1.95 115.052 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 23.3 m -78.97 130.18 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 114.432 1.271 . . . . 3.64 114.432 -168.383 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.7 m -85.23 154.96 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 126.119 1.767 . . . . 2.52 112.113 -170.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.57 -134.4 8.46 Favored Glycine 0 CA--C 1.53 0.994 0 C-N-CA 124.442 1.02 . . . . 1.64 113.273 179.321 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -166.31 161.04 12.43 Favored Pre-proline 0 CA--C 1.547 0.831 0 C-N-CA 125.498 1.519 . . . . 3.25 112.326 -165.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo . . . . . 0 C--O 1.254 1.323 0 C-N-CA 124.821 3.681 . . . . 2.66 112.249 152.161 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo . . . . . 0 N--CA 1.487 1.097 0 CA-C-O 119.017 -0.493 . . . . 2.2 111.099 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -71.78 -138.87 0.02 OUTLIER 'Trans proline' 0 CA--C 1.546 1.1 0 C-N-CA 123.465 2.776 . . . . 1.76 107.988 157.704 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.87 168.48 37.59 Favored Glycine 0 CA--C 1.54 1.598 0 CA-C-N 119.383 0.992 . . . . 1.12 112.23 166.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -79.28 -43.65 0.14 Allowed 'Trans proline' 0 CA--C 1.535 0.555 0 C-N-CA 123.021 2.481 . . . . 3.65 113.662 -176.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.491 HE21 ' H ' ' C' ' 16' ' ' GLY . 30.4 tp60 171.61 141.12 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 127.452 2.301 . . . . 1.35 105.865 -154.355 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . 0.491 ' H ' HE21 ' C' ' 15' ' ' GLN . . . -91.17 173.37 37.56 Favored Glycine 0 N--CA 1.466 0.634 0 C-N-CA 126.263 1.887 . . . . 0.89 114.474 171.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . 0.521 ' H ' HD12 ' C' ' 17' ' ' ILE . 3.9 mp -63.03 132.0 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 C-N-CA 124.464 1.106 . . . . 3.13 111.303 -175.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.66 135.05 57.18 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.824 0.85 . . . . 1.26 112.337 175.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -68.06 139.18 33.93 Favored Glycine 0 C--N 1.334 0.446 0 C-N-CA 124.835 1.207 . . . . 1.29 111.014 -173.202 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 98.8 mm-40 -93.19 158.22 15.87 Favored 'General case' 0 C--N 1.324 -0.501 0 O-C-N 122.026 -0.691 . . . . 4.69 111.856 -168.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.51 133.56 46.06 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 115.866 -0.606 . . . . 4.01 110.146 178.208 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.62 163.95 49.12 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 123.328 0.489 . . . . 1.11 113.491 -172.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 1.7 t -64.82 154.9 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 C-N-CA 123.372 0.669 . . . . 2.03 110.517 175.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 30.5 m -75.54 -173.5 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.816 0 C-N-CA 124.704 1.202 . . . . 3.08 110.898 170.611 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.97 -132.66 0.14 Allowed Glycine 0 CA--C 1.536 1.396 0 C-N-CA 125.078 1.323 . . . . 3.43 112.583 167.303 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 7.7 tt . . . . . 0 C--O 1.251 1.143 0 C-N-CA 126.643 1.977 . . . . 4.87 112.771 178.722 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo . . . . . 0 N--CA 1.46 -0.491 0 N-CA-C 110.9 -0.461 . . . . 2.06 110.9 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.12 176.45 9.74 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 127.938 2.495 . . . . 2.56 114.357 -172.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.9 177.44 44.77 Favored Glycine 0 N--CA 1.48 1.633 0 N-CA-C 116.8 1.48 . . . . 1.3 116.8 -169.404 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 7.8 pt -70.04 147.84 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 O-C-N 121.192 -1.181 . . . . 2.85 110.608 -173.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.14 134.78 44.24 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.77 0.795 . . . . 1.85 112.154 -179.058 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.76 144.85 25.78 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 126.364 1.935 . . . . 1.21 112.814 173.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 84.7 mm-40 -67.91 125.22 25.61 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 108.651 -0.87 . . . . 3.13 108.651 -170.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 32.1 ttt-85 -69.53 145.43 52.63 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-O 121.832 0.825 . . . . 4.76 112.779 -156.016 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.28 144.31 37.34 Favored Glycine 0 CA--C 1.524 0.611 0 CA-C-O 122.296 0.942 . . . . 1.69 113.458 -175.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.3 t -62.79 150.17 9.31 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.521 0 C-N-CA 127.398 2.279 . . . . 2.65 111.444 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.4 m -48.44 158.83 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 C-N-CA 125.809 1.644 . . . . 2.01 113.993 173.154 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.85 174.09 40.52 Favored Glycine 0 CA--C 1.53 1.027 0 CA-C-N 115.999 -0.546 . . . . 1.41 111.931 160.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 79.8 mt -113.04 157.3 41.14 Favored Pre-proline 0 CA--C 1.539 0.526 0 C-N-CA 124.219 1.008 . . . . 3.61 110.181 -178.375 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.402 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 29.1 Cg_endo -79.74 -158.26 0.09 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.793 0 C-N-CA 123.395 2.73 . . . . 2.28 108.96 160.13 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.225 0 CA-C-O 118.06 -1.411 . . . . 3.4 113.251 154.182 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo . . . . . 0 CA--C 1.544 1.01 0 CA-C-O 119.493 -0.295 . . . . 2.06 111.769 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.15 170.72 37.2 Favored Glycine 0 CA--C 1.54 1.614 0 CA-C-O 118.86 -0.967 . . . . 1.35 112.175 125.557 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -72.23 -179.78 4.29 Favored 'Trans proline' 0 CA--C 1.541 0.829 0 C-N-CA 123.439 2.759 . . . . 2.37 108.742 148.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 pm0 -70.39 -175.15 0.95 Allowed 'General case' 0 CA--C 1.546 0.8 0 N-CA-C 113.946 1.091 . . . . 4.31 113.946 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.89 168.12 50.65 Favored Glycine 0 CA--C 1.528 0.901 0 O-C-N 120.347 -1.471 . . . . 0.92 114.187 -178.507 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 79.0 mt -76.01 145.56 10.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 124.569 1.148 . . . . 2.82 108.988 167.465 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -73.65 152.78 40.38 Favored 'General case' 0 CA--C 1.543 0.686 0 N-CA-C 115.161 1.541 . . . . 1.31 115.161 -170.51 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.36 132.74 21.12 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 125.615 1.579 . . . . 1.5 110.863 173.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -95.16 143.68 26.39 Favored 'General case' 0 N--CA 1.465 0.29 0 O-C-N 121.501 -0.999 . . . . 3.25 111.195 -172.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 3.2 mtm180 -55.83 150.89 12.26 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 125.605 1.562 . . . . 5.57 113.802 175.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.79 179.22 44.26 Favored Glycine 0 CA--C 1.538 1.521 0 C-N-CA 124.929 1.252 . . . . 1.96 113.252 165.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 58.4 t -112.43 148.63 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 C-N-CA 125.138 1.375 . . . . 3.91 113.019 -154.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.9 p -53.19 152.56 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 128.92 2.888 . . . . 3.75 115.708 -172.382 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.38 -131.59 3.4 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 125.097 1.332 . . . . 2.16 111.193 165.299 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.402 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.5 pt? -172.68 161.57 3.94 Favored Pre-proline 0 CA--C 1.544 0.745 0 C-N-CA 126.153 1.781 . . . . 3.46 111.018 -165.082 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo . . . . . 0 C--O 1.255 1.371 0 C-N-CA 124.644 3.563 . . . . 3.1 112.045 154.05 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo . . . . . 0 CA--C 1.547 1.14 0 CA-C-O 119.265 -0.389 . . . . 1.9 112.302 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -71.37 -132.24 0.01 OUTLIER 'Trans proline' 0 CA--C 1.542 0.893 0 C-N-CA 123.413 2.742 . . . . 1.69 108.121 162.524 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.3 162.09 34.72 Favored Glycine 0 CA--C 1.534 1.242 0 CA-C-N 119.821 1.191 . . . . 1.37 112.532 166.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -73.59 -49.11 0.22 Allowed 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 122.795 2.33 . . . . 3.62 112.079 176.293 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.547 HE21 ' N ' ' C' ' 16' ' ' GLY . 18.2 tp60 175.26 138.35 0.05 OUTLIER 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.129 1.772 . . . . 1.48 107.392 -152.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . 0.547 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -87.42 166.43 36.36 Favored Glycine 0 CA--C 1.527 0.84 0 C-N-CA 125.807 1.67 . . . . 0.93 112.677 169.256 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 72.6 mt -69.18 138.57 22.0 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 O-C-N 121.84 -0.8 . . . . 2.2 109.335 -179.33 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -65.13 158.72 25.14 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.868 1.062 . . . . 1.11 113.868 177.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -82.51 -168.36 42.07 Favored Glycine 0 CA--C 1.528 0.859 0 CA-C-O 122.384 0.991 . . . . 1.52 111.14 170.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -158.44 179.72 8.87 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 124.265 1.026 . . . . 3.0 109.711 -172.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 5.1 tmm_? -64.95 141.97 58.59 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 125.781 1.632 . . . . 5.27 111.791 -174.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.73 -165.66 35.71 Favored Glycine 0 CA--C 1.532 1.148 0 C-N-CA 125.144 1.354 . . . . 1.4 115.542 -174.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 48.6 t -64.49 147.43 12.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.807 1.643 . . . . 2.06 110.029 176.043 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 33.3 m -102.17 -178.49 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 C-N-CA 125.351 1.46 . . . . 2.71 112.223 -175.126 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.51 171.4 6.84 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 125.061 1.315 . . . . 1.81 115.503 176.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 2.7 mm? . . . . . 0 C--O 1.249 1.072 0 C-N-CA 126.408 1.883 . . . . 3.48 113.116 -166.185 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo . . . . . 0 CA--C 1.537 0.647 0 CA-C-O 121.14 0.391 . . . . 3.01 111.29 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.95 -152.16 0.35 Allowed 'General case' 0 CA--C 1.548 0.889 0 C-N-CA 126.789 2.036 . . . . 2.73 110.449 175.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.37 162.63 44.03 Favored Glycine 0 N--CA 1.473 1.12 0 O-C-N 120.629 -1.295 . . . . 1.47 114.268 -173.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 25.4 pt -69.88 149.03 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 O-C-N 121.226 -1.161 . . . . 2.51 110.525 178.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.98 132.56 50.25 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 123.555 0.742 . . . . 1.81 111.767 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.2 136.69 25.46 Favored Glycine 0 CA--C 1.522 0.498 0 C-N-CA 126.021 1.772 . . . . 2.11 112.13 169.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 77.7 mm-40 -72.48 140.14 48.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.198 -0.501 . . . . 3.47 110.438 -166.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 46.8 ttt85 -66.63 134.24 51.91 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-O 121.372 0.606 . . . . 6.12 111.287 -172.625 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.53 146.77 46.33 Favored Glycine 0 CA--C 1.527 0.798 0 CA-C-O 122.08 0.822 . . . . 1.78 113.41 178.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.6 t -67.01 118.61 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 C-N-CA 125.819 1.648 . . . . 2.22 110.475 -171.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 24.3 m -44.84 143.71 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 C-N-CA 125.042 1.337 . . . . 2.55 114.383 -170.093 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -75.08 174.06 52.12 Favored Glycine 0 CA--C 1.533 1.174 0 N-CA-C 111.884 -0.486 . . . . 1.68 111.884 165.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 7.0 mp -122.24 160.32 48.3 Favored Pre-proline 0 CA--C 1.539 0.541 0 C-N-CA 125.273 1.429 . . . . 3.45 109.943 175.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.414 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 41.4 Cg_endo -75.98 -158.22 0.08 OUTLIER 'Trans proline' 0 CA--C 1.537 0.666 0 C-N-CA 122.882 2.388 . . . . 3.08 109.256 157.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.192 0 CA-C-O 116.76 -2.133 . . . . 5.32 112.532 142.762 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo . . . . . 0 N--CA 1.491 1.352 0 N-CA-C 109.089 -1.158 . . . . 3.24 109.089 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.27 144.88 36.74 Favored Glycine 0 CA--C 1.543 1.822 0 CA-C-O 118.697 -1.057 . . . . 1.81 111.415 164.652 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -77.04 -176.12 3.02 Favored 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 124.675 3.583 . . . . 2.52 110.134 163.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -61.19 173.47 0.84 Allowed 'General case' 0 CA--C 1.546 0.804 0 N-CA-C 116.336 1.976 . . . . 4.16 116.336 -175.247 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -90.01 154.37 23.7 Favored Glycine 0 CA--C 1.526 0.726 0 O-C-N 121.147 -0.971 . . . . 1.18 113.677 -174.062 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 79.7 mt -60.63 134.12 26.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 108.347 -0.983 . . . . 3.08 108.347 168.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.09 152.21 39.97 Favored 'General case' 0 CA--C 1.544 0.719 0 N-CA-C 112.752 0.649 . . . . 1.77 112.752 -177.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -83.81 -168.9 44.43 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 124.076 0.846 . . . . 2.5 111.003 169.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -148.6 176.21 10.53 Favored 'General case' 0 CA--C 1.536 0.431 0 O-C-N 120.961 -1.317 . . . . 3.82 112.231 171.048 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.2 ttm180 -59.65 159.47 8.53 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 125.661 1.585 . . . . 6.03 115.07 -164.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -63.66 157.91 40.94 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-N 116.276 -0.42 . . . . 2.42 114.136 170.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 35.9 t -85.61 121.27 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 C-N-CA 123.742 0.817 . . . . 3.41 111.86 -165.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.445 HG12 ' H ' ' C' ' 23' ' ' VAL . 6.3 m -69.06 156.51 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 126.154 1.781 . . . . 3.01 113.715 -170.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.29 -142.66 10.99 Favored Glycine 0 N--CA 1.469 0.878 0 C-N-CA 124.17 0.89 . . . . 2.04 112.436 167.059 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.414 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.6 pt? -172.73 160.48 3.87 Favored Pre-proline 0 CA--C 1.545 0.786 0 C-N-CA 124.854 1.262 . . . . 4.34 111.714 -158.428 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo . . . . . 0 C--O 1.255 1.336 0 C-N-CA 124.828 3.686 . . . . 3.02 112.329 155.292 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo . . . . . 0 N--CA 1.487 1.092 0 CA-C-O 119.2 -0.417 . . . . 2.5 111.125 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.56 -131.27 0.01 OUTLIER 'Trans proline' 0 CA--C 1.542 0.895 0 C-N-CA 122.362 2.041 . . . . 1.72 106.859 152.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.99 -179.78 48.74 Favored Glycine 0 CA--C 1.535 1.326 0 CA-C-N 119.558 1.072 . . . . 1.38 113.075 169.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -78.45 -110.0 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.039 0 C-N-CA 124.867 3.712 . . . . 2.59 109.718 161.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.581 HE21 ' N ' ' C' ' 16' ' ' GLY . 8.5 tp60 -146.58 134.51 21.37 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 127.904 2.482 . . . . 1.89 107.676 -159.395 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . 0.581 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -74.34 169.52 54.01 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 124.614 1.102 . . . . 1.45 113.728 170.51 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 65.8 mt -73.16 131.44 34.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 121.745 -0.856 . . . . 2.94 111.221 -174.083 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.37 154.17 35.16 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 113.693 0.997 . . . . 1.52 113.693 178.483 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -82.99 162.4 40.71 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 124.806 1.193 . . . . 1.47 112.711 177.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 13.9 mp0 -101.69 -175.87 2.97 Favored 'General case' 0 CA--C 1.545 0.753 0 O-C-N 121.425 -1.044 . . . . 3.12 111.189 -178.115 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.46 140.66 54.07 Favored 'General case' 0 CA--C 1.541 0.601 0 O-C-N 121.514 -0.741 . . . . 5.16 111.561 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.57 154.63 36.49 Favored Glycine 0 N--CA 1.47 0.942 0 C-N-CA 125.517 1.532 . . . . 1.76 113.151 179.327 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . 0.445 ' H ' HG12 ' B' ' 24' ' ' VAL . 17.7 t -64.0 144.86 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 124.525 1.13 . . . . 2.8 111.02 -179.015 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 78.2 t -101.47 168.58 1.94 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.896 0 C-N-CA 126.603 1.961 . . . . 4.58 109.484 -175.143 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.25 177.43 3.35 Favored Glycine 0 CA--C 1.538 1.516 0 C-N-CA 124.196 0.903 . . . . 3.43 114.181 169.212 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 11.9 mt . . . . . 0 N--CA 1.484 1.241 0 N-CA-C 114.711 1.374 . . . . 4.45 114.711 -169.401 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo . . . . . 0 CA--C 1.535 0.563 0 N-CA-C 110.327 -0.682 . . . . 1.99 110.327 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 14.8 mm100 -56.51 -177.6 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 129.084 2.953 . . . . 4.59 116.256 -173.221 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -91.35 -173.05 43.26 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 124.309 0.957 . . . . 1.23 112.968 161.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 9.5 mt -72.05 128.09 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 N-CA-C 109.229 -0.656 . . . . 1.97 109.229 -177.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -52.92 135.15 36.99 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.487 0.715 . . . . 1.8 110.727 174.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.65 154.55 48.61 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 125.327 1.441 . . . . 1.27 113.387 -170.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 71.4 mm-40 -69.91 106.55 3.21 Favored 'General case' 0 CA--C 1.532 0.258 0 N-CA-C 109.877 -0.416 . . . . 3.04 109.877 -171.11 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.0 ttp180 -61.49 143.17 56.37 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 125.069 1.348 . . . . 4.3 114.186 -163.111 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.26 136.96 30.73 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 124.839 1.209 . . . . 1.57 113.517 -167.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 8.8 p -60.9 134.88 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 C-N-CA 125.493 1.517 . . . . 3.23 111.005 177.112 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 30.0 m -46.13 157.96 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.984 0 C-N-CA 127.148 2.179 . . . . 2.3 115.616 -171.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.42 171.6 43.36 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-N 115.424 -0.807 . . . . 1.35 113.476 168.315 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 87.6 mt -120.36 159.68 46.81 Favored Pre-proline 0 CA--C 1.54 0.566 0 C-N-CA 124.952 1.301 . . . . 2.64 110.776 -173.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -76.42 -169.56 0.72 Allowed 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 123.208 2.605 . . . . 1.83 109.797 161.006 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.182 0 CA-C-O 117.837 -1.535 . . . . 3.14 113.189 155.143 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo . . . . . 0 CA--C 1.545 1.073 0 CA-C-O 119.209 -0.413 . . . . 2.18 111.317 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.25 171.42 10.35 Favored Glycine 0 CA--C 1.54 1.613 0 C-N-CA 119.259 -1.448 . . . . 1.28 112.634 123.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -75.73 -57.89 0.05 OUTLIER 'Trans proline' 0 CA--C 1.535 0.554 0 C-N-CA 123.974 3.116 . . . . 2.7 111.042 170.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 175.55 152.38 0.14 Allowed 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 127.464 2.306 . . . . 4.43 107.702 -164.309 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.66 153.88 35.39 Favored Glycine 0 CA--C 1.527 0.785 0 C-N-CA 123.817 0.722 . . . . 0.91 112.695 174.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.49 ' H ' HD12 ' B' ' 17' ' ' ILE . 4.7 mp -67.36 136.1 27.29 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 108.657 -0.868 . . . . 2.69 108.657 173.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.24 153.85 41.43 Favored 'General case' 0 CA--C 1.541 0.634 0 N-CA-C 113.277 0.843 . . . . 1.52 113.277 -179.154 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -66.98 141.73 40.29 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 111.312 -0.715 . . . . 1.63 111.312 172.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -81.04 164.96 22.1 Favored 'General case' 0 CA--C 1.54 0.576 0 O-C-N 120.899 -1.354 . . . . 2.85 112.218 173.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -63.6 146.15 54.3 Favored 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 125.926 1.69 . . . . 4.69 112.586 173.231 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.55 157.97 53.4 Favored Glycine 0 CA--C 1.533 1.216 0 N-CA-C 115.087 0.795 . . . . 2.25 115.087 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 17.9 m -91.65 133.08 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 N-CA-C 114.708 1.373 . . . . 3.99 114.708 -164.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -56.36 150.81 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 C-N-CA 127.791 2.436 . . . . 3.12 115.164 -165.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -84.72 -122.49 1.05 Allowed Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.217 0.913 . . . . 2.12 111.182 165.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.3 pt? -170.8 156.65 5.04 Favored Pre-proline 0 CA--C 1.543 0.696 0 C-N-CA 124.756 1.223 . . . . 3.31 112.014 -161.291 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo . . . . . 0 CA--C 1.552 1.379 0 C-N-CA 124.123 3.215 . . . . 2.57 111.767 159.1 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo . . . . . 0 N--CA 1.488 1.168 0 CA-C-O 118.779 -0.592 . . . . 2.73 111.591 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 80.0 Cg_exo -50.6 177.41 0.03 OUTLIER 'Trans proline' 0 CA--C 1.537 0.656 1 C-N-CA 125.565 4.177 . . . . 1.87 113.568 162.599 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.26 178.85 53.69 Favored Glycine 0 CA--C 1.541 1.711 0 C-N-CA 123.575 0.607 . . . . 0.95 112.6 167.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_endo -70.18 156.78 61.47 Favored 'Trans proline' 0 N--CA 1.457 -0.628 0 C-N-CA 123.319 2.679 . . . . 2.49 111.571 171.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.0 tp60 -39.25 126.21 1.69 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 127.609 2.363 . . . . 1.4 113.046 164.182 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.9 168.48 49.92 Favored Glycine 0 CA--C 1.529 0.922 0 C-N-CA 124.75 1.167 . . . . 0.89 112.67 170.058 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 29.7 mt -67.51 143.26 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 O-C-N 121.228 -1.16 . . . . 2.33 110.747 -172.512 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.77 151.82 28.62 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 112.891 0.7 . . . . 1.08 112.891 172.349 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.0 169.64 52.13 Favored Glycine 0 CA--C 1.527 0.816 0 CA-C-O 122.823 1.235 . . . . 1.12 113.519 178.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 40.0 mt-30 -95.84 154.29 17.3 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.355 -1.085 . . . . 3.88 111.767 -170.029 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -62.72 135.17 57.22 Favored 'General case' 0 C--O 1.234 0.253 0 N-CA-C 109.207 -0.664 . . . . 5.08 109.207 168.501 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -66.65 173.07 26.97 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 116.204 1.242 . . . . 1.06 116.204 -165.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 61.0 t -66.95 136.88 25.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 C-N-CA 124.443 1.097 . . . . 1.82 109.013 173.264 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 33.9 m -100.82 -169.68 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 C-N-CA 124.53 1.132 . . . . 2.41 110.845 -169.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.33 155.22 4.91 Favored Glycine 0 CA--C 1.532 1.154 0 C-N-CA 124.657 1.122 . . . . 1.58 114.27 172.39 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 8.8 mt . . . . . 0 C--O 1.249 1.079 0 CA-C-O 117.637 -1.173 . . . . 3.94 113.998 -162.871 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo . . . . . 0 N--CA 1.461 -0.436 0 N-CA-C 110.534 -0.602 . . . . 2.08 110.534 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.72 -179.14 0.35 Allowed 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.931 2.493 . . . . 3.32 113.978 176.559 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.98 -178.74 44.64 Favored Glycine 0 CA--C 1.527 0.797 0 C-N-CA 125.556 1.551 . . . . 1.29 114.686 174.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.8 mt -65.63 134.0 30.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 123.951 0.9 . . . . 2.43 109.922 -172.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.93 129.76 38.84 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 123.703 0.801 . . . . 2.34 111.471 173.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.78 166.77 54.18 Favored Glycine 0 CA--C 1.522 0.477 0 C-N-CA 127.44 2.447 . . . . 1.47 113.069 -177.396 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 14.0 mp0 -82.38 113.58 20.25 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 108.591 -0.892 . . . . 4.13 108.591 -162.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 73.8 ttt180 -49.56 130.66 20.71 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 124.2 1.0 . . . . 4.05 112.199 -173.368 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.26 145.58 39.5 Favored Glycine 0 N--CA 1.464 0.523 0 C-N-CA 124.75 1.167 . . . . 1.66 113.102 -173.544 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 28.2 m -63.89 161.28 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 124.566 1.147 . . . . 2.2 111.615 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.8 m -47.97 157.22 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 125.443 1.497 . . . . 2.1 113.667 177.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.29 173.33 39.87 Favored Glycine 0 CA--C 1.527 0.812 0 CA-C-N 115.391 -0.822 . . . . 1.42 112.171 162.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 87.6 mt -111.57 158.19 37.1 Favored Pre-proline 0 CA--C 1.537 0.451 0 C-N-CA 123.687 0.795 . . . . 3.89 110.523 -178.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -81.39 -160.56 0.13 Allowed 'Trans proline' 0 N--CA 1.454 -0.829 0 C-N-CA 123.302 2.668 . . . . 2.74 108.889 158.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.135 0 CA-C-O 117.75 -1.583 . . . . 3.91 113.021 152.076 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo . . . . . 0 CA--C 1.543 0.927 0 CA-C-O 119.157 -0.435 . . . . 2.17 111.664 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.57 162.99 43.93 Favored Glycine 0 CA--C 1.543 1.834 0 C-N-CA 119.516 -1.326 . . . . 1.38 111.766 130.018 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -76.49 -53.54 0.08 OUTLIER 'Trans proline' 0 CA--C 1.536 0.618 0 C-N-CA 124.876 3.717 . . . . 3.22 113.055 177.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -177.13 159.16 1.6 Allowed 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 128.45 2.7 . . . . 3.69 106.8 -162.471 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.11 155.26 22.88 Favored Glycine 0 N--CA 1.468 0.817 0 C-N-CA 124.189 0.899 . . . . 1.03 113.039 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 34.4 mm -67.94 130.37 33.1 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 N-CA-C 109.107 -0.701 . . . . 2.69 109.107 172.601 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -73.28 166.76 22.57 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 113.866 1.062 . . . . 2.12 113.866 -174.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -73.93 113.63 4.25 Favored Glycine 0 CA--C 1.53 1.027 0 C-N-CA 124.313 0.958 . . . . 2.21 112.516 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 -66.23 141.51 58.02 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 123.683 0.793 . . . . 4.61 112.769 178.44 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 9.2 mtt85 -62.05 159.44 14.43 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 115.096 1.517 . . . . 5.66 115.096 -176.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.99 -179.29 44.46 Favored Glycine 0 CA--C 1.538 1.474 0 C-N-CA 125.453 1.501 . . . . 1.74 113.151 163.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 15.6 m -112.03 146.97 16.2 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 N-CA-C 115.015 1.487 . . . . 3.15 115.015 -158.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 8.9 p -54.36 152.42 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 127.973 2.509 . . . . 3.71 115.351 -170.332 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -85.72 -129.23 2.24 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 124.599 1.095 . . . . 1.99 111.062 162.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -170.79 159.94 5.71 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 125.252 1.421 . . . . 3.36 111.777 -168.594 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo . . . . . 0 C--O 1.256 1.397 1 C-N-CA 125.306 4.004 . . . . 2.69 111.931 155.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo . . . . . 0 CA--C 1.547 1.149 0 CA-C-O 118.318 -0.784 . . . . 2.47 111.433 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -54.04 -169.49 0.02 OUTLIER 'Trans proline' 0 CA--C 1.541 0.864 1 C-N-CA 126.043 4.495 . . . . 1.55 113.595 164.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -83.83 175.03 51.76 Favored Glycine 0 CA--C 1.542 1.779 0 O-C-N 121.769 -0.582 . . . . 1.12 112.345 165.378 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -69.47 157.91 59.26 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 122.996 2.464 . . . . 2.53 111.166 170.076 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 tp60 -41.09 124.87 2.32 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.82 2.048 . . . . 1.48 113.439 165.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.65 154.65 53.01 Favored Glycine 0 CA--C 1.53 0.974 0 C-N-CA 124.391 0.996 . . . . 1.03 112.382 171.135 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 1.8 mp -67.87 146.1 13.21 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 C-N-CA 124.524 1.129 . . . . 2.51 110.99 -168.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.95 142.0 54.54 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 125.216 1.406 . . . . 1.4 113.197 178.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -76.07 134.04 15.21 Favored Glycine 0 C--N 1.333 0.366 0 N-CA-C 110.384 -1.086 . . . . 1.41 110.384 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -88.09 171.9 9.92 Favored 'General case' 0 CA--C 1.542 0.644 0 CA-C-N 115.088 -0.556 . . . . 2.96 109.524 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -61.12 155.27 20.95 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.711 0.767 . . . . 4.98 112.279 179.544 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.44 -176.62 25.09 Favored Glycine 0 CA--C 1.53 1.012 0 C-N-CA 124.995 1.283 . . . . 1.45 113.512 179.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 49.0 t -59.13 143.5 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.879 1.272 . . . . 2.42 110.279 176.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 30.9 m -97.76 -175.75 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.056 1.342 . . . . 3.44 112.024 -173.665 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.43 167.35 19.02 Favored Glycine 0 CA--C 1.532 1.127 0 C-N-CA 124.984 1.278 . . . . 2.23 114.867 175.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 9.6 mp . . . . . 0 C--O 1.249 1.046 0 C-N-CA 126.516 1.927 . . . . 3.83 113.463 -166.9 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo . . . . . 0 CA--C 1.538 0.704 0 N-CA-C 109.981 -0.815 . . . . 4.07 109.981 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.9 -137.18 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 124.583 1.153 . . . . 2.88 110.188 157.295 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.52 -148.78 17.59 Favored Glycine 0 N--CA 1.468 0.83 0 CA-C-O 122.827 1.237 . . . . 1.87 114.75 172.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.9 mt -84.1 158.38 3.6 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.506 0 C-N-CA 124.131 0.972 . . . . 3.52 108.435 177.371 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.65 46.69 0.09 Allowed 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 126.807 2.043 . . . . 4.24 112.599 170.239 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 61.56 -155.09 37.51 Favored Glycine 0 C--N 1.337 0.609 0 C-N-CA 125.289 1.424 . . . . 2.07 112.627 -171.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -105.56 160.92 14.8 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.935 0.874 . . . . 4.99 110.408 158.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.4 tpt180 -66.0 141.24 58.25 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.203 -0.908 . . . . 4.01 109.828 163.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -93.29 -167.18 38.39 Favored Glycine 0 C--O 1.227 -0.308 0 C-N-CA 125.324 1.44 . . . . 2.45 112.787 177.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 52.8 t -82.61 132.93 30.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 124.524 1.13 . . . . 2.95 109.035 -176.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.8 m -56.37 145.61 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 C-N-CA 124.47 1.108 . . . . 2.88 112.926 -178.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.96 145.13 17.64 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 109.951 -1.26 . . . . 1.75 109.951 165.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 85.3 mt -91.18 156.43 43.86 Favored Pre-proline 0 N--CA 1.472 0.662 0 CA-C-O 117.161 -1.4 . . . . 3.94 110.444 171.202 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -80.24 -158.04 0.09 OUTLIER 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 123.645 2.897 . . . . 3.46 109.23 166.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.24 0 CA-C-O 117.549 -1.695 . . . . 5.43 113.458 154.643 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo . . . . . 0 N--CA 1.491 1.364 0 N-CA-C 109.165 -1.129 . . . . 4.26 109.165 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.04 140.92 30.72 Favored Glycine 0 CA--C 1.539 1.55 0 CA-C-O 118.044 -1.42 . . . . 2.31 110.003 158.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -68.62 -175.01 0.79 Allowed 'Trans proline' 0 CA--C 1.538 0.695 0 C-N-CA 123.787 2.991 . . . . 2.43 109.878 162.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 4.7 tp-100 -50.47 148.79 3.5 Favored 'General case' 0 CA--C 1.541 0.599 0 N-CA-C 114.734 1.383 . . . . 4.64 114.734 -174.476 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.15 165.83 48.62 Favored Glycine 0 C--N 1.339 0.736 0 CA-C-O 123.285 1.492 . . . . 1.97 112.854 169.145 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 8.2 mm -71.67 160.84 5.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 123.279 1.514 . . . . 4.01 110.722 178.336 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -46.35 147.67 1.09 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.854 1.261 . . . . 2.82 112.975 153.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -82.55 169.16 48.79 Favored Glycine 0 C--N 1.336 0.574 0 CA-C-O 122.626 1.125 . . . . 2.78 112.681 178.726 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -118.41 123.59 45.61 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 123.487 0.715 . . . . 3.58 111.014 -166.247 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 14.9 ptt180 -55.16 134.21 49.42 Favored 'General case' 0 N--CA 1.47 0.546 0 O-C-N 122.056 -0.403 . . . . 5.37 110.703 179.112 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.18 -45.4 93.76 Favored Glycine 0 N--CA 1.477 1.407 0 N-CA-C 114.825 0.69 . . . . 4.28 114.825 -150.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 55.3 t -158.99 164.37 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.877 1 C-N-CA 132.117 4.167 . . . . 3.77 105.613 179.699 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 23.0 m -134.34 156.25 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 C-N-CA 125.989 1.716 . . . . 3.74 109.051 168.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -79.62 -175.28 47.54 Favored Glycine 0 C--N 1.335 0.515 0 CA-C-O 122.189 0.883 . . . . 2.9 114.263 179.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -159.08 158.11 28.5 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 126.982 2.113 . . . . 6.11 109.921 175.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.256 1.381 0 C-N-CA 125.293 3.996 . . . . 5.34 111.831 164.375 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo . . . . . 0 N--CA 1.486 1.04 0 CA-C-O 118.616 -0.66 . . . . 3.57 111.097 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -68.73 -163.78 0.1 OUTLIER 'Trans proline' 0 CA--C 1.544 0.987 0 C-N-CA 123.469 2.779 . . . . 2.93 109.466 157.182 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.91 154.09 52.72 Favored Glycine 0 CA--C 1.541 1.706 0 O-C-N 121.751 -0.593 . . . . 1.64 113.8 172.102 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -79.83 87.15 1.56 Allowed 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 124.504 3.469 . . . . 2.97 111.664 -173.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 30.4 tp60 67.8 -124.12 0.19 Allowed 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.615 1.166 . . . . 2.82 108.777 -176.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.63 -179.4 41.07 Favored Glycine 0 CA--C 1.534 1.256 1 C-N-CA 131.956 4.598 . . . . 1.89 107.523 -171.58 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -74.69 156.44 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 O-C-N 120.726 -1.455 . . . . 2.27 110.223 176.232 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.26 159.03 30.99 Favored 'General case' 0 CA--C 1.543 0.675 0 O-C-N 120.215 -1.553 . . . . 1.86 112.165 173.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -97.93 160.75 20.9 Favored Glycine 0 CA--C 1.53 0.988 0 C-N-CA 124.502 1.049 . . . . 1.73 112.124 177.576 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 22.9 mp0 -101.87 -179.79 4.11 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 124.376 1.071 . . . . 3.0 111.862 -170.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 6.2 tpt85 -66.8 138.62 57.49 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.908 0.883 . . . . 3.73 110.103 162.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.83 172.07 30.78 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 124.175 0.893 . . . . 1.43 112.009 172.214 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . 0.414 HG23 ' H ' ' C' ' 23' ' ' VAL . 1.9 t -57.15 144.64 9.07 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 124.914 1.285 . . . . 2.18 110.872 -179.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.446 HG22 ' H ' ' C' ' 25' ' ' GLY . 7.5 p -75.9 -169.32 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.189 0 C-N-CA 124.557 1.143 . . . . 4.13 109.129 164.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.446 ' H ' HG22 ' C' ' 24' ' ' VAL . . . -52.5 168.29 0.83 Allowed Glycine 0 CA--C 1.541 1.656 0 CA-C-N 119.858 1.208 . . . . 1.98 113.913 161.414 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 10.2 mp . . . . . 0 C--O 1.249 1.03 0 C-N-CA 125.72 1.608 . . . . 4.69 112.723 -171.784 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo . . . . . 0 N--CA 1.458 -0.596 0 CA-C-O 121.035 0.348 . . . . 1.86 111.312 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -60.92 167.07 3.04 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 126.473 1.909 . . . . 3.12 113.627 173.654 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -78.48 166.52 52.43 Favored Glycine 0 CA--C 1.518 0.247 0 CA-C-N 114.986 -1.007 . . . . 1.39 113.587 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 21.2 mt -51.93 124.76 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 C-N-CA 125.698 1.599 . . . . 2.43 109.557 178.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -42.9 132.45 3.91 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.715 1.206 . . . . 1.97 112.597 178.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.43 149.78 51.67 Favored Glycine 0 CA--C 1.517 0.195 0 C-N-CA 125.129 1.347 . . . . 1.17 111.673 -178.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 7.3 mp0 -62.68 114.53 3.64 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 114.962 -0.619 . . . . 4.3 109.636 -173.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 48.6 ttt85 -54.56 139.75 37.08 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.686 1.195 . . . . 4.45 112.435 -173.673 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.41 142.62 32.91 Favored Glycine 0 CA--C 1.525 0.698 0 C-N-CA 124.242 0.925 . . . . 1.73 112.71 -175.525 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -60.37 153.42 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 C-N-CA 126.4 1.88 . . . . 2.15 113.231 178.035 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 m -66.99 150.61 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 124.85 1.26 . . . . 2.33 112.924 -175.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.58 153.34 51.51 Favored Glycine 0 CA--C 1.531 1.037 0 CA-C-N 115.899 -0.591 . . . . 1.48 112.436 170.44 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 10.1 mp -83.62 160.25 59.29 Favored Pre-proline 0 CA--C 1.544 0.723 0 C-N-CA 123.882 0.873 . . . . 3.45 111.166 176.608 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -81.9 -158.71 0.1 OUTLIER 'Trans proline' 0 CA--C 1.537 0.649 0 C-N-CA 123.997 3.131 . . . . 1.75 109.127 158.228 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.169 0 CA-C-O 117.336 -1.813 . . . . 3.09 112.843 155.802 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo . . . . . 0 CA--C 1.545 1.056 0 CA-C-O 119.289 -0.38 . . . . 2.02 111.143 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.08 -178.49 10.44 Favored Glycine 0 CA--C 1.544 1.882 0 CA-C-O 119.035 -0.869 . . . . 1.59 112.625 125.512 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -77.83 -134.99 0.02 OUTLIER 'Trans proline' 0 CA--C 1.546 1.1 1 C-N-CA 125.642 4.228 . . . . 2.18 109.071 160.535 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.37 176.44 9.68 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 124.986 1.314 . . . . 3.66 110.99 166.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.14 157.85 39.49 Favored Glycine 0 N--CA 1.472 1.047 0 O-C-N 121.357 -0.839 . . . . 0.93 112.698 154.318 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 28.3 mm -77.88 131.49 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 108.596 -0.89 . . . . 3.25 108.596 173.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -77.4 157.67 30.46 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 114.078 1.14 . . . . 1.72 114.078 -173.063 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.01 121.31 8.39 Favored Glycine 0 CA--C 1.529 0.957 0 C-N-CA 124.298 0.951 . . . . 1.68 111.687 -179.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.96 155.54 40.7 Favored 'General case' 0 CA--C 1.54 0.58 0 O-C-N 121.496 -1.003 . . . . 2.72 111.759 174.344 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.7 ptt-85 -66.14 161.47 21.83 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 122.297 1.046 . . . . 4.54 113.045 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.75 -179.18 49.12 Favored Glycine 0 CA--C 1.529 0.91 0 C-N-CA 125.59 1.567 . . . . 1.89 111.865 172.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 7.0 m -100.89 139.79 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 N-CA-C 114.253 1.205 . . . . 3.37 114.253 -160.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 26.5 m -64.49 160.27 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 C-N-CA 126.292 1.837 . . . . 2.52 113.502 -174.386 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -88.92 -135.82 5.53 Favored Glycine 0 CA--C 1.529 0.914 0 C-N-CA 124.147 0.879 . . . . 1.71 111.84 171.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -167.29 163.65 9.94 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 125.576 1.55 . . . . 3.21 110.745 -167.031 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo . . . . . 0 C--O 1.257 1.445 0 C-N-CA 124.264 3.309 . . . . 2.61 112.163 167.177 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo . . . . . 0 N--CA 1.487 1.102 0 CA-C-O 119.059 -0.476 . . . . 2.04 111.837 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.28 -137.78 0.02 OUTLIER 'Trans proline' 0 CA--C 1.54 0.825 0 C-N-CA 123.298 2.665 . . . . 1.45 108.226 163.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -79.0 151.7 35.65 Favored Glycine 0 CA--C 1.542 1.753 0 CA-C-N 119.557 1.071 . . . . 0.95 112.758 173.431 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -85.19 64.08 6.08 Favored 'Trans proline' 0 CA--C 1.541 0.849 0 C-N-CA 124.556 3.504 . . . . 3.17 111.34 -176.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 71.89 151.52 0.11 Allowed 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 125.343 1.457 . . . . 2.55 112.716 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.03 153.74 22.05 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 124.769 1.176 . . . . 1.17 111.416 166.152 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 66.0 mt -71.62 144.77 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.8 0 O-C-N 121.805 -0.821 . . . . 2.06 111.193 -177.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.17 149.02 48.68 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.97 1.308 . . . . 1.3 113.205 175.413 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -88.7 140.95 16.23 Favored Glycine 0 CA--C 1.532 1.138 0 C-N-CA 125.106 1.336 . . . . 1.11 114.686 -175.124 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . 0.572 HE21 ' N ' ' C' ' 20' ' ' GLN . 0.0 OUTLIER -71.51 157.15 38.52 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 126.641 1.976 . . . . 3.89 112.059 168.628 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 46.3 ttp180 -62.07 158.12 17.35 Favored 'General case' 0 CA--C 1.54 0.581 0 N-CA-C 114.331 1.234 . . . . 3.87 114.331 176.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -66.14 168.96 32.66 Favored Glycine 0 CA--C 1.537 1.434 0 CA-C-O 122.112 0.84 . . . . 1.04 113.237 158.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.2 t -68.03 160.85 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 125.86 1.664 . . . . 2.15 111.097 179.111 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 28.6 m -83.17 -175.19 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 125.896 1.678 . . . . 2.28 111.774 175.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.37 173.5 5.38 Favored Glycine 0 CA--C 1.537 1.409 0 C-N-CA 125.164 1.364 . . . . 1.61 114.55 169.073 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 5.7 mt . . . . . 0 C--O 1.25 1.113 0 N-CA-C 114.136 1.162 . . . . 3.63 114.136 -159.072 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo . . . . . 0 CA--C 1.541 0.848 0 N-CA-C 109.571 -0.973 . . . . 2.19 109.571 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.435 ' CD ' ' H ' ' A' ' 15' ' ' GLN . 0.0 OUTLIER -87.07 -168.68 2.33 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 127.414 2.286 . . . . 3.02 111.909 168.142 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.91 177.98 45.0 Favored Glycine 0 N--CA 1.474 1.209 0 C-N-CA 125.978 1.752 . . . . 1.63 112.957 161.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.588 ' H ' HD12 ' A' ' 17' ' ' ILE . 2.8 mp -61.98 141.44 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 O-C-N 121.813 -0.816 . . . . 2.59 110.372 -174.544 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.88 133.88 56.52 Favored 'General case' 0 CA--C 1.537 0.469 0 CA-C-N 119.039 0.836 . . . . 1.74 110.946 170.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.57 146.53 41.08 Favored Glycine 0 CA--C 1.523 0.581 0 C-N-CA 126.569 2.033 . . . . 1.43 114.603 -178.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 73.1 mm-40 -77.56 134.89 38.16 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 114.604 -0.798 . . . . 3.69 110.816 -166.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 31.6 mtt180 -59.21 137.46 57.96 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 121.642 0.734 . . . . 4.41 112.529 -171.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -78.35 -179.41 50.77 Favored Glycine 0 CA--C 1.523 0.581 0 CA-C-O 123.271 1.484 . . . . 1.87 115.363 -168.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -71.6 156.56 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 CA-C-N 113.489 -1.356 . . . . 2.38 111.826 -169.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 p -56.4 143.06 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 125.263 1.425 . . . . 5.25 111.967 168.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.48 ' H ' ' HB ' ' B' ' 23' ' ' VAL . . . -93.62 -162.78 36.25 Favored Glycine 0 N--CA 1.472 1.059 0 C-N-CA 124.426 1.013 . . . . 2.42 113.873 170.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 93.0 mt -142.43 153.47 62.46 Favored Pre-proline 0 N--CA 1.471 0.59 0 C-N-CA 126.044 1.738 . . . . 3.52 109.823 172.761 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -79.21 -155.6 0.06 OUTLIER 'Trans proline' 0 CA--C 1.539 0.752 0 C-N-CA 123.138 2.559 . . . . 2.21 108.909 159.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.291 0 CA-C-O 118.002 -1.443 . . . . 3.84 113.51 158.225 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo . . . . . 0 CA--C 1.544 0.994 0 CA-C-O 118.791 -0.587 . . . . 2.24 111.773 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.0 159.66 49.28 Favored Glycine 0 CA--C 1.548 2.147 0 C-N-CA 118.977 -1.582 . . . . 1.23 110.886 127.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -75.84 -66.84 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.617 1 C-N-CA 125.349 4.033 . . . . 3.04 111.809 177.061 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.16 161.64 41.18 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 128.892 2.877 . . . . 4.23 107.182 -176.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.42 160.44 31.72 Favored Glycine 0 N--CA 1.464 0.555 0 C-N-CA 123.629 0.633 . . . . 1.04 112.922 174.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.3 pp -78.23 149.37 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 O-C-N 122.313 -0.522 . . . . 4.05 111.215 176.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.8 153.12 38.89 Favored 'General case' 0 CA--C 1.543 0.698 0 N-CA-C 113.528 0.936 . . . . 1.29 113.528 -174.777 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.81 147.7 26.7 Favored Glycine 0 CA--C 1.528 0.866 0 C-N-CA 125.947 1.737 . . . . 1.59 114.572 -172.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 37.4 tt0 -77.95 148.08 34.65 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 126.386 1.874 . . . . 4.15 111.599 172.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 31.6 mtt180 -64.86 164.37 12.57 Favored 'General case' 0 N--CA 1.473 0.702 0 O-C-N 121.306 -0.871 . . . . 4.15 112.299 174.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.3 -144.1 3.47 Favored Glycine 0 CA--C 1.534 1.222 0 CA-C-N 114.959 -1.018 . . . . 2.51 110.96 161.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . 0.48 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 49.8 t -53.26 137.52 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 C-N-CA 124.3 1.04 . . . . 5.26 112.687 -176.44 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 26.4 m -103.12 162.41 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 125.651 1.58 . . . . 3.4 111.23 172.442 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.14 171.7 24.75 Favored Glycine 0 C--N 1.338 0.656 0 C-N-CA 125.412 1.482 . . . . 2.54 113.507 -176.18 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -169.38 157.59 6.92 Favored Pre-proline 0 CA--C 1.545 0.754 0 C-N-CA 126.105 1.762 . . . . 3.94 111.521 -168.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo . . . . . 0 C--O 1.256 1.39 0 C-N-CA 124.611 3.541 . . . . 3.49 111.803 159.363 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo . . . . . 0 CA--C 1.548 1.178 0 CA-C-O 118.951 -0.521 . . . . 2.43 111.667 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -56.18 -174.4 0.04 OUTLIER 'Trans proline' 0 CA--C 1.539 0.756 0 C-N-CA 124.994 3.796 . . . . 1.72 112.863 164.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.71 178.13 54.1 Favored Glycine 0 CA--C 1.541 1.682 0 C-N-CA 123.628 0.633 . . . . 1.01 112.145 165.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -67.91 155.96 67.75 Favored 'Trans proline' 0 N--CA 1.457 -0.62 0 C-N-CA 122.904 2.403 . . . . 2.59 111.001 171.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 22.0 tp60 -40.55 121.36 1.42 Allowed 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 127.384 2.274 . . . . 1.51 112.946 169.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.4 157.08 44.72 Favored Glycine 0 CA--C 1.527 0.814 0 C-N-CA 124.29 0.948 . . . . 0.91 112.091 170.757 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 2.2 mp -65.22 140.55 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 123.548 0.739 . . . . 2.18 110.486 -169.129 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.51 156.57 15.98 Favored 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 123.065 1.412 . . . . 1.05 114.748 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.83 145.85 39.04 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 108.994 -1.643 . . . . 1.0 108.994 174.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 7.2 mp0 -82.99 -179.46 7.45 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.884 0.85 . . . . 3.63 110.441 -170.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 1.9 tmt_? -57.63 138.39 55.39 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-O 121.618 0.723 . . . . 3.4 110.095 169.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.46 148.25 51.09 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 124.367 0.985 . . . . 1.82 112.04 178.299 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 91.2 t -64.86 148.43 11.96 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.603 0 C-N-CA 124.246 1.018 . . . . 2.3 110.447 -173.172 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 12.3 p -97.24 171.79 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.995 0 C-N-CA 127.982 2.513 . . . . 2.97 111.059 -178.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.5 -168.66 0.61 Allowed Glycine 0 CA--C 1.54 1.614 0 C-N-CA 125.203 1.382 . . . . 2.08 116.083 171.102 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 15.5 mt . . . . . 0 C--O 1.249 1.047 0 C-N-CA 125.736 1.614 . . . . 3.55 115.12 -170.544 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo . . . . . 0 N--CA 1.458 -0.575 0 N-CA-C 111.39 -0.273 . . . . 2.21 111.39 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 31.2 tp60 -46.07 163.73 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 129.228 3.011 . . . . 3.66 115.53 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.56 172.47 42.82 Favored Glycine 0 CA--C 1.524 0.638 0 C-N-CA 124.388 0.994 . . . . 1.21 114.616 168.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.558 ' H ' HD12 ' A' ' 17' ' ' ILE . 3.0 mp -60.41 140.53 18.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 C-N-CA 124.975 1.31 . . . . 3.02 109.858 -179.369 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.41 130.01 37.82 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 123.318 0.647 . . . . 2.4 111.291 170.512 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.59 161.49 54.22 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 126.122 1.82 . . . . 1.43 113.58 176.447 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 11.0 mm100 -74.33 115.35 13.74 Favored 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 109.675 -0.491 . . . . 3.6 109.675 -168.248 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -58.46 139.26 55.86 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.564 0.746 . . . . 3.93 112.219 -175.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.38 147.3 35.65 Favored Glycine 0 CA--C 1.522 0.527 0 C-N-CA 125.848 1.689 . . . . 1.59 113.542 -173.093 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.0 p -66.6 144.82 14.32 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 125.465 1.506 . . . . 3.63 110.573 176.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -50.69 157.61 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 126.09 1.756 . . . . 2.15 114.716 -175.257 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.5 175.4 53.49 Favored Glycine 0 N--CA 1.474 1.207 0 N-CA-C 110.787 -0.925 . . . . 1.69 110.787 158.311 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 17.6 mt -149.84 157.04 38.46 Favored Pre-proline 0 N--CA 1.471 0.621 0 N-CA-C 115.884 1.809 . . . . 3.41 115.884 -152.383 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -68.2 104.66 1.09 Allowed 'Trans proline' 0 N--CA 1.449 -1.09 0 N-CA-C 106.529 -2.143 . . . . 2.5 106.529 154.637 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.231 0 CA-C-O 118.923 -0.932 . . . . 6.39 114.218 -160.405 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo . . . . . 0 CA--C 1.544 0.987 0 N-CA-C 110.993 -0.426 . . . . 2.73 110.993 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.63 -170.4 0.41 Allowed Glycine 0 CA--C 1.538 1.488 0 C-N-CA 120.457 -0.878 . . . . 1.86 113.875 125.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -74.38 -123.39 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 0.998 0 C-N-CA 124.069 3.179 . . . . 2.07 107.545 157.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -100.29 178.7 4.68 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.309 1.443 . . . . 6.16 112.218 175.137 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.46 145.72 25.46 Favored Glycine 0 N--CA 1.472 1.047 0 O-C-N 121.202 -0.936 . . . . 1.22 112.684 164.215 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 96.7 mt -63.38 132.77 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 O-C-N 121.079 -1.248 . . . . 3.24 108.659 170.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -77.55 157.05 30.53 Favored 'General case' 0 CA--C 1.542 0.65 0 N-CA-C 114.151 1.167 . . . . 2.13 114.151 -169.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.54 140.27 40.64 Favored Glycine 0 CA--C 1.524 0.634 0 C-N-CA 126.229 1.871 . . . . 1.8 110.5 169.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 10.4 mp0 -95.95 147.86 23.24 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 123.308 0.643 . . . . 3.91 110.84 -165.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 3.8 ttt180 -64.12 154.76 33.61 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 124.525 1.13 . . . . 5.09 113.722 -176.229 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.68 155.86 52.35 Favored Glycine 0 CA--C 1.531 1.05 0 C-N-CA 124.042 0.83 . . . . 1.99 115.115 176.053 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 27.7 m -75.58 136.8 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 114.677 1.362 . . . . 3.22 114.677 -174.023 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.6 m -56.43 156.5 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.002 0 N-CA-C 116.729 2.122 . . . . 2.82 116.729 -162.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.56 -177.06 42.93 Favored Glycine 0 C--N 1.34 0.753 0 C-N-CA 125.864 1.697 . . . . 2.08 115.8 -167.087 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.6 mp -147.72 158.37 42.92 Favored Pre-proline 0 CA--C 1.546 0.813 0 C-N-CA 125.453 1.501 . . . . 4.63 113.031 -165.428 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo . . . . . 0 C--O 1.255 1.343 0 C-N-CA 123.843 3.029 . . . . 3.42 112.635 148.585 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo . . . . . 0 CA--C 1.547 1.151 0 CA-C-O 118.323 -0.782 . . . . 2.26 111.855 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_exo -49.58 -179.35 0.02 OUTLIER 'Trans proline' 0 C--N 1.35 0.655 1 C-N-CA 126.571 4.847 . . . . 1.9 114.402 166.549 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.26 148.55 51.41 Favored Glycine 0 CA--C 1.547 2.035 0 CA-C-O 119.368 -0.685 . . . . 1.38 112.059 162.327 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -81.55 61.95 8.17 Favored 'Trans proline' 0 CA--C 1.542 0.899 0 C-N-CA 125.036 3.824 . . . . 3.6 113.058 -169.056 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 74.7 147.32 0.09 Allowed 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.402 1.881 . . . . 2.48 112.774 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -85.85 146.08 21.17 Favored Glycine 0 CA--C 1.527 0.842 0 O-C-N 121.299 -0.875 . . . . 1.08 112.145 170.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 97.5 mt -63.46 148.77 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 124.607 1.163 . . . . 2.18 110.883 175.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.97 150.43 39.02 Favored 'General case' 0 CA--C 1.548 0.887 0 N-CA-C 114.383 1.253 . . . . 1.1 114.383 177.426 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -80.63 152.79 34.1 Favored Glycine 0 C--N 1.338 0.679 0 C-N-CA 125.44 1.495 . . . . 1.03 111.176 177.211 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 10.5 mp0 -101.18 161.0 13.92 Favored 'General case' 0 C--N 1.326 -0.419 0 O-C-N 121.726 -0.867 . . . . 3.27 110.095 -172.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -53.34 134.85 39.71 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 123.483 0.713 . . . . 3.83 109.804 172.62 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.25 177.19 29.4 Favored Glycine 0 CA--C 1.522 0.483 0 CA-C-N 115.713 -0.676 . . . . 1.06 112.105 -175.281 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 45.2 t -58.58 131.74 23.0 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 CA-C-O 121.464 0.65 . . . . 1.87 110.564 -177.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 8.7 p -70.23 158.68 5.99 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.394 0 C-N-CA 129.374 3.069 . . . . 3.53 112.774 177.322 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.72 167.1 1.09 Allowed Glycine 0 CA--C 1.538 1.53 0 N-CA-C 115.288 0.875 . . . . 1.81 115.288 159.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 2.8 mm? . . . . . 0 C--O 1.25 1.094 0 C-N-CA 125.595 1.558 . . . . 3.95 113.683 -164.968 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo . . . . . 0 CA--C 1.54 0.821 0 N-CA-C 109.927 -0.836 . . . . 2.09 109.927 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -87.74 -173.14 4.18 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.074 1.75 . . . . 3.14 112.187 169.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -93.37 -171.61 39.69 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 125.884 1.707 . . . . 1.32 113.881 163.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.2 mt -62.24 139.88 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.103 0 O-C-N 121.784 -0.833 . . . . 2.06 110.481 -173.477 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -57.32 133.35 55.04 Favored 'General case' 0 CA--C 1.536 0.426 0 CA-C-N 118.692 0.678 . . . . 1.82 110.509 168.712 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.46 147.14 18.88 Favored Glycine 0 CA--C 1.52 0.405 0 C-N-CA 127.546 2.498 . . . . 1.23 113.665 177.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 87.3 mm-40 -71.57 125.72 27.8 Favored 'General case' 0 CA--C 1.535 0.403 0 N-CA-C 108.159 -1.052 . . . . 3.2 108.159 -177.182 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.9 ttt180 -57.97 137.07 57.11 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 123.639 0.776 . . . . 5.19 111.54 -169.781 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -65.8 163.33 40.72 Favored Glycine 0 C--N 1.338 0.679 0 C-N-CA 124.985 1.279 . . . . 1.54 115.577 -169.623 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 45.3 t -66.88 132.17 32.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 C-N-CA 126.617 1.967 . . . . 2.83 109.5 -175.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.415 HG23 ' H ' ' A' ' 24' ' ' VAL . 1.7 t -56.26 145.78 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 124.974 1.31 . . . . 2.58 112.224 -173.526 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.11 175.33 42.46 Favored Glycine 0 CA--C 1.535 1.286 0 N-CA-C 112.019 -0.432 . . . . 1.46 112.019 163.408 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 6.4 mp -129.68 156.71 78.36 Favored Pre-proline 0 CA--C 1.538 0.505 0 C-N-CA 124.636 1.174 . . . . 2.9 109.447 178.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.401 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 30.4 Cg_endo -77.74 -165.03 0.3 Allowed 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.951 2.434 . . . . 1.77 109.44 161.264 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.259 0 CA-C-O 117.67 -1.628 . . . . 3.38 112.588 153.863 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo . . . . . 0 CA--C 1.54 0.81 0 CA-C-O 118.047 -0.897 . . . . 2.61 110.573 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.77 162.87 25.32 Favored Glycine 0 CA--C 1.551 2.299 0 C-N-CA 118.882 -1.628 . . . . 1.57 111.144 126.414 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -79.0 -51.8 0.06 OUTLIER 'Trans proline' 0 CA--C 1.536 0.599 0 C-N-CA 124.746 3.631 . . . . 3.21 112.302 178.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 177.93 160.58 0.53 Allowed 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 129.731 3.213 . . . . 3.74 105.443 -165.381 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.07 -173.78 46.48 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 116.873 1.509 . . . . 1.31 116.873 -168.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.513 ' H ' HD12 ' B' ' 17' ' ' ILE . 4.0 mp -71.78 121.31 21.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 108.473 -0.936 . . . . 3.64 108.473 168.284 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -68.5 137.63 54.55 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-O 121.542 0.686 . . . . 1.5 111.419 176.611 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.09 147.2 40.81 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 124.698 1.142 . . . . 1.64 112.826 -170.717 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . 0.402 ' NE2' ' H ' ' B' ' 20' ' ' GLN . 0.0 OUTLIER -82.08 147.79 28.92 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 123.764 0.826 . . . . 3.63 111.327 169.541 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 6.0 ptt180 -52.27 157.17 1.47 Allowed 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 114.63 1.344 . . . . 5.38 114.63 168.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.03 179.1 53.16 Favored Glycine 0 CA--C 1.532 1.111 0 C-N-CA 124.331 0.967 . . . . 1.87 114.035 177.131 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 24.2 t -91.93 122.33 43.28 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 N-CA-C 113.648 0.981 . . . . 3.05 113.648 -152.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.1 m -58.89 154.28 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 127.06 2.144 . . . . 2.48 114.272 -173.096 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.63 -146.71 16.91 Favored Glycine 0 CA--C 1.53 0.996 0 C-N-CA 124.196 0.903 . . . . 1.62 112.026 163.069 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.401 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.5 pt? -171.12 161.06 5.42 Favored Pre-proline 0 CA--C 1.546 0.823 0 C-N-CA 126.097 1.759 . . . . 3.59 111.568 -164.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo . . . . . 0 CA--C 1.552 1.386 0 C-N-CA 125.292 3.995 . . . . 2.83 112.595 153.901 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 CA--C 1.547 1.125 0 CA-C-O 118.765 -0.598 . . . . 3.18 111.467 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -55.94 -179.4 0.08 OUTLIER 'Trans proline' 0 CA--C 1.537 0.652 0 C-N-CA 124.477 3.452 . . . . 2.18 112.583 164.071 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.84 179.54 47.27 Favored Glycine 0 CA--C 1.54 1.615 0 C-N-CA 124.662 1.125 . . . . 1.13 114.028 176.227 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_endo -70.61 156.69 60.62 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 123.383 2.722 . . . . 2.39 111.116 172.322 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 22.2 tp60 -32.22 120.34 0.29 Allowed 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 127.648 2.379 . . . . 1.33 113.546 167.055 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.62 158.35 53.63 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.345 -0.702 . . . . 0.9 111.345 166.376 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 68.1 mt -61.84 143.55 15.0 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 C-N-CA 123.203 0.601 . . . . 2.2 111.528 -169.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -67.7 158.44 32.28 Favored 'General case' 0 CA--C 1.545 0.754 0 CA-C-O 122.722 1.248 . . . . 1.04 114.234 177.177 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.28 163.18 54.44 Favored Glycine 0 CA--C 1.527 0.782 0 C-N-CA 124.625 1.107 . . . . 1.2 112.909 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 9.8 mp0 -96.38 -178.83 4.42 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 124.264 1.026 . . . . 3.95 111.491 -171.193 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.49 142.91 46.78 Favored 'General case' 0 N--CA 1.473 0.686 0 O-C-N 121.06 -1.025 . . . . 3.41 110.868 172.438 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.41 173.26 55.21 Favored Glycine 0 N--CA 1.47 0.919 0 C-N-CA 124.895 1.236 . . . . 1.01 112.817 177.121 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 38.1 t -71.3 138.45 21.71 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 C-N-CA 123.803 0.841 . . . . 1.99 110.164 179.206 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -91.81 173.45 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 C-N-CA 127.277 2.231 . . . . 2.64 109.763 -179.301 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -50.99 149.13 7.34 Favored Glycine 0 CA--C 1.533 1.182 0 CA-C-N 119.076 0.853 . . . . 1.79 113.13 170.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 8.6 tt . . . . . 0 C--O 1.25 1.097 0 C-N-CA 127.322 2.249 . . . . 4.15 113.766 -167.205 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo . . . . . 0 CA--C 1.534 0.515 0 N-CA-C 110.965 -0.436 . . . . 2.35 110.965 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.58 -155.44 0.15 Allowed 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.933 1.693 . . . . 2.71 111.034 165.586 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -85.67 173.0 47.09 Favored Glycine 0 N--CA 1.47 0.943 0 N-CA-C 115.701 1.041 . . . . 1.47 115.701 -173.29 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.558 ' H ' HD12 ' A' ' 17' ' ' ILE . 2.8 mp -66.16 137.49 24.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 108.468 -0.938 . . . . 2.52 108.468 177.517 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.73 131.26 50.35 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 121.569 0.699 . . . . 1.71 110.632 170.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.78 153.17 30.07 Favored Glycine 0 CA--C 1.519 0.301 0 C-N-CA 126.651 2.072 . . . . 1.62 113.004 174.135 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 5.4 mp0 -74.37 143.66 44.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 114.78 -0.71 . . . . 3.87 110.738 -164.173 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 16.8 tpp85 -52.22 135.55 31.97 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 123.553 0.741 . . . . 4.51 110.992 173.101 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.84 167.54 54.44 Favored Glycine 0 CA--C 1.522 0.485 0 CA-C-O 122.587 1.104 . . . . 1.51 113.819 -173.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 15.4 t -66.06 129.2 30.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 C-N-CA 125.78 1.632 . . . . 2.45 109.392 -178.497 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 31.4 m -58.69 146.98 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 N-CA-C 114.355 1.243 . . . . 2.13 114.355 -172.268 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.11 159.48 53.52 Favored Glycine 0 CA--C 1.536 1.358 0 CA-C-O 121.903 0.724 . . . . 1.37 112.051 161.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.544 HD13 HH21 ' C' ' 21' ' ' ARG . 11.0 mp -120.05 136.82 25.25 Favored Pre-proline 0 CA--C 1.532 0.262 0 C-N-CA 126.314 1.846 . . . . 2.8 109.815 -177.152 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -74.42 -172.05 1.08 Allowed 'Trans proline' 0 N--CA 1.456 -0.679 0 C-N-CA 122.729 2.286 . . . . 2.49 109.861 169.666 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.245 0 CA-C-O 117.659 -1.634 . . . . 4.58 113.095 151.359 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo . . . . . 0 N--CA 1.491 1.347 0 N-CA-C 109.248 -1.097 . . . . 2.59 109.248 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.64 147.38 49.65 Favored Glycine 0 CA--C 1.541 1.678 0 CA-C-O 118.898 -0.946 . . . . 1.35 111.308 162.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -77.42 176.94 9.46 Favored 'Trans proline' 0 CA--C 1.538 0.707 0 C-N-CA 124.116 3.211 . . . . 2.28 110.315 164.041 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.1 tp-100 -38.91 143.61 0.15 Allowed 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 127.743 2.417 . . . . 3.74 115.594 176.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.14 163.36 53.11 Favored Glycine 0 CA--C 1.529 0.949 0 C-N-CA 124.031 0.824 . . . . 1.02 113.028 175.298 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.511 ' H ' HD12 ' B' ' 17' ' ' ILE . 2.9 mp -65.28 134.7 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 O-C-N 121.733 -0.863 . . . . 2.75 109.328 175.118 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.68 148.76 51.47 Favored 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 119.093 0.86 . . . . 1.46 112.196 176.427 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -68.41 153.2 52.85 Favored Glycine 0 CA--C 1.527 0.826 0 C-N-CA 124.57 1.081 . . . . 1.75 111.746 174.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.59 155.26 25.77 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.999 0.92 . . . . 2.87 111.332 -176.64 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 41.0 mtt-85 -53.53 148.1 9.92 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 125.204 1.402 . . . . 5.84 113.905 -169.076 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.78 166.43 54.3 Favored Glycine 0 CA--C 1.535 1.299 0 CA-C-N 116.133 -0.485 . . . . 1.92 113.813 175.445 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 27.6 t -72.59 121.77 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 N-CA-C 113.56 0.948 . . . . 2.93 113.56 -161.114 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -65.95 161.37 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 125.481 1.512 . . . . 2.51 114.758 -165.615 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -85.0 -155.91 24.91 Favored Glycine 0 CA--C 1.528 0.903 0 C-N-CA 125.776 1.655 . . . . 1.7 113.461 175.294 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.1 pp -161.9 145.86 9.55 Favored Pre-proline 0 CA--C 1.541 0.63 0 C-N-CA 124.628 1.171 . . . . 2.99 111.499 -177.113 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo . . . . . 0 C--O 1.255 1.367 1 C-N-CA 126.087 4.524 . . . . 3.14 112.765 158.012 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo . . . . . 0 CA--C 1.543 0.93 0 CA-C-O 118.607 -0.664 . . . . 2.14 111.959 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -70.98 -150.23 0.03 OUTLIER 'Trans proline' 0 CA--C 1.541 0.869 0 C-N-CA 123.95 3.1 . . . . 1.52 108.523 164.515 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.66 169.49 40.98 Favored Glycine 0 CA--C 1.531 1.072 0 O-C-N 121.575 -0.703 . . . . 0.93 113.29 172.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -72.49 160.88 45.68 Favored 'Trans proline' 0 N--CA 1.454 -0.794 0 C-N-CA 123.081 2.521 . . . . 2.46 110.674 171.137 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 34.0 tp60 -52.77 120.13 5.38 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 126.249 1.82 . . . . 1.75 112.798 170.642 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -60.06 150.28 40.29 Favored Glycine 0 CA--C 1.53 1.028 0 C-N-CA 123.876 0.751 . . . . 0.89 111.639 168.599 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 78.0 mt -67.14 145.86 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.409 1.084 . . . . 2.7 110.676 -176.037 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.13 154.89 29.65 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 114.824 1.416 . . . . 1.12 114.824 178.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -76.75 148.24 34.84 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 124.739 1.162 . . . . 0.94 112.596 176.151 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -83.33 171.11 13.87 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.475 1.11 . . . . 5.28 112.294 -177.159 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . 0.544 HH21 HD13 ' A' ' 26' ' ' LEU . 0.0 OUTLIER -61.29 138.49 58.24 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 121.398 -0.814 . . . . 3.52 111.97 178.672 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.84 159.0 51.26 Favored Glycine 0 CA--C 1.528 0.857 0 C-N-CA 125.657 1.598 . . . . 0.98 112.933 177.183 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 23.7 t -68.76 136.43 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 124.054 0.941 . . . . 1.74 109.095 171.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 31.0 m -87.9 -165.54 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.843 0 C-N-CA 125.053 1.341 . . . . 2.71 111.623 -179.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.51 -138.79 0.15 Allowed Glycine 0 CA--C 1.54 1.628 0 C-N-CA 125.109 1.338 . . . . 1.69 113.562 164.365 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.251 1.162 0 C-N-CA 126.413 1.885 . . . . 6.5 114.682 -177.017 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo . . . . . 0 N--CA 1.459 -0.534 0 N-CA-C 111.229 -0.335 . . . . 1.76 111.229 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.99 162.68 8.85 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 126.253 1.821 . . . . 3.58 113.695 172.744 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.71 -179.54 47.92 Favored Glycine 0 CA--C 1.525 0.693 0 C-N-CA 124.639 1.114 . . . . 1.29 112.547 171.42 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.401 HG13 ' H ' ' A' ' 17' ' ' ILE . 3.3 mt -61.28 138.01 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 C-N-CA 123.488 0.715 . . . . 2.14 109.506 -172.402 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.93 135.62 56.67 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-O 120.961 0.41 . . . . 2.04 110.727 170.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.26 151.79 49.84 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 126.286 1.898 . . . . 1.31 112.876 179.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 57.7 mm-40 -69.86 155.71 40.15 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 114.744 -0.728 . . . . 3.93 111.336 -174.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -68.0 145.8 54.16 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 121.028 0.442 . . . . 5.47 111.961 -177.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.45 141.48 28.81 Favored Glycine 0 C--N 1.333 0.413 0 CA-C-N 115.52 -0.764 . . . . 1.59 112.1 -178.156 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 27.2 m -61.4 141.42 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 CA-C-O 121.173 0.511 . . . . 2.43 111.248 -179.615 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.1 m -48.89 150.9 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 125.585 1.554 . . . . 2.54 113.878 -172.14 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.83 -153.8 26.16 Favored Glycine 0 N--CA 1.471 1.0 0 C-N-CA 123.165 0.412 . . . . 1.94 112.556 165.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 85.7 mt -149.48 155.47 39.13 Favored Pre-proline 0 N--CA 1.472 0.631 0 C-N-CA 125.677 1.591 . . . . 3.28 109.532 178.186 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -80.04 -162.1 0.17 Allowed 'Trans proline' 0 CA--C 1.539 0.747 0 C-N-CA 122.641 2.227 . . . . 2.41 109.392 158.08 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.239 0 CA-C-O 117.071 -1.961 . . . . 4.47 112.069 142.241 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_exo . . . . . 0 CA--C 1.544 1.015 0 N-CA-C 111.154 -0.364 . . . . 3.1 111.154 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -63.66 -177.49 4.49 Favored Glycine 0 CA--C 1.542 1.728 0 C-N-CA 120.187 -1.006 . . . . 2.52 112.446 126.217 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -74.64 -135.7 0.01 OUTLIER 'Trans proline' 0 CA--C 1.546 1.113 0 C-N-CA 124.571 3.514 . . . . 2.29 108.19 155.623 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 -87.33 -176.88 5.8 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 124.903 1.281 . . . . 3.98 111.454 171.812 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -84.75 158.97 34.13 Favored Glycine 0 CA--C 1.528 0.899 0 O-C-N 121.86 -0.525 . . . . 1.03 111.955 161.183 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 53.5 mt -72.77 133.26 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 123.389 0.676 . . . . 3.62 109.291 179.116 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.52 145.41 52.68 Favored 'General case' 0 CA--C 1.547 0.834 0 CA-C-N 119.39 0.995 . . . . 1.45 113.387 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.72 140.5 29.18 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 125.328 1.442 . . . . 1.52 111.694 173.591 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -95.37 153.09 17.85 Favored 'General case' 0 CA--C 1.532 0.257 0 O-C-N 121.729 -0.865 . . . . 3.15 111.604 -175.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 5.7 ttt85 -62.94 149.57 44.33 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.086 1.355 . . . . 6.68 112.221 -172.195 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.73 -174.86 26.61 Favored Glycine 0 CA--C 1.532 1.14 0 N-CA-C 114.463 0.545 . . . . 1.8 114.463 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 75.8 t -44.66 142.17 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 C-N-CA 128.016 2.526 . . . . 4.29 114.057 -172.501 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -93.1 156.95 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 124.13 0.972 . . . . 3.17 113.613 178.059 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.18 -162.62 29.57 Favored Glycine 0 C--N 1.341 0.828 0 C-N-CA 125.535 1.541 . . . . 1.89 114.23 -178.251 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.8 pp -153.76 141.83 13.98 Favored Pre-proline 0 CA--C 1.542 0.656 0 C-N-CA 124.287 1.035 . . . . 3.85 110.904 174.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo . . . . . 0 C--O 1.254 1.292 1 C-N-CA 126.282 4.654 . . . . 4.59 113.147 160.135 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo . . . . . 0 CA--C 1.547 1.152 0 CA-C-O 119.178 -0.426 . . . . 3.11 111.917 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -72.5 -135.59 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.075 0 C-N-CA 123.502 2.802 . . . . 1.97 108.351 162.447 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -81.04 175.42 54.78 Favored Glycine 0 CA--C 1.543 1.786 0 CA-C-N 119.303 0.956 . . . . 1.34 111.552 163.355 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -80.14 170.64 16.13 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 123.676 2.917 . . . . 2.42 110.46 161.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 28.7 tp60 -43.31 117.58 1.14 Allowed 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 125.33 1.452 . . . . 1.51 112.133 161.005 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.5 145.98 49.96 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.331 -1.108 . . . . 1.07 110.331 166.558 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 36.2 mm -66.51 145.33 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 O-C-N 122.367 -0.49 . . . . 4.11 110.567 -174.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -68.52 166.56 16.72 Favored 'General case' 0 CA--C 1.543 0.687 0 N-CA-C 114.394 1.257 . . . . 1.71 114.394 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.58 155.17 43.0 Favored Glycine 0 CA--C 1.527 0.81 0 C-N-CA 125.007 1.289 . . . . 1.04 112.6 -179.384 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -95.92 167.73 11.06 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.1 0.96 . . . . 4.89 111.164 -176.671 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.69 134.5 51.37 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.243 0.617 . . . . 3.87 111.038 178.501 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -63.72 178.49 7.12 Favored Glycine 0 N--CA 1.469 0.868 0 C-N-CA 126.41 1.957 . . . . 1.07 114.667 -175.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 93.1 t -74.83 138.09 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 108.969 -0.752 . . . . 2.14 108.969 -179.023 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 13.9 m -99.93 174.35 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 C-N-CA 126.305 1.842 . . . . 2.49 110.335 -178.386 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.92 -178.16 9.6 Favored Glycine 0 CA--C 1.534 1.227 0 C-N-CA 123.615 0.626 . . . . 1.81 113.673 167.308 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.479 0.987 0 N-CA-C 114.649 1.351 . . . . 5.57 114.649 173.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo . . . . . 0 CA--C 1.538 0.716 0 N-CA-C 110.249 -0.712 . . . . 2.06 110.249 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.427 ' HA ' ' HD2' ' B' ' 14' ' ' PRO 0.253 0.0 OUTLIER -89.99 -156.65 0.43 Allowed 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 125.984 1.714 . . . . 3.18 111.699 173.435 . . . . . . . . 4 4 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.03 178.47 45.03 Favored Glycine 0 N--CA 1.475 1.257 0 C-N-CA 124.95 1.262 . . . . 1.33 114.535 178.354 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.9 mt -76.06 130.41 36.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 O-C-N 121.261 -1.14 . . . . 2.54 108.579 -176.724 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.66 127.65 30.93 Favored 'General case' 0 CA--C 1.539 0.554 0 CA-C-N 119.318 0.963 . . . . 2.02 111.571 178.73 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.86 164.29 35.68 Favored Glycine 0 CA--C 1.528 0.869 0 C-N-CA 126.097 1.808 . . . . 1.28 112.803 -176.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -71.95 112.3 7.92 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 121.894 -0.768 . . . . 5.28 110.574 -169.431 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 67.4 ttt-85 -60.9 127.04 29.63 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 123.425 0.69 . . . . 4.0 109.402 177.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -78.57 171.99 55.19 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 125.002 1.287 . . . . 1.55 115.318 -166.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -64.38 147.52 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 CA-C-N 113.78 -1.21 . . . . 2.69 110.538 -173.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.0 m -54.14 150.58 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 123.146 0.578 . . . . 2.59 111.491 167.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.2 148.98 46.71 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 110.538 -1.025 . . . . 1.98 110.538 159.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 7.4 mp -101.35 167.04 11.27 Favored Pre-proline 0 C--N 1.328 -0.337 0 C-N-CA 124.027 0.931 . . . . 3.53 110.748 174.512 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.421 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 44.3 Cg_endo -69.94 -155.38 0.04 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 121.789 1.659 . . . . 1.81 108.55 155.113 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.259 0 CA-C-O 117.019 -1.989 . . . . 3.31 112.683 152.373 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_exo . . . . . 0 N--CA 1.481 0.765 0 CA-C-O 117.618 -1.076 . . . . 2.31 110.268 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -63.97 153.08 48.15 Favored Glycine 0 CA--C 1.548 2.131 0 C-N-CA 119.758 -1.211 . . . . 1.32 111.06 144.055 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 15' ' ' GLN . 57.8 Cg_endo -78.88 -47.96 0.09 OUTLIER 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 124.461 3.44 . . . . 2.88 114.628 -179.417 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.8 tp-100 -170.8 146.76 2.64 Favored 'General case' 0 N--CA 1.463 0.204 0 C-N-CA 124.285 1.034 . . . . 3.52 110.722 -161.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -86.51 149.8 22.94 Favored Glycine 0 CA--C 1.527 0.792 0 CA-C-O 121.822 0.679 . . . . 0.95 113.149 -178.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 65.7 mt -69.31 122.45 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 108.481 -0.933 . . . . 3.02 108.481 175.592 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.92 136.65 58.06 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 113.126 0.788 . . . . 1.21 113.126 -174.008 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -67.81 129.38 27.21 Favored Glycine 0 CA--C 1.523 0.533 0 C-N-CA 125.287 1.422 . . . . 1.65 110.183 169.429 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 8.8 tp-100 -96.89 150.34 20.86 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 123.685 0.794 . . . . 7.25 110.195 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.96 157.17 10.33 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 112.912 0.708 . . . . 4.62 112.912 171.461 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.46 -174.65 49.43 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 124.417 1.008 . . . . 1.83 112.455 170.701 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 13.4 m -93.31 141.9 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 115.133 1.531 . . . . 3.76 115.133 -156.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 12.9 m -69.5 154.17 8.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 125.796 1.638 . . . . 2.47 113.274 -166.816 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.72 -136.66 9.45 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 123.931 0.777 . . . . 1.77 113.117 170.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.421 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.6 pt? -172.18 158.57 4.18 Favored Pre-proline 0 CA--C 1.546 0.804 0 C-N-CA 126.085 1.754 . . . . 3.16 110.788 -157.41 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo . . . . . 0 C--O 1.256 1.424 0 C-N-CA 122.294 1.996 . . . . 2.56 111.013 160.851 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo . . . . . 0 CA--C 1.544 1.015 0 CA-C-O 118.783 -0.59 . . . . 2.64 111.939 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -55.39 -176.1 0.04 OUTLIER 'Trans proline' 0 CA--C 1.536 0.625 0 C-N-CA 124.707 3.605 . . . . 1.74 112.582 162.14 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -89.64 -172.85 45.55 Favored Glycine 0 CA--C 1.537 1.425 0 C-N-CA 124.882 1.23 . . . . 1.06 113.202 171.047 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -72.96 159.13 48.68 Favored 'Trans proline' 0 N--CA 1.456 -0.703 0 C-N-CA 123.211 2.607 . . . . 2.57 111.858 178.443 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.481 ' HA ' HE21 ' C' ' 15' ' ' GLN . 0.0 OUTLIER -45.7 130.02 9.1 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.461 1.904 . . . . 1.75 112.947 161.916 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -79.15 174.77 55.26 Favored Glycine 0 CA--C 1.53 0.981 0 C-N-CA 125.471 1.51 . . . . 1.17 114.06 174.521 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 97.0 mt -63.98 145.87 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 124.958 1.303 . . . . 2.82 111.76 -174.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -85.44 157.24 20.52 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 125.609 1.563 . . . . 1.34 114.115 177.189 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -98.02 138.06 13.66 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 124.945 1.26 . . . . 1.19 112.605 178.269 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -70.73 -179.07 2.04 Favored 'General case' 0 CA--C 1.543 0.709 0 CA-C-O 122.479 1.133 . . . . 5.2 111.797 170.199 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 17.8 ttt85 -55.41 149.34 13.43 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 124.588 1.155 . . . . 4.11 110.917 161.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.45 171.54 46.58 Favored Glycine 0 CA--C 1.533 1.17 0 N-CA-C 111.423 -0.671 . . . . 1.05 111.423 161.87 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 6.3 t -66.53 144.02 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 C-N-CA 124.13 0.972 . . . . 1.91 110.972 -179.457 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 12.4 m -85.77 175.0 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 C-N-CA 127.342 2.257 . . . . 2.71 112.497 179.384 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.26 173.71 10.53 Favored Glycine 0 CA--C 1.537 1.419 0 C-N-CA 124.619 1.104 . . . . 2.15 114.809 162.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 21.7 mt . . . . . 0 N--CA 1.484 1.242 0 N-CA-C 115.474 1.657 . . . . 3.41 115.474 -155.556 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo . . . . . 0 N--CA 1.459 -0.553 0 CA-C-O 120.897 0.29 . . . . 2.31 111.477 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.1 161.96 23.36 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 127.269 2.228 . . . . 2.87 113.257 175.29 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.26 -152.02 21.94 Favored Glycine 0 N--CA 1.472 1.053 0 C-N-CA 125.454 1.502 . . . . 1.55 115.457 -170.515 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -66.92 132.18 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 O-C-N 121.09 -1.241 . . . . 2.55 109.796 -176.384 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -72.39 64.49 0.59 Allowed 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 125.797 1.639 . . . . 3.43 112.435 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.35 -175.35 32.99 Favored Glycine 0 CA--C 1.527 0.784 0 C-N-CA 125.722 1.629 . . . . 2.06 112.402 -174.064 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 80.4 mm-40 -106.92 154.94 20.33 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.222 -0.658 . . . . 3.73 109.222 145.371 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 24.0 ttt180 -70.89 107.54 4.08 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 108.673 -0.862 . . . . 5.09 108.673 169.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -76.81 -81.81 0.57 Allowed Glycine 0 N--CA 1.472 1.083 0 C-N-CA 124.696 1.141 . . . . 4.36 112.91 -159.662 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 2.6 m -150.59 152.16 11.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 C-N-CA 123.963 0.905 . . . . 2.52 108.647 -178.311 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 20.5 m -62.23 162.68 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 125.998 1.719 . . . . 2.51 113.633 -179.158 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.09 -160.47 3.75 Favored Glycine 0 CA--C 1.537 1.407 0 N-CA-C 111.431 -0.667 . . . . 2.36 111.431 155.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 94.2 mt -140.82 161.66 52.88 Favored Pre-proline 0 N--CA 1.474 0.738 0 CA-C-N 118.055 0.928 . . . . 3.44 111.017 178.02 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -86.52 -158.75 0.09 OUTLIER 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 123.968 3.112 . . . . 1.95 109.152 156.023 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.212 0 CA-C-O 117.239 -1.867 . . . . 3.0 112.546 148.642 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo . . . . . 0 CA--C 1.545 1.042 0 CA-C-O 119.454 -0.311 . . . . 2.33 111.39 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.18 -178.58 8.79 Favored Glycine 0 CA--C 1.541 1.711 0 O-C-N 121.108 -0.995 . . . . 1.34 112.382 128.253 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -74.73 -135.64 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.038 0 C-N-CA 124.789 3.659 . . . . 2.42 108.313 158.514 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 -86.71 -173.17 4.36 Favored 'General case' 0 CA--C 1.541 0.632 0 O-C-N 121.056 -1.027 . . . . 4.57 111.586 172.577 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.59 158.04 29.37 Favored Glycine 0 CA--C 1.534 1.266 0 O-C-N 121.514 -0.741 . . . . 1.11 112.097 159.689 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 88.2 mt -78.68 154.16 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.076 0 C-N-CA 124.344 1.058 . . . . 3.27 109.799 173.674 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.42 150.39 43.71 Favored 'General case' 0 CA--C 1.547 0.854 0 O-C-N 120.932 -1.105 . . . . 1.44 113.801 177.802 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -87.46 170.78 41.04 Favored Glycine 0 CA--C 1.526 0.771 0 C-N-CA 125.748 1.642 . . . . 1.93 114.286 -176.517 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -72.41 128.41 35.54 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.646 1.178 . . . . 4.63 111.927 -175.1 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -62.07 153.3 30.23 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 122.586 0.354 . . . . 5.62 111.667 179.266 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.39 158.61 26.69 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 124.209 0.909 . . . . 1.73 115.189 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 13.2 m -84.96 134.68 26.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 N-CA-C 113.645 0.98 . . . . 3.7 113.645 -178.524 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.6 m -88.85 162.02 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 126.151 1.781 . . . . 2.38 113.215 -164.206 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.92 -131.1 7.1 Favored Glycine 0 CA--C 1.529 0.945 0 C-N-CA 124.925 1.25 . . . . 1.83 113.468 177.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.0 pp -172.38 153.83 3.02 Favored Pre-proline 0 CA--C 1.543 0.675 0 C-N-CA 124.302 1.041 . . . . 3.64 112.043 -152.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo . . . . . 0 C--O 1.255 1.359 1 C-N-CA 125.429 4.086 . . . . 2.42 112.548 153.764 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo . . . . . 0 N--CA 1.488 1.181 0 CA-C-O 118.947 -0.522 . . . . 2.52 112.009 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -72.01 -133.98 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 123.761 2.974 . . . . 1.94 108.107 162.536 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.85 166.16 54.72 Favored Glycine 0 CA--C 1.539 1.578 0 CA-C-N 119.905 1.23 . . . . 1.2 111.107 163.29 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -81.87 -37.64 0.25 Allowed 'Trans proline' 0 CA--C 1.536 0.589 0 C-N-CA 122.919 2.412 . . . . 3.5 113.072 -179.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 31.8 tp60 170.04 134.14 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 127.672 2.389 . . . . 1.37 107.117 -157.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -97.49 178.11 32.48 Favored Glycine 0 CA--C 1.528 0.872 0 C-N-CA 125.119 1.342 . . . . 0.97 113.027 167.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . 0.463 ' H ' HD12 ' C' ' 17' ' ' ILE . 3.4 mp -63.72 134.75 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 124.152 0.981 . . . . 2.55 111.486 -177.146 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.45 146.46 48.62 Favored 'General case' 0 CA--C 1.541 0.622 0 O-C-N 121.31 -0.869 . . . . 1.31 113.05 -178.582 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.28 87.42 0.5 Allowed Glycine 0 CA--C 1.527 0.788 0 C-N-CA 127.04 2.257 . . . . 2.59 112.748 -173.532 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -59.21 164.16 3.33 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 124.66 1.184 . . . . 5.07 113.444 -171.189 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 10.5 ttp-105 -46.19 127.75 8.98 Favored 'General case' 0 C--O 1.239 0.525 0 C-N-CA 124.771 1.229 . . . . 5.86 112.809 176.571 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.31 -174.24 8.49 Favored Glycine 0 CA--C 1.524 0.627 0 CA-C-N 113.134 -1.848 . . . . 1.49 113.306 175.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.9 t -63.65 143.63 15.44 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 C-N-CA 124.011 0.924 . . . . 1.88 110.237 175.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -89.78 -168.39 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.801 0 C-N-CA 125.787 1.635 . . . . 2.52 110.302 179.063 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.57 -168.49 2.3 Favored Glycine 0 CA--C 1.539 1.567 0 C-N-CA 124.133 0.873 . . . . 1.87 114.385 169.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 14.8 mt . . . . . 0 N--CA 1.483 1.189 0 C-N-CA 124.269 1.028 . . . . 3.45 113.703 176.956 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo . . . . . 0 N--CA 1.453 -0.91 0 N-CA-C 104.867 -2.782 . . . . 2.35 104.867 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 26.7 mm100 -70.76 172.18 9.22 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 125.708 1.603 . . . . 4.41 114.12 -164.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -61.46 145.53 48.68 Favored Glycine 0 C--N 1.335 0.483 0 N-CA-C 110.442 -1.063 . . . . 1.72 110.442 160.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.416 HG13 ' H ' ' A' ' 17' ' ' ILE . 2.7 mt -54.47 125.1 8.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 107.068 -1.456 . . . . 2.38 107.068 175.264 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -50.11 150.54 2.34 Favored 'General case' 0 CA--C 1.536 0.435 0 CA-C-O 121.773 0.797 . . . . 2.25 111.897 -176.397 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.81 167.27 34.39 Favored Glycine 0 CA--C 1.527 0.795 0 C-N-CA 124.461 1.029 . . . . 1.55 114.064 -173.139 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 13.5 mp0 -71.49 166.12 22.42 Favored 'General case' 0 CA--C 1.542 0.635 0 O-C-N 122.187 -0.596 . . . . 5.15 111.972 -175.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.8 tpt180 -68.05 132.69 47.71 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 113.94 1.089 . . . . 4.67 113.94 -162.261 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.78 93.07 1.36 Allowed Glycine 0 C--N 1.336 0.564 0 N-CA-C 109.786 -1.326 . . . . 1.81 109.786 170.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 28.5 m -58.22 140.62 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 123.76 0.824 . . . . 2.64 112.011 -176.439 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.7 t -50.99 142.96 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 126.26 1.824 . . . . 3.57 112.301 -170.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.82 148.28 50.36 Favored Glycine 0 N--CA 1.477 1.373 0 O-C-N 121.507 -0.746 . . . . 1.64 112.304 173.04 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -85.19 156.78 59.95 Favored Pre-proline 0 CA--C 1.541 0.609 0 CA-C-O 118.872 -0.585 . . . . 3.26 110.736 176.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.417 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 30.3 Cg_endo -85.38 -154.09 0.05 OUTLIER 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 123.517 2.811 . . . . 1.78 108.973 157.451 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.344 0 CA-C-O 117.631 -1.649 . . . . 3.09 113.437 148.89 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo . . . . . 0 N--CA 1.482 0.832 0 CA-C-O 119.379 -0.342 . . . . 3.5 112.799 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -79.78 136.83 17.8 Favored Glycine 0 CA--C 1.533 1.175 0 N-CA-C 110.216 -1.154 . . . . 1.31 110.216 157.017 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -76.6 177.23 9.09 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.988 2.459 . . . . 2.27 108.806 160.449 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -41.14 138.41 1.14 Allowed 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.318 1.447 . . . . 4.38 112.366 168.51 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -73.78 168.26 54.15 Favored Glycine 0 CA--C 1.526 0.756 0 C-N-CA 125.782 1.658 . . . . 1.05 115.248 -173.047 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 15.4 mm -61.79 140.14 19.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 CA-C-N 114.673 -0.764 . . . . 2.79 110.038 172.011 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.04 142.89 58.21 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 123.488 0.715 . . . . 1.76 111.531 173.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.38 -70.24 1.05 Allowed Glycine 0 N--CA 1.472 1.048 0 C-N-CA 123.934 0.778 . . . . 4.8 112.776 -168.399 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 178.48 -170.86 0.11 Allowed 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 128.376 2.67 . . . . 5.76 109.871 162.188 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 2.1 ttt-85 -117.96 152.0 36.34 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.452 1.101 . . . . 5.71 110.965 168.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.07 150.66 52.07 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 113.95 0.34 . . . . 1.97 113.95 -179.44 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 46.3 t -76.5 124.95 35.75 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.389 0 C-N-CA 123.409 0.684 . . . . 3.22 110.583 178.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.4 m -66.34 151.5 10.21 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 C-N-CA 125.451 1.501 . . . . 2.45 113.338 -167.563 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.73 -142.77 10.33 Favored Glycine 0 CA--C 1.527 0.805 0 C-N-CA 123.808 0.718 . . . . 1.76 112.659 169.274 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.417 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 3.2 pp -165.83 154.73 10.49 Favored Pre-proline 0 CA--C 1.54 0.584 0 C-N-CA 123.785 0.834 . . . . 3.31 112.249 -153.857 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo . . . . . 0 C--O 1.255 1.372 0 C-N-CA 125.3 4.0 . . . . 2.71 112.477 160.58 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo . . . . . 0 N--CA 1.484 0.916 0 CA-C-O 118.569 -0.68 . . . . 2.15 111.073 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -62.38 -151.05 0.02 OUTLIER 'Trans proline' 0 CA--C 1.544 0.984 1 C-N-CA 125.346 4.031 . . . . 1.75 111.998 159.201 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -104.97 167.26 15.01 Favored Glycine 0 CA--C 1.544 1.856 0 N-CA-C 116.954 1.541 . . . . 1.3 116.954 -170.116 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_endo -87.2 55.77 3.06 Favored 'Trans proline' 0 CA--C 1.543 0.942 1 C-N-CA 125.717 4.278 . . . . 3.76 113.145 -171.357 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 70.59 155.31 0.14 Allowed 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 125.467 1.507 . . . . 2.1 112.387 -176.389 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -101.93 176.72 26.15 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 126.68 2.086 . . . . 1.01 114.338 167.355 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 14.9 mt -72.82 126.92 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 O-C-N 121.126 -1.22 . . . . 3.58 112.177 -170.217 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -42.44 132.19 3.58 Favored 'General case' 0 CA--C 1.537 0.481 0 C-N-CA 125.399 1.48 . . . . 1.57 112.656 168.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.46 147.06 32.27 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 110.39 -1.084 . . . . 1.05 110.39 179.191 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -105.67 151.27 24.6 Favored 'General case' 0 C--N 1.327 -0.388 0 O-C-N 122.201 -0.587 . . . . 3.21 110.882 -173.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 12.1 ttp180 -54.71 134.55 47.44 Favored 'General case' 0 N--CA 1.447 -0.602 0 C-N-CA 123.347 0.659 . . . . 5.12 110.369 175.14 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.45 168.93 8.56 Favored Glycine 0 CA--C 1.528 0.846 0 C-N-CA 123.431 0.539 . . . . 1.01 113.094 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.3 t -61.2 143.42 14.9 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 O-C-N 122.039 -0.683 . . . . 1.71 110.162 174.356 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 3.3 p -85.32 176.03 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 C-N-CA 127.736 2.414 . . . . 2.5 110.426 -178.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.27 177.66 2.33 Favored Glycine 0 CA--C 1.54 1.651 0 CA-C-N 118.886 0.766 . . . . 1.82 113.405 161.77 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 17.9 mt . . . . . 0 C--O 1.253 1.246 0 N-CA-C 115.26 1.578 . . . . 3.38 115.26 -163.861 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo . . . . . 0 N--CA 1.455 -0.793 0 CA-C-O 121.433 0.514 . . . . 1.87 111.306 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -77.49 -177.12 4.56 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.848 1.659 . . . . 2.75 112.16 167.164 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.92 -177.82 40.19 Favored Glycine 0 CA--C 1.529 0.959 0 C-N-CA 123.89 0.757 . . . . 1.3 114.128 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 9.3 mt -67.82 133.59 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 O-C-N 121.911 -0.758 . . . . 2.04 109.795 -174.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.7 131.96 47.9 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 123.881 0.872 . . . . 1.82 110.874 172.281 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.27 152.85 51.13 Favored Glycine 0 CA--C 1.523 0.538 0 C-N-CA 126.405 1.955 . . . . 1.27 113.398 -173.831 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 82.2 mm-40 -74.77 134.65 41.8 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 115.139 -0.531 . . . . 3.8 110.589 -166.195 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 22.9 ttt180 -67.45 140.74 57.12 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-O 121.409 0.624 . . . . 5.21 112.355 -169.018 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -76.12 171.52 54.58 Favored Glycine 0 CA--C 1.522 0.525 0 C-N-CA 125.252 1.406 . . . . 1.47 115.068 -174.125 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 60.4 t -65.89 148.5 12.02 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 125.873 1.669 . . . . 2.98 109.456 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.8 m -51.84 154.7 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.757 0.823 . . . . 2.12 111.828 173.318 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -78.43 132.8 12.01 Favored Glycine 0 C--N 1.336 0.582 0 N-CA-C 107.777 -2.129 . . . . 2.17 107.777 158.146 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . 0.481 HD13 ' HE ' ' C' ' 21' ' ' ARG . 6.6 mp -87.95 -176.58 0.72 Allowed Pre-proline 0 C--N 1.323 -0.578 0 C-N-CA 122.746 0.418 . . . . 3.1 110.368 -174.487 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.563 ' C ' ' H ' ' C' ' 25' ' ' GLY . 85.3 Cg_endo -56.63 -166.66 0.02 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 120.244 0.629 . . . . 2.39 110.79 136.794 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.152 0 CA-C-O 118.019 -1.434 . . . . 5.61 115.543 167.085 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo . . . . . 0 N--CA 1.489 1.246 0 N-CA-C 108.972 -1.203 . . . . 2.53 108.972 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.3 148.76 44.54 Favored Glycine 0 CA--C 1.54 1.655 0 CA-C-O 118.697 -1.057 . . . . 1.28 111.01 164.429 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -76.97 169.08 22.3 Favored 'Trans proline' 0 CA--C 1.538 0.676 0 C-N-CA 124.189 3.26 . . . . 2.27 110.684 166.134 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -53.25 136.94 35.76 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 124.641 1.176 . . . . 4.06 111.273 172.432 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.01 161.38 37.11 Favored Glycine 0 CA--C 1.525 0.669 0 C-N-CA 124.501 1.048 . . . . 1.1 114.696 -170.362 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 32.3 pt -56.48 131.69 20.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 O-C-N 122.172 -0.605 . . . . 3.32 111.341 178.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.02 151.12 45.9 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-O 121.975 0.893 . . . . 1.47 113.198 -171.198 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -70.63 145.38 40.23 Favored Glycine 0 CA--C 1.526 0.759 0 C-N-CA 125.117 1.341 . . . . 1.84 110.712 173.27 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -123.06 159.28 28.79 Favored 'General case' 0 C--N 1.329 -0.295 0 O-C-N 121.634 -0.921 . . . . 2.68 110.81 178.068 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 3.2 ptt180 -54.96 159.75 2.24 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 115.585 1.698 . . . . 4.31 115.585 178.526 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.02 -119.18 0.08 OUTLIER Glycine 0 CA--C 1.535 1.307 0 C-N-CA 127.332 2.396 . . . . 2.94 114.187 -173.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 10.5 m -143.69 142.22 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 C-N-CA 124.701 1.201 . . . . 3.54 112.24 -176.328 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 22.6 m -83.1 161.18 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.151 0 C-N-CA 126.615 1.966 . . . . 2.35 115.679 -159.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.22 -126.11 4.85 Favored Glycine 0 CA--C 1.533 1.171 0 C-N-CA 126.22 1.867 . . . . 1.88 113.636 177.852 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.44 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.6 pt? -169.36 159.77 7.46 Favored Pre-proline 0 CA--C 1.554 1.12 0 N-CA-C 115.053 1.501 . . . . 3.58 115.053 -148.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo . . . . . 0 C--O 1.255 1.343 0 C-N-CA 123.558 2.839 . . . . 3.41 111.565 156.617 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_endo . . . . . 0 CA--C 1.546 1.124 0 CA-C-O 118.729 -0.613 . . . . 2.29 110.923 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -68.34 -155.16 0.03 OUTLIER 'Trans proline' 0 CA--C 1.546 1.093 0 C-N-CA 123.493 2.795 . . . . 1.7 109.618 157.018 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -100.61 -178.68 29.64 Favored Glycine 0 CA--C 1.534 1.251 0 C-N-CA 123.934 0.778 . . . . 1.25 112.775 172.088 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -75.35 164.83 32.0 Favored 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.446 2.764 . . . . 2.29 112.098 176.054 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -40.81 129.01 2.65 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.296 2.238 . . . . 1.63 113.451 163.226 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.98 152.77 52.71 Favored Glycine 0 CA--C 1.529 0.908 0 C-N-CA 124.641 1.115 . . . . 1.08 113.447 169.642 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 96.7 mt -56.73 148.5 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 124.4 1.08 . . . . 2.82 111.732 179.026 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -77.0 164.37 25.82 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 115.07 1.507 . . . . 1.49 115.07 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -84.7 168.92 44.22 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 124.968 1.27 . . . . 1.05 114.003 -174.401 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 8.9 mp0 -104.98 -179.22 3.88 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.177 1.391 . . . . 3.61 111.043 -166.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . 0.481 ' HE ' HD13 ' A' ' 26' ' ' LEU . 59.3 ttt180 -66.38 148.58 51.65 Favored 'General case' 0 N--CA 1.48 1.054 0 O-C-N 120.938 -1.102 . . . . 4.19 109.437 161.229 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -78.25 -173.58 42.03 Favored Glycine 0 CA--C 1.533 1.19 0 O-C-N 121.119 -0.988 . . . . 1.34 112.067 169.082 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 4.1 t -71.3 139.15 20.35 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 123.693 0.797 . . . . 1.94 109.123 176.551 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 16.0 m -71.47 173.6 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 C-N-CA 126.876 2.07 . . . . 2.82 112.65 176.425 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.563 ' H ' ' C ' ' A' ' 27' ' ' PRO . . . -53.26 172.42 0.52 Allowed Glycine 0 CA--C 1.538 1.509 0 C-N-CA 125.398 1.475 . . . . 1.74 115.895 158.323 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 7.1 mp . . . . . 0 C--O 1.252 1.212 0 C-N-CA 125.831 1.652 . . . . 3.98 114.761 -157.619 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo . . . . . 0 N--CA 1.459 -0.52 0 CA-C-O 120.924 0.302 . . . . 2.2 112.135 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.99 151.68 17.97 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 127.028 2.131 . . . . 4.18 111.567 167.441 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.11 -102.26 0.04 OUTLIER Glycine 0 N--CA 1.471 1.016 0 C-N-CA 125.112 1.339 . . . . 1.94 113.923 -179.355 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.9 mt -123.17 143.51 35.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 O-C-N 121.634 -0.921 . . . . 3.14 108.978 -177.231 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.57 53.05 0.21 Allowed 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 125.403 1.481 . . . . 3.7 111.97 170.056 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 86.11 -164.49 36.98 Favored Glycine 0 C--N 1.335 0.502 0 C-N-CA 127.813 2.625 . . . . 2.3 112.993 172.403 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 36.1 mm-40 -106.37 124.89 50.29 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 106.162 -1.792 . . . . 3.0 106.162 141.353 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 48.8 ttt85 -63.99 142.43 58.41 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.588 0.755 . . . . 4.59 110.84 -174.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.96 146.33 41.25 Favored Glycine 0 CA--C 1.523 0.59 0 C-N-CA 125.201 1.382 . . . . 1.56 112.272 -173.494 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 14.3 m -73.57 133.44 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 C-N-CA 124.83 1.252 . . . . 2.64 110.989 -174.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.4 p -50.77 147.75 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 C-N-CA 126.386 1.875 . . . . 3.33 114.973 -164.042 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -76.27 -179.95 47.34 Favored Glycine 0 CA--C 1.535 1.31 0 O-C-N 121.969 -0.457 . . . . 1.69 112.338 166.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.8 mt -143.97 158.01 56.55 Favored Pre-proline 0 N--CA 1.477 0.904 0 CA-C-O 118.175 -0.917 . . . . 3.72 112.399 -167.334 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -66.53 -173.45 0.37 Allowed 'Trans proline' 0 CA--C 1.537 0.653 0 C-N-CA 122.017 1.811 . . . . 2.3 110.188 158.119 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.271 0 CA-C-O 117.828 -1.54 . . . . 3.41 113.007 152.384 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo . . . . . 0 CA--C 1.541 0.861 0 CA-C-O 118.621 -0.658 . . . . 2.09 111.486 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -70.84 173.86 40.85 Favored Glycine 0 CA--C 1.54 1.606 0 CA-C-N 119.127 0.876 . . . . 1.38 111.885 143.226 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -71.17 163.03 40.57 Favored 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 123.707 2.938 . . . . 2.63 109.87 158.041 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.22 138.81 54.32 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 124.445 1.098 . . . . 3.63 111.901 179.707 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -57.63 142.79 42.94 Favored Glycine 0 C--N 1.342 0.887 0 C-N-CA 124.497 1.046 . . . . 1.21 114.195 -175.175 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 47.7 mm -73.61 142.72 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 123.893 0.877 . . . . 4.56 110.842 -177.214 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -52.17 139.11 24.37 Favored 'General case' 0 CA--C 1.544 0.717 0 N-CA-C 115.222 1.564 . . . . 1.58 115.222 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -66.32 141.87 41.74 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 126.096 1.807 . . . . 1.62 111.702 176.321 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 6.7 mp0 -79.74 151.85 30.16 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.194 0.598 . . . . 3.29 110.949 -173.388 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 12.7 mtt180 -60.76 150.12 33.51 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 118.857 0.753 . . . . 5.78 112.492 177.297 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.2 153.12 35.8 Favored Glycine 0 CA--C 1.531 1.065 0 CA-C-N 115.955 -0.566 . . . . 2.06 112.736 168.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 22.6 t -75.72 130.43 36.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 N-CA-C 112.613 0.598 . . . . 3.16 112.613 -164.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 m -60.03 157.62 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 N-CA-C 115.41 1.633 . . . . 2.78 115.41 -163.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.14 -178.07 45.95 Favored Glycine 0 C--N 1.338 0.652 0 C-N-CA 125.696 1.617 . . . . 1.77 115.548 -167.234 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.7 mp -134.97 130.9 19.68 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 123.78 0.832 . . . . 4.89 112.287 -170.444 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo . . . . . 0 C--O 1.256 1.383 0 C-N-CA 123.826 3.017 . . . . 2.67 112.017 146.947 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo . . . . . 0 N--CA 1.489 1.208 0 CA-C-O 118.73 -0.613 . . . . 2.43 111.511 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.93 -126.63 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.943 0 C-N-CA 124.246 3.298 . . . . 1.86 108.461 167.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -83.47 148.05 24.79 Favored Glycine 0 CA--C 1.538 1.515 0 CA-C-N 119.229 0.922 . . . . 1.22 112.522 172.498 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -74.18 96.76 0.97 Allowed 'Trans proline' 0 N--CA 1.456 -0.703 0 C-N-CA 123.285 2.656 . . . . 2.96 109.329 172.192 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.455 ' HG3' ' H ' ' C' ' 16' ' ' GLY . 16.5 tp60 59.1 -126.27 1.31 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.176 0.99 . . . . 2.98 109.239 179.819 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . 0.455 ' H ' ' HG3' ' C' ' 15' ' ' GLN . . . 174.25 161.78 24.79 Favored Glycine 0 CA--C 1.535 1.33 1 C-N-CA 132.048 4.642 . . . . 1.15 108.763 -179.769 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . 0.426 ' H ' HD12 ' C' ' 17' ' ' ILE . 3.7 mp -66.69 145.58 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 CA-C-N 119.34 1.57 . . . . 3.02 110.984 -177.576 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -78.56 145.93 34.54 Favored 'General case' 0 CA--C 1.545 0.765 0 O-C-N 120.915 -1.116 . . . . 1.58 113.024 178.311 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -88.84 161.08 30.45 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 125.305 1.431 . . . . 1.25 113.15 -179.603 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 58.7 mt-30 -87.2 160.28 18.54 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 123.95 0.9 . . . . 4.31 113.129 -174.539 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.24 138.42 45.09 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 109.511 -0.552 . . . . 3.62 109.511 163.413 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.9 165.73 52.68 Favored Glycine 0 CA--C 1.523 0.534 0 C-N-CA 123.728 0.68 . . . . 1.02 113.005 -177.096 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 91.2 t -63.67 138.33 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 C-N-CA 123.765 0.826 . . . . 1.78 108.899 173.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 25.6 m -101.89 -175.79 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.802 0 C-N-CA 125.139 1.376 . . . . 3.12 111.057 -177.831 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -58.96 173.75 3.57 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 124.582 1.087 . . . . 1.86 114.744 171.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 22.7 mt . . . . . 0 C--O 1.25 1.102 0 C-N-CA 125.261 1.425 . . . . 3.07 114.434 -168.297 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo . . . . . 0 N--CA 1.458 -0.6 0 CA-C-O 121.306 0.461 . . . . 1.9 111.535 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.43 169.28 16.7 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 127.35 2.26 . . . . 3.13 113.039 170.417 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.84 -174.98 40.8 Favored Glycine 0 CA--C 1.528 0.848 0 C-N-CA 125.21 1.386 . . . . 1.2 113.006 169.619 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 14.6 pt -74.18 155.3 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 O-C-N 121.754 -0.851 . . . . 2.7 111.096 -173.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -57.81 139.84 53.13 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.421 0.688 . . . . 1.84 111.597 172.727 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -57.56 150.65 30.27 Favored Glycine 0 CA--C 1.518 0.244 0 C-N-CA 127.259 2.361 . . . . 1.27 113.492 172.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 10.4 mm100 -64.93 118.26 8.8 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 114.716 -0.742 . . . . 3.75 109.194 -178.076 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.8 ttp180 -58.97 139.67 56.48 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 113.013 0.746 . . . . 4.34 113.013 -170.137 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.04 158.47 53.18 Favored Glycine 0 CA--C 1.519 0.331 0 C-N-CA 125.165 1.364 . . . . 1.54 113.38 -169.436 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 33.3 m -68.13 150.22 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-N 114.858 -0.671 . . . . 2.44 110.72 -175.318 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.5 m -51.05 147.8 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 124.192 0.997 . . . . 1.99 111.883 173.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.77 133.44 19.07 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 109.627 -1.389 . . . . 1.76 109.627 162.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 9.5 mp -77.18 169.92 18.84 Favored Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 122.882 0.473 . . . . 2.98 110.823 177.493 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.463 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 97.7 Cg_endo -77.17 -148.08 0.03 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 121.843 1.695 . . . . 2.02 108.277 154.338 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 1.41 0 CA-C-O 117.365 -1.797 . . . . 3.9 112.98 151.723 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo . . . . . 0 N--CA 1.484 0.938 0 CA-C-O 118.554 -0.686 . . . . 2.07 111.363 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.14 150.46 50.44 Favored Glycine 0 CA--C 1.546 1.994 0 CA-C-O 118.849 -0.973 . . . . 1.55 111.947 157.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -76.74 44.31 1.4 Allowed 'Trans proline' 0 CA--C 1.547 1.148 1 C-N-CA 126.986 5.124 . . . . 3.24 114.127 -172.662 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.1 tp-100 73.19 -175.44 0.16 Allowed 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 125.132 1.373 . . . . 4.95 109.606 -163.476 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -94.4 170.26 29.73 Favored Glycine 0 N--CA 1.473 1.126 0 O-C-N 121.091 -1.006 . . . . 1.16 113.12 166.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 50.1 mt -72.85 125.63 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 C-N-CA 123.564 0.746 . . . . 3.08 110.967 -176.438 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.82 143.75 57.72 Favored 'General case' 0 CA--C 1.545 0.762 0 O-C-N 121.203 -0.935 . . . . 1.48 113.253 -178.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.43 171.24 55.16 Favored Glycine 0 CA--C 1.529 0.919 0 C-N-CA 125.656 1.598 . . . . 1.74 113.578 -177.726 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -135.34 156.19 49.34 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 125.415 1.486 . . . . 2.97 110.224 -172.269 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.8 ptt-85 -71.99 152.5 42.43 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 114.747 1.388 . . . . 6.41 114.747 -172.48 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.23 176.99 54.53 Favored Glycine 0 CA--C 1.536 1.36 0 C-N-CA 125.317 1.437 . . . . 1.77 113.763 176.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 46.9 t -83.3 142.02 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 124.854 1.261 . . . . 3.11 112.98 -164.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 20.1 m -76.08 163.54 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 126.769 2.028 . . . . 2.43 114.323 -165.612 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -96.27 -127.03 5.3 Favored Glycine 0 CA--C 1.53 1.013 0 C-N-CA 125.107 1.337 . . . . 2.23 113.567 176.054 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.463 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 3.8 pp -171.82 159.04 4.6 Favored Pre-proline 0 CA--C 1.547 0.854 0 C-N-CA 125.769 1.627 . . . . 4.67 111.72 -156.529 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_endo . . . . . 0 C--O 1.256 1.383 0 C-N-CA 123.978 3.119 . . . . 3.23 111.767 153.807 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo . . . . . 0 N--CA 1.487 1.1 0 CA-C-O 119.181 -0.425 . . . . 1.98 111.627 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -71.54 -138.43 0.02 OUTLIER 'Trans proline' 0 CA--C 1.545 1.034 0 C-N-CA 123.317 2.678 . . . . 1.66 108.672 165.075 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -90.21 170.21 35.61 Favored Glycine 0 CA--C 1.538 1.52 0 N-CA-C 110.593 -1.003 . . . . 1.32 110.593 165.112 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.07 -58.63 0.04 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.4 2.067 . . . . 3.82 110.705 173.029 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.433 HE21 ' N ' ' C' ' 16' ' ' GLY . 23.0 tp60 -174.88 133.51 0.34 Allowed 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 126.316 1.846 . . . . 1.28 106.292 -148.04 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . 0.433 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -80.38 160.52 43.98 Favored Glycine 0 CA--C 1.523 0.575 0 C-N-CA 123.649 0.642 . . . . 1.0 111.658 170.216 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 37.1 mm -66.11 144.08 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 O-C-N 121.817 -0.813 . . . . 3.49 110.089 174.638 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.05 161.18 5.33 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 114.505 1.298 . . . . 1.19 114.505 177.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.44 170.46 52.22 Favored Glycine 0 CA--C 1.528 0.877 0 C-N-CA 124.562 1.077 . . . . 1.21 113.298 179.22 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 8.7 mp0 -95.64 177.88 5.65 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 124.339 1.056 . . . . 4.41 112.064 -168.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 14.6 ttt85 -72.87 141.25 47.93 Favored 'General case' 0 N--CA 1.473 0.692 0 O-C-N 120.369 -1.457 . . . . 3.5 110.329 167.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.95 173.69 34.53 Favored Glycine 0 CA--C 1.534 1.263 0 O-C-N 121.731 -0.606 . . . . 1.32 112.111 167.343 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.2 t -69.94 141.66 16.87 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.657 0 C-N-CA 124.409 1.084 . . . . 1.89 109.636 179.483 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 10.9 m -74.81 178.88 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 C-N-CA 124.432 1.093 . . . . 2.57 111.377 175.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.37 -171.68 0.94 Allowed Glycine 0 CA--C 1.538 1.489 0 C-N-CA 124.735 1.16 . . . . 1.68 114.193 162.84 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 15.5 mt . . . . . 0 N--CA 1.481 1.088 0 CA-C-O 117.199 -1.381 . . . . 3.58 113.719 -168.858 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo . . . . . 0 CA--C 1.535 0.543 0 CA-C-O 120.838 0.266 . . . . 2.69 111.982 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -78.91 176.96 9.13 Favored 'General case' 0 CA--C 1.553 1.092 0 C-N-CA 129.842 3.257 . . . . 3.7 111.563 -178.044 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -90.85 -172.93 43.97 Favored Glycine 0 N--CA 1.478 1.45 0 C-N-CA 125.189 1.376 . . . . 1.76 113.66 176.601 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.6 mm -76.45 134.96 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 N-CA-C 108.27 -1.011 . . . . 3.72 108.27 174.217 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.22 71.16 0.26 Allowed 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.074 1.35 . . . . 4.43 111.561 172.271 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 63.98 -146.52 50.4 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 125.021 1.296 . . . . 2.47 111.495 -169.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -142.9 128.7 19.37 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 106.269 -1.752 . . . . 5.48 106.269 150.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -53.02 126.92 22.17 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 118.769 0.713 . . . . 5.81 109.725 -177.362 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.46 -83.59 0.26 Allowed Glycine 0 N--CA 1.471 1.017 0 O-C-N 123.407 0.442 . . . . 3.18 112.088 -165.677 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -148.92 153.94 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 124.562 1.145 . . . . 2.06 112.161 175.813 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.5 m -65.87 161.52 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 C-N-CA 123.972 0.909 . . . . 2.99 111.233 168.196 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -76.24 174.07 53.62 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 123.585 0.612 . . . . 1.39 112.505 168.184 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -101.67 159.82 28.32 Favored Pre-proline 0 CA--C 1.542 0.663 0 C-N-CA 124.352 1.061 . . . . 3.14 110.854 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_endo -78.77 -166.67 0.42 Allowed 'Trans proline' 0 CA--C 1.537 0.675 0 C-N-CA 123.326 2.684 . . . . 2.19 109.324 157.663 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.274 0 CA-C-O 117.834 -1.537 . . . . 3.51 112.826 154.858 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_exo . . . . . 0 CA--C 1.542 0.921 0 N-CA-C 110.308 -0.689 . . . . 2.96 110.308 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.41 -167.91 2.73 Favored Glycine 0 CA--C 1.545 1.958 0 C-N-CA 119.659 -1.257 . . . . 2.16 112.033 124.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_endo -89.51 -138.97 0.02 OUTLIER 'Trans proline' 0 CA--C 1.546 1.077 0 C-N-CA 125.004 3.802 . . . . 2.86 109.287 175.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.82 138.57 32.44 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 127.288 2.235 . . . . 4.0 107.14 162.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -59.27 131.96 51.84 Favored Glycine 0 N--CA 1.468 0.807 0 N-CA-C 111.264 -0.734 . . . . 1.9 111.264 174.188 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 32.2 mm -60.56 150.37 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 O-C-N 122.334 -0.509 . . . . 5.87 110.982 175.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.57 137.5 58.25 Favored 'General case' 0 CA--C 1.55 0.952 0 O-C-N 120.7 -1.25 . . . . 3.01 114.315 176.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -93.13 -162.6 36.69 Favored Glycine 0 CA--C 1.533 1.196 0 C-N-CA 125.79 1.662 . . . . 2.9 112.211 171.123 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -157.73 174.31 15.51 Favored 'General case' 0 CA--C 1.537 0.442 0 O-C-N 121.064 -1.257 . . . . 3.98 113.944 -173.282 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 8.4 ptt180 -58.11 158.46 6.87 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 115.656 1.724 . . . . 4.54 115.656 172.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.17 -161.41 35.36 Favored Glycine 0 CA--C 1.535 1.29 0 C-N-CA 125.462 1.506 . . . . 2.34 111.499 162.283 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 43.8 t -120.3 145.21 26.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.041 0 C-N-CA 124.557 1.143 . . . . 4.62 112.528 -159.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 14.9 p -56.03 159.03 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 128.834 2.854 . . . . 3.72 114.359 -178.548 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.93 -126.7 1.08 Allowed Glycine 0 CA--C 1.53 1.023 0 C-N-CA 124.535 1.064 . . . . 2.23 111.204 166.218 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -167.26 162.76 10.37 Favored Pre-proline 0 CA--C 1.542 0.646 0 C-N-CA 125.343 1.457 . . . . 3.85 110.867 -166.74 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_endo . . . . . 0 CA--C 1.552 1.386 0 C-N-CA 124.47 3.447 . . . . 3.29 112.15 165.844 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 67.2 Cg_endo . . . . . 0 N--CA 1.487 1.122 0 CA-C-O 118.339 -0.775 . . . . 3.23 111.233 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -62.32 -152.38 0.02 OUTLIER 'Trans proline' 0 CA--C 1.542 0.924 0 C-N-CA 124.91 3.74 . . . . 2.5 111.696 163.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.39 168.66 54.4 Favored Glycine 0 CA--C 1.541 1.712 0 N-CA-C 109.985 -1.246 . . . . 1.56 109.985 163.39 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -76.64 176.65 9.83 Favored 'Trans proline' 0 N--CA 1.452 -0.941 0 C-N-CA 123.142 2.561 . . . . 2.66 110.681 170.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 9.5 tp60 -40.38 122.24 1.55 Allowed 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.279 1.432 . . . . 1.6 111.217 148.113 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.94 -169.37 27.54 Favored Glycine 0 CA--C 1.527 0.795 0 CA-C-O 121.993 0.774 . . . . 1.52 112.731 169.021 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 18.9 mt -63.82 124.33 18.33 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 O-C-N 121.638 -0.919 . . . . 2.87 110.833 175.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -65.52 155.85 34.4 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.582 1.153 . . . . 1.36 113.135 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -80.83 -179.24 52.87 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-O 123.23 1.461 . . . . 1.65 111.672 176.289 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.82 -160.48 1.03 Allowed 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.749 1.22 . . . . 3.25 109.149 178.309 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -85.19 152.46 23.33 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.892 1.277 . . . . 5.72 112.342 -179.181 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.26 176.85 43.88 Favored Glycine 0 CA--C 1.533 1.192 0 N-CA-C 111.03 -0.828 . . . . 1.01 111.03 164.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.0 t -59.84 149.39 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 124.042 0.937 . . . . 2.24 110.178 174.28 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 26.9 m -80.83 -173.34 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 C-N-CA 123.866 0.866 . . . . 2.65 111.079 173.227 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -55.98 160.12 7.27 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 124.154 0.883 . . . . 2.04 114.162 173.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 5.3 mt . . . . . 0 C--O 1.25 1.104 0 N-CA-C 114.246 1.202 . . . . 4.07 114.246 -163.079 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo . . . . . 0 N--CA 1.459 -0.533 0 N-CA-C 110.924 -0.452 . . . . 2.25 110.924 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 41.4 tp60 -48.65 151.76 1.09 Allowed 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 127.747 2.419 . . . . 4.14 114.866 -179.69 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.26 176.59 52.9 Favored Glycine 0 N--CA 1.465 0.618 0 C-N-CA 124.676 1.132 . . . . 1.27 115.199 173.957 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 14.4 mt -66.29 134.71 29.56 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 125.107 1.363 . . . . 2.34 110.568 -176.325 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.99 137.35 55.78 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 123.943 0.897 . . . . 1.99 112.267 175.313 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -66.72 157.76 50.33 Favored Glycine 0 CA--C 1.528 0.851 0 C-N-CA 125.485 1.517 . . . . 1.26 113.934 -176.507 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 53.1 mm-40 -62.5 128.98 38.56 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 114.738 -0.731 . . . . 3.36 109.668 -179.169 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 14.8 ttt180 -70.47 143.28 51.79 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 112.291 0.478 . . . . 4.73 112.291 -164.828 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -76.85 138.18 21.79 Favored Glycine 0 CA--C 1.522 0.528 0 C-N-CA 123.844 0.735 . . . . 1.93 111.414 -178.144 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 33.2 m -66.89 162.41 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 124.538 1.135 . . . . 2.24 112.493 -174.628 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.1 m -54.76 160.64 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 C-N-CA 124.527 1.131 . . . . 2.33 112.965 174.373 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.56 168.41 39.2 Favored Glycine 0 CA--C 1.527 0.817 0 CA-C-N 115.448 -0.796 . . . . 1.44 113.285 164.716 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 8.6 mp -99.46 156.63 35.19 Favored Pre-proline 0 CA--C 1.541 0.598 0 C-N-CA 124.004 0.922 . . . . 4.45 109.659 176.835 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -84.58 -164.32 0.24 Allowed 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 123.541 2.827 . . . . 2.55 109.163 162.449 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.239 0 CA-C-O 117.77 -1.572 . . . . 3.64 112.812 158.151 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_exo . . . . . 0 CA--C 1.544 0.998 0 CA-C-O 119.095 -0.46 . . . . 2.77 111.724 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.84 164.46 27.15 Favored Glycine 0 CA--C 1.542 1.752 0 CA-C-N 119.676 1.126 . . . . 1.44 113.153 138.975 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -80.69 63.58 8.79 Favored 'Trans proline' 0 CA--C 1.541 0.827 1 C-N-CA 126.176 4.584 . . . . 3.41 111.278 -179.58 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 22.8 tp60 67.85 173.04 0.27 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.188 1.395 . . . . 4.28 111.698 -172.625 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.15 160.33 29.48 Favored Glycine 0 CA--C 1.531 1.039 0 O-C-N 120.734 -1.229 . . . . 1.05 111.925 155.783 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 48.9 mm -74.65 129.94 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 O-C-N 121.708 -0.878 . . . . 3.18 109.955 176.195 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.73 149.23 50.83 Favored 'General case' 0 CA--C 1.544 0.734 0 N-CA-C 113.945 1.091 . . . . 1.52 113.945 -179.116 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.97 151.74 47.78 Favored Glycine 0 CA--C 1.531 1.073 0 C-N-CA 123.843 0.735 . . . . 1.47 111.557 177.299 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -109.17 156.85 19.38 Favored 'General case' 0 N--CA 1.465 0.307 0 O-C-N 121.644 -0.915 . . . . 2.71 111.649 175.287 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 6.5 ptt180 -64.32 158.31 23.82 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.426 1.89 . . . . 4.97 114.463 178.42 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -90.67 -167.69 41.78 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 126.275 1.893 . . . . 1.92 112.729 170.606 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 11.8 m -100.77 146.52 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 N-CA-C 115.849 1.796 . . . . 3.33 115.849 -162.329 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.6 p -46.35 153.67 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 128.888 2.875 . . . . 3.84 114.938 -178.664 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.33 -127.92 1.09 Allowed Glycine 0 CA--C 1.528 0.893 0 C-N-CA 123.714 0.673 . . . . 2.51 112.165 169.57 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.0 pp -162.67 151.57 12.56 Favored Pre-proline 0 CA--C 1.543 0.675 0 C-N-CA 124.141 0.976 . . . . 4.78 112.135 -164.64 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo . . . . . 0 C--O 1.255 1.367 1 C-N-CA 125.375 4.05 . . . . 3.17 112.397 162.306 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo . . . . . 0 CA--C 1.547 1.153 0 CA-C-O 119.107 -0.455 . . . . 1.88 112.046 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -62.58 -166.81 0.06 OUTLIER 'Trans proline' 0 CA--C 1.54 0.8 0 C-N-CA 124.096 3.197 . . . . 1.59 111.737 166.488 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.53 143.83 34.65 Favored Glycine 0 CA--C 1.54 1.629 0 O-C-N 121.124 -0.985 . . . . 1.03 113.108 -171.753 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -78.52 61.08 7.82 Favored 'Trans proline' 0 CA--C 1.54 0.82 0 C-N-CA 124.847 3.698 . . . . 3.19 112.196 -174.914 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 40.6 tp60 75.66 145.4 0.08 Allowed 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 126.543 1.937 . . . . 2.39 113.643 169.314 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.95 148.57 24.65 Favored Glycine 0 CA--C 1.528 0.848 0 O-C-N 120.875 -1.141 . . . . 1.1 112.838 169.397 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 38.3 mm -65.78 148.08 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 O-C-N 122.201 -0.588 . . . . 3.33 110.786 174.774 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.53 151.76 43.64 Favored 'General case' 0 CA--C 1.543 0.675 0 N-CA-C 113.093 0.775 . . . . 1.12 113.093 176.601 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.76 155.25 35.07 Favored Glycine 0 CA--C 1.529 0.957 0 CA-C-O 122.449 1.027 . . . . 0.95 112.342 174.878 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 18.2 mp0 -91.96 178.27 5.94 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 124.988 1.315 . . . . 3.16 110.556 -179.513 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 15.5 ptp180 -71.11 162.02 30.13 Favored 'General case' 0 N--CA 1.475 0.791 0 O-C-N 121.112 -0.992 . . . . 6.29 112.85 176.931 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.55 -171.82 42.26 Favored Glycine 0 CA--C 1.535 1.327 0 C-N-CA 124.023 0.821 . . . . 1.41 112.876 174.867 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 47.2 t -68.4 139.9 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 124.374 1.069 . . . . 2.05 110.699 -178.721 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 27.8 m -81.68 -176.1 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.705 1.202 . . . . 2.89 111.751 -176.957 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.56 161.82 15.85 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 123.91 0.767 . . . . 1.72 113.707 173.362 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 9.4 mt . . . . . 0 C--O 1.249 1.059 0 N-CA-C 114.717 1.377 . . . . 3.68 114.717 -164.717 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo . . . . . 0 CA--C 1.538 0.686 0 N-CA-C 110.38 -0.661 . . . . 3.47 110.38 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.409 ' HA ' ' HD2' ' B' ' 14' ' ' PRO . 0.0 OUTLIER -86.55 -143.77 0.11 Allowed 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 125.288 1.435 . . . . 2.57 111.073 169.32 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -82.98 -127.91 1.22 Allowed Glycine 0 N--CA 1.472 1.062 0 C-N-CA 125.611 1.577 . . . . 1.18 112.753 170.761 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 10.2 mm -111.59 160.17 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.071 0 C-N-CA 124.504 1.122 . . . . 3.58 110.861 -176.466 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -78.78 81.61 5.07 Favored 'General case' 0 CA--C 1.546 0.807 0 O-C-N 120.47 -1.394 . . . . 3.72 110.237 164.438 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.59 -170.35 42.92 Favored Glycine 0 N--CA 1.466 0.644 0 C-N-CA 126.418 1.961 . . . . 3.08 113.397 -172.288 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -94.39 119.64 33.43 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 105.856 -1.905 . . . . 6.55 105.856 127.773 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 35.7 ttm180 -62.42 136.36 57.87 Favored 'General case' 0 CA--C 1.534 0.361 0 O-C-N 121.109 -0.994 . . . . 5.57 111.377 -178.986 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.32 170.43 53.53 Favored Glycine 0 N--CA 1.465 0.583 0 C-N-CA 125.021 1.296 . . . . 1.9 113.831 -178.082 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.1 m -87.55 156.93 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 CA-C-N 114.043 -1.078 . . . . 2.71 111.614 -175.823 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.1 m -57.16 147.71 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.442 1.097 . . . . 2.59 112.388 -178.807 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -74.44 169.44 54.13 Favored Glycine 0 CA--C 1.529 0.928 0 N-CA-C 110.362 -1.095 . . . . 1.89 110.362 157.773 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 24.0 mt -116.18 172.09 4.1 Favored Pre-proline 0 N--CA 1.471 0.614 0 O-C-N 122.149 -0.618 . . . . 4.5 111.794 170.74 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.433 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 47.4 Cg_endo -69.78 -153.59 0.03 OUTLIER 'Trans proline' 0 CA--C 1.536 0.616 0 C-N-CA 122.717 2.278 . . . . 2.43 108.884 148.029 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.301 0 CA-C-O 116.971 -2.016 . . . . 3.82 113.106 159.693 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo . . . . . 0 N--CA 1.491 1.356 0 N-CA-C 108.774 -1.279 . . . . 3.52 108.774 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.16 147.95 51.16 Favored Glycine 0 CA--C 1.549 2.219 0 CA-C-O 118.27 -1.295 . . . . 2.36 110.635 157.879 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 15' ' ' GLN . 87.5 Cg_endo -83.42 -51.41 0.04 OUTLIER 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 124.229 3.286 . . . . 3.42 112.874 -173.969 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -170.66 -178.99 2.76 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 128.15 2.58 . . . . 4.9 108.358 178.284 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -98.74 157.57 20.24 Favored Glycine 0 CA--C 1.528 0.857 0 CA-C-O 122.16 0.867 . . . . 1.73 113.739 177.744 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.515 ' H ' HD12 ' B' ' 17' ' ' ILE . 3.5 mp -72.71 157.27 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 124.204 1.002 . . . . 3.17 109.096 175.37 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.41 127.75 32.99 Favored 'General case' 0 CA--C 1.545 0.78 0 O-C-N 120.647 -1.283 . . . . 2.68 112.507 170.125 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -86.59 171.63 43.69 Favored Glycine 0 C--N 1.339 0.7 0 C-N-CA 125.178 1.37 . . . . 2.31 112.608 177.09 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -104.94 147.35 27.87 Favored 'General case' 0 N--CA 1.462 0.174 0 O-C-N 121.855 -0.791 . . . . 2.94 111.259 -179.068 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 6.6 ptt180 -67.99 155.74 38.83 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.167 -0.47 . . . . 4.41 110.796 158.002 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.17 -172.83 43.18 Favored Glycine 0 CA--C 1.533 1.212 0 C-N-CA 123.946 0.784 . . . . 1.93 113.066 178.255 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 15.3 m -93.67 145.59 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 N-CA-C 116.012 1.856 . . . . 3.66 116.012 -155.841 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.8 m -85.84 155.02 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.916 1.687 . . . . 2.6 112.888 -171.373 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.73 -134.15 8.13 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 124.637 1.113 . . . . 1.67 113.25 175.203 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.433 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.4 pt? -168.56 163.38 8.26 Favored Pre-proline 0 CA--C 1.551 0.988 0 C-N-CA 126.323 1.849 . . . . 3.47 111.028 -163.475 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo . . . . . 0 C--O 1.255 1.346 0 C-N-CA 124.383 3.389 . . . . 2.49 111.502 159.184 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo . . . . . 0 N--CA 1.486 1.043 0 CA-C-O 118.819 -0.575 . . . . 3.27 111.987 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -64.29 -166.83 0.08 OUTLIER 'Trans proline' 0 CA--C 1.54 0.796 0 C-N-CA 123.616 2.878 . . . . 2.52 110.233 159.413 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -89.87 174.95 41.4 Favored Glycine 0 CA--C 1.534 1.26 0 C-N-CA 124.005 0.812 . . . . 1.49 112.589 175.338 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -70.59 169.31 20.27 Favored 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 123.03 2.487 . . . . 2.47 111.941 170.527 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 26.3 tp60 -34.67 146.28 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 129.066 2.947 . . . . 1.92 114.673 168.601 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.7 171.22 41.13 Favored Glycine 0 CA--C 1.525 0.672 0 C-N-CA 123.427 0.537 . . . . 1.9 112.631 168.346 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . 0.612 ' H ' HD12 ' C' ' 17' ' ' ILE . 3.3 mp -59.21 130.48 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 123.157 0.583 . . . . 3.3 110.489 178.089 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.32 143.56 50.24 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 125.574 1.55 . . . . 2.34 114.797 -170.514 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -85.16 145.91 21.64 Favored Glycine 0 C--N 1.339 0.736 0 N-CA-C 109.664 -1.374 . . . . 1.56 109.664 171.706 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 5.7 mp0 -85.83 -169.67 2.75 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 123.941 0.896 . . . . 3.42 110.503 179.894 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 16.2 ttt180 -64.88 145.11 56.74 Favored 'General case' 0 N--CA 1.467 0.421 0 O-C-N 121.172 -0.955 . . . . 4.57 109.49 156.297 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.17 162.35 36.19 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 111.414 -0.674 . . . . 1.26 111.414 161.94 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.57 140.15 20.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 C-N-CA 123.445 0.698 . . . . 2.41 109.796 176.221 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 13.4 p -79.67 178.9 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 C-N-CA 127.041 2.136 . . . . 4.12 110.872 178.479 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.34 179.36 2.62 Favored Glycine 0 CA--C 1.537 1.41 0 C-N-CA 124.553 1.073 . . . . 2.28 114.735 169.155 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 10.0 mp . . . . . 0 C--O 1.249 1.078 0 C-N-CA 126.001 1.72 . . . . 3.87 113.296 -162.571 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo . . . . . 0 N--CA 1.459 -0.524 0 N-CA-C 111.318 -0.301 . . . . 1.75 111.318 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -58.58 166.69 1.71 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.774 2.029 . . . . 3.33 114.041 168.871 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.59 -118.45 0.03 OUTLIER Glycine 0 N--CA 1.475 1.287 0 C-N-CA 127.452 2.453 . . . . 2.23 115.798 -176.652 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.2 mp -120.07 137.01 55.3 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 O-C-N 120.916 -1.344 . . . . 2.47 108.874 -179.824 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -52.17 128.41 24.8 Favored 'General case' 0 CA--C 1.542 0.651 0 CA-C-N 118.275 0.489 . . . . 1.9 110.706 170.135 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -62.34 156.7 37.93 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 125.777 1.656 . . . . 1.26 113.713 -177.076 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.9 mm-40 -73.0 116.34 13.39 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 108.734 -0.839 . . . . 3.33 108.734 -171.929 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 7.4 ttt180 -64.22 140.58 58.88 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 122.72 0.408 . . . . 5.14 112.029 -163.283 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.67 158.17 53.62 Favored Glycine 0 C--N 1.335 0.502 0 C-N-CA 123.926 0.774 . . . . 1.77 111.908 -179.644 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 33.3 m -75.97 160.99 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 CA-C-N 115.084 -0.558 . . . . 2.73 111.606 -174.636 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.1 m -51.98 164.76 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 125.531 1.532 . . . . 2.61 112.857 177.283 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.56 124.45 29.26 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.989 -0.844 . . . . 2.06 110.989 163.421 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 9.5 mp -82.31 170.92 13.2 Favored Pre-proline 0 CA--C 1.533 0.321 0 C-N-CA 124.493 1.117 . . . . 3.74 110.856 175.479 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -60.0 -165.77 0.03 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 121.77 1.647 . . . . 3.42 110.821 152.135 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.667 0 CA-C-O 118.647 -1.085 . . . . 6.19 114.984 160.141 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo . . . . . 0 N--CA 1.481 0.776 0 CA-C-O 118.551 -0.687 . . . . 2.1 111.694 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.29 161.44 48.0 Favored Glycine 0 CA--C 1.54 1.628 0 CA-C-O 119.078 -0.845 . . . . 1.26 111.669 152.709 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -76.0 163.68 32.75 Favored 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 124.235 3.29 . . . . 2.47 110.641 165.797 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -53.94 140.17 31.74 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.761 1.224 . . . . 4.27 111.79 170.948 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.23 161.67 53.24 Favored Glycine 0 CA--C 1.529 0.912 0 C-N-CA 124.167 0.889 . . . . 1.42 114.421 -174.512 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 35.6 mm -60.78 119.32 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 O-C-N 121.542 -0.975 . . . . 2.9 111.086 -175.772 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.76 155.04 27.78 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 114.492 1.293 . . . . 1.59 114.492 -172.176 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.24 136.7 28.68 Favored Glycine 0 CA--C 1.527 0.809 0 C-N-CA 126.3 1.905 . . . . 1.62 111.391 -179.534 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -106.3 143.62 34.16 Favored 'General case' 0 N--CA 1.465 0.323 0 O-C-N 121.633 -0.922 . . . . 3.2 110.133 -172.415 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 32.0 ptt180 -72.22 157.6 37.43 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.344 1.058 . . . . 4.41 112.997 175.823 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.86 -174.95 26.77 Favored Glycine 0 CA--C 1.539 1.534 0 N-CA-C 117.061 1.584 . . . . 2.27 117.061 -170.099 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 60.9 t -96.33 136.1 28.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 C-N-CA 124.201 1.001 . . . . 4.49 113.517 -157.873 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.9 p -32.39 143.21 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 131.232 3.813 . . . . 4.33 118.44 -170.32 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.14 -118.79 4.11 Favored Glycine 0 CA--C 1.528 0.905 0 C-N-CA 124.968 1.27 . . . . 2.45 112.211 169.469 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 1.6 pp -168.76 153.39 5.9 Favored Pre-proline 0 CA--C 1.552 1.025 0 N-CA-C 115.565 1.691 . . . . 5.91 115.565 -150.246 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo . . . . . 0 C--O 1.254 1.298 0 C-N-CA 123.739 2.96 . . . . 4.65 111.741 152.935 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo . . . . . 0 N--CA 1.486 1.068 0 CA-C-O 118.582 -0.674 . . . . 2.13 111.096 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -71.12 -150.0 0.03 OUTLIER 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 123.65 2.9 . . . . 1.61 109.581 166.11 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -99.27 -172.77 31.15 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-N 118.688 0.676 . . . . 1.21 112.662 172.232 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.81 167.69 23.46 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 123.248 2.632 . . . . 2.36 112.213 176.608 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 8.7 tp60 -37.23 127.16 1.0 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.696 2.398 . . . . 1.39 113.024 160.583 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -62.5 147.75 49.46 Favored Glycine 0 CA--C 1.527 0.786 0 C-N-CA 124.321 0.962 . . . . 1.01 112.741 168.584 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 47.0 mm -57.9 147.14 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 O-C-N 121.933 -0.745 . . . . 3.35 111.557 -178.952 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -72.4 156.81 38.67 Favored 'General case' 0 CA--C 1.542 0.658 0 O-C-N 121.293 -0.879 . . . . 1.2 112.792 178.72 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -91.94 153.75 22.1 Favored Glycine 0 C--N 1.338 0.644 0 CA-C-O 122.299 0.944 . . . . 1.09 112.046 -178.528 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 25.1 mp0 -92.02 -174.12 3.69 Favored 'General case' 0 CA--C 1.544 0.721 0 CA-C-O 122.024 0.916 . . . . 2.92 111.398 -175.954 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -58.83 139.33 56.56 Favored 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 125.15 1.38 . . . . 4.65 111.653 169.093 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.9 -171.01 6.81 Favored Glycine 0 C--N 1.337 0.628 0 C-N-CA 125.384 1.469 . . . . 1.58 113.481 175.825 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 21.4 t -65.0 127.46 25.95 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.696 0 O-C-N 122.305 -0.527 . . . . 2.77 110.473 -178.833 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 4.3 p -64.31 160.93 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 126.864 2.066 . . . . 4.17 112.133 178.007 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -51.9 176.52 0.1 Allowed Glycine 0 CA--C 1.542 1.728 0 C-N-CA 124.52 1.057 . . . . 1.84 115.236 159.518 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 3.3 mm? . . . . . 0 C--O 1.253 1.248 0 CA-C-O 117.016 -1.469 . . . . 3.57 112.623 -161.156 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.406 ' O ' ' HA3' ' B' ' 13' ' ' GLY . 83.5 Cg_endo . . . . . 0 CA--C 1.534 0.489 0 CA-C-O 120.661 0.192 . . . . 2.88 111.635 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.01 153.55 36.93 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 127.31 2.244 . . . . 3.14 113.605 178.706 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.7 -122.91 0.05 OUTLIER Glycine 0 CA--C 1.534 1.271 0 C-N-CA 127.146 2.308 . . . . 2.4 115.717 -179.051 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.8 mt -122.42 131.8 72.46 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 O-C-N 121.097 -1.237 . . . . 1.97 109.191 -177.248 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.91 134.33 55.41 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 123.442 0.697 . . . . 2.08 110.81 173.399 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.69 155.18 48.13 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 126.744 2.116 . . . . 1.83 114.33 -173.463 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 72.7 mm-40 -77.76 154.09 32.31 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 114.767 -0.717 . . . . 4.14 112.47 -166.256 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.45 132.16 53.04 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 123.509 0.723 . . . . 6.85 111.759 -177.672 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.9 151.64 44.52 Favored Glycine 0 N--CA 1.467 0.763 0 N-CA-C 115.584 0.994 . . . . 1.74 115.584 -167.879 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 2.5 m -69.1 130.93 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 124.938 1.295 . . . . 2.57 110.893 176.138 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.5 m -55.61 146.07 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 125.062 1.345 . . . . 2.58 114.029 -167.638 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.02 -163.93 7.91 Favored Glycine 0 CA--C 1.534 1.276 0 N-CA-C 111.39 -0.684 . . . . 1.98 111.39 161.032 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.1 mt -143.95 167.02 16.46 Favored Pre-proline 0 N--CA 1.475 0.813 0 C-N-CA 124.551 1.14 . . . . 2.95 111.479 179.951 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . 0.426 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 29.2 Cg_endo -76.73 -152.61 0.04 OUTLIER 'Trans proline' 0 CA--C 1.539 0.736 0 C-N-CA 122.981 2.454 . . . . 1.92 108.584 150.914 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.288 0 CA-C-O 117.017 -1.99 . . . . 3.12 112.774 143.671 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_exo . . . . . 0 CA--C 1.543 0.966 0 N-CA-C 111.512 -0.226 . . . . 3.51 111.512 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . 0.406 ' HA3' ' O ' ' A' ' 14' ' ' PRO . . . -69.05 176.44 30.06 Favored Glycine 0 CA--C 1.538 1.474 0 C-N-CA 120.284 -0.96 . . . . 1.72 112.935 127.561 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -79.94 156.28 23.56 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 C-N-CA 125.011 3.807 . . . . 2.54 110.795 158.646 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -60.86 140.63 57.62 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 125.158 1.383 . . . . 4.33 110.455 168.24 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.32 162.14 40.83 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 115.508 0.963 . . . . 1.45 115.508 -172.114 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 41.0 pt -55.41 139.19 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 O-C-N 122.376 -0.485 . . . . 4.12 111.213 176.765 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.15 154.04 42.72 Favored 'General case' 0 CA--C 1.54 0.589 0 CA-C-O 121.539 0.685 . . . . 1.73 112.828 -176.638 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.02 161.96 51.71 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 125.094 1.33 . . . . 2.23 113.635 -178.338 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 3.0 tp-100 -90.56 131.06 36.51 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 123.663 0.785 . . . . 3.83 109.709 -174.163 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.28 153.26 3.94 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-O 122.678 1.228 . . . . 8.13 114.161 -177.77 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.91 166.54 54.41 Favored Glycine 0 CA--C 1.531 1.086 0 CA-C-N 113.998 -1.456 . . . . 1.78 112.541 171.298 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 17.6 m -89.71 139.28 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 115.05 1.5 . . . . 3.7 115.05 -162.841 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.1 m -104.22 155.8 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 124.809 1.244 . . . . 2.62 112.708 -163.211 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -107.49 -130.33 6.34 Favored Glycine 0 CA--C 1.529 0.907 0 C-N-CA 125.118 1.342 . . . . 1.66 113.218 177.801 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . 0.426 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.7 pt? -179.14 161.82 1.0 Allowed Pre-proline 0 CA--C 1.547 0.842 0 C-N-CA 126.045 1.738 . . . . 3.33 110.753 -152.996 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo . . . . . 0 C--O 1.257 1.437 0 C-N-CA 124.014 3.143 . . . . 2.89 111.949 156.159 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo . . . . . 0 CA--C 1.547 1.173 0 CA-C-O 119.181 -0.425 . . . . 3.22 112.03 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -66.07 -160.66 0.04 OUTLIER 'Trans proline' 0 CA--C 1.543 0.942 0 C-N-CA 123.066 2.511 . . . . 2.28 110.129 161.67 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -90.89 -177.57 43.74 Favored Glycine 0 CA--C 1.535 1.31 0 O-C-N 121.163 -0.96 . . . . 1.5 111.897 169.043 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -77.77 170.51 18.94 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.946 2.43 . . . . 2.57 111.981 175.405 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.8 tp60 -34.99 127.01 0.53 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 127.557 2.343 . . . . 1.74 113.325 152.499 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.18 155.4 53.16 Favored Glycine 0 CA--C 1.528 0.869 0 C-N-CA 124.944 1.259 . . . . 1.49 112.338 167.304 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 82.3 mt -62.95 139.57 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 O-C-N 121.593 -0.946 . . . . 2.56 110.731 -175.582 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.26 159.15 12.76 Favored 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 122.292 1.044 . . . . 2.15 113.31 178.904 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -61.76 124.99 35.75 Favored Glycine 0 CA--C 1.524 0.638 0 CA-C-O 122.279 0.933 . . . . 1.95 112.679 -170.905 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . 0.567 ' NE2' ' H ' ' C' ' 20' ' ' GLN . 0.0 OUTLIER -60.59 129.76 43.15 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.672 1.589 . . . . 6.1 110.919 -175.982 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.47 129.71 22.51 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.526 0.731 . . . . 3.13 111.862 -174.898 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -62.6 154.98 41.65 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 115.168 -0.924 . . . . 1.03 113.311 -176.466 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.5 t -57.4 146.59 6.76 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 C-N-CA 124.913 1.285 . . . . 1.61 110.288 171.876 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 27.2 m -98.54 -169.87 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.817 0 C-N-CA 125.687 1.595 . . . . 2.39 110.557 179.091 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.6 -168.31 3.94 Favored Glycine 0 CA--C 1.538 1.485 0 C-N-CA 124.339 0.971 . . . . 1.9 113.944 167.356 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 13.5 mt . . . . . 0 N--CA 1.485 1.315 0 N-CA-C 114.329 1.233 . . . . 3.61 114.329 -174.977 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo . . . . . 0 N--CA 1.457 -0.676 0 N-CA-C 111.328 -0.297 . . . . 5.17 111.328 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -64.38 161.71 16.44 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 128.294 2.638 . . . . 4.46 111.451 166.577 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.41 -143.17 0.46 Allowed Glycine 0 CA--C 1.535 1.34 0 C-N-CA 126.66 2.076 . . . . 3.27 114.307 173.367 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.1 mt -101.06 127.92 53.79 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 O-C-N 121.375 -1.074 . . . . 4.24 108.409 179.202 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.89 140.79 56.41 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 118.901 0.773 . . . . 2.45 110.29 168.186 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -61.75 141.95 47.9 Favored Glycine 0 CA--C 1.523 0.58 0 C-N-CA 124.587 1.089 . . . . 1.18 112.291 175.423 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 54.2 mm-40 -68.32 130.22 42.25 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 109.847 -0.427 . . . . 3.08 109.847 -177.516 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -66.69 137.26 56.56 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 121.512 0.672 . . . . 3.96 111.175 -171.765 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.63 126.1 8.33 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-O 122.599 1.11 . . . . 2.48 111.562 176.611 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.8 t -65.28 155.26 6.8 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.835 0 C-N-CA 126.498 1.919 . . . . 4.27 111.822 -178.141 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.3 m -61.62 152.32 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 O-C-N 121.121 -0.987 . . . . 3.57 112.791 173.805 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -97.02 -153.88 29.7 Favored Glycine 0 N--CA 1.468 0.795 0 C-N-CA 124.023 0.821 . . . . 2.03 112.478 167.642 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 89.2 mt -143.26 158.89 57.23 Favored Pre-proline 0 N--CA 1.47 0.536 0 C-N-CA 126.117 1.767 . . . . 5.58 110.246 176.444 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -76.41 -146.21 0.03 OUTLIER 'Trans proline' 0 CA--C 1.54 0.791 0 C-N-CA 122.58 2.186 . . . . 3.93 107.803 154.03 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.169 0 CA-C-O 116.701 -2.166 . . . . 4.72 111.979 151.902 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo . . . . . 0 N--CA 1.481 0.774 0 CA-C-O 118.705 -0.623 . . . . 4.03 111.68 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.6 159.01 50.88 Favored Glycine 0 CA--C 1.539 1.581 0 CA-C-O 118.761 -1.021 . . . . 2.08 111.682 154.443 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_endo -70.8 158.67 54.96 Favored 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 123.782 2.988 . . . . 4.16 109.819 162.134 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -82.34 174.29 11.27 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.909 0.861 . . . . 6.66 113.114 178.593 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.22 154.36 52.53 Favored Glycine 0 CA--C 1.52 0.389 0 CA-C-O 122.615 1.119 . . . . 1.95 114.248 -177.705 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 43.8 pt -61.39 144.69 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 CA-C-N 114.383 -0.909 . . . . 5.38 110.718 161.518 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -85.35 133.4 34.14 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 123.822 0.849 . . . . 2.1 112.495 177.749 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -75.08 125.62 8.32 Favored Glycine 0 CA--C 1.525 0.691 0 C-N-CA 125.653 1.597 . . . . 1.58 110.546 173.272 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -89.71 157.51 17.95 Favored 'General case' 0 CA--C 1.535 0.382 0 O-C-N 121.865 -0.785 . . . . 4.32 110.384 166.321 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.92 162.08 29.92 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 123.235 0.614 . . . . 4.03 111.712 166.029 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -84.19 -141.8 5.1 Favored Glycine 0 CA--C 1.533 1.198 0 N-CA-C 110.991 -0.843 . . . . 2.52 110.991 163.602 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 99.5 t -40.62 131.38 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 126.415 1.886 . . . . 4.88 113.816 -173.944 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 15.3 m -103.78 149.4 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 125.083 1.353 . . . . 3.96 109.02 161.371 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.515 ' H ' HG23 ' C' ' 23' ' ' VAL . . . -102.55 167.63 17.84 Favored Glycine 0 C--N 1.333 0.392 0 C-N-CA 124.843 1.211 . . . . 5.24 115.266 -163.574 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -171.57 158.99 4.83 Favored Pre-proline 0 CA--C 1.544 0.713 0 C-N-CA 127.626 2.37 . . . . 7.26 111.028 -173.824 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo . . . . . 0 C--O 1.255 1.354 0 C-N-CA 124.063 3.175 . . . . 4.97 112.155 152.631 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo . . . . . 0 N--CA 1.486 1.085 0 CA-C-O 118.604 -0.665 . . . . 5.14 111.305 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -69.06 -152.88 0.03 OUTLIER 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 123.394 2.729 . . . . 4.32 109.761 163.632 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -91.45 177.28 40.69 Favored Glycine 0 CA--C 1.535 1.293 0 N-CA-C 111.424 -0.67 . . . . 2.66 111.424 166.684 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -78.26 168.07 22.23 Favored 'Trans proline' 0 N--CA 1.455 -0.772 0 C-N-CA 123.111 2.541 . . . . 3.85 111.858 172.637 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 27.0 tp60 -40.51 121.91 1.52 Allowed 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 128.217 2.607 . . . . 2.8 113.98 160.046 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.74 157.74 51.91 Favored Glycine 0 CA--C 1.527 0.841 0 C-N-CA 124.82 1.2 . . . . 1.53 111.637 163.953 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 51.2 mm -65.56 132.2 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 O-C-N 121.81 -0.818 . . . . 2.89 111.903 -172.458 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.52 145.92 38.77 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 123.77 0.828 . . . . 1.46 111.862 171.731 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -80.44 -173.21 46.19 Favored Glycine 0 C--N 1.338 0.673 0 CA-C-O 122.684 1.158 . . . . 1.02 111.513 -179.959 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 12.5 mp0 -115.95 158.84 22.44 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 108.214 -1.032 . . . . 3.29 108.214 179.367 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 2.8 tmt_? -63.45 134.12 55.1 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 107.611 -1.255 . . . . 6.43 107.611 153.804 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.61 153.66 52.92 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 111.626 -0.589 . . . . 2.79 111.626 -179.249 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . 0.515 HG23 ' H ' ' B' ' 25' ' ' GLY . 15.5 m -67.03 162.66 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 O-C-N 121.429 -1.042 . . . . 4.62 111.95 -176.291 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 16.0 m -90.61 173.93 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 126.889 2.076 . . . . 4.88 110.776 171.552 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.15 -171.87 2.45 Favored Glycine 0 CA--C 1.54 1.632 0 C-N-CA 125.249 1.404 . . . . 3.74 115.132 164.808 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 mm? . . . . . 0 C--O 1.25 1.117 0 C-N-CA 126.69 1.996 . . . . 7.44 112.36 -166.274 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo . . . . . 0 N--CA 1.459 -0.516 0 CA-C-O 121.018 0.341 . . . . 1.92 112.606 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.62 153.47 10.29 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 129.304 3.041 . . . . 3.55 112.464 170.072 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.12 -144.26 3.41 Favored Glycine 0 N--CA 1.475 1.287 0 C-N-CA 126.667 2.079 . . . . 1.67 117.01 -171.8 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 33.2 pt -98.94 139.32 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 O-C-N 121.24 -1.153 . . . . 2.59 108.692 174.848 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.84 146.4 49.77 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-O 121.38 0.609 . . . . 1.78 111.052 179.558 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -45.86 141.64 4.96 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 126.423 1.963 . . . . 1.23 114.017 174.884 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 80.3 mm-40 -63.69 132.82 52.25 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 108.925 -0.768 . . . . 3.3 108.925 -178.54 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.4 tmt_? -64.55 134.31 54.13 Favored 'General case' 0 CA--C 1.536 0.425 0 N-CA-C 112.421 0.526 . . . . 4.83 112.421 -162.481 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.54 160.79 53.7 Favored Glycine 0 N--CA 1.466 0.66 0 CA-C-O 122.823 1.235 . . . . 1.49 115.6 -169.58 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 11.1 t -79.01 145.25 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 126.15 1.78 . . . . 2.24 111.847 -167.272 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.9 m -58.49 147.26 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 C-N-CA 124.965 1.306 . . . . 2.51 113.59 -179.396 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.72 -163.88 34.34 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 124.267 0.937 . . . . 2.01 112.263 167.215 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.1 mt -145.9 160.44 43.62 Favored Pre-proline 0 N--CA 1.474 0.768 0 C-N-CA 128.053 2.541 . . . . 3.14 108.177 174.868 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -77.11 -157.12 0.07 OUTLIER 'Trans proline' 0 CA--C 1.541 0.866 0 C-N-CA 122.187 1.925 . . . . 2.0 109.129 164.677 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.205 0 CA-C-O 117.358 -1.801 . . . . 3.39 112.696 154.383 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo . . . . . 0 N--CA 1.481 0.762 0 CA-C-O 118.479 -0.717 . . . . 2.46 111.391 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.49 166.26 30.73 Favored Glycine 0 CA--C 1.543 1.814 0 CA-C-O 119.006 -0.886 . . . . 1.64 112.885 149.724 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -76.62 41.76 0.95 Allowed 'Trans proline' 0 CA--C 1.546 1.078 1 C-N-CA 127.014 5.143 . . . . 3.7 113.176 -179.123 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 66.27 178.17 0.22 Allowed 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 125.274 1.43 . . . . 4.4 112.053 -165.1 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.64 163.54 31.08 Favored Glycine 0 CA--C 1.541 1.696 0 C-N-CA 124.429 1.014 . . . . 0.95 113.447 159.367 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 67.5 mt -77.77 148.71 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 126.05 1.74 . . . . 2.87 111.718 176.469 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -73.58 147.97 43.39 Favored 'General case' 0 CA--C 1.548 0.877 0 N-CA-C 114.362 1.245 . . . . 1.29 114.362 -177.616 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -78.02 169.89 54.72 Favored Glycine 0 CA--C 1.536 1.378 0 C-N-CA 125.52 1.533 . . . . 1.5 112.476 173.188 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.94 170.35 12.35 Favored 'General case' 0 N--CA 1.467 0.408 0 O-C-N 121.321 -1.105 . . . . 3.26 112.06 -177.35 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -59.42 148.4 32.83 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 124.6 1.16 . . . . 4.97 113.328 -176.243 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.6 -54.96 5.22 Favored Glycine 0 N--CA 1.472 1.045 0 N-CA-C 114.418 0.527 . . . . 4.31 114.418 -173.404 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 11.1 t -146.65 158.91 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 128.478 2.711 . . . . 4.73 107.864 -176.518 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.0 p -121.06 153.58 24.55 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 C-N-CA 127.87 2.468 . . . . 3.32 109.32 178.103 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.02 -168.29 43.73 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-O 121.857 0.698 . . . . 1.74 114.582 177.162 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.9 pp -159.79 150.92 16.07 Favored Pre-proline 0 CA--C 1.543 0.699 0 C-N-CA 125.996 1.718 . . . . 3.16 110.97 -179.265 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo . . . . . 0 C--O 1.254 1.306 1 C-N-CA 125.584 4.189 . . . . 3.09 112.881 167.594 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo . . . . . 0 N--CA 1.485 1.001 0 CA-C-O 118.834 -0.569 . . . . 2.06 111.267 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -71.99 -143.16 0.02 OUTLIER 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 123.943 3.095 . . . . 1.55 109.257 169.091 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.33 146.61 39.45 Favored Glycine 0 CA--C 1.54 1.623 0 CA-C-O 118.713 -1.048 . . . . 1.07 110.506 165.659 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -68.25 -43.04 4.91 Favored 'Trans proline' 0 CA--C 1.534 0.49 0 C-N-CA 123.024 2.483 . . . . 3.28 113.285 178.208 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.427 HE21 ' N ' ' C' ' 16' ' ' GLY . 16.9 tp60 174.2 115.2 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 126.185 1.794 . . . . 1.32 107.948 -166.201 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . 0.427 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -65.83 164.71 38.77 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 123.663 0.649 . . . . 0.92 112.979 169.616 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 35.0 mm -69.59 128.55 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 O-C-N 121.527 -0.984 . . . . 2.25 110.761 -171.498 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.15 149.98 22.48 Favored 'General case' 0 CA--C 1.543 0.691 0 N-CA-C 113.748 1.018 . . . . 1.25 113.748 176.806 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -73.32 138.46 25.28 Favored Glycine 0 CA--C 1.526 0.746 0 C-N-CA 124.11 0.862 . . . . 1.04 111.36 -177.44 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 -75.81 167.73 21.34 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.138 0.975 . . . . 5.45 111.827 175.529 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.18 147.79 19.75 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 125.619 1.568 . . . . 3.78 112.151 171.374 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -56.32 146.82 32.56 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 125.734 1.635 . . . . 1.08 113.328 166.832 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 34.8 m -75.01 137.89 22.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 107.2 -1.408 . . . . 3.38 107.2 162.698 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 34.9 m -92.19 -152.36 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.799 0 C-N-CA 124.034 0.934 . . . . 2.87 110.991 -168.35 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.98 169.53 1.25 Allowed Glycine 0 CA--C 1.542 1.751 0 C-N-CA 124.033 0.825 . . . . 1.81 114.103 162.189 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 12.8 mt . . . . . 0 C--O 1.249 1.028 0 C-N-CA 124.897 1.279 . . . . 3.65 114.024 -163.845 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo . . . . . 0 CA--C 1.535 0.548 0 N-CA-C 111.331 -0.296 . . . . 2.29 111.331 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? -74.81 165.96 24.4 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 126.739 2.016 . . . . 3.75 113.594 175.534 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.11 -157.58 3.36 Favored Glycine 0 N--CA 1.476 1.365 0 C-N-CA 129.493 3.425 . . . . 1.5 116.915 -170.267 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.9 mt -77.96 125.74 37.78 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 O-C-N 120.403 -1.645 . . . . 2.15 107.942 174.736 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.0 128.41 30.33 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 123.117 0.567 . . . . 1.94 111.274 174.713 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.77 150.23 42.85 Favored Glycine 0 CA--C 1.521 0.466 0 C-N-CA 126.455 1.979 . . . . 1.26 112.856 -174.554 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 76.8 mm-40 -74.46 135.15 42.29 Favored 'General case' 0 C--N 1.332 -0.175 0 O-C-N 122.333 -0.51 . . . . 3.7 110.652 -167.268 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 35.2 ttp180 -54.48 130.96 41.51 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 123.539 0.736 . . . . 5.99 110.908 176.33 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.89 -178.03 29.83 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 124.441 1.02 . . . . 2.2 114.189 -171.646 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.412 HG23 ' H ' ' A' ' 23' ' ' VAL . 0.9 OUTLIER -61.11 142.36 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 C-N-CA 123.916 0.886 . . . . 2.76 110.03 174.846 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.7 m -52.22 154.08 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 C-N-CA 124.184 0.994 . . . . 3.03 112.944 173.6 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -83.9 -149.43 9.61 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 123.797 0.713 . . . . 2.43 112.591 166.298 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 82.8 mt -146.73 162.5 33.45 Favored Pre-proline 0 N--CA 1.475 0.789 0 C-N-CA 127.015 2.126 . . . . 3.46 109.687 170.581 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -83.06 -152.92 0.04 OUTLIER 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 123.298 2.665 . . . . 2.17 108.515 154.228 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.207 0 CA-C-O 117.61 -1.661 . . . . 3.83 113.103 156.191 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_exo . . . . . 0 N--CA 1.479 0.676 0 CA-C-O 118.196 -0.835 . . . . 2.24 111.392 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.48 158.21 27.81 Favored Glycine 0 CA--C 1.546 2.01 0 CA-C-N 119.178 0.899 . . . . 1.99 112.816 154.342 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -76.13 47.5 2.03 Favored 'Trans proline' 0 CA--C 1.545 1.071 1 C-N-CA 127.374 5.383 . . . . 3.99 113.419 -175.958 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.4 tp-100 69.88 -169.65 0.17 Allowed 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 124.819 1.248 . . . . 4.22 109.871 -161.33 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -106.93 154.88 16.58 Favored Glycine 0 CA--C 1.533 1.201 0 C-N-CA 126.192 1.853 . . . . 1.15 110.576 158.558 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 18.3 tt -63.58 144.81 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 C-N-CA 124.228 1.011 . . . . 4.05 112.521 177.393 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -75.0 148.36 39.98 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 113.624 0.972 . . . . 1.61 113.624 178.91 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.63 148.39 43.42 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 125.635 1.588 . . . . 1.74 113.8 -177.747 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 19.5 tt0 -80.25 148.34 30.83 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.222 1.009 . . . . 3.88 112.418 -177.86 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.5 mtm180 -63.87 130.75 45.4 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 124.747 1.219 . . . . 4.61 111.829 178.125 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.48 2.72 45.18 Favored Glycine 0 N--CA 1.476 1.34 0 N-CA-C 119.6 2.6 . . . . 4.68 119.6 -155.365 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . 0.278 0.9 OUTLIER 173.3 156.92 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 130.302 3.441 . . . . 4.96 108.741 179.214 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 42.1 t -132.54 141.51 44.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 C-N-CA 126.245 1.818 . . . . 4.46 107.911 178.052 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -88.05 -177.69 47.58 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-O 122.496 1.053 . . . . 2.53 114.779 -170.3 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.1 pt? -161.19 156.96 21.55 Favored Pre-proline 0 CA--C 1.542 0.651 0 C-N-CA 126.419 1.888 . . . . 3.98 110.243 -177.734 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo . . . . . 0 C--O 1.255 1.374 0 C-N-CA 124.129 3.219 . . . . 3.32 111.229 164.112 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo . . . . . 0 N--CA 1.487 1.097 0 CA-C-O 119.019 -0.492 . . . . 2.55 111.555 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -70.0 -148.83 0.02 OUTLIER 'Trans proline' 0 CA--C 1.541 0.857 0 C-N-CA 123.616 2.878 . . . . 1.98 109.553 165.768 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -81.95 176.45 53.96 Favored Glycine 0 CA--C 1.537 1.454 0 O-C-N 121.279 -0.888 . . . . 1.13 111.542 168.88 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -79.24 -177.58 4.0 Favored 'Trans proline' 0 N--CA 1.452 -0.952 0 C-N-CA 123.095 2.53 . . . . 2.37 109.792 162.125 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.7 tp60 -41.55 119.29 1.22 Allowed 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 125.981 1.712 . . . . 1.8 113.875 159.363 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.32 161.88 41.22 Favored Glycine 0 CA--C 1.528 0.855 0 C-N-CA 125.772 1.654 . . . . 1.13 112.531 167.518 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 33.4 mm -68.77 142.39 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 O-C-N 121.576 -0.955 . . . . 3.72 110.511 -172.714 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.81 154.63 40.36 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.31 0.856 . . . . 1.42 113.31 177.1 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.59 157.52 53.25 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 124.274 0.94 . . . . 1.15 113.131 -179.095 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 14.4 mp0 -82.31 173.98 11.57 Favored 'General case' 0 CA--C 1.541 0.615 0 O-C-N 121.869 -0.783 . . . . 3.0 111.26 179.024 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.3 135.31 57.13 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 123.287 0.635 . . . . 3.69 110.426 169.15 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -65.35 167.3 32.52 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.93 1.253 . . . . 1.34 113.972 -176.675 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 87.2 t -75.52 148.4 7.49 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 C-N-CA 123.876 0.871 . . . . 2.06 109.458 -176.865 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 98.7 t -97.28 174.69 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.991 0 C-N-CA 127.297 2.239 . . . . 2.83 109.613 -174.891 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -56.3 173.17 1.67 Allowed Glycine 0 CA--C 1.538 1.504 0 C-N-CA 124.974 1.273 . . . . 2.01 114.723 165.25 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 8.8 mt . . . . . 0 C--O 1.25 1.097 0 N-CA-C 113.821 1.045 . . . . 4.43 113.821 -158.143 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo . . . . . 0 CA--C 1.532 0.404 0 N-CA-C 111.491 -0.234 . . . . 1.92 111.491 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.84 177.76 0.71 Allowed 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 127.73 2.412 . . . . 3.73 114.656 -178.227 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.16 173.09 44.25 Favored Glycine 0 CA--C 1.526 0.728 0 C-N-CA 125.904 1.716 . . . . 1.26 113.793 177.323 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.546 ' H ' HD12 ' A' ' 17' ' ' ILE . 3.2 mp -67.42 135.24 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.51 0 N-CA-C 109.292 -0.633 . . . . 2.37 109.292 -173.189 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -53.95 133.0 43.16 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 118.427 0.558 . . . . 1.79 110.482 170.613 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.12 168.68 24.27 Favored Glycine 0 CA--C 1.521 0.417 0 C-N-CA 126.115 1.816 . . . . 1.31 114.778 -167.995 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 85.6 mm-40 -71.46 96.28 1.48 Allowed 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 108.598 -0.89 . . . . 3.19 108.598 179.793 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.2 ttp-105 -62.29 138.63 58.46 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 124.836 1.254 . . . . 4.96 113.23 -165.155 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.7 149.97 39.04 Favored Glycine 0 C--N 1.332 0.355 0 CA-C-O 122.421 1.012 . . . . 2.26 113.704 -171.211 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 32.7 m -76.64 163.11 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 CA-C-N 113.676 -1.262 . . . . 2.74 111.173 -174.624 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.0 m -60.75 167.69 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 124.257 1.023 . . . . 3.54 112.395 177.355 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.72 146.97 39.4 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 110.407 -1.077 . . . . 2.1 110.407 157.957 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 8.5 mp -101.62 169.57 7.53 Favored Pre-proline 0 CA--C 1.538 0.516 0 C-N-CA 124.041 0.936 . . . . 3.64 111.95 -170.833 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -69.11 115.11 3.84 Favored 'Trans proline' 0 N--CA 1.445 -1.337 0 N-CA-C 106.989 -1.966 . . . . 2.98 106.989 151.775 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.147 0 CA-C-O 118.584 -1.12 . . . . 6.8 114.773 -157.294 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo . . . . . 0 CA--C 1.544 0.995 0 N-CA-C 111.313 -0.303 . . . . 2.1 111.313 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.44 167.7 13.23 Favored Glycine 0 CA--C 1.541 1.717 0 C-N-CA 120.13 -1.033 . . . . 1.3 112.902 127.473 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -76.69 -64.4 0.03 OUTLIER 'Trans proline' 0 CA--C 1.538 0.702 0 C-N-CA 124.974 3.782 . . . . 2.85 112.694 175.678 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 8.3 tp-100 -166.6 157.4 12.39 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 127.943 2.497 . . . . 3.25 107.639 -164.711 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.36 159.23 25.02 Favored Glycine 0 CA--C 1.527 0.783 0 C-N-CA 124.324 0.964 . . . . 0.97 113.469 175.549 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . 0.53 ' H ' HD12 ' B' ' 17' ' ' ILE . 3.8 mp -70.28 127.89 32.82 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 N-CA-C 108.855 -0.795 . . . . 3.49 108.855 176.851 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.62 146.76 38.01 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 118.973 0.806 . . . . 1.27 112.416 178.873 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -78.63 141.27 24.4 Favored Glycine 0 CA--C 1.527 0.8 0 C-N-CA 124.643 1.116 . . . . 1.53 111.668 179.268 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.65 164.77 12.82 Favored 'General case' 0 N--CA 1.468 0.463 0 O-C-N 121.43 -1.041 . . . . 4.14 111.132 166.75 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -82.3 167.12 18.91 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.285 1.034 . . . . 5.24 112.022 167.138 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.71 -174.02 45.65 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 124.609 1.1 . . . . 2.68 112.619 164.945 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 11.0 m -100.9 160.05 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 C-N-CA 125.039 1.336 . . . . 5.2 114.568 -166.243 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.7 p -42.37 150.38 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 C-N-CA 129.016 2.926 . . . . 4.1 115.221 -178.117 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.44 -114.93 1.93 Allowed Glycine 0 CA--C 1.528 0.85 0 CA-C-O 119.154 -0.803 . . . . 2.24 111.343 167.334 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -172.43 177.23 0.83 Allowed Pre-proline 0 CA--C 1.556 1.204 0 C-N-CA 126.977 2.111 . . . . 3.81 110.55 -164.572 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_endo . . . . . 0 C--O 1.255 1.36 0 C-N-CA 123.926 3.084 . . . . 5.26 112.725 174.571 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo . . . . . 0 CA--C 1.546 1.101 0 CA-C-O 118.532 -0.695 . . . . 1.89 111.426 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -61.72 -154.05 0.02 OUTLIER 'Trans proline' 0 CA--C 1.545 1.054 0 C-N-CA 124.934 3.756 . . . . 1.72 111.679 164.682 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -84.21 -177.9 51.45 Favored Glycine 0 CA--C 1.543 1.805 0 O-C-N 121.068 -1.02 . . . . 0.96 113.157 173.53 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -79.54 169.49 18.44 Favored 'Trans proline' 0 CA--C 1.535 0.535 0 C-N-CA 124.219 3.279 . . . . 2.3 111.304 173.865 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 -48.04 116.92 1.68 Allowed 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 124.209 1.004 . . . . 1.47 111.288 160.717 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.58 163.22 36.39 Favored Glycine 0 CA--C 1.529 0.94 0 C-N-CA 124.852 1.215 . . . . 0.87 112.577 172.171 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 3.1 mp -65.96 145.27 14.02 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.667 0 C-N-CA 123.852 0.861 . . . . 2.67 110.673 -168.628 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -68.8 163.72 23.51 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.517 0.932 . . . . 1.2 113.517 179.084 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.11 149.46 17.96 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 109.946 -1.262 . . . . 1.01 109.946 168.6 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 7.2 mm100 -93.39 -167.86 1.8 Allowed 'General case' 0 CA--C 1.541 0.621 0 O-C-N 121.978 -0.719 . . . . 4.77 110.831 -178.07 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 2.6 ttt180 -63.33 154.44 31.76 Favored 'General case' 0 N--CA 1.467 0.41 0 O-C-N 121.272 -0.893 . . . . 3.8 110.898 168.524 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.24 -171.44 45.1 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 123.726 0.679 . . . . 1.04 111.653 165.355 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.0 t -70.3 136.8 25.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 C-N-CA 124.266 1.026 . . . . 1.79 111.855 -170.623 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -44.94 124.58 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 C-N-CA 126.599 1.959 . . . . 3.78 112.671 161.264 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.34 127.45 8.88 Favored Glycine 0 CA--C 1.525 0.698 0 C-N-CA 123.342 0.496 . . . . 3.63 112.823 179.613 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 16.9 mt . . . . . 0 C--O 1.254 1.313 0 CA-C-O 117.107 -1.425 . . . . 7.05 109.623 146.124 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo . . . . . 0 CA--C 1.536 0.614 0 CA-C-O 120.842 0.268 . . . . 2.74 111.96 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -58.46 153.4 15.97 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 128.863 2.865 . . . . 3.06 112.972 173.282 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.46 -135.01 5.01 Favored Glycine 0 N--CA 1.476 1.306 0 C-N-CA 125.996 1.76 . . . . 1.94 115.981 -171.703 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 24.0 pt -102.46 143.35 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 O-C-N 121.751 -0.852 . . . . 2.85 110.863 -178.417 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.34 143.57 28.05 Favored 'General case' 0 CA--C 1.538 0.509 0 CA-C-O 121.845 0.831 . . . . 1.77 112.007 178.612 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.46 152.21 16.39 Favored Glycine 0 CA--C 1.52 0.379 0 C-N-CA 127.637 2.541 . . . . 1.5 115.529 178.367 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 84.8 mm-40 -66.19 152.87 43.91 Favored 'General case' 0 CA--C 1.531 0.236 0 CA-C-N 113.957 -1.121 . . . . 3.21 111.172 -176.424 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -63.95 141.95 58.58 Favored 'General case' 0 N--CA 1.466 0.348 0 O-C-N 122.04 -0.413 . . . . 3.83 111.659 -179.538 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.6 164.27 45.05 Favored Glycine 0 CA--C 1.523 0.591 0 CA-C-N 115.621 -0.718 . . . . 1.53 113.096 176.609 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 2.1 t -64.55 150.07 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 124.565 1.146 . . . . 2.76 112.277 -167.69 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.8 t -53.81 132.51 16.58 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.686 0 C-N-CA 125.497 1.519 . . . . 3.83 111.587 167.88 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -85.42 155.93 30.07 Favored Glycine 0 CA--C 1.528 0.863 0 C-N-CA 124.847 1.213 . . . . 1.42 111.255 165.971 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 94.4 mt -118.16 156.52 50.44 Favored Pre-proline 0 N--CA 1.468 0.456 0 CA-C-O 117.537 -1.22 . . . . 2.86 109.937 -177.12 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -71.22 -158.47 0.06 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.875 0 C-N-CA 121.567 1.512 . . . . 1.86 109.304 161.849 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.307 0 CA-C-O 117.455 -1.747 . . . . 3.14 112.936 154.918 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo . . . . . 0 CA--C 1.544 0.992 0 N-CA-C 111.302 -0.307 . . . . 3.06 111.302 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.55 -173.02 3.19 Favored Glycine 0 CA--C 1.541 1.66 0 C-N-CA 120.097 -1.049 . . . . 1.56 113.339 123.922 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -77.9 -128.97 0.01 OUTLIER 'Trans proline' 0 CA--C 1.546 1.083 0 C-N-CA 124.864 3.709 . . . . 2.47 108.233 161.533 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -87.01 -171.01 3.31 Favored 'General case' 0 CA--C 1.552 1.038 0 C-N-CA 125.844 1.657 . . . . 4.25 111.304 171.378 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.32 166.87 33.63 Favored Glycine 0 CA--C 1.541 1.692 0 O-C-N 121.204 -0.935 . . . . 1.08 111.875 149.412 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 46.8 mm -67.95 143.39 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.02 -1.282 . . . . 3.67 110.212 168.241 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.72 157.89 34.49 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 114.791 1.404 . . . . 1.39 114.791 -173.11 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -78.27 161.2 48.56 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 125.908 1.718 . . . . 1.78 113.561 -175.51 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.41 156.37 18.6 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 121.651 -0.911 . . . . 3.27 111.133 175.431 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.9 155.26 16.84 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 112.208 0.447 . . . . 8.19 112.208 178.177 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.38 -125.45 0.6 Allowed Glycine 0 CA--C 1.529 0.917 0 C-N-CA 123.995 0.807 . . . . 2.65 111.174 172.008 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 82.2 t -64.06 158.34 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 C-N-CA 124.738 1.215 . . . . 4.93 110.715 179.312 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 6.2 m -129.57 157.47 42.26 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 C-N-CA 126.429 1.891 . . . . 2.99 109.362 174.005 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.478 ' H ' HG23 ' C' ' 23' ' ' VAL . . . -87.72 176.74 46.32 Favored Glycine 0 C--N 1.336 0.545 0 C-N-CA 125.395 1.474 . . . . 1.89 115.305 -170.147 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -165.67 157.98 12.85 Favored Pre-proline 0 CA--C 1.549 0.928 0 C-N-CA 125.437 1.495 . . . . 3.22 113.262 -168.805 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_endo . . . . . 0 C--O 1.255 1.343 0 C-N-CA 123.748 2.965 . . . . 2.72 111.786 159.837 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo . . . . . 0 N--CA 1.487 1.119 0 CA-C-O 118.882 -0.549 . . . . 2.47 111.694 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -69.44 -139.37 0.01 OUTLIER 'Trans proline' 0 CA--C 1.542 0.923 0 C-N-CA 123.617 2.878 . . . . 1.54 108.713 163.385 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.1 163.73 53.91 Favored Glycine 0 CA--C 1.54 1.629 0 O-C-N 120.924 -1.11 . . . . 1.26 111.492 165.283 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -79.46 -43.06 0.15 Allowed 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 122.697 2.265 . . . . 3.67 112.511 -178.926 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.452 HE21 ' N ' ' C' ' 16' ' ' GLY . 17.3 tp60 167.84 133.09 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.81 2.444 . . . . 1.6 105.913 -154.445 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . 0.452 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -75.41 158.96 51.05 Favored Glycine 0 CA--C 1.534 1.225 0 C-N-CA 124.358 0.98 . . . . 1.19 113.654 167.649 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 73.3 mt -62.7 147.28 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 O-C-N 121.495 -1.003 . . . . 2.2 110.394 175.509 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.36 163.91 17.21 Favored 'General case' 0 CA--C 1.545 0.778 0 N-CA-C 114.014 1.116 . . . . 1.8 114.014 -177.148 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.86 154.17 46.46 Favored Glycine 0 CA--C 1.529 0.924 0 CA-C-N 115.443 -0.799 . . . . 1.62 111.66 170.562 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -84.76 168.72 14.92 Favored 'General case' 0 CA--C 1.539 0.54 0 CA-C-O 121.66 0.743 . . . . 3.38 111.909 -174.266 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 1.1 tmt_? -60.79 136.51 58.09 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 123.596 0.758 . . . . 3.15 110.861 -179.492 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.07 138.21 29.26 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.793 -0.923 . . . . 1.12 110.793 175.002 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . 0.478 HG23 ' H ' ' B' ' 25' ' ' GLY . 18.9 m -61.04 154.62 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 117.931 0.866 . . . . 2.76 111.696 -176.652 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 10.5 p -85.03 177.34 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 C-N-CA 126.876 2.071 . . . . 2.87 110.082 172.908 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.43 -164.72 0.61 Allowed Glycine 0 CA--C 1.54 1.646 0 C-N-CA 125.21 1.385 . . . . 1.58 115.875 169.851 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 16.5 mt . . . . . 0 N--CA 1.481 1.082 0 C-N-CA 125.507 1.523 . . . . 3.27 114.481 -162.439 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo . . . . . 0 N--CA 1.46 -0.458 0 N-CA-C 111.554 -0.21 . . . . 2.55 111.554 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.37 154.29 28.57 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.226 2.21 . . . . 3.17 113.517 178.955 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.08 -116.54 0.04 OUTLIER Glycine 0 CA--C 1.534 1.224 0 C-N-CA 126.937 2.208 . . . . 2.54 115.369 179.481 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.9 mt -134.79 132.95 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 O-C-N 121.211 -1.17 . . . . 1.92 109.739 -174.239 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.11 133.84 55.94 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.644 0.778 . . . . 1.76 112.324 176.44 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.99 163.12 41.73 Favored Glycine 0 CA--C 1.527 0.829 0 C-N-CA 126.885 2.183 . . . . 1.35 113.827 -175.15 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 8.6 mp0 -67.31 130.21 42.35 Favored 'General case' 0 N--CA 1.468 0.438 0 O-C-N 122.527 -0.396 . . . . 4.94 110.851 -164.056 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 42.4 ttt180 -63.09 126.59 27.87 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 118.363 0.529 . . . . 4.24 110.16 179.662 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.74 142.38 36.56 Favored Glycine 0 C--N 1.336 0.575 0 N-CA-C 114.634 0.613 . . . . 1.7 114.634 -160.204 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 35.9 m -64.4 122.93 16.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-N 114.792 -0.704 . . . . 2.53 109.484 -177.199 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 9.8 p -39.16 149.46 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 127.167 2.187 . . . . 2.86 113.566 -176.934 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.92 -155.28 0.61 Allowed Glycine 0 CA--C 1.531 1.054 0 O-C-N 121.405 -0.809 . . . . 1.9 114.296 172.343 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.9 mt -136.66 161.57 61.08 Favored Pre-proline 0 CA--C 1.541 0.6 0 C-N-CA 125.521 1.528 . . . . 2.9 110.751 176.377 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -84.14 -151.65 0.04 OUTLIER 'Trans proline' 0 CA--C 1.539 0.74 0 C-N-CA 123.89 3.06 . . . . 1.82 108.232 159.697 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.153 0 CA-C-O 117.211 -1.883 . . . . 3.16 112.438 141.901 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_exo . . . . . 0 CA--C 1.542 0.907 0 N-CA-C 111.716 -0.148 . . . . 2.53 111.716 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.38 177.19 25.9 Favored Glycine 0 CA--C 1.538 1.492 0 C-N-CA 120.074 -1.06 . . . . 1.28 112.989 128.045 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -82.2 155.93 17.08 Favored 'Trans proline' 0 CA--C 1.539 0.729 1 C-N-CA 125.418 4.079 . . . . 2.7 111.009 159.403 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -59.6 139.86 56.83 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 125.143 1.377 . . . . 3.95 110.757 169.746 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.29 161.94 47.44 Favored Glycine 0 C--N 1.338 0.646 0 C-N-CA 124.052 0.834 . . . . 1.12 114.932 -173.663 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 42.3 pt -57.78 145.71 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 C-N-CA 122.885 0.474 . . . . 3.9 111.892 179.707 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.19 149.31 48.73 Favored 'General case' 0 CA--C 1.543 0.675 0 O-C-N 121.525 -0.735 . . . . 1.42 112.322 175.803 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.61 152.15 51.35 Favored Glycine 0 CA--C 1.53 1.001 0 N-CA-C 110.318 -1.113 . . . . 1.56 110.318 166.942 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.91 151.56 22.25 Favored 'General case' 0 N--CA 1.468 0.456 0 O-C-N 121.356 -1.085 . . . . 3.25 110.449 176.015 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 31.4 ptt180 -61.81 159.57 13.52 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.072 0.949 . . . . 5.68 113.368 -179.566 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.68 160.84 53.82 Favored Glycine 0 CA--C 1.532 1.122 0 C-N-CA 124.825 1.202 . . . . 2.1 114.816 -178.418 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 43.9 t -89.47 131.59 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 124.598 1.159 . . . . 2.88 113.673 -168.424 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 11.5 m -79.46 160.65 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 C-N-CA 126.143 1.777 . . . . 2.6 113.301 -168.381 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.12 -128.31 6.18 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 125.036 1.303 . . . . 1.69 112.812 176.926 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -170.9 156.89 5.0 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 125.359 1.464 . . . . 3.11 112.076 -163.837 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo . . . . . 0 C--O 1.254 1.295 0 C-N-CA 124.571 3.514 . . . . 2.57 112.28 155.584 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo . . . . . 0 CA--C 1.547 1.167 0 CA-C-O 118.964 -0.515 . . . . 2.49 111.517 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -65.91 -157.74 0.03 OUTLIER 'Trans proline' 0 CA--C 1.544 0.975 0 C-N-CA 123.192 2.595 . . . . 1.93 109.967 161.669 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -93.16 -176.73 40.66 Favored Glycine 0 CA--C 1.534 1.26 0 O-C-N 121.171 -0.956 . . . . 1.22 111.859 170.721 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -79.37 170.67 17.09 Favored 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 123.277 2.652 . . . . 2.53 112.295 173.65 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.442 ' HA ' HE21 ' C' ' 15' ' ' GLN . 0.0 OUTLIER -38.03 135.98 0.64 Allowed 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 127.917 2.487 . . . . 1.96 114.333 154.736 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.81 173.18 54.66 Favored Glycine 0 CA--C 1.529 0.944 0 C-N-CA 126.193 1.854 . . . . 1.01 114.996 174.077 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 96.4 mt -67.57 144.1 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.601 1.161 . . . . 2.74 112.415 -171.133 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.98 132.08 46.18 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.593 1.157 . . . . 1.75 112.967 174.707 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -62.21 122.84 29.6 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 108.293 -1.923 . . . . 1.43 108.293 157.323 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -82.19 160.54 23.02 Favored 'General case' 0 C--N 1.327 -0.407 0 O-C-N 121.736 -0.861 . . . . 3.48 110.9 -173.723 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 9.0 tpp180 -48.31 136.04 12.86 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 124.552 1.141 . . . . 5.17 111.612 173.647 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.1 157.56 52.98 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 115.098 -0.955 . . . . 1.15 112.091 176.119 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.2 t -65.17 155.39 6.66 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 C-N-CA 124.882 1.273 . . . . 2.25 110.58 176.215 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 30.4 m -68.84 -171.18 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.547 0.864 0 C-N-CA 126.392 1.877 . . . . 2.33 112.054 171.42 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.33 -108.24 0.01 OUTLIER Glycine 0 CA--C 1.534 1.273 0 C-N-CA 124.748 1.166 . . . . 2.37 111.884 163.3 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 55.8 mt . . . . . 0 C--O 1.249 1.069 0 CA-C-O 117.647 -1.168 . . . . 4.16 111.563 166.448 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.61 0 CA-C-O 116.417 -2.324 . . . . 3.0 109.524 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -72.05 168.38 24.16 Favored 'Trans proline' 0 N--CA 1.457 -0.644 0 C-N-CA 122.791 2.328 . . . . 2.37 111.236 179.439 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -92.49 175.26 6.9 Favored 'General case' 0 CA--C 1.546 0.825 0 C-N-CA 127.892 2.477 . . . . 2.81 113.084 -177.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.94 173.48 52.43 Favored Glycine 0 N--CA 1.479 1.542 0 N-CA-C 116.595 1.398 . . . . 1.66 116.595 -168.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 36.2 pt -71.51 145.09 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 O-C-N 120.905 -1.35 . . . . 3.03 110.256 -177.079 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.94 139.9 58.36 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-O 121.441 0.638 . . . . 1.78 112.207 -176.33 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -52.51 161.14 2.53 Favored Glycine 0 CA--C 1.526 0.744 0 C-N-CA 127.202 2.334 . . . . 1.31 115.682 178.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 22.1 mp0 -68.17 148.9 50.23 Favored 'General case' 0 CA--C 1.535 0.393 0 CA-C-N 113.708 -1.246 . . . . 4.11 110.042 -174.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.86 130.41 45.57 Favored 'General case' 0 CA--C 1.532 0.258 0 O-C-N 121.774 -0.579 . . . . 6.82 110.277 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.04 150.38 50.26 Favored Glycine 0 CA--C 1.526 0.723 0 C-N-CA 124.073 0.844 . . . . 1.47 111.841 175.021 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 32.9 m -64.04 145.11 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 123.968 0.907 . . . . 2.24 111.514 -179.648 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 19.1 m -52.83 149.74 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 124.177 0.991 . . . . 2.16 113.359 -177.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.15 158.64 53.02 Favored Glycine 0 CA--C 1.528 0.898 0 CA-C-N 115.985 -0.552 . . . . 1.56 112.091 168.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 9.0 mp -89.2 158.04 47.08 Favored Pre-proline 0 CA--C 1.544 0.72 0 C-N-CA 123.221 0.608 . . . . 4.9 110.813 -176.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 26.7 Cg_endo -78.19 -166.04 0.37 Allowed 'Trans proline' 0 CA--C 1.537 0.633 0 C-N-CA 123.596 2.864 . . . . 2.52 109.446 160.267 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.153 0 CA-C-O 117.35 -1.806 . . . . 3.58 111.952 150.297 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_exo . . . . . 0 N--CA 1.481 0.759 0 CA-C-O 118.484 -0.715 . . . . 2.2 111.482 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.02 159.62 51.09 Favored Glycine 0 CA--C 1.539 1.588 0 N-CA-C 110.886 -0.886 . . . . 1.29 110.886 150.245 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -72.09 177.45 7.14 Favored 'Trans proline' 0 CA--C 1.539 0.76 0 C-N-CA 123.244 2.63 . . . . 2.18 108.859 156.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 11.5 tt0 -60.19 172.63 0.78 Allowed 'General case' 0 CA--C 1.544 0.731 0 N-CA-C 114.935 1.457 . . . . 4.66 114.935 -175.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.17 159.48 51.77 Favored Glycine 0 CA--C 1.527 0.811 0 O-C-N 120.995 -1.066 . . . . 1.0 113.563 176.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 29.9 mm -60.25 141.48 16.78 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 C-N-CA 123.669 0.788 . . . . 3.24 109.578 168.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.42 151.63 31.97 Favored 'General case' 0 CA--C 1.542 0.66 0 CA-C-O 122.756 1.265 . . . . 1.35 113.773 -179.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.19 137.67 38.25 Favored Glycine 0 CA--C 1.523 0.531 0 C-N-CA 125.25 1.405 . . . . 1.55 112.42 -179.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 94.9 mm-40 -81.92 124.84 30.08 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 114.577 -0.811 . . . . 3.96 109.167 -175.039 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 10.9 ptt180 -55.15 153.64 6.55 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 126.215 1.806 . . . . 6.64 114.064 -179.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.92 173.65 54.69 Favored Glycine 0 CA--C 1.529 0.922 0 C-N-CA 124.133 0.873 . . . . 1.73 113.355 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 59.5 t -93.43 131.64 39.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 124.503 1.121 . . . . 2.98 112.83 -165.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 19.0 m -60.39 159.99 1.76 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 C-N-CA 127.61 2.364 . . . . 2.5 114.414 -173.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.81 -136.7 5.25 Favored Glycine 0 CA--C 1.529 0.908 0 C-N-CA 124.191 0.9 . . . . 2.15 112.09 168.462 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -170.71 160.81 5.88 Favored Pre-proline 0 CA--C 1.543 0.705 0 C-N-CA 124.766 1.226 . . . . 3.48 111.534 -161.359 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo . . . . . 0 C--O 1.256 1.42 0 C-N-CA 124.586 3.524 . . . . 2.84 112.249 161.422 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo . . . . . 0 N--CA 1.486 1.076 0 CA-C-O 118.989 -0.505 . . . . 2.2 111.251 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 63.8 Cg_endo -73.18 -130.07 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.939 0 C-N-CA 123.198 2.599 . . . . 2.01 107.778 162.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -82.29 168.23 48.14 Favored Glycine 0 CA--C 1.536 1.391 0 CA-C-N 119.509 1.049 . . . . 1.35 111.496 164.294 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.99 -44.83 0.31 Allowed 'Trans proline' 0 N--CA 1.458 -0.562 0 C-N-CA 122.578 2.185 . . . . 3.95 112.329 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.423 HE21 ' N ' ' C' ' 16' ' ' GLY . 30.5 tp60 166.83 137.44 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.448 0 C-N-CA 127.926 2.49 . . . . 1.65 105.526 -153.169 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . 0.423 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -83.36 160.04 37.67 Favored Glycine 0 N--CA 1.468 0.823 0 C-N-CA 125.958 1.742 . . . . 1.07 112.927 169.228 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 46.7 mt -61.69 143.73 14.76 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 124.055 0.942 . . . . 2.2 111.022 -179.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.88 148.14 21.72 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.313 1.045 . . . . 1.24 113.559 174.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.87 149.42 34.61 Favored Glycine 0 C--N 1.339 0.712 0 C-N-CA 123.778 0.704 . . . . 0.97 111.375 -178.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 13.5 mp0 -90.85 -177.84 5.07 Favored 'General case' 0 CA--C 1.539 0.536 0 O-C-N 122.156 -0.614 . . . . 3.33 109.956 177.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 9.6 ptp180 -67.22 164.48 18.15 Favored 'General case' 0 CA--C 1.539 0.533 0 CA-C-O 122.301 1.048 . . . . 5.6 113.592 -174.2 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.9 165.62 49.5 Favored Glycine 0 CA--C 1.531 1.031 0 C-N-CA 124.77 1.176 . . . . 1.17 111.862 166.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.7 t -64.08 144.99 14.14 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.282 1.033 . . . . 1.9 110.782 177.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 29.6 m -79.83 -171.67 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.833 0 C-N-CA 125.081 1.353 . . . . 2.98 111.622 -179.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.13 179.42 7.05 Favored Glycine 0 CA--C 1.533 1.174 0 C-N-CA 124.842 1.211 . . . . 2.21 114.775 174.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 7.5 mt . . . . . 0 C--O 1.249 1.057 0 N-CA-C 114.527 1.306 . . . . 4.09 114.527 -169.77 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.555 0 CA-C-O 115.845 -2.642 . . . . 3.17 108.493 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -76.82 169.53 21.54 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 123.133 2.555 . . . . 2.21 111.225 177.276 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -76.32 -166.96 0.69 Allowed 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 127.017 2.127 . . . . 2.97 112.681 167.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.19 174.48 49.59 Favored Glycine 0 N--CA 1.472 1.088 0 O-C-N 121.308 -0.87 . . . . 1.5 114.737 -178.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 33.2 pt -73.15 150.38 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 O-C-N 122.329 -0.512 . . . . 3.12 109.693 178.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -49.1 131.98 19.26 Favored 'General case' 0 CA--C 1.538 0.499 0 CA-C-O 121.775 0.798 . . . . 1.9 112.421 177.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -51.55 148.36 9.49 Favored Glycine 0 CA--C 1.519 0.344 0 C-N-CA 127.305 2.383 . . . . 1.25 112.856 166.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 78.7 mm-40 -80.64 132.61 35.62 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.081 -0.559 . . . . 3.69 109.534 -166.354 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 60.6 ttp180 -52.88 127.94 25.29 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 125.76 1.624 . . . . 7.94 113.292 -173.273 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.21 159.83 53.61 Favored Glycine 0 N--CA 1.468 0.78 0 N-CA-C 116.012 1.165 . . . . 1.72 116.012 -170.521 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 27.8 m -72.39 143.13 14.36 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 C-N-CA 124.357 1.063 . . . . 2.57 111.365 176.114 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 31.0 m -50.58 156.48 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.182 0 C-N-CA 126.803 2.041 . . . . 2.59 116.116 -168.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -81.27 -173.54 47.94 Favored Glycine 0 CA--C 1.533 1.187 0 C-N-CA 123.804 0.716 . . . . 1.81 113.028 162.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 7.2 mp -120.88 163.09 31.56 Favored Pre-proline 0 CA--C 1.542 0.656 0 C-N-CA 125.745 1.618 . . . . 4.18 111.427 178.707 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -83.17 -138.11 0.02 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.691 0 C-N-CA 123.738 2.959 . . . . 2.38 107.708 156.285 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.329 0 CA-C-O 116.907 -2.052 . . . . 3.41 113.292 142.836 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo . . . . . 0 N--CA 1.489 1.259 0 N-CA-C 109.306 -1.075 . . . . 2.44 109.306 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.13 147.46 37.87 Favored Glycine 0 CA--C 1.538 1.52 0 CA-C-O 118.546 -1.141 . . . . 1.41 110.718 162.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -72.29 179.89 4.61 Favored 'Trans proline' 0 CA--C 1.54 0.797 0 C-N-CA 123.871 3.047 . . . . 2.15 109.9 163.059 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 12.1 tt0 -53.71 162.82 0.79 Allowed 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 125.087 1.355 . . . . 4.42 114.437 178.511 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.25 161.23 51.7 Favored Glycine 0 N--CA 1.47 0.965 0 O-C-N 121.289 -0.882 . . . . 1.11 112.989 -178.415 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.6 pp -65.58 150.13 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.889 0 O-C-N 121.944 -0.739 . . . . 4.39 111.117 171.628 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.47 147.15 49.75 Favored 'General case' 0 CA--C 1.541 0.602 0 N-CA-C 114.431 1.271 . . . . 1.71 114.431 -175.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.58 158.45 53.19 Favored Glycine 0 CA--C 1.527 0.839 0 C-N-CA 124.821 1.2 . . . . 1.77 111.492 170.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 21.2 mp0 -69.1 150.52 47.49 Favored 'General case' 0 CA--C 1.536 0.418 0 O-C-N 121.979 -0.718 . . . . 3.69 111.408 -173.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 17.0 mtt180 -67.55 148.74 51.05 Favored 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 109.693 -0.484 . . . . 6.03 109.693 160.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.3 165.53 43.04 Favored Glycine 0 CA--C 1.533 1.165 0 N-CA-C 115.052 0.781 . . . . 1.95 115.052 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 23.3 m -78.97 130.18 36.52 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 N-CA-C 114.432 1.271 . . . . 3.64 114.432 -168.383 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.7 m -85.23 154.96 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 C-N-CA 126.119 1.767 . . . . 2.52 112.113 -170.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.57 -134.4 8.46 Favored Glycine 0 CA--C 1.53 0.994 0 C-N-CA 124.442 1.02 . . . . 1.64 113.273 179.321 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -166.31 161.04 12.43 Favored Pre-proline 0 CA--C 1.547 0.831 0 C-N-CA 125.498 1.519 . . . . 3.25 112.326 -165.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo . . . . . 0 C--O 1.254 1.323 0 C-N-CA 124.821 3.681 . . . . 2.66 112.249 152.161 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 60.5 Cg_endo . . . . . 0 N--CA 1.487 1.097 0 CA-C-O 119.017 -0.493 . . . . 2.2 111.099 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -71.78 -138.87 0.02 OUTLIER 'Trans proline' 0 CA--C 1.546 1.1 0 C-N-CA 123.465 2.776 . . . . 1.76 107.988 157.704 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.87 168.48 37.59 Favored Glycine 0 CA--C 1.54 1.598 0 CA-C-N 119.383 0.992 . . . . 1.12 112.23 166.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -79.28 -43.65 0.14 Allowed 'Trans proline' 0 CA--C 1.535 0.555 0 C-N-CA 123.021 2.481 . . . . 3.65 113.662 -176.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.491 HE21 ' H ' ' C' ' 16' ' ' GLY . 30.4 tp60 171.61 141.12 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 127.452 2.301 . . . . 1.35 105.865 -154.355 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . 0.491 ' H ' HE21 ' C' ' 15' ' ' GLN . . . -91.17 173.37 37.56 Favored Glycine 0 N--CA 1.466 0.634 0 C-N-CA 126.263 1.887 . . . . 0.89 114.474 171.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . 0.521 ' H ' HD12 ' C' ' 17' ' ' ILE . 3.9 mp -63.03 132.0 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.533 0 C-N-CA 124.464 1.106 . . . . 3.13 111.303 -175.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.66 135.05 57.18 Favored 'General case' 0 CA--C 1.542 0.649 0 C-N-CA 123.824 0.85 . . . . 1.26 112.337 175.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -68.06 139.18 33.93 Favored Glycine 0 C--N 1.334 0.446 0 C-N-CA 124.835 1.207 . . . . 1.29 111.014 -173.202 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 98.8 mm-40 -93.19 158.22 15.87 Favored 'General case' 0 C--N 1.324 -0.501 0 O-C-N 122.026 -0.691 . . . . 4.69 111.856 -168.264 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.51 133.56 46.06 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 115.866 -0.606 . . . . 4.01 110.146 178.208 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.62 163.95 49.12 Favored Glycine 0 CA--C 1.526 0.737 0 C-N-CA 123.328 0.489 . . . . 1.11 113.491 -172.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 1.7 t -64.82 154.9 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 C-N-CA 123.372 0.669 . . . . 2.03 110.517 175.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 30.5 m -75.54 -173.5 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.816 0 C-N-CA 124.704 1.202 . . . . 3.08 110.898 170.611 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.97 -132.66 0.14 Allowed Glycine 0 CA--C 1.536 1.396 0 C-N-CA 125.078 1.323 . . . . 3.43 112.583 167.303 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 7.7 tt . . . . . 0 C--O 1.251 1.143 0 C-N-CA 126.643 1.977 . . . . 4.87 112.771 178.722 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.564 0 CA-C-O 116.782 -2.121 . . . . 3.18 110.134 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -70.44 167.15 26.16 Favored 'Trans proline' 0 C--N 1.348 0.525 0 C-N-CA 123.241 2.628 . . . . 2.06 110.9 177.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -80.12 176.45 9.74 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 127.938 2.495 . . . . 2.56 114.357 -172.929 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.9 177.44 44.77 Favored Glycine 0 N--CA 1.48 1.633 0 N-CA-C 116.8 1.48 . . . . 1.3 116.8 -169.404 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 7.8 pt -70.04 147.84 11.45 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.799 0 O-C-N 121.192 -1.181 . . . . 2.85 110.608 -173.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.14 134.78 44.24 Favored 'General case' 0 CA--C 1.538 0.495 0 CA-C-O 121.77 0.795 . . . . 1.85 112.154 -179.058 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.76 144.85 25.78 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 126.364 1.935 . . . . 1.21 112.814 173.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 84.7 mm-40 -67.91 125.22 25.61 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 108.651 -0.87 . . . . 3.13 108.651 -170.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 32.1 ttt-85 -69.53 145.43 52.63 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-O 121.832 0.825 . . . . 4.76 112.779 -156.016 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.28 144.31 37.34 Favored Glycine 0 CA--C 1.524 0.611 0 CA-C-O 122.296 0.942 . . . . 1.69 113.458 -175.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.3 t -62.79 150.17 9.31 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.521 0 C-N-CA 127.398 2.279 . . . . 2.65 111.444 179.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.4 m -48.44 158.83 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 C-N-CA 125.809 1.644 . . . . 2.01 113.993 173.154 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.85 174.09 40.52 Favored Glycine 0 CA--C 1.53 1.027 0 CA-C-N 115.999 -0.546 . . . . 1.41 111.931 160.786 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 79.8 mt -113.04 157.3 41.14 Favored Pre-proline 0 CA--C 1.539 0.526 0 C-N-CA 124.219 1.008 . . . . 3.61 110.181 -178.375 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.402 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 29.1 Cg_endo -79.74 -158.26 0.09 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.793 0 C-N-CA 123.395 2.73 . . . . 2.28 108.96 160.13 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.225 0 CA-C-O 118.06 -1.411 . . . . 3.4 113.251 154.182 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo . . . . . 0 CA--C 1.544 1.01 0 CA-C-O 119.493 -0.295 . . . . 2.06 111.769 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.15 170.72 37.2 Favored Glycine 0 CA--C 1.54 1.614 0 CA-C-O 118.86 -0.967 . . . . 1.35 112.175 125.557 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -72.23 -179.78 4.29 Favored 'Trans proline' 0 CA--C 1.541 0.829 0 C-N-CA 123.439 2.759 . . . . 2.37 108.742 148.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.6 pm0 -70.39 -175.15 0.95 Allowed 'General case' 0 CA--C 1.546 0.8 0 N-CA-C 113.946 1.091 . . . . 4.31 113.946 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.89 168.12 50.65 Favored Glycine 0 CA--C 1.528 0.901 0 O-C-N 120.347 -1.471 . . . . 0.92 114.187 -178.507 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 79.0 mt -76.01 145.56 10.36 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.844 0 C-N-CA 124.569 1.148 . . . . 2.82 108.988 167.465 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -73.65 152.78 40.38 Favored 'General case' 0 CA--C 1.543 0.686 0 N-CA-C 115.161 1.541 . . . . 1.31 115.161 -170.51 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.36 132.74 21.12 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 125.615 1.579 . . . . 1.5 110.863 173.488 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -95.16 143.68 26.39 Favored 'General case' 0 N--CA 1.465 0.29 0 O-C-N 121.501 -0.999 . . . . 3.25 111.195 -172.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 3.2 mtm180 -55.83 150.89 12.26 Favored 'General case' 0 N--CA 1.473 0.683 0 C-N-CA 125.605 1.562 . . . . 5.57 113.802 175.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.79 179.22 44.26 Favored Glycine 0 CA--C 1.538 1.521 0 C-N-CA 124.929 1.252 . . . . 1.96 113.252 165.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 58.4 t -112.43 148.63 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 C-N-CA 125.138 1.375 . . . . 3.91 113.019 -154.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.9 p -53.19 152.56 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 128.92 2.888 . . . . 3.75 115.708 -172.382 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.38 -131.59 3.4 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 125.097 1.332 . . . . 2.16 111.193 165.299 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.402 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.5 pt? -172.68 161.57 3.94 Favored Pre-proline 0 CA--C 1.544 0.745 0 C-N-CA 126.153 1.781 . . . . 3.46 111.018 -165.082 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo . . . . . 0 C--O 1.255 1.371 0 C-N-CA 124.644 3.563 . . . . 3.1 112.045 154.05 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo . . . . . 0 CA--C 1.547 1.14 0 CA-C-O 119.265 -0.389 . . . . 1.9 112.302 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -71.37 -132.24 0.01 OUTLIER 'Trans proline' 0 CA--C 1.542 0.893 0 C-N-CA 123.413 2.742 . . . . 1.69 108.121 162.524 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.3 162.09 34.72 Favored Glycine 0 CA--C 1.534 1.242 0 CA-C-N 119.821 1.191 . . . . 1.37 112.532 166.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -73.59 -49.11 0.22 Allowed 'Trans proline' 0 N--CA 1.457 -0.669 0 C-N-CA 122.795 2.33 . . . . 3.62 112.079 176.293 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.547 HE21 ' N ' ' C' ' 16' ' ' GLY . 18.2 tp60 175.26 138.35 0.05 OUTLIER 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.129 1.772 . . . . 1.48 107.392 -152.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . 0.547 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -87.42 166.43 36.36 Favored Glycine 0 CA--C 1.527 0.84 0 C-N-CA 125.807 1.67 . . . . 0.93 112.677 169.256 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 72.6 mt -69.18 138.57 22.0 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 O-C-N 121.84 -0.8 . . . . 2.2 109.335 -179.33 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -65.13 158.72 25.14 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.868 1.062 . . . . 1.11 113.868 177.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -82.51 -168.36 42.07 Favored Glycine 0 CA--C 1.528 0.859 0 CA-C-O 122.384 0.991 . . . . 1.52 111.14 170.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -158.44 179.72 8.87 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 124.265 1.026 . . . . 3.0 109.711 -172.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 5.1 tmm_? -64.95 141.97 58.59 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 125.781 1.632 . . . . 5.27 111.791 -174.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.73 -165.66 35.71 Favored Glycine 0 CA--C 1.532 1.148 0 C-N-CA 125.144 1.354 . . . . 1.4 115.542 -174.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 48.6 t -64.49 147.43 12.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.731 0 C-N-CA 125.807 1.643 . . . . 2.06 110.029 176.043 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 33.3 m -102.17 -178.49 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 C-N-CA 125.351 1.46 . . . . 2.71 112.223 -175.126 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.51 171.4 6.84 Favored Glycine 0 CA--C 1.536 1.345 0 C-N-CA 125.061 1.315 . . . . 1.81 115.503 176.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 2.7 mm? . . . . . 0 C--O 1.249 1.072 0 C-N-CA 126.408 1.883 . . . . 3.48 113.116 -166.185 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.645 0 CA-C-O 115.79 -2.672 . . . . 4.95 109.045 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -76.7 179.12 6.77 Favored 'Trans proline' 0 CA--C 1.537 0.647 0 C-N-CA 123.395 2.73 . . . . 3.01 111.29 176.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.95 -152.16 0.35 Allowed 'General case' 0 CA--C 1.548 0.889 0 C-N-CA 126.789 2.036 . . . . 2.73 110.449 175.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.37 162.63 44.03 Favored Glycine 0 N--CA 1.473 1.12 0 O-C-N 120.629 -1.295 . . . . 1.47 114.268 -173.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 25.4 pt -69.88 149.03 10.85 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 O-C-N 121.226 -1.161 . . . . 2.51 110.525 178.789 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.98 132.56 50.25 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 123.555 0.742 . . . . 1.81 111.767 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -50.2 136.69 25.46 Favored Glycine 0 CA--C 1.522 0.498 0 C-N-CA 126.021 1.772 . . . . 2.11 112.13 169.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 77.7 mm-40 -72.48 140.14 48.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.198 -0.501 . . . . 3.47 110.438 -166.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 46.8 ttt85 -66.63 134.24 51.91 Favored 'General case' 0 CA--C 1.531 0.214 0 CA-C-O 121.372 0.606 . . . . 6.12 111.287 -172.625 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.53 146.77 46.33 Favored Glycine 0 CA--C 1.527 0.798 0 CA-C-O 122.08 0.822 . . . . 1.78 113.41 178.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 12.6 t -67.01 118.61 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 C-N-CA 125.819 1.648 . . . . 2.22 110.475 -171.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 24.3 m -44.84 143.71 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 C-N-CA 125.042 1.337 . . . . 2.55 114.383 -170.093 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -75.08 174.06 52.12 Favored Glycine 0 CA--C 1.533 1.174 0 N-CA-C 111.884 -0.486 . . . . 1.68 111.884 165.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 7.0 mp -122.24 160.32 48.3 Favored Pre-proline 0 CA--C 1.539 0.541 0 C-N-CA 125.273 1.429 . . . . 3.45 109.943 175.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.414 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 41.4 Cg_endo -75.98 -158.22 0.08 OUTLIER 'Trans proline' 0 CA--C 1.537 0.666 0 C-N-CA 122.882 2.388 . . . . 3.08 109.256 157.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.192 0 CA-C-O 116.76 -2.133 . . . . 5.32 112.532 142.762 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo . . . . . 0 N--CA 1.491 1.352 0 N-CA-C 109.089 -1.158 . . . . 3.24 109.089 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.27 144.88 36.74 Favored Glycine 0 CA--C 1.543 1.822 0 CA-C-O 118.697 -1.057 . . . . 1.81 111.415 164.652 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -77.04 -176.12 3.02 Favored 'Trans proline' 0 CA--C 1.541 0.865 0 C-N-CA 124.675 3.583 . . . . 2.52 110.134 163.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -61.19 173.47 0.84 Allowed 'General case' 0 CA--C 1.546 0.804 0 N-CA-C 116.336 1.976 . . . . 4.16 116.336 -175.247 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -90.01 154.37 23.7 Favored Glycine 0 CA--C 1.526 0.726 0 O-C-N 121.147 -0.971 . . . . 1.18 113.677 -174.062 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 79.7 mt -60.63 134.12 26.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 N-CA-C 108.347 -0.983 . . . . 3.08 108.347 168.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.09 152.21 39.97 Favored 'General case' 0 CA--C 1.544 0.719 0 N-CA-C 112.752 0.649 . . . . 1.77 112.752 -177.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -83.81 -168.9 44.43 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 124.076 0.846 . . . . 2.5 111.003 169.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -148.6 176.21 10.53 Favored 'General case' 0 CA--C 1.536 0.431 0 O-C-N 120.961 -1.317 . . . . 3.82 112.231 171.048 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.2 ttm180 -59.65 159.47 8.53 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 125.661 1.585 . . . . 6.03 115.07 -164.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -63.66 157.91 40.94 Favored Glycine 0 CA--C 1.525 0.708 0 CA-C-N 116.276 -0.42 . . . . 2.42 114.136 170.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 35.9 t -85.61 121.27 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 C-N-CA 123.742 0.817 . . . . 3.41 111.86 -165.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.445 HG12 ' H ' ' C' ' 23' ' ' VAL . 6.3 m -69.06 156.51 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 126.154 1.781 . . . . 3.01 113.715 -170.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -106.29 -142.66 10.99 Favored Glycine 0 N--CA 1.469 0.878 0 C-N-CA 124.17 0.89 . . . . 2.04 112.436 167.059 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.414 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.6 pt? -172.73 160.48 3.87 Favored Pre-proline 0 CA--C 1.545 0.786 0 C-N-CA 124.854 1.262 . . . . 4.34 111.714 -158.428 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_endo . . . . . 0 C--O 1.255 1.336 0 C-N-CA 124.828 3.686 . . . . 3.02 112.329 155.292 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo . . . . . 0 N--CA 1.487 1.092 0 CA-C-O 119.2 -0.417 . . . . 2.5 111.125 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -67.56 -131.27 0.01 OUTLIER 'Trans proline' 0 CA--C 1.542 0.895 0 C-N-CA 122.362 2.041 . . . . 1.72 106.859 152.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.99 -179.78 48.74 Favored Glycine 0 CA--C 1.535 1.326 0 CA-C-N 119.558 1.072 . . . . 1.38 113.075 169.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 69.5 Cg_endo -78.45 -110.0 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.039 0 C-N-CA 124.867 3.712 . . . . 2.59 109.718 161.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.581 HE21 ' N ' ' C' ' 16' ' ' GLY . 8.5 tp60 -146.58 134.51 21.37 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 127.904 2.482 . . . . 1.89 107.676 -159.395 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . 0.581 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -74.34 169.52 54.01 Favored Glycine 0 CA--C 1.533 1.218 0 C-N-CA 124.614 1.102 . . . . 1.45 113.728 170.51 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 65.8 mt -73.16 131.44 34.88 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 O-C-N 121.745 -0.856 . . . . 2.94 111.221 -174.083 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.37 154.17 35.16 Favored 'General case' 0 CA--C 1.541 0.621 0 N-CA-C 113.693 0.997 . . . . 1.52 113.693 178.483 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -82.99 162.4 40.71 Favored Glycine 0 CA--C 1.53 0.979 0 C-N-CA 124.806 1.193 . . . . 1.47 112.711 177.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 13.9 mp0 -101.69 -175.87 2.97 Favored 'General case' 0 CA--C 1.545 0.753 0 O-C-N 121.425 -1.044 . . . . 3.12 111.189 -178.115 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.46 140.66 54.07 Favored 'General case' 0 CA--C 1.541 0.601 0 O-C-N 121.514 -0.741 . . . . 5.16 111.561 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.57 154.63 36.49 Favored Glycine 0 N--CA 1.47 0.942 0 C-N-CA 125.517 1.532 . . . . 1.76 113.151 179.327 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . 0.445 ' H ' HG12 ' B' ' 24' ' ' VAL . 17.7 t -64.0 144.86 14.26 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 124.525 1.13 . . . . 2.8 111.02 -179.015 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 78.2 t -101.47 168.58 1.94 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.896 0 C-N-CA 126.603 1.961 . . . . 4.58 109.484 -175.143 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.25 177.43 3.35 Favored Glycine 0 CA--C 1.538 1.516 0 C-N-CA 124.196 0.903 . . . . 3.43 114.181 169.212 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 11.9 mt . . . . . 0 N--CA 1.484 1.241 0 N-CA-C 114.711 1.374 . . . . 4.45 114.711 -169.401 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.567 0 CA-C-O 116.258 -2.412 . . . . 2.79 109.321 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -67.57 170.02 14.62 Favored 'Trans proline' 0 CA--C 1.535 0.563 0 C-N-CA 123.029 2.486 . . . . 1.99 110.327 170.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 14.8 mm100 -56.51 -177.6 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 129.084 2.953 . . . . 4.59 116.256 -173.221 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -91.35 -173.05 43.26 Favored Glycine 0 CA--C 1.528 0.888 0 C-N-CA 124.309 0.957 . . . . 1.23 112.968 161.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 9.5 mt -72.05 128.09 34.67 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.815 0 N-CA-C 109.229 -0.656 . . . . 1.97 109.229 -177.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -52.92 135.15 36.99 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.487 0.715 . . . . 1.8 110.727 174.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.65 154.55 48.61 Favored Glycine 0 CA--C 1.525 0.702 0 C-N-CA 125.327 1.441 . . . . 1.27 113.387 -170.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 71.4 mm-40 -69.91 106.55 3.21 Favored 'General case' 0 CA--C 1.532 0.258 0 N-CA-C 109.877 -0.416 . . . . 3.04 109.877 -171.11 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.0 ttp180 -61.49 143.17 56.37 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 125.069 1.348 . . . . 4.3 114.186 -163.111 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.26 136.96 30.73 Favored Glycine 0 C--N 1.339 0.701 0 C-N-CA 124.839 1.209 . . . . 1.57 113.517 -167.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 8.8 p -60.9 134.88 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 C-N-CA 125.493 1.517 . . . . 3.23 111.005 177.112 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 30.0 m -46.13 157.96 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.984 0 C-N-CA 127.148 2.179 . . . . 2.3 115.616 -171.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.42 171.6 43.36 Favored Glycine 0 CA--C 1.527 0.841 0 CA-C-N 115.424 -0.807 . . . . 1.35 113.476 168.315 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 87.6 mt -120.36 159.68 46.81 Favored Pre-proline 0 CA--C 1.54 0.566 0 C-N-CA 124.952 1.301 . . . . 2.64 110.776 -173.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -76.42 -169.56 0.72 Allowed 'Trans proline' 0 N--CA 1.457 -0.649 0 C-N-CA 123.208 2.605 . . . . 1.83 109.797 161.006 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.182 0 CA-C-O 117.837 -1.535 . . . . 3.14 113.189 155.143 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_exo . . . . . 0 CA--C 1.545 1.073 0 CA-C-O 119.209 -0.413 . . . . 2.18 111.317 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.25 171.42 10.35 Favored Glycine 0 CA--C 1.54 1.613 0 C-N-CA 119.259 -1.448 . . . . 1.28 112.634 123.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -75.73 -57.89 0.05 OUTLIER 'Trans proline' 0 CA--C 1.535 0.554 0 C-N-CA 123.974 3.116 . . . . 2.7 111.042 170.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 175.55 152.38 0.14 Allowed 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 127.464 2.306 . . . . 4.43 107.702 -164.309 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.66 153.88 35.39 Favored Glycine 0 CA--C 1.527 0.785 0 C-N-CA 123.817 0.722 . . . . 0.91 112.695 174.793 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.49 ' H ' HD12 ' B' ' 17' ' ' ILE . 4.7 mp -67.36 136.1 27.29 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 108.657 -0.868 . . . . 2.69 108.657 173.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.24 153.85 41.43 Favored 'General case' 0 CA--C 1.541 0.634 0 N-CA-C 113.277 0.843 . . . . 1.52 113.277 -179.154 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -66.98 141.73 40.29 Favored Glycine 0 CA--C 1.532 1.098 0 N-CA-C 111.312 -0.715 . . . . 1.63 111.312 172.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -81.04 164.96 22.1 Favored 'General case' 0 CA--C 1.54 0.576 0 O-C-N 120.899 -1.354 . . . . 2.85 112.218 173.86 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 15.6 ttp180 -63.6 146.15 54.3 Favored 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 125.926 1.69 . . . . 4.69 112.586 173.231 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.55 157.97 53.4 Favored Glycine 0 CA--C 1.533 1.216 0 N-CA-C 115.087 0.795 . . . . 2.25 115.087 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 17.9 m -91.65 133.08 34.35 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 N-CA-C 114.708 1.373 . . . . 3.99 114.708 -164.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -56.36 150.81 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 C-N-CA 127.791 2.436 . . . . 3.12 115.164 -165.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -84.72 -122.49 1.05 Allowed Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.217 0.913 . . . . 2.12 111.182 165.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.3 pt? -170.8 156.65 5.04 Favored Pre-proline 0 CA--C 1.543 0.696 0 C-N-CA 124.756 1.223 . . . . 3.31 112.014 -161.291 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo . . . . . 0 CA--C 1.552 1.379 0 C-N-CA 124.123 3.215 . . . . 2.57 111.767 159.1 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo . . . . . 0 N--CA 1.488 1.168 0 CA-C-O 118.779 -0.592 . . . . 2.73 111.591 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 80.0 Cg_exo -50.6 177.41 0.03 OUTLIER 'Trans proline' 0 CA--C 1.537 0.656 1 C-N-CA 125.565 4.177 . . . . 1.87 113.568 162.599 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.26 178.85 53.69 Favored Glycine 0 CA--C 1.541 1.711 0 C-N-CA 123.575 0.607 . . . . 0.95 112.6 167.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_endo -70.18 156.78 61.47 Favored 'Trans proline' 0 N--CA 1.457 -0.628 0 C-N-CA 123.319 2.679 . . . . 2.49 111.571 171.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.0 tp60 -39.25 126.21 1.69 Allowed 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 127.609 2.363 . . . . 1.4 113.046 164.182 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.9 168.48 49.92 Favored Glycine 0 CA--C 1.529 0.922 0 C-N-CA 124.75 1.167 . . . . 0.89 112.67 170.058 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 29.7 mt -67.51 143.26 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 O-C-N 121.228 -1.16 . . . . 2.33 110.747 -172.512 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.77 151.82 28.62 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 112.891 0.7 . . . . 1.08 112.891 172.349 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.0 169.64 52.13 Favored Glycine 0 CA--C 1.527 0.816 0 CA-C-O 122.823 1.235 . . . . 1.12 113.519 178.532 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 40.0 mt-30 -95.84 154.29 17.3 Favored 'General case' 0 CA--C 1.533 0.305 0 O-C-N 121.355 -1.085 . . . . 3.88 111.767 -170.029 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 6.6 tmm_? -62.72 135.17 57.22 Favored 'General case' 0 C--O 1.234 0.253 0 N-CA-C 109.207 -0.664 . . . . 5.08 109.207 168.501 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -66.65 173.07 26.97 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 116.204 1.242 . . . . 1.06 116.204 -165.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 61.0 t -66.95 136.88 25.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 C-N-CA 124.443 1.097 . . . . 1.82 109.013 173.264 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 33.9 m -100.82 -169.68 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 C-N-CA 124.53 1.132 . . . . 2.41 110.845 -169.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.33 155.22 4.91 Favored Glycine 0 CA--C 1.532 1.154 0 C-N-CA 124.657 1.122 . . . . 1.58 114.27 172.39 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 8.8 mt . . . . . 0 C--O 1.249 1.079 0 CA-C-O 117.637 -1.173 . . . . 3.94 113.998 -162.871 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.52 0 CA-C-O 116.317 -2.379 . . . . 3.23 109.063 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -63.17 161.7 29.28 Favored 'Trans proline' 0 C--N 1.348 0.526 0 C-N-CA 122.83 2.353 . . . . 2.08 110.534 173.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.72 -179.14 0.35 Allowed 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.931 2.493 . . . . 3.32 113.978 176.559 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.98 -178.74 44.64 Favored Glycine 0 CA--C 1.527 0.797 0 C-N-CA 125.556 1.551 . . . . 1.29 114.686 174.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.8 mt -65.63 134.0 30.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 C-N-CA 123.951 0.9 . . . . 2.43 109.922 -172.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.93 129.76 38.84 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 123.703 0.801 . . . . 2.34 111.471 173.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.78 166.77 54.18 Favored Glycine 0 CA--C 1.522 0.477 0 C-N-CA 127.44 2.447 . . . . 1.47 113.069 -177.396 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 14.0 mp0 -82.38 113.58 20.25 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 108.591 -0.892 . . . . 4.13 108.591 -162.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 73.8 ttt180 -49.56 130.66 20.71 Favored 'General case' 0 N--CA 1.468 0.46 0 C-N-CA 124.2 1.0 . . . . 4.05 112.199 -173.368 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.26 145.58 39.5 Favored Glycine 0 N--CA 1.464 0.523 0 C-N-CA 124.75 1.167 . . . . 1.66 113.102 -173.544 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 28.2 m -63.89 161.28 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 124.566 1.147 . . . . 2.2 111.615 179.469 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.8 m -47.97 157.22 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 125.443 1.497 . . . . 2.1 113.667 177.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.29 173.33 39.87 Favored Glycine 0 CA--C 1.527 0.812 0 CA-C-N 115.391 -0.822 . . . . 1.42 112.171 162.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 87.6 mt -111.57 158.19 37.1 Favored Pre-proline 0 CA--C 1.537 0.451 0 C-N-CA 123.687 0.795 . . . . 3.89 110.523 -178.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_endo -81.39 -160.56 0.13 Allowed 'Trans proline' 0 N--CA 1.454 -0.829 0 C-N-CA 123.302 2.668 . . . . 2.74 108.889 158.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.135 0 CA-C-O 117.75 -1.583 . . . . 3.91 113.021 152.076 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo . . . . . 0 CA--C 1.543 0.927 0 CA-C-O 119.157 -0.435 . . . . 2.17 111.664 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.57 162.99 43.93 Favored Glycine 0 CA--C 1.543 1.834 0 C-N-CA 119.516 -1.326 . . . . 1.38 111.766 130.018 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -76.49 -53.54 0.08 OUTLIER 'Trans proline' 0 CA--C 1.536 0.618 0 C-N-CA 124.876 3.717 . . . . 3.22 113.055 177.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -177.13 159.16 1.6 Allowed 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 128.45 2.7 . . . . 3.69 106.8 -162.471 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.11 155.26 22.88 Favored Glycine 0 N--CA 1.468 0.817 0 C-N-CA 124.189 0.899 . . . . 1.03 113.039 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 34.4 mm -67.94 130.37 33.1 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 N-CA-C 109.107 -0.701 . . . . 2.69 109.107 172.601 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -73.28 166.76 22.57 Favored 'General case' 0 CA--C 1.545 0.767 0 N-CA-C 113.866 1.062 . . . . 2.12 113.866 -174.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -73.93 113.63 4.25 Favored Glycine 0 CA--C 1.53 1.027 0 C-N-CA 124.313 0.958 . . . . 2.21 112.516 178.167 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 13.5 mm100 -66.23 141.51 58.02 Favored 'General case' 0 CA--C 1.536 0.409 0 C-N-CA 123.683 0.793 . . . . 4.61 112.769 178.44 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 9.2 mtt85 -62.05 159.44 14.43 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 115.096 1.517 . . . . 5.66 115.096 -176.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.99 -179.29 44.46 Favored Glycine 0 CA--C 1.538 1.474 0 C-N-CA 125.453 1.501 . . . . 1.74 113.151 163.822 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 15.6 m -112.03 146.97 16.2 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 N-CA-C 115.015 1.487 . . . . 3.15 115.015 -158.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 8.9 p -54.36 152.42 1.4 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 127.973 2.509 . . . . 3.71 115.351 -170.332 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -85.72 -129.23 2.24 Favored Glycine 0 CA--C 1.53 0.998 0 C-N-CA 124.599 1.095 . . . . 1.99 111.062 162.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -170.79 159.94 5.71 Favored Pre-proline 0 CA--C 1.544 0.742 0 C-N-CA 125.252 1.421 . . . . 3.36 111.777 -168.594 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo . . . . . 0 C--O 1.256 1.397 1 C-N-CA 125.306 4.004 . . . . 2.69 111.931 155.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo . . . . . 0 CA--C 1.547 1.149 0 CA-C-O 118.318 -0.784 . . . . 2.47 111.433 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -54.04 -169.49 0.02 OUTLIER 'Trans proline' 0 CA--C 1.541 0.864 1 C-N-CA 126.043 4.495 . . . . 1.55 113.595 164.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -83.83 175.03 51.76 Favored Glycine 0 CA--C 1.542 1.779 0 O-C-N 121.769 -0.582 . . . . 1.12 112.345 165.378 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -69.47 157.91 59.26 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 122.996 2.464 . . . . 2.53 111.166 170.076 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 3.6 tp60 -41.09 124.87 2.32 Favored 'General case' 0 CA--C 1.54 0.568 0 C-N-CA 126.82 2.048 . . . . 1.48 113.439 165.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.65 154.65 53.01 Favored Glycine 0 CA--C 1.53 0.974 0 C-N-CA 124.391 0.996 . . . . 1.03 112.382 171.135 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 1.8 mp -67.87 146.1 13.21 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.533 0 C-N-CA 124.524 1.129 . . . . 2.51 110.99 -168.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.95 142.0 54.54 Favored 'General case' 0 C--O 1.235 0.334 0 C-N-CA 125.216 1.406 . . . . 1.4 113.197 178.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -76.07 134.04 15.21 Favored Glycine 0 C--N 1.333 0.366 0 N-CA-C 110.384 -1.086 . . . . 1.41 110.384 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -88.09 171.9 9.92 Favored 'General case' 0 CA--C 1.542 0.644 0 CA-C-N 115.088 -0.556 . . . . 2.96 109.524 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 6.7 ptp180 -61.12 155.27 20.95 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.711 0.767 . . . . 4.98 112.279 179.544 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.44 -176.62 25.09 Favored Glycine 0 CA--C 1.53 1.012 0 C-N-CA 124.995 1.283 . . . . 1.45 113.512 179.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 49.0 t -59.13 143.5 13.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 C-N-CA 124.879 1.272 . . . . 2.42 110.279 176.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 30.9 m -97.76 -175.75 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 125.056 1.342 . . . . 3.44 112.024 -173.665 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.43 167.35 19.02 Favored Glycine 0 CA--C 1.532 1.127 0 C-N-CA 124.984 1.278 . . . . 2.23 114.867 175.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 9.6 mp . . . . . 0 C--O 1.249 1.046 0 C-N-CA 126.516 1.927 . . . . 3.83 113.463 -166.9 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.731 0 CA-C-O 116.337 -2.368 . . . . 5.59 108.929 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -77.37 -172.43 1.45 Allowed 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 122.943 2.429 . . . . 4.07 109.981 171.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -78.9 -137.18 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 124.583 1.153 . . . . 2.88 110.188 157.295 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.52 -148.78 17.59 Favored Glycine 0 N--CA 1.468 0.83 0 CA-C-O 122.827 1.237 . . . . 1.87 114.75 172.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.9 mt -84.1 158.38 3.6 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.506 0 C-N-CA 124.131 0.972 . . . . 3.52 108.435 177.371 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.65 46.69 0.09 Allowed 'General case' 0 CA--C 1.552 1.025 0 C-N-CA 126.807 2.043 . . . . 4.24 112.599 170.239 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 61.56 -155.09 37.51 Favored Glycine 0 C--N 1.337 0.609 0 C-N-CA 125.289 1.424 . . . . 2.07 112.627 -171.122 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -105.56 160.92 14.8 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.935 0.874 . . . . 4.99 110.408 158.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.4 tpt180 -66.0 141.24 58.25 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.203 -0.908 . . . . 4.01 109.828 163.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -93.29 -167.18 38.39 Favored Glycine 0 C--O 1.227 -0.308 0 C-N-CA 125.324 1.44 . . . . 2.45 112.787 177.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 52.8 t -82.61 132.93 30.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 124.524 1.13 . . . . 2.95 109.035 -176.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.8 m -56.37 145.61 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 C-N-CA 124.47 1.108 . . . . 2.88 112.926 -178.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.96 145.13 17.64 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 109.951 -1.26 . . . . 1.75 109.951 165.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 85.3 mt -91.18 156.43 43.86 Favored Pre-proline 0 N--CA 1.472 0.662 0 CA-C-O 117.161 -1.4 . . . . 3.94 110.444 171.202 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -80.24 -158.04 0.09 OUTLIER 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 123.645 2.897 . . . . 3.46 109.23 166.393 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.24 0 CA-C-O 117.549 -1.695 . . . . 5.43 113.458 154.643 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo . . . . . 0 N--CA 1.491 1.364 0 N-CA-C 109.165 -1.129 . . . . 4.26 109.165 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.04 140.92 30.72 Favored Glycine 0 CA--C 1.539 1.55 0 CA-C-O 118.044 -1.42 . . . . 2.31 110.003 158.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 89.5 Cg_endo -68.62 -175.01 0.79 Allowed 'Trans proline' 0 CA--C 1.538 0.695 0 C-N-CA 123.787 2.991 . . . . 2.43 109.878 162.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 4.7 tp-100 -50.47 148.79 3.5 Favored 'General case' 0 CA--C 1.541 0.599 0 N-CA-C 114.734 1.383 . . . . 4.64 114.734 -174.476 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.15 165.83 48.62 Favored Glycine 0 C--N 1.339 0.736 0 CA-C-O 123.285 1.492 . . . . 1.97 112.854 169.145 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 8.2 mm -71.67 160.84 5.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 123.279 1.514 . . . . 4.01 110.722 178.336 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -46.35 147.67 1.09 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.854 1.261 . . . . 2.82 112.975 153.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -82.55 169.16 48.79 Favored Glycine 0 C--N 1.336 0.574 0 CA-C-O 122.626 1.125 . . . . 2.78 112.681 178.726 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -118.41 123.59 45.61 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 123.487 0.715 . . . . 3.58 111.014 -166.247 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 14.9 ptt180 -55.16 134.21 49.42 Favored 'General case' 0 N--CA 1.47 0.546 0 O-C-N 122.056 -0.403 . . . . 5.37 110.703 179.112 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.18 -45.4 93.76 Favored Glycine 0 N--CA 1.477 1.407 0 N-CA-C 114.825 0.69 . . . . 4.28 114.825 -150.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 55.3 t -158.99 164.37 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.877 1 C-N-CA 132.117 4.167 . . . . 3.77 105.613 179.699 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 23.0 m -134.34 156.25 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 C-N-CA 125.989 1.716 . . . . 3.74 109.051 168.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -79.62 -175.28 47.54 Favored Glycine 0 C--N 1.335 0.515 0 CA-C-O 122.189 0.883 . . . . 2.9 114.263 179.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -159.08 158.11 28.5 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 126.982 2.113 . . . . 6.11 109.921 175.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.256 1.381 0 C-N-CA 125.293 3.996 . . . . 5.34 111.831 164.375 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo . . . . . 0 N--CA 1.486 1.04 0 CA-C-O 118.616 -0.66 . . . . 3.57 111.097 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -68.73 -163.78 0.1 OUTLIER 'Trans proline' 0 CA--C 1.544 0.987 0 C-N-CA 123.469 2.779 . . . . 2.93 109.466 157.182 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.91 154.09 52.72 Favored Glycine 0 CA--C 1.541 1.706 0 O-C-N 121.751 -0.593 . . . . 1.64 113.8 172.102 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -79.83 87.15 1.56 Allowed 'Trans proline' 0 CA--C 1.536 0.624 0 C-N-CA 124.504 3.469 . . . . 2.97 111.664 -173.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 30.4 tp60 67.8 -124.12 0.19 Allowed 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.615 1.166 . . . . 2.82 108.777 -176.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . 167.63 -179.4 41.07 Favored Glycine 0 CA--C 1.534 1.256 1 C-N-CA 131.956 4.598 . . . . 1.89 107.523 -171.58 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -74.69 156.44 6.27 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 O-C-N 120.726 -1.455 . . . . 2.27 110.223 176.232 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.26 159.03 30.99 Favored 'General case' 0 CA--C 1.543 0.675 0 O-C-N 120.215 -1.553 . . . . 1.86 112.165 173.792 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -97.93 160.75 20.9 Favored Glycine 0 CA--C 1.53 0.988 0 C-N-CA 124.502 1.049 . . . . 1.73 112.124 177.576 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 22.9 mp0 -101.87 -179.79 4.11 Favored 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 124.376 1.071 . . . . 3.0 111.862 -170.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 6.2 tpt85 -66.8 138.62 57.49 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 123.908 0.883 . . . . 3.73 110.103 162.713 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -94.83 172.07 30.78 Favored Glycine 0 CA--C 1.527 0.838 0 C-N-CA 124.175 0.893 . . . . 1.43 112.009 172.214 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . 0.414 HG23 ' H ' ' C' ' 23' ' ' VAL . 1.9 t -57.15 144.64 9.07 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 C-N-CA 124.914 1.285 . . . . 2.18 110.872 -179.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.446 HG22 ' H ' ' C' ' 25' ' ' GLY . 7.5 p -75.9 -169.32 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.189 0 C-N-CA 124.557 1.143 . . . . 4.13 109.129 164.716 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.446 ' H ' HG22 ' C' ' 24' ' ' VAL . . . -52.5 168.29 0.83 Allowed Glycine 0 CA--C 1.541 1.656 0 CA-C-N 119.858 1.208 . . . . 1.98 113.913 161.414 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 10.2 mp . . . . . 0 C--O 1.249 1.03 0 C-N-CA 125.72 1.608 . . . . 4.69 112.723 -171.784 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.588 0 CA-C-O 116.864 -2.076 . . . . 2.71 110.148 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.7 Cg_endo -73.66 166.9 28.61 Favored 'Trans proline' 0 N--CA 1.458 -0.596 0 C-N-CA 123.268 2.645 . . . . 1.86 111.312 -177.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -60.92 167.07 3.04 Favored 'General case' 0 CA--C 1.532 0.283 0 C-N-CA 126.473 1.909 . . . . 3.12 113.627 173.654 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -78.48 166.52 52.43 Favored Glycine 0 CA--C 1.518 0.247 0 CA-C-N 114.986 -1.007 . . . . 1.39 113.587 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 21.2 mt -51.93 124.76 4.76 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 C-N-CA 125.698 1.599 . . . . 2.43 109.557 178.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -42.9 132.45 3.91 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.715 1.206 . . . . 1.97 112.597 178.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.43 149.78 51.67 Favored Glycine 0 CA--C 1.517 0.195 0 C-N-CA 125.129 1.347 . . . . 1.17 111.673 -178.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 7.3 mp0 -62.68 114.53 3.64 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 114.962 -0.619 . . . . 4.3 109.636 -173.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 48.6 ttt85 -54.56 139.75 37.08 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.686 1.195 . . . . 4.45 112.435 -173.673 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.41 142.62 32.91 Favored Glycine 0 CA--C 1.525 0.698 0 C-N-CA 124.242 0.925 . . . . 1.73 112.71 -175.525 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -60.37 153.42 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 C-N-CA 126.4 1.88 . . . . 2.15 113.231 178.035 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 m -66.99 150.61 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 C-N-CA 124.85 1.26 . . . . 2.33 112.924 -175.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.58 153.34 51.51 Favored Glycine 0 CA--C 1.531 1.037 0 CA-C-N 115.899 -0.591 . . . . 1.48 112.436 170.44 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 10.1 mp -83.62 160.25 59.29 Favored Pre-proline 0 CA--C 1.544 0.723 0 C-N-CA 123.882 0.873 . . . . 3.45 111.166 176.608 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -81.9 -158.71 0.1 OUTLIER 'Trans proline' 0 CA--C 1.537 0.649 0 C-N-CA 123.997 3.131 . . . . 1.75 109.127 158.228 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.169 0 CA-C-O 117.336 -1.813 . . . . 3.09 112.843 155.802 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo . . . . . 0 CA--C 1.545 1.056 0 CA-C-O 119.289 -0.38 . . . . 2.02 111.143 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.08 -178.49 10.44 Favored Glycine 0 CA--C 1.544 1.882 0 CA-C-O 119.035 -0.869 . . . . 1.59 112.625 125.512 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -77.83 -134.99 0.02 OUTLIER 'Trans proline' 0 CA--C 1.546 1.1 1 C-N-CA 125.642 4.228 . . . . 2.18 109.071 160.535 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.37 176.44 9.68 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 124.986 1.314 . . . . 3.66 110.99 166.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.14 157.85 39.49 Favored Glycine 0 N--CA 1.472 1.047 0 O-C-N 121.357 -0.839 . . . . 0.93 112.698 154.318 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 28.3 mm -77.88 131.49 34.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 108.596 -0.89 . . . . 3.25 108.596 173.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -77.4 157.67 30.46 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 114.078 1.14 . . . . 1.72 114.078 -173.063 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.01 121.31 8.39 Favored Glycine 0 CA--C 1.529 0.957 0 C-N-CA 124.298 0.951 . . . . 1.68 111.687 -179.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.96 155.54 40.7 Favored 'General case' 0 CA--C 1.54 0.58 0 O-C-N 121.496 -1.003 . . . . 2.72 111.759 174.344 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.7 ptt-85 -66.14 161.47 21.83 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 122.297 1.046 . . . . 4.54 113.045 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.75 -179.18 49.12 Favored Glycine 0 CA--C 1.529 0.91 0 C-N-CA 125.59 1.567 . . . . 1.89 111.865 172.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 7.0 m -100.89 139.79 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 N-CA-C 114.253 1.205 . . . . 3.37 114.253 -160.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 26.5 m -64.49 160.27 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.809 0 C-N-CA 126.292 1.837 . . . . 2.52 113.502 -174.386 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -88.92 -135.82 5.53 Favored Glycine 0 CA--C 1.529 0.914 0 C-N-CA 124.147 0.879 . . . . 1.71 111.84 171.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -167.29 163.65 9.94 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 125.576 1.55 . . . . 3.21 110.745 -167.031 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo . . . . . 0 C--O 1.257 1.445 0 C-N-CA 124.264 3.309 . . . . 2.61 112.163 167.177 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo . . . . . 0 N--CA 1.487 1.102 0 CA-C-O 119.059 -0.476 . . . . 2.04 111.837 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.28 -137.78 0.02 OUTLIER 'Trans proline' 0 CA--C 1.54 0.825 0 C-N-CA 123.298 2.665 . . . . 1.45 108.226 163.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -79.0 151.7 35.65 Favored Glycine 0 CA--C 1.542 1.753 0 CA-C-N 119.557 1.071 . . . . 0.95 112.758 173.431 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -85.19 64.08 6.08 Favored 'Trans proline' 0 CA--C 1.541 0.849 0 C-N-CA 124.556 3.504 . . . . 3.17 111.34 -176.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 47.0 tp60 71.89 151.52 0.11 Allowed 'General case' 0 CA--C 1.546 0.814 0 C-N-CA 125.343 1.457 . . . . 2.55 112.716 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.03 153.74 22.05 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 124.769 1.176 . . . . 1.17 111.416 166.152 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 66.0 mt -71.62 144.77 12.97 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.8 0 O-C-N 121.805 -0.821 . . . . 2.06 111.193 -177.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.17 149.02 48.68 Favored 'General case' 0 CA--C 1.542 0.671 0 C-N-CA 124.97 1.308 . . . . 1.3 113.205 175.413 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -88.7 140.95 16.23 Favored Glycine 0 CA--C 1.532 1.138 0 C-N-CA 125.106 1.336 . . . . 1.11 114.686 -175.124 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . 0.572 HE21 ' N ' ' C' ' 20' ' ' GLN . 0.0 OUTLIER -71.51 157.15 38.52 Favored 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 126.641 1.976 . . . . 3.89 112.059 168.628 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 46.3 ttp180 -62.07 158.12 17.35 Favored 'General case' 0 CA--C 1.54 0.581 0 N-CA-C 114.331 1.234 . . . . 3.87 114.331 176.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -66.14 168.96 32.66 Favored Glycine 0 CA--C 1.537 1.434 0 CA-C-O 122.112 0.84 . . . . 1.04 113.237 158.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.2 t -68.03 160.85 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 125.86 1.664 . . . . 2.15 111.097 179.111 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 28.6 m -83.17 -175.19 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 125.896 1.678 . . . . 2.28 111.774 175.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.37 173.5 5.38 Favored Glycine 0 CA--C 1.537 1.409 0 C-N-CA 125.164 1.364 . . . . 1.61 114.55 169.073 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 5.7 mt . . . . . 0 C--O 1.25 1.113 0 N-CA-C 114.136 1.162 . . . . 3.63 114.136 -159.072 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.354 0 CA-C-O 116.197 -2.446 . . . . 3.02 107.782 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -69.16 -170.03 0.33 Allowed 'Trans proline' 0 CA--C 1.541 0.848 0 C-N-CA 122.256 1.971 . . . . 2.19 109.571 156.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.435 ' CD ' ' H ' ' A' ' 15' ' ' GLN . 0.0 OUTLIER -87.07 -168.68 2.33 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 127.414 2.286 . . . . 3.02 111.909 168.142 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.91 177.98 45.0 Favored Glycine 0 N--CA 1.474 1.209 0 C-N-CA 125.978 1.752 . . . . 1.63 112.957 161.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.588 ' H ' HD12 ' A' ' 17' ' ' ILE . 2.8 mp -61.98 141.44 17.72 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.987 0 O-C-N 121.813 -0.816 . . . . 2.59 110.372 -174.544 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.88 133.88 56.52 Favored 'General case' 0 CA--C 1.537 0.469 0 CA-C-N 119.039 0.836 . . . . 1.74 110.946 170.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.57 146.53 41.08 Favored Glycine 0 CA--C 1.523 0.581 0 C-N-CA 126.569 2.033 . . . . 1.43 114.603 -178.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 73.1 mm-40 -77.56 134.89 38.16 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 114.604 -0.798 . . . . 3.69 110.816 -166.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 31.6 mtt180 -59.21 137.46 57.96 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 121.642 0.734 . . . . 4.41 112.529 -171.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -78.35 -179.41 50.77 Favored Glycine 0 CA--C 1.523 0.581 0 CA-C-O 123.271 1.484 . . . . 1.87 115.363 -168.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -71.6 156.56 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.819 0 CA-C-N 113.489 -1.356 . . . . 2.38 111.826 -169.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 p -56.4 143.06 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 125.263 1.425 . . . . 5.25 111.967 168.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.48 ' H ' ' HB ' ' B' ' 23' ' ' VAL . . . -93.62 -162.78 36.25 Favored Glycine 0 N--CA 1.472 1.059 0 C-N-CA 124.426 1.013 . . . . 2.42 113.873 170.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 93.0 mt -142.43 153.47 62.46 Favored Pre-proline 0 N--CA 1.471 0.59 0 C-N-CA 126.044 1.738 . . . . 3.52 109.823 172.761 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -79.21 -155.6 0.06 OUTLIER 'Trans proline' 0 CA--C 1.539 0.752 0 C-N-CA 123.138 2.559 . . . . 2.21 108.909 159.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.291 0 CA-C-O 118.002 -1.443 . . . . 3.84 113.51 158.225 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo . . . . . 0 CA--C 1.544 0.994 0 CA-C-O 118.791 -0.587 . . . . 2.24 111.773 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.0 159.66 49.28 Favored Glycine 0 CA--C 1.548 2.147 0 C-N-CA 118.977 -1.582 . . . . 1.23 110.886 127.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -75.84 -66.84 0.02 OUTLIER 'Trans proline' 0 CA--C 1.536 0.617 1 C-N-CA 125.349 4.033 . . . . 3.04 111.809 177.061 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -155.16 161.64 41.18 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 128.892 2.877 . . . . 4.23 107.182 -176.812 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.42 160.44 31.72 Favored Glycine 0 N--CA 1.464 0.555 0 C-N-CA 123.629 0.633 . . . . 1.04 112.922 174.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 2.3 pp -78.23 149.37 5.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 O-C-N 122.313 -0.522 . . . . 4.05 111.215 176.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.8 153.12 38.89 Favored 'General case' 0 CA--C 1.543 0.698 0 N-CA-C 113.528 0.936 . . . . 1.29 113.528 -174.777 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.81 147.7 26.7 Favored Glycine 0 CA--C 1.528 0.866 0 C-N-CA 125.947 1.737 . . . . 1.59 114.572 -172.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 37.4 tt0 -77.95 148.08 34.65 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 126.386 1.874 . . . . 4.15 111.599 172.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 31.6 mtt180 -64.86 164.37 12.57 Favored 'General case' 0 N--CA 1.473 0.702 0 O-C-N 121.306 -0.871 . . . . 4.15 112.299 174.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.3 -144.1 3.47 Favored Glycine 0 CA--C 1.534 1.222 0 CA-C-N 114.959 -1.018 . . . . 2.51 110.96 161.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . 0.48 ' HB ' ' H ' ' A' ' 25' ' ' GLY . 49.8 t -53.26 137.52 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.954 0 C-N-CA 124.3 1.04 . . . . 5.26 112.687 -176.44 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 26.4 m -103.12 162.41 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 C-N-CA 125.651 1.58 . . . . 3.4 111.23 172.442 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.14 171.7 24.75 Favored Glycine 0 C--N 1.338 0.656 0 C-N-CA 125.412 1.482 . . . . 2.54 113.507 -176.18 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -169.38 157.59 6.92 Favored Pre-proline 0 CA--C 1.545 0.754 0 C-N-CA 126.105 1.762 . . . . 3.94 111.521 -168.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 11.1 Cg_endo . . . . . 0 C--O 1.256 1.39 0 C-N-CA 124.611 3.541 . . . . 3.49 111.803 159.363 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 85.1 Cg_endo . . . . . 0 CA--C 1.548 1.178 0 CA-C-O 118.951 -0.521 . . . . 2.43 111.667 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -56.18 -174.4 0.04 OUTLIER 'Trans proline' 0 CA--C 1.539 0.756 0 C-N-CA 124.994 3.796 . . . . 1.72 112.863 164.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -80.71 178.13 54.1 Favored Glycine 0 CA--C 1.541 1.682 0 C-N-CA 123.628 0.633 . . . . 1.01 112.145 165.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -67.91 155.96 67.75 Favored 'Trans proline' 0 N--CA 1.457 -0.62 0 C-N-CA 122.904 2.403 . . . . 2.59 111.001 171.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 22.0 tp60 -40.55 121.36 1.42 Allowed 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 127.384 2.274 . . . . 1.51 112.946 169.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.4 157.08 44.72 Favored Glycine 0 CA--C 1.527 0.814 0 C-N-CA 124.29 0.948 . . . . 0.91 112.091 170.757 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 2.2 mp -65.22 140.55 19.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 C-N-CA 123.548 0.739 . . . . 2.18 110.486 -169.129 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.51 156.57 15.98 Favored 'General case' 0 CA--C 1.545 0.775 0 CA-C-O 123.065 1.412 . . . . 1.05 114.748 179.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.83 145.85 39.04 Favored Glycine 0 C--N 1.335 0.495 0 N-CA-C 108.994 -1.643 . . . . 1.0 108.994 174.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 7.2 mp0 -82.99 -179.46 7.45 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.884 0.85 . . . . 3.63 110.441 -170.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 1.9 tmt_? -57.63 138.39 55.39 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-O 121.618 0.723 . . . . 3.4 110.095 169.119 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.46 148.25 51.09 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 124.367 0.985 . . . . 1.82 112.04 178.299 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 91.2 t -64.86 148.43 11.96 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.603 0 C-N-CA 124.246 1.018 . . . . 2.3 110.447 -173.172 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 12.3 p -97.24 171.79 1.15 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.995 0 C-N-CA 127.982 2.513 . . . . 2.97 111.059 -178.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.5 -168.66 0.61 Allowed Glycine 0 CA--C 1.54 1.614 0 C-N-CA 125.203 1.382 . . . . 2.08 116.083 171.102 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 15.5 mt . . . . . 0 C--O 1.249 1.047 0 C-N-CA 125.736 1.614 . . . . 3.55 115.12 -170.544 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.511 0 CA-C-O 116.915 -2.047 . . . . 3.38 110.172 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -71.62 162.02 43.46 Favored 'Trans proline' 0 N--CA 1.458 -0.575 0 C-N-CA 123.611 2.874 . . . . 2.21 111.39 -177.722 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 31.2 tp60 -46.07 163.73 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 129.228 3.011 . . . . 3.66 115.53 179.282 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.56 172.47 42.82 Favored Glycine 0 CA--C 1.524 0.638 0 C-N-CA 124.388 0.994 . . . . 1.21 114.616 168.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.558 ' H ' HD12 ' A' ' 17' ' ' ILE . 3.0 mp -60.41 140.53 18.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 C-N-CA 124.975 1.31 . . . . 3.02 109.858 -179.369 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.41 130.01 37.82 Favored 'General case' 0 CA--C 1.542 0.639 0 C-N-CA 123.318 0.647 . . . . 2.4 111.291 170.512 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.59 161.49 54.22 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 126.122 1.82 . . . . 1.43 113.58 176.447 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 11.0 mm100 -74.33 115.35 13.74 Favored 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 109.675 -0.491 . . . . 3.6 109.675 -168.248 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 78.4 ttt180 -58.46 139.26 55.86 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 123.564 0.746 . . . . 3.93 112.219 -175.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.38 147.3 35.65 Favored Glycine 0 CA--C 1.522 0.527 0 C-N-CA 125.848 1.689 . . . . 1.59 113.542 -173.093 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.0 p -66.6 144.82 14.32 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.472 0 C-N-CA 125.465 1.506 . . . . 3.63 110.573 176.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -50.69 157.61 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.082 0 C-N-CA 126.09 1.756 . . . . 2.15 114.716 -175.257 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.5 175.4 53.49 Favored Glycine 0 N--CA 1.474 1.207 0 N-CA-C 110.787 -0.925 . . . . 1.69 110.787 158.311 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 17.6 mt -149.84 157.04 38.46 Favored Pre-proline 0 N--CA 1.471 0.621 0 N-CA-C 115.884 1.809 . . . . 3.41 115.884 -152.383 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -68.2 104.66 1.09 Allowed 'Trans proline' 0 N--CA 1.449 -1.09 0 N-CA-C 106.529 -2.143 . . . . 2.5 106.529 154.637 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.231 0 CA-C-O 118.923 -0.932 . . . . 6.39 114.218 -160.405 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo . . . . . 0 CA--C 1.544 0.987 0 N-CA-C 110.993 -0.426 . . . . 2.73 110.993 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -59.63 -170.4 0.41 Allowed Glycine 0 CA--C 1.538 1.488 0 C-N-CA 120.457 -0.878 . . . . 1.86 113.875 125.537 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -74.38 -123.39 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 0.998 0 C-N-CA 124.069 3.179 . . . . 2.07 107.545 157.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -100.29 178.7 4.68 Favored 'General case' 0 CA--C 1.543 0.674 0 C-N-CA 125.309 1.443 . . . . 6.16 112.218 175.137 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -81.46 145.72 25.46 Favored Glycine 0 N--CA 1.472 1.047 0 O-C-N 121.202 -0.936 . . . . 1.22 112.684 164.215 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 96.7 mt -63.38 132.77 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 O-C-N 121.079 -1.248 . . . . 3.24 108.659 170.375 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -77.55 157.05 30.53 Favored 'General case' 0 CA--C 1.542 0.65 0 N-CA-C 114.151 1.167 . . . . 2.13 114.151 -169.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.54 140.27 40.64 Favored Glycine 0 CA--C 1.524 0.634 0 C-N-CA 126.229 1.871 . . . . 1.8 110.5 169.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 10.4 mp0 -95.95 147.86 23.24 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 123.308 0.643 . . . . 3.91 110.84 -165.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 3.8 ttt180 -64.12 154.76 33.61 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 124.525 1.13 . . . . 5.09 113.722 -176.229 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.68 155.86 52.35 Favored Glycine 0 CA--C 1.531 1.05 0 C-N-CA 124.042 0.83 . . . . 1.99 115.115 176.053 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 27.7 m -75.58 136.8 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 N-CA-C 114.677 1.362 . . . . 3.22 114.677 -174.023 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 18.6 m -56.43 156.5 1.3 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.002 0 N-CA-C 116.729 2.122 . . . . 2.82 116.729 -162.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.56 -177.06 42.93 Favored Glycine 0 C--N 1.34 0.753 0 C-N-CA 125.864 1.697 . . . . 2.08 115.8 -167.087 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.6 mp -147.72 158.37 42.92 Favored Pre-proline 0 CA--C 1.546 0.813 0 C-N-CA 125.453 1.501 . . . . 4.63 113.031 -165.428 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo . . . . . 0 C--O 1.255 1.343 0 C-N-CA 123.843 3.029 . . . . 3.42 112.635 148.585 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo . . . . . 0 CA--C 1.547 1.151 0 CA-C-O 118.323 -0.782 . . . . 2.26 111.855 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_exo -49.58 -179.35 0.02 OUTLIER 'Trans proline' 0 C--N 1.35 0.655 1 C-N-CA 126.571 4.847 . . . . 1.9 114.402 166.549 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.26 148.55 51.41 Favored Glycine 0 CA--C 1.547 2.035 0 CA-C-O 119.368 -0.685 . . . . 1.38 112.059 162.327 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -81.55 61.95 8.17 Favored 'Trans proline' 0 CA--C 1.542 0.899 0 C-N-CA 125.036 3.824 . . . . 3.6 113.058 -169.056 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 74.7 147.32 0.09 Allowed 'General case' 0 CA--C 1.54 0.581 0 C-N-CA 126.402 1.881 . . . . 2.48 112.774 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -85.85 146.08 21.17 Favored Glycine 0 CA--C 1.527 0.842 0 O-C-N 121.299 -0.875 . . . . 1.08 112.145 170.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 97.5 mt -63.46 148.77 11.16 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 C-N-CA 124.607 1.163 . . . . 2.18 110.883 175.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.97 150.43 39.02 Favored 'General case' 0 CA--C 1.548 0.887 0 N-CA-C 114.383 1.253 . . . . 1.1 114.383 177.426 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -80.63 152.79 34.1 Favored Glycine 0 C--N 1.338 0.679 0 C-N-CA 125.44 1.495 . . . . 1.03 111.176 177.211 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 10.5 mp0 -101.18 161.0 13.92 Favored 'General case' 0 C--N 1.326 -0.419 0 O-C-N 121.726 -0.867 . . . . 3.27 110.095 -172.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -53.34 134.85 39.71 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 123.483 0.713 . . . . 3.83 109.804 172.62 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.25 177.19 29.4 Favored Glycine 0 CA--C 1.522 0.483 0 CA-C-N 115.713 -0.676 . . . . 1.06 112.105 -175.281 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 45.2 t -58.58 131.74 23.0 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 CA-C-O 121.464 0.65 . . . . 1.87 110.564 -177.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 8.7 p -70.23 158.68 5.99 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.394 0 C-N-CA 129.374 3.069 . . . . 3.53 112.774 177.322 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -52.72 167.1 1.09 Allowed Glycine 0 CA--C 1.538 1.53 0 N-CA-C 115.288 0.875 . . . . 1.81 115.288 159.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 2.8 mm? . . . . . 0 C--O 1.25 1.094 0 C-N-CA 125.595 1.558 . . . . 3.95 113.683 -164.968 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.558 0 CA-C-O 117.175 -1.903 . . . . 3.11 109.31 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -71.82 -168.65 0.38 Allowed 'Trans proline' 0 CA--C 1.54 0.821 0 C-N-CA 123.384 2.722 . . . . 2.09 109.927 165.185 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -87.74 -173.14 4.18 Favored 'General case' 0 CA--C 1.544 0.717 0 C-N-CA 126.074 1.75 . . . . 3.14 112.187 169.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -93.37 -171.61 39.69 Favored Glycine 0 CA--C 1.53 1.021 0 C-N-CA 125.884 1.707 . . . . 1.32 113.881 163.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.2 mt -62.24 139.88 20.2 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.103 0 O-C-N 121.784 -0.833 . . . . 2.06 110.481 -173.477 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -57.32 133.35 55.04 Favored 'General case' 0 CA--C 1.536 0.426 0 CA-C-N 118.692 0.678 . . . . 1.82 110.509 168.712 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -53.46 147.14 18.88 Favored Glycine 0 CA--C 1.52 0.405 0 C-N-CA 127.546 2.498 . . . . 1.23 113.665 177.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 87.3 mm-40 -71.57 125.72 27.8 Favored 'General case' 0 CA--C 1.535 0.403 0 N-CA-C 108.159 -1.052 . . . . 3.2 108.159 -177.182 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.9 ttt180 -57.97 137.07 57.11 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 123.639 0.776 . . . . 5.19 111.54 -169.781 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -65.8 163.33 40.72 Favored Glycine 0 C--N 1.338 0.679 0 C-N-CA 124.985 1.279 . . . . 1.54 115.577 -169.623 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 45.3 t -66.88 132.17 32.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 C-N-CA 126.617 1.967 . . . . 2.83 109.5 -175.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.415 HG23 ' H ' ' A' ' 24' ' ' VAL . 1.7 t -56.26 145.78 6.3 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 124.974 1.31 . . . . 2.58 112.224 -173.526 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.11 175.33 42.46 Favored Glycine 0 CA--C 1.535 1.286 0 N-CA-C 112.019 -0.432 . . . . 1.46 112.019 163.408 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 6.4 mp -129.68 156.71 78.36 Favored Pre-proline 0 CA--C 1.538 0.505 0 C-N-CA 124.636 1.174 . . . . 2.9 109.447 178.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.401 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 30.4 Cg_endo -77.74 -165.03 0.3 Allowed 'Trans proline' 0 N--CA 1.457 -0.671 0 C-N-CA 122.951 2.434 . . . . 1.77 109.44 161.264 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.259 0 CA-C-O 117.67 -1.628 . . . . 3.38 112.588 153.863 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo . . . . . 0 CA--C 1.54 0.81 0 CA-C-O 118.047 -0.897 . . . . 2.61 110.573 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.77 162.87 25.32 Favored Glycine 0 CA--C 1.551 2.299 0 C-N-CA 118.882 -1.628 . . . . 1.57 111.144 126.414 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 69.2 Cg_endo -79.0 -51.8 0.06 OUTLIER 'Trans proline' 0 CA--C 1.536 0.599 0 C-N-CA 124.746 3.631 . . . . 3.21 112.302 178.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 177.93 160.58 0.53 Allowed 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 129.731 3.213 . . . . 3.74 105.443 -165.381 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.07 -173.78 46.48 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 116.873 1.509 . . . . 1.31 116.873 -168.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.513 ' H ' HD12 ' B' ' 17' ' ' ILE . 4.0 mp -71.78 121.31 21.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 N-CA-C 108.473 -0.936 . . . . 3.64 108.473 168.284 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -68.5 137.63 54.55 Favored 'General case' 0 CA--C 1.541 0.605 0 CA-C-O 121.542 0.686 . . . . 1.5 111.419 176.611 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.09 147.2 40.81 Favored Glycine 0 CA--C 1.527 0.831 0 C-N-CA 124.698 1.142 . . . . 1.64 112.826 -170.717 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . 0.402 ' NE2' ' H ' ' B' ' 20' ' ' GLN . 0.0 OUTLIER -82.08 147.79 28.92 Favored 'General case' 0 CA--C 1.538 0.501 0 C-N-CA 123.764 0.826 . . . . 3.63 111.327 169.541 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 6.0 ptt180 -52.27 157.17 1.47 Allowed 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 114.63 1.344 . . . . 5.38 114.63 168.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.03 179.1 53.16 Favored Glycine 0 CA--C 1.532 1.111 0 C-N-CA 124.331 0.967 . . . . 1.87 114.035 177.131 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 24.2 t -91.93 122.33 43.28 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 N-CA-C 113.648 0.981 . . . . 3.05 113.648 -152.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.1 m -58.89 154.28 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 C-N-CA 127.06 2.144 . . . . 2.48 114.272 -173.096 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.63 -146.71 16.91 Favored Glycine 0 CA--C 1.53 0.996 0 C-N-CA 124.196 0.903 . . . . 1.62 112.026 163.069 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.401 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.5 pt? -171.12 161.06 5.42 Favored Pre-proline 0 CA--C 1.546 0.823 0 C-N-CA 126.097 1.759 . . . . 3.59 111.568 -164.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo . . . . . 0 CA--C 1.552 1.386 0 C-N-CA 125.292 3.995 . . . . 2.83 112.595 153.901 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 CA--C 1.547 1.125 0 CA-C-O 118.765 -0.598 . . . . 3.18 111.467 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo -55.94 -179.4 0.08 OUTLIER 'Trans proline' 0 CA--C 1.537 0.652 0 C-N-CA 124.477 3.452 . . . . 2.18 112.583 164.071 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -87.84 179.54 47.27 Favored Glycine 0 CA--C 1.54 1.615 0 C-N-CA 124.662 1.125 . . . . 1.13 114.028 176.227 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_endo -70.61 156.69 60.62 Favored 'Trans proline' 0 N--CA 1.456 -0.683 0 C-N-CA 123.383 2.722 . . . . 2.39 111.116 172.322 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 22.2 tp60 -32.22 120.34 0.29 Allowed 'General case' 0 CA--C 1.535 0.396 0 C-N-CA 127.648 2.379 . . . . 1.33 113.546 167.055 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.62 158.35 53.63 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 111.345 -0.702 . . . . 0.9 111.345 166.376 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 68.1 mt -61.84 143.55 15.0 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.848 0 C-N-CA 123.203 0.601 . . . . 2.2 111.528 -169.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -67.7 158.44 32.28 Favored 'General case' 0 CA--C 1.545 0.754 0 CA-C-O 122.722 1.248 . . . . 1.04 114.234 177.177 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.28 163.18 54.44 Favored Glycine 0 CA--C 1.527 0.782 0 C-N-CA 124.625 1.107 . . . . 1.2 112.909 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 9.8 mp0 -96.38 -178.83 4.42 Favored 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 124.264 1.026 . . . . 3.95 111.491 -171.193 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.49 142.91 46.78 Favored 'General case' 0 N--CA 1.473 0.686 0 O-C-N 121.06 -1.025 . . . . 3.41 110.868 172.438 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.41 173.26 55.21 Favored Glycine 0 N--CA 1.47 0.919 0 C-N-CA 124.895 1.236 . . . . 1.01 112.817 177.121 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 38.1 t -71.3 138.45 21.71 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.613 0 C-N-CA 123.803 0.841 . . . . 1.99 110.164 179.206 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -91.81 173.45 0.89 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.755 0 C-N-CA 127.277 2.231 . . . . 2.64 109.763 -179.301 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -50.99 149.13 7.34 Favored Glycine 0 CA--C 1.533 1.182 0 CA-C-N 119.076 0.853 . . . . 1.79 113.13 170.71 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 8.6 tt . . . . . 0 C--O 1.25 1.097 0 C-N-CA 127.322 2.249 . . . . 4.15 113.766 -167.205 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.756 0 CA-C-O 115.971 -2.572 . . . . 4.12 108.813 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -77.68 178.3 7.77 Favored 'Trans proline' 0 CA--C 1.534 0.515 0 C-N-CA 123.162 2.575 . . . . 2.35 110.965 177.386 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -82.58 -155.44 0.15 Allowed 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 125.933 1.693 . . . . 2.71 111.034 165.586 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -85.67 173.0 47.09 Favored Glycine 0 N--CA 1.47 0.943 0 N-CA-C 115.701 1.041 . . . . 1.47 115.701 -173.29 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.558 ' H ' HD12 ' A' ' 17' ' ' ILE . 2.8 mp -66.16 137.49 24.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 N-CA-C 108.468 -0.938 . . . . 2.52 108.468 177.517 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.73 131.26 50.35 Favored 'General case' 0 CA--C 1.538 0.504 0 CA-C-O 121.569 0.699 . . . . 1.71 110.632 170.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.78 153.17 30.07 Favored Glycine 0 CA--C 1.519 0.301 0 C-N-CA 126.651 2.072 . . . . 1.62 113.004 174.135 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 5.4 mp0 -74.37 143.66 44.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 114.78 -0.71 . . . . 3.87 110.738 -164.173 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 16.8 tpp85 -52.22 135.55 31.97 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 123.553 0.741 . . . . 4.51 110.992 173.101 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.84 167.54 54.44 Favored Glycine 0 CA--C 1.522 0.485 0 CA-C-O 122.587 1.104 . . . . 1.51 113.819 -173.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 15.4 t -66.06 129.2 30.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 C-N-CA 125.78 1.632 . . . . 2.45 109.392 -178.497 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 31.4 m -58.69 146.98 7.88 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.942 0 N-CA-C 114.355 1.243 . . . . 2.13 114.355 -172.268 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.11 159.48 53.52 Favored Glycine 0 CA--C 1.536 1.358 0 CA-C-O 121.903 0.724 . . . . 1.37 112.051 161.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.544 HD13 HH21 ' C' ' 21' ' ' ARG . 11.0 mp -120.05 136.82 25.25 Favored Pre-proline 0 CA--C 1.532 0.262 0 C-N-CA 126.314 1.846 . . . . 2.8 109.815 -177.152 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -74.42 -172.05 1.08 Allowed 'Trans proline' 0 N--CA 1.456 -0.679 0 C-N-CA 122.729 2.286 . . . . 2.49 109.861 169.666 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.245 0 CA-C-O 117.659 -1.634 . . . . 4.58 113.095 151.359 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo . . . . . 0 N--CA 1.491 1.347 0 N-CA-C 109.248 -1.097 . . . . 2.59 109.248 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.64 147.38 49.65 Favored Glycine 0 CA--C 1.541 1.678 0 CA-C-O 118.898 -0.946 . . . . 1.35 111.308 162.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -77.42 176.94 9.46 Favored 'Trans proline' 0 CA--C 1.538 0.707 0 C-N-CA 124.116 3.211 . . . . 2.28 110.315 164.041 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.1 tp-100 -38.91 143.61 0.15 Allowed 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 127.743 2.417 . . . . 3.74 115.594 176.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.14 163.36 53.11 Favored Glycine 0 CA--C 1.529 0.949 0 C-N-CA 124.031 0.824 . . . . 1.02 113.028 175.298 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.511 ' H ' HD12 ' B' ' 17' ' ' ILE . 2.9 mp -65.28 134.7 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 O-C-N 121.733 -0.863 . . . . 2.75 109.328 175.118 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.68 148.76 51.47 Favored 'General case' 0 CA--C 1.542 0.635 0 CA-C-N 119.093 0.86 . . . . 1.46 112.196 176.427 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -68.41 153.2 52.85 Favored Glycine 0 CA--C 1.527 0.826 0 C-N-CA 124.57 1.081 . . . . 1.75 111.746 174.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.59 155.26 25.77 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.999 0.92 . . . . 2.87 111.332 -176.64 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 41.0 mtt-85 -53.53 148.1 9.92 Favored 'General case' 0 N--CA 1.475 0.783 0 C-N-CA 125.204 1.402 . . . . 5.84 113.905 -169.076 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.78 166.43 54.3 Favored Glycine 0 CA--C 1.535 1.299 0 CA-C-N 116.133 -0.485 . . . . 1.92 113.813 175.445 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 27.6 t -72.59 121.77 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 N-CA-C 113.56 0.948 . . . . 2.93 113.56 -161.114 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -65.95 161.37 3.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 C-N-CA 125.481 1.512 . . . . 2.51 114.758 -165.615 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -85.0 -155.91 24.91 Favored Glycine 0 CA--C 1.528 0.903 0 C-N-CA 125.776 1.655 . . . . 1.7 113.461 175.294 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.1 pp -161.9 145.86 9.55 Favored Pre-proline 0 CA--C 1.541 0.63 0 C-N-CA 124.628 1.171 . . . . 2.99 111.499 -177.113 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_endo . . . . . 0 C--O 1.255 1.367 1 C-N-CA 126.087 4.524 . . . . 3.14 112.765 158.012 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo . . . . . 0 CA--C 1.543 0.93 0 CA-C-O 118.607 -0.664 . . . . 2.14 111.959 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -70.98 -150.23 0.03 OUTLIER 'Trans proline' 0 CA--C 1.541 0.869 0 C-N-CA 123.95 3.1 . . . . 1.52 108.523 164.515 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -86.66 169.49 40.98 Favored Glycine 0 CA--C 1.531 1.072 0 O-C-N 121.575 -0.703 . . . . 0.93 113.29 172.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -72.49 160.88 45.68 Favored 'Trans proline' 0 N--CA 1.454 -0.794 0 C-N-CA 123.081 2.521 . . . . 2.46 110.674 171.137 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 34.0 tp60 -52.77 120.13 5.38 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 126.249 1.82 . . . . 1.75 112.798 170.642 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -60.06 150.28 40.29 Favored Glycine 0 CA--C 1.53 1.028 0 C-N-CA 123.876 0.751 . . . . 0.89 111.639 168.599 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 78.0 mt -67.14 145.86 13.54 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.409 1.084 . . . . 2.7 110.676 -176.037 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.13 154.89 29.65 Favored 'General case' 0 CA--C 1.545 0.755 0 N-CA-C 114.824 1.416 . . . . 1.12 114.824 178.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -76.75 148.24 34.84 Favored Glycine 0 CA--C 1.529 0.958 0 C-N-CA 124.739 1.162 . . . . 0.94 112.596 176.151 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -83.33 171.11 13.87 Favored 'General case' 0 CA--C 1.544 0.731 0 C-N-CA 124.475 1.11 . . . . 5.28 112.294 -177.159 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . 0.544 HH21 HD13 ' A' ' 26' ' ' LEU . 0.0 OUTLIER -61.29 138.49 58.24 Favored 'General case' 0 N--CA 1.472 0.65 0 O-C-N 121.398 -0.814 . . . . 3.52 111.97 178.672 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.84 159.0 51.26 Favored Glycine 0 CA--C 1.528 0.857 0 C-N-CA 125.657 1.598 . . . . 0.98 112.933 177.183 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 23.7 t -68.76 136.43 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.592 0 C-N-CA 124.054 0.941 . . . . 1.74 109.095 171.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 31.0 m -87.9 -165.54 0.1 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.843 0 C-N-CA 125.053 1.341 . . . . 2.71 111.623 -179.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.51 -138.79 0.15 Allowed Glycine 0 CA--C 1.54 1.628 0 C-N-CA 125.109 1.338 . . . . 1.69 113.562 164.365 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.251 1.162 0 C-N-CA 126.413 1.885 . . . . 6.5 114.682 -177.017 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.641 0 CA-C-O 116.849 -2.084 . . . . 2.57 110.072 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -72.28 167.97 25.45 Favored 'Trans proline' 0 N--CA 1.459 -0.534 0 C-N-CA 123.458 2.772 . . . . 1.76 111.229 179.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -61.99 162.68 8.85 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 126.253 1.821 . . . . 3.58 113.695 172.744 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.71 -179.54 47.92 Favored Glycine 0 CA--C 1.525 0.693 0 C-N-CA 124.639 1.114 . . . . 1.29 112.547 171.42 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.401 HG13 ' H ' ' A' ' 17' ' ' ILE . 3.3 mt -61.28 138.01 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 C-N-CA 123.488 0.715 . . . . 2.14 109.506 -172.402 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.93 135.62 56.67 Favored 'General case' 0 CA--C 1.535 0.389 0 CA-C-O 120.961 0.41 . . . . 2.04 110.727 170.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.26 151.79 49.84 Favored Glycine 0 CA--C 1.521 0.457 0 C-N-CA 126.286 1.898 . . . . 1.31 112.876 179.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 57.7 mm-40 -69.86 155.71 40.15 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 114.744 -0.728 . . . . 3.93 111.336 -174.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -68.0 145.8 54.16 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 121.028 0.442 . . . . 5.47 111.961 -177.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.45 141.48 28.81 Favored Glycine 0 C--N 1.333 0.413 0 CA-C-N 115.52 -0.764 . . . . 1.59 112.1 -178.156 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 27.2 m -61.4 141.42 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 CA-C-O 121.173 0.511 . . . . 2.43 111.248 -179.615 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.1 m -48.89 150.9 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.962 0 C-N-CA 125.585 1.554 . . . . 2.54 113.878 -172.14 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -87.83 -153.8 26.16 Favored Glycine 0 N--CA 1.471 1.0 0 C-N-CA 123.165 0.412 . . . . 1.94 112.556 165.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 85.7 mt -149.48 155.47 39.13 Favored Pre-proline 0 N--CA 1.472 0.631 0 C-N-CA 125.677 1.591 . . . . 3.28 109.532 178.186 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -80.04 -162.1 0.17 Allowed 'Trans proline' 0 CA--C 1.539 0.747 0 C-N-CA 122.641 2.227 . . . . 2.41 109.392 158.08 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.239 0 CA-C-O 117.071 -1.961 . . . . 4.47 112.069 142.241 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 70.8 Cg_exo . . . . . 0 CA--C 1.544 1.015 0 N-CA-C 111.154 -0.364 . . . . 3.1 111.154 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -63.66 -177.49 4.49 Favored Glycine 0 CA--C 1.542 1.728 0 C-N-CA 120.187 -1.006 . . . . 2.52 112.446 126.217 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -74.64 -135.7 0.01 OUTLIER 'Trans proline' 0 CA--C 1.546 1.113 0 C-N-CA 124.571 3.514 . . . . 2.29 108.19 155.623 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 -87.33 -176.88 5.8 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 124.903 1.281 . . . . 3.98 111.454 171.812 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -84.75 158.97 34.13 Favored Glycine 0 CA--C 1.528 0.899 0 O-C-N 121.86 -0.525 . . . . 1.03 111.955 161.183 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 53.5 mt -72.77 133.26 32.11 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 123.389 0.676 . . . . 3.62 109.291 179.116 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.52 145.41 52.68 Favored 'General case' 0 CA--C 1.547 0.834 0 CA-C-N 119.39 0.995 . . . . 1.45 113.387 179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.72 140.5 29.18 Favored Glycine 0 CA--C 1.53 1.014 0 C-N-CA 125.328 1.442 . . . . 1.52 111.694 173.591 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -95.37 153.09 17.85 Favored 'General case' 0 CA--C 1.532 0.257 0 O-C-N 121.729 -0.865 . . . . 3.15 111.604 -175.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 5.7 ttt85 -62.94 149.57 44.33 Favored 'General case' 0 CA--C 1.537 0.459 0 C-N-CA 125.086 1.355 . . . . 6.68 112.221 -172.195 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.73 -174.86 26.61 Favored Glycine 0 CA--C 1.532 1.14 0 N-CA-C 114.463 0.545 . . . . 1.8 114.463 -179.619 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 75.8 t -44.66 142.17 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.208 0 C-N-CA 128.016 2.526 . . . . 4.29 114.057 -172.501 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.5 m -93.1 156.95 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 C-N-CA 124.13 0.972 . . . . 3.17 113.613 178.059 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.18 -162.62 29.57 Favored Glycine 0 C--N 1.341 0.828 0 C-N-CA 125.535 1.541 . . . . 1.89 114.23 -178.251 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.8 pp -153.76 141.83 13.98 Favored Pre-proline 0 CA--C 1.542 0.656 0 C-N-CA 124.287 1.035 . . . . 3.85 110.904 174.241 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 13.2 Cg_endo . . . . . 0 C--O 1.254 1.292 1 C-N-CA 126.282 4.654 . . . . 4.59 113.147 160.135 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo . . . . . 0 CA--C 1.547 1.152 0 CA-C-O 119.178 -0.426 . . . . 3.11 111.917 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_endo -72.5 -135.59 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.075 0 C-N-CA 123.502 2.802 . . . . 1.97 108.351 162.447 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -81.04 175.42 54.78 Favored Glycine 0 CA--C 1.543 1.786 0 CA-C-N 119.303 0.956 . . . . 1.34 111.552 163.355 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -80.14 170.64 16.13 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 123.676 2.917 . . . . 2.42 110.46 161.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 28.7 tp60 -43.31 117.58 1.14 Allowed 'General case' 0 CA--C 1.538 0.505 0 C-N-CA 125.33 1.452 . . . . 1.51 112.133 161.005 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.5 145.98 49.96 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.331 -1.108 . . . . 1.07 110.331 166.558 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 36.2 mm -66.51 145.33 13.94 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 O-C-N 122.367 -0.49 . . . . 4.11 110.567 -174.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -68.52 166.56 16.72 Favored 'General case' 0 CA--C 1.543 0.687 0 N-CA-C 114.394 1.257 . . . . 1.71 114.394 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.58 155.17 43.0 Favored Glycine 0 CA--C 1.527 0.81 0 C-N-CA 125.007 1.289 . . . . 1.04 112.6 -179.384 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -95.92 167.73 11.06 Favored 'General case' 0 CA--C 1.536 0.423 0 C-N-CA 124.1 0.96 . . . . 4.89 111.164 -176.671 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.69 134.5 51.37 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 123.243 0.617 . . . . 3.87 111.038 178.501 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -63.72 178.49 7.12 Favored Glycine 0 N--CA 1.469 0.868 0 C-N-CA 126.41 1.957 . . . . 1.07 114.667 -175.773 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 93.1 t -74.83 138.09 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 108.969 -0.752 . . . . 2.14 108.969 -179.023 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 13.9 m -99.93 174.35 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 C-N-CA 126.305 1.842 . . . . 2.49 110.335 -178.386 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.92 -178.16 9.6 Favored Glycine 0 CA--C 1.534 1.227 0 C-N-CA 123.615 0.626 . . . . 1.81 113.673 167.308 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.479 0.987 0 N-CA-C 114.649 1.351 . . . . 5.57 114.649 173.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.689 0 CA-C-O 116.827 -2.096 . . . . 3.15 109.604 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_endo -70.11 177.15 6.11 Favored 'Trans proline' 0 CA--C 1.538 0.716 0 C-N-CA 123.153 2.568 . . . . 2.06 110.249 166.08 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.427 ' HA ' ' HD2' ' B' ' 14' ' ' PRO 0.253 0.0 OUTLIER -89.99 -156.65 0.43 Allowed 'General case' 0 CA--C 1.548 0.879 0 C-N-CA 125.984 1.714 . . . . 3.18 111.699 173.435 . . . . . . . . 4 4 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.03 178.47 45.03 Favored Glycine 0 N--CA 1.475 1.257 0 C-N-CA 124.95 1.262 . . . . 1.33 114.535 178.354 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.9 mt -76.06 130.41 36.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 O-C-N 121.261 -1.14 . . . . 2.54 108.579 -176.724 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.66 127.65 30.93 Favored 'General case' 0 CA--C 1.539 0.554 0 CA-C-N 119.318 0.963 . . . . 2.02 111.571 178.73 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.86 164.29 35.68 Favored Glycine 0 CA--C 1.528 0.869 0 C-N-CA 126.097 1.808 . . . . 1.28 112.803 -176.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -71.95 112.3 7.92 Favored 'General case' 0 N--CA 1.468 0.428 0 O-C-N 121.894 -0.768 . . . . 5.28 110.574 -169.431 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 67.4 ttt-85 -60.9 127.04 29.63 Favored 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 123.425 0.69 . . . . 4.0 109.402 177.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -78.57 171.99 55.19 Favored Glycine 0 CA--C 1.524 0.619 0 C-N-CA 125.002 1.287 . . . . 1.55 115.318 -166.7 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -64.38 147.52 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 CA-C-N 113.78 -1.21 . . . . 2.69 110.538 -173.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.0 m -54.14 150.58 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.739 0 C-N-CA 123.146 0.578 . . . . 2.59 111.491 167.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.2 148.98 46.71 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 110.538 -1.025 . . . . 1.98 110.538 159.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 7.4 mp -101.35 167.04 11.27 Favored Pre-proline 0 C--N 1.328 -0.337 0 C-N-CA 124.027 0.931 . . . . 3.53 110.748 174.512 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.421 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 44.3 Cg_endo -69.94 -155.38 0.04 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 121.789 1.659 . . . . 1.81 108.55 155.113 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.259 0 CA-C-O 117.019 -1.989 . . . . 3.31 112.683 152.373 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_exo . . . . . 0 N--CA 1.481 0.765 0 CA-C-O 117.618 -1.076 . . . . 2.31 110.268 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -63.97 153.08 48.15 Favored Glycine 0 CA--C 1.548 2.131 0 C-N-CA 119.758 -1.211 . . . . 1.32 111.06 144.055 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 15' ' ' GLN . 57.8 Cg_endo -78.88 -47.96 0.09 OUTLIER 'Trans proline' 0 CA--C 1.537 0.668 0 C-N-CA 124.461 3.44 . . . . 2.88 114.628 -179.417 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.8 tp-100 -170.8 146.76 2.64 Favored 'General case' 0 N--CA 1.463 0.204 0 C-N-CA 124.285 1.034 . . . . 3.52 110.722 -161.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -86.51 149.8 22.94 Favored Glycine 0 CA--C 1.527 0.792 0 CA-C-O 121.822 0.679 . . . . 0.95 113.149 -178.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 65.7 mt -69.31 122.45 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 108.481 -0.933 . . . . 3.02 108.481 175.592 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.92 136.65 58.06 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 113.126 0.788 . . . . 1.21 113.126 -174.008 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -67.81 129.38 27.21 Favored Glycine 0 CA--C 1.523 0.533 0 C-N-CA 125.287 1.422 . . . . 1.65 110.183 169.429 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 8.8 tp-100 -96.89 150.34 20.86 Favored 'General case' 0 C--N 1.328 -0.337 0 C-N-CA 123.685 0.794 . . . . 7.25 110.195 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.96 157.17 10.33 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 112.912 0.708 . . . . 4.62 112.912 171.461 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.46 -174.65 49.43 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 124.417 1.008 . . . . 1.83 112.455 170.701 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 13.4 m -93.31 141.9 14.04 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 115.133 1.531 . . . . 3.76 115.133 -156.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 12.9 m -69.5 154.17 8.38 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 C-N-CA 125.796 1.638 . . . . 2.47 113.274 -166.816 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.72 -136.66 9.45 Favored Glycine 0 CA--C 1.53 1.03 0 C-N-CA 123.931 0.777 . . . . 1.77 113.117 170.802 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.421 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.6 pt? -172.18 158.57 4.18 Favored Pre-proline 0 CA--C 1.546 0.804 0 C-N-CA 126.085 1.754 . . . . 3.16 110.788 -157.41 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo . . . . . 0 C--O 1.256 1.424 0 C-N-CA 122.294 1.996 . . . . 2.56 111.013 160.851 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo . . . . . 0 CA--C 1.544 1.015 0 CA-C-O 118.783 -0.59 . . . . 2.64 111.939 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_exo -55.39 -176.1 0.04 OUTLIER 'Trans proline' 0 CA--C 1.536 0.625 0 C-N-CA 124.707 3.605 . . . . 1.74 112.582 162.14 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -89.64 -172.85 45.55 Favored Glycine 0 CA--C 1.537 1.425 0 C-N-CA 124.882 1.23 . . . . 1.06 113.202 171.047 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -72.96 159.13 48.68 Favored 'Trans proline' 0 N--CA 1.456 -0.703 0 C-N-CA 123.211 2.607 . . . . 2.57 111.858 178.443 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.481 ' HA ' HE21 ' C' ' 15' ' ' GLN . 0.0 OUTLIER -45.7 130.02 9.1 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 126.461 1.904 . . . . 1.75 112.947 161.916 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -79.15 174.77 55.26 Favored Glycine 0 CA--C 1.53 0.981 0 C-N-CA 125.471 1.51 . . . . 1.17 114.06 174.521 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 97.0 mt -63.98 145.87 13.46 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.874 0 C-N-CA 124.958 1.303 . . . . 2.82 111.76 -174.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -85.44 157.24 20.52 Favored 'General case' 0 CA--C 1.545 0.764 0 C-N-CA 125.609 1.563 . . . . 1.34 114.115 177.189 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -98.02 138.06 13.66 Favored Glycine 0 CA--C 1.528 0.86 0 C-N-CA 124.945 1.26 . . . . 1.19 112.605 178.269 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -70.73 -179.07 2.04 Favored 'General case' 0 CA--C 1.543 0.709 0 CA-C-O 122.479 1.133 . . . . 5.2 111.797 170.199 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 17.8 ttt85 -55.41 149.34 13.43 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 124.588 1.155 . . . . 4.11 110.917 161.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.45 171.54 46.58 Favored Glycine 0 CA--C 1.533 1.17 0 N-CA-C 111.423 -0.671 . . . . 1.05 111.423 161.87 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 6.3 t -66.53 144.02 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 C-N-CA 124.13 0.972 . . . . 1.91 110.972 -179.457 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 12.4 m -85.77 175.0 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.795 0 C-N-CA 127.342 2.257 . . . . 2.71 112.497 179.384 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.26 173.71 10.53 Favored Glycine 0 CA--C 1.537 1.419 0 C-N-CA 124.619 1.104 . . . . 2.15 114.809 162.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 21.7 mt . . . . . 0 N--CA 1.484 1.242 0 N-CA-C 115.474 1.657 . . . . 3.41 115.474 -155.556 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.582 0 CA-C-O 116.953 -2.026 . . . . 3.13 110.13 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 83.0 Cg_endo -75.02 167.22 27.5 Favored 'Trans proline' 0 N--CA 1.459 -0.553 0 C-N-CA 123.294 2.663 . . . . 2.31 111.477 -177.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.1 161.96 23.36 Favored 'General case' 0 CA--C 1.539 0.53 0 C-N-CA 127.269 2.228 . . . . 2.87 113.257 175.29 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.26 -152.02 21.94 Favored Glycine 0 N--CA 1.472 1.053 0 C-N-CA 125.454 1.502 . . . . 1.55 115.457 -170.515 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 1.7 mt -66.92 132.18 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 O-C-N 121.09 -1.241 . . . . 2.55 109.796 -176.384 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -72.39 64.49 0.59 Allowed 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 125.797 1.639 . . . . 3.43 112.435 179.269 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.35 -175.35 32.99 Favored Glycine 0 CA--C 1.527 0.784 0 C-N-CA 125.722 1.629 . . . . 2.06 112.402 -174.064 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 80.4 mm-40 -106.92 154.94 20.33 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 109.222 -0.658 . . . . 3.73 109.222 145.371 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 24.0 ttt180 -70.89 107.54 4.08 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 108.673 -0.862 . . . . 5.09 108.673 169.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -76.81 -81.81 0.57 Allowed Glycine 0 N--CA 1.472 1.083 0 C-N-CA 124.696 1.141 . . . . 4.36 112.91 -159.662 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 2.6 m -150.59 152.16 11.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 C-N-CA 123.963 0.905 . . . . 2.52 108.647 -178.311 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 20.5 m -62.23 162.68 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.965 0 C-N-CA 125.998 1.719 . . . . 2.51 113.633 -179.158 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.09 -160.47 3.75 Favored Glycine 0 CA--C 1.537 1.407 0 N-CA-C 111.431 -0.667 . . . . 2.36 111.431 155.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 94.2 mt -140.82 161.66 52.88 Favored Pre-proline 0 N--CA 1.474 0.738 0 CA-C-N 118.055 0.928 . . . . 3.44 111.017 178.02 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 27.7 Cg_endo -86.52 -158.75 0.09 OUTLIER 'Trans proline' 0 CA--C 1.538 0.688 0 C-N-CA 123.968 3.112 . . . . 1.95 109.152 156.023 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.212 0 CA-C-O 117.239 -1.867 . . . . 3.0 112.546 148.642 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo . . . . . 0 CA--C 1.545 1.042 0 CA-C-O 119.454 -0.311 . . . . 2.33 111.39 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.18 -178.58 8.79 Favored Glycine 0 CA--C 1.541 1.711 0 O-C-N 121.108 -0.995 . . . . 1.34 112.382 128.253 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -74.73 -135.64 0.01 OUTLIER 'Trans proline' 0 CA--C 1.545 1.038 0 C-N-CA 124.789 3.659 . . . . 2.42 108.313 158.514 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 -86.71 -173.17 4.36 Favored 'General case' 0 CA--C 1.541 0.632 0 O-C-N 121.056 -1.027 . . . . 4.57 111.586 172.577 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.59 158.04 29.37 Favored Glycine 0 CA--C 1.534 1.266 0 O-C-N 121.514 -0.741 . . . . 1.11 112.097 159.689 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 88.2 mt -78.68 154.16 4.96 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.076 0 C-N-CA 124.344 1.058 . . . . 3.27 109.799 173.674 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.42 150.39 43.71 Favored 'General case' 0 CA--C 1.547 0.854 0 O-C-N 120.932 -1.105 . . . . 1.44 113.801 177.802 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -87.46 170.78 41.04 Favored Glycine 0 CA--C 1.526 0.771 0 C-N-CA 125.748 1.642 . . . . 1.93 114.286 -176.517 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -72.41 128.41 35.54 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.646 1.178 . . . . 4.63 111.927 -175.1 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 5.1 ttt180 -62.07 153.3 30.23 Favored 'General case' 0 CA--C 1.54 0.562 0 C-N-CA 122.586 0.354 . . . . 5.62 111.667 179.266 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.39 158.61 26.69 Favored Glycine 0 CA--C 1.53 0.986 0 C-N-CA 124.209 0.909 . . . . 1.73 115.189 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 13.2 m -84.96 134.68 26.47 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 N-CA-C 113.645 0.98 . . . . 3.7 113.645 -178.524 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.6 m -88.85 162.02 2.62 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 C-N-CA 126.151 1.781 . . . . 2.38 113.215 -164.206 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.92 -131.1 7.1 Favored Glycine 0 CA--C 1.529 0.945 0 C-N-CA 124.925 1.25 . . . . 1.83 113.468 177.386 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.0 pp -172.38 153.83 3.02 Favored Pre-proline 0 CA--C 1.543 0.675 0 C-N-CA 124.302 1.041 . . . . 3.64 112.043 -152.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo . . . . . 0 C--O 1.255 1.359 1 C-N-CA 125.429 4.086 . . . . 2.42 112.548 153.764 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo . . . . . 0 N--CA 1.488 1.181 0 CA-C-O 118.947 -0.522 . . . . 2.52 112.009 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -72.01 -133.98 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.93 0 C-N-CA 123.761 2.974 . . . . 1.94 108.107 162.536 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -73.85 166.16 54.72 Favored Glycine 0 CA--C 1.539 1.578 0 CA-C-N 119.905 1.23 . . . . 1.2 111.107 163.29 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 93.6 Cg_endo -81.87 -37.64 0.25 Allowed 'Trans proline' 0 CA--C 1.536 0.589 0 C-N-CA 122.919 2.412 . . . . 3.5 113.072 -179.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 31.8 tp60 170.04 134.14 0.02 OUTLIER 'General case' 0 CA--C 1.541 0.61 0 C-N-CA 127.672 2.389 . . . . 1.37 107.117 -157.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -97.49 178.11 32.48 Favored Glycine 0 CA--C 1.528 0.872 0 C-N-CA 125.119 1.342 . . . . 0.97 113.027 167.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . 0.463 ' H ' HD12 ' C' ' 17' ' ' ILE . 3.4 mp -63.72 134.75 28.47 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 C-N-CA 124.152 0.981 . . . . 2.55 111.486 -177.146 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.45 146.46 48.62 Favored 'General case' 0 CA--C 1.541 0.622 0 O-C-N 121.31 -0.869 . . . . 1.31 113.05 -178.582 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -72.28 87.42 0.5 Allowed Glycine 0 CA--C 1.527 0.788 0 C-N-CA 127.04 2.257 . . . . 2.59 112.748 -173.532 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 94.5 mm-40 -59.21 164.16 3.33 Favored 'General case' 0 C--N 1.331 -0.238 0 C-N-CA 124.66 1.184 . . . . 5.07 113.444 -171.189 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 10.5 ttp-105 -46.19 127.75 8.98 Favored 'General case' 0 C--O 1.239 0.525 0 C-N-CA 124.771 1.229 . . . . 5.86 112.809 176.571 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.31 -174.24 8.49 Favored Glycine 0 CA--C 1.524 0.627 0 CA-C-N 113.134 -1.848 . . . . 1.49 113.306 175.647 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.9 t -63.65 143.63 15.44 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.604 0 C-N-CA 124.011 0.924 . . . . 1.88 110.237 175.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -89.78 -168.39 0.13 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.801 0 C-N-CA 125.787 1.635 . . . . 2.52 110.302 179.063 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.57 -168.49 2.3 Favored Glycine 0 CA--C 1.539 1.567 0 C-N-CA 124.133 0.873 . . . . 1.87 114.385 169.748 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 14.8 mt . . . . . 0 N--CA 1.483 1.189 0 C-N-CA 124.269 1.028 . . . . 3.45 113.703 176.956 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.855 0 CA-C-O 117.153 -1.915 . . . . 5.61 108.801 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -64.34 111.35 1.6 Allowed 'Trans proline' 0 N--CA 1.453 -0.91 0 N-CA-C 104.867 -2.782 . . . . 2.35 104.867 151.61 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 26.7 mm100 -70.76 172.18 9.22 Favored 'General case' 0 C--N 1.328 -0.369 0 C-N-CA 125.708 1.603 . . . . 4.41 114.12 -164.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -61.46 145.53 48.68 Favored Glycine 0 C--N 1.335 0.483 0 N-CA-C 110.442 -1.063 . . . . 1.72 110.442 160.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.416 HG13 ' H ' ' A' ' 17' ' ' ILE . 2.7 mt -54.47 125.1 8.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 107.068 -1.456 . . . . 2.38 107.068 175.264 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -50.11 150.54 2.34 Favored 'General case' 0 CA--C 1.536 0.435 0 CA-C-O 121.773 0.797 . . . . 2.25 111.897 -176.397 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.81 167.27 34.39 Favored Glycine 0 CA--C 1.527 0.795 0 C-N-CA 124.461 1.029 . . . . 1.55 114.064 -173.139 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 13.5 mp0 -71.49 166.12 22.42 Favored 'General case' 0 CA--C 1.542 0.635 0 O-C-N 122.187 -0.596 . . . . 5.15 111.972 -175.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 4.8 tpt180 -68.05 132.69 47.71 Favored 'General case' 0 CA--C 1.54 0.59 0 N-CA-C 113.94 1.089 . . . . 4.67 113.94 -162.261 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.78 93.07 1.36 Allowed Glycine 0 C--N 1.336 0.564 0 N-CA-C 109.786 -1.326 . . . . 1.81 109.786 170.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 28.5 m -58.22 140.62 16.29 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.971 0 C-N-CA 123.76 0.824 . . . . 2.64 112.011 -176.439 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.7 t -50.99 142.96 2.96 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 126.26 1.824 . . . . 3.57 112.301 -170.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.82 148.28 50.36 Favored Glycine 0 N--CA 1.477 1.373 0 O-C-N 121.507 -0.746 . . . . 1.64 112.304 173.04 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -85.19 156.78 59.95 Favored Pre-proline 0 CA--C 1.541 0.609 0 CA-C-O 118.872 -0.585 . . . . 3.26 110.736 176.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.417 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 30.3 Cg_endo -85.38 -154.09 0.05 OUTLIER 'Trans proline' 0 CA--C 1.536 0.604 0 C-N-CA 123.517 2.811 . . . . 1.78 108.973 157.451 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.344 0 CA-C-O 117.631 -1.649 . . . . 3.09 113.437 148.89 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 32.2 Cg_exo . . . . . 0 N--CA 1.482 0.832 0 CA-C-O 119.379 -0.342 . . . . 3.5 112.799 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -79.78 136.83 17.8 Favored Glycine 0 CA--C 1.533 1.175 0 N-CA-C 110.216 -1.154 . . . . 1.31 110.216 157.017 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -76.6 177.23 9.09 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 C-N-CA 122.988 2.459 . . . . 2.27 108.806 160.449 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -41.14 138.41 1.14 Allowed 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.318 1.447 . . . . 4.38 112.366 168.51 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -73.78 168.26 54.15 Favored Glycine 0 CA--C 1.526 0.756 0 C-N-CA 125.782 1.658 . . . . 1.05 115.248 -173.047 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 15.4 mm -61.79 140.14 19.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.623 0 CA-C-N 114.673 -0.764 . . . . 2.79 110.038 172.011 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.04 142.89 58.21 Favored 'General case' 0 CA--C 1.542 0.644 0 C-N-CA 123.488 0.715 . . . . 1.76 111.531 173.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -58.38 -70.24 1.05 Allowed Glycine 0 N--CA 1.472 1.048 0 C-N-CA 123.934 0.778 . . . . 4.8 112.776 -168.399 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 178.48 -170.86 0.11 Allowed 'General case' 0 CA--C 1.543 0.698 0 C-N-CA 128.376 2.67 . . . . 5.76 109.871 162.188 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 2.1 ttt-85 -117.96 152.0 36.34 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.452 1.101 . . . . 5.71 110.965 168.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.07 150.66 52.07 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 113.95 0.34 . . . . 1.97 113.95 -179.44 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 46.3 t -76.5 124.95 35.75 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.389 0 C-N-CA 123.409 0.684 . . . . 3.22 110.583 178.761 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.4 m -66.34 151.5 10.21 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 C-N-CA 125.451 1.501 . . . . 2.45 113.338 -167.563 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -90.73 -142.77 10.33 Favored Glycine 0 CA--C 1.527 0.805 0 C-N-CA 123.808 0.718 . . . . 1.76 112.659 169.274 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.417 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 3.2 pp -165.83 154.73 10.49 Favored Pre-proline 0 CA--C 1.54 0.584 0 C-N-CA 123.785 0.834 . . . . 3.31 112.249 -153.857 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_endo . . . . . 0 C--O 1.255 1.372 0 C-N-CA 125.3 4.0 . . . . 2.71 112.477 160.58 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo . . . . . 0 N--CA 1.484 0.916 0 CA-C-O 118.569 -0.68 . . . . 2.15 111.073 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -62.38 -151.05 0.02 OUTLIER 'Trans proline' 0 CA--C 1.544 0.984 1 C-N-CA 125.346 4.031 . . . . 1.75 111.998 159.201 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -104.97 167.26 15.01 Favored Glycine 0 CA--C 1.544 1.856 0 N-CA-C 116.954 1.541 . . . . 1.3 116.954 -170.116 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_endo -87.2 55.77 3.06 Favored 'Trans proline' 0 CA--C 1.543 0.942 1 C-N-CA 125.717 4.278 . . . . 3.76 113.145 -171.357 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 70.59 155.31 0.14 Allowed 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 125.467 1.507 . . . . 2.1 112.387 -176.389 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -101.93 176.72 26.15 Favored Glycine 0 CA--C 1.53 1.029 0 C-N-CA 126.68 2.086 . . . . 1.01 114.338 167.355 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 14.9 mt -72.82 126.92 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 O-C-N 121.126 -1.22 . . . . 3.58 112.177 -170.217 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -42.44 132.19 3.58 Favored 'General case' 0 CA--C 1.537 0.481 0 C-N-CA 125.399 1.48 . . . . 1.57 112.656 168.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.46 147.06 32.27 Favored Glycine 0 C--N 1.335 0.501 0 N-CA-C 110.39 -1.084 . . . . 1.05 110.39 179.191 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 4.2 mp0 -105.67 151.27 24.6 Favored 'General case' 0 C--N 1.327 -0.388 0 O-C-N 122.201 -0.587 . . . . 3.21 110.882 -173.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 12.1 ttp180 -54.71 134.55 47.44 Favored 'General case' 0 N--CA 1.447 -0.602 0 C-N-CA 123.347 0.659 . . . . 5.12 110.369 175.14 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.45 168.93 8.56 Favored Glycine 0 CA--C 1.528 0.846 0 C-N-CA 123.431 0.539 . . . . 1.01 113.094 -179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.3 t -61.2 143.42 14.9 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 O-C-N 122.039 -0.683 . . . . 1.71 110.162 174.356 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 3.3 p -85.32 176.03 0.69 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.926 0 C-N-CA 127.736 2.414 . . . . 2.5 110.426 -178.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.27 177.66 2.33 Favored Glycine 0 CA--C 1.54 1.651 0 CA-C-N 118.886 0.766 . . . . 1.82 113.405 161.77 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 17.9 mt . . . . . 0 C--O 1.253 1.246 0 N-CA-C 115.26 1.578 . . . . 3.38 115.26 -163.861 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.56 0 CA-C-O 115.779 -2.678 . . . . 3.43 108.527 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -76.01 164.18 31.93 Favored 'Trans proline' 0 N--CA 1.455 -0.793 0 C-N-CA 122.636 2.224 . . . . 1.87 111.306 -178.085 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -77.49 -177.12 4.56 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 125.848 1.659 . . . . 2.75 112.16 167.164 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -74.92 -177.82 40.19 Favored Glycine 0 CA--C 1.529 0.959 0 C-N-CA 123.89 0.757 . . . . 1.3 114.128 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 9.3 mt -67.82 133.59 31.4 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.717 0 O-C-N 121.911 -0.758 . . . . 2.04 109.795 -174.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.7 131.96 47.9 Favored 'General case' 0 CA--C 1.538 0.487 0 C-N-CA 123.881 0.872 . . . . 1.82 110.874 172.281 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.27 152.85 51.13 Favored Glycine 0 CA--C 1.523 0.538 0 C-N-CA 126.405 1.955 . . . . 1.27 113.398 -173.831 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 82.2 mm-40 -74.77 134.65 41.8 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 115.139 -0.531 . . . . 3.8 110.589 -166.195 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 22.9 ttt180 -67.45 140.74 57.12 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-O 121.409 0.624 . . . . 5.21 112.355 -169.018 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -76.12 171.52 54.58 Favored Glycine 0 CA--C 1.522 0.525 0 C-N-CA 125.252 1.406 . . . . 1.47 115.068 -174.125 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 60.4 t -65.89 148.5 12.02 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 125.873 1.669 . . . . 2.98 109.456 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.8 m -51.84 154.7 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 123.757 0.823 . . . . 2.12 111.828 173.318 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -78.43 132.8 12.01 Favored Glycine 0 C--N 1.336 0.582 0 N-CA-C 107.777 -2.129 . . . . 2.17 107.777 158.146 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . 0.481 HD13 ' HE ' ' C' ' 21' ' ' ARG . 6.6 mp -87.95 -176.58 0.72 Allowed Pre-proline 0 C--N 1.323 -0.578 0 C-N-CA 122.746 0.418 . . . . 3.1 110.368 -174.487 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.563 ' C ' ' H ' ' C' ' 25' ' ' GLY . 85.3 Cg_endo -56.63 -166.66 0.02 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.026 0 C-N-CA 120.244 0.629 . . . . 2.39 110.79 136.794 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.152 0 CA-C-O 118.019 -1.434 . . . . 5.61 115.543 167.085 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo . . . . . 0 N--CA 1.489 1.246 0 N-CA-C 108.972 -1.203 . . . . 2.53 108.972 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.3 148.76 44.54 Favored Glycine 0 CA--C 1.54 1.655 0 CA-C-O 118.697 -1.057 . . . . 1.28 111.01 164.429 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -76.97 169.08 22.3 Favored 'Trans proline' 0 CA--C 1.538 0.676 0 C-N-CA 124.189 3.26 . . . . 2.27 110.684 166.134 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -53.25 136.94 35.76 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 124.641 1.176 . . . . 4.06 111.273 172.432 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.01 161.38 37.11 Favored Glycine 0 CA--C 1.525 0.669 0 C-N-CA 124.501 1.048 . . . . 1.1 114.696 -170.362 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 32.3 pt -56.48 131.69 20.13 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 O-C-N 122.172 -0.605 . . . . 3.32 111.341 178.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.02 151.12 45.9 Favored 'General case' 0 CA--C 1.539 0.546 0 CA-C-O 121.975 0.893 . . . . 1.47 113.198 -171.198 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -70.63 145.38 40.23 Favored Glycine 0 CA--C 1.526 0.759 0 C-N-CA 125.117 1.341 . . . . 1.84 110.712 173.27 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -123.06 159.28 28.79 Favored 'General case' 0 C--N 1.329 -0.295 0 O-C-N 121.634 -0.921 . . . . 2.68 110.81 178.068 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 3.2 ptt180 -54.96 159.75 2.24 Favored 'General case' 0 CA--C 1.539 0.556 0 N-CA-C 115.585 1.698 . . . . 4.31 115.585 178.526 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.02 -119.18 0.08 OUTLIER Glycine 0 CA--C 1.535 1.307 0 C-N-CA 127.332 2.396 . . . . 2.94 114.187 -173.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 10.5 m -143.69 142.22 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.062 0 C-N-CA 124.701 1.201 . . . . 3.54 112.24 -176.328 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 22.6 m -83.1 161.18 3.47 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.151 0 C-N-CA 126.615 1.966 . . . . 2.35 115.679 -159.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -111.22 -126.11 4.85 Favored Glycine 0 CA--C 1.533 1.171 0 C-N-CA 126.22 1.867 . . . . 1.88 113.636 177.852 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.44 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.6 pt? -169.36 159.77 7.46 Favored Pre-proline 0 CA--C 1.554 1.12 0 N-CA-C 115.053 1.501 . . . . 3.58 115.053 -148.862 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo . . . . . 0 C--O 1.255 1.343 0 C-N-CA 123.558 2.839 . . . . 3.41 111.565 156.617 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 66.4 Cg_endo . . . . . 0 CA--C 1.546 1.124 0 CA-C-O 118.729 -0.613 . . . . 2.29 110.923 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -68.34 -155.16 0.03 OUTLIER 'Trans proline' 0 CA--C 1.546 1.093 0 C-N-CA 123.493 2.795 . . . . 1.7 109.618 157.018 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -100.61 -178.68 29.64 Favored Glycine 0 CA--C 1.534 1.251 0 C-N-CA 123.934 0.778 . . . . 1.25 112.775 172.088 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_endo -75.35 164.83 32.0 Favored 'Trans proline' 0 CA--C 1.537 0.631 0 C-N-CA 123.446 2.764 . . . . 2.29 112.098 176.054 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.7 tp60 -40.81 129.01 2.65 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 127.296 2.238 . . . . 1.63 113.451 163.226 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.98 152.77 52.71 Favored Glycine 0 CA--C 1.529 0.908 0 C-N-CA 124.641 1.115 . . . . 1.08 113.447 169.642 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 96.7 mt -56.73 148.5 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 C-N-CA 124.4 1.08 . . . . 2.82 111.732 179.026 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -77.0 164.37 25.82 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 115.07 1.507 . . . . 1.49 115.07 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -84.7 168.92 44.22 Favored Glycine 0 CA--C 1.528 0.861 0 C-N-CA 124.968 1.27 . . . . 1.05 114.003 -174.401 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 8.9 mp0 -104.98 -179.22 3.88 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 125.177 1.391 . . . . 3.61 111.043 -166.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . 0.481 ' HE ' HD13 ' A' ' 26' ' ' LEU . 59.3 ttt180 -66.38 148.58 51.65 Favored 'General case' 0 N--CA 1.48 1.054 0 O-C-N 120.938 -1.102 . . . . 4.19 109.437 161.229 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -78.25 -173.58 42.03 Favored Glycine 0 CA--C 1.533 1.19 0 O-C-N 121.119 -0.988 . . . . 1.34 112.067 169.082 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 4.1 t -71.3 139.15 20.35 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 123.693 0.797 . . . . 1.94 109.123 176.551 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 16.0 m -71.47 173.6 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 C-N-CA 126.876 2.07 . . . . 2.82 112.65 176.425 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.563 ' H ' ' C ' ' A' ' 27' ' ' PRO . . . -53.26 172.42 0.52 Allowed Glycine 0 CA--C 1.538 1.509 0 C-N-CA 125.398 1.475 . . . . 1.74 115.895 158.323 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 7.1 mp . . . . . 0 C--O 1.252 1.212 0 C-N-CA 125.831 1.652 . . . . 3.98 114.761 -157.619 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.614 0 CA-C-O 116.662 -2.188 . . . . 2.92 109.511 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -77.05 164.27 29.79 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 123.234 2.623 . . . . 2.2 112.135 -171.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -57.99 151.68 17.97 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 127.028 2.131 . . . . 4.18 111.567 167.441 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.11 -102.26 0.04 OUTLIER Glycine 0 N--CA 1.471 1.016 0 C-N-CA 125.112 1.339 . . . . 1.94 113.923 -179.355 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.9 mt -123.17 143.51 35.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 O-C-N 121.634 -0.921 . . . . 3.14 108.978 -177.231 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.57 53.05 0.21 Allowed 'General case' 0 CA--C 1.548 0.899 0 C-N-CA 125.403 1.481 . . . . 3.7 111.97 170.056 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 86.11 -164.49 36.98 Favored Glycine 0 C--N 1.335 0.502 0 C-N-CA 127.813 2.625 . . . . 2.3 112.993 172.403 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 36.1 mm-40 -106.37 124.89 50.29 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 106.162 -1.792 . . . . 3.0 106.162 141.353 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 48.8 ttt85 -63.99 142.43 58.41 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 123.588 0.755 . . . . 4.59 110.84 -174.848 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.96 146.33 41.25 Favored Glycine 0 CA--C 1.523 0.59 0 C-N-CA 125.201 1.382 . . . . 1.56 112.272 -173.494 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 14.3 m -73.57 133.44 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.593 0 C-N-CA 124.83 1.252 . . . . 2.64 110.989 -174.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 5.4 p -50.77 147.75 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.014 0 C-N-CA 126.386 1.875 . . . . 3.33 114.973 -164.042 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -76.27 -179.95 47.34 Favored Glycine 0 CA--C 1.535 1.31 0 O-C-N 121.969 -0.457 . . . . 1.69 112.338 166.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.8 mt -143.97 158.01 56.55 Favored Pre-proline 0 N--CA 1.477 0.904 0 CA-C-O 118.175 -0.917 . . . . 3.72 112.399 -167.334 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -66.53 -173.45 0.37 Allowed 'Trans proline' 0 CA--C 1.537 0.653 0 C-N-CA 122.017 1.811 . . . . 2.3 110.188 158.119 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.534 1.271 0 CA-C-O 117.828 -1.54 . . . . 3.41 113.007 152.384 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_exo . . . . . 0 CA--C 1.541 0.861 0 CA-C-O 118.621 -0.658 . . . . 2.09 111.486 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -70.84 173.86 40.85 Favored Glycine 0 CA--C 1.54 1.606 0 CA-C-N 119.127 0.876 . . . . 1.38 111.885 143.226 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 69.1 Cg_endo -71.17 163.03 40.57 Favored 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 123.707 2.938 . . . . 2.63 109.87 158.041 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.22 138.81 54.32 Favored 'General case' 0 CA--C 1.537 0.466 0 C-N-CA 124.445 1.098 . . . . 3.63 111.901 179.707 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -57.63 142.79 42.94 Favored Glycine 0 C--N 1.342 0.887 0 C-N-CA 124.497 1.046 . . . . 1.21 114.195 -175.175 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 47.7 mm -73.61 142.72 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 123.893 0.877 . . . . 4.56 110.842 -177.214 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -52.17 139.11 24.37 Favored 'General case' 0 CA--C 1.544 0.717 0 N-CA-C 115.222 1.564 . . . . 1.58 115.222 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -66.32 141.87 41.74 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 126.096 1.807 . . . . 1.62 111.702 176.321 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 6.7 mp0 -79.74 151.85 30.16 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.194 0.598 . . . . 3.29 110.949 -173.388 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 12.7 mtt180 -60.76 150.12 33.51 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 118.857 0.753 . . . . 5.78 112.492 177.297 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -60.2 153.12 35.8 Favored Glycine 0 CA--C 1.531 1.065 0 CA-C-N 115.955 -0.566 . . . . 2.06 112.736 168.194 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 22.6 t -75.72 130.43 36.19 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.669 0 N-CA-C 112.613 0.598 . . . . 3.16 112.613 -164.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 21.8 m -60.03 157.62 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.982 0 N-CA-C 115.41 1.633 . . . . 2.78 115.41 -163.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.14 -178.07 45.95 Favored Glycine 0 C--N 1.338 0.652 0 C-N-CA 125.696 1.617 . . . . 1.77 115.548 -167.234 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.7 mp -134.97 130.9 19.68 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 123.78 0.832 . . . . 4.89 112.287 -170.444 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo . . . . . 0 C--O 1.256 1.383 0 C-N-CA 123.826 3.017 . . . . 2.67 112.017 146.947 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo . . . . . 0 N--CA 1.489 1.208 0 CA-C-O 118.73 -0.613 . . . . 2.43 111.511 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 64.4 Cg_endo -73.93 -126.63 0.01 OUTLIER 'Trans proline' 0 CA--C 1.543 0.943 0 C-N-CA 124.246 3.298 . . . . 1.86 108.461 167.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -83.47 148.05 24.79 Favored Glycine 0 CA--C 1.538 1.515 0 CA-C-N 119.229 0.922 . . . . 1.22 112.522 172.498 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -74.18 96.76 0.97 Allowed 'Trans proline' 0 N--CA 1.456 -0.703 0 C-N-CA 123.285 2.656 . . . . 2.96 109.329 172.192 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.455 ' HG3' ' H ' ' C' ' 16' ' ' GLY . 16.5 tp60 59.1 -126.27 1.31 Allowed 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.176 0.99 . . . . 2.98 109.239 179.819 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . 0.455 ' H ' ' HG3' ' C' ' 15' ' ' GLN . . . 174.25 161.78 24.79 Favored Glycine 0 CA--C 1.535 1.33 1 C-N-CA 132.048 4.642 . . . . 1.15 108.763 -179.769 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . 0.426 ' H ' HD12 ' C' ' 17' ' ' ILE . 3.7 mp -66.69 145.58 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 CA-C-N 119.34 1.57 . . . . 3.02 110.984 -177.576 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -78.56 145.93 34.54 Favored 'General case' 0 CA--C 1.545 0.765 0 O-C-N 120.915 -1.116 . . . . 1.58 113.024 178.311 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -88.84 161.08 30.45 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 125.305 1.431 . . . . 1.25 113.15 -179.603 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 58.7 mt-30 -87.2 160.28 18.54 Favored 'General case' 0 C--O 1.235 0.335 0 C-N-CA 123.95 0.9 . . . . 4.31 113.129 -174.539 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.24 138.42 45.09 Favored 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 109.511 -0.552 . . . . 3.62 109.511 163.413 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.9 165.73 52.68 Favored Glycine 0 CA--C 1.523 0.534 0 C-N-CA 123.728 0.68 . . . . 1.02 113.005 -177.096 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 91.2 t -63.67 138.33 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 C-N-CA 123.765 0.826 . . . . 1.78 108.899 173.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 25.6 m -101.89 -175.79 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.802 0 C-N-CA 125.139 1.376 . . . . 3.12 111.057 -177.831 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -58.96 173.75 3.57 Favored Glycine 0 CA--C 1.538 1.497 0 C-N-CA 124.582 1.087 . . . . 1.86 114.744 171.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 22.7 mt . . . . . 0 C--O 1.25 1.102 0 C-N-CA 125.261 1.425 . . . . 3.07 114.434 -168.297 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.62 0 CA-C-O 116.009 -2.55 . . . . 2.86 108.799 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -72.99 167.96 25.99 Favored 'Trans proline' 0 N--CA 1.458 -0.6 0 C-N-CA 122.991 2.461 . . . . 1.9 111.535 -179.413 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -72.43 169.28 16.7 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 127.35 2.26 . . . . 3.13 113.039 170.417 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.84 -174.98 40.8 Favored Glycine 0 CA--C 1.528 0.848 0 C-N-CA 125.21 1.386 . . . . 1.2 113.006 169.619 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 14.6 pt -74.18 155.3 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 O-C-N 121.754 -0.851 . . . . 2.7 111.096 -173.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -57.81 139.84 53.13 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 123.421 0.688 . . . . 1.84 111.597 172.727 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -57.56 150.65 30.27 Favored Glycine 0 CA--C 1.518 0.244 0 C-N-CA 127.259 2.361 . . . . 1.27 113.492 172.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 10.4 mm100 -64.93 118.26 8.8 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 114.716 -0.742 . . . . 3.75 109.194 -178.076 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.8 ttp180 -58.97 139.67 56.48 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 113.013 0.746 . . . . 4.34 113.013 -170.137 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.04 158.47 53.18 Favored Glycine 0 CA--C 1.519 0.331 0 C-N-CA 125.165 1.364 . . . . 1.54 113.38 -169.436 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 33.3 m -68.13 150.22 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-N 114.858 -0.671 . . . . 2.44 110.72 -175.318 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.5 m -51.05 147.8 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 C-N-CA 124.192 0.997 . . . . 1.99 111.883 173.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.77 133.44 19.07 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 109.627 -1.389 . . . . 1.76 109.627 162.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 9.5 mp -77.18 169.92 18.84 Favored Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 122.882 0.473 . . . . 2.98 110.823 177.493 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.463 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 97.7 Cg_endo -77.17 -148.08 0.03 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 121.843 1.695 . . . . 2.02 108.277 154.338 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 1.41 0 CA-C-O 117.365 -1.797 . . . . 3.9 112.98 151.723 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo . . . . . 0 N--CA 1.484 0.938 0 CA-C-O 118.554 -0.686 . . . . 2.07 111.363 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.14 150.46 50.44 Favored Glycine 0 CA--C 1.546 1.994 0 CA-C-O 118.849 -0.973 . . . . 1.55 111.947 157.844 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -76.74 44.31 1.4 Allowed 'Trans proline' 0 CA--C 1.547 1.148 1 C-N-CA 126.986 5.124 . . . . 3.24 114.127 -172.662 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 2.1 tp-100 73.19 -175.44 0.16 Allowed 'General case' 0 N--CA 1.479 0.994 0 C-N-CA 125.132 1.373 . . . . 4.95 109.606 -163.476 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -94.4 170.26 29.73 Favored Glycine 0 N--CA 1.473 1.126 0 O-C-N 121.091 -1.006 . . . . 1.16 113.12 166.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 50.1 mt -72.85 125.63 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.096 0 C-N-CA 123.564 0.746 . . . . 3.08 110.967 -176.438 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.82 143.75 57.72 Favored 'General case' 0 CA--C 1.545 0.762 0 O-C-N 121.203 -0.935 . . . . 1.48 113.253 -178.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -77.43 171.24 55.16 Favored Glycine 0 CA--C 1.529 0.919 0 C-N-CA 125.656 1.598 . . . . 1.74 113.578 -177.726 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -135.34 156.19 49.34 Favored 'General case' 0 C--N 1.328 -0.341 0 C-N-CA 125.415 1.486 . . . . 2.97 110.224 -172.269 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.8 ptt-85 -71.99 152.5 42.43 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 114.747 1.388 . . . . 6.41 114.747 -172.48 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.23 176.99 54.53 Favored Glycine 0 CA--C 1.536 1.36 0 C-N-CA 125.317 1.437 . . . . 1.77 113.763 176.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 46.9 t -83.3 142.02 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 124.854 1.261 . . . . 3.11 112.98 -164.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 20.1 m -76.08 163.54 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 C-N-CA 126.769 2.028 . . . . 2.43 114.323 -165.612 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -96.27 -127.03 5.3 Favored Glycine 0 CA--C 1.53 1.013 0 C-N-CA 125.107 1.337 . . . . 2.23 113.567 176.054 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.463 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 3.8 pp -171.82 159.04 4.6 Favored Pre-proline 0 CA--C 1.547 0.854 0 C-N-CA 125.769 1.627 . . . . 4.67 111.72 -156.529 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_endo . . . . . 0 C--O 1.256 1.383 0 C-N-CA 123.978 3.119 . . . . 3.23 111.767 153.807 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_endo . . . . . 0 N--CA 1.487 1.1 0 CA-C-O 119.181 -0.425 . . . . 1.98 111.627 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 65.6 Cg_endo -71.54 -138.43 0.02 OUTLIER 'Trans proline' 0 CA--C 1.545 1.034 0 C-N-CA 123.317 2.678 . . . . 1.66 108.672 165.075 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -90.21 170.21 35.61 Favored Glycine 0 CA--C 1.538 1.52 0 N-CA-C 110.593 -1.003 . . . . 1.32 110.593 165.112 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -77.07 -58.63 0.04 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 122.4 2.067 . . . . 3.82 110.705 173.029 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.433 HE21 ' N ' ' C' ' 16' ' ' GLY . 23.0 tp60 -174.88 133.51 0.34 Allowed 'General case' 0 N--CA 1.444 -0.764 0 C-N-CA 126.316 1.846 . . . . 1.28 106.292 -148.04 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . 0.433 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -80.38 160.52 43.98 Favored Glycine 0 CA--C 1.523 0.575 0 C-N-CA 123.649 0.642 . . . . 1.0 111.658 170.216 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 37.1 mm -66.11 144.08 15.05 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 O-C-N 121.817 -0.813 . . . . 3.49 110.089 174.638 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.05 161.18 5.33 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 114.505 1.298 . . . . 1.19 114.505 177.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.44 170.46 52.22 Favored Glycine 0 CA--C 1.528 0.877 0 C-N-CA 124.562 1.077 . . . . 1.21 113.298 179.22 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 8.7 mp0 -95.64 177.88 5.65 Favored 'General case' 0 CA--C 1.544 0.745 0 C-N-CA 124.339 1.056 . . . . 4.41 112.064 -168.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 14.6 ttt85 -72.87 141.25 47.93 Favored 'General case' 0 N--CA 1.473 0.692 0 O-C-N 120.369 -1.457 . . . . 3.5 110.329 167.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.95 173.69 34.53 Favored Glycine 0 CA--C 1.534 1.263 0 O-C-N 121.731 -0.606 . . . . 1.32 112.111 167.343 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.2 t -69.94 141.66 16.87 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.657 0 C-N-CA 124.409 1.084 . . . . 1.89 109.636 179.483 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 10.9 m -74.81 178.88 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.639 0 C-N-CA 124.432 1.093 . . . . 2.57 111.377 175.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -61.37 -171.68 0.94 Allowed Glycine 0 CA--C 1.538 1.489 0 C-N-CA 124.735 1.16 . . . . 1.68 114.193 162.84 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 15.5 mt . . . . . 0 N--CA 1.481 1.088 0 CA-C-O 117.199 -1.381 . . . . 3.58 113.719 -168.858 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.598 0 CA-C-O 117.035 -1.981 . . . . 3.25 110.153 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 62.9 Cg_endo -70.02 154.5 66.64 Favored 'Trans proline' 0 CA--C 1.535 0.543 0 C-N-CA 123.631 2.887 . . . . 2.69 111.982 179.332 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -78.91 176.96 9.13 Favored 'General case' 0 CA--C 1.553 1.092 0 C-N-CA 129.842 3.257 . . . . 3.7 111.563 -178.044 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -90.85 -172.93 43.97 Favored Glycine 0 N--CA 1.478 1.45 0 C-N-CA 125.189 1.376 . . . . 1.76 113.66 176.601 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.6 mm -76.45 134.96 27.8 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.485 0 N-CA-C 108.27 -1.011 . . . . 3.72 108.27 174.217 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.22 71.16 0.26 Allowed 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 125.074 1.35 . . . . 4.43 111.561 172.271 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 63.98 -146.52 50.4 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 125.021 1.296 . . . . 2.47 111.495 -169.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -142.9 128.7 19.37 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 106.269 -1.752 . . . . 5.48 106.269 150.964 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -53.02 126.92 22.17 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 118.769 0.713 . . . . 5.81 109.725 -177.362 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.46 -83.59 0.26 Allowed Glycine 0 N--CA 1.471 1.017 0 O-C-N 123.407 0.442 . . . . 3.18 112.088 -165.677 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -148.92 153.94 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 C-N-CA 124.562 1.145 . . . . 2.06 112.161 175.813 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.5 m -65.87 161.52 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.625 0 C-N-CA 123.972 0.909 . . . . 2.99 111.233 168.196 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -76.24 174.07 53.62 Favored Glycine 0 CA--C 1.53 0.99 0 C-N-CA 123.585 0.612 . . . . 1.39 112.505 168.184 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 3.4 mm? -101.67 159.82 28.32 Favored Pre-proline 0 CA--C 1.542 0.663 0 C-N-CA 124.352 1.061 . . . . 3.14 110.854 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_endo -78.77 -166.67 0.42 Allowed 'Trans proline' 0 CA--C 1.537 0.675 0 C-N-CA 123.326 2.684 . . . . 2.19 109.324 157.663 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.274 0 CA-C-O 117.834 -1.537 . . . . 3.51 112.826 154.858 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.6 Cg_exo . . . . . 0 CA--C 1.542 0.921 0 N-CA-C 110.308 -0.689 . . . . 2.96 110.308 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -66.41 -167.91 2.73 Favored Glycine 0 CA--C 1.545 1.958 0 C-N-CA 119.659 -1.257 . . . . 2.16 112.033 124.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 16.2 Cg_endo -89.51 -138.97 0.02 OUTLIER 'Trans proline' 0 CA--C 1.546 1.077 0 C-N-CA 125.004 3.802 . . . . 2.86 109.287 175.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.82 138.57 32.44 Favored 'General case' 0 CA--C 1.535 0.394 0 C-N-CA 127.288 2.235 . . . . 4.0 107.14 162.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -59.27 131.96 51.84 Favored Glycine 0 N--CA 1.468 0.807 0 N-CA-C 111.264 -0.734 . . . . 1.9 111.264 174.188 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 32.2 mm -60.56 150.37 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 O-C-N 122.334 -0.509 . . . . 5.87 110.982 175.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.57 137.5 58.25 Favored 'General case' 0 CA--C 1.55 0.952 0 O-C-N 120.7 -1.25 . . . . 3.01 114.315 176.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -93.13 -162.6 36.69 Favored Glycine 0 CA--C 1.533 1.196 0 C-N-CA 125.79 1.662 . . . . 2.9 112.211 171.123 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -157.73 174.31 15.51 Favored 'General case' 0 CA--C 1.537 0.442 0 O-C-N 121.064 -1.257 . . . . 3.98 113.944 -173.282 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 8.4 ptt180 -58.11 158.46 6.87 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 115.656 1.724 . . . . 4.54 115.656 172.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -86.17 -161.41 35.36 Favored Glycine 0 CA--C 1.535 1.29 0 C-N-CA 125.462 1.506 . . . . 2.34 111.499 162.283 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 43.8 t -120.3 145.21 26.99 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.041 0 C-N-CA 124.557 1.143 . . . . 4.62 112.528 -159.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 14.9 p -56.03 159.03 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 C-N-CA 128.834 2.854 . . . . 3.72 114.359 -178.548 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.93 -126.7 1.08 Allowed Glycine 0 CA--C 1.53 1.023 0 C-N-CA 124.535 1.064 . . . . 2.23 111.204 166.218 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -167.26 162.76 10.37 Favored Pre-proline 0 CA--C 1.542 0.646 0 C-N-CA 125.343 1.457 . . . . 3.85 110.867 -166.74 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 11.3 Cg_endo . . . . . 0 CA--C 1.552 1.386 0 C-N-CA 124.47 3.447 . . . . 3.29 112.15 165.844 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 67.2 Cg_endo . . . . . 0 N--CA 1.487 1.122 0 CA-C-O 118.339 -0.775 . . . . 3.23 111.233 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_exo -62.32 -152.38 0.02 OUTLIER 'Trans proline' 0 CA--C 1.542 0.924 0 C-N-CA 124.91 3.74 . . . . 2.5 111.696 163.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -74.39 168.66 54.4 Favored Glycine 0 CA--C 1.541 1.712 0 N-CA-C 109.985 -1.246 . . . . 1.56 109.985 163.39 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -76.64 176.65 9.83 Favored 'Trans proline' 0 N--CA 1.452 -0.941 0 C-N-CA 123.142 2.561 . . . . 2.66 110.681 170.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 9.5 tp60 -40.38 122.24 1.55 Allowed 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.279 1.432 . . . . 1.6 111.217 148.113 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.94 -169.37 27.54 Favored Glycine 0 CA--C 1.527 0.795 0 CA-C-O 121.993 0.774 . . . . 1.52 112.731 169.021 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 18.9 mt -63.82 124.33 18.33 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 O-C-N 121.638 -0.919 . . . . 2.87 110.833 175.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -65.52 155.85 34.4 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.582 1.153 . . . . 1.36 113.135 179.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -80.83 -179.24 52.87 Favored Glycine 0 CA--C 1.526 0.757 0 CA-C-O 123.23 1.461 . . . . 1.65 111.672 176.289 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -128.82 -160.48 1.03 Allowed 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.749 1.22 . . . . 3.25 109.149 178.309 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 21.2 ttm180 -85.19 152.46 23.33 Favored 'General case' 0 C--O 1.234 0.278 0 C-N-CA 124.892 1.277 . . . . 5.72 112.342 -179.181 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.26 176.85 43.88 Favored Glycine 0 CA--C 1.533 1.192 0 N-CA-C 111.03 -0.828 . . . . 1.01 111.03 164.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.0 t -59.84 149.39 6.86 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 124.042 0.937 . . . . 2.24 110.178 174.28 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 26.9 m -80.83 -173.34 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.814 0 C-N-CA 123.866 0.866 . . . . 2.65 111.079 173.227 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -55.98 160.12 7.27 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 124.154 0.883 . . . . 2.04 114.162 173.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 5.3 mt . . . . . 0 C--O 1.25 1.104 0 N-CA-C 114.246 1.202 . . . . 4.07 114.246 -163.079 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.738 0 CA-C-O 116.517 -2.268 . . . . 3.68 109.755 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -73.53 160.86 43.51 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 122.685 2.256 . . . . 2.25 110.924 -177.103 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 41.4 tp60 -48.65 151.76 1.09 Allowed 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 127.747 2.419 . . . . 4.14 114.866 -179.69 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.26 176.59 52.9 Favored Glycine 0 N--CA 1.465 0.618 0 C-N-CA 124.676 1.132 . . . . 1.27 115.199 173.957 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 14.4 mt -66.29 134.71 29.56 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 125.107 1.363 . . . . 2.34 110.568 -176.325 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.99 137.35 55.78 Favored 'General case' 0 CA--C 1.54 0.566 0 C-N-CA 123.943 0.897 . . . . 1.99 112.267 175.313 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -66.72 157.76 50.33 Favored Glycine 0 CA--C 1.528 0.851 0 C-N-CA 125.485 1.517 . . . . 1.26 113.934 -176.507 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 53.1 mm-40 -62.5 128.98 38.56 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 114.738 -0.731 . . . . 3.36 109.668 -179.169 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 14.8 ttt180 -70.47 143.28 51.79 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 112.291 0.478 . . . . 4.73 112.291 -164.828 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -76.85 138.18 21.79 Favored Glycine 0 CA--C 1.522 0.528 0 C-N-CA 123.844 0.735 . . . . 1.93 111.414 -178.144 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 33.2 m -66.89 162.41 3.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 124.538 1.135 . . . . 2.24 112.493 -174.628 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.1 m -54.76 160.64 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 C-N-CA 124.527 1.131 . . . . 2.33 112.965 174.373 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.56 168.41 39.2 Favored Glycine 0 CA--C 1.527 0.817 0 CA-C-N 115.448 -0.796 . . . . 1.44 113.285 164.716 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 8.6 mp -99.46 156.63 35.19 Favored Pre-proline 0 CA--C 1.541 0.598 0 C-N-CA 124.004 0.922 . . . . 4.45 109.659 176.835 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_endo -84.58 -164.32 0.24 Allowed 'Trans proline' 0 N--CA 1.455 -0.744 0 C-N-CA 123.541 2.827 . . . . 2.55 109.163 162.449 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.239 0 CA-C-O 117.77 -1.572 . . . . 3.64 112.812 158.151 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 94.3 Cg_exo . . . . . 0 CA--C 1.544 0.998 0 CA-C-O 119.095 -0.46 . . . . 2.77 111.724 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -62.84 164.46 27.15 Favored Glycine 0 CA--C 1.542 1.752 0 CA-C-N 119.676 1.126 . . . . 1.44 113.153 138.975 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -80.69 63.58 8.79 Favored 'Trans proline' 0 CA--C 1.541 0.827 1 C-N-CA 126.176 4.584 . . . . 3.41 111.278 -179.58 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 22.8 tp60 67.85 173.04 0.27 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 125.188 1.395 . . . . 4.28 111.698 -172.625 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.15 160.33 29.48 Favored Glycine 0 CA--C 1.531 1.039 0 O-C-N 120.734 -1.229 . . . . 1.05 111.925 155.783 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 48.9 mm -74.65 129.94 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 O-C-N 121.708 -0.878 . . . . 3.18 109.955 176.195 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.73 149.23 50.83 Favored 'General case' 0 CA--C 1.544 0.734 0 N-CA-C 113.945 1.091 . . . . 1.52 113.945 -179.116 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.97 151.74 47.78 Favored Glycine 0 CA--C 1.531 1.073 0 C-N-CA 123.843 0.735 . . . . 1.47 111.557 177.299 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -109.17 156.85 19.38 Favored 'General case' 0 N--CA 1.465 0.307 0 O-C-N 121.644 -0.915 . . . . 2.71 111.649 175.287 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 6.5 ptt180 -64.32 158.31 23.82 Favored 'General case' 0 CA--C 1.538 0.492 0 C-N-CA 126.426 1.89 . . . . 4.97 114.463 178.42 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -90.67 -167.69 41.78 Favored Glycine 0 CA--C 1.534 1.237 0 C-N-CA 126.275 1.893 . . . . 1.92 112.729 170.606 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 11.8 m -100.77 146.52 9.22 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 N-CA-C 115.849 1.796 . . . . 3.33 115.849 -162.329 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 10.6 p -46.35 153.67 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.864 0 C-N-CA 128.888 2.875 . . . . 3.84 114.938 -178.664 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.33 -127.92 1.09 Allowed Glycine 0 CA--C 1.528 0.893 0 C-N-CA 123.714 0.673 . . . . 2.51 112.165 169.57 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 3.0 pp -162.67 151.57 12.56 Favored Pre-proline 0 CA--C 1.543 0.675 0 C-N-CA 124.141 0.976 . . . . 4.78 112.135 -164.64 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo . . . . . 0 C--O 1.255 1.367 1 C-N-CA 125.375 4.05 . . . . 3.17 112.397 162.306 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo . . . . . 0 CA--C 1.547 1.153 0 CA-C-O 119.107 -0.455 . . . . 1.88 112.046 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -62.58 -166.81 0.06 OUTLIER 'Trans proline' 0 CA--C 1.54 0.8 0 C-N-CA 124.096 3.197 . . . . 1.59 111.737 166.488 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.53 143.83 34.65 Favored Glycine 0 CA--C 1.54 1.629 0 O-C-N 121.124 -0.985 . . . . 1.03 113.108 -171.753 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -78.52 61.08 7.82 Favored 'Trans proline' 0 CA--C 1.54 0.82 0 C-N-CA 124.847 3.698 . . . . 3.19 112.196 -174.914 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 40.6 tp60 75.66 145.4 0.08 Allowed 'General case' 0 CA--C 1.545 0.774 0 C-N-CA 126.543 1.937 . . . . 2.39 113.643 169.314 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -83.95 148.57 24.65 Favored Glycine 0 CA--C 1.528 0.848 0 O-C-N 120.875 -1.141 . . . . 1.1 112.838 169.397 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 38.3 mm -65.78 148.08 12.25 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 O-C-N 122.201 -0.588 . . . . 3.33 110.786 174.774 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.53 151.76 43.64 Favored 'General case' 0 CA--C 1.543 0.675 0 N-CA-C 113.093 0.775 . . . . 1.12 113.093 176.601 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -81.76 155.25 35.07 Favored Glycine 0 CA--C 1.529 0.957 0 CA-C-O 122.449 1.027 . . . . 0.95 112.342 174.878 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 18.2 mp0 -91.96 178.27 5.94 Favored 'General case' 0 CA--C 1.545 0.787 0 C-N-CA 124.988 1.315 . . . . 3.16 110.556 -179.513 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 15.5 ptp180 -71.11 162.02 30.13 Favored 'General case' 0 N--CA 1.475 0.791 0 O-C-N 121.112 -0.992 . . . . 6.29 112.85 176.931 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.55 -171.82 42.26 Favored Glycine 0 CA--C 1.535 1.327 0 C-N-CA 124.023 0.821 . . . . 1.41 112.876 174.867 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 47.2 t -68.4 139.9 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 124.374 1.069 . . . . 2.05 110.699 -178.721 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 27.8 m -81.68 -176.1 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.705 1.202 . . . . 2.89 111.751 -176.957 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.56 161.82 15.85 Favored Glycine 0 CA--C 1.532 1.136 0 C-N-CA 123.91 0.767 . . . . 1.72 113.707 173.362 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 9.4 mt . . . . . 0 C--O 1.249 1.059 0 N-CA-C 114.717 1.377 . . . . 3.68 114.717 -164.717 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.846 0 CA-C-O 116.061 -2.522 . . . . 5.48 108.935 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -80.15 -174.99 2.48 Favored 'Trans proline' 0 CA--C 1.538 0.686 0 C-N-CA 122.829 2.352 . . . . 3.47 110.38 176.831 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.409 ' HA ' ' HD2' ' B' ' 14' ' ' PRO . 0.0 OUTLIER -86.55 -143.77 0.11 Allowed 'General case' 0 CA--C 1.55 0.956 0 C-N-CA 125.288 1.435 . . . . 2.57 111.073 169.32 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -82.98 -127.91 1.22 Allowed Glycine 0 N--CA 1.472 1.062 0 C-N-CA 125.611 1.577 . . . . 1.18 112.753 170.761 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 10.2 mm -111.59 160.17 11.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.071 0 C-N-CA 124.504 1.122 . . . . 3.58 110.861 -176.466 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -78.78 81.61 5.07 Favored 'General case' 0 CA--C 1.546 0.807 0 O-C-N 120.47 -1.394 . . . . 3.72 110.237 164.438 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 69.59 -170.35 42.92 Favored Glycine 0 N--CA 1.466 0.644 0 C-N-CA 126.418 1.961 . . . . 3.08 113.397 -172.288 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -94.39 119.64 33.43 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 105.856 -1.905 . . . . 6.55 105.856 127.773 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 35.7 ttm180 -62.42 136.36 57.87 Favored 'General case' 0 CA--C 1.534 0.361 0 O-C-N 121.109 -0.994 . . . . 5.57 111.377 -178.986 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.32 170.43 53.53 Favored Glycine 0 N--CA 1.465 0.583 0 C-N-CA 125.021 1.296 . . . . 1.9 113.831 -178.082 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 25.1 m -87.55 156.93 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.902 0 CA-C-N 114.043 -1.078 . . . . 2.71 111.614 -175.823 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 29.1 m -57.16 147.71 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.879 0 C-N-CA 124.442 1.097 . . . . 2.59 112.388 -178.807 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -74.44 169.44 54.13 Favored Glycine 0 CA--C 1.529 0.928 0 N-CA-C 110.362 -1.095 . . . . 1.89 110.362 157.773 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 24.0 mt -116.18 172.09 4.1 Favored Pre-proline 0 N--CA 1.471 0.614 0 O-C-N 122.149 -0.618 . . . . 4.5 111.794 170.74 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.433 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 47.4 Cg_endo -69.78 -153.59 0.03 OUTLIER 'Trans proline' 0 CA--C 1.536 0.616 0 C-N-CA 122.717 2.278 . . . . 2.43 108.884 148.029 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.301 0 CA-C-O 116.971 -2.016 . . . . 3.82 113.106 159.693 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo . . . . . 0 N--CA 1.491 1.356 0 N-CA-C 108.774 -1.279 . . . . 3.52 108.774 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.16 147.95 51.16 Favored Glycine 0 CA--C 1.549 2.219 0 CA-C-O 118.27 -1.295 . . . . 2.36 110.635 157.879 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . 0.409 ' HD2' ' HA ' ' A' ' 15' ' ' GLN . 87.5 Cg_endo -83.42 -51.41 0.04 OUTLIER 'Trans proline' 0 CA--C 1.536 0.61 0 C-N-CA 124.229 3.286 . . . . 3.42 112.874 -173.969 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -170.66 -178.99 2.76 Favored 'General case' 0 N--CA 1.467 0.398 0 C-N-CA 128.15 2.58 . . . . 4.9 108.358 178.284 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -98.74 157.57 20.24 Favored Glycine 0 CA--C 1.528 0.857 0 CA-C-O 122.16 0.867 . . . . 1.73 113.739 177.744 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.515 ' H ' HD12 ' B' ' 17' ' ' ILE . 3.5 mp -72.71 157.27 6.58 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 124.204 1.002 . . . . 3.17 109.096 175.37 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.41 127.75 32.99 Favored 'General case' 0 CA--C 1.545 0.78 0 O-C-N 120.647 -1.283 . . . . 2.68 112.507 170.125 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -86.59 171.63 43.69 Favored Glycine 0 C--N 1.339 0.7 0 C-N-CA 125.178 1.37 . . . . 2.31 112.608 177.09 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -104.94 147.35 27.87 Favored 'General case' 0 N--CA 1.462 0.174 0 O-C-N 121.855 -0.791 . . . . 2.94 111.259 -179.068 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 6.6 ptt180 -67.99 155.74 38.83 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.167 -0.47 . . . . 4.41 110.796 158.002 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -79.17 -172.83 43.18 Favored Glycine 0 CA--C 1.533 1.212 0 C-N-CA 123.946 0.784 . . . . 1.93 113.066 178.255 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 15.3 m -93.67 145.59 7.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.849 0 N-CA-C 116.012 1.856 . . . . 3.66 116.012 -155.841 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.8 m -85.84 155.02 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.744 0 C-N-CA 125.916 1.687 . . . . 2.6 112.888 -171.373 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.73 -134.15 8.13 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 124.637 1.113 . . . . 1.67 113.25 175.203 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.433 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.4 pt? -168.56 163.38 8.26 Favored Pre-proline 0 CA--C 1.551 0.988 0 C-N-CA 126.323 1.849 . . . . 3.47 111.028 -163.475 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo . . . . . 0 C--O 1.255 1.346 0 C-N-CA 124.383 3.389 . . . . 2.49 111.502 159.184 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo . . . . . 0 N--CA 1.486 1.043 0 CA-C-O 118.819 -0.575 . . . . 3.27 111.987 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -64.29 -166.83 0.08 OUTLIER 'Trans proline' 0 CA--C 1.54 0.796 0 C-N-CA 123.616 2.878 . . . . 2.52 110.233 159.413 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -89.87 174.95 41.4 Favored Glycine 0 CA--C 1.534 1.26 0 C-N-CA 124.005 0.812 . . . . 1.49 112.589 175.338 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -70.59 169.31 20.27 Favored 'Trans proline' 0 N--CA 1.454 -0.819 0 C-N-CA 123.03 2.487 . . . . 2.47 111.941 170.527 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 26.3 tp60 -34.67 146.28 0.02 OUTLIER 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 129.066 2.947 . . . . 1.92 114.673 168.601 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.7 171.22 41.13 Favored Glycine 0 CA--C 1.525 0.672 0 C-N-CA 123.427 0.537 . . . . 1.9 112.631 168.346 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . 0.612 ' H ' HD12 ' C' ' 17' ' ' ILE . 3.3 mp -59.21 130.48 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.74 0 C-N-CA 123.157 0.583 . . . . 3.3 110.489 178.089 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.32 143.56 50.24 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 125.574 1.55 . . . . 2.34 114.797 -170.514 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -85.16 145.91 21.64 Favored Glycine 0 C--N 1.339 0.736 0 N-CA-C 109.664 -1.374 . . . . 1.56 109.664 171.706 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 5.7 mp0 -85.83 -169.67 2.75 Favored 'General case' 0 CA--C 1.545 0.754 0 C-N-CA 123.941 0.896 . . . . 3.42 110.503 179.894 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 16.2 ttt180 -64.88 145.11 56.74 Favored 'General case' 0 N--CA 1.467 0.421 0 O-C-N 121.172 -0.955 . . . . 4.57 109.49 156.297 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -64.17 162.35 36.19 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 111.414 -0.674 . . . . 1.26 111.414 161.94 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.7 t -63.57 140.15 20.12 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 C-N-CA 123.445 0.698 . . . . 2.41 109.796 176.221 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 13.4 p -79.67 178.9 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.738 0 C-N-CA 127.041 2.136 . . . . 4.12 110.872 178.479 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.34 179.36 2.62 Favored Glycine 0 CA--C 1.537 1.41 0 C-N-CA 124.553 1.073 . . . . 2.28 114.735 169.155 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 10.0 mp . . . . . 0 C--O 1.249 1.078 0 C-N-CA 126.001 1.72 . . . . 3.87 113.296 -162.571 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.791 0 CA-C-O 116.154 -2.47 . . . . 2.68 109.216 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_endo -79.04 163.95 25.22 Favored 'Trans proline' 0 N--CA 1.459 -0.524 0 C-N-CA 123.0 2.466 . . . . 1.75 111.318 -174.941 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -58.58 166.69 1.71 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.774 2.029 . . . . 3.33 114.041 168.871 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -69.59 -118.45 0.03 OUTLIER Glycine 0 N--CA 1.475 1.287 0 C-N-CA 127.452 2.453 . . . . 2.23 115.798 -176.652 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.2 mp -120.07 137.01 55.3 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 O-C-N 120.916 -1.344 . . . . 2.47 108.874 -179.824 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -52.17 128.41 24.8 Favored 'General case' 0 CA--C 1.542 0.651 0 CA-C-N 118.275 0.489 . . . . 1.9 110.706 170.135 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -62.34 156.7 37.93 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 125.777 1.656 . . . . 1.26 113.713 -177.076 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 88.9 mm-40 -73.0 116.34 13.39 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 108.734 -0.839 . . . . 3.33 108.734 -171.929 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 7.4 ttt180 -64.22 140.58 58.88 Favored 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 122.72 0.408 . . . . 5.14 112.029 -163.283 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.67 158.17 53.62 Favored Glycine 0 C--N 1.335 0.502 0 C-N-CA 123.926 0.774 . . . . 1.77 111.908 -179.644 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 33.3 m -75.97 160.99 4.87 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 CA-C-N 115.084 -0.558 . . . . 2.73 111.606 -174.636 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.1 m -51.98 164.76 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 125.531 1.532 . . . . 2.61 112.857 177.283 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.56 124.45 29.26 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.989 -0.844 . . . . 2.06 110.989 163.421 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 9.5 mp -82.31 170.92 13.2 Favored Pre-proline 0 CA--C 1.533 0.321 0 C-N-CA 124.493 1.117 . . . . 3.74 110.856 175.479 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -60.0 -165.77 0.03 OUTLIER 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 121.77 1.647 . . . . 3.42 110.821 152.135 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.667 0 CA-C-O 118.647 -1.085 . . . . 6.19 114.984 160.141 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo . . . . . 0 N--CA 1.481 0.776 0 CA-C-O 118.551 -0.687 . . . . 2.1 111.694 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.29 161.44 48.0 Favored Glycine 0 CA--C 1.54 1.628 0 CA-C-O 119.078 -0.845 . . . . 1.26 111.669 152.709 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 82.0 Cg_endo -76.0 163.68 32.75 Favored 'Trans proline' 0 CA--C 1.536 0.593 0 C-N-CA 124.235 3.29 . . . . 2.47 110.641 165.797 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -53.94 140.17 31.74 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.761 1.224 . . . . 4.27 111.79 170.948 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.23 161.67 53.24 Favored Glycine 0 CA--C 1.529 0.912 0 C-N-CA 124.167 0.889 . . . . 1.42 114.421 -174.512 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 35.6 mm -60.78 119.32 4.62 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 O-C-N 121.542 -0.975 . . . . 2.9 111.086 -175.772 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.76 155.04 27.78 Favored 'General case' 0 CA--C 1.543 0.68 0 N-CA-C 114.492 1.293 . . . . 1.59 114.492 -172.176 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.24 136.7 28.68 Favored Glycine 0 CA--C 1.527 0.809 0 C-N-CA 126.3 1.905 . . . . 1.62 111.391 -179.534 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -106.3 143.62 34.16 Favored 'General case' 0 N--CA 1.465 0.323 0 O-C-N 121.633 -0.922 . . . . 3.2 110.133 -172.415 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 32.0 ptt180 -72.22 157.6 37.43 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.344 1.058 . . . . 4.41 112.997 175.823 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -102.86 -174.95 26.77 Favored Glycine 0 CA--C 1.539 1.534 0 N-CA-C 117.061 1.584 . . . . 2.27 117.061 -170.099 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 60.9 t -96.33 136.1 28.3 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 C-N-CA 124.201 1.001 . . . . 4.49 113.517 -157.873 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.9 p -32.39 143.21 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 131.232 3.813 . . . . 4.33 118.44 -170.32 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.14 -118.79 4.11 Favored Glycine 0 CA--C 1.528 0.905 0 C-N-CA 124.968 1.27 . . . . 2.45 112.211 169.469 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 1.6 pp -168.76 153.39 5.9 Favored Pre-proline 0 CA--C 1.552 1.025 0 N-CA-C 115.565 1.691 . . . . 5.91 115.565 -150.246 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_endo . . . . . 0 C--O 1.254 1.298 0 C-N-CA 123.739 2.96 . . . . 4.65 111.741 152.935 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo . . . . . 0 N--CA 1.486 1.068 0 CA-C-O 118.582 -0.674 . . . . 2.13 111.096 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -71.12 -150.0 0.03 OUTLIER 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 123.65 2.9 . . . . 1.61 109.581 166.11 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -99.27 -172.77 31.15 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-N 118.688 0.676 . . . . 1.21 112.662 172.232 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 97.4 Cg_endo -77.81 167.69 23.46 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 123.248 2.632 . . . . 2.36 112.213 176.608 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 8.7 tp60 -37.23 127.16 1.0 Allowed 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 127.696 2.398 . . . . 1.39 113.024 160.583 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -62.5 147.75 49.46 Favored Glycine 0 CA--C 1.527 0.786 0 C-N-CA 124.321 0.962 . . . . 1.01 112.741 168.584 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 47.0 mm -57.9 147.14 6.73 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.008 0 O-C-N 121.933 -0.745 . . . . 3.35 111.557 -178.952 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -72.4 156.81 38.67 Favored 'General case' 0 CA--C 1.542 0.658 0 O-C-N 121.293 -0.879 . . . . 1.2 112.792 178.72 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -91.94 153.75 22.1 Favored Glycine 0 C--N 1.338 0.644 0 CA-C-O 122.299 0.944 . . . . 1.09 112.046 -178.528 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 25.1 mp0 -92.02 -174.12 3.69 Favored 'General case' 0 CA--C 1.544 0.721 0 CA-C-O 122.024 0.916 . . . . 2.92 111.398 -175.954 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 66.1 ttt180 -58.83 139.33 56.56 Favored 'General case' 0 N--CA 1.468 0.461 0 C-N-CA 125.15 1.38 . . . . 4.65 111.653 169.093 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -68.9 -171.01 6.81 Favored Glycine 0 C--N 1.337 0.628 0 C-N-CA 125.384 1.469 . . . . 1.58 113.481 175.825 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 21.4 t -65.0 127.46 25.95 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.696 0 O-C-N 122.305 -0.527 . . . . 2.77 110.473 -178.833 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 4.3 p -64.31 160.93 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.769 0 C-N-CA 126.864 2.066 . . . . 4.17 112.133 178.007 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -51.9 176.52 0.1 Allowed Glycine 0 CA--C 1.542 1.728 0 C-N-CA 124.52 1.057 . . . . 1.84 115.236 159.518 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 3.3 mm? . . . . . 0 C--O 1.253 1.248 0 CA-C-O 117.016 -1.469 . . . . 3.57 112.623 -161.156 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.784 0 CA-C-O 116.837 -2.09 . . . . 3.93 110.139 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.406 ' O ' ' HA3' ' B' ' 13' ' ' GLY . 83.5 Cg_endo -76.27 162.11 34.24 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 123.436 2.758 . . . . 2.88 111.635 -174.989 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.01 153.55 36.93 Favored 'General case' 0 CA--C 1.542 0.635 0 C-N-CA 127.31 2.244 . . . . 3.14 113.605 178.706 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.7 -122.91 0.05 OUTLIER Glycine 0 CA--C 1.534 1.271 0 C-N-CA 127.146 2.308 . . . . 2.4 115.717 -179.051 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.8 mt -122.42 131.8 72.46 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.011 0 O-C-N 121.097 -1.237 . . . . 1.97 109.191 -177.248 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.91 134.33 55.41 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 123.442 0.697 . . . . 2.08 110.81 173.399 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.69 155.18 48.13 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 126.744 2.116 . . . . 1.83 114.33 -173.463 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 72.7 mm-40 -77.76 154.09 32.31 Favored 'General case' 0 CA--C 1.536 0.432 0 CA-C-N 114.767 -0.717 . . . . 4.14 112.47 -166.256 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -60.45 132.16 53.04 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 123.509 0.723 . . . . 6.85 111.759 -177.672 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.9 151.64 44.52 Favored Glycine 0 N--CA 1.467 0.763 0 N-CA-C 115.584 0.994 . . . . 1.74 115.584 -167.879 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 2.5 m -69.1 130.93 34.25 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 124.938 1.295 . . . . 2.57 110.893 176.138 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.5 m -55.61 146.07 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 C-N-CA 125.062 1.345 . . . . 2.58 114.029 -167.638 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.02 -163.93 7.91 Favored Glycine 0 CA--C 1.534 1.276 0 N-CA-C 111.39 -0.684 . . . . 1.98 111.39 161.032 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 88.1 mt -143.95 167.02 16.46 Favored Pre-proline 0 N--CA 1.475 0.813 0 C-N-CA 124.551 1.14 . . . . 2.95 111.479 179.951 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . 0.426 ' HA ' ' H ' ' B' ' 26' ' ' LEU . 29.2 Cg_endo -76.73 -152.61 0.04 OUTLIER 'Trans proline' 0 CA--C 1.539 0.736 0 C-N-CA 122.981 2.454 . . . . 1.92 108.584 150.914 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.288 0 CA-C-O 117.017 -1.99 . . . . 3.12 112.774 143.671 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_exo . . . . . 0 CA--C 1.543 0.966 0 N-CA-C 111.512 -0.226 . . . . 3.51 111.512 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . 0.406 ' HA3' ' O ' ' A' ' 14' ' ' PRO . . . -69.05 176.44 30.06 Favored Glycine 0 CA--C 1.538 1.474 0 C-N-CA 120.284 -0.96 . . . . 1.72 112.935 127.561 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 67.3 Cg_endo -79.94 156.28 23.56 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 C-N-CA 125.011 3.807 . . . . 2.54 110.795 158.646 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -60.86 140.63 57.62 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 125.158 1.383 . . . . 4.33 110.455 168.24 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.32 162.14 40.83 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 115.508 0.963 . . . . 1.45 115.508 -172.114 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 41.0 pt -55.41 139.19 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.835 0 O-C-N 122.376 -0.485 . . . . 4.12 111.213 176.765 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.15 154.04 42.72 Favored 'General case' 0 CA--C 1.54 0.589 0 CA-C-O 121.539 0.685 . . . . 1.73 112.828 -176.638 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.02 161.96 51.71 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 125.094 1.33 . . . . 2.23 113.635 -178.338 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 3.0 tp-100 -90.56 131.06 36.51 Favored 'General case' 0 C--N 1.331 -0.218 0 C-N-CA 123.663 0.785 . . . . 3.83 109.709 -174.163 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -53.28 153.26 3.94 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-O 122.678 1.228 . . . . 8.13 114.161 -177.77 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.91 166.54 54.41 Favored Glycine 0 CA--C 1.531 1.086 0 CA-C-N 113.998 -1.456 . . . . 1.78 112.541 171.298 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 17.6 m -89.71 139.28 17.75 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.805 0 N-CA-C 115.05 1.5 . . . . 3.7 115.05 -162.841 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.1 m -104.22 155.8 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 C-N-CA 124.809 1.244 . . . . 2.62 112.708 -163.211 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -107.49 -130.33 6.34 Favored Glycine 0 CA--C 1.529 0.907 0 C-N-CA 125.118 1.342 . . . . 1.66 113.218 177.801 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . 0.426 ' H ' ' HA ' ' A' ' 27' ' ' PRO . 2.7 pt? -179.14 161.82 1.0 Allowed Pre-proline 0 CA--C 1.547 0.842 0 C-N-CA 126.045 1.738 . . . . 3.33 110.753 -152.996 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_endo . . . . . 0 C--O 1.257 1.437 0 C-N-CA 124.014 3.143 . . . . 2.89 111.949 156.159 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo . . . . . 0 CA--C 1.547 1.173 0 CA-C-O 119.181 -0.425 . . . . 3.22 112.03 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -66.07 -160.66 0.04 OUTLIER 'Trans proline' 0 CA--C 1.543 0.942 0 C-N-CA 123.066 2.511 . . . . 2.28 110.129 161.67 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -90.89 -177.57 43.74 Favored Glycine 0 CA--C 1.535 1.31 0 O-C-N 121.163 -0.96 . . . . 1.5 111.897 169.043 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 95.3 Cg_endo -77.77 170.51 18.94 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.946 2.43 . . . . 2.57 111.981 175.405 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.8 tp60 -34.99 127.01 0.53 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 127.557 2.343 . . . . 1.74 113.325 152.499 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -68.18 155.4 53.16 Favored Glycine 0 CA--C 1.528 0.869 0 C-N-CA 124.944 1.259 . . . . 1.49 112.338 167.304 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 82.3 mt -62.95 139.57 21.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.859 0 O-C-N 121.593 -0.946 . . . . 2.56 110.731 -175.582 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.26 159.15 12.76 Favored 'General case' 0 CA--C 1.543 0.69 0 CA-C-O 122.292 1.044 . . . . 2.15 113.31 178.904 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -61.76 124.99 35.75 Favored Glycine 0 CA--C 1.524 0.638 0 CA-C-O 122.279 0.933 . . . . 1.95 112.679 -170.905 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . 0.567 ' NE2' ' H ' ' C' ' 20' ' ' GLN . 0.0 OUTLIER -60.59 129.76 43.15 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.672 1.589 . . . . 6.1 110.919 -175.982 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.47 129.71 22.51 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.526 0.731 . . . . 3.13 111.862 -174.898 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -62.6 154.98 41.65 Favored Glycine 0 CA--C 1.531 1.034 0 CA-C-N 115.168 -0.924 . . . . 1.03 113.311 -176.466 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.5 t -57.4 146.59 6.76 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.612 0 C-N-CA 124.913 1.285 . . . . 1.61 110.288 171.876 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 27.2 m -98.54 -169.87 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.817 0 C-N-CA 125.687 1.595 . . . . 2.39 110.557 179.091 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.6 -168.31 3.94 Favored Glycine 0 CA--C 1.538 1.485 0 C-N-CA 124.339 0.971 . . . . 1.9 113.944 167.356 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 13.5 mt . . . . . 0 N--CA 1.485 1.315 0 N-CA-C 114.329 1.233 . . . . 3.61 114.329 -174.977 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.558 0 CA-C-O 116.121 -2.488 . . . . 4.67 108.856 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -76.57 162.52 32.99 Favored 'Trans proline' 0 N--CA 1.457 -0.676 0 C-N-CA 122.593 2.195 . . . . 5.17 111.328 -176.841 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.3 tm0? -64.38 161.71 16.44 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 128.294 2.638 . . . . 4.46 111.451 166.577 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.41 -143.17 0.46 Allowed Glycine 0 CA--C 1.535 1.34 0 C-N-CA 126.66 2.076 . . . . 3.27 114.307 173.367 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 3.1 mt -101.06 127.92 53.79 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.628 0 O-C-N 121.375 -1.074 . . . . 4.24 108.409 179.202 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.89 140.79 56.41 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 118.901 0.773 . . . . 2.45 110.29 168.186 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -61.75 141.95 47.9 Favored Glycine 0 CA--C 1.523 0.58 0 C-N-CA 124.587 1.089 . . . . 1.18 112.291 175.423 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 54.2 mm-40 -68.32 130.22 42.25 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 109.847 -0.427 . . . . 3.08 109.847 -177.516 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -66.69 137.26 56.56 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 121.512 0.672 . . . . 3.96 111.175 -171.765 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.63 126.1 8.33 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-O 122.599 1.11 . . . . 2.48 111.562 176.611 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 21.8 t -65.28 155.26 6.8 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.835 0 C-N-CA 126.498 1.919 . . . . 4.27 111.822 -178.141 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.3 m -61.62 152.32 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.102 0 O-C-N 121.121 -0.987 . . . . 3.57 112.791 173.805 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -97.02 -153.88 29.7 Favored Glycine 0 N--CA 1.468 0.795 0 C-N-CA 124.023 0.821 . . . . 2.03 112.478 167.642 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 89.2 mt -143.26 158.89 57.23 Favored Pre-proline 0 N--CA 1.47 0.536 0 C-N-CA 126.117 1.767 . . . . 5.58 110.246 176.444 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -76.41 -146.21 0.03 OUTLIER 'Trans proline' 0 CA--C 1.54 0.791 0 C-N-CA 122.58 2.186 . . . . 3.93 107.803 154.03 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.169 0 CA-C-O 116.701 -2.166 . . . . 4.72 111.979 151.902 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo . . . . . 0 N--CA 1.481 0.774 0 CA-C-O 118.705 -0.623 . . . . 4.03 111.68 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -67.6 159.01 50.88 Favored Glycine 0 CA--C 1.539 1.581 0 CA-C-O 118.761 -1.021 . . . . 2.08 111.682 154.443 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 77.9 Cg_endo -70.8 158.67 54.96 Favored 'Trans proline' 0 N--CA 1.458 -0.566 0 C-N-CA 123.782 2.988 . . . . 4.16 109.819 162.134 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -82.34 174.29 11.27 Favored 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 121.909 0.861 . . . . 6.66 113.114 178.593 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.22 154.36 52.53 Favored Glycine 0 CA--C 1.52 0.389 0 CA-C-O 122.615 1.119 . . . . 1.95 114.248 -177.705 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 43.8 pt -61.39 144.69 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 CA-C-N 114.383 -0.909 . . . . 5.38 110.718 161.518 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -85.35 133.4 34.14 Favored 'General case' 0 CA--C 1.54 0.596 0 C-N-CA 123.822 0.849 . . . . 2.1 112.495 177.749 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -75.08 125.62 8.32 Favored Glycine 0 CA--C 1.525 0.691 0 C-N-CA 125.653 1.597 . . . . 1.58 110.546 173.272 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -89.71 157.51 17.95 Favored 'General case' 0 CA--C 1.535 0.382 0 O-C-N 121.865 -0.785 . . . . 4.32 110.384 166.321 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.92 162.08 29.92 Favored 'General case' 0 N--CA 1.473 0.687 0 C-N-CA 123.235 0.614 . . . . 4.03 111.712 166.029 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -84.19 -141.8 5.1 Favored Glycine 0 CA--C 1.533 1.198 0 N-CA-C 110.991 -0.843 . . . . 2.52 110.991 163.602 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 99.5 t -40.62 131.38 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 126.415 1.886 . . . . 4.88 113.816 -173.944 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 15.3 m -103.78 149.4 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.534 0 C-N-CA 125.083 1.353 . . . . 3.96 109.02 161.371 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.515 ' H ' HG23 ' C' ' 23' ' ' VAL . . . -102.55 167.63 17.84 Favored Glycine 0 C--N 1.333 0.392 0 C-N-CA 124.843 1.211 . . . . 5.24 115.266 -163.574 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -171.57 158.99 4.83 Favored Pre-proline 0 CA--C 1.544 0.713 0 C-N-CA 127.626 2.37 . . . . 7.26 111.028 -173.824 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo . . . . . 0 C--O 1.255 1.354 0 C-N-CA 124.063 3.175 . . . . 4.97 112.155 152.631 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo . . . . . 0 N--CA 1.486 1.085 0 CA-C-O 118.604 -0.665 . . . . 5.14 111.305 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 93.1 Cg_endo -69.06 -152.88 0.03 OUTLIER 'Trans proline' 0 CA--C 1.544 1.019 0 C-N-CA 123.394 2.729 . . . . 4.32 109.761 163.632 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -91.45 177.28 40.69 Favored Glycine 0 CA--C 1.535 1.293 0 N-CA-C 111.424 -0.67 . . . . 2.66 111.424 166.684 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -78.26 168.07 22.23 Favored 'Trans proline' 0 N--CA 1.455 -0.772 0 C-N-CA 123.111 2.541 . . . . 3.85 111.858 172.637 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 27.0 tp60 -40.51 121.91 1.52 Allowed 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 128.217 2.607 . . . . 2.8 113.98 160.046 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.74 157.74 51.91 Favored Glycine 0 CA--C 1.527 0.841 0 C-N-CA 124.82 1.2 . . . . 1.53 111.637 163.953 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 51.2 mm -65.56 132.2 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 O-C-N 121.81 -0.818 . . . . 2.89 111.903 -172.458 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.52 145.92 38.77 Favored 'General case' 0 CA--C 1.541 0.597 0 C-N-CA 123.77 0.828 . . . . 1.46 111.862 171.731 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -80.44 -173.21 46.19 Favored Glycine 0 C--N 1.338 0.673 0 CA-C-O 122.684 1.158 . . . . 1.02 111.513 -179.959 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 12.5 mp0 -115.95 158.84 22.44 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 108.214 -1.032 . . . . 3.29 108.214 179.367 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 2.8 tmt_? -63.45 134.12 55.1 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 107.611 -1.255 . . . . 6.43 107.611 153.804 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -67.61 153.66 52.92 Favored Glycine 0 CA--C 1.531 1.034 0 N-CA-C 111.626 -0.589 . . . . 2.79 111.626 -179.249 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . 0.515 HG23 ' H ' ' B' ' 25' ' ' GLY . 15.5 m -67.03 162.66 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 O-C-N 121.429 -1.042 . . . . 4.62 111.95 -176.291 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 16.0 m -90.61 173.93 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 126.889 2.076 . . . . 4.88 110.776 171.552 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.15 -171.87 2.45 Favored Glycine 0 CA--C 1.54 1.632 0 C-N-CA 125.249 1.404 . . . . 3.74 115.132 164.808 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 mm? . . . . . 0 C--O 1.25 1.117 0 C-N-CA 126.69 1.996 . . . . 7.44 112.36 -166.274 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.69 0 CA-C-O 116.307 -2.385 . . . . 2.84 109.047 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 85.0 Cg_endo -78.43 164.85 25.96 Favored 'Trans proline' 0 N--CA 1.459 -0.516 0 C-N-CA 123.144 2.562 . . . . 1.92 112.606 -170.612 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -56.62 153.47 10.29 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 129.304 3.041 . . . . 3.55 112.464 170.072 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.12 -144.26 3.41 Favored Glycine 0 N--CA 1.475 1.287 0 C-N-CA 126.667 2.079 . . . . 1.67 117.01 -171.8 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 33.2 pt -98.94 139.32 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 O-C-N 121.24 -1.153 . . . . 2.59 108.692 174.848 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.84 146.4 49.77 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-O 121.38 0.609 . . . . 1.78 111.052 179.558 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -45.86 141.64 4.96 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 126.423 1.963 . . . . 1.23 114.017 174.884 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 80.3 mm-40 -63.69 132.82 52.25 Favored 'General case' 0 CA--C 1.534 0.329 0 N-CA-C 108.925 -0.768 . . . . 3.3 108.925 -178.54 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 1.4 tmt_? -64.55 134.31 54.13 Favored 'General case' 0 CA--C 1.536 0.425 0 N-CA-C 112.421 0.526 . . . . 4.83 112.421 -162.481 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.54 160.79 53.7 Favored Glycine 0 N--CA 1.466 0.66 0 CA-C-O 122.823 1.235 . . . . 1.49 115.6 -169.58 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 11.1 t -79.01 145.25 9.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 126.15 1.78 . . . . 2.24 111.847 -167.272 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 35.9 m -58.49 147.26 7.35 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 C-N-CA 124.965 1.306 . . . . 2.51 113.59 -179.396 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -82.72 -163.88 34.34 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 124.267 0.937 . . . . 2.01 112.263 167.215 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 72.1 mt -145.9 160.44 43.62 Favored Pre-proline 0 N--CA 1.474 0.768 0 C-N-CA 128.053 2.541 . . . . 3.14 108.177 174.868 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -77.11 -157.12 0.07 OUTLIER 'Trans proline' 0 CA--C 1.541 0.866 0 C-N-CA 122.187 1.925 . . . . 2.0 109.129 164.677 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.205 0 CA-C-O 117.358 -1.801 . . . . 3.39 112.696 154.383 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo . . . . . 0 N--CA 1.481 0.762 0 CA-C-O 118.479 -0.717 . . . . 2.46 111.391 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.49 166.26 30.73 Favored Glycine 0 CA--C 1.543 1.814 0 CA-C-O 119.006 -0.886 . . . . 1.64 112.885 149.724 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -76.62 41.76 0.95 Allowed 'Trans proline' 0 CA--C 1.546 1.078 1 C-N-CA 127.014 5.143 . . . . 3.7 113.176 -179.123 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 66.27 178.17 0.22 Allowed 'General case' 0 CA--C 1.548 0.876 0 C-N-CA 125.274 1.43 . . . . 4.4 112.053 -165.1 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.64 163.54 31.08 Favored Glycine 0 CA--C 1.541 1.696 0 C-N-CA 124.429 1.014 . . . . 0.95 113.447 159.367 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 67.5 mt -77.77 148.71 6.31 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 126.05 1.74 . . . . 2.87 111.718 176.469 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -73.58 147.97 43.39 Favored 'General case' 0 CA--C 1.548 0.877 0 N-CA-C 114.362 1.245 . . . . 1.29 114.362 -177.616 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -78.02 169.89 54.72 Favored Glycine 0 CA--C 1.536 1.378 0 C-N-CA 125.52 1.533 . . . . 1.5 112.476 173.188 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.94 170.35 12.35 Favored 'General case' 0 N--CA 1.467 0.408 0 O-C-N 121.321 -1.105 . . . . 3.26 112.06 -177.35 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -59.42 148.4 32.83 Favored 'General case' 0 N--CA 1.47 0.55 0 C-N-CA 124.6 1.16 . . . . 4.97 113.328 -176.243 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.6 -54.96 5.22 Favored Glycine 0 N--CA 1.472 1.045 0 N-CA-C 114.418 0.527 . . . . 4.31 114.418 -173.404 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 11.1 t -146.65 158.91 10.43 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 C-N-CA 128.478 2.711 . . . . 4.73 107.864 -176.518 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 9.0 p -121.06 153.58 24.55 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 C-N-CA 127.87 2.468 . . . . 3.32 109.32 178.103 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.02 -168.29 43.73 Favored Glycine 0 C--N 1.339 0.727 0 CA-C-O 121.857 0.698 . . . . 1.74 114.582 177.162 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.9 pp -159.79 150.92 16.07 Favored Pre-proline 0 CA--C 1.543 0.699 0 C-N-CA 125.996 1.718 . . . . 3.16 110.97 -179.265 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo . . . . . 0 C--O 1.254 1.306 1 C-N-CA 125.584 4.189 . . . . 3.09 112.881 167.594 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo . . . . . 0 N--CA 1.485 1.001 0 CA-C-O 118.834 -0.569 . . . . 2.06 111.267 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 69.7 Cg_endo -71.99 -143.16 0.02 OUTLIER 'Trans proline' 0 CA--C 1.542 0.903 0 C-N-CA 123.943 3.095 . . . . 1.55 109.257 169.091 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -72.33 146.61 39.45 Favored Glycine 0 CA--C 1.54 1.623 0 CA-C-O 118.713 -1.048 . . . . 1.07 110.506 165.659 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -68.25 -43.04 4.91 Favored 'Trans proline' 0 CA--C 1.534 0.49 0 C-N-CA 123.024 2.483 . . . . 3.28 113.285 178.208 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.427 HE21 ' N ' ' C' ' 16' ' ' GLY . 16.9 tp60 174.2 115.2 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 126.185 1.794 . . . . 1.32 107.948 -166.201 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . 0.427 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -65.83 164.71 38.77 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 123.663 0.649 . . . . 0.92 112.979 169.616 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 35.0 mm -69.59 128.55 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 O-C-N 121.527 -0.984 . . . . 2.25 110.761 -171.498 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.15 149.98 22.48 Favored 'General case' 0 CA--C 1.543 0.691 0 N-CA-C 113.748 1.018 . . . . 1.25 113.748 176.806 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -73.32 138.46 25.28 Favored Glycine 0 CA--C 1.526 0.746 0 C-N-CA 124.11 0.862 . . . . 1.04 111.36 -177.44 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 -75.81 167.73 21.34 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.138 0.975 . . . . 5.45 111.827 175.529 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -56.18 147.79 19.75 Favored 'General case' 0 N--CA 1.47 0.526 0 C-N-CA 125.619 1.568 . . . . 3.78 112.151 171.374 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -56.32 146.82 32.56 Favored Glycine 0 CA--C 1.526 0.776 0 C-N-CA 125.734 1.635 . . . . 1.08 113.328 166.832 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 34.8 m -75.01 137.89 22.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 107.2 -1.408 . . . . 3.38 107.2 162.698 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 34.9 m -92.19 -152.36 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.546 0.799 0 C-N-CA 124.034 0.934 . . . . 2.87 110.991 -168.35 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.98 169.53 1.25 Allowed Glycine 0 CA--C 1.542 1.751 0 C-N-CA 124.033 0.825 . . . . 1.81 114.103 162.189 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 12.8 mt . . . . . 0 C--O 1.249 1.028 0 C-N-CA 124.897 1.279 . . . . 3.65 114.024 -163.845 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.647 0 CA-C-O 116.042 -2.532 . . . . 3.24 108.965 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_endo -76.38 166.1 28.1 Favored 'Trans proline' 0 CA--C 1.535 0.548 0 C-N-CA 122.839 2.36 . . . . 2.29 111.331 -177.79 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? -74.81 165.96 24.4 Favored 'General case' 0 CA--C 1.539 0.527 0 C-N-CA 126.739 2.016 . . . . 3.75 113.594 175.534 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -72.11 -157.58 3.36 Favored Glycine 0 N--CA 1.476 1.365 0 C-N-CA 129.493 3.425 . . . . 1.5 116.915 -170.267 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 2.9 mt -77.96 125.74 37.78 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 O-C-N 120.403 -1.645 . . . . 2.15 107.942 174.736 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.0 128.41 30.33 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 123.117 0.567 . . . . 1.94 111.274 174.713 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -60.77 150.23 42.85 Favored Glycine 0 CA--C 1.521 0.466 0 C-N-CA 126.455 1.979 . . . . 1.26 112.856 -174.554 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 76.8 mm-40 -74.46 135.15 42.29 Favored 'General case' 0 C--N 1.332 -0.175 0 O-C-N 122.333 -0.51 . . . . 3.7 110.652 -167.268 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 35.2 ttp180 -54.48 130.96 41.51 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 123.539 0.736 . . . . 5.99 110.908 176.33 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -71.89 -178.03 29.83 Favored Glycine 0 CA--C 1.523 0.558 0 C-N-CA 124.441 1.02 . . . . 2.2 114.189 -171.646 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.412 HG23 ' H ' ' A' ' 23' ' ' VAL . 0.9 OUTLIER -61.11 142.36 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 C-N-CA 123.916 0.886 . . . . 2.76 110.03 174.846 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 27.7 m -52.22 154.08 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.477 0.886 0 C-N-CA 124.184 0.994 . . . . 3.03 112.944 173.6 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -83.9 -149.43 9.61 Favored Glycine 0 CA--C 1.531 1.068 0 C-N-CA 123.797 0.713 . . . . 2.43 112.591 166.298 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 82.8 mt -146.73 162.5 33.45 Favored Pre-proline 0 N--CA 1.475 0.789 0 C-N-CA 127.015 2.126 . . . . 3.46 109.687 170.581 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 26.1 Cg_endo -83.06 -152.92 0.04 OUTLIER 'Trans proline' 0 CA--C 1.544 0.978 0 C-N-CA 123.298 2.665 . . . . 2.17 108.515 154.228 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.207 0 CA-C-O 117.61 -1.661 . . . . 3.83 113.103 156.191 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 91.3 Cg_exo . . . . . 0 N--CA 1.479 0.676 0 CA-C-O 118.196 -0.835 . . . . 2.24 111.392 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -60.48 158.21 27.81 Favored Glycine 0 CA--C 1.546 2.01 0 CA-C-N 119.178 0.899 . . . . 1.99 112.816 154.342 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -76.13 47.5 2.03 Favored 'Trans proline' 0 CA--C 1.545 1.071 1 C-N-CA 127.374 5.383 . . . . 3.99 113.419 -175.958 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 1.4 tp-100 69.88 -169.65 0.17 Allowed 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 124.819 1.248 . . . . 4.22 109.871 -161.33 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -106.93 154.88 16.58 Favored Glycine 0 CA--C 1.533 1.201 0 C-N-CA 126.192 1.853 . . . . 1.15 110.576 158.558 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 18.3 tt -63.58 144.81 14.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 C-N-CA 124.228 1.011 . . . . 4.05 112.521 177.393 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -75.0 148.36 39.98 Favored 'General case' 0 CA--C 1.542 0.658 0 N-CA-C 113.624 0.972 . . . . 1.61 113.624 178.91 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.63 148.39 43.42 Favored Glycine 0 CA--C 1.53 1.005 0 C-N-CA 125.635 1.588 . . . . 1.74 113.8 -177.747 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 19.5 tt0 -80.25 148.34 30.83 Favored 'General case' 0 CA--C 1.54 0.564 0 C-N-CA 124.222 1.009 . . . . 3.88 112.418 -177.86 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 7.5 mtm180 -63.87 130.75 45.4 Favored 'General case' 0 N--CA 1.471 0.625 0 C-N-CA 124.747 1.219 . . . . 4.61 111.829 178.125 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -74.48 2.72 45.18 Favored Glycine 0 N--CA 1.476 1.34 0 N-CA-C 119.6 2.6 . . . . 4.68 119.6 -155.365 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . 0.278 0.9 OUTLIER 173.3 156.92 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 C-N-CA 130.302 3.441 . . . . 4.96 108.741 179.214 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 42.1 t -132.54 141.51 44.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.319 0 C-N-CA 126.245 1.818 . . . . 4.46 107.911 178.052 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -88.05 -177.69 47.58 Favored Glycine 0 C--N 1.338 0.648 0 CA-C-O 122.496 1.053 . . . . 2.53 114.779 -170.3 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.1 pt? -161.19 156.96 21.55 Favored Pre-proline 0 CA--C 1.542 0.651 0 C-N-CA 126.419 1.888 . . . . 3.98 110.243 -177.734 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo . . . . . 0 C--O 1.255 1.374 0 C-N-CA 124.129 3.219 . . . . 3.32 111.229 164.112 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo . . . . . 0 N--CA 1.487 1.097 0 CA-C-O 119.019 -0.492 . . . . 2.55 111.555 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 91.6 Cg_endo -70.0 -148.83 0.02 OUTLIER 'Trans proline' 0 CA--C 1.541 0.857 0 C-N-CA 123.616 2.878 . . . . 1.98 109.553 165.768 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -81.95 176.45 53.96 Favored Glycine 0 CA--C 1.537 1.454 0 O-C-N 121.279 -0.888 . . . . 1.13 111.542 168.88 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -79.24 -177.58 4.0 Favored 'Trans proline' 0 N--CA 1.452 -0.952 0 C-N-CA 123.095 2.53 . . . . 2.37 109.792 162.125 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 4.7 tp60 -41.55 119.29 1.22 Allowed 'General case' 0 CA--C 1.543 0.693 0 C-N-CA 125.981 1.712 . . . . 1.8 113.875 159.363 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -65.32 161.88 41.22 Favored Glycine 0 CA--C 1.528 0.855 0 C-N-CA 125.772 1.654 . . . . 1.13 112.531 167.518 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 33.4 mm -68.77 142.39 16.28 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.811 0 O-C-N 121.576 -0.955 . . . . 3.72 110.511 -172.714 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.81 154.63 40.36 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.31 0.856 . . . . 1.42 113.31 177.1 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -71.59 157.52 53.25 Favored Glycine 0 CA--C 1.528 0.886 0 C-N-CA 124.274 0.94 . . . . 1.15 113.131 -179.095 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 14.4 mp0 -82.31 173.98 11.57 Favored 'General case' 0 CA--C 1.541 0.615 0 O-C-N 121.869 -0.783 . . . . 3.0 111.26 179.024 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.3 135.31 57.13 Favored 'General case' 0 N--CA 1.468 0.454 0 C-N-CA 123.287 0.635 . . . . 3.69 110.426 169.15 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -65.35 167.3 32.52 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.93 1.253 . . . . 1.34 113.972 -176.675 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 87.2 t -75.52 148.4 7.49 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.531 0 C-N-CA 123.876 0.871 . . . . 2.06 109.458 -176.865 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 98.7 t -97.28 174.69 0.85 Allowed 'Isoleucine or valine' 0 CA--C 1.551 0.991 0 C-N-CA 127.297 2.239 . . . . 2.83 109.613 -174.891 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -56.3 173.17 1.67 Allowed Glycine 0 CA--C 1.538 1.504 0 C-N-CA 124.974 1.273 . . . . 2.01 114.723 165.25 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 8.8 mt . . . . . 0 C--O 1.25 1.097 0 N-CA-C 113.821 1.045 . . . . 4.43 113.821 -158.143 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.647 0 CA-C-O 116.623 -2.209 . . . . 3.13 110.08 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 60.0 Cg_endo -63.39 159.86 38.04 Favored 'Trans proline' 0 C--N 1.349 0.585 0 C-N-CA 123.849 3.033 . . . . 1.92 111.491 179.79 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.84 177.76 0.71 Allowed 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 127.73 2.412 . . . . 3.73 114.656 -178.227 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -87.16 173.09 44.25 Favored Glycine 0 CA--C 1.526 0.728 0 C-N-CA 125.904 1.716 . . . . 1.26 113.793 177.323 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.546 ' H ' HD12 ' A' ' 17' ' ' ILE . 3.2 mp -67.42 135.24 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.51 0 N-CA-C 109.292 -0.633 . . . . 2.37 109.292 -173.189 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -53.95 133.0 43.16 Favored 'General case' 0 CA--C 1.539 0.543 0 CA-C-N 118.427 0.558 . . . . 1.79 110.482 170.613 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -64.12 168.68 24.27 Favored Glycine 0 CA--C 1.521 0.417 0 C-N-CA 126.115 1.816 . . . . 1.31 114.778 -167.995 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 85.6 mm-40 -71.46 96.28 1.48 Allowed 'General case' 0 CA--C 1.53 0.196 0 N-CA-C 108.598 -0.89 . . . . 3.19 108.598 179.793 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 33.2 ttp-105 -62.29 138.63 58.46 Favored 'General case' 0 N--CA 1.451 -0.405 0 C-N-CA 124.836 1.254 . . . . 4.96 113.23 -165.155 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -75.7 149.97 39.04 Favored Glycine 0 C--N 1.332 0.355 0 CA-C-O 122.421 1.012 . . . . 2.26 113.704 -171.211 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 32.7 m -76.64 163.11 4.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.568 0 CA-C-N 113.676 -1.262 . . . . 2.74 111.173 -174.624 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.0 m -60.75 167.69 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 124.257 1.023 . . . . 3.54 112.395 177.355 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.72 146.97 39.4 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 110.407 -1.077 . . . . 2.1 110.407 157.957 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 8.5 mp -101.62 169.57 7.53 Favored Pre-proline 0 CA--C 1.538 0.516 0 C-N-CA 124.041 0.936 . . . . 3.64 111.95 -170.833 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -69.11 115.11 3.84 Favored 'Trans proline' 0 N--CA 1.445 -1.337 0 N-CA-C 106.989 -1.966 . . . . 2.98 106.989 151.775 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.147 0 CA-C-O 118.584 -1.12 . . . . 6.8 114.773 -157.294 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_exo . . . . . 0 CA--C 1.544 0.995 0 N-CA-C 111.313 -0.303 . . . . 2.1 111.313 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -61.44 167.7 13.23 Favored Glycine 0 CA--C 1.541 1.717 0 C-N-CA 120.13 -1.033 . . . . 1.3 112.902 127.473 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 59.5 Cg_endo -76.69 -64.4 0.03 OUTLIER 'Trans proline' 0 CA--C 1.538 0.702 0 C-N-CA 124.974 3.782 . . . . 2.85 112.694 175.678 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 8.3 tp-100 -166.6 157.4 12.39 Favored 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 127.943 2.497 . . . . 3.25 107.639 -164.711 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -92.36 159.23 25.02 Favored Glycine 0 CA--C 1.527 0.783 0 C-N-CA 124.324 0.964 . . . . 0.97 113.469 175.549 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . 0.53 ' H ' HD12 ' B' ' 17' ' ' ILE . 3.8 mp -70.28 127.89 32.82 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.67 0 N-CA-C 108.855 -0.795 . . . . 3.49 108.855 176.851 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -76.62 146.76 38.01 Favored 'General case' 0 CA--C 1.541 0.614 0 CA-C-N 118.973 0.806 . . . . 1.27 112.416 178.873 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -78.63 141.27 24.4 Favored Glycine 0 CA--C 1.527 0.8 0 C-N-CA 124.643 1.116 . . . . 1.53 111.668 179.268 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -94.65 164.77 12.82 Favored 'General case' 0 N--CA 1.468 0.463 0 O-C-N 121.43 -1.041 . . . . 4.14 111.132 166.75 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -82.3 167.12 18.91 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.285 1.034 . . . . 5.24 112.022 167.138 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -89.71 -174.02 45.65 Favored Glycine 0 CA--C 1.538 1.522 0 C-N-CA 124.609 1.1 . . . . 2.68 112.619 164.945 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 11.0 m -100.9 160.05 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 C-N-CA 125.039 1.336 . . . . 5.2 114.568 -166.243 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 7.7 p -42.37 150.38 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.044 0 C-N-CA 129.016 2.926 . . . . 4.1 115.221 -178.117 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.44 -114.93 1.93 Allowed Glycine 0 CA--C 1.528 0.85 0 CA-C-O 119.154 -0.803 . . . . 2.24 111.343 167.334 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -172.43 177.23 0.83 Allowed Pre-proline 0 CA--C 1.556 1.204 0 C-N-CA 126.977 2.111 . . . . 3.81 110.55 -164.572 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_endo . . . . . 0 C--O 1.255 1.36 0 C-N-CA 123.926 3.084 . . . . 5.26 112.725 174.571 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_endo . . . . . 0 CA--C 1.546 1.101 0 CA-C-O 118.532 -0.695 . . . . 1.89 111.426 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -61.72 -154.05 0.02 OUTLIER 'Trans proline' 0 CA--C 1.545 1.054 0 C-N-CA 124.934 3.756 . . . . 1.72 111.679 164.682 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -84.21 -177.9 51.45 Favored Glycine 0 CA--C 1.543 1.805 0 O-C-N 121.068 -1.02 . . . . 0.96 113.157 173.53 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -79.54 169.49 18.44 Favored 'Trans proline' 0 CA--C 1.535 0.535 0 C-N-CA 124.219 3.279 . . . . 2.3 111.304 173.865 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.0 tp60 -48.04 116.92 1.68 Allowed 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 124.209 1.004 . . . . 1.47 111.288 160.717 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -64.58 163.22 36.39 Favored Glycine 0 CA--C 1.529 0.94 0 C-N-CA 124.852 1.215 . . . . 0.87 112.577 172.171 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 3.1 mp -65.96 145.27 14.02 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.667 0 C-N-CA 123.852 0.861 . . . . 2.67 110.673 -168.628 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -68.8 163.72 23.51 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.517 0.932 . . . . 1.2 113.517 179.084 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -102.11 149.46 17.96 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 109.946 -1.262 . . . . 1.01 109.946 168.6 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 7.2 mm100 -93.39 -167.86 1.8 Allowed 'General case' 0 CA--C 1.541 0.621 0 O-C-N 121.978 -0.719 . . . . 4.77 110.831 -178.07 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 2.6 ttt180 -63.33 154.44 31.76 Favored 'General case' 0 N--CA 1.467 0.41 0 O-C-N 121.272 -0.893 . . . . 3.8 110.898 168.524 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.24 -171.44 45.1 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 123.726 0.679 . . . . 1.04 111.653 165.355 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 3.0 t -70.3 136.8 25.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 C-N-CA 124.266 1.026 . . . . 1.79 111.855 -170.623 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 p -44.94 124.58 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 C-N-CA 126.599 1.959 . . . . 3.78 112.671 161.264 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.34 127.45 8.88 Favored Glycine 0 CA--C 1.525 0.698 0 C-N-CA 123.342 0.496 . . . . 3.63 112.823 179.613 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 16.9 mt . . . . . 0 C--O 1.254 1.313 0 CA-C-O 117.107 -1.425 . . . . 7.05 109.623 146.124 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.645 0 CA-C-O 117.014 -1.992 . . . . 4.3 110.063 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -79.68 168.37 19.58 Favored 'Trans proline' 0 CA--C 1.536 0.614 0 C-N-CA 123.473 2.782 . . . . 2.74 111.96 -176.073 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -58.46 153.4 15.97 Favored 'General case' 0 CA--C 1.541 0.612 0 C-N-CA 128.863 2.865 . . . . 3.06 112.972 173.282 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -88.46 -135.01 5.01 Favored Glycine 0 N--CA 1.476 1.306 0 C-N-CA 125.996 1.76 . . . . 1.94 115.981 -171.703 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 24.0 pt -102.46 143.35 15.1 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.792 0 O-C-N 121.751 -0.852 . . . . 2.85 110.863 -178.417 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -55.34 143.57 28.05 Favored 'General case' 0 CA--C 1.538 0.509 0 CA-C-O 121.845 0.831 . . . . 1.77 112.007 178.612 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -55.46 152.21 16.39 Favored Glycine 0 CA--C 1.52 0.379 0 C-N-CA 127.637 2.541 . . . . 1.5 115.529 178.367 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 84.8 mm-40 -66.19 152.87 43.91 Favored 'General case' 0 CA--C 1.531 0.236 0 CA-C-N 113.957 -1.121 . . . . 3.21 111.172 -176.424 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -63.95 141.95 58.58 Favored 'General case' 0 N--CA 1.466 0.348 0 O-C-N 122.04 -0.413 . . . . 3.83 111.659 -179.538 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -81.6 164.27 45.05 Favored Glycine 0 CA--C 1.523 0.591 0 CA-C-N 115.621 -0.718 . . . . 1.53 113.096 176.609 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 2.1 t -64.55 150.07 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 124.565 1.146 . . . . 2.76 112.277 -167.69 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 38.8 t -53.81 132.51 16.58 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.686 0 C-N-CA 125.497 1.519 . . . . 3.83 111.587 167.88 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -85.42 155.93 30.07 Favored Glycine 0 CA--C 1.528 0.863 0 C-N-CA 124.847 1.213 . . . . 1.42 111.255 165.971 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 94.4 mt -118.16 156.52 50.44 Favored Pre-proline 0 N--CA 1.468 0.456 0 CA-C-O 117.537 -1.22 . . . . 2.86 109.937 -177.12 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -71.22 -158.47 0.06 OUTLIER 'Trans proline' 0 N--CA 1.453 -0.875 0 C-N-CA 121.567 1.512 . . . . 1.86 109.304 161.849 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.535 1.307 0 CA-C-O 117.455 -1.747 . . . . 3.14 112.936 154.918 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_exo . . . . . 0 CA--C 1.544 0.992 0 N-CA-C 111.302 -0.307 . . . . 3.06 111.302 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -64.55 -173.02 3.19 Favored Glycine 0 CA--C 1.541 1.66 0 C-N-CA 120.097 -1.049 . . . . 1.56 113.339 123.922 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -77.9 -128.97 0.01 OUTLIER 'Trans proline' 0 CA--C 1.546 1.083 0 C-N-CA 124.864 3.709 . . . . 2.47 108.233 161.533 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 6.5 tt0 -87.01 -171.01 3.31 Favored 'General case' 0 CA--C 1.552 1.038 0 C-N-CA 125.844 1.657 . . . . 4.25 111.304 171.378 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -89.32 166.87 33.63 Favored Glycine 0 CA--C 1.541 1.692 0 O-C-N 121.204 -0.935 . . . . 1.08 111.875 149.412 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 46.8 mm -67.95 143.39 15.36 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 O-C-N 121.02 -1.282 . . . . 3.67 110.212 168.241 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -74.72 157.89 34.49 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 114.791 1.404 . . . . 1.39 114.791 -173.11 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -78.27 161.2 48.56 Favored Glycine 0 CA--C 1.529 0.935 0 C-N-CA 125.908 1.718 . . . . 1.78 113.561 -175.51 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -106.41 156.37 18.6 Favored 'General case' 0 CA--C 1.533 0.324 0 O-C-N 121.651 -0.911 . . . . 3.27 111.133 175.431 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.9 155.26 16.84 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 112.208 0.447 . . . . 8.19 112.208 178.177 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -80.38 -125.45 0.6 Allowed Glycine 0 CA--C 1.529 0.917 0 C-N-CA 123.995 0.807 . . . . 2.65 111.174 172.008 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 82.2 t -64.06 158.34 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 C-N-CA 124.738 1.215 . . . . 4.93 110.715 179.312 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 6.2 m -129.57 157.47 42.26 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 C-N-CA 126.429 1.891 . . . . 2.99 109.362 174.005 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.478 ' H ' HG23 ' C' ' 23' ' ' VAL . . . -87.72 176.74 46.32 Favored Glycine 0 C--N 1.336 0.545 0 C-N-CA 125.395 1.474 . . . . 1.89 115.305 -170.147 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -165.67 157.98 12.85 Favored Pre-proline 0 CA--C 1.549 0.928 0 C-N-CA 125.437 1.495 . . . . 3.22 113.262 -168.805 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 16.3 Cg_endo . . . . . 0 C--O 1.255 1.343 0 C-N-CA 123.748 2.965 . . . . 2.72 111.786 159.837 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo . . . . . 0 N--CA 1.487 1.119 0 CA-C-O 118.882 -0.549 . . . . 2.47 111.694 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 87.0 Cg_endo -69.44 -139.37 0.01 OUTLIER 'Trans proline' 0 CA--C 1.542 0.923 0 C-N-CA 123.617 2.878 . . . . 1.54 108.713 163.385 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.1 163.73 53.91 Favored Glycine 0 CA--C 1.54 1.629 0 O-C-N 120.924 -1.11 . . . . 1.26 111.492 165.283 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -79.46 -43.06 0.15 Allowed 'Trans proline' 0 CA--C 1.534 0.524 0 C-N-CA 122.697 2.265 . . . . 3.67 112.511 -178.926 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.452 HE21 ' N ' ' C' ' 16' ' ' GLY . 17.3 tp60 167.84 133.09 0.01 OUTLIER 'General case' 0 CA--C 1.538 0.5 0 C-N-CA 127.81 2.444 . . . . 1.6 105.913 -154.445 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . 0.452 ' N ' HE21 ' C' ' 15' ' ' GLN . . . -75.41 158.96 51.05 Favored Glycine 0 CA--C 1.534 1.225 0 C-N-CA 124.358 0.98 . . . . 1.19 113.654 167.649 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 73.3 mt -62.7 147.28 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 O-C-N 121.495 -1.003 . . . . 2.2 110.394 175.509 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -66.36 163.91 17.21 Favored 'General case' 0 CA--C 1.545 0.778 0 N-CA-C 114.014 1.116 . . . . 1.8 114.014 -177.148 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -74.86 154.17 46.46 Favored Glycine 0 CA--C 1.529 0.924 0 CA-C-N 115.443 -0.799 . . . . 1.62 111.66 170.562 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -84.76 168.72 14.92 Favored 'General case' 0 CA--C 1.539 0.54 0 CA-C-O 121.66 0.743 . . . . 3.38 111.909 -174.266 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 1.1 tmt_? -60.79 136.51 58.09 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 123.596 0.758 . . . . 3.15 110.861 -179.492 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -70.07 138.21 29.26 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.793 -0.923 . . . . 1.12 110.793 175.002 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . 0.478 HG23 ' H ' ' B' ' 25' ' ' GLY . 18.9 m -61.04 154.62 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.78 0 CA-C-N 117.931 0.866 . . . . 2.76 111.696 -176.652 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 10.5 p -85.03 177.34 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.97 0 C-N-CA 126.876 2.071 . . . . 2.87 110.082 172.908 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -63.43 -164.72 0.61 Allowed Glycine 0 CA--C 1.54 1.646 0 C-N-CA 125.21 1.385 . . . . 1.58 115.875 169.851 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 16.5 mt . . . . . 0 N--CA 1.481 1.082 0 C-N-CA 125.507 1.523 . . . . 3.27 114.481 -162.439 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.756 0 CA-C-O 116.838 -2.09 . . . . 3.44 110.108 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 84.6 Cg_endo -76.47 161.74 34.11 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 123.395 2.73 . . . . 2.55 111.554 -175.278 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.37 154.29 28.57 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 127.226 2.21 . . . . 3.17 113.517 178.955 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -70.08 -116.54 0.04 OUTLIER Glycine 0 CA--C 1.534 1.224 0 C-N-CA 126.937 2.208 . . . . 2.54 115.369 179.481 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.9 mt -134.79 132.95 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 O-C-N 121.211 -1.17 . . . . 1.92 109.739 -174.239 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.11 133.84 55.94 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.644 0.778 . . . . 1.76 112.324 176.44 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -65.99 163.12 41.73 Favored Glycine 0 CA--C 1.527 0.829 0 C-N-CA 126.885 2.183 . . . . 1.35 113.827 -175.15 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 20' ' ' GLN . . . . . . . . . . . . . 8.6 mp0 -67.31 130.21 42.35 Favored 'General case' 0 N--CA 1.468 0.438 0 O-C-N 122.527 -0.396 . . . . 4.94 110.851 -164.056 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 42.4 ttt180 -63.09 126.59 27.87 Favored 'General case' 0 CA--C 1.535 0.376 0 CA-C-N 118.363 0.529 . . . . 4.24 110.16 179.662 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . -69.74 142.38 36.56 Favored Glycine 0 C--N 1.336 0.575 0 N-CA-C 114.634 0.613 . . . . 1.7 114.634 -160.204 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 35.9 m -64.4 122.93 16.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-N 114.792 -0.704 . . . . 2.53 109.484 -177.199 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 9.8 p -39.16 149.46 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 127.167 2.187 . . . . 2.86 113.566 -176.934 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.92 -155.28 0.61 Allowed Glycine 0 CA--C 1.531 1.054 0 O-C-N 121.405 -0.809 . . . . 1.9 114.296 172.343 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 26' ' ' LEU . . . . . . . . . . . . . 96.9 mt -136.66 161.57 61.08 Favored Pre-proline 0 CA--C 1.541 0.6 0 C-N-CA 125.521 1.528 . . . . 2.9 110.751 176.377 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 27' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_endo -84.14 -151.65 0.04 OUTLIER 'Trans proline' 0 CA--C 1.539 0.74 0 C-N-CA 123.89 3.06 . . . . 1.82 108.232 159.697 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.153 0 CA-C-O 117.211 -1.883 . . . . 3.16 112.438 141.901 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' B' B ' 12' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_exo . . . . . 0 CA--C 1.542 0.907 0 N-CA-C 111.716 -0.148 . . . . 2.53 111.716 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' B' B ' 13' ' ' GLY . . . . . . . . . . . . . . . -68.38 177.19 25.9 Favored Glycine 0 CA--C 1.538 1.492 0 C-N-CA 120.074 -1.06 . . . . 1.28 112.989 128.045 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 14' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -82.2 155.93 17.08 Favored 'Trans proline' 0 CA--C 1.539 0.729 1 C-N-CA 125.418 4.079 . . . . 2.7 111.009 159.403 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -59.6 139.86 56.83 Favored 'General case' 0 N--CA 1.47 0.573 0 C-N-CA 125.143 1.377 . . . . 3.95 110.757 169.746 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 16' ' ' GLY . . . . . . . . . . . . . . . -67.29 161.94 47.44 Favored Glycine 0 C--N 1.338 0.646 0 C-N-CA 124.052 0.834 . . . . 1.12 114.932 -173.663 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 17' ' ' ILE . . . . . . . . . . . . . 42.3 pt -57.78 145.71 8.47 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.825 0 C-N-CA 122.885 0.474 . . . . 3.9 111.892 179.707 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 18' ' ' ALA . . . . . . . . . . . . . . . -69.19 149.31 48.73 Favored 'General case' 0 CA--C 1.543 0.675 0 O-C-N 121.525 -0.735 . . . . 1.42 112.322 175.803 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 19' ' ' GLY . . . . . . . . . . . . . . . -69.61 152.15 51.35 Favored Glycine 0 CA--C 1.53 1.001 0 N-CA-C 110.318 -1.113 . . . . 1.56 110.318 166.942 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 20' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.91 151.56 22.25 Favored 'General case' 0 N--CA 1.468 0.456 0 O-C-N 121.356 -1.085 . . . . 3.25 110.449 176.015 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' B' B ' 21' ' ' ARG . . . . . . . . . . . . . 31.4 ptt180 -61.81 159.57 13.52 Favored 'General case' 0 N--CA 1.47 0.543 0 C-N-CA 124.072 0.949 . . . . 5.68 113.368 -179.566 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 22' ' ' GLY . . . . . . . . . . . . . . . -73.68 160.84 53.82 Favored Glycine 0 CA--C 1.532 1.122 0 C-N-CA 124.825 1.202 . . . . 2.1 114.816 -178.418 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 23' ' ' VAL . . . . . . . . . . . . . 43.9 t -89.47 131.59 36.36 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 C-N-CA 124.598 1.159 . . . . 2.88 113.673 -168.424 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 11.5 m -79.46 160.65 4.28 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 C-N-CA 126.143 1.777 . . . . 2.6 113.301 -168.381 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -99.12 -128.31 6.18 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 125.036 1.303 . . . . 1.69 112.812 176.926 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 26' ' ' LEU . . . . . . . . . . . . . 2.4 pt? -170.9 156.89 5.0 Favored Pre-proline 0 CA--C 1.545 0.77 0 C-N-CA 125.359 1.464 . . . . 3.11 112.076 -163.837 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' B' B ' 27' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo . . . . . 0 C--O 1.254 1.295 0 C-N-CA 124.571 3.514 . . . . 2.57 112.28 155.584 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' C' C ' 11' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo . . . . . 0 CA--C 1.547 1.167 0 CA-C-O 118.964 -0.515 . . . . 2.49 111.517 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' C' C ' 12' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -65.91 -157.74 0.03 OUTLIER 'Trans proline' 0 CA--C 1.544 0.975 0 C-N-CA 123.192 2.595 . . . . 1.93 109.967 161.669 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' C' C ' 13' ' ' GLY . . . . . . . . . . . . . . . -93.16 -176.73 40.66 Favored Glycine 0 CA--C 1.534 1.26 0 O-C-N 121.171 -0.956 . . . . 1.22 111.859 170.721 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' C' C ' 14' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -79.37 170.67 17.09 Favored 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 123.277 2.652 . . . . 2.53 112.295 173.65 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.442 ' HA ' HE21 ' C' ' 15' ' ' GLN . 0.0 OUTLIER -38.03 135.98 0.64 Allowed 'General case' 0 CA--C 1.543 0.704 0 C-N-CA 127.917 2.487 . . . . 1.96 114.333 154.736 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' C' C ' 16' ' ' GLY . . . . . . . . . . . . . . . -80.81 173.18 54.66 Favored Glycine 0 CA--C 1.529 0.944 0 C-N-CA 126.193 1.854 . . . . 1.01 114.996 174.077 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' C' C ' 17' ' ' ILE . . . . . . . . . . . . . 96.4 mt -67.57 144.1 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.601 1.161 . . . . 2.74 112.415 -171.133 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' C' C ' 18' ' ' ALA . . . . . . . . . . . . . . . -54.98 132.08 46.18 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.593 1.157 . . . . 1.75 112.967 174.707 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' C' C ' 19' ' ' GLY . . . . . . . . . . . . . . . -62.21 122.84 29.6 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 108.293 -1.923 . . . . 1.43 108.293 157.323 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' C' C ' 20' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -82.19 160.54 23.02 Favored 'General case' 0 C--N 1.327 -0.407 0 O-C-N 121.736 -0.861 . . . . 3.48 110.9 -173.723 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' C' C ' 21' ' ' ARG . . . . . . . . . . . . . 9.0 tpp180 -48.31 136.04 12.86 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 124.552 1.141 . . . . 5.17 111.612 173.647 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' C' C ' 22' ' ' GLY . . . . . . . . . . . . . . . -72.1 157.56 52.98 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 115.098 -0.955 . . . . 1.15 112.091 176.119 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' C' C ' 23' ' ' VAL . . . . . . . . . . . . . 2.2 t -65.17 155.39 6.66 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.618 0 C-N-CA 124.882 1.273 . . . . 2.25 110.58 176.215 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 30.4 m -68.84 -171.18 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.547 0.864 0 C-N-CA 126.392 1.877 . . . . 2.33 112.054 171.42 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.33 -108.24 0.01 OUTLIER Glycine 0 CA--C 1.534 1.273 0 C-N-CA 124.748 1.166 . . . . 2.37 111.884 163.3 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' C' C ' 26' ' ' LEU . . . . . . . . . . . . . 55.8 mt . . . . . 0 C--O 1.249 1.069 0 CA-C-O 117.647 -1.168 . . . . 4.16 111.563 166.448 . . . . . . . . 0 0 . 1 stop_ save_